PN 77001
RN 00583 
AN 78099755
AU Kaiser-G-I.  Laszlo-A.  Gyurkovits-K.
TI Cystic fibrosis: a HLA associated hereditary disease?.
SO Acta-Paediatr-Acad-Sci-Hung. 1977. 18(1). P 27-9.
MJ CYSTIC-FIBROSIS: fg.  HLA-ANTIGENS.
MN CYSTIC-FIBROSIS: im.  HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.
AB Twelve homozygote patients and thirty-two heterozygote gene carriers
   from families with cystic fibrosis were HLA-typed. Diagnostic
   criteria were sweat electrolyte concentration, pancreatic enzyme
   levels from duodenal juice and stool, Szczepanski's bromide test in
   the group of homozygotes, and the latter only in the cases of
   heterozygotes. In comparison with 130 healthy blood donors typed for
   29 HLA antigens. B18 proved to be more frequent in the group of
   patients and gene carriers, with 50 and 31%, respectively, and 14% in
   the normal population. The association seems to be stronger in the
   homozygotes than in the heterozygotes (p less than 0.02,
   respectively).
RF 001   DAUSSET J             PRESSE MED                      76  1397 968
   002   DAUSSET J             NOUV REV FR HEMATOL              7   161 967
   003   DAUSSET J             CLIN IMMUNOL IMMUNOPATHOL        3   127 974
   004   GOTZ M                Z KINDERHEILK                  117   183 974
   005   POLYMENIDIS Z         LANCET                           2  1452 973
   006   VAN ROOD JJ           TRANSPLANT REV                  22    75 975
   007   SNELL GD              FOLIA BIOL                      14   335 968
   008   SVEJGAARD A           TRANSPLANT REV                  22     3 975
   009   SZCZEPANSKI Z         Z KINDERHEILK                  113   297 972
   010   WOODROW JC            PROC R SOC MED                  68   802 975
   011   ANON                  EUR J IMMUNOL                    5   889 975
CT   1   RUSH PJ               SEM ARTHRITIS RHEUM             15   213 986

PN 77002
RN 00584 
AN 78099754
AU Takacs-O.  Sohar-I.  Laszlo-A.  Penzes-P.  Gyurkovits-K.
TI Distribution of serum amylase isoenzymes in cystic fibrosis
   homozygotes and heterozygotes.
SO Acta-Paediatr-Acad-Sci-Hung. 1977. 18(1). P 21-6.
MJ AMYLASES: bl.  CYSTIC-FIBROSIS: fg.  ISOENZYMES: bl.
MN ADULT.  CHILD.  CYSTIC-FIBROSIS: di, en.  HETEROZYGOTE.  HOMOZYGOTE.
   HUMAN.
AB A simple method has been elaborated for the routine separation and
   quantitative determination of amylase isoenzymes. The ratio P/S, the
   quotient of the activity values obtained by densitometric evaluation
   of the pancreatic and salivary isoenzymes, is used to characterize
   their distribution. In healthy adults and children the value for P/S
   is above 1 in 80% of the cases, with a mean of 1.87 +/- 0.23. In 90%
   of heterozygote CF gene-carriers, the P/S is below 1 with a mean of
   0.68 +/- 0.13. In addition to the higher total amylase activity, in
   MV homozygote patients P/S is less than 0.1, and even 0.001. The
   phenomenon is explained by a compensatory enhancement of salivary
   activity. The method is a suitable diagnostic test of the exocrine
   function of the pancreas and for evaluation of the serum amylase
   isoenzymes. The P/S value allows to differentiate heterozygote CF
   gene-carriers from homozygotes and healthy individuals.
RF 001   DAVIES TJ             J CLIN PATHOL                   25   266 972
   002   DOGGETT RG            NATURE NEW BIOL                243   251 973
   003   GYURKOVITS K          ACTA PAEDIATR ACAD SCI HUNG     15    49 974
   005   MERRITT AD            AM J HUM GENET                  25   510 973
   006   NIKOLAJEK WP          EUR J PEDIATR                  122   289 976
   007   OJALA K               SCAND J CLIN LAB INVEST         35   163 975
   008   OTSUKI M              CLIN CHIM ACTA                  22   439 976
   009   SKUDE G               SCAND J CLIN LAB INVEST         35    41 975
   010   TAKEUCHI T            CLIN CHIM ACTA                  54   137 974
   011   TAUSSIG LM            PEDIATRICS                      54   229 974
   012   WARD JC               AM J HUM GENET                  23   403 971
   013   WOLF RO               AM J CLIN PATHOL                49   871 968
   014$  WOLF RO               NATURE                         213   439 976

PN 77003
RN 00585 
AN 77131159
AU Redmond-A-O.  Buchanan-K-D.  Trimble-E-R.
TI Insulin and glucagon response to arginine infusion in cystic
   fibrosis.
SO Acta-Paediatr-Scand. 1977 Mar. 66(2). P 199-204.
MJ ARGININE: du.  CYSTIC-FIBROSIS: pp.  GLUCAGON: se.  INSULIN: se.
MN ARGININE: ad.  BLOOD-GLUCOSE: an.  BODY-HEIGHT.  BODY-WEIGHT.  CHILD.
   CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: di.  FASTING.  FEMALE.  HUMAN.
   INJECTIONS-INTRAVENOUS.  MALE.
AB The glucagon and insulin responses to intravenous arginine were
   studied in 17 children with cystic fibrosis and in 9 control
   children. It was found that the overall secretion of insulin was
   diminished; however, four of the CF children did have a normal
   output. The glucagon responses did not parallel those of insulin. The
   glucagon output varied in the CF children--seven had normal, four
   excessively high and six low output. Three of the four children with
   extremely high output had more severe disease and were below the
   third centile on the weight chart. These four had a fasting
   hypoglycaemia and also a very low glucose and insulin response. We
   have confirmed diminished insulin secretion in cystic fibrosis, but
   diminished glucagon secretion was only noted when some insulin
   secretion was preserved. The high levels of glucagon seen in the most
   insulin deficient subjects may be derived from extrapancreatic
   sources, or may be associated with 'stress' reaction in these
   patients who also had most severe pulmonary involvement. The data
   would be consistent with diminished glucagon and insulin secretion
   from the pancreas but as the disease progresses an excessive
   secretion of extra pancreatic glucagon results.
RF 001   BARBERO GJ            CF CLUB ABST                           4 967
   002   BILBREY GL            J CLIN INVEST                   53   841 974
   003   BUCHANAN KD           IN: KIRKHAM KE                       136 971
   004   BUCHANAN KD           LANCET                           1  1394 972
   005   BUCHANAN KD           THESIS                                47 973
   006   CHARLES RN            J CHRON DIS                     14   381 961
   007   CONLON JM             DIABETOLOGICA ABST 39 NO 4      11   336 975
   008   FLANAGAN RWJ          DIABETOLOGICA                   10   365 974
   009   HANDWERGER S          N ENGL J MED                   281   451 969
   010   HEDING LG             DIABETES                        23   257 971
   011   JORGENSEN KH          HORM METAB RES                   4   223 972
   012   KALK WJ               DIABETES                        23   257 974
   013   KALK WJ               DIABETES                        24   851 975
   014   MARCO J               N ENGL J MED                   289  1107 973
   015   MARLISS EB            J CLIN INVEST                   49  2256 970
   016   MATSOYAMA T           PROC SOC EXP BIOL MED          147   197 974
   017   MEGUID MM             LANCET                           2  1145 972
   018   MILNER AD             ARCH DIS CHILD                  44   351 969
   019   MILUNSKY A            AM J DIS CHILD                 121    15 971
   020   PORTE D               J CLIN INVEST                   45   228 966
   021   ROSAN RC              AM J DIS CHILD                 104   625 962
   022   SCHMIDT FH            IN: PFEIFFER EF                  2   938 971
   023   STAHL M               J PEDIATR                       84   821 974
   024   UNGER RH              J CLIN INVEST                   49   837 970
   025   VRANIC M              DIABETES                        23   905 974
   026   WANG CI               CF CLUB ABST                     8     1 967
   027   WILMORE DW            LANCET                           1    73 974

PN 77004
RN 00586 
AN 78183831
AU Falkman-C.
TI Cystic fibrosis--a psychological study of 52 children and their
   families.
SO Acta-Paediatr-Scand [Suppl]. 1977. (269). P 1-93.
MJ CYSTIC-FIBROSIS: px.
MN ADOLESCENCE.  ADULT.  CASE-REPORT.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: di, fg.  ENURESIS: et.  FEMALE.  HUMAN.
   INTERVIEW-PSYCHOLOGICAL.  MALE.  PARENT-CHILD-RELATIONS.  PARENTS.
   PSYCHOLOGICAL-TESTS.  QUESTIONNAIRES.  SLEEP-DISORDERS: et.
   SOCIOECONOMIC-FACTORS.  SWEDEN.
EX The primary goal of this investigation has been to disclose special
   characteristics among children with Cystic Fibrosis and their
   families and to focus on important consequences of the illness.  The
   main issues have been: (1) to explore the quality and the magnitude
   of psychological problems that CF imposes on the child and on its
   parents; (2) to investigate how the CF child experiences and reacts
   to its illness; (3) to assess if the CF child differs emotionally,
   intellectually or in visual-motor functioning from peers; (4) to see
   how the parents adapt to their child's condition and cope with the
   problems; (5) to assess the need of help and how it can be given.
RF 001   AGLE DP               ARCH INTERN MED                114    76 964
   002   AGLE DP               MODERN TREATMENT                 5   111 968
   003   AGLE DP               BIBL HAEMAT                     34    89 970
   004   ALLAN JL              AUST PAEDIATR J                 10   136 974
   005   ALLEN F               MED PSYCH                        8   212 928
   006   ANNELL AL             PERTUSSIS IN INFANCY AS A CAU            953
   007   ARTHUR G              ARTHUR ADAPT LEITER INT PERF             970
   008   BECK L                DYSLEXIA IN PATIENTS WITH CYS            969
   009   BENDER L              INSTRUCT USE VISU MOT GESTALT            946
   010   BLAESING S            NURS CLIN NORTH AM               7   597 972
   011   BLUMENTHAL MD         ARCH GEN PSYCHIAT               21   160 969
   012   BOYLE IR              J PEDIATR                       88   318 976
   013   BRAITHWAITE JV        PRACTITIONER                   165   273 950
   014   BROWNE JW             AM J ORTHOPSYCHIATRY            30   730 960
   015   BURTON L              PROC EWGCF 3RD ANNU MTG                  972
   016   BURTON L              PROC INVALID CHLD 84TH ANN MT            972
   017   BYRD E                IN: MURSTEIN BJ                          968
   018   CARNE S               PROC R SOC MED                  68   277 975
   019   CARR P                LANCET                           2  1075 971
   020   CHODOFF P             AM J PSYCHIATRY                120   743 964
   021   CLAWSON A             J PROJ TECHN                    23   198 959
   022   CULLBERG J            PSYKISKA TRAUMAT KRIST KRISP             973
   023   CYTRYN L              IN: ANTHONY EJ                        37 973
   024   DENNING CR            IN: MANGOS JA                        127 976
   025   DUBO S                AM J ORTHOPSYCHIATRY            20   520 950
   026   EMERY AEH             BR MED J                         1   724 973
   027   EYSENCK HJ            MANUAL OF THE EYSENCK PERSONA            964
   028   FEIGELSON J           ARCH FR PEDIATR                 26   937 969
   029   FRANKLIN AW           LANCET                           1   256 958
   030   FRIEDMAN SB           PEDIATRICS                      32   610 963
   031   FALLSTROM K           ACTA PAEDIATR SCAND SUPPL      251       974
   032   GAYTON WF             PEDIATR CLIN NORTH AM           22   161 975
   033   GIBSON LE             PEDIATRICS                      23   545 959
   034   GLASER HH             PEDIATRICS                      33   367 964
   035   GLASER HH             AM J DIS CHILD                 102   344 961
   036   GOLDY FB              CHILDREN                        10   189 963
   037   GOODENOUGH F          MEASUREMENT OF INTELLIGENCE B            926
   038   GREEN M               CHILDREN                        12   185 965
   039   GREEN MN              PEDIATRICS                      29   438 962
   040   GREEN MN              PEDIATRICS                      34    58 964
   041   HALLGREN B            ACTA NEUROL SCAND               31   379 956
   042   HAMBURG DA            ARCH GEN PSYCHIAT               17   277 967
   043   HARRIS DB             IN: BUROS OK                         401 972
   044   HECHT F               N ENGL J MED                   287   464 972
   045A  HEISLER VA            HANDICAPPED CHILD IN THE FAMI            972
   045B  HILL R                IN: PARAD HJ                          32 965
   046   HUANG NN              GUIDE TO DRUG THERAPY IN PATI            972
   047   HUANG NN              J PEDIATR                       59   512 961
   048   HUTT M                HUTT ADAPTATION OF THE BE                969
   049   JORDAN TE             MERRILL PALMER QUART             8   243 962
   050   KAHN RL               DYNAMICS OF INTERVIEWING                 957
   051   KAHN AU               AM J PSYCHIATRY                127  1194 971
   052   KALES A               N ENGL J MED                   290   487 974
   053   KANOF A               PEDIATRICS                      29    37 962
   054   KAUFMAN RV            PEDIATRICS                      48   123 971
   055   KELLOGG R             WHAT CHILDREN SCRIBBLE AND WH            959
   056   KITAY PM              IN: BUROS OK                         394 972
   057   KLACKENBERG G         ACTA PAEDIATR SCAND SUPPL      224       971
   058   KOLLBERG H            CYSTISK FIBROS SYNPUNKT DIAG             969
   059   KOLLBERG H            MEDLEMSBLAD FUR DE NORDISKA C            969
   060   KOLLBERG H            FYSIKALISK TERAPI VID CYSTISK            970
   061   KOLLBERG H            CYSTISK FIBROS MUCOVISCIDOS              970
   062   KOLLBERG H            CYSTISK FIBROS MUCOVISCIDOS              970
   063   KOLLBERG H            THESIS                                   974
   064   KOLLBERG H            LAKARTIDNINGEN                  73   847 976
   065   KOLLBERG H            CYSTISK FIBROS FORSLAG TILL V            976
   066   KOPPITZ EM            BENDER GESTALT TEST FOR CHILD            964
   067   KOPPITZ EM            PSYCHOLOGICAL EVALUATION OF C            968
   068   KORSCH BC             J PEDIATR                       44   703 954
   069   KULCZYCKI LL          CLIN PROC CHILD HOSP DC         25   320 969
   070   LAGERSTROM L          SOCIAL SECURITY IN SWEDEN                977
   071   LAWLER RH             CAN MED ASSOC J                 94  1043 966
   072   LAWSON D              ARCH DIS CHILD                  47     1 972
   073   LEIBMAN R             AM J PSYCHIATRY                131   535 974
   074   LINDBERG T            LAKARTIDNINGEN                  73  2989 976
   075   LINDEMANN E           AM J PSYCHIATRY                101   141 944
   076   LINDER R              MED CHILD NEUROL                12   202 970
   077   LIPOWSKI ZJ           PSYCHIAT MED                     2    91 970
   078   MACHOVER K            PERSONALITY PROJECTION IN THE            949
   079   MAIER HW              THREE THEORIES OF CHILD DEVEL            969
   080   MANDELBAUM A          SOC CASEWK                      41   360 960
   081   MATTSSON A            PEDIATRICS                      50   801 972
   082   MATTSSON A            PEDIATR CLIN NORTH AM           22    77 975
   083   MATTSSON A            J AM ACAD CHILD PSYCHIAT        11   558 972
   084   MATTSSON A            AM J PSYCHIATRY                122  1349 966
   085   MATTSSON A            J PEDIATR                       68   952 966
   086   MCCOLLUM AT           J PEDIATR                       77   571 970
   087   MECHANIC D            PEDIATRICS                      33   444 964
   088   MEYER H               SCHWEIZ MED WOCHENSCHR          99  1738 969
   089   MEYEROWITZ JH         SOC SCI MED                      1   249 967
   090   NEWMAN J              IN: CRUICKSHANK                      218 962
   091   OPPEL WC              PEDIATRICS                      42   614 968
   092   OPPENHEIMER EH        J PEDIATR                       77   991 970
   093$  PACELLA M             J CLIN PSYCHOL                   6    18 962
   094   PASCAL G              BENDER GESTALT TEST                      951
   095   PEARN JH              J MED GENET                     10   129 973
   096   PECKHAM CS            PROC R SOC MED                  66   701 973
   097   POZANSKI EO           REHAB LIT                       34   322 973
   098   PRUGH DG              WIDENING WORLD OF CHILDHOOD              962
   099   PRUGH DG              IN: SOLNIT AJ                        246 963
   100   RICHMOND JB           AM J DIS CHILD                  89    42 955
   101   ROBINSON LH           J PSYCHOTHERAPY                 28   397 974
   102   RODGERS B             NURS RES                        23   420 974
   103   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   104   SCHMIDT FF            ARBETSLAGSTIFTNING-                      975
   105   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            971
   106   SILVERSTEIN AB        J CONSULT CLIN PSYCHOL          25   146 961
   107   SPOCK A               NC MED J                        27   426 966
   108   ANON                  DOCUMENTATIONS ON SWEDEN                 977
   109   TAUSSIG LM            N ENGL J MED                   287   586 972
   110   TAYLOR K              AM J DIS CHILD                 119   209 970
   111   TEICHER JD            CALIF MED                      110   371 969
   112   TIPS RL               BIRTH DEF ORIG ART SER           4   110 968
   113   TROPAUER A            AM J DIS CHILD                 119   424 970
   114   TURK J                PEDIATRICS                      34    67 964
   115   WARWICK WJ            IN: LAWSON D PROC 5TH INT CF         320 969
   117   ANON                  WISC MANUAL WECHSLER INTELLIG            970
   118   WERRY JS              CAN MED ASSOC J                 97   319 967
   119   WILLIAMS JI           SOC SCI MED                      5   219 971
   120   WRIGHT SW             IN: LAWSON D PROC 5TH INT CF          91 969
CT   1   SINNEMA G             ACTA PAEDIATR SCAND             72   427 983
     2   DEWET B               S AFR MED J                     65   526 984
     3   DEWET B               S AFR MED J                     67   292 985
     4   DEWET B               S AFR MED J                     67   370 985
     5   PUMARIEGA AJ          J AM ACAD CHILD PSYCHIAT        25   269 986
     6   MOLLERING M           KLIN PAEDIATR                  198   369 986

PN 77005
RN 00587 
AN 78036889
AU Ryssing-E.
TI Assessment of cor pulmonale in cystic fibrosis by echocardiography.
SO Acta-Paediatr-Scand. 1977 Nov. 66(6). P 753-6.
MJ CYSTIC-FIBROSIS: co.  ECHOCARDIOGRAPHY.
   PULMONARY-HEART-DISEASE: di.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: di.
   FEMALE.  HEART-ENLARGEMENT.  HUMAN.  MALE.
   PEAK-EXPIRATORY-FLOW-RATE.  PULMONARY-HEART-DISEASE: co.
   VITAL-CAPACITY.
AB Thirty-one patients with cystic fibrosis of varying severity were
   examined by echocardiography. Right ventricular dimension (RVD) was
   above upper normal limit in 14 patients and right ventricular
   dimension index (RVD index) was higher than the upper normal limit in
   11 patients. Furthermore, there was a significant relationship
   between increasing RVD index and 1) decreasing forced vital capacity
   (FVC) both actual test results and average 6 months values; and 2)
   decreasing peak-expiratory flow rate (PEFR) both actual test results
   and average 6 months values. This observation suggests a persistent
   heart involvement. Five patients had either heart failure and/or
   electrocardiographic evidence of right ventricular abnormality. These
   patients had increased RVD index and one patient with the highest RVD
   index died 8 weeks after the examination. The present study has shown
   the usefulness of echocardiographic measurement of right ventricular
   dimension and of septal motion in assessing cor pulmonale, before
   development of electrocardiographic abnormalities and right heart
   failure.
RF 001   DIAMOND MA            CIRCULATION                     43   129 971
   002   FEIGENBAUM H          ECHOCARDIOGRAPHY                         972
   003   GOLDRING RM           J PEDIATR                       65   501 964
   004   GOODMAN DJ            AM J CARDIOL                    33   438 974
   005   HOYBYE G              UGESKR LAEGER                  132  2007 970
   006   LAURENCEAU JL         CHEST                           69   388 976
   007   LUNDSTROM NR          ACTA PAEDIATR SCAND SUPPL      243       974
   008   LUNDSTROM NR          ACTA PAEDIATR SCAND             63   257 974
   009   LYONS HA              AM J DIS CHILD                 100   196 960
   010   MCCANN WD             JAMA                           221  1243 972
   011   MOSS AJ               J PEDIATR                       67   797 965
   012   PADMAVATI S           BR HEART J                      34   658 972
   013   POPP RL               AM J CARDIOL                    24   523 969
   014   ROSENTHAL A           PEDIATR CLIN NORTH AM           23   327 976
   015   SIASSI B              J PEDIATR                       78   794 971
   016   TAJIK AJ              CIRCULATION                     46    36 972
   017   WEYMAN AE             CIRCULATION                     54   179 976
CT   1   SANTAGNESE PAD        AM J MED                        66   121 979
     2   HIRSCHFELD SS         CHEST                           75   351 979
     3   MATTHAY RA            BR HEART J                      43   474 980
     4   LESTER LA             J PEDIATR                       97   742 980
     5   MATTHAY RA            MED CLIN NORTH AM               65   489 981
     6   JACOBSTEIN MD         CHEST                           80   399 981
     7   MOSS AJ               PEDIATRICS                      70   728 982
     8   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
     9   JOHNSON SR            OBSTET GYNECOL                  61  S  2 983
    10   LESTER LA             SEM RESPIR MED                   6   285 985

PN 77006
RN 00588 
AN 77131198
AU Schiotz-P-O.  Hoiby-N.  Juhl-F.  Permin-H.  Nielsen-H.  Svehag-S-E.
TI Immune complexes in cystic fibrosis.
SO Acta-Pathol-Microbiol-Scand [C]. 1977 Feb. 85(1). P 57-64.
MJ ANTIGEN-ANTIBODY-COMPLEX.  CYSTIC-FIBROSIS: im.
MN ADOLESCENCE.  ADULT.  ANTINUCLEAR-FACTORS: an.  CHILD.
   CHRONIC-DISEASE.  COMPLEMENT: an.  CYSTIC-FIBROSIS: co.  FEMALE.
   HAPTOGLOBINS: an.  HUMAN.  IMMUNOGLOBULINS: an.  MALE.
   PRECIPITINS: an.  PSEUDOMONAS-INFECTIONS: co, im.
   RESPIRATORY-TRACT-INFECTIONS: co, im.  RHEUMATOID-FACTOR: an.
   SKIN: im.
AB Eleven patients with cystic fibrosis (CF) chronically infected with
   mucoid P. aeruginosa and ten patients without P. aeruginosa infection
   were examined for occurrence of circulating immune complexes, for
   immune complex deposits in the dermo-epidermal junction of the skin
   and for precipitins against P. aeruginosa, S. aureus, H. influenzae
   and D. pneumoniae antigens. The serum concentrations of haptoglobin,
   orosomucoid, immunoglobulins, C1q, C3, C4 and total haemolytic
   complement, antinuclear and rheumatoid factor activities as well as
   white blood cell counts and erythrocyte sedimentation rates were
   determined also. The results indicated that 6 patients from the
   chronically P. aeruginosa infected group, exhibiting a spectrum of
   serum precipitins against P. aeruginosa antigens, also had immune
   complexes in the serum, while only one patient (suffering from
   selective IgA deficiency) in the group without P. aeruginosa
   infection was positive for soluble immune complexes. Granular
   deposits of IgM was found in the skin of 10 of the chronically P.
   aeruginosa infected patients and in 7 of the patients without P.
   aeruginosa infection. A few pactients in both groups had dermo-
   epidermal deposits of C1q, C3 or fibrinogen as well. Eight of the
   patients in the chronically infected group and five in the group
   without P. aeruginosa infection had organ non-specific antinuclear
   factors. The haptoglobin levels appeared to be elevated in the
   chronically infected patients (p less than 0.05). None of the other
   parameters showed any significant difference between the two groups.
RF 001   BAART DE LA FAILLE-E  THESIS                                   969
   002   BONOMO L              AM J CLIN PATHOL                45   313 966
   003   DIEM K                DOCUMENTA GEIGY SCIENTIFIC TA            962
   004   GORDON DS             AM REV RESPIR DIS              108   127 973
   005   HOFF GE               ACTA PATH MICROBIOL SCAND (B)   83   219 975
   006   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   007   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   008   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   009   HOIBY N               ACTA PAEDIATR SCAND             63   843 974
   010   HOIBY N               SCAND J RESPIR DIS              56    38 975
   011   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   83   459 975
   012   JOHNSON KJ            J CLIN INVEST                   54   349 974
   013   JOHNSON U             ACTA PATH MICROBIOL SCAND (C)   83   285 975
   014   KOCH C                ACTA PATH MICROBIOL SCAND (C)   83   144 975
   015   KOFFLER D             J EXP MED                      126   607 967
   016   LANDRY M              J CLIN INVEST                   52  1861 973
   017   LAURELL CB            SCAND J CLIN LAB INVEST SUPPL  124    21 972
   018   LEBER PD              IN: ZWEIFACH BW                  3   401 974
   019   MASS B                AM REV RESPIR DIS              106   384 972
   020   MAYER MM              IN: KABAT EA                         133 961
   021   MCFARLANE H           BR MED J                         1   423 975
   022   MCINTOSH RM           Q J MED                         44   286 975
   023   NIELSEN H             ACTA PATH MICROBIOL SCAND (C)   84   261 976
   024   NIELSEN H             EUROPEAN IMMUNOLOGY MTG ABST             975
   025   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   83   469 975
   026   TAN EM                POSTGRAD MED                    54   143 973
   027   TAN EM                J CLIN INVEST                   45  1732 966
   028   THUESEN-PEDERSEN J    DAN MED BULL                    21    12 974
   029   TUFFANELLI DL         ARCH DERMATOL                   99   652 969
   030   TURNER-WARWICK M      BR MED J                         3   492 970
   031   WIIK A                IMMUNOLOGY                      23    53 972
   032   WIIK A                ANN RHEUM DIS                   33   515 974
CT   1   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     2   FARRELL C             SCAND J IMMUNOL                  6  1233 977
     3   PERMIN H              SCAND J RHEUMATOL                6   105 977
     4   ZUBLER RH             PROG ALLERGY                    24     1 978
     5   NIELSEN HE            ACTA PAEDIATR SCAND             67   443 978
     6   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   86    37 978
     7   GUPTA RK              CANCER IMMUNOL IMMUNOTHER        6   211 979
     8   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   87   229 979
     9   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   87     1 979
    10   PERMIN H              ACTA MED SCAND                 205   333 979
    11   BERDISCHEWSKY M       PEDIATR RES                     14   830 980
    12   HODSON ME             THORAX                          35   801 980
    13   SKOV PS               ALLERGY                         35    23 980
    14   MOSS RB               AM REV RESPIR DIS              121    23 980
    15   MATTHEWS WJ           N ENGL J MED                   302   245 980
    16   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
    17   EGESKJOLD EM          ALLERGY                         36   573 981
    18   PENNINGTON JE         J CLIN INVEST                   68  1140 981
    19   CHURCH JA             CHEST                           80   405 981
    20   MOSS RB               J PEDIATR                       99   215 981
    21   SORENSEN RU           AM REV RESPIR DIS              123    37 981
    22   DANIELE RP            AM REV RESPIR DIS              124   738 981
    23   FROLAND SS            SCAND J INFECT DIS            1981    72 981
    24   VANGEFFEL R           ANN IMMUNOL (PARIS)           D133   293 982
    25   PERMIN H              ALLERGY                         37    93 982
    26   MOSS RB               CLIN EXP IMMUNOL                47   301 982
    27   PITCHERWILMOTT RW     ARCH DIS CHILD                  57   577 982
    28   MANTHEI U             AM REV RESPIR DIS              126   253 982
    29   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
    30   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    63 982
    31   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
    32   ANON                  LANCET                           2   257 983
    33   KLINGER JD            INFECT IMMUN                    39  1377 983
    34   SORENSEN RU           EUR J RESPIR DIS                64   524 983
    35   WALLACE JM            AM REV RESPIR DIS              128  1077 983
    36   DORING G              J INFECT DIS                   147   744 983
    37   DAVIS CA              HUM PATHOL                      15   244 984
    38   DORING G              ACTA PATH MICROB IMMU SCA (C)   92   307 984
    39   HODSON ME             CLIN ALLERGY                    15   363 985
    40   WISNIESKI JJ          AM REV RESPIR DIS              132   770 985
    41   KHARAZMI A            EUR J CLIN INVEST               16   143 986
    42   HOIBY N               ANNU REV MICROBIOL              40    29 986
    43   PHILLIPS BM           J ROY SOC MED                   79    44 986
    44   MOSS RB               AM REV RESPIR DIS              133   648 986
    45   BOGART BI             J CHROMATOGR                   381    29 986
    46   DASGUPTA MK           J CLIN IMMUNOL                   7    51 987

PN 77007
RN 00589 
AN 77178547
AU Holby-N.  Olling-S.
TI Pseudomonas aeruginosa infection in cystic fibrosis.  Bactericidal
   effect of serum from normal individuals and patients with cystic
   fibrosis on P. aeruginosa strains from patients with cystic fibrosis
   or other diseases.
SO Acta-Pathol-Microbiol-Scand [C]. 1977 Apr. 85(2). P 107-14.
MJ BLOOD-BACTERICIDAL-ACTIVITY.  CYSTIC-FIBROSIS: im.
   PSEUDOMONAS-AERUGINOSA.  PSEUDOMONAS-INFECTIONS: co.
MN ADOLESCENCE.  ANTIBODIES-BACTERIAL: an.  CHILD.  COMPARATIVE-STUDY.
   CYSTIC-FIBROSIS: co.  HUMAN.  PSEUDOMONAS-INFECTIONS: im.
AB P. aeruginosa strains originating from the respiratory tract of
   patients with cystic fibrosis (CF) and patients with other diseases
   (non-CF) were analysed with regard to their sensitivity to the
   bactericidal activity of human serum. P. aeruginosa strains isolated
   from CF patients were more sensitive than strains from non-CF
   patients to the bactericidal activity of normal human serum. The
   bactericidal activity was heatlabile. As regards the sensitivity to
   normal human serum, mucoid and non-mucoid variants were not found to
   differ. Strains originating from chronically infected CF patients
   with many precipitins against these bacteria did not differ with
   respect to serum sensitivity from strains originating from
   intermittently colonized CF patients without P. aeruginosa
   precipitins. Compared with normal sera, CF sera showed similar or
   higher bactericidal activity against a panel of P. aeruginosa
   strains. In this respect, any difference between CF sera with
   precipitins and CF sera without precipitins against P. aeurginosa was
   not found. Sera from three CF patients chronically infected with P.
   aeruginosa, and with many precipitins against these bacteria, showed
   a selective inability in bactericidal activity against the patients'
   own P. aeruginosa isolate possibly reflecting the presence of
   "bactericidal blocking" antibodies.
RF 001   BERGAN T              ACTA PATH MICROBIOL SCAND (B)   83   553 975
   002   BIGGAR WD             PROC NAT ACAD SCI USA           68  1716 971
   003   BJORNSON AB           INFECT IMMUN                     2   453 970
   004   BJORNSON AB           INFECT IMMUN                     4   462 971
   005   BJORNSON AB           INFECT IMMUN                     5   775 972
   006   BJORNSON AB           J INFECT DIS SUPPL             130   119 974
   007   BJORNSON AB           J INFECT DIS SUPPL             130   127 974
   008   BOXERBAUM B           AM REV RESPIR DIS              108   777 973
   009   CROWDER JG            J LAB CLIN MED                  83   853 974
   010   DIEM K                DOCUMENTA GEIGY SCIENTIFIC TA            962
   011   DOGGETT RG            IN: LAWSON D PROC 5TH INT CF         175 969
   012   GOLDMAN JN            INFECT DIS                     129   444 974
   013   GOVAN JRW             J MED MICROBIOL                  8   513 975
   014   GRIFFISS JM           J IMMUNOL                      114  1779 975
   015   GUTTMAN RM            CLIN EXP IMMUNOL                19   121 975
   016   HOWARD CJ             IMMUNOLOGY                      20   767 971
   017   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   018   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   019   HOIBY N               SCAND J IMMUNOL SUPPL 2          4   187 975
   020   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   549 975
   021   KOCH C                ACTA PATH MICROBIOL SCAND (C)   83   144 975
   022   LINDBERG U            ACTA PAEDIATR SCAND             64   432 975
   023   MARTIN DR             J MED MICROBIOL                  6   111 973
   024   MOREAU SC             SCIENCE                        190   278 975
   025   MUSCHEL LH            J IMMUNOL                       76     1 956
   026   OLLING S              INFECTION                        1    24 973
   027   REED WP               IMMUNOLOGY                      26   205 974
   028   ROWLEY D              IN: KASS E                           162 973
   029   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   83   469 975
   030   SIMBERKOFF MS         J LAB CLIN MED                  87   207 976
   031   TAYLOR PW             CLIN SCI                        43   705 972
   032   TAYLOR PW             J GEN MICROBIOL                 89    57 975
   033   TAUB WH               INFECT IMMUN                    13  1343 976
   034   WAISBREN BA           J IMMUNOL                       97   431 966
   035   YOUNG LS              J INFECT DIS                   126   257 972
   036   YOUNG LS              J INFECT DIS                   126   257 972
   037   YOUNG LS              J INFECT DIS SUPPL             130   111 974
   038   ZIERDT CH             J BACTERIOL                     87  1003 964
CT   1   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     2   LARSSON P             MED MICROBIOL IMMUNOL          163    77 977
     3   LIDINJANSON G         MED MICROBIOL IMMUNOL          164   247 978
     4   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   87   229 979
     5   HODSON ME             THORAX                          35   801 980
     6   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   88   125 980
     7   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
     8   KOEPP LH              INFECT IMMUN                    33   788 981
     9   THOMASSEN MJ          INFECT IMMUN                    33   512 981
    10   FICK RB               J CLIN INVEST                   68   899 981
    11   MARKS MI              J PEDIATR                       98   173 981
    12   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
    13   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    63 982
    14   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    15   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
    16   OFFREDOHEMMER C       ANN MICROBIOL (PARIS)         A134   281 983
    17   BOROWSKI RS           CURRENT MICROBIOL                9    25 983
    18   PENKETH ARL           J MED MICROBIOL                 16   401 983
    19   JAGGER KN             J CLIN MICROBIOL                17    55 983
    20   SCHILLER NL           PEDIATR RES                     17   747 983
    21   FICK RB               BULL EUR PHYSIOPATH RESP        19   151 983
    22   CRYZ SJ               INFECT IMMUN                    39  1072 983
    23   TAYLOR PW             MICROBIOL REV                   47    46 983
    24   PENKETH A             AM REV RESPIR DIS              127   605 983
    25   SCHILLER NL           CURRENT MICROBIOL               10   185 984
    26   MESHULAM T            CLIN IMMUNOL IMMUNOPATHOL       32   151 984
    27   KHARAZMI A            INFECT IMMUN                    43   161 984
    28   SCHILLER NL           INFECT IMMUN                    45   748 984
    29   THOMASSEN MJ          INFECT IMMUN                    45   741 984
    30   FICK RB               J CLIN INVEST                   74   236 984
    31   FALKENHAGEN U         Z UROL NEPHROL                  77   629 984
    32   PIER GB               J INFECT DIS                   150   223 984
    33   NICAS TI              EUR J CLIN MICROBIOL             4   175 985
    34   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
    35   PAJDAK E              ARCH IMMUNOL THER EXP           33   499 985
    36   OJENIYI B             ACTA PATH MICROB IMMU SCA (B)   93     7 985
    37   SAWADA S              J INFECT DIS                   152  1290 985
    38   SCHILLER NL           INFECT IMMUN                    54   689 986
    39   FALKENHAGEN U         Z UROL NEPHROL                  79   619 986
    40   FICK RB               AM REV RESPIR DIS              133   418 986
    41   SPEERT DP             J HOSP INFECT                    9    11 987

PN 77008
RN 00590 
AN 78036942
AU Hoiby-N.
TI Pseudomonas aeruginosa infection in cystic fibrosis.  Diagnostic and
   prognostic significance of pseudomonas aeruginosa precipitins
   determined by means of crossed immunoelectrophoresis.  A survey.
SO Acta-Pathol-Microbiol-Scand [Suppl]. 1977. (262). P 1-96. (REVIEW).
MJ CYSTIC-FIBROSIS: im.  PRECIPITINS.  PSEUDOMONAS-INFECTIONS: im.
MN ANTIBODIES-BACTERIAL: an.  ANTIGENS-BACTERIAL: an.  CROSS-REACTIONS.
   CYSTIC-FIBROSIS: co.  HUMAN.  IMMUNOELECTROPHORESIS-TWO-DIMENSIONAL.
   PRECIPITINS: an.  PROGNOSIS.  PSEUDOMONAS-AERUGINOSA: im.
   PSEUDOMONAS-INFECTIONS: co.  REVIEW.
EX The purpose of the first part of the present work is to review the
   literature concerning the lower respiratory tract infections and the
   antimicrobial resistance mechanisms in cystic fibrosis patients.
   The second part of the work deals with the most important
   therapeutical problem in cystic fibrosis today, viz. the Pseudomonas
   aeruginosa lung infection.  A survey is made of the investigations
   of the present author and his colleagues into the immune response
   against Pseudomonas aeruginosa infection and the literature
   concerning these subjects.  Furthermore, the possible mechanisms of
   tissue damage in the respiratory tract of cystic fibrosis patients
   during these infections are discussed.
RF 001   ADLER JL              ARCH INTERN MED                127   760 971
   002   ALLEN JC              INFECT IMMUN                    12   318 975
   003$  ALLISON AC            TRANSPLANT REV                  19     3 975
   004   ANDERSEN B            IN: PEDERSEN J                       120 971
   005   ANDERSEN B            NORD MED                        39  1575 948
   006   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   007   ANDERSEN DH           PEDIATRICS                       3   406 949
   008   ANDERSEN DH           J CHRON DIS                      7    58 958
   009   ANDERSEN V            CLIN EXP IMMUNOL                26   469 976
   010   ANDERSON EL           SOUTH MED J                     67   771 974
   011   ASAY LD               N ENGL J MED                   262  1062 960
   012   AXELSEN NH            INFECT IMMUN                     4   525 971
   013   AXELSEN NH            PROTIDES BIOL FLUIDS            19   561 971
   014   AXELSEN NH            J IMMUNOL METH                   1   109 972
   015   AXELSEN NH            INFECT IMMUN                     7   949 973
   016   AXELSEN NH            SCAND J IMMUNOL SUPPL 2          1    71 973
   017   AXELSEN NH            SCAND J IMMUNOL SUPPL 2          1    91 973
   018   AXELSEN NH            SCAND J IMMUNOL SUPPL 2          1   101 973
   019   AXELSEN NH            J IMMUNOL METH                   2   393 973
   020   AXELSEN NH            J IMMUNOL METH                   2   245 973
   021   AXELSEN NH            SCAND J IMMUNOL SUPPL 2          1       973
   022   AXELSEN NH            CLIN EXP IMMUNOL                17   385 974
   023   AXELSEN NH            INFECT IMMUN                     9   952 974
   024   AXELSEN NH            SCAND J IMMUNOL SUPPL 2          4     1 975
   025   AXELSEN NH            SCAND J IMMUNOL SUPPL 2          4   217 975
   026   AXELSEN NH            SCAND J IMMUNOL                  5   177 976
   027   BAIRD IM              ANTIMICROB AGENTS CHEMOTHER     10   626 976
   028   BARDANA EJ JR         AM J DIS CHILD                 129  1164 975
   029   BARSON AJ             ARCH DIS CHILD                  46    55 971
   030   BARTON AD             J LAB CLIN MED                  88   423 976
   031   BEDROSSIAN CWM        HUM PATHOL                       7   195 976
   032   BERGAN T              IN: BROWN MRW                        189 975
   033   BERGAN T              ACTA PATH MICROBIOL SCAND (B)   83   553 975
   034   BIGGAR WD             PROC NAT ACAD SCI USA           68  1716 971
   035   BIGGAR WD             AM REV RESPIR DIS              109   403 974
   036   BJERRUM OJ            SCAND J IMMUNOL SUPPL 1          2   133 973
   037   BJERRUM OJ            SCAND J IMMUNOL SUPPL 2          4    89 975
   038   BJORNSON AB           J INFECT DIS SUPPL             130   119 974
   039   BJORNSON AB           J INFECT DIS SUPPL             130   127 974
   040   BLACKFAN KD           J PEDIATR                       13   627 938
   041   BOCK E                J NEUROCHEM                     18  2435 971
   042   BOCK E                J IMMUNOL METH                   2    75 972
   043   BOCK E                SCAND J IMMUNOL SUPPL 1          2    95 973
   044   BODE FR               MEDICINE (BALTIMORE)            53   255 974
   045   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   046   BOG-HANSEN TC         ANAL BIOCHEM                    56   480 973
   047   BOHME B               HELV PAEDIATR ACTA              27   607 972
   048   BOXERBAUM B           AM REV RESPIR DIS              108   777 973
   049   BOXERBAUM B           AM REV RESPIR DIS              109   403 974
   050   BRADLEY DE            J HYG LOND                      74   419 975
   051   BRADSHAW MW           LANCET                           1  1095 971
   052   BRENTJENS JR          J EXP MED                      140   105 974
   053   BROGAN TD             IMMUNOLOGY                       7   626 964
   054   BROGAN TD             THORAX                          30    72 975
   055   BROGREN CH            SCAND J IMMUNOL SUPPL 2          4    37 975
   056   BRYANT DH             J ALLERGY CLIN IMMUNOL          56   417 975
   057   BUCKLEY RH            J CLIN INVEST                   55   157 975
   058   BURNS MW              AUSTRALAS ANN MED               17   289 968
   059   BURNS MW              LANCET                           1   270 968
   060   BURNS MW              BR MED J                         3   382 973
   061   CALDWELL HD           J IMMUNOL                      115   963 975
   062   CALDWELL HD           J IMMUNOL                      115   969 975
   063   CAMPBELL PA           BACT REV                        40   284 976
   064   CARLSON DM            BIOCHEMISTRY                     5  2817 966
   065   CETIN ET              J BACTERIOL                     89  1432 965
   066   CHANGUS JE            ARCH PATHOL LAB MED            100     7 976
   067   CLARKE CW             POSTGRAD MED J                  51   147 975
   068   CLARKE HGM            PROTIDES BIOL FLUIDS            14   503 966
   069   CLOSS O               SCAND J IMMUNOL SUPPL 2          4   173 975
   070   COCHRANE CG           IN: ZWEIFACH BW                  3    85 974
   071   COOMBS RRA            IN: GELL PGH                         761 975
   072   COOPER RG             MED J AUST                       1   527 967
   073   CROZIER DN            PEDIATR CLIN NORTH AM           21   935 974
   074   CURTIN JA             ANN INTERN MED                  54  1077 961
   075   DAHR P                DTSCH MED WSCHR                 61  1879 935
   076   DANES BS              LANCET                           1  1061 968
   077   DANES BS              AM J HUM GENET                  23   297 971
   078   DANES BS              CLIN GENET                      11    83 977
   079   DEFOREST A            CF CLUB ABST                             976
   080   DIAZ F                J INFECT DIS                   121   269 970
   081   DICKEY LB             DIS CHEST                       17   151 950
   082   DIEM K                DOCUMENTA GEIGY SCIENTIFIC TA            962
   083   DI SANTAGNESE PA      AM J DIS CHILD                  72    17 946
   084   DI SANTAGNESE PA      PEDIATRICS                      12   178 953
   085   DI SANTAGNESE PA      DIS CHEST                       27   654 955
   086   DI SANTAGNESE PA      AM J MED                        21   406 956
   087   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   088   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   089   DOGGETT RG            J BACTERIOL                     87   427 964
   090   DOGGETT RG            J BACTERIOL                     89   476 965
   091   DOGGETT RG            J PEDIATR                       68   215 966
   092   DOGGETT RG            APPL MICROBIOL                  18   936 969
   093   DOGGETT RG            IN: LAWSON D PROC 5TH INT CF         175 969
   094   DOGGETT RG            INFECT IMMUN                     6   628 972
   095   DOGGETT RG            CF CLUB ABST                             976
   097   ANON                  NUTR REV                        34   210 976
   098   EICHENWALD HF         IN: MCINTOSH R                        89 960
   099   ELSTON HR             AM J CLIN PATHOL                48   519 967
   100   ESTERLY JR            JOHNS HOPKINS MED J            122    94 968
   101   ESTERLY JR            IN: MANGOS JA                        115 976
   102   EVANS LR              J BACTERIOL                    116   915 973
   103   FANCONI G             WIEN MED WOCHENSCHR             86   753 936
   104   FARBER S              ARCH PATHOL                     37   238 944
   105   FEIGELSON J           MOD PROBL PEDIATR               10   214 967
   106   FEIGHERY C            BR MED J                         1   524 976
   107   FEIGIN RD             J PEDIATR                       87   677 975
   108   FLENSBORG EW          NORD MED                        39  1574 948
   109   FLENSBORG EW          MDSKR PRAKT LAEGEG              50   269 972
   110   FOLEY FD              TEX MED                         65    36 969
   111   FORKNER CE            PSEUDOMONAS AERUGINOSA INFECT         69 960
   112   FORSGREN A            INFECT IMMUN                    10   402 974
   113   FRIIS B               PROC INT CF CONG 7TH                     976
   114   FAERO O               UGESKR LAEGER                  138  2551 976
   115   GALANT SP             AM REV RESPIR DIS              114   325 976
   116   GALLIN JI             IN: KIRKPATRICK CH                   161 976
   117   ANON                  GAP CONF REP PSEUDOMON IN CF             974
   118   GARRARD SD            PEDIATRICS                       8   482 951
   119   GELFAND EW            PEDIATR CLIN NORTH AM           21   745 974
   120   GIBBONS A             BR MED J                         1   120 976
   121   GIFFORD RM            J S CAROLINA MED ASSOC          68   204 972
   122   GORDON DS             AM REV RESPIR DIS              108   127 973
   123   GOVAN JRW             J MED MICROBIOL                  8   513 975
   124   GOVAN JRW             J ANTIMICROB CHEMOTHER           2   215 976
   125   GRABAR P              BIOCHIM BIOPHYS ACTA            10   193 953
   126   GRANT JA              J IMMUNOL                      114  1101 975
   127   GREEN GM              MED CLIN NORTH AM               57   547 973
   128   GRIFFISS JM           J IMMUNOL                      114  1779 975
   129   GROV A                ACTA PATH MICROBIOL SCAND (C)   84    71 976
   130   GRUBB A               SCAND J CLIN LAB INVEST SUPPL  124    59 972
   131   GUGLER EC             J PEDIATR                       73   548 968
   132   GUTTMAN RM            CLIN EXP IMMUNOL                19   121 975
   133   GOTZ M                Z KINDERHEILK                  117   183 974
   134   HABBOUSHE C           PEDIATRICS                      48   973 971
   135   HALBERT SP            PEDIATRICS                      26   792 960
   136   HALBERT SP            MOD PROBL PEDIATR               10   144 967
   137   HANN S                INFECT IMMUN                    14   114 976
   138   HARBOE N              SCAND J IMMUNOL SUPPL 1          2   161 973
   139   HARRISON GM           CF Q ANNOTATED REFERENCES       13    30 975
   140   HENRIKSEN SD          ACTA PATH MICROBIOL SCAND       25   485 948
   141   HERTZ JB              ACTA PATH MICROBIOL SCAND (B)   84   386 976
   142   HILL HR               J PEDIATR                       84    55 974
   143   HIRSCHHORN R          IN: ZWEIFACH BW                  1   259 974
   144   HOBBS G               J APPL BACT                     27    83 964
   145   HOFF GE               SCAND J INFECT DIS               6   333 974
   146   HOFF GE               ACTA PATH MICROBIOL SCAND (B)   83   219 975
   147   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   148   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   149   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   150   HOIBY N               ACTA PAEDIATR SCAND             63   843 974
   151   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   559 974
   152   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   321 975
   153   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   328 975
   154   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   433 975
   155   HOIBY N               SCAND J IMMUNOL SUPPL 2          4   187 975
   156   HOIBY N               SCAND J IMMUNOL SUPPL 2          4   187 975
   157   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   549 975
   158   HOIBY N               SCAND J RESPIR DIS              56    38 975
   159   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   83   459 975
   160   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   84   372 976
   161   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   84   372 976
   162   HOIBY N               SCAND J RESPIR DIS              57   103 976
   163   HOIBY N               SCAND J RESPIR DIS              57    37 976
   164   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   84   372 976
   165   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   85   142 977
   166   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   85   142 977
   167   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   85   107 977
   168   HOIBY N               SCAND J RESPIR DIS              58    65 977
   169   HOLMBERG K            THESIS                                 1 975
   170   HOLZHAUER RJ          CF CLUB ABST                    17    22 976
   171   HOMMA JY              JAPAN J EXP MED                 42   583 972
   172   HOMMA JY              JAPAN J EXP MED                 44     1 974
   173   HOOK WA               J IMMUNOL                      114  1185 975
   174   HUANG NN              J PEDIATR                       59   512 961
   175   HUANG NN              AM J DIS CHILD                 120   289 970
   176   HUANG NN              CF CLUB ABST                          43 976
   177   HUANG NN              CF CLUB ABST                             976
   178   HUGHES DE             IN: NORRIS JR                   5B     1 971
   179   IACOCCA VF            AM J DIS CHILD                 106   315 963
   180   IACOCCA VF            ARCH DIS CHILD                  43   220 968
   181   JACKSON AE            J LAB CLIN MED                  69   833 967
   182   JESSEN O              THESIS                                61 965
   183   JOHANSEN KS           UGESKR LAEGER                  138  2772 976
   184   JOHNSON KJ            J CLIN INVEST                   54   349 974
   185   KAIJSER B             INT ARCH ALLERGY                48    72 975
   186   KALTREIDER HB         AM REV RESPIR DIS              113   347 976
   187   KALTREIDER HB         IN: KIRKPATRICK CH                    73 976
   188   KILBOURN JP           J PEDIATR                       73   408 968
   189   KIRKPATRICK CH        IMMUNOL INFECT REACT LUNG              1 976
   190   KIRKPATRICK CH        IN: KIRKPATRICK CH                   211 976
   191   KLEINMAIER H          ZENTRALBL BAKTERIOL ORIG A     172    54 958
   192   KLINEBERGER C         MUNCH MED WOCHENSCHR            54  1330 907
   193   KLINEBERGER C         Z IMMUN FORSCH                   2   686 909
   194   KOCH C                ACTA PATH MICROBIOL SCAND (B)   81   787 973
   195   KOCH C                ACTA PATH MICROBIOL SCAND (B)   82   439 974
   196   KOCH C                ACTA PATH MICROBIOL SCAND (C)   83   144 975
   197   KOLLBERG H            THESIS                                   974
   198   KONTOMICHALOU P       ANTIMICROB AGENTS CHEMOTHER      9   866 976
   199   KRONVALL G            INFECT IMMUN                    13  1132 976
   200   LAMM LU               ANN HUM GENET                   38   383 975
   201   LANYI B               ACTA MICROBIOL ACAD SCI HUNG    19   259 972
   202   LANYI B               ACTA MICROBIOL ACAD SCI HUNG    20   249 973
   203   LANYI B               ACTA MICROBIOL ACAD SCI HUNG    20   337 973
   204   LARAYA-CUASAY LR      J PEDIATR                       89    23 976
   205   LAURELL CB            SCAND J CLIN LAB INVEST SUPPL  124    21 972
   206   LAWSON D              IN: WATT PJ                           69 970
   207   LEBER PD              IN: ZWEIFACH BW                  3   401 974
   208   LIND I                ACTA PATH MICROBIOL SCAND       73   637 968
   209   LINKER A              J BIOL CHEM                    241  3845 966
   210   LIU PV                J INFECT DIS SUPPL             130    94 974
   211   LLOYD-STILL JD        PEDIATRICS                      53   678 974
   212   LOPEZ M               ANNU REV MED                    27   453 976
   213   LOWBURY EJL           J MED MICROBIOL                  3    39 970
   214   LYKKEGAARD E          DAN MED BULL                    21   241 974
   215   MARGARETTEN W         N ENGL J MED                   265   773 961
   216   MARTIN DR             J MED MICROBIOL                  6   111 973
   217   MARTINEZ-TELLO FJ     J IMMUNOL                      101   989 968
   218   MATTHEWS LW           J PEDIATR                       65   558 964
   219   MAY JR                CHEMOTHERAPY OF CHRONIC BRONC            968
   220   MAY JR                ARCH DIS CHILD                  47   908 972
   221   MAY JR                J MED MICROBIOL                  6    77 973
   222   MAY JR                POSTGRAD MED J                  51   144 975
   223   MCCOMBS ML            TEX REP BIOL MED                31   615 973
   224   MCCOMBS RP            N ENGL J MED                   286  1186 972
   225   MCCRAE WM             SCOTT MED J                     19   187 974
   226   MCFARLANE H           BR MED J                         1   423 975
   227   MCFARLANE H           BR MED J                         1   524 976
   228   MEARNS MB             LANCET                           1   538 967
   229   MEARNS MB             ARCH DIS CHILD                  47     5 972
   230   MEARNS MB             ARCH DIS CHILD                  47   902 972
   231   MITCHELL-HEGGS PF     Q J MED                         45   479 976
   232   MURAKAWA T            JAPAN J MICROBIOL               17   273 973
   233   MURAKAWA T            JAPAN J MICROBIOL               17   513 973
   234   MYEROWITZ RL          LANCET                           2   250 972
   235   NELSON RA JR          IN: ZWEIFACH BW                  3    37 974
   236   NETER E               J INFECT DIS SUPPL             130   132 974
   237   NEWHOUSE M            N ENGL J MED                   295   990 976
   238   NIELSEN EL            UGESKR LAEGER                  133  1017 971
   239   NIELSEN H             ACTA PATH MICROBIOL SCAND (C)   84   261 976
   240   OGILVIE BM            BR MED BULL                     32   177 976
   241   OLITZKI AL            BOLL IST SIEROTER MILAN         42   213 963
   242   ORES CN               CF Q ANNOTATED REFERENCES       13    31 975
   243   THUESEN-PEDERSEN J    DAN MED BULL                    21    12 974
   244   PENNINGTON JE         AM J MED                        55   155 973
   245   PENNINGTON JE         J INFECT DIS SUPPL             130   159 974
   246   PENNINGTON JE         AM J MED                        58   629 975
   247   PITTMAN FE            PEDIATRICS                      24    40 959
   248   POLLEY MJ             J MED GENET                     11   249 974
   249   REYNOLDS HY           J IMMUNOL                      111   358 973
   250   REYNOLDS HY           J IMMUNOL                      111   358 973
   251   REYNOLDS HY           J INFECT DIS SUPPL             130   134 974
   252   REYNOLDS HY           J CLIN INVEST                   53  1351 974
   253   REYNOLDS HY           ANN INTERN MED                  82   819 975
   254   REYNOLDS HY           J CLIN INVEST                   56   376 975
   255   REYNOLDS HY           J IMMUNOL                      114  1813 975
   256   REYNOLDS HY           IN: KIRKPATRICK CH                   143 976
   257   REYNOLDS HY           IN: KIRKPATRICK CH                     3 976
   258   ROBINSON MJ           ARCH DIS CHILD                  50   962 975
   259   ROE EA                BR J EXP PATHOL                 55   336 974
   260   ROSENLUND ML          CRC CRIT REV CLIN LAB SCI        3   257 972
   261   SADOFF JC             J INFECT DIS SUPPL             130    61 974
   262   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   83   469 975
   263   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   85    57 977
   264   SCHWAB JH             BACT REV                        39   121 975
   265   SCHWARTZ RH           AM J DIS CHILD                 111   408 966
   266   SCHWARTZ RH           AM J DIS CHILD                 120   432 970
   267   SCHWARZMANN S         INFECT IMMUN                     3   762 971
   268   SCHWARZ LH            J BACTERIOL                     54    30 947
   269   SEIDMON EJ            J PEDIATR                       87   528 975
   270   SHWACHMAN H           CLIN PEDIATR                    14  1115 975
   271   SHIRAGANIAN RP        J IMMUNOL                      116   639 976
   272   SLAVIN RG             POSTGRAD MED                    59   137 976
   273   SMYTH CJ              INFECT IMMUN                    13  1273 976
   275   SOLBERG CO            LANCET                           2   727 972
   276   SONNENSCHEIN C        ZENTRALBL BAKTERIOL            104   365 927
   277   SOUTAR CA             THORAX                          31   158 976
   278   SOUTH MA              J PEDIATR                       71   645 967
   279   SOUTHERN PM           J LAB CLIN MED                  76   548 970
   280   SOUTHERN PM           APPL MICROBIOL                  21   377 971
   281   SPOCK A               PEDIATR RES                      1   173 967
   282   STERN RC              J PEDIATR                       89   406 976
   283   STOSSEL TP            N ENGL J MED                   290   717 974
   284   SULLIVAN JF           AM J DIS CHILD                 125   702 973
   285   SUTHERLAND IW         IN: WEIR DM                      1     1 973
   286   SWEET GH              J IMMUNOL                      111   554 973
   287   SVENDSEN PJ           J IMMUNOL METH                   1   169 972
   288   TALAMO RC             IN: MANGOS JA                        195 976
   289   TAUSSIG LM            J PEDIATR                       84   724 974
   290   TAUSSIG LM            CF CLUB ABST                    17    21 976
   291   TAYLOR PW             CLIN SCI                        43   705 972
   292   THERKELSEN AJ         MEDICINSK STATISTIK AKADEMISK            968
   293   THIRKILL CE           J IMMUNOL                      114  1107 975
   294   TUNSTALL AM           J APPL BACT                     38   159 975
   295   TURK JL               BOLL IST SIEROTER MILAN SUPPL   53   208 974
   296   TURNER-WARWICK M      THORAX                          30   601 975
   297   URIEL J               IN: GRABAR P                          30 964
   298   VAWTER GF             GAP CONF REP PATHOL OF CF              9 972
   299   VERBRUGGEN R          CLIN CHEM                       21     5 975
   300   VESTERGAARD BJ        ACTA PATH MICROBIOL SCAND (B)   81   808 973
   301   WAISBREN BA           J IMMUNOL                       97   431 966
   302   WALDMAN RH            J INFECT DIS                   130   419 974
   303   WALLWORK JC           CLIN EXP IMMUNOL                18   303 974
   304   WARNER JO             ARCH DIS CHILD                  51   507 976
   305   WARREN CPW            CLIN ALLERGY                     5     1 975
   306   WARREN SL             ANN ALLERGY                     36   337 976
   307   WARWICK WJ            J ASTHMA RES                     5   277 968
   308   WARWICK WJ            J CHRON DIS                     28   609 975
   309   WEEKE B               SCAND J CLIN LAB INVEST         21   351 968
   310   WEEKE B               PROTIDES BIOL FLUIDS            19   547 971
   311   WEEKE B               SCAND J IMMUNOL SUPPL 1          2    37 973
   312   WEEKE B               SCAND J IMMUNOL SUPPL 1          3    47 973
   313   WEEKE B               SCAND J IMMUNOL SUPPL 1          2   149 973
   314   WEEKE B               DAN MED BULL                    23   155 976
   315   WEINSTEIN RJ          J CLIN INVEST                   58   190 976
   316   WIGLESWORTH FW        AM J MED SCI                   212   351 946
   317   WILLIAMS RJ           J MED MICROBIOL                  6   409 973
   318   WILSON GS             TOPLEY WILSONS PRINCIPLES OF     1   368 975
   319   WISSLER H             HELV PAEDIATR ACTA SUPPL 1       1     3 945
   320   WOOD RE               AM REV RESPIR DIS              113   833 976
   321   WRETLIND B            J MED MICROBIOL                  6    91 973
   322   WRIGHT GL JR          IMMUNOL COMMUN                   3    35 974
   323   WRIGHT PF             J INFECT DIS                   134   144 976
   324   WULFF HR              RATIONEL KLINIK                          973
   325   YOUNG LS              J INFECT DIS                   126   257 972
   326   YOUNG LS              J INFECT DIS                   126   257 972
   327   YOUNG LS              CRC CRIT REV CLIN LAB SCI        3   291 972
   328   YOUNG LS              J INFECT DIS SUPPL             130   111 974
   329   ZAVALA DC             J ALLERGY CLIN IMMUNOL          56   450 975
   330   ZEGERS BJM            N ENGL J MED                   294  1026 976
   331   ZIERDT CH             J BACTERIOL                     87  1003 964
   332   ZIERDT CH             J CLIN MICROBIOL                 1   521 975
   333   ZUELZER WW            PEDIATRICS                       4    53 949
CT   1   THOMASSEN MJ          PEDIATR RES                     13  1085 979
     2   THOMASSEN MJ          J INFECT DIS                   140   873 979
     3   BERDISCHEWSKY M       PEDIATR RES                     14   830 980
     4   THOMASSEN MJ          PEDIATR RES                     14   715 980
     5   GOSCINIAK G           ARCH IMMUNOL THER EXP           28   619 980
     6   HODSON ME             THORAX                          35   801 980
     7   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   88   149 980
     8   BEAUDRY PH            J PEDIATR                       97   144 980
     9   FICK RB               CLIN CHEST MED                   2    91 981
    10   PETERSEN NT           ACTA PAEDIATR SCAND             70   623 981
    11   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   89   185 981
    12   MARKS MI              J PEDIATR                       98   173 981
    13   MOSS RB               J PEDIATR                       99   215 981
    14   MOLLER NE             SCAND J INFECT DIS            1981    87 981
    15   MOROZ AF              ZH MIKROBIO EPIDEMIO IMMUNOBI 1981     6 981
    16   SEALE TW              ANN CLIN LAB SCI                12   415 982
    17   BREMMELGAARD A        SCAND J INFECT DIS              14   271 982
    18   PUGASHETTI BK         J CLIN MICROBIOL                16   686 982
    19   BAKER NR              IN VITRO                        18   369 982
    20   SORDELLI DO           CLIN IMMUNOL IMMUNOPATHOL       22   153 982
    21   BAKER NR              CAN J MICROBIOL                 28   248 982
    22   PERMIN H              ALLERGY                         37    93 982
    23   MOLLER NE             EUR J RESPIR DIS                63   130 982
    24   SZAFF M               ACTA PAEDIATR SCAND             71   821 982
    25   ZIELINSKI CC          N ENGL J MED                   306   486 982
    26   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
    27   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    28   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    63 982
    29   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
    30   MICHALSEN H           ACTA PAEDIATR SCAND SUPPL 301 1982   101 982
    31   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
    32   ZIMAKOFF J            J HOSP INFECT                    4    31 983
    33   HOOGKAMPKORSTANJE JAA J ANTIMICROB CHEMOTHER          12   175 983
    34   PERMIN H              J ANTIMICROB CHEMOTHER          12   313 983
    35   HEILESEN AM           SCAND J INFECT DIS              15   271 983
    36   SCHILLER NL           PEDIATR RES                     17   747 983
    37   MARESZBABCZYSZYN J    ARCH IMMUNOL THER EXP           31   199 983
    38   DORING G              INFECT IMMUN                    42   197 983
    39   LAM JS                INFECT IMMUN                    42    88 983
    40   BROOK I               EUR J RESPIR DIS                64    51 983
    41   DORING G              J INFECT DIS                   147   744 983
    42   CAPLAN DB             REV INFECT DIS                   6  S705 984
    43   SCHILLER NL           CURRENT MICROBIOL               10   185 984
    44   ANWAR H               FEMS MICROBIOL LETTERS          24   235 984
    45   EFTHIMIOU J           THORAX                          39   150 984
    46   MCNEILL WF            AM J CLIN PATHOL                81   742 984
    47   DORING G              ACTA PATH MICROB IMMU SCA (C)   92   307 984
    48   ISLES A               J PEDIATR                      104   206 984
    49   THOMASSEN MJ          J PEDIATR                      104   352 984
    50   LYNN AR               J BACTERIOL                    158  1161 984
    51   KLINGER KW            EUR J CLIN MICROBIOL             4   201 985
    52   ROE EA                BURNS                           11   252 985
    53   BRAUNER A             SCAND J INFECT DIS              17    63 985
    54   BAEK L                J CLIN MICROBIOL                22   229 985
    55   WARREN RL             ANTIMICROB AGENTS CHEMOTHER     27   468 985
    56   REYNOLDS HY           DISEASE A MONTH                 31     1 985
    57   LUZAR MA              INFECT IMMUN                    50   572 985
    58   LUZAR MA              INFECT IMMUN                    50   577 985
    59   WINKLER U             KLIN WSCHR                      63   490 985
    60   OJENIYI B             ACTA PATH MICROB IMMU SCA (B)   93     7 985
    61   THOMASSEN MJ          AM REV RESPIR DIS              131   791 985
    62   FICK RB               J INFECT DIS                   151   589 985
    63   ILYUKHIN VI           ZH MIKROBIO EPIDEMIO IMMUNOBI         88 986
    64   PADGETT PJ            CURRENT MICROBIOL               14   187 986
    65   PEDERSEN SS           SCAND J INFECT DIS              18   133 986
    66   FICK RB               PEDIATR RES                     20  1258 986
    67   BRETT MM              J CLIN PATHOL                   39  1124 986
    68   BRETT MM              ARCH DIS CHILD                  61  1114 986
    69   MOSS RB               AM REV RESPIR DIS              133   648 986
    70   WANG EEL              PEDIATR INFECT DIS J             6   256 987
    71   DASGUPTA MK           J CLIN IMMUNOL                   7    51 987
    72   HINDERSSON P          J GEN MICROBIOL                133   587 987

PN 77009
RN 00591 
AN 77178552
AU Holby-N.
TI Pseudomonas aeruginosa infection in cystic fibrosis.  Relative
   prevalence of antibodies in serum against cathodic and anodic
   migrating P. aeruginosa antigens determined by immunoelectrophoretic
   methods.
SO Acta-Pathol-Microbiol-Scand [C]. 1977 Apr. 85(2). P 149-52.
MJ CYSTIC-FIBROSIS: co.  PSEUDOMONAS-INFECTIONS: co.
MN ADOLESCENCE.  ADULT.  ANTIBODIES-BACTERIAL: an.
   ANTIGENIC-DETERMINANTS.  ANTIGENS-BACTERIAL: an.  CHILD.
   CHILD-PRESCHOOL.  COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: im.  FEMALE.
   HUMAN.  IMMUNOELECTROPHORESIS.
   IMMUNOELECTROPHORESIS-TWO-DIMENSIONAL.  INFANT.  MALE.
   PSEUDOMONAS-AERUGINOSA: im.  PSEUDOMONAS-INFECTIONS: im.
AB Sera from 119 patients with cystic fibrosis were examined for
   precipitating antibodies against anodic migrating P. aeruginosa
   antigens by means of crossed immunoelectrophoresis. The presence of
   precipitins against cathodic migrating P. aeruginosa antigens was
   investigated by means of classical immunoelectrophoresis. Thirty-six
   per cent of the sera contained precipitins against both anodic and
   cathodic antigens, 20% contained only precipitins against anodic
   antigens, none contained only precipitins against cathodic antigens,
   and 44% had no demonstrable P. aeurginosa precipitins. The amount of
   extra information obtained by combining the results of classical
   immunoelectrophoresis with the results of crossed
   immunoelectrophoresis was small.
RF 001   AXELSEN NH            SCAND J IMMUNOL                  5   177 976
   002   BURNS MW              LANCET                           1   270 968
   003   BURNS MW              MED J AUST                       2   697 972
   004   DIEM K                DOCUMENTA GEIGY SCIENTIFIC TA            962
   005   DOGGETT RG            INFECT IMMUN                     6   628 972
   006   GRABAR P              BIOCHIM BIOPHYS ACTA            10   193 953
   007   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   008   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   321 975
   009   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   433 975
   010   HOIBY N               SCAND J IMMUNOL SUPPL 2          4   187 975
   011   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   84   372 976
   013   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   85   142 977
   014   MAY JR                ARCH DIS CHILD                  47   908 972
   015   WEEKE B               SCAND J IMMUNOL SUPPL 1          2    15 973
CT   1   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     2   NEGASSI K             CLIN EXP IMMUNOL                38   135 979
     3   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (B)   87   329 979
     4   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (B)   87   337 979
     5   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   89   185 981
     6   EMMETT M              J IMMUNOL METH                  50  R 65 982
     7   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982

PN 77010
RN 00592 
AN 78057956
AU Reid-L.
TI Treatment of mucus hypersecretion in human disease.
SO Adv-Exp-Med-Biol. 1977. 89. P 469-76.
MJ BRONCHIAL-DISEASES: th.  MUCUS: se.
MN AIRWAY-OBSTRUCTION: me.  ATROPINE: tu.  BRONCHIAL-DISEASES: me.
   COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: th.  EXUDATES-AND-TRANSUDATES.
   GLYCOPROTEINS: an.  HUMAN.  SPUTUM: an.  SUPPURATION.  VISCOSITY.
EX Treatment of mucus hypersecretion in human disease should first be
   directed at prevention.  The hypersecretion of mucus, even in the
   absence of pus in the sputum or of other signs of infection, is of
   itself associated with significantly poor lung function.  Infection
   is probably the important stimulus in cystic fibrosis.  Certain
   anti-inflammatory agents are now known to cause retention of mucus
   within the secretory cells although the rate of synthesis is not
   raised.  It may be that this offers a new way of control.  On the
   other hand, the cells become larger and this may be undesirable.  I
   would prefer to see a study of the effect of drugs on the cellular
   stages of synthesis and discharge rather than concentration on
   mucolytic agents.
RF 001   BURGI H               MED THORAC                      21   156 964
   002   CHARMAN J             BIORHEOLOGY                     10   295 973
   003   GREGG I               PROC ASPEN EMPHYSEM CONF 9TH         235 968
   004   HILLIS BR             LANCET                           1  1230 952
   005   JONES R               BR J EXP PATHOL                 54   229 973
   006   KEAL EE               POSTGRAD MED J                  47   171 971
   007   LOPEZ-VIDRIERO MT     BULL PHYSIOPATH RESPIR NANCY     9   339 973
   008   LOPEZ-VIDRIERO MT     THORAX                          30   624 975
   009   LOPEZ-VIDRIERO MT     THORAX                          30   543 975
   010   MAY JR                IN: TAVERNER D                         6 968
   011   MILLER DL             AM REV RESPIR DIS               88   473 963
   012   REID L                BULL PHYSIOPATH RESPIR NANCY     9    15 973
   013   ROBERTS GP            ARCH BIOCHEM BIOPHYS           173   528 976
   014   STURGESS JM           CLIN SCI                        43   533 972
   015   WHITE JC              J PATHOL BACTERIOL              67   105 954

PN 77011
RN 00593 
AN 78057939
AU Mitchell-Heggs-P.
TI Physical properties of bronchial secretion.
SO Adv-Exp-Med-Biol. 1977. 89. P 203-15.
MJ BRONCHI: se.  SPUTUM.
MN ASTHMA: pa.  BRONCHIECTASIS: pa.  BRONCHITIS: pa.  COMPARATIVE-STUDY.
   CYSTIC-FIBROSIS: pa.  ELASTICITY.  HUMAN.  RHEOLOGY.  VISCOSITY.
EX The Weissenberg rheogoniometer is designed to estimate viscosity at
   a single applied shear.  By varying this shear, the associated
   detailed variation of viscosity may be studied.  The level of
   viscosity depends more on the macroscopic appearance of the sample
   than the disease with which it may be associated.  This has
   particular significance in relation to cystic fibrosis.  In cystic
   fibrosis, the sputum viscosity is not abnormally high.  It is not
   higher than that of macroscopically similar sputum from chronic
   bronchitis or asthma.  Whatever the feature differentiating cystic
   fibrosis from other diseases, it is not the viscosity of the sputum.
RF 001   AIACHE JM             POUMON COEUR                    26    35 970
   002   BAMBERG H             MED WELT                        37  1997 968
   003   BLANSHARD G           ARCH MIDDX HOSP                  5   222 955
   004   BRUCE RA              BR J CLIN PRACT                 22   289 968
   005   CHARMAN J             BIORHEOLOGY                      9   185 972
   006   DAVIS SS              BIORHEOLOGY                      6    11 969
   007   FEATHER EA            BR J DIS CHEST                  64   192 970
   008   GOLDFARB H            CLIN RES                        12   291 964
   009   KEAL EE               POUMON COEUR                    26    51 970
   010   KINGHORN FC           PHYS MED BIOL                   13   455 968
   011   LIEBERMAN J           AM REV RESPIR DIS               97   654 968
   012   MITCHELL-HEGGS PF     BULL PHYSIOPATH RESPIR NANCY     9   163 973
   013   MITCHELL-HEGGS PF     THESIS                                   974
   014   MITCHELL-HEGGS PF     PROC EUROP CONG RHEUM 7TH ABS            971
   015   MITCHELL-HEGGS PF     BIORHEOLOGY                     11   417 974
   016   PALMER KNV            BR J DIS CHEST                  64   185 970
   017   REID L                PROC ROY INST GR BR             43   438 970
   018   SHEFFNER AL           AM REV RESPIR DIS               90   721 964
   019   STRESEMANN E          KLIN WOCHENSCHR                 42  1165 964
   020   STURGESS JM           IN: LAWSON D PROC 5TH INT CF         368 969
   021   STURGESS JM           CLIN SCI                        38   145 970
CT   1   MARRIOTT C            THORAX                          33   545 978

PN 77012
RN 00594 
AN 78100225
AU Lheureux-P-R.  Isenberg-J-N.  Sharp-H-L.  Warwick-W-J.
TI Gallbladder disease in cystic fibrosis.
SO AJR. 1977 Jun. 128(6). P 953-6.
MJ CYSTIC-FIBROSIS: co.  GALLBLADDER-DISEASES: et.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CHOLELITHIASIS: et, ra.
   FEMALE.  GALLBLADDER-DISEASES: ra.  HUMAN.  INFANT.  MALE.
AB In 84 consecutive patients with cystic fibrosis, oral
   cholecystography was abnormal in 39 (46.4%). The incidence of
   abnormal cholecystograms increased with patient age. The 26 patients
   with a nonvisualized gallbladder following double-dosage oral
   cholecystography were evaluated with intravenous cholangiography; 19
   (70.3%) of these were abnormal. Ten patients were found to have
   calculi, an incidence of 11.9%. Awareness of the high incidence of
   cholecystographic abnormalities and calculi should be helpful in the
   evaluation of patients with cystic fibrosis, particularly since
   symptoms of abdominal pain are frequent in such patients and may lead
   to radiographic investigations.
RF 001   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   002   ESTERLY JR            BULL JOHNS HOPKINS HOSP        110   247 962
   003   FEIGELSON J           ACTA PAEDIATR SCAND             59   539 970
   004   SLOTH K               ACTA PAEDIATR SCAND             61   380 972
   005   VILLA-VENZANO G       RAD MED FAK ZAGREBU             47   747 961
   006   MACARINI N            CONG NAZIONALE DI RADIOLOGIA             968
   007   FEIGELSON J           JOURNEES PARISIENNES PEDIATR          77 969
   008   VICHI GF              FRACASTORO (VERONA)             63   366 970
   009   ROVSING H             ACTA RADIOL DIAGN STOCKH        14   588 973
   010   FEIGELSON J           MED CHIR DIG                     4   121 975
   011   JONES MD              J PEDIATR                       53   172 958
   012   WOOD RE               AM REV RESPIR DIS              113   833 976
   013   WARWICK WJ            J CHRON DIS                     28   609 975
   014   POGUE RE              MINN MED                        52   279 969
   015   NEWMAN DE             PEDIATR RADIOL                   1   100 973
   016   ZIMMERMAN HJ          IN: BECKER FF                    5   225 974
   017   WEBER AM              N ENGL J MED                   289  1001 973
   018   GOODCHILD MC          PROC EWGCF 5TH ANNU MTG                  974
   019   BENNION LJ            N ENGL J MED                   294   189 976
   020   BAKER HL JR           RADIOLOGY                       74   239 960
   021   MUJAHED Z             RADIOLOGY                      112     1 974
   022   WISE RE               RADIOL CLIN NORTH AM             4   521 966
   023   BARTURM RJ            JAMA                           236  1147 976
   024   LAPEY A               J PEDIATR                       84   328 974
   025   ISENBERG JN           AM J GASTROENTEROL              65   134 976
CT   1   PARK RW               GASTROENTEROLOGY                81  1143 981
     2   TABACHNIK NF          SURG GYNECOL OBSTET            152   837 981
     3   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
     4   ISDALE JM             S AFR MED J                     62   160 982
     5   ABDULKARIM FW         GASTROENTEROLOGY                82   758 982
     6   HENSCHKE CI           J ULTRASOUND MED                 2   481 983
     7   KRAMER NR             J CAN ASSOC RADIOL              34   271 983
     8   BASS S                GASTROENTEROLOGY                84  1592 983
     9   FITZPATRICK SB        CHEST                           86   863 984
    10   HUBBARD VS            SEM RESPIR MED                   6   299 985
    11   STERN RC              J PEDIATR GASTROENTEROL NUTR     5    35 986

PN 77013
RN 00595 
AN 78142570
AU Patredis-K.
TI An evaluation of the sensory integrative development of young
   children with cystic fibrosis.
SO Ala-J-Med-Sci. 1977 Oct. 14(4). P 437.
MJ CHILD-DEVELOPMENT.  CYSTIC-FIBROSIS: px.
MN CHILD.  CHILD-PRESCHOOL.  HUMAN.  SENSATION.
EX Studies have shown that children with chronic illnesses are more
   prone to develop secondary handicaps in the areas of educational
   achievement, behavior, and psychological maladjustment than are
   'normal' children.  Besides his physical symptoms, the child with a
   chronic illness must endure prolonged hospitalization, psychological
   stresses, decreased activity, and is often denied opportunity for
   skill practice and peer group activities.  All these factors result
   in an overall decrease in sensory stimulation which could impair
   perceptual-motor functioning as well as the child's ability to
   successfully adapt to his disease.  Therefore, the purpose of this
   research was to obtain a general idea of the perceptual-motor or
   sensory integrative development of children with CF, to determine if
   there is, in fact, a need for sensory integrative treatment in the
   care of these children.

PN 77014
RN 00596 
AN 77109030
AU Andorsky-M.  Finley-A.  Davidson-M.
TI Pediatric gastroenterology 1/1/69-12/31/75: a review.  Part I.
   Hollow viscera and the pancreas.
SO Am-J-Dig-Dis. 1977 Jan. 22(1). P 56-68. (REVIEW).
MJ GASTROINTESTINAL-DISEASES.
MN ABDOMINAL-WALL: ab.  ADOLESCENCE.  ADULT.  ANIMAL.  ANUS: ab.
   CELIAC-DISEASE: di.  CHILD.  CHILD-PRESCHOOL.  COLONIC-DISEASES: co.
   CONSTIPATION.  CYSTIC-FIBROSIS: di.  DIARRHEA-INFANTILE: mi.
   ENTEROCOLITIS-PSEUDOMEMBRANOUS.  ESOPHAGEAL-ATRESIA: su.
   FOOD-HYPERSENSITIVITY: di.  HEMORRHAGE-GASTROINTESTINAL: et.
   HERNIA-HIATAL: su.  HUMAN.  INFANT.  INFANT-NEWBORN.
   INTESTINAL-POLYPS.  LYMPHANGIECTASIS-INTESTINAL.
   MALABSORPTION-SYNDROMES.  MEGACOLON: et.  PANCREATITIS: et.
   PARENTERAL-HYPERALIMENTATION: ae.  PEPTIC-ULCER.
   PYLORIC-STENOSIS: su.  RECTUM: ab.  REVIEW.
EX Cumulative survival in cystic fibrosis (CF) for three successive
   5-year periods between 1952 and 1967 is 35%, 64%, and 77%,
   respectively.  Operative mortality in meconium ileus is not reduced
   to 25% from 70%.  N-Acetylcysteine effectively cleanses the bowel of
   tenacious meconium plugs when directly injected during laparotomy.
   However, Mucomist enema alone generally does not suffice.  Selected
   cases have been treated successfully with hyperosmolar Gastrograffin
   enema.  Several screening tests, based on the increased albumin
   concentrations present in the meconium, are available for CF.  The
   Boehringer-Mannheim test strip is favored, and yielded no false
   positives in 69,000 tests of meconium.  However, 4 of 60 neonates
   who subsequently proved to have CF had false negative tests.  A
   pathognomonic elevation of sodium and chloride concentrations in the
   sweat collected by pilocarpine iontophoresis remains the definitive
   diagnostic test.  Bile acid malabsorption occurs in CF but not in
   celiac disease.  The authors postulate that the presence of
   maldigested materials or the absence of pancreatic enzymes
   interferes with bile acid absorption.  The defect disappears with
   pancreatic extracts.  Substitution of medium-chain triglycerides for
   dietary long-chain fatty acids reduces steatorrhea in CF.  However,
   the positive effect of MCT on weight gain is transitory.  Growth
   retardation correlates better with the degree of pulmonary disease
   than with pancreatic insufficiency.
RF 001   SILVERBERG M          GASTROENTEROLOGY                58   229 970
   002   SILVERMAN A           PEDIATR CLIN GASTROENTEROL               971
   002   ROY CC                PEDIATR CLIN GASTROENTEROL               975
   003   ANDERSON CM           PEDIATRIC GASTROENTEROLOGY               975
   004   GRYBOSKI J            MAJ PROB CLIN PEDIATR           13   450 975
   005   MICHENER WM           PEDIATR CLIN NORTH AM           14   159 967
   006   GRAND RJ              PEDIATR CLIN NORTH AM           22       975
   007   GRAND RJ              GASTROENTEROLOGY                70   790 976
   008   HENDREN WH            N ENGL J MED                   289   456 973
   009   LOUW JH               LANCET                           2  1065 955
   010   FAVARA BE             AM J DIS CHILD                 122   501 971
   011   STEVENSON RE          J PEDIATR                       81  1123 972
   012   KOOP CE               PEDIATRICS                      54   558 974
   013   HOFMANN S             J PEDIATR SURG                  11   257 976
   014   MAHOUR GH             J PEDIATR SURG                   9   373 974
   015   PIERETTI R            J PEDIATR SURG                   9   355 974
   016   GROTTE G              ACTA PAEDIATR SCAND             60    59 970
   017   LOUHIMO I             J PEDIATR SURG                   4   663 969
   018   SCHARLI A             J PEDIATR SURG                   4   108 969
   019$  HUGUENARD JR          J PEDIATR                        8    45 972
   020   SHIM WKT              J PEDIATR                       76    89 970
   021   STEPHENS FD           SURG CLIN NORTH AM              50   919 970
   022   SANTULLI TV           J PEDIATR SURG                   5   281 970
   023   TAYLOR I              J PEDIATR SURG                   8   497 973
   024   ARHAN P               J PEDIATR SURG                  11   157 976
   025   KERREMANS RPJ         AM J DIS CHILD                 128   811 974
   026   HOLLABAUGH RS         J PEDIATR SURG                   8   263 973
   027   WESSELHOEFT CW        PEDIATRICS                      44   101 969
   028   FRIEDLAND GW          AM J ROENTG RAD THER NUCL MED  120   305 974
   029   DARLING DB            PEDIATRICS                      54   450 974
   030   CARCASSONNE M         J PEDIATR SURG                   8   575 973
   031   CARRE IJ              ARCH DIS CHILD                  34   344 959
   032   CARRE IJ              ACTA PAEDIATR SCAND             61   492 972
   033   PRINSEN JE            J PEDIATR SURG                  10    97 975
   034   RANDOLPH JG           ANN SURG                       180   479 974
   035   JEWETT TC JR          J PEDIATR SURG                  10   757 975
   036   WOODWARD ER           ANN SURG                       173   782 971
   037   SEAGRAM CGF           J PEDIATR SURG                   8   407 973
   039   RAVITCH MM            ANN SURG                       171   641 970
   040   TSUCHIDA Y            J PEDIATR SURG                   9   499 974
   041   SPENCER R             SURGERY                         55   718 964
   042   COLLINS REC           ARCH DIS CHILD                  46   110 971
   043   GLEASON WA JR         J PEDIATR                       85   810 974
   044   AMENT ME              GASTROENTEROLOGY                68   858 975
   045   ROSENTHALL L          RADIOLOGY                      105   371 972
   046   LEONIDAS JC           ARCH DIS CHILD                  49    21 974
   047   JAROS R               J PEDIATR                       82    42 973
   048   SILVERBERG SG         AM J DIG DIS                    15   617 970
   049   SACHATELLO CR         GASTROENTEROLOGY                58   699 970
   050   RUYMANN FB            GASTROENTEROLOGY                57   431 969
   051   BUSSEY HJR            GUT                             11   970 970
   052   COLI RD               AM J DIG DIS                    15   551 970
   053   DONALDSON MH          PEDIATRICS                      48   307 971
   054   LOEHR WJ              ANN SURG                       170   232 969
   055   SWENSON O             J PEDIATR SURG                   8   587 973
   056   EARLAM RJ             AM J DIG DIS                    17   255 972
   057   NIXON HH              ARCH DIS CHILD                  41   147 966
   058   TOULOUKIAN RJ         J PEDIATR SURG                   8   191 973
   059   SUSTER G              AM J DIS CHILD                 119   494 970
   060   EHRENPREIS T          AM J DIG DIS                    16  1032 971
   061   SHERRY SN             J PEDIATR                       46   158 955
   062   CAMPBELL PE           J PEDIATR SURG                   4   410 969
   063   USTACH TJ             ARCH DIS CHILD                  44   694 969
   064   VERDER H              ACTA PAEDIATR SCAND             62    59 973
   065   HOLSCHNEIDER AM       J PEDIATR SURG                  11   151 976
   066   WILCOX MW             J PEDIATR SURG                   7   168 972
   067   APLEY J               CHILD WITH ABDOMINAL PAIN                975
   068   APLEY J               BR MED J                         3     7 973
   069   OSTER J               PEDIATRICS                      50   429 972
   070   BAYLESS TM            PEDIATRICS                      47  1029 971
   071   DOUGLAS EF            J PEDIATR                       78    59 971
   072   BAKWIN H              AM J DIS CHILD                 121   179 971
   073   LEVINE MD             PEDIATRICS                      56   412 975
   074   OLATAWURA MO          ACTA PAEDIATR SCAND             62   358 973
   075   DAVIDSON M            J PEDIATR                       62   261 963
   076   BELLMAN M             ACTA PAEDIATR SCAND SUPPL      170     1 966
   077   BACKLOW NR            ANN INTERN MED                  76   993 972
   078   BISHOP RF             LANCET                           2  1281 973
   079   FLEWETT TH            LANCET                           2    61 974
   080   SCHREIBER DS          N ENGL J MED                   288  1318 973
   081   BISHOP RF             LANCET                           1   149 974
   082   SOUTH MA              J PEDIATR                       79     1 971
   083   GRADY GF              N ENGL J MED                   285   891 971
   084   DUPONT HL             N ENGL J MED                   285     1 971
   085   MERSON MH             N ENGL J MED                   294  1299 976
   086   SMITH HW              J MED MICROBIOL                  3   403 970
   087   MCCRACKEN GH JR       J PEDIATR                       75   923 969
   088   CARPENTER CCJ         J PEDIATR                       80   874 972
   089   GOLDMAN AS            J PEDIATR                       82  1082 973
   090   GINDRAT JJ            ACTA PAEDIATR SCAND             61   587 972
   091   GRADY GF              N ENGL J MED                   285   831 971
   092   SMITH ER              CAN MED ASSOC J                104  1004 971
   093   KAZEMI M              J PEDIATR                       83   646 973
   094   BERGSTRAND CG         ACTA PAEDIATR SCAND             63   875 974
   095   BRADFORD WD           ARCH PATHOL                     98    17 974
   096   EGAN-MITCHELL B       ARCH DIS CHILD                  47   238 972
   097   HAMILTON JR           Q J MED                         38   135 969
   098   MYLOTTE M             Q J MED                         43   359 974
   099   YOUNG WF              ARCH DIS CHILD                  46   421 971
   100   VISAKORPI JK          ACTA PAEDIATR SCAND             59   481 970
   101   WALKER WA             J PEDIATR                       83   711 973
   102   HOBBS JR              LANCET                           2   649 969
   103   SHINER M              GUT                             14     1 973
   104   JULIUS R              J PEDIATR                       83  1007 973
   105   MOYNAHAN EJ           LANCET                           2   399 974
   106   KAYDEN HJ             J PEDIATR                       83   993 973
   107   ROBERTSON AF          PEDIATRICS                      55   783 975
   108   PITTMAN FE            PEDIATRICS                      54    81 974
   109   VARDY PA              PEDIATRICS                      55   842 975
   110   AMIRHAKIMI GH         AM J DIS CHILD                 117   178 969
   111   GRACEY M              ARCH DIS CHILD                  45   445 970
   112   GERRARD JW            ACTA PAEDIATR SCAND SUPPL      234     1 973
   113   SHINER M              LANCET                           1   136 975
   114   KUITUNEN P            ACTA PAEDIATR SCAND             62   585 973
   115   FREIER S              J PEDIATR                       75   623 969
   116   GOLDMAN AS            PEDIATRICS                      32   425 963
   117   KUITUNEN P            ARCH DIS CHILD                  50   351 975
   118   FREIER S              LANCET                           1   913 973
   119   DAVIDSON AG           PEDIATRICS                      46   632 970
   120   SOEPARTO P            ARCH DIS CHILD                  47    56 972
   121   NEWCOMER AD           GASTROENTEROLOGY                50   340 966
   122   KEIFFER JM            PEDIATRICS                      56   718 975
   123   METZ G                LANCET                           1  1155 975
   124   RODRIGUIZ DE CURET H  GASTROENTEROLOGY                59   396 970
   125   LIFSHITZ F            J PEDIATR                       79   760 971
   126   RANSOME-KUTI O        GASTROENTEROLOGY                68   431 975
   127   SAHI T                ACTA PAEDIATR SCAND             61    11 972
   128   HABTE D               ACTA PAEDIATR SCAND             62   649 973
   129   MEEUWISSE GW          ACTA PAEDIATR SCAND SUPPL      188       969
   130   TORRES-PINEDO R       J CLIN INVEST                   45  1916 966
   131   LIFSHITZ F            J PEDIATR                       77   595 970
   132   HIRSCHHORN N          J PEDIATR                       83   562 973
   133   HUANG NN              AM J DIS CHILD                 120   289 970
   134   GEORGE L              ARCH DIS CHILD                  46   139 971
   135   SHAW A                J PEDIATR SURG                   4   119 969
   136   NOBLETT HR            J PEDIATR SURG                   4   190 969
   137   STEPHAN U             PEDIATRICS                      55    35 975
   138   ANON                  J PEDIATR                       88   711 976
   139   WEBER AM              N ENGL J MED                   289  1001 973
   140   GRACEY M              ARCH DIS CHILD                  44   401 969
   141   LAPEY A               J PEDIATR                       84   328 974
   142   SIBERT JR             ARCH DIS CHILD                  50   443 975
   143   MALONE JI             J PEDIATR                       85   825 974
   144   RIEMENSCHNEIDER TA    PEDIATRICS                      41   428 968
   145   PENA SDJ              J PEDIATR                       83  1026 973
   146   ATTARD J              BR J SURG                       56   235 969
   147   BONGIOVI JJ           J PEDIATR SURG                   4   220 969
   148   KATTWINKEL J          PEDIATRICS                      51    55 973
   149   MCELROY R             AM J MED                        52   228 972
   150   FARMER RG             AM J MED                        54   161 973
   151   SHWACHMAN H           PEDIATRICS                      55    86 975
   152   DI SANTAGNESE PA      GASTROENTEROLOGY                40    64 961
   153   DAVIDSON I            CLIN DIAG LAB METHODS                870 974
   154   TAUSSIG LM            PEDIATRICS                      54   229 974
   155   FILLER RM             N ENGL J MED                   281   589 969
   156   WILMORE DW            J PEDIATR SURG                   4   181 969
   157   WILMORE DW            J PEDIATR                       80    88 972
   158   BELL MJ               J PEDIATR SURG                   8   197 973
   159   WINICK M              J PEDIATR                       74   667 969
   160   HEIRD WC              J PEDIATR                       86     2 975
   161   PEDEN VH              J PEDIATR                       81   137 972
   162   AVERY GB              PEDIATRICS                      41   712 968
   163   LLOYD-STILL JD        AM J DIS CHILD                 125   358 973
   164   FISCHER JE            AM J SURG                      125   165 973
   165   HEIRD WC              J PEDIATR                       80   351 972
   166   GHADIMI H             PEDIATRICS                      48   955 971
   167   HEIRD WC              J PEDIATR                       81   162 972
   168   COHEN MI              IN: WINTERS RW                       293 975
   169   ROGER R               J PEDIATR                       86   264 975
   170   TOULOUKIAN RJ         J PEDIATR                       86   270 975
   171   ASCH MJ               J PEDIATR SURG                   7   213 972
   172   CORAN AG              J PEDIATR SURG                   8   801 973
   173   GUSTAFSON A           ACTA PAEDIATR SCAND             63   177 974
   174   WHITE HB              J PEDIATR                       83   490 973
   175   PEDEN VH              J PEDIATR                       83   305 973
   176   FRANTZ ID 3RD         J PEDIATR                       86   259 975
   177   SANTULLI TV           PEDIATRICS                      55   376 975
   178   HOPKINS GB            AM J DIS CHILD                 120   229 970
   179   BOOK LS               PEDIATR RES ABST                 8   379 974
   180   TORMA MJ              AM J SURG                      126   758 973
   181   JOSHI W               AM J DIS CHILD                 126   113 973
   182   STEIN H               BR MED J                         2   616 972
   183   PITT J                PEDIATR RES                      8   384 974
   184   ENGEL RR              PEDIATR RES                      7   292 973
   185   BELL MJ               J PEDIATR SURG                   8   601 973
   186   KRASNA IH             J PEDIATR SURG                   8   615 973
   187   KRASNA IH             J PEDIATR SURG                   5   200 970
   188   EHRENPREIS TH         ACTA PAEDIATR SCAND             60   209 971
   189   AMENT ME              J PEDIATR                       86   322 975
   190   BINDER V              SCAND J GASTROENTEROL            8   161 973
   191   MILLER RC             AM J DIS CHILD                 122   301 971
   192   LINDSLEY CB           J PEDIATR                       84    16 974
   193   DEVROEDE GJ           N ENGL J MED                   285    17 971
   194   TRUELOVE SC           N ENGL J MED                   285    50 971
   195   WEEDON DD             N ENGL J MED                   289  1099 973
   196   MCCAFFERY TD          PEDIATRICS                      45   386 970
   197   GOTLIN RW             GUT                             14   191 973
   198   MCCAFFERY TD          PEDIATRICS                      45   386 970
   199   SADEGHI NEJAD A       PEDIATRICS                      43   870 969
   200   DAVIDSON M            IN: KIRSNER JB                       312 975
   201   GUTTMAN FM            J PEDIATR SURG                   9   115 974
   202   HARRIS BH             J PEDIATR SURG                   9   301 974
   203   DE DOMBAL FT          GUT                             12   519 971
   204   STAHLGREN LH          JAMA                           175   986 961
   205   LEVINE AM             J PEDIATR SURG                   9   715 974

PN 77015
RN 00597 
AN 77131731
AU Gewitz-M.  Eshaghpour-E.  Holsclaw-D-S.  Miller-H-A.  Kawai-N.
TI Echocardiography in cystic fibrosis.
SO Am-J-Dis-Child. 1977 Mar. 131(3). P 275-80.
MJ CYSTIC-FIBROSIS: co.  ECHOCARDIOGRAPHY.
   PULMONARY-HEART-DISEASE: di.
MN ADOLESCENCE.  ADULT.  CHILD.  COMPARATIVE-STUDY.
   ELECTROCARDIOGRAPHY.  HUMAN.  PULMONARY-HEART-DISEASE: et.
   RESPIRATORY-FUNCTION-TESTS.  VECTORCARDIOGRAPHY.
AB Echocardiograms were obtained for 25 patients with cystic fibrosis
   (CF) and 20 controls to evaluate this technique as a means of
   assessment of right ventricular changes in patients with CF. Right
   ventricular anterior wall thickness per square meter of body surface
   (RVAW/sq m) and right ventricular internal dimension per square meter
   of body surface (RVID/sq m) were compared with other techniques for
   detection of cor pulmonale. Significant correlations existed between
   both RVAW/sq m and RVID/sq m and the forced vital capacity, forced
   expiratory volume in one second, midmaximal expiratory flow rate,
   clinical score of severity of disease, and roentgenographic score of
   pulmonary involvement. The RVAW/sq m was slightly more sensitive than
   RVID/sq m; RVAW/sq m thickness on echocardiogram in vivo compared
   well with actual measurements at autopsy in five patients. No
   correlations were found between echocardiography and
   electrocardiograms, vectorcardiograms, thoracic index, or
   cardiothoracic ratio.
RF 001   ROYCE SW              PEDIATRICS                       8   255 951
   002   GOLDRING RM           J PEDIATR                       65   501 964
   003   MOSS AJ               MOD PROBL PEDIATR               10   187 967
   004   SIASSI B              J PEDIATR                       78   794 971
   005   LIEBMAN J             CIRCULATION                     35   552 967
   006   LIEBMAN J             CHEST                           63   218 973
   007   POPP RL               AM J CARDIOL                    24   523 969
   008   DIXON WJ              INTRO STATISTICAL ANALYSIS           204 969
   009   MOSS AJ               PRACT PEDIATRIC ELECTROCARDIO         58 973
   010   SIMON G               ARCH DIS CHILD                  47   373 972
   011   WARING WW             THORACIC DEPTH WIDTH CHARTS                 
   012   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   013   EPSTEIN ML            CIRCULATION                     51  1124 975
   014   MEYER RA              PROG CARDIOVASC DIS             15   341 973
   015   HAGAN AD              CIRCULATION                     48  1221 973
   016   GRAMIAK R             RADIOLOGY                       92   939 969
   017   LUNDSTROM NR          ACTA PAEDIATR SCAND SUPPL      243       974
   018   MEYER RA              AM J CARDIOL                    30   349 972
   019   TAJIK AJ              CIRCULATION                     46    36 972
   020   MEYER RA              PEDIATRICS                      54   266 974
   021   MASON DT              PROG CARDIOVASC DIS             12   507 970
CT   1   NUSSBAUM E            J PEDIATR                       93   931 978
     2   NEWTH CJL             THORAX                          34   428 979
     3   ALLEN HD              CHEST                           75   428 979
     4   HIRSCHFELD SS         CHEST                           75   351 979
     5   CHIPPS BE             J PEDIATR                       95   379 979
     6   TSUDA T               BR HEART J                      44    55 980
     7   MORIN DP              PEDIATRICS                      65    44 980
     8   LESTER LA             J PEDIATR                       97   742 980
     9   FOWLER RS             J ELECTROCARDIOL                14   319 981
    10   JACOBSTEIN MD         CHEST                           80   399 981
    11   NEWTH CJL             AM REV RESPIR DIS              124   463 981
    12   MOSS AJ               PEDIATRICS                      70   728 982
    13   COATES AL             CHEST                           82   543 982
    14   CHERON G              ACTA PAEDIATR SCAND             73   697 984
    15   MOSKOWITZ WB          PEDIATR PHARMACOL                5   139 985
    16   LESTER LA             SEM RESPIR MED                   6   285 985
    17   PANIDIS IP            J AM COLL CARDIOL                6   701 985

PN 77016
RN 00598 
AN 77239487
AU Ristow-S-C.  Condemi-J-J.  Stuard-I-D.  Schwartz-R-H.  Bryson-M-F.
TI Systemic amyloidosis in cystic fibrosis.
SO Am-J-Dis-Child. 1977 Aug. 131(8). P 886-8.
MJ AMYLOIDOSIS: co.  CYSTIC-FIBROSIS: co.
MN ADULT.  AMYLOIDOSIS: fg.  CASE-REPORT.  CYSTIC-FIBROSIS: fg.  FEMALE.
   HUMAN.  MALE.  SUPPORT-U-S-GOVT-P-H-S.
AB We report two siblings with cystic fibrosis and systemic amyloidosis.
   The major clinical problem in both cases was recurrent respiratory
   infection with pulmonary fibrosis and bronchiectasis prior to death
   at ages 20 and 22 years. Findings from postmortem examinations
   disclosed diffuse amyloidosis. In addition, amyloid infiltration
   developed in both patients, with enlargement of the thyroid gland,
   and one required thyroidectomy. An autopsy review of 17 additional
   cases of cystic fibrosis failed to disclose any other instances of
   systemic amyloidosis.
RF 001   BRIGGS GW             ANN INTERN MED                  55   953 961
   002   COHEN AS              N ENGL J MED                   277   522 967
   003   BRANDT K              AM J MED                        44   955 968
   004   BROWNSTEIN MH         SOUTH MED J                     64   491 971
   005   KYLE RA               MEDICINE (BALTIMORE)            54   271 975
   006   MISSMAHL HP           FORTSCHR MED                    85   621 967
   007   EHRLICH JC            AM J PATHOL                     38    49 961
   008   COOPER JH             J CLIN PATHOL                   22   410 969
   009   AUERBACH O            ARCH INTERN MED                 74   244 944
   010   WALD MH               ANN INTERN MED                  43   383 955
   011   WIMAN L               SCAND J RESPIR DIS              55     5 974
   012   AREAN VM              J CLIN PATHOL                   36   341 961
   013   SHAPIRO ST            ARCH OTOLARYNGOL                93   203 971
   014   JAMES PD              J CLIN PATHOL                   25   683 972
   015   KENNEDY JS            Q J MED                         43   127 974
   016   LANDING BH            ANN NY ACAD SCI                 93   518 962
CT   1   PRIOR J               BR J DIS CHEST                  74    84 980
     2   KYLE RA               INT J DERMATOL                  20    75 981
     3   VILASECA J            AM J DIS CHILD                 135   667 981
     4   MARHAUG G             ACTA PAEDIATR SCAND             72   861 983
     5   BIBERSTEIN M          AM J CLIN PATHOL                80   752 983
     6   MICHALSEN H           EUR J RESPIR DIS                66   306 985
     7   CANCIANI M            ACTA PAEDIATR SCAND             74   613 985
     8   CASTILE R             AM J DIS CHILD                 139   728 985
     9   KIRSCHNER BS          J PEDIATR GASTROENTEROL NUTR     5   816 986
    10   RUSH PJ               SEM ARTHRITIS RHEUM             15   213 986
    11   TRAVIS WD             AM J CLIN PATHOL                85   419 986
    12   MCGLENNEN RC          ARCH PATHOL LAB MED            110   879 986

PN 77017
RN 00599 
AN 77264053
AU Orenstein-D-M.  Boat-T-F.  Stern-R-C.  Tucker-A-S.  Charnock-E-L.
   Matthews-L-W.  Doershuk-C-F.
TI The effect of early diagnosis and treatment in cystic fibrosis: a
   seven-year study of 16 sibling pairs.
SO Am-J-Dis-Child. 1977 Sep. 131(9). P 973-5.
MJ CYSTIC-FIBROSIS: di, th.
MN CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: fg.
   EXPIRATORY-RESERVE-VOLUME.  FEMALE.  HUMAN.  INFANT.  LUNG: pp.
   MALE.  PROGNOSIS.  RESIDUAL-VOLUME.  THORACIC-RADIOGRAPHY.
   TOTAL-LUNG-CAPACITY.  SUPPORT-U-S-GOVT-P-H-S.
AB Data on 16 sibling pairs with cystic fibrosis were analyzed to test
   the hypothesis that early treatment of this condition improves
   prognosis. Younger siblings' conditions were diagnosed before 1 year
   of age, usually before the onset of pulmonary disease. Older
   siblings' conditions were diagnosed after 1 year of age and after the
   onset of pulmonary disease. Although the sibling pairs received
   similar treatment, comparison at 7 years of age showed that the
   younger siblings had significantly better chest roentgenogram scores,
   total clinical scores, residual lung volumes, and ratios of residual
   volume to total lung volume. Younger siblings also required fewer
   hospital admissions to control their lung disease. The results
   suggest that, in general, early initiation of therapy is beneficial
   for patients with cystic fibrosis.
RF 001   WARWICK WJ            IN: LAWSON D PROC 5TH INT CF         320 969
   002   GEORGE L              ARCH DIS CHILD                  46   139 971
   003   HUANG NN              AM J DIS CHILD                 120   289 970
   004   SHWACHMAN H           PEDIATRICS                      46   335 970
   005   DOERSHUK CF           PEDIATRICS                      36   675 965
   006   GELLIS SS             YEARBOOK OF PEDIATRICS               164 976
   007   MATTHEWS LW           J PEDIATR                       65   558 964
   008   MATTHEWS LW           IN: MANGOS JA                        303 973
   009   DOERSHUK CF           J PEDIATR                       65   677 964
   010   HELLIESEN PJ          PEDIATRICS                      22    80 958
   011   DUBOIS AB             J CLIN INVEST                   35   322 956
   012   LEVISON H             IN: MANGOS JA                          3 976
   013   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   014   LAPEY A               J PEDIATR                       84   328 974
CT   1   SCHWARZ HP            HELV PAEDIATR ACTA              33   351 978
     2   PHELAN PD             MED J AUST                       1   261 979
     3   GURWITZ D             PEDIATR CLIN NORTH AM           26   603 979
     4   RYLEY HC              ARCH DIS CHILD                  54    92 979
     5   SANTAGNESE PAD        AM J MED                        66   121 979
     6   WOOD RE               SOUTH MED J                     72   189 979
     7   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     8   KRAEMER R             SCHWEIZ MED WOCHENSCHR         109    39 979
     9   TRAVERT G             J GENET HUM                     28   141 980
    10   WARWICK WJ            J CHRON DIS                     33   685 980
    11   LITTLEWOOD JM         PRACTITIONER                   224   305 980
    12   ROMEO G               RIV ITAL PEDIATR                 7   201 981
    13   TRAVERT G             NOUV PRESSE MED                 10  2093 981
    14   EVANS RT              J CLIN PATHOL                   34   911 981
    15   CONGDEN PJ            ARCH DIS CHILD                  56   708 981
    16   SCHONI M              SCHWEIZ MED WOCHENSCHR         111   658 981
    17   CROSSLEY JR           CLIN CHIM ACTA                 113   111 981
    18   GITZELMANN R          HELV PAEDIATR ACTA              36   493 982
    19   PHELAN PD             ARCH DIS CHILD                  57   779 982
    20   HELLSING K            ACTA PAEDIATR SCAND             71   827 982
    21   STERN RC              GASTROENTEROLOGY                82   707 982
    22   TUMMLER B             MONATSSCHR KINDERHEILKD        130   157 982
    23   FRATES RC             AM J DIS CHILD                 136   279 982
    24   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
    25   ORENSTEIN DM          JAMA                           248  2113 982
    26   ROSENSTEIN BJ         JAMA                           248  2113 982
    27   KOLLBERG H            ACTA PAEDIATR SCAND SUPPL 301 1982    15 982
    28   PEDERZINI F           RIV ITAL PEDIATR                 9   445 983
    29   TRAVERT G             ARCH FR PEDIATR                 40   295 983
    30   ANON                  PEDIATRICS                      72   741 983
    31   WILCKEN B             J PEDIATR                      102   383 983
    32   GROBE H               MONATSSCHR KINDERHEILKD        131   806 983
    33   POSSELT HG            ATEMWEGS LUNGENKRANKH           10   345 984
    34   BLYTHE SA             CLIN BIOCHEM                    17   277 984
    35   MATTHEWS LW           PEDIATR CLIN NORTH AM           31   133 984
    36   LEWIS MI              S AFR MED J                     65   641 984
    37   CASSIO A              ACTA PAEDIATR SCAND             73   554 984
    38   FARRELL PM            PEDIATRICS                      73   115 984
    39   REARDON MC            J PEDIATR                      105   271 984
    40   ORENSTEIN DM          SEM RESPIR MED                   6   252 985
    41   NAYLOR EW             SEM PERINATOL                    9   232 985
    42   BERKIN KE             EUR J RESPIR DIS                67   103 985
    43   GRUTTNER R            MONATSSCHR KINDERHEILKD        133    54 985
    44   ABMAN SH              J PEDIATR GASTROENTEROL NUTR     5   393 986
    45   MAHANEY MC            ARCH ORAL BIOL                  31   363 986
    46   DUHAMEL JF            ARCH FR PEDIATR                 43   229 986
    47   DANKERTROELSE JE      ACTA PAEDIATR SCAND             76   209 987

PN 77018
RN 00600 
AN 77108964
AU Bruns-W-T.  Connell-T-R.  Lacey-J-A.  Whisler-K-E.
TI Test strip meconium screening for cystic fibrosis.
SO Am-J-Dis-Child. 1977 Jan. 131(1). P 71-3.
MJ CYSTIC-FIBROSIS: di.  INDICATORS-AND-REAGENTS.  MASS-SCREENING.
   MECONIUM: an.  PHENOLPHTHALEINS: du.  REAGENT-STRIPS.
MN ALBUMINS: an.  FALSE-NEGATIVE-REACTIONS.  FALSE-POSITIVE-REACTIONS.
   FEMALE.  HUMAN.  INFANT-NEWBORN.  SWEAT: an.  WISCONSIN.
AB The Boehringer-Mannheim Corporation (BMC) strip test is extremely
   reliable in indicating an albumin content above 20 mg/gm of dried
   meconium. All infants born during one year in 14 Milwaukee area
   hospitals were tested. Of 16,224 newborns, two were diagnosed
   correctly as suffering from cystic fibrosis and two were missed.
   False-positive tests were obtained in 0.9% of infants (prematurity,
   melena, gastroschisis, and intrauterine infection). The strip test
   is, at present, the best available but not the perfect screening
   method for cystic fibrosis.
RF 001   GREEN MN              PEDIATRICS                      41   989 968
   002   STEPHAN U             PADIATRISCHE PRAXIS             12   487 973
   003   PROSSER R             ARCH DIS CHILD                  49   597 974
   004   STEPHAN U             PEDIATRICS                      55    35 975
   005   KAISER D              HELV PAEDIATR ACTA              29    51 974
   006   KOLLBERG H            ARCH DIS CHILD                  47   836 972
   007   HELLSING K            SCAND J CLIN LAB INVEST         33   333 974
   008   FRANKENBURG WK        PEDIATRICS                      54   612 974
   009   NORTH AF JR           PEDIATRICS                      54   631 974
   010   DI SANTAGNESE PA      PEDIATRICS                      15   683 955
   011   HOLTZMAN NA           J PUBLIC HEALTH                 64   775 974
   012   HOLTZMAN NA           JAMA                           229   667 974
CT   1   BRUNS WT              AM J DIS CHILD                 131   853 977
     2   RYLEY HC              MONOGR PAEDIATR                 10   151 979
     3   TRAVERT G             J GENET HUM                     28   141 980
     4   TRAVERT G             NOUV PRESSE MED                 10  2093 981
     5   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982

PN 77019
RN 00601 
AN 78078190
AU Colon-A-R.
TI Hepatic steatosis in children.
SO Am-J-Gastroenterol. 1977. 68(3). P 260-9. (REVIEW).
MJ FATTY-LIVER.
MN ADOLESCENCE.  AFLATOXINS: po.  ALPHA-1-ANTITRYPSIN: df.  CHILD.
   CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: co.  FATTY-LIVER: et, me, th.
   FATTY-LIVER-ALCOHOLIC.  GANGLIOSIDOSIS: co.  GLYCOGENOSIS: co.
   HISTIOCYTOSIS-X: co.  HUMAN.  HYPERLIPIDEMIA: co.  INFANT.
   INFANT-NEWBORN.  INFLAMMATION: co.  NUTRITION-DISORDERS: co.  REVIEW.
   TOXINS: po.  TRIGLYCERIDES: me.
EX Childhood hepatic steatosis is a commonly and generally benign
   reaction that occurs in many pathophysiologic states.  Steatosis
   can result from the following mechanism(s): impaired TGC clearance;
   increased hepatic lipogenesis; decreased FA oxidation; and increased
   lipolysis.  Cystic fibrosis  and syndromes producing pancreatic
   insufficiency (pancreatitis) result in a variable degree of
   steatosis most probably dependent on the nutritional and hormonal
   state of the patient.  Patients with cystic fibrosis have impaired
   glucagon and insulin release which alters their fat metabolism.  The
   treatment of hepatic steatosis is aimed at the primary cause.
RF 001   HARTFORD WS           IN: GALL EA                          113 973
   002   HOYUMPA AM            AM J DIG DIS                    20  1142 975
   003   GOLDRICK RB           IN: JOHNSON AR                       501 971
   004   HAVEL RJ              FED PROC                        34  2250 975
   005   GLUECK CJ             N ENGL J MED                   292  1347 975
   006   LIEBER CS             HOSP PRACT                      12    73 977
   007   LIEBER CS             N ENGL J MED                   288   356 973
   008   JUDAH JD              AM J MED                        49   609 970
   009   WAKIL SJ              IN: WAKIL SJ                           1 970
   010   WOGAN GN              ANN NY ACAD SCI                174   623 970
   011   REES KR               GUT                              7   205 966
   012   BUTLER WH             BR J CANCER                     18   756 964
   013   BOURGEOIS CH          LAB INVEST                      24   206 971
   014   AMLA C                AM J CLIN NUTR                  24   609 971
   015   COLON AR              AM J DIG DIS                    19  1091 974
   016   LAMPE K               PLANT TOXICITY AND DERMAT            131 973
   017   ANON                  NAT COMM MARIJUANA DRUG ABUSE            973
   018   RYBACK RS             N ENGL J MED                   293   719 975
   019   HASSAL CH             WEST INDIAN MED J                4    83 955
   020   CORREDOR CK           PROC NAT ACAD SCI USA           58  2299 967
   021   RUBIN E               AM J DIS CHILD                 119   132 970
   022   COMBES B              PROG LIVER DIS                   4   589 972
   023   KERN WH               AM J CLIN PATHOL                61   763 974
   024   SOPER RT              J PEDIATR SURG                  10    51 975
   025   BUCHWALD H            CURR PROB SURG                  12    35 975
   026   SILVERMAN A           PEDIATR CLIN GASTROENTEROL               971
   027   SHINGLETON WW         MALABSORPTION SYNDROMES               79 968
   028   MORENS DM             AM J DIS CHILD                 128   401 974
   029   STAHL M               J PEDIATR                       84   821 974
   030   OLEFSKY JM            AM J MED                        57   551 974
   031   CAHILL G              N ENGL J MED                   282   668 970
   032   ALPERS DH             IN: SCHIFF L                         824 975
   033   SEGAL S               IN: STANBURY JB                      174 972
   034   HOWELL RR             IN: STANBURY JB                      149 972
   035   FORGET P              PEDIATR RES                      8   114 974
   036   LEES RS               N ENGL J MED                   284   186 971
   037   BRICKER LA            MED CLIN NORTH AM               55   403 971
   038   FROESCH ER            IN: STANBURY JB                      131 972
   039   WADLINGTON WB         PEDIATRICS                      51   192 973
   040   SATRAN L              J PEDIATR                       75    39 969
   041   PEREMAN J             J PEDIATR                       69  1108 966
   042   PARR J                PEDIATRICS                      35   770 965
   043   GAUTIER E             HELV MED ACTA                   35   423 970
   044   MORROW G              IN: NYHAN WL                          61 974
   045   STREETEN D            JAMA                           232   944 975
   046   BUIST NRM             IN: NYHAN WL                         160 974
   047   STERNLEID I           ANN INTERN MED                  76    59 972
   048   EADE MN               ANN INTERN MED                  72   475 970
   049   STROLE WE             N ENGL J MED                   289   964 973
   050   MOROZ SP              J PEDIATR                       88    19 976
   051   DEHNER LP             PEDIATRIC SURGICAL PATHOLOGY         332 975
   052   SILVERSTEIN MN        N ENGL J MED                   282     1 970
   053   FRANKEN FH            IN: SCHNAFFNER F                     117 974
   054   COLON AR              PEDIATR PORTFOLIO                3     8 975
   055   PARTIN JC             N ENGL J MED                   285  1339 971
   057   FAVARA BE             MED COM                                  973
   058   COHEN MI              IN: WINTERS RW                       293 975
   059   BROWN RE              N ENGL J MED                   286   787 972
   060   MASSARRAT S           ACTA HEPATOGASTROENTEROL        21   176 974
CT   1   DONZELLI F            RIV ITAL PEDIATR                 7   171 981

PN 77020
RN 00602 
AN 77219194
AU Taussig-L-M.
TI Isoamylase abnormalities in cystic fibrosis [letter].
SO Am-J-Hum-Genet. 1977 Jul. 29(4). P 408-9.
MJ CYSTIC-FIBROSIS: en.  GLYCOSIDE-HYDROLASES: me.  ISOAMYLASE: me.
MN HUMAN.  POLYMORPHISM-GENETICS.
EX The article by Townes et al. provides confirmation of our initial
   studies with reference to the isoamylase patterns of serum, duodenal
   fluid, and urine in patients with cystic fibrosis (CF).  However, the
   impression given by Townes et al. in their article is that their data
   are the first demonstration of isoamylase abnormalities in cystic
   fibrosis.  I wish to point out that out previous work published 2
   years earlier and not referenced by Townes et al. demonstrated that
   CF patients had decreased amounts of pancreatic isoamylase in their
   serum and urine and that the duodenal aspirates in CF patients
   contained both salivary and pancreatic amylase.  We concluded, as
   eluded to by Townes et al., that salivary amylase in the duodenal
   fluid was probably secondary to the intubation procedure.
RF 001   TOWNES PL             AM J HUM GENET                  28   378 976
   002   TAUSSIG LM            PEDIATRICS                      54   229 974
   003   TAUSSIG LM            PEDIATRICS                      54   229 974
   004   TOWNES PL             AM J HUM GENET                  28   378 976

PN 77021
RN 00603 
AN 77264147
AU Scott-J.  Elias-E.  Moult-P-J.  Barnes-S.  Wills-M-R.
TI Rickets in adult cystic fibrosis with myopathy, pancreatic
   insufficiency and proximal renal tubular dysfunction.
SO Am-J-Med. 1977 Sep. 63(3). P 488-92.
MJ CYSTIC-FIBROSIS: co.  KIDNEY-TUBULES-PROXIMAL: pp.
   MUSCULAR-DISEASES: et.  PANCREATIC-DISEASES: et.  RICKETS: et.
MN ADULT.  CASE-REPORT.  HUMAN.  HYPERPARATHYROIDISM-SECONDARY: et.
   KIDNEY-DISEASES: et.  LIVER-CIRRHOSIS-BILIARY: et.  MALE.
   MUSCULAR-DISEASES: dt.  RICKETS: dt.  VITAMIN-D: me, tu.
AB Rickets is reported in a 19 year old white man with cystic fibrosis
   in whom pancreatic and hepatic involvement was advanced. There was
   evidence of secondary hyperparathyroidism with proximal renal tubular
   acidosis, aminoaciduria, phosphaturia and hypophosphatemia. Treatment
   with oral pancreatic and parenteral vitamin D supplements led to full
   recovery of the rachitic syndrome and the proximal renal tubular
   dysfunction.
RF 001   CROZIER DN            PEDIATR CLIN NORTH AM           21   935 974
   002   LAPEY A               J PEDIATR                       84   328 974
   003   DI SANTAGNESE PA      ANN INTERN MED                  50  1321 959
   004   COATES EO JR          DIS CHEST                       49   195 966
   005   HUNTON DB             GASTROENTEROLOGY                50    99 966
   006   TYSON KRT             J PEDIATR SURG                   3   271 968
   007   HARRIES JT            ARCH DIS CHILD                  46   341 971
   008   UNDERWOOD BA          PEDIATR RES                      6    26 972
   009   JAMES O               GUT                             14   582 973
   010   SPROUL A              J PEDIATR                       65   664 964
   011   SIMOPOULOS AP         CF CLUB ABST                          13 971
   012   OPPENHEIMER EH        BULL JOHNS HOPKINS HOSP         98   353 956
   013   SIWE SA               DTSCH ARCH KLIN MED            173   339 932
   014   SHWACHMAN H           AM J DIS CHILD                  92   347 956
   015   CLARK ML              IN: MCCHOLL I                        209 975
   016   WEBER AM              GUT                             17   295 976
   017   STERN RC              GASTROENTEROLOGY                70   645 976
   018   MULDOWNEY FP          Q J MED                         37   517 968
   019   MULDOWNEY FP          Q J MED                         40   487 971
   020   SCHOTT GD             LANCET                           1   626 976
   021   PATTEN BM             ANN INTERN MED                  80   182 974
   022   SUNG JH               EXP NEUROL                      23   567 963
   023   MALAMUD N             ANN NY ACAD SCI                 52   135 949
CT   1   SITRIN M              ARCH INTERN MED                138   886 978
     2   SANTAGNESE PAD        AM J MED                        66   121 979
     3   CHASE HP              J PEDIATR                       95   337 979
     4   MISCHLER EH           AM J DIS CHILD                 133   632 979
     5   MEREDITH SC           CLIN ENDOCRINOL METAB            9   131 980
     6   BOROVIKOVA TM         TER ARKH                        52   125 980
     7   ELIAS E               LANCET                           2  1319 981
     8   DUNCOMBE VM           CLIN GASTROENTEROL              10   653 981
     9   PITT MJ               RADIOL CLIN NORTH AM            19   581 981
    10   PIERIDES AM           DRUGS                           21   241 981
    11   CONGDEN PJ            ARCH DIS CHILD                  56   708 981
    12   PARK RW               GASTROENTEROLOGY                81  1143 981
    13   PALING MR             SKELETAL RADIOL                  8    63 982
    14   ABRAMOWSKY CR         HUM PATHOL                      13   934 982
    15   DIBBLE JB             Q J MED                         53   119 984
    16   HANLY JG              Q J MED                         56   377 985
    17   MINGUELLA JF          MED CLIN                        84   700 985
    18   FRIEDMAN HZ           GASTROENTEROLOGY                88   808 985

PN 77022
RN 00604 
AN 77132666
AU Sahu-S.  Lynn-W-S.
TI Lipid composition of airway secretions from patients with asthma and
   patients with cystic fibrosis.
SO Am-Rev-Respir-Dis. 1977 Feb. 115(2). P 233-9.
MJ ASTHMA: me.  CYSTIC-FIBROSIS: me.  LIPIDS: se.  LUNG: se.
MN ADOLESCENCE.  ADULT.  CERAMIDES: se.  CHILD.  CHOLESTEROL: se.
   DIGLYCERIDES: se.  GLYCOLIPIDS: an, se.  HUMAN.  IRRIGATION.
   LUNG: an.  PHOSPHATIDYLCHOLINES: se.  PHOSPHATIDYLETHANOLAMINES: se.
   PHOSPHOLIPIDS: an, se.  TRIGLYCERIDES: se.  SUPPORT-U-S-GOVT-P-H-S.
AB Lipids from the particulate material obtained from pulmonary lavage
   of patients with asthma and cystic fibrosis were isolated and
   characterized. In both cases, lipids constituted 30 to 40 per cent of
   the dry insoluble material and phosphatidylcholine was the
   predominant lipid. Significant amounts of phosphatidylethanolamine
   and phosphatidyglycerol were present. Hexosyl ceramides,
   spingomyelin, phosphatidylinositol, phosphatidylserine, and
   lyso(bis)phosphatidic acid were present as minor lipid components.
   Appreciable quantities of neutral lipids were also found. Significant
   amounts of lysophosphatides and free fatty acids were present only in
   the lavage sediment from patients with asthma, and not in patients
   with cystic fibrosis. Phosphatidylcholine, lysophosphatidycholine,
   sphingomyelin, and phosphatidylglycerol of asthmatic lavage, but not
   cystic lavage, were highly saturated, containing mostly palmitic
   acid.
RF 001   KYLSTRA JA            AM REV RESPIR DIS              103   651 971
   002   KING RJ               AM J PHYSIOL                   223   715 972
   003   BAXTER CF             LIPIDS                           4   243 969
   004   ROONEY SA             BIOCHIM BIOPHYS ACTA           360    56 974
   005   CHERNICK WS           PEDIATRICS                      24   739 959
   006   MATTHEWS LW           AM REV RESPIR DIS               88   199 963
   007   ROSENLUND ML          NATURE                         251   719 974
   008   CAREN R               J CLIN ENDOCRINOL METAB         26   470 966
   009   RAMIREZ RJ            AM J MED                        45   502 968
   010   LEWIS RW              LIPIDS                           6   859 971
   011   GALLAI-HATCHARD JJ    BIOCHIM BIOPHYS ACTA           116   532 966
   012   ADAMS EP              CHEM PHYS LIPIDS                 1   368 967
   013   SAHU S                AM REV RESPIR DIS              114   177 976
   014   FOLCH J               J BIOL CHEM                    226   497 957
   015   ROUSER G              METHODS ENZYMOL                 14   272 969
   016   ESSELMAN WJ           METHODS ENZYMOL                 28   140 972
   017   VIOQUE E              J AM OIL CHEM SOC               39    63 962
   018   SKIPSKI VP            METHODS ENZYMOL                 14   530 969
   019   ROONEY SA             J LIPID RES                     16   418 975
   020   TARLOV AR             J BIOL CHEM                    240    49 965
   021   DITMER JC             METHODS ENZYMOL                 14   482 969
   022   BARTLETT GR           J BIOL CHEM                    234   466 959
   023   FARKAS J              J LIPID RES                     14   344 973
   024   VANHANDEL E           J LAB CLIN MED                  50   152 957
   025   RUDEL LL              J LIPID RES                     14   364 973
   026   LAUTER CJ             J LIPID RES                      3   136 962
   027   TAO RVP               J LIPID RES                     14    16 973
   028   HARLAN WR             AM J PHYSIOL                   211   855 966
   029   MIKOLASEV V           LIPIDS                           9   827 974
   030   GLUCK L               PEDIATR RES                      1   237 967
   031   MORGAN TE             BIOCHIM BIOPHYS ACTA           106   403 965
   032   GRAY GM               BIOCHIM BIOPHYS ACTA           144   519 967
   033   HENDERSON RF          LIPIDS                           7   492 972
   034   KING RJ               AM J PHYSIOL                   224   788 973
   035   GODINEZ RI            BIOCHEMISTRY                    14   830 975
   036   HALLMAN M             J LIPID RES                     17   257 976
   037   MASON RJ              J CLIN INVEST                   51  2399 972
CT   1   CREETH JM             BR MED BULL                     34    17 978
     2   LOPEZVIDRIERO MT      BR MED BULL                     34    63 978
     3   ROUSSEL P             LUNG                           154   241 978
     4   SAHU S                BIOCHEM J                      173   565 978
     5   MAWHINNEY TP          PEDIATR RES                     13   760 979
     6   LYNN WS               BULL EUR PHYSIOPATH RESP        15  P 18 979
     7   RIORDAN JR            BIOCHIM BIOPHYS ACTA           574    39 979
     8   SAHU SC               INFLAMMATION                     4   107 980
     9   CASSINO RJJ           PEDIATR RES                     14  1212 980
    10   ABBRUZZESE A          ITAL J BIOCHEM                  29   450 980
    11   BOAT TF               FED PROC                        39  3067 980
    12   LOPEZVIDRIERO MT      CHEST                           80   799 981
    13   MACONE AB             N ENGL J MED                   304  1445 981
    14   ROGIERS V             PEDIATR RES                     16   761 982
    15   WOODWARD H            BIOCHEMISTRY                    21   694 982
    16   BERTHOLON JF          BIOMED PHARMACOTHER             36   189 982
    17   JOUANEL P             ANN BIOL CLIN                   40   255 982
    18   SLOMIANY BL           J DENT RES                      61  1163 982
    19   SLOMIANY A            BIOCHIM BIOPHYS ACTA           710   106 982
    20   WITAS H               CARBOHYD RES                   120    67 983
    21   SLOMIANY A            J BIOL CHEM                    258  8535 983
    22   SLOMIANY A            BIOCHIM BIOPHYS ACTA           750   253 983
    23   ROGIERS V             PEDIATR RES                     18   704 984
    24   HENDERSON RF          ENVIRON HEALTH PERSPECT         56   115 984
    25   STELANDER M           EUR J RESPIR DIS                65     5 984
    26   COLES SJ              CIBA FOUND SYMP                109    40 984
    27   JOZWIAK Z             BIOCHIM BIOPHYS ACTA           802   282 984
    28   BHASKAR KR            EXP LUNG RES                     9   289 985
    29   RAMI J                BULL EUR PHYSIOPATH RESP        21   331 985
    30   RAO GA                TOXICOL LETT                    29   207 985
    31   WIDDICOMBE JG         EUR J RESPIR DIS                67     1 985
    32   MILLER FJ             TOXICOL APPL PHARMACOL          79    11 985
    33   GILLJAM H             SCAND J CLIN LAB INVEST         46   511 986

PN 77023
RN 00605 
AN 77219997
AU Wanner-A.
TI Clinical aspects of mucociliary transport.
SO Am-Rev-Respir-Dis. 1977 Jul. 116(1). P 73-125. (REVIEW).
MJ CILIA: ph.  LUNG: ph.  MUCUS: ph.
MN AIR-POLLUTANTS-ENVIRONMENTAL: ae.  ANESTHETICS: pd.  ANIMAL.
   ASTHMA: pp.  BRONCHITIS: pp.  CHRONIC-DISEASE.  CILIA: cy, de.
   CYSTIC-FIBROSIS: pp.  HUMAN.  LUNG: cy, de, pp.  MUCUS: cy, de.
   OXYGEN.  RESPIRATORY-TRACT-INFECTIONS: pp.  REVIEW.  RHEOLOGY.
   SMOKING: pp.  SYMPATHOMIMETICS: pd.  WEATHER.
EX It has long been believed that the mucociliary apparatus of the
   airways serves to remove inhaled particulate matter from the
   tracheobronchial mucosa, thereby contributing to pulmonary host
   defense.  This review deals mainly with factors affecting
   mucociliary transport that may be of clinical importance.  The
   information available at present strongly suggests that mucociliary
   transport, at least in central airways, is impaired in most patients
   with cystic fibrosis; however, it is still unclear whether this
   disorder is a nonspecific feature of the chronic inflammatory airway
   disease or represents an essential factor in the pathogenesis of the
   pulmonary abnormalities.
RF 001   SLEIGH MA             BIOLOGY OF CILIA AND FLAG                962
   002   GRAY C                CILIARY MOVEMENT                         928
   003   RIVERA JA             CILIA CILIATED EPITHELIUM AND            962
   004   KINOSITA H            PHYSIOL REV                     47    53 967
   005   KILBURN KH            AM REV RESPIR DIS               93   184 966
   006   HILDING AC            MINN MED                        50   916 967
   007   KILBURN KH            YALE J BIOL MED                 40   339 968
   008   KILBURN KH            AM REV RESPIR DIS               98   449 968
   009   OKESON GC             MAYO CLIN PROC                  45   361 970
   010   ASMUNDSSON T          IN: DULFANO MJ                       107 973
   011   DELAHUNTY JE          J LARYNGOL OTOL                 83   803 969
   012   LEESON TS             J ANAT                          98   183 964
   013   VON HAYCK H           HUMAN LUNG                               960
   014   GILLESPIE JR          AM REV RESPIR DIS               95   477 967
   015   RHODIN J              ANN OTOL RHINOL LARYNGOL        68   964 959
   016   ALEXANDER I           THORAX                          30   171 975
   017   RHODIN JAG            AM REV RESPIR DIS SUPPL 3       93     1 966
   018   YONEDA K              AM REV RESPIR DIS              114   837 976
   019   SERAFINI SM           BULL PHYSIOPATH RESPIR NANCY    12   415 976
   021   VAN AS A              ENVIRON RES                      7     1 974
   022   VANAS A               S AFR MED J                     46   347 972
   023   HOLMA B               ARCH ENVIRON HEALTH             18   330 969
   024   RHODIN J              Z ZELLFORSCH MIKROSK ANAT       44   415 956
   025   FAWCETT DW            J MORPHOL                       94   221 954
   026   BARBER VC             Z ZELLFORSCH MIKROSK ANAT       84   269 968
   027   GIBBONS IR            J BIOPHYS BIOCHEM CYTOL          7   697 960
   028   GIBBONS IR            J BIOPHYS BIOCHEM CYTOL         11   179 961
   029   ROTH LE               J CELL BIOL                     20   249 964
   030   DULFANO MJ            IN: DULFANO MJ                         3 973
   031   SPICER SS             IN: DULFANO MJ                        22 973
   032   ELFTMAN AG            AM J ANAT                       72     1 943
   033   LARSELL O             AM J ANAT                       52   125 933
   034   EBERT RV              AM REV RESPIR DIS              114   567 976
   035   KILBURN KH            IN: DULFANO MJ                        69 973
   036   LUCAS AM              ARCH OTOLARYNGOL                20   518 934
   037   NOWELL JA             AM REV RESPIR DIS              103   313 971
   038   SADE J                AM REV RESPIR DIS              102    48 970
   039   ASMUNDSSON T          AM REV RESPIR DIS              102   388 970
   040   BARCLAY AE            J PHYSIOL (LOND)                90   482 937
   041   HILDING AC            AM J PHYSIOL                   191   404 957
   042   LIGHTOWLER NM         BR J EXP PATHOL                 50   139 969
   043   PROCTOR DF            AM REV RESPIR DIS              115    97 977
   044   WILHELM DL            J PATHOL BACTERIOL              67   361 954
   045   BATTISTA SP           TOXICOL APPL PHARMACOL          22    56 972
   046   BANG FB               AM REV RESPIR DIS               93   142 966
   047   HILDING AC            ACTA OTOLARYNGOL STOCKH         57   352 964
   048   LUCAS AM              IN: KOWDRY EV                        409 932
   049   WILSON GB             TRANS AM MICROSC SOC            94    43 975
   050   SATIR P               IN: SLEIGH MA                        131 974
   051   PITELKA DR            IN: SLEIGH MA                        437 974
   052   GIBBONS IR            J CELL BIOL                     26   707 965
   053   SAAVEDRA S            EXP CELL RES                    90   439 975
   054   USUKI I               SCI REP RES INST TOHOKU UNIV    26    65 959
   055   ALEXANDROV VY         DOKL AKAD NAUK SSSR            110   457 956
   056$  BORHAUS EF            SCIENCE                         92   553 953
   057   GOSSELIN RE           AM REV RESPIR DIS               93    41 966
   058   GRAY J                PROC R SOC LOND BIOL            93   104 922
   059   SLEIGH MA             AM REV RESPIR DIS               93    16 966
   060   KNIGHT-JONES EW       Q J MICR SCI                    95   503 954
   061   BROKAW CJ             AM REV RESPIR DIS               93    32 966
   062   IRAVANI J             PFLUEGERS ARCH                 305   199 969
   063   BAUER V               Z ALLG PHYSIOL                  10   230 910
   064   AIELLO EL             SCIENCE                        146  1692 964
   065   KINOSITA H            J FAC SCI UNIV TOKYO             7     1 954
   066   KINOSITA H            J FAC SCI UNIV TOKYO            10   304 963
   067   KAMADA T              J FAC SCI UNIV TOKYO             2   285 931
   068   UEDA K                ANNOT ZOOL JAPON                34    99 961
   069   MURAKAMI A            NATURE                         257    48 975
   070   PEHLE K               ARCH EXP PATHOL PHARMAKOL      159   452 931
   071   MCDONALD JF           AM J PHYSIOL                    85   395 928
   072   RAZANSKY N            RUSS FIZIOL Z                    9   556 926
   073   BRODY JS              CLIN RES                        29   507 971
   074   REID L                ARCH ENVIRON HEALTH             10   265 965
   075   REID L                BULL PHYSIOPATH RESPIR NANCY     9    15 973
   076   TOREMALM NG           ACTA OTOLARYNGOL STOCKH SUPPL  158    43 960
   077   GROTE JJ              ACTA OTOLARYNGOL STOCKH         79   124 975
   078   BOAT TF               IN: DULFANO MJ                       243 973
   079   BARTON AD             ARCH INTERN MED                131   140 973
   080   NEGUS VE              ACTA OTOLARYNGOL STOCKH         56   204 963
   081   LITT M                ARCH INTERN MED                126   417 970
   082   RICHARDSON JB         CLIN RES                        23  647A 975
   083   OLVER RE              AM REV RESPIR DIS              112   811 975
   084   JENSSEN AO            SCAND J RESPIR DIS              54   290 973
   085   SHARPEY W             EDINB MED SURG J                34   113 830
   086   LOMMEL F              DTSCH ARCH KLIN MED             94   265 908
   087   STEWART WC            AM J PHYSIOL                   152     1 948
   088   HILDING AC            ANN OTOL RHINOL LARYNGOL        54   725 945
   089   HILDING AC            N ENGL J MED                   256    34 957
   090   IRAVANI J             BULL PHYSIOPATH RESPIR NANCY     9   397 975
   092   HIRSCH JA             ARCH ENVIRON HEALTH             30   249 975
   093   SACKNER MA            ANN INTERN MED                  82    40 975
   094   CAMNER P              ARCH ENVIRON HEALTH             24    82 972
   095   CAMNER P              AM REV RESPIR DIS              112   807 975
   097   KING MA               AM REV RESPIR DIS              110   740 974
   098   BARNETT B             ANN NY ACAD SCI                130   891 966
   099   DULFANO MJ            AM REV RESPIR DIS              112   341 975
   100   PUCHELLE E            BULL PHYSIOPATH RESPIR NANCY    12   771 976
   101   ADLER K               J LAB CLIN MED                  88    22 976
   102   SLEIGH MA             NATURE                         191   931 961
   103   MILLER CE             J EXP BIOL                      49   617 968
   104   IRAVANI J             ARCH PHARMAKON                  32   248 975
   105   IRAVANI J             J PATHOL                       106    81 972
   106   KINOSITA H            ANNOT ZOOL JAPON                25     8 952
   108   FRIEDMAN M            AM REV RESPIR DIS              115    67 977
   109   GOLDSTEIN SF          IN: SLEIGH MA                        111 974
   110   RIVERA JA             CILIA CILIATED EPITHELIUM AND            962
   112   CORSSEN HL            TEX REP BIOL MED                16   194 958
   113   BALLENGER JJ          AM REV RESPIR DIS               93    61 966
   114   BALLENGER JJ          ANN OTOL RHINOL LARYNGOL        72    31 963
   115   BLECKER JD            ACTA OTOLARYNGOL STOCKH         71   726 971
   116   BERNFELD P            AM REV RESPIR DIS SUPPL         93    74 966
   117   RYLANDER R            AM REV RESPIR DIS               93    67 966
   118   MERCKE U              ACTA OTOLARYNGOL STOCKH         78   444 974
   119   PROETZ AW             ARCH OTOLARYNGOL                19   608 934
   120   MERCKE U              ACTA OTOLARYNGOL STOCKH         78   118 974
   121   DALHAMN T             ACTA PHYSIOL SCAND SUPPL 36          123 956
   122   ADLER KB              ARCH ENVIRON HEALTH             27   364 973
   123   DAVIS SS              BULL PHYSIOPATH RESPIR NANCY     9    47 973
   124   AIACHE JM             BIORHEOLOGY                     11   375 974
   125   OBRECHT B             BIORHEOLOGY                     12   211 975
   126   DAVIS SS              IN: GABELNICK HL                     158 973
   127   MCCUTCHEN CW          BIORHEOLOGY                     11   265 974
   128   BLECKER JD            ANN OTOL RHINOL LARYNGOL        82   248 973
   129   WARDELL JR JR         AM REV RESPIR DIS              191   741 970
   130   LUTZ RJ               IN: GABELNICK HL                     119 973
   131   ADAMS GK              J APPL PHYSIOL                  40   247 976
   132   POWELL RL             J APPL PHYSIOL                  37   447 974
   133   GILBOA A              BIORHEOLOGY                     13    67 976
   134   MICHAELSON ED         PHYSIOLOGIST                    19   295 976
   135   PHILIPPOFF W          BIORHEOLOGY                      7    55 970
   136   BARNETT B             AM REV RESPIR DIS              101   773 970
   137   MORROW PE             AM REV RESPIR DIS               96  1209 967
   138   TAPLIN GV             RADIOLOGY                       85   365 965
   139   ALBERT RE             ARCH ENVIRON HEALTH             14    10 967
   140   ALBERT RE             ARCH INTERN MED                131   115 973
   141   CAMNER P              ARCH ENVIRON HEALTH             26   294 973
   142   MULLER M              KLIN WOCHENSCHR                 53   815 975
   143   SANCHIS J             J APPL PHYSIOL                  33   757 972
   144   ALBERT RE             ARCH ENVIRON HEALTH             18   738 969
   145   YEATES DB             J APPL PHYSIOL                  39   487 975
   146   WOOD PB               CAN ANAESTH SOC J               20   192 973
   147   GIORDANO AM JR        ARCH ENVIRON HEALTH             25   443 972
   148   BERKE HL              AM IND HYG ASSOC J              32   174 971
   149   IRAVANI J             PNEUMONOLOGIE                  144    93 971
   150   GOLDHAMER RE          METHOD FOR STUDYING MUCUS F              964
   151   LAURENZI GA           PROC ASPEN EMPHYSEM CONF 10TH         27 967
   152   GIORDANO A            ANN OTOL RHINOL LARYNGOL        85   631 976
   153   SAKAKURA Y            PROC SOC EXP BIOL MED          140   870 972
   154   MARIN MG              J APPL PHYSIOL                  27   385 969
   155   WANNER A              ARCH ENVIRON HEALTH             27   370 973
   156   LANDA JF              J APPL PHYSIOL                  38   946 975
   158   LIERLE DM             ARCH OTOLARYNGOL                19    55 934
   159   SCUDI JV              J PHARMACOL EXP THER           102   132 951
   160   BOYD EM               ARCH OTOLARYNGOL                33   909 941
   161   HILL JR               J PHYSIOL (LOND)               139   157 957
   162   HILL L                LANCET                           2   802 928
   163   KENSLER CJ            AM REV RESPIR DIS SUPPL         93    93 966
   164   CARSON S              AM REV RESPIR DIS SUPPL         93    86 966
   165   LAURENZI GA           N ENGL J MED                   279   333 968
   166   BATTISTA SP           ARCH ENVIRON HEALTH             20   326 970
   167   IRAVANI J             PFLUEGERS ARCH                 297   221 967
   168   BAETJER AM            AM REV RESPIR DIS               93    79 966
   169   BAETJER AM            J APPL PHYSIOL                  23   498 967
   170   PROCTOR DF            ARCH INTERN MED                131   132 973
   171   QUINLAN MF            AM REV RESPIR DIS               99    13 969
   172   EWERT G               ACTA OTOLARYNGOL STOCKH SUPPL  200    32 965
   173   SACKNER MA            J APPL PHYSIOL                  34   495 973
   174   SANTA CRUZ R          AM REV RESPIR DIS              109   458 974
   175   WOOD RE               AM REV RESPIR DIS              113   833 976
   176   ANDERSEN IB           AM REV RESPIR DIS              106   438 972
   177   PARKS CR              AM REV RESPIR DIS              104    99 971
   178   PARKS CR              AM REV RESPIR DIS              108   513 973
   179   BOHNING DE            J APPL PHYSIOL                  41   920 976
   180   BAETJER AM            ARCH ENVIRON HEALTH             26    61 973
   181   BANG BG               PROC SOC EXP BIOL MED          106   516 961
   182   PROETZ AW             ANN OTOL RHINOL LARYNGOL        42   778 933
   183   ASMUNDSSON T          AM REV RESPIR DIS              102   388 970
   184   TOREMALM NG           ACTA OTOLARYNGOL STOCKH         53   442 961
   185   HIRSCH JA             J APPL PHYSIOL                  39   242 975
   186   FORBES AR             BR J ANAESTH                    45   874 973
   187   PALMER KNV            LANCET                           1    91 960
   188   LIFSCHITZ MI          AM REV RESPIR DIS              102   456 970
   189   MATTHEWS LW           PEDIATRICS                      39   176 967
   190   HIRSCH SR             IN: STEIN M                          351 975
   191   CRAGG J               ARCH INTERN MED                107    81 967
   192   BURTON JDK            LANCET                           1   235 962
   193   TOREMALM NG           ACTA OTOLARYNGOL STOCKH         52   461 960
   194   MERCKE U              ACTA OTOLARYNGOL STOCKH         78   253 974
   195   IRAVANI J             PFLUEGERS ARCH                 297   221 967
   196   IRAVANI J             PFLUEGERS ARCH                 297   221 967
   197   TANAKA AT             J OTOLARYNGOL JAP               70  2091 967
   198   DALHAMN T             ACTA PHYSIOL SCAND              49   242 960
   199   MERCKE U              ACTA OTOLARYNGOL STOCKH         79   133 975
   201   OLIPHANT JF           PHYSIOL ZOOL                    11    19 938
   202   JENNINGS HS           AM J PHYSIOL                     2   311 899
   203   PARKER GH             AM J PHYSIOL                    13     1 905
   204   MERTON H              BIOL ZENTRALBL                  55   268 935
   205   KAMADA T              PROC IMP ACAD TOKYO             16   125 940
   206   HEE J                 BULL PHYSIOPATH RESPIR NANCY     9   377 973
   207   KRUEGER AP            PROC SOC EXP BIOL MED           94   807 957
   208   KRUEGER AP            PROC SOC EXP BIOL MED          102   355 959
   209   KRUEGER AD            J GEN PHYSIOL                   44   269 960
   210   GUILLERM R            C R ACAD SCI (D)(PARIS)        266   528 968
   211   GUILLERM R            C R ACAD SCI (D)(PARIS)        262   669 966
   212   BADRE R               ANN PHARM FR                    24   469 966
   213   KENSLER CJ            AM REV RESPIR DIS SUPPL         93    93 966
   214   BALDETORP L           ACTA RADIOL THER STOCKH         15   225 976
   215   BOUSHY SF             AM J ROENTG RAD THER NUCL MED  108   287 970
   216   MENDENHALL WL         J PHARMACOL EXP THER            60   111 937
   217   MENDENHALL WL         J PHARMACOL EXP THER            69   295 940
   218   HILDING AC            N ENGL J MED                   254  1155 956
   219   DALHAMN T             ARCH OTOLARYNGOL                70   166 959
   220   DALHAMN T             AM REV RESPIR DIS SUPPL         93   108 966
   221   KENSLER CJ            N ENGL J MED                   269  1161 963
   222   FALK HL               J NATL CANCER INST              23   999 959
   223   GUILLERM R            BULL ACAD NATL MED             145   416 961
   224   BATTISTA SP           FED PROC                        21   701 962
   225   AUERBACH O            CANCER                          20  2055 967
   226   LEUCHTENBERGER C      CANCER                          11   490 958
   227   RYLANDER R            ARCH ENVIRON HEALTH             29   329 974
   228   FRASCA JM             EXP MOL PATH                    21   300 974
   229   REGLAND B             SCAND J RESPIR DIS              57   171 976
   230   NIEWOEHNER DE         N ENGL J MED                   291   755 974
   231   MATSUBA K             AM REV RESPIR DIS              104   516 971
   232   PROETZ AW             ANN OTOL RHINOL LARYNGOL        48   176 939
   233   WEISS W               ARCH ENVIRON HEALTH              9    50 964
   234   WANG H                NATURE                         197   946 963
   235   BALLENGER JJ          N ENGL J MED                   263   832 960
   235   JAKAB GJ              AM REV RESPIR DIS              115    33 977
   236   GUILLERM R            REV TUBERC PNEUMOL              36   187 972
   237   DALHAMN T             ARCH ENVIRON HEALTH             21   633 970
   238   GRAY JP               ARCH ENVIRON HEALTH             28   283 974
   239   KENNEDY JR            SCIENCE                        168  1097 970
   240   ALBERT RE             ARCH ENVIRON HEALTH             29    96 974
   241   CARSON S              AM REV RESPIR DIS SUPPL         93    86 966
   242   RAKIETEN N            ARCH OTOLARYNGOL                56   495 952
   243   TSUCHIYA M            FED PROC                        18   453 959
   244   DALHAMN T             ARCH OTOLARYNGOL                84   325 966
   245   BERNFELD P            TOXICOL APPL PHARMACOL           6   103 964
   246   DALHAMN T             ARCH OTOLARYNGOL                87   162 968
   247   WYNDER E              CANCER                          16  1222 963
   248   IRAVANI J             RESPIRATION                     29   480 972
   249   DALHAMN T             AM REV RESPIR DIS               89   870 964
   250   HOLMA B               ARCH ENVIRON HEALTH             18   171 969
   251   DALHAMN T             AM REV RESPIR DIS               99   447 969
   252   KAMIMSKI EJ           ARCH ENVIRON HEALTH             16   188 968
   253   ALBERT RE             ARCH ENVIRON HEALTH             18    30 969
   254   LA BELLE CW           ARCH ENVIRON HEALTH             12   588 966
   255   BAIR WJ               IN: DAVIES CN                    2   251 967
   256   DALHAMN T             ARCH ENVIRON HEALTH             17   746 968
   257   FRANCES R             ARCH ENVIRON HEALTH             21    25 970
   258$  RYLAND R              ARCH ENVIRON HEALTH             23   321 961
   259   DALHAMN T             AM REV RESPIR DIS              103   855 971
   260   CAMNER P              ARCH ENVIRON HEALTH             23   421 971
   261   ALBERT RE             ARCH ENVIRON HEALTH             30   361 975
   262   YERGIN B              AM REV RESPIR DIS SUPPL        115   183 977
   263   IRAVANI J             RESPIRATION                     31   358 974
   264   PAVIA D               NATURE                         226  1228 970
   265   THOMSON ML            ARCH ENVIRON HEALTH             26    86 973
   266   LOURENCO RV           J CLIN INVEST                   50  1411 971
   267   CAMNER P              ARCH ENVIRON HEALTH             26    90 973
   268   CAMNER P              ARCH ENVIRON HEALTH             25    60 972
   269   BOHNING DE            ARCH ENVIRON HEALTH             30   457 975
   270   ALBERT RE             ARCH ENVIRON HEALTH             22    12 971
   271   DALHAMN T             AM REV RESPIR DIS SUPPL         93   108 966
   272   HILDING AC            ANN OTOL RHINOL LARYNGOL        41    52 932
   273   CRALLEY LV            J IND HYG TOXICOL               24   193 942
   274   CAMNER P              ARCH ENVIRON HEALTH             27    81 973
   275   BALCHUM OJ            J APPL PHYSIOL                  15    62 960
   276   NADEL JA              ARCH ENVIRON HEALTH             10   175 965
   277   GOLDRING IP           ARCH ENVIRON HEALTH             15   167 967
   278   SPICER SS             AM REV RESPIR DIS              110    13 974
   279   CHAKRIN LW            LAB INVEST                      30   145 974
   280   MARTIN SW             ARCH ENVIRON HEALTH             25   158 972
   281   REID L                ARCH INTERN MED                126   428 970
   282   QUEVAUVILLER A        C R SOC BIOL (PARIS)           160  1845 961
   283   DALHAMN T             AM REV RESPIR DIS               83   566 961
   284   SPIEGELMAN JR         ARCH ENVIRON HEALTH             17   321 968
   285   ANDERSEN I            ARCH ENVIRON HEALTH             28    31 974
   286   WOLFF RK              ARCH ENVIRON HEALTH             30   521 975
   287   AMDUR MO              ARCH ENVIRON HEALTH             16   460 968
   288   DALHAMN T             ARCH ENVIRON HEALTH             16   821 968
   289   FAIRCHILD GA          ARCH ENVIRON HEALTH             30   538 975
   290   FAIRCHILD GA          ARCH ENVIRON HEALTH             25   174 972
   291   ANON                  AIR QUALITY CRITERIA FOR SULF            969
   292   FRANK NR              ARCH ENVIRON HEALTH             18   315 969
   293   HAAGEN-SMIT AJ        ARCH INDUST HEALTH              20   399 959
   294   LEWIS TR              ARCH ENVIRON HEALTH             18   596 969
   295   STRESEMANN E          STAUB REINHALT LUFT             30    33 970
   296   FREEMAN G             AM REV RESPIR DIS              106   563 972
   297   DAVIDSON JT           AM REV RESPIR DIS               95   790 967
   298   BLAIR WH              ARCH ENVIRON HEALTH             18   186 969
   299   BUCKLEY RD            ARCH ENVIRON HEALTH             18   588 969
   300   FREEMAN G             ARCH ENVIRON HEALTH             18   609 969
   301   FREEMAN G             ARCH ENVIRON HEALTH             17   181 968
   302   WAGNER WD             ARCH ENVIRON HEALTH             10   455 965
   303   EHRLICH R             ARCH ENVIRON HEALTH             17   860 968
   304   ANON                  AIR QUALITY CRITERIA FOR NIT             971
   305   STOKINGER HE          ANNU REV PHARMACOL              12   407 972
   306   BATES DV              J APPL PHYSIOL                  32   176 972
   307   LINN WS               AM REV RESPIR DIS              114   477 976
   308   MOORMAN WJ            ARCH ENVIRON HEALTH             26   153 973
   309   TREMER HM             J NATL CANCER INST              23   979 959
   310   FALK HL               ANN NY ACAD SCI                106   583 963
   311   JAFFE LS              AM IND HYG ASSOC J              28   267 967
   312   PLOPPER CG            AM J PATHOL                     71   375 973
   313   FREEMAN G             ARCH ENVIRON HEALTH             26   209 973
   314   STOKINGER HE          IN: STERN AC                         446 968
   315   WOLBACH SB            J EXP MED                       42   753 925
   316   SACKNER MA            AM REV RESPIR DIS SUPPL        115   241 977
   317   SHY CM                ARCH ENVIRON HEALTH             27   123 973
   318   SACKNER MA            AM REV RESPIR DIS SUPPL        115   240 977
   319   CLARK JM              PHARMACOL REV                   32    37 971
   320   BOAT TF               PEDIATR RES                      7   607 973
   321   GUILLERM R            J PHYSIOL (PARIS)               58   228 966
   322   SACKNER MA            BULL PHYSIOPATH RESPIR NANCY     9   403 973
   323   KRAUNITZ J            J MT SINAI HOSP                 12   411 945
   324   WOLFE WG              SURGERY                         72   236 972
   325   WOLFE WG              SURG FORUM                      21   217 970
   326   SACKNER MA            CHEST                           69   164 976
   327   LUDWIN SK             LAB INVEST                      31   425 974
   328   TORIKATA C            VIRCHOWS ARCH PATHOL NAT HIS   371   121 976
   329   CLARK JM              J APPL PHYSIOL                  30   739 971
   330   COMROE JH JR          JAMA                           128   710 945
   331   FISHER AB             J APPL PHYSIOL                  24   529 968
   332   DWAR KMS              J APPL PHYSIOL                  32   486 972
   333   PAEGLE RD             ANESTHESIOLOGY                  44   287 976
   334   KUHNE W               ARCH MIKROSK ANAT                2   372 966
   335   DALHAMN T             ARCH ENVIRON HEALTH             16   271 968
   336   KITCHING JA           J CELL COMP PHYSIOL             14   227 939
   337   WELLER H              PROC SOC EXP BIOL MED           81    65 952
   338   USUKI I               SCI REP RES INST TOHOKU UNIV    22    49 955
   339   USUKI I               SCI REP RES INST TOHOKU UNIV    22   137 955
   340   USUKI I               SCI REP RES INST TOHOKU UNIV    22   143 955
   341   BRIDGER GP            LARYNGOSCOPE                    82   218 972
   342   LICHTIGER M           ANESTHESIOLOGY                  42   753 975
   343   NUNN JF               J CELL SCI                      15   537 974
   344   FORBES AR             ANESTHESIOLOGY                  45    59 976
   345   CRALLEY LV            J IND HYG TOXICOL               24   193 942
   346   DALHAMN T             ACTA PHYSIOL SCAND SUPPL 36          123 956
   347   MANCUSO TF            INDIAN MED SURG                 20   393 951
   348   ANON                  CHROMIUM COMMITTEE ON MEDICAL            974
   349   MASS MJ               ARCH ENVIRON HEALTH             31    96 976
   350   FRANK R               AM REV RESPIR DIS              112   485 975
   351   SACKNER MA            CHEST                           69   593 976
   352   BOHNING DE            AM IND HYG ASSOC J              35   902 975
   353   BERGMAN M             N ENGL J MED                   266   750 962
   354   GOWDY JM              ARCH ENVIRON HEALTH             25   191 972
   355   MCLAUGHLIN AIG        FOOD COSMET TOXICOL              1  1971 963
   356   DRAIZE JH             PROC SCI SEC TOILET GOODS ASS   31    28 959
   357   CALANDRA J            PROC SCI SEC TOILET GOODS ASS   39    41 958
   358   ZUSKIN E              N ENGL J MED                   290   660 974
   359   COHEN BM              AM REV RESPIR DIS              113   123 976
   360   ANON                  AM REV RESPIR DIS               85   762 962
   361   REID L                PATHOLOGY OF EMPHYSEMA                   967
   362   WRIGHT RR             MED THORAC                      22   210 965
   363   KLEINERMAN J          IN: BAUM GL                              974
   364   ANON                  LANCET                           1   775 965
   365   HOGG JC               N ENGL J MED                   278  1355 968
   366   AUERBACH O            N ENGL J MED                   267   111 962
   367   MISKOVITZ G           ACTA MORPHOL ACAD SCI HUNG      22    91 974
   368   LEES AW               LANCET                           2  1112 959
   369   WANNER A              RESPIRATION                     30   561 973
   370   LEEDER S              J INFECT DIS                   131   731 975
   371   HILDING AC            MED THORAC                      22   329 965
   372   MACKLEM PT            ANN INTERN MED                  74   167 971
   373   GOODMAN RM            FED PROC                        36   607 977
   374   LOURENCO RV           AM REV RESPIR DIS              101   460 970
   375   CAMNER P              SCAND J RESPIR DIS              54   272 973
   376   LUCHSINGER PC         AM REV RESPIR DIS               97  1046 968
   377   PATRICK G             J APPL PHYSIOL                  42   451 977
   378   CAMNER P              ARCH ENVIRON HEALTH             26    90 973
   379   THOMSON ML            J APPL PHYSIOL                  26   535 969
   380   PIRCHER FT            AM J ROENTG RAD THER NUCL MED   94   807 965
   381   LOPEZ-VIDRIERO MT     BULL PHYSIOPATH RESPIR NANCY     9   339 973
   382   TOIGO A               AM REV RESPIR DIS               87   487 963
   384   PUCHELLE E            BULL PHYSIOPATH RESPIR NANCY     9   237 973
   385   LOPATA M              AM REV RESPIR DIS              110   730 974
   386   BONOMO L              CLIN CHIM ACTA                  10   214 964
   387   REID L                IN: LIEBOW AA                         87 968
   388   REID L                LANCET                           1   275 954
   389   DULFANO MJ            AM REV RESPIR DIS              104    88 971
   390   CHARMAN J             BIORHEOLOGY                      9   185 972
   391   MITCHELL-HEGGS PF     BIORHEOLOGY                     11   417 974
   392   ZUELZER WW            PEDIATRICS                       4    53 949
   393   ESTERLY JR            JOHNS HOPKINS MED J            122    94 968
   394   MATTHEWS LW           AM REV RESPIR DIS               88   199 963
   395   LAMBLIN G             CLIN CHIM ACTA                  36   329 972
   396   ROUSSEL P             J BIOL CHEM                    250  2114 975
   397   BOAT TF               IN: MANGOS JA                        165 976
   398   STURGESS JM           IN: LAWSON D PROC 5TH INT CF         368 969
   399   FEATHER EA            BR J DIS CHEST                  64   192 970
   400   SPOCK A               PEDIATR RES                      1   173 967
   401   BOWMAN BH             SCIENCE                        164   325 969
   402   POSSELT HG            Z KINDERHEILK                  110    93 971
   403   CHRISTENSEN J         IN: LAWSON D PROC 5TH INT CF          49 969
   404   CONOVER JH            LANCET                           1  1194 973
   405   LEDERBERG S           IN: MANGOS JA                        259 976
   406   WOOD RE               LANCET                           2  1452 973
   408   WOOD RE               AM REV RESPIR DIS              111   733 975
   409   YEATES DB             ARCH DIS CHILD                  51    28 976
   410   SANCHIS J             N ENGL J MED                   288   651 973
   411   THOMSON ML            N ENGL J MED                   289   749 973
   412   HUBER HL              ARCH INTERN MED                 30   689 922
   413   ALEXANDER HL          J ALLERGY                       34   305 963
   414$  DUNNILL MS            J CLIN PATHOL                   13    27 960
   415   HILDING AC            ANN OTOL RHINOL LARYNGOL        52     5 943
   416   SANTA CRUZ R          AM REV RESPIR DIS              109   458 974
   417   MOSSBERG B            SCAND J RESPIR DIS              57   119 976
   418   BALLENGER JJ          ANN OTOL RHINOL LARYNGOL        58   351 949
   419   MILLER DL             BR MED J                         1   291 965
   420   BARTON AD             CHEST SUPPL                     63    59 973
   421   BURGI H               BULL PHYSIOPATH RESPIR NANCY     9   191 973
   422   SALVATO G             THORAX                          23   168 968
   423   GUIRGIS HA            J ALLERGY CLIN IMMUNOL          51    86 973
   424   DENNIS EG             J ALLERGY                       35   464 964
   425   RYLEY HC              BR J EXP PATHOL                 49   625 968
   426   HOFFNIANVOU H         ALLERG ASTHMAFORSCH             14   227 968
   427   RYLEY HC              BR J EXP PATHOL                 49   625 968
   428   KEAL EE               IN: STEIN M                          223 975
   429   SQUERKIN NG           J PATHOL                        89   535 965
   430   WANNER A              J APPL PHYSIOL                  39   950 975
   431   PECORA DV             J THORAC CARDIOVASC SURG        37   653 959
   432   LAURENZI GA           N ENGL J MED                   265  1273 961
   433   LAURENZI GA           AM REV RESPIR DIS               93   134 966
   434   SPENCER H             PATHOLOGY OF THE LUNG                    968
   435   HERS JFP              LANCET                           2  1141 958
   436   WALSH JJ              ARCH INTERN MED                108   376 961
   437   FRANCIS T JR          J EXP MED                       68   789 938
   438   LEMERCIER G           ARCH GESAMTE VIRUSFORSCH        44   337 974
   439   CREASIA DA            HEALTH PHYS                     23   865 972
   440   BIBERFELD C           J BACTERIOL                    102   855 970
   441   COLLIER AM            INFECT IMMUN                     3   694 971
   442   PUCHELLE E            PATHOL BIOL (PARIS)             24    93 976
   443   BARTON AD             J LAB CLIN MED                  88   423 976
   444   PUCHELLE E            BULL PHYSIOPATH RESPIR NANCY     9   237 973
   445   CHERNICK WS           PEDIATRICS                      24   739 959
   446   BANG FB               AM J HYG                        79   260 964
   447   LOURENCO RV           J CLIN INVEST                   50   62A 971
   448   CAMNER P              AM REV RESPIR DIS              108   131 973
   449   JARSTRAND C           AM REV RESPIR DIS              110   415 974
   450   LINDHOLM CE           ACTA ANAESTHESIOL SCAND SUPPL   33     1 969
   451   AMIKAM B              AM REV RESPIR DIS              105   747 972
   452   SACKNER MA            CHEST                           64   284 973
   453   HILDING AC            ANN OTOL RHINOL LARYNGOL        80   565 971
   454   PAEGLE RD             ANESTH ANALG CLEVE              54   340 975
   455   KLAINER AS            AM J MED                        58   674 975
   456   SACKNER MA            BULL PHYSIOPATH RESPIR NANCY     9   403 973
   457   SACKNER MA            CHEST                           68   774 975
   458   HILDING AC            AM REV RESPIR DIS               98   646 968
   459   HILDING AC            TRANS AM ACAD OPHTHALMOL OTOL   72   604 968
   460   HILDING AC            ANN OTOL RHINOL LARYNGOL        71   455 962
   461$  MORINARI H            J THORAC CARDIOVASC SURG        47   484 974
   462   EDMUNDS LH            SURGERY                         66    15 969
   463   BRODY JS              J APPL PHYSIOL                  32   160 972
   464   MACKLIN CC            J THORAC SURG                   31   238 956
   465   CORYLLOS PN           ARCH SURG                       21  1214 930
   466   LAVER MB              PROG SURG                        5     1 966
   467   GAMSU G               AM REV RESPIR DIS              114   673 976
   468   MOERSCH HJ            DIS CHEST                       23   621 953
   469   AUERBACH O            CANCER                           9    76 956
   470   RYAN RF               PROC STAFF MTG MAYO CLIN        31   478 956
   471   IRAVANI J             RESPIRATION                     32   157 975
   472   CORSSEN G             ANESTHESIOLOGY                  21   237 960
   473   CORSSEN G             ANAESTHETIST                     7   309 958
   474   BANG FB               AM REV RESPIR DIS               93   142 966
   475$  EWERT G               ANN OTOLARYNGOL                 76   359 967
   476   ROSSMAN CM            AM REV RESPIR DIS SUPPL        115   239 977
   477   PLATTNER F            PFLUEGERS ARCH                 228   281 931
   478   LUCAS AM              ARCH OTOLARYNGOL                21   285 935
   479   ANNIS P               ANESTHESIOLOGY                  44    74 976
   480   FOSTER WM             J APPL PHYSIOL                  41   146 976
   481   PAVIA D               LANCET                           1   449 971
   482   BLAIR AMJN            BR J PHARMACOL                  35   379 969
   483   INNES IR              IN: GOODMAN LS                       530 970
   484   LOPEZ-VIDRIERO MT     THORAX                          30   543 975
   485   BULBRING E            PROC R SOC LOND BIOL           141   445 953
   486   KORDIK P              BR J PHARMACOL                   7    67 952
   487   CORSSEN G             J APPL PHYSIOL                  14   901 959
   488   NELSON DJ             J PHYSIOL (LOND)               243    63 974
   489   IRAVANI J             INT J CLIN PHARMACOL SUPPL 4          20 972
   491   NOMURA S              PROC SOC EXP BIOL MED           25   252 928
   492   DONGEN K VAN          ACTA PHYSIOL PHARMACOL           4   500 956
   493   DONGEN K VAN          ARCH INT PHARMACODYN THER       93   261 953
   494   LAURENZI GA           AM REV RESPIR DIS               93    60 966
   495   GOSSELIN RE           AM REV RESPIR DIS               93    41 966
   496   IRAVANI J             PNEUMONOLOGIE SUPPL                  267 976
   497   IRAVANI J             RESPIRATION                     31   350 974
   498   STURGESS JM           BR J EXP PATHOL                 54   388 973
   499   STURGESS JM           CLIN SCI                        43   533 972
   500$  DAVIS B               AM REV RESPIR DIS              112    57 975
   501   VAN AS A              RESPIRATION                     31   146 974
   502   CARSON S              AM REV RESPIR DIS SUPPL         93    86 966
   503   CAMNER P              ARCH ENVIRON HEALTH             29    79 976
   504   KONIETZKO N           PNEUMONOLOGIE                  152   203 975
   505   MOSSBERG B            SCAND J RESPIR DIS              57   119 976
   506   SEAMAN GR             J CELL COMP PHYSIOL             37   309 951
   507   FLOREY HW             BR J EXP PATHOL                 13   269 932
   508   BAKER AP              AM REV RESPIR DIS              111   423 975
   509   CHAKRIN LW            AM REV RESPIR DIS              108    69 973
   510   STURGESS J            EXP MOL PATH                    16   362 972
   511   UMEDA T               ACTA DERMATOL (KYOTO)           14   629 929
   512   KENSLER CJ            AM REV RESPIR DIS SUPPL         93   102 966
   513   CAMNER P              ARCH ENVIRON HEALTH             29   220 974
   514   GOSSELIN RE           J CELL COMP PHYSIOL             58    17 961
   515   GOSSELIN RE           J GEN PHYSIOL                   46   277 962
   516   SCHOR SL              SCIENCE                        148   500 965
   517   DADAIAN JH            AM REV RESPIR DIS              103   808 971
   518   BLAICH W              ARCH EXP PATHOL PHARMAKOL      211    67 950
   519   GREENWOOD G           ARCH OTOLARYNGOL                43   632 946
   520   CUTHBERT MF           PROC R SOC MED                  64    15 971
   521   KEAL EE               POSTGRAD MED J                  47   171 971
   523   BOYD EM               PHARMACOL REV                    6   521 954
   524   PERRY WF              J PHARMACOL EXP THER            73    65 941
   525   HIRSCH SR             J LAB CLIN MED                  74   346 969
   526   SHEFFNER AL           ANN NY ACAD SCI                106   298 963
   527   LIEBERMAN J           J CLIN INVEST                   43  1892 964
   528   DULFANO MJ            JAMA                           207  1310 968
   529   BOYD EM               RESPIRATORY TRACT FLUID                  972
   530   EDWARDS GF            CHEST                           70   506 976
   531   IRAVANI J             ARZNEIMITTEL FORSCH             24   849 974
   532   IRAVANI J             ARZNEIMITTEL FORSCH             22  1744 972
   533   KONIETZKO N           BULL PHYSIOPATH RESPIR NANCY    11   145 975
   534   THOMSON ML            THORAX                          28   742 973
   535   THOMSON ML            THORAX                          30   669 975
   536   SLEIGH MA             J EXP BIOL                      33    15 956
   537   GOSSELIN RE           AM REV RESPIR DIS               93    41 966
   538   LAURENZI GA           AM REV RESPIR DIS              103   800 971
   539   PAVIA D               AM REV RESPIR DIS              113    92 976
   540   BANG FB               AM REV RESPIR DIS               93   142 966
CT   1   BATEMAN JRM           CLIN SCI MOL MED                55   523 978
     2   CHOPRA SK             AM REV RESPIR DIS              118   367 978
     3   CONNOLLY TP           AM REV RESPIR DIS              118   965 978
     4   HARRIS CC             NATURE                         272   633 978
     5   SCHLESINGER RB        J ENVIRON PATHOL TOXICOL         2  1351 979
     6   CLARK DG              PHARMACOL THER                   5   149 979
     7   HANNA CJ              AGENTS ACTIONS                   9   301 979
     8   OKUYAMA H             J ENVIRON SCI HEALTH (C)        13   267 979
     9   SACKNER MA            BULL EUR PHYSIOPATH RESP        15   505 979
    10   REZNIKSCHULLER H      INT REV EXP PATHOL              20   211 979
    11   MELLIS CM             PEDIATR CLIN NORTH AM           26   553 979
    12   STURGESS JM           PEDIATR CLIN NORTH AM           26   481 979
    13   NADEL JA              ANNU REV PHYSIOL                41   369 979
    14   KING M                J APPL PHYSIOL                  47    26 979
    15   FORBES AR             ANESTHESIOLOGY                  50    26 979
    16   TATTERSFIELD AE       BR J ANAESTH                    51   681 979
    17   BATEMAN JRM           CLIN SCI                        56  P  9 979
    18   GULSVIK A             SCAND J RESPIR DIS              60   275 979
    19   PUCHELLE E            SCAND J RESPIR DIS              60   307 979
    20   HSU IC                J CLIN INVEST                   64  1245 979
    21   WANNER A              AM J MED                        67   477 979
    22   DREISIN RB            J LAB CLIN MED                  93   674 979
    23   BATEMAN JRM           AM REV RESPIR DIS              119   200 979
    24   LARSEN GL             AM REV RESPIR DIS              119   399 979
    25   PATERSON JW           AM REV RESPIR DIS              120  1149 979
    26   SMALDONE GC           AM REV RESPIR DIS              120   747 979
    27   WOLFF RK              AM REV RESPIR DIS              120   137 979
    28   DUNNILL MS            J PATHOL                       128   221 979
    29   KARASICK D            AM J ROENTGENOL                132   459 979
    30   LEW CD                CLIN CHEST MED                   1   297 980
    31   FEIN A                CRIT CARE MED                    8    94 980
    32   RISSER NL             HEART LUNG                       9    57 980
    33   AHMED T               CLIN RESP PHYSIOL               16   533 980
    34   PAVIA D               CLIN RESP PHYSIOL               16   335 980
    35   VERDUGO P             FERTIL STERIL                   33   193 980
    36   LIPPMANN M            BR J IND MED                    37   337 980
    37   COHEN BS              HEALTH PHYS                     39   619 980
    38   VERDUGO P             J APPL PHYSIOL                  48   868 980
    39   WELSH MJ              J APPL PHYSIOL                  49   905 980
    40   MIRRAKHIMOV MM        TER ARKH                        52    22 980
    41   BATEMAN JRM           CLIN SCI                        58  P  6 980
    42   MATTHYS H             EUR J RESPIR DIS                61    98 980
    43   MOSSBERG B            EUR J RESPIR DIS                61    51 980
    44   MOSSBERG B            EUR J RESPIR DIS                61     8 980
    45   PUCHELLE E            EUR J RESPIR DIS                61   195 980
    46   PUCHELLE E            EUR J RESPIR DIS                61    29 980
    47   ROOKLIN AR            PEDIATRICS                      66   526 980
    48   MEDICI TC             SCHWEIZ MED WOCHENSCHR         110   237 980
    49   MEYER MB              AM REV RESPIR DIS              121   887 980
    50   ISAWA T               TOHOKU J EXP MED               130   189 980
    51   WEISS T               FORTSCHR GEB RONTG NUKL        133   594 980
    52   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
    53   DIRKSEN ER            CELL MOTIL                       1   247 981
    54   BOUCHER RC            CLIN CHEST MED                   2   377 981
    55   YEATES DB             ANN BIOMED ENG                   9   577 981
    56   SVARTENGREN M         CLIN RESP PHYSIOL               17    87 981
    57   YANAURA S             JAP J PHARMACOL                 31   951 981
    58   JAUREGUI WO           MED (BUENOS AIRES)              41    75 981
    59   LEIKAUF G             AM IND HYG ASSOC J              42   273 981
    60   BOUCHER RC            J APPL PHYSIOL                  50   613 981
    61   MIRRAKHIMOV MM        TER ARKH                        53   110 981
    62   MIDDLETON E           MED CLIN NORTH AM               65  1013 981
    63   REYNOLDS HY           MED CLIN NORTH AM               65   667 981
    64   WEISSBERGER D         J ALLERGY CLIN IMMUNOL          67   357 981
    65   GALANT SP             J CLIN INVEST                   68   253 981
    66   CAMNER P              CHEST                           80   824 981
    67   FAZIO F               CHEST                           80   827 981
    68   RUTLAND J             CHEST                           80   865 981
    69   SADOUL P              CHEST                           80   885 981
    70   WANNER A              CHEST                           80   867 981
    71   WEISS T               CHEST                           80   881 981
    72   KNOWLES MR            AM REV RESPIR DIS              124   484 981
    73   LAVIOLETTE M          AM REV RESPIR DIS              124   397 981
    74   MARTIN DW             WEST J MED                     135   300 981
    75   ANON                  LANCET                           1   203 982
    76   SCHOONOVER GA         J CLIN SURG APP PHYSIOL METAB    1   125 982
    77   PERSSON CGA           MED HYPOTHESES                   8   515 982
    78   RUTLAND J             BR J CLIN PHARMACOL             13   679 982
    79   CLEE MD               PHARMACOL THER                  16   283 982
    80   TATTERSFIELD AE       PHARMACOL THER                  17   299 982
    81   ANDERSSON KE          ACTA ANAESTHESIOL SCAND         26    12 982
    82   COCKCROFT DW          CURR THER RES CLIN EXP          31   138 982
    83   SCHLESINGER RB        BIOSCIENCE                      32    45 982
    84   BIGNON J              ANN BIOL CLIN                   40   209 982
    85   SCHLESINGER RB        HEALTH PHYS                     42    73 982
    86   SWINBURNE S           BR J CANCER                     46   625 982
    87   MARIN MG              J APPL PHYSIOL                  52   198 982
    88   MAURER DR             J APPL PHYSIOL                  52  1018 982
    89   FLOOD PR              ACTA ZOOL                       63    17 982
    90   GULSVIK A             EUR J RESPIR DIS                63    15 982
    91   HYBBINETTE JC         ACTA OTOLARYNGOL STOCKH         93   465 982
    92   HYBBINETTE JC         ACTA OTOLARYNGOL STOCKH         93   151 982
    93   HYBBINETTE JC         ACTA OTOLARYNGOL STOCKH         94   121 982
    94   HYBBINETTE JC         ACTA OTOLARYNGOL STOCKH         94   351 982
    95   WOLFF RK              AM REV RESPIR DIS              126   505 982
    96   IRWIN RS              J INFECT DIS                   145   234 982
    97   PUCHELLE E            AM J PHYSIOL                   242  C 31 982
    98   CHRETIEN J            SCHWEIZ MED WOCHENSCHR                36 983
    99   ZANKER KS             ATEMWEGS LUNGENKRANKH            9   181 983
   100   GALANT SP             PEDIATR CLIN NORTH AM           30   931 983
   101   NELSON R              AM J VET RES                    44  1165 983
   102   WEISS T               RESPIRATION                     44   338 983
   103   CLARK TJH             POSTGRAD MED J                  59    54 983
   104   DVORETSKY LI          KLIN MED                        61    20 983
   105   KOHLER D              KLIN WSCHR                      61   243 983
   106   MINETTE A             EUR J RESPIR DIS                64   401 983
   107   CHEN LC               TOXICOL APPL PHARMACOL          71   123 983
   108   WELSH MJ              J CLIN INVEST                   71  1614 983
   109   MURPHY S              PEDIATRICS                      72     1 983
   110   CLOUTIER MM           POSTGRAD MED                    73   169 983
   111   KASAMATSU S           FOLIA PHARMACOL JAP             81    29 983
   112   BELSON TP             LARYNGOSCOPE                    93   549 983
   113   GAIL DB               AM REV RESPIR DIS              127   366 983
   114   WALLACE JM            AM REV RESPIR DIS              128  1077 983
   115   BOUCHER RC            LUNG                           161     1 983
   116   OHASHI Y              ACTA OTOLARYNGOL STOCKH SUPPL  397    49 983
   117   TODRES ID             SEM ANESTHES                     3    98 984
   118   GLECKMAN RA           PHARMACOTHERAPY                  4    81 984
   119   MORGAN KT             FUND APPL TOXICOL                4    58 984
   120   ABRAHAM WM            SEM RESPIR MED                   5   324 984
   121   CLARKE SW             SEM RESPIR MED                   5   319 984
   122   PAVIA D               SEM RESPIR MED                   5   345 984
   123   STURGESS JM           SEM RESPIR MED                   5   301 984
   124   WANNER A              SEM RESPIR MED                   5   329 984
   125   HECK HD               REV BIOCHEM TOXICOL              6   155 984
   126   BORUM P               CLIN OTOLARYNGOL                 9   329 984
   127   GOLDSTEIN E           J TOXICOL ENVIRON HEALTH        13   415 984
   128   LIPPMANN M            J TOXICOL ENVIRON HEALTH        13   441 984
   129   SVARTENGREN M         BULL EUR PHYSIOPATH RESP        20   133 984
   130   WANNER A              BULL EUR PHYSIOPATH RESP        20   477 984
   131   JULIANO RL            PHARMACOL THER                  24   355 984
   132   ALEXOPOULOS C         ACTA ANAESTHESIOL SCAND         28    68 984
   133   SCHLESINGER RB        ENVIRON RES                     34   268 984
   134   STANLEY PJ            THORAX                          39   239 984
   135   LAFORTUNA CL          RESPIRATION                     45   111 984
   136   LEIKAUF GD            AM IND HYG ASSOC J              45   285 984
   137   TODISCO T             RESPIRATION                     45   303 984
   138   BELL JA               MT SINAI J MED                  51   215 984
   139   KNOWLES M             J APPL PHYSIOL                  56   868 984
   140   PETRUSON B            ARCH OTOLARYNGOL               110   576 984
   141   LOKE J                ARCH SURG                      119   956 984
   142   CURTIS LN             AM REV RESPIR DIS              129   816 984
   143   GROSS NJ              AM REV RESPIR DIS              129   856 984
   144   MARTIN TR             AM REV RESPIR DIS              130   778 984
   145   MORGAN KT             AM REV RESPIR DIS              130   275 984
   146   DULL WL               ARCH INTERN MED                144  2399 984
   147   LURIE A               REV MALAD RESPIR                 2   117 985
   148   SCHLESINGER RB        FUND APPL TOXICOL                5   435 985
   149   MORGAN KT             ACTA PHARMACOL SINICA            6   113 985
   150   BICKERT WG            COMPEND CONT ED PRACT VET        7  S309 985
   151   SAKAKURA Y            CLIN OTOLARYNGOL                10    79 985
   152   AKKOCLU G             ATEMWEGS LUNGENKRANKH           11   527 985
   153   KONIETZKO N           ATEMWEGS LUNGENKRANKH           11   145 985
   154   MAJIMA Y              ANN BIOMED ENG                  13   515 985
   155   SHENAI JP             PEDIATR RES                     19   185 985
   156   DOWNES JJ             INT ANESTHESIOL CLIN            23    37 985
   157   MAGNUSSEN H           INTERNIST                       26   201 985
   158   PAUWELS R             ACTA CLIN BELG                  40     1 985
   159   PERRUCHOUD AP         THER UMSCH                      42   126 985
   160   RONCORONI AJ          MED (BUENOS AIRES)              45   183 985
   161   SCHLESINGER RB        ENVIRON HEALTH PERSPECT         63    25 985
   162   LINDBERG S            EUR J RESPIR DIS                66    40 985
   163   VASTAG E              EUR J RESPIR DIS                66    93 985
   164   WANNER A              EUR J RESPIR DIS                66    49 985
   165   SCHUYLER MR           J ALLERGY CLIN IMMUNOL          76   614 985
   166   ROTH RM               SOUTH MED J                     78   573 985
   167   WANNER A              AM J MED                        79    16 985
   168   HARADA RN             CHEST                           87   247 985
   169   WANNER A              AM REV RESPIR DIS              131  S 36 985
   170   MARTIN TR             AM REV RESPIR DIS              132   254 985
   171   ISAWA T               TOHOKU J EXP MED               145   259 985
   172   ROTH Y                BRAIN RES                      330   291 985
   173   FALING LJ             CLIN CHEST MED                   7   599 986
   174   KNOWLES MR            CLIN CHEST MED                   7   285 986
   175   WANNER A              CLIN CHEST MED                   7   247 986
   176   KOHLER D              ATEMWEGS LUNGENKRANKH           12   358 986
   177   WHALEY SL             J TOXICOL ENVIRON HEALTH        19   569 986
   178   WORMAN HJ             BIOCHEMISTRY                    25  1549 986
   179   HINGLEY ST            INFECT IMMUN                    51   254 986
   180   HENNESSY SJ           J APPL PHYSIOL                  60  2109 986
   181   ROBERT C              PHARM ACTA HELV                 61   210 986
   182   WOLFF RK              ENVIRON HEALTH PERSPECT         66   223 986
   183   KOHLER D              EUR J RESPIR DIS                69   319 986
   184   KONIETZKO N           EUR J RESPIR DIS                69    72 986
   185   YEATES DB             EUR J RESPIR DIS                69   100 986
   186   WANNER A              AM J MED                        81    23 986
   187   MORGAN KT             TOXICOL APPL PHARMACOL          86   448 986
   188   MIYATA T              FOLIA PHARMACOL JAP             88    57 986
   189   BURMAN WJ             CHEST                           89   410 986
   190   LINDBERG S            ANN OTOL RHINOL LARYNGOL        95    94 986
   191   MAURIZI M             ACTA OTOLARYNGOL STOCKH        102   136 986
   192   WINKLER GC            AM J PATHOL                    122   541 986
   193   LAZARUS SC            AM J PHYSIOL                   251  C387 986
   194   KARLSSON JA           ARCH INT PHARMACODYN THER      280   191 986
   195   YOKOYAMA E            ENVIRON RES                     42   114 987
   196   KIM CS                J APPL PHYSIOL                  62   959 987
   197   WHALEY SL             J APPL PHYSIOL                  62  1331 987
   198   WANNER A              CHEST                           91  S 49 987

PN 77024
RN 00606 
AN 78038523
AU Keens-T-G.  Krastins-I-R.  Wannamaker-E-M.  Levison-H.  Crozier-D-N.
   Bryan-A-C.
TI Ventilatory muscle endurance training in normal subjects and
   patients with cystic fibrosis.
SO Am-Rev-Respir-Dis. 1977 Nov. 116(5). P 853-60.
MJ CYSTIC-FIBROSIS: pp.  MUSCLES: pp.
MN ADOLESCENCE.  ADULT.  EXERTION.  HUMAN.
   PHYSICAL-EDUCATION-AND-TRAINING.  PHYSICAL-ENDURANCE.  RESPIRATION.
   RESPIRATORY-FUNCTION-TESTS: is, mt.  TIME-FACTORS.
AB Ventilatory muscles can become fatigued, and this can contribute to
   respiratory failure. Patients with chronic obstructive lung disease
   may benefit from improving their ventilatory muscle endurance to
   improve resistance to fatigue. Ventilatory muscle endurance was
   measured in 30 normal subjects and 55 patients with cystic fibrosis
   by finding the highest level of normocapnic hyperpnea that could be
   sustained for 15 min. Subjects with cystic fibrosis had 36 per cent
   higher ventilatory muscle endurance than normal subjects, reflecting
   the chronic training stress of breathing against increased
   respiratory loads. Four normal subjects and 4 subjects with cystic
   fibrosis participated in a specific ventilatory muscle endurance
   training program consisting of 25 min per day of maximal normocapnic
   hyperpnea 5 days per week for 4 weeks. The cystic fibrosis patients
   who trained improved their ventilatory muscle endurance by 51.6 per
   cent, whereas the normal subjects who trained showed a 22.1 per cent
   increase in ventilatory muscle endurance. Seven subjects with cystic
   fibrosis participated in a 4-week physical activity training program
   consisting of at least 1.5 hours per day of intensive swimming and
   canoeing at summer camp. They increased their ventilatory muscle
   endurance by 56.7 per cent. There were no other pulmonary function
   changes. Ventilatory muscle endurance can be readily improved in
   cystic fibrosis equally well by specific ventilatory muscle endurance
   exercise.
RF 001   ROUSSOS CS            PHYSIOLOGIST                    19   345 976
   002   LEITH DE              J APPL PHYSIOL                  41   508 976
   003   ZOCCHE GP             J APPL PHYSIOL                  15  1073 960
   004   TENNEY SM             RESPIR PHYSIOL                   5   187 968
   005   FREEDMAN S            RESPIR PHYSIOL                   8   230 970
   006   LEVISON H             J APPL PHYSIOL                  25    21 968
   007   CLARK TJH             CLIN SCI                        36   307 969
   008   POTTER WA             J CLIN INVEST                   50   910 971
   009   ASTRAND PO            J APPL PHYSIOL                   7   218 954
   010   SNEDECOR GW           STATISTICAL METHODS                      974
   011   LANDAU LI             AM REV RESPIR DIS              111   725 975
   012   LIEBERMAN DA          AM J PHYSIOL                   222   556 972
   013   SANTAMBROGIO A        RESPIR PHYSIOL                  10   236 970
   014   KEENS TG              FED PROC                        36   614 977
   015   PAEZ PN               AM REV RESPIR DIS               95   944 967
CT   1   DERENNE JP            AM REV RESPIR DIS              118   119 978
     2   PERESS L              BULL EUR PHYSIOPATH RESP        15    91 979
     3   ROCHESTER DF          BULL EUR PHYSIOPATH RESP        15   951 979
     4   SMIDT U               BULL EUR PHYSIOPATH RESP        15    95 979
     5   GURWITZ D             PEDIATR CLIN NORTH AM           26   603 979
     6   KEENS TG              PEDIATR CLIN NORTH AM           26   517 979
     7   ANDERSEN JB           SCAND J RESPIR DIS              60   151 979
     8   MACKLEM PT            AM REV RESPIR DIS              119    93 979
     9   GROSS D               AM J MED                        68    27 980
    10   COATES AL             ACTA PAEDIATR SCAND             69   353 980
    11   BELMAN MJ             AM REV RESPIR DIS              121   273 980
    12   CAMPBELL JA           AM REV RESPIR DIS              122   679 980
    13   ROCHESTER DF          AM REV RESPIR DIS              122   133 980
    14   HUBBARD VS            AM J DIS CHILD                 134   317 980
    15   MOSER KM              ARCH INTERN MED                140  1596 980
    16   ZACH MS               LANCET                           2  1201 981
    17   BELMAN MJ             EUR J RESPIR DIS                62   391 981
    18   ORENSTEIN DM          CHEST                           80   392 981
    19   LISBOA C              REV MED CHIL                   109   476 981
    20   MORENO R              REV MED CHIL                   109   393 981
    21   PARDY RL              AM REV RESPIR DIS              123   426 981
    22   JARDIM J              AM REV RESPIR DIS              124   274 981
    23   MARTIN BJ             INT J SPORTS MED                 3   100 982
    24   MILES DS              ERGONOMICS                      25   239 982
    25   MILLER M              AM J CLIN NUTR                  36   492 982
    26   GIMENEZ M             EUR J APP PHYSI OCCUP PHYSIOL   49   379 982
    27   NICKERSON BG          J APPL PHYSIOL                  52   768 982
    28   ROBINSON EP           J APPL PHYSIOL                  52  1400 982
    29   ZACH M                ARCH DIS CHILD                  57   587 982
    30   COHEN CA              AM J MED                        73   308 982
    31   BELMAN MJ             CHEST                           81   440 982
    32   SONNE LJ              CHEST                           81   436 982
    33   BELMAN MJ             CHEST                           82   761 982
    34   ALDRICH TK            AM REV RESPIR DIS              126   195 982
    35   ARORA NS              AM REV RESPIR DIS              126     5 982
    36   ASHER MI              AM REV RESPIR DIS              126   855 982
    37   DELGADO HR            AM REV RESPIR DIS              126   200 982
    38   ROUSSOS C             N ENGL J MED                   307   786 982
    39   SHEPHERD RW           J PEDIATR GASTROENTEROL NUTR     2   439 983
    40   SHARP JT              CLIN CHEST MED                   4   421 983
    41   GROSS D               ISR J MED SCI                   19   383 983
    42   FANTA CH              J APPL PHYSIOL                  54  1618 983
    43   ROCHESTER DF          MED CLIN NORTH AM               67   573 983
    44   NICKERSON BG          PEDIATRICS                      71   147 983
    45   MORENO R              REV MED CHIL                   111   647 983
    46   WEISMAN IM            AM REV RESPIR DIS              127   641 983
    47   ONEILL S              AM REV RESPIR DIS              128  1051 983
    48   PARDY RL              CLIN CHEST MED                   5    35 984
    49   CARRIERI VK           HEART LUNG                      13   436 984
    50   KIM MJ                HEART LUNG                      13   333 984
    51   KOTTKE TE             PREV MED                        13    47 984
    52   MOXHAM J              BULL EUR PHYSIOPATH RESP        20   437 984
    53   HODSON ME             POSTGRAD MED J                  60   225 984
    54   FARKAS GA             J CLIN INVEST                   74  1214 984
    55   HODGES P              J AM DIET ASSOC                 84   664 984
    56   JEDERLINIC P          CHEST                           86   870 984
    57   SONNE LJ              CHEST                           86   939 984
    58   WAGENER JS            AM REV RESPIR DIS              129   873 984
    59   DIMARCO AF            MUSCLE NERVE                     8   284 985
    60   GREEN M               CLIN SCI                        68     1 985
    61   SHARP JT              CHEST                           88  S118 985
    62   RENZI G               UNION MED CAN                  114   897 985
    63   BELMAN MJ             AM REV RESPIR DIS              131   226 985
    64   CHEN HI               AM REV RESPIR DIS              131   251 985
    65   ZACH M                MONATSSCHR KINDERHEILKD        133   868 985
    66   ALDRICH TK            LUNG                           163    15 985
    67   HUGHES RL             ACTA PAEDIATR SCAND SUPPL 317 1985    42 985
    68   HADDAD GG             CLIN CHEST MED                   7    79 986
    69   KELSEN SG             CLIN CHEST MED                   7   101 986
    70   MCKEON JL             AUST NZ J MED                   16   648 986
    71   MARTIN AJ             DEVELOP MED CHILD NEUROL        28   314 986
    72   ESTRUP C              RESPIRATION                     50    36 986
    73   MACINTYRE NR          CHEST                           89   677 986
    74   BELMAN MJ             CHEST                           90   662 986
    75   RIES AL               CHEST                           90   285 986
    76   MOCELLIN R            WIEN KLIN WOCHENSCHR            98   735 986
    77   LEVINE S              AM REV RESPIR DIS              133   400 986
    78   EDLUND LD             AM J DIS CHILD                 140    80 986
    79   CLANTON TL            J APPL PHYSIOL                  62    39 987
    80   CROPP A               AM REV RESPIR DIS              135  1056 987

PN 77025
RN 00607 
AN 77219983
AU Boat-T-F.  Petty-T-L.
TI Chronic bronchitis and cystic fibrosis: two chronic obstructive lung
   diseases of adults [editorial].
SO Am-Rev-Respir-Dis. 1977 Jul. 116(1). P 1-2.
MJ BRONCHITIS.  CYSTIC-FIBROSIS.
MN ADULT.  BRONCHITIS: di, th.  CHRONIC-DISEASE.
   CYSTIC-FIBROSIS: di, th.  HUMAN.  PROGNOSIS.
EX As patients with cystic fibrosis survive longer, the number of
   adults with this chronic obstructive lung disease is increasing
   rapidly.  Chronic bronchitis and cystic fibrosis are similar in a
   number of respects.  The treatment of cystic fibrosis and chronic
   bronchitis has some similarities.  But chronic bronchitis and cystic
   fibrosis also differ in many respects.  The pathogenesis of chronic
   bronchitis is more clearly related to exogonous factors such as
   smoking and air pollution than is cystic fibrosis, which is
   genetically determined.  Clinical differences also exist.  Major
   differences in treatment between cystic fibrosis and chronic
   bronchitis are currently in vogue.  Because of the special problems
   of adulthood, it is appropriate that many adult patients with cystic
   fibrosis be cared for by internists who have previously focused
   their attention on chronic bronchitis and emphysema.  Increased
   communication between internists and pediatricians on the issue of
   cystic fibrosis is badly needed today.
CT   1   HOWIE AD              SCOTT MED J                     24   193 979
     2   SANTAGNESE PAD        AM J MED                        66   121 979
     3   HENRY RL              AUST PAEDIATR J                 18    43 982
     4   GOTZ M                ATEMWEGS LUNGENKRANKH           10   594 984
     5   KAUFFMANN F           BULL EUR PHYSIOPATH RESP        20   163 984
     6   DAVIS PB              CHEST                           85   802 984
     7   GOTZ M                MED KLIN                        80   657 985

PN 77026
RN 00608 
AN 78058877
AU Lieberman-J.  Kaneshiro-W.
TI Abnormal response of cultured lymphocytes to phytohemagglutinin and
   autologous serum in cystic fibrosis.
SO Am-Rev-Respir-Dis. 1977 Dec. 116(6). P 1047-55.
MJ CYSTIC-FIBROSIS: im.  LYMPHOCYTE-TRANSFORMATION.  LYMPHOCYTES: im.
MN ADOLESCENCE.  ADULT.  BLOOD-TRANSFUSION-AUTOLOGOUS.  CELLS-CULTURED.
   COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: fg.  FEMALE.  GLUCURONIDASE: an.
   HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.  IN-VITRO.  LYMPHOCYTES: an.
   MALE.  LECTINS.  PROTEINS: an.  SUPPORT-U-S-GOVT-P-H-S.
AB Lymphocytes from adults homozygous or heterozygous for cystic
   fibrosis show biochemical abnormalities when cultured for 48 hours in
   the presence of phytohemagglutinin and autologous serum. In contrast
   to the 45 per cent increase in total protein and beta-glucuronidase
   concentrations seen in healthy control subjects when measured per
   10(10) cells, both concentrations decreased by 1 per cent in adults
   heterozygous for cystic fibrosis and by 18 per cent in adults
   homozygous for cystic fibrosis. The abnormal response of the
   lymphocytes from persons with cystic fibrosis was due to a serum
   factor and not to any intrinsic abnormality of the lymphocytes. An
   abnormal response to hytohemagglutinin occurred in only 14 per cent
   of 44 healthy control subjects, but in 100 per cent of 14 adults
   homozygous for cystic fibrosis and in 85 per cent of 26 adults
   presumed to be heterozygous for cystic fibrosis. As a result of this
   phenomenon, lymphocytic beta-glucuronidase concentrations were
   significantly lower than normal in patients with cystic fibrosis when
   the cells were cultured with phytohemagglutinin and autologous serum.
   The demonstration of this phenomenon in both homozygotes and presumed
   heterozygotes (parents) suggests a relationship to the genetic defect
   in cystic fibrosis.
RF 001   LIEBERMAN J           CHEST                           70   433 976
   002   WOOD RE               AM REV RESPIR DIS              113   833 976
   003   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   004   DANES BS              NATURE                         222   685 969
   005   DANES BS              LANCET                           2   437 969
   006   GRIFFIN GD            PROC SOC EXP BIOL MED          137   438 971
   007   ANTONOWICZ I          PEDIATR RES                      6   803 972
   008   RENNERT OM            CLIN PEDIATR                    11   351 972
   009   MARCHI AG             HELV PAEDIATR ACTA              28   427 973
   010   CONOVER JH            PEDIATR RES                      7   224 973
   011   STEELE WM             PEDIATR RES                      7   394 973
   012   BOZKOWA K             BOLL IST SIEROTER MILAN         53   266 974
   013   DANES BS              BIOCHEM GENET                   12   359 974
   014   SHAPIRO BL            LANCET                           2  1020 974
   015   OGRADY LR             CF CLUB ABST                          16 975
   016   BRAUNSTEIN M          CF CLUB ABST                          28 975
   017   BEUTLER E             J EXP MED                      143   975 976
   018   THURMAN GB            CLIN EXP IMMUNOL                15   289 973
   019   HIRSCHHORN K          SCIENCE                        166  1632 969
CT   1   LIEBERMAN J           LANCET                           1   985 978
     2   MARCHI AG             HELV PAEDIATR ACTA              33   517 978
     3   SORENSEN RU           INFECT IMMUN                    23   398 979
     4   LIEBERMAN J           CHEST                           75   220 979
     5   HODSON ME             THORAX                          35   801 980
     6   WILSON GB             J CLIN INVEST                   66  1010 980
     7   SORENSEN RU           PEDIATR RES                     15    14 981
     8   SORENSEN RU           AM REV RESPIR DIS              123    37 981
     9   SEALE TW              ANN CLIN LAB SCI                12   415 982
    10   DISTELHORST CW        CELL IMMUNOL                    75   188 983
    11   LIEBERMAN J           AM J MED                        77   678 984
    12   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985

PN 77027
RN 00609 
AN 77179912
AU Berry-D-H.  Brewster-M-A.
TI Granulocyte NADH oxidase in cystic fibrosis.
SO Ann-Allergy. 1977 May. 38(5). P 316-9.
MJ BACTERIAL-INFECTIONS: di.  CYSTIC-FIBROSIS: en.  GRANULOCYTES: en.
   LEUKOCYTES: en.  NADH-NADPH-OXIDOREDUCTASES: bl.
MN BACTERIAL-INFECTIONS: co.  CYSTIC-FIBROSIS: bl, co.  HUMAN.
   NITROBLUE-TETRAZOLIUM: du.
AB The nitro blue tetrazolium dye test was evaluated for its usefulness
   in detecting superimposed bacterial infection in 50 children with
   cystic fibrosis.  No correlation of percentage of positive
   neutrophils to superimposed infection, clinical status or to
   bacterial organisms could be determined.  Cystic fibrosis
   granulocytes generally have greater NADH oxidase activity than do
   controls.
RF 001   KARNOVSKY ML          SEMIN HEMATOL                    5   156 968
   002   NATHAN DG             J CLIN INVEST                   48    85 969
   003   BAEHNER RL            N ENGL J MED                   278   971 968
   004   PARK BH               LANCET                           2   532 968
   005   FEIGIN RD             J PEDIATR                       78   230 971
   006   MATULA G              N ENGL J MED                   285   311 971
   007   EVANS TJ              LANCET                           1   992 974
   008   FEIGIN RD             CLIN MED                        81    16 974
   009   STEIGBIGEL RT         N ENGL J MED                   290   235 974
   010   FINEBERG H            N ENGL J MED                   290  1144 974
   011   SULLIVAN JF           AM J DIS CHILD                 125   702 973

PN 77028
RN 00610 
AN 77155815
AU Ten-Kate-L-P.
TI A method for analysing fertility of heterozygotes for autosomal
   recessive disorders, with special reference to cystic fibrosis,
   Tay-Sachs disease and phenylketonuria.
SO Ann-Hum-Genet. 1977 Jan. 40(3). P 287-97.
MJ FERTILITY.  GENES-RECESSIVE.  HEREDITARY-DISEASES: fg.
   HETEROZYGOTE.
MN LIPOIDOSIS: fg.  CYSTIC-FIBROSIS: fg.  GENETICS-POPULATION.  HUMAN.
   PHENYLKETONURIA: fg.  STATISTICS.
AB Increased fertility of heterozygotes with respect to decreased foetal
   loss among offspring of heterozygotes has been proposed by several
   authors as a possible explanation for the high gene frequency of CF,
   TSD and PKU in certain populations. Studies comparing reproductive
   outcome of heterozygotes with reproductive performance in the general
   population or in special control groups have been done on several
   occasions. These studies, however, are known to be heavily biased, on
   the one side by the fact that ascertainment of heterozygotes through
   affected offspinrg will tend to underestimate the relative frequency
   of smaller families, and on the other side because of the inadequacy
   of census data for comparison and the biases inherent in selection of
   control families. Careful analysis of the biases involved provides
   suggestions for proper corrections. From this a method has been
   developed which offers a better approach to the study of heterozygote
   fertility in those autosomal recessive conditions which lack a test
   for direct heterozygote detection.
RF 001   BARRAI I              AM J HUM GENET                  17   221 965
   002   BAUMANN T             HELV PAEDIATR ACTA SUPPL 8      13     1 958
   003   BRUNECKY Z            PAEDIATR GRENZGEB                8    99 969
   004   CHASE GA              AM J HUM GENET                  24   339 972
   005   ANON                  HUMANGENETIK                    30   273 975
   006   CONNEALLY PM          TEX REP BIOL MED                31   639 973
   007   DANKS DM              ANN HUM GENET                   28   323 965
   008   ELANDT-JOHNSON RC     PROB MODELS AND STAT METH IN             971
   009   GERY G                J GENET HUM                     19   275 971
   010   GILLY R               ARCH FR PEDIATR                 28    49 971
   011   GOLD RJM              ANN HUM GENET                   37   315 974
   012   GOODMAN HO            AM J HUM GENET                   4    59 952
   013   HIRSCHHORN K          IN: MANGOS JA                         11 973
   014   KAARIAINEN R          HEREDITAS                       75   241 973
   015   KAARIAINEN R          HEREDITAS                       75   109 973
   016   KNUDSON AG JR         AM J HUM GENET                  19   388 967
   017   LENZ W                ACTA GENETICA                    9   169 959
   018   MASTERSON J           PROC EWGCF 6TH ANNU MTG                  975
   019   MAYO O                ANN HUM GENET                   33   307 970
   020   MYRIANTHOPOULOS NC    IN: ARONSON SM                           962
   021   MYRIANTHOPOULOS NC    AM J HUM GENET                  18   313 966
   022   OAKES MW              ANN HUM GENET                   32   173 968
   023   OBRIEN JS             N ENGL J MED                   283    15 970
   024   RAO CR                IN: PATIL GP                             965
   025   RAO DC                AM J HUM GENET                  25   594 973
   026   RECORD RG             BR J PREV SOC MED               29   267 975
   027   SAUGSTAD LE           CLIN GENET                       4   105 973
   028   SIMANKOVA N           CESK PEDIATR                    25    77 970
   029   SINISCALCO M          MAANDSCHRIFT VOOR KINDERGENEE   37   134 969
   030   ANON                  STATISTISCHES JAHRBUCH DER SC            955
   031   STEINBERG AG          AM J HUM GENET                  12   416 960
   032   STEPHAN U             PEDIATRICS                      55    35 975
   033   WAGENER DK            AM J HUM GENET                  27   348 975
   034   WESTWOOD A            J MED GENET                     12   327 975
   035   WOOLF LI              ANN HUM GENET                   38   461 975
   036   WRIGHT SW             IN: LAWSON D PROC 5TH INT CF          91 969
   037   WRIGHT SW             AM J HUM GENET                  20   157 968
CT   1   MAYO O                HUM HERED                       28   270 978
     2   TENKATE LP            ANN HUM GENET                   41   463 978
     3   TENKATE LP            ANN HUM GENET                   41   397 978
     4   MACCLUER JW           ANN HUM GENET                   42    59 978
     5   JAKEL HP              BIOL ZENTRALBL                  98    55 979

PN 77029
RN 00611 
AN 77240385
AU Stern-R-C.  Boat-T-F.  Doershuk-C-F.  Tucker-A-S.  Miller-R-B.
   Matthews-L-W.
TI Cystic fibrosis diagnosed after age 13.  Twenty-five teenage and
   adult patients including three asymptomatic men.
SO Ann-Intern-Med. 1977 Aug. 87(2). P 188-91.
MJ CYSTIC-FIBROSIS: di.
MN ADOLESCENCE.  ADULT.  AGE-FACTORS.  CYSTIC-FIBROSIS: co, mi.  FEMALE.
   HUMAN.  LUNG-DISEASES: et.  MALE.  PSEUDOMONAS-INFECTIONS: et.
   INFERTILITY-MALE: et.  SUPPORT-U-S-GOVT-P-H-S.
AB Cystic fibrosis was diagnosed after age 13 in 25 patients. All had an
   elevated sweat chloride and either a sibling with cystic fibrosis or
   typical pulmonary infection or digestive symptoms caused by exocrine
   pancreatic deficiency. Fourteen had long-standing pulmonary or
   digestive symptoms. In contrast, four of eight patients whose
   symptoms began after age 13 presented with biliary cirrhosis. Three
   male patients were asymptomatic at diagnosis. Opacification of all
   paranasal sinuses was found in all patients examined radiologically.
   At diagnosis, pulmonary-function testing showed obstructive changes
   in 19 patients and sputum cultures showed Pseudomonas aeruginosa in
   15 patients. Delayed menarche in five of seven female patients and
   infertility in the asymptomatic male patient (two of whom were found
   to have aspermia) could have led to earlier diagnosis. Teenagers and
   young adults with long-standing pulmonary or digestive symptoms,
   unexplained cirrhosis, aspermia, or a sibling with cystic fibrosis
   should be sweat-tested by pilocarpine iontophoresis.
RF 001   SHWACHMAN H           PROC INT CF CONG 7TH                  90 976
   002   CROZIER DN            PEDIATR CLIN NORTH AM           21   935 974
   003   STERN RC              J PEDIATR                       89   406 976
   004   MITCHELL-HEGGS PF     Q J MED                         45   479 976
   005   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   006   ADDINGTON WW          CHEST                           59   306 971
   007   LOBER CW              CHEST                           66   332 974
   008   COATES EO JR          DIS CHEST                       49   195 966
   009   TOMASHEFSKI JF        CHEST                           57    28 970
   010   NOLAN AJ              CAN MED ASSOC J                114   142 976
   011   STERN RC              GASTROENTEROLOGY                70   645 976
   012   KAPLAN E              N ENGL J MED                   279    65 968
   013   DENNING CR            PEDIATRICS                      41     7 968
   014   COMROE JH JR          LUNG CLINICAL PHYSIOLOGY AND             962
   015   WILLMON TL            AM J PHYSIOL                   153   138 948
   016   DUBOIS AB             J CLIN INVEST                   35   322 956
   017   DOERSHUK CF           J PEDIATR                       65   677 964
   018   GHARIB R              AM J DIS CHILD                 108   499 964
   019   LOBECK CC             PEDIATRICS                      30   172 962
   020   MURTHY MSN            OHIO STATE MED J                69   768 973
   021   SHWACHMAN H           PEDIATRICS                      55    86 975
   022   MEARNS MB             ARCH DIS CHILD                  47   902 972
CT   1   SCHWARZ HP            HELV PAEDIATR ACTA              33   351 978
     2   FINK RJ               CHEST                           74   643 978
     3   ANDREWS C             ANN INTERN MED                  88   128 978
     4   HOWIE AD              SCOTT MED J                     24   193 979
     5   SANTAGNESE PAD        AM J MED                        66   121 979
     6   HOLSCLAW DS           CLIN CHEST MED                   1   407 980
     7   ALLAN JL              AUST PAEDIATR J                 16   270 980
     8   SANDERS JS            CHEST                           77   226 980
     9   REYNOLDS HY           CLIN CHEST MED                   2   103 981
    10   FRIEDMAN PJ           AM J ROENTGENOL                136  1131 981
    11   COLTEN HR             N ENGL J MED                   304   831 981
    12   STERN RC              LANCET                           1  1401 982
    13   MASARYK TJ            DIG DIS SCI                     28   874 983
    14   VANSCOY RE            MED CLIN NORTH AM               67   173 983
    15   MATTHEWS LW           PEDIATR CLIN NORTH AM           31   133 984
    16   LEWIS MI              S AFR MED J                     65   641 984
    17   ROSENSTEIN BJ         SOUTH MED J                     77  1383 984
    18   HANDELSMAN DJ         N ENGL J MED                   310     3 984
    19   DAVIS PB              SEM RESPIR MED                   6   314 985
    20   ORENSTEIN DM          SEM RESPIR MED                   6   252 985
    21   REINIG JW             PEDIATR RADIOL                  15   222 985
    22   REYNOLDS HY           DISEASE A MONTH                 31     1 985
    23   SCOGGIN CH            POSTGRAD MED                    77   243 985
    24   ISPIZUA AU            MED CLIN                        85   628 985
    25   HILL DJS              MED J AUST                     143   230 985
    26   OCONNOR KW            ARCH INTERN MED                145   153 985
    27   ISPIZUA AU            REV CLIN ESP                   176   417 985
    28   BOUE A                HUM GENET                       74   288 986
    29   ROSENSTEIN BJ         SOUTH MED J                     79   319 986
    30   SARNELLI  R           AM J MED                        80   541 986
    31   ABDULKARIM FW         ARCH PATHOL LAB MED            110   602 986

PN 77030
RN 00612 
AN 78079393
AU Schwarz-V.  Simpson-N-I.  Ahuja-A-S.
TI Limitations of diagnostic value of the sweat test.
SO Arch-Dis-Child. 1977 Nov. 52(11). P 870-4.
MJ CYSTIC-FIBROSIS: di.  SODIUM: an.  SWEAT: an.
MN ADOLESCENCE.  ASTHMA: di.  CHILD.  CHILD-PRESCHOOL.
   DIAGNOSIS-DIFFERENTIAL.  HUMAN.  SWEAT: se.  TIME-FACTORS.
AB The sweat test, even if carried out by an experienced technician,
   sometimes lacks reproducibility owing presumably to physiological
   variations (patient's diet, temperature, and other factors at present
   unrecognized). Some patients are particularly prone to exhibit this
   variability and in them a single sweat test is almost valueless. The
   aldosterone status is believed to be responsible for a reciprocal
   relationship between sweat sodium and potassium concentrations: tests
   done on 8 patients show that a high sweat potassium is associated
   with a correspondingly lower sodium--a circumstance which must be
   borne in mind when interpreting a patient's sweat sodium. Of 30
   patients presenting with a variety of symptoms compatible with a
   diagnosis of cystic fibrosis and with sweat sodium ranging from 50 to
   75 mEq/1 (50-75 mmol/1), only 4 have proved to have cystic fibrosis
   after several years of observations; 13 have later been diagnosed as
   having asthma. The problem of the 'grey area' of uncertainty is
   aggravated by the heterozygous state which is also associated with a
   sweat sodium in this range. Repeated sweat tests are indicated if the
   sweat sodium lies within the 'grey area', and the diagnostic
   importance accorded the test should diminish as the sodium value
   approaches this area. The diagnosis of cystic fibrosis must remain in
   doubt unless there is strong supportive clinical evidence.
RF 001   ANDERSON CM           CF A MANUAL OF DIAGNOSIS AND             976
   002   ANON                  J PEDIATR                       88   711 976
   003   DARLING RC            AM J MED SCI                   225    67 953
   004   DI SANTAGNESE PA      J PEDIATR                       81   196 972
   005   GIBSON LE             J PEDIATR                       81   193 972
   006   GIBSON LE             PEDIATRICS                      23   545 959
   007   MCKENDRICK T          LANCET                           1   183 962
   008   SCHWARZ V             IN: PORTER R                    32       968
   009   SCHWARZ V             ARCH DIS CHILD                  43   695 968
   010   SUTCLIFFE CH          PROC R SOC MED                  61   297 968
CT   1   CHAZALETTE JP         PEDIATRE                        13   303 977
     2   ANON                  LANCET                           2  1032 978
     3   SMALLEY CA            LANCET                           2   415 978
     4   BARNES GL             AUST PAEDIATR J                 14    78 978
     5   SMALLEY CA            ARCH DIS CHILD                  53   351 978
     6   TARNOKY AL            J ROY SOC MED                   73    73 980
     7   LITTLEWOOD JM         PRACTITIONER                   224   305 980
     8   DAVID TJ              LANCET                           2  1204 982
     9   HEELEY AF             CLIN CHEM                       29  2011 983

PN 77031
RN 00613 
AN 77200637
AU Partington-M-W.  Ferguson-A-C.
TI Serotonin metabolism in cystic fibrosis.
SO Arch-Dis-Child. 1977 May. 52(5). P 386-90.
MJ CYSTIC-FIBROSIS: bl.  SEROTONIN: bl.
MN ADOLESCENCE.  BLOOD-CELL-COUNT.  BLOOD-PLATELETS.  CHILD.
   CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: im.  FEMALE.  HUMAN.
   HYDROXYINDOLEACETIC-ACID: ur.  IGE: an.  INFANT.  MALE.
AB The average blood serotonin level of 67 children with cystic fibrosis
   was found to be about twice that of age-matched normal children.
   There was no corresponding increase in the urinary excretion of 5-
   hydroxyindoleacetic acid (5-HIAA). Children with cystic fibrosis were
   well able to metabolize serotonin taken by mouth. No significant
   correlations were found between the blood serotonin level and the
   platelet count, height, weight, skinfold thickness, and pulmonary
   function test, 5 out of 44 patients had raised serum IgE levels, and
   their mean blood serotonin was higher than in those with normal IgE
   levels. No explanation for this emerged. Comparable findings (raised
   blood serotonin normal platelet count, normal urinary 5-HIAA) have
   been reported only in severe mental retardation. Further study of
   this phenomenon is warranted because (a) a raised blood serotonin
   level is sufficiently characteristic of cystic fibrosis to explore
   its use in diagnosis, and (b) it may help to explain the pathogenesis
   of cystic fibrosis and (c) the metabolism and function of serotonin.
RF 001   ASHCROFT GW           CLIN CHIM ACTA                   9   364 964
   002$  BELLANTI JA           IMMUNOLOGY                           226 972
   003   BERMAN JL             J PEDIATR                       67   603 965
   004   CHALLACOMBE DN        ARCH DIS CHILD                  47   442 972
   005   DICKMAN ML            AM REV RESPIR DIS              104   680 971
   006   FISHMAN AP            N ENGL J MED                   291   884 974
   007   GRAHAME-SMITH DG      CARCINOID SYNDROME                       972
   008   HAVERBACK BJ          GASTROENTEROLOGY                35   570 958
   009   KJELLMAN NIM          CLIN ALLERGY                     6    51 976
   011   KORF J                CLIN CHIM ACTA                  26   301 969
   012   LOTT IT               PEDIATR RES                      6   730 972
   013   MCCOY EE              N ENGL J MED                   291   950 974
   014   PARE CMB              J NEUROL NEUROSURG PSYCHIAT     23   341 960
   015   PARTINGTON MW         DEVELOP MED CHILD NEUROL        15   616 973
   016   PIMPARKAR BD          GASTROENTEROLOGY                40   504 961
   017   RACHELEFSKY GS        AM J DIS CHILD                 128   355 974
   018   SPITZ E               J ALLERGY CLIN IMMUNOL          49   337 972
   019   TANNER JM             BR MED J                         1   446 962
   020   TANNER JM             ARCH DIS CHILD                  41   454 966
   021   TEOTIA M              AM J CLIN NUTR                  28  1284 975
   022   TU JB                 DEVELOP MED CHILD NEUROL        14   457 972
   023   UDENFRIEND S          ARCH BIOCHEM BIOPHYS            85   487 959
   024   WAALKES TP            SCIENCE                        127   648 958
CT   1   CUSACK D              HORM METAB RES                  11   448 979
     2   SCHONI MH             PEDIATR RES                     19    47 985

PN 77032
RN 00614 
AN 78038980
AU Strunk-R-C.  Sieber-O-F.  Taussig-L-M.  Gall-E-P.
TI Serum complement depression during viral lower respiratory tract
   illness in cystic fibrosis.
SO Arch-Dis-Child. 1977 Sep. 52(9). P 687-90.
MJ COMPLEMENT: an.  CYSTIC-FIBROSIS: co.
   RESPIRATORY-TRACT-INFECTIONS: im.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  COMPLEMENT-3: an.
   COMPLEMENT-4: an.  CYSTIC-FIBROSIS: im.  FEMALE.  HUMAN.  INFANT.
   MALE.  RESPIRATORY-TRACT-INFECTIONS: co.  SUPPORT-U-S-GOVT-P-H-S.
   VIRUS-DISEASES: im.
AB Cystic fibrosis (CF) patients with viral lower respiratory tract
   illnesses (LRI) had depressed levels of the third and fourth
   components of complement, which returned to normal after recovery.
   There was no clinical evidence of immune complex disease. CF patients
   with LRI and no virus isolates, CF patients in stable status, and non-
   CF patients with LRI did not have complement depression. It is
   postulated that antigen-antibody complex activation of complement may
   occur in CF patients with viral LRI.
RF 001   CONOVER JH            LANCET                           2  1501 973
   002   DEFOREST A            PEDIATR RES                      6   388 972
   003   GAITHER TA            J IMMUNOL                      113   574 974
   004   HANN S                LANCET                           2   520 974
   005   LENNETTE EH           DIAGN PROCEDURES FOR VIRAL AN            969
   006   MCFARLANE H           BR MED J                         1   423 975
   007   MANCINI G             IMMUNOCHEMISTRY                  2   235 965
   008   MAYER MM              IN: KABAT EA                         133 961
   009   NADLER HL             IN: STANBURY JB                     1683 978
   010   OLDSTONE MBA          PROG MED VIROL                  19    84 975
   011   POLLEY MJ             J MED GENET                     11   249 974
   012   STEIN AA              J PEDIATR                       65   495 964
   013   TAUSSIG LM            J PEDIATR                       82   380 973
   014   WALLWORK JC           CLIN EXP IMMUNOL                18   303 974
CT   1   HOWIE AD              SCOTT MED J                     24   193 979
     2   STRAUSS RG            HELV PAEDIATR ACTA              34   429 979
     3   MOSS RB               AM REV RESPIR DIS              121    23 980
     4   PETERSEN NT           ACTA PAEDIATR SCAND             70   623 981
     5   CHURCH JA             CHEST                           80   405 981
     6   MANTHEI U             AM REV RESPIR DIS              126   253 982
     7   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
     8   GUPTA AK              BR J OPHTHALMOL                 68   350 984
     9   SEN DK                BR J OPHTHALMOL                 69   707 985
    10   FRIEND PA             J INFECT                        13    55 986

PN 77033
RN 00615 
AN 77110778
AU Hide-D-W.  Martlew-R.
TI Cystic fibrosis and myocardial fibrosis [letter].
SO Arch-Dis-Child. 1977 Feb. 52(2). P 163.
MJ CYSTIC-FIBROSIS: co.  ENDOMYOCARDIAL-FIBROSIS: co.
MN CASE-REPORT.  CHILD-PRESCHOOL.  HUMAN.  MALE.
EX We were interested in the case reported by Mukherji et al., which
   suggested that cystic fibrosis might be an acid
   mucopolysaccharidosis.  We have seen a similar child.  Aged 5 years
   he was admitted to hospital with pneumonia.  In spite of conventional
   treatment with cloxacillin and colistin he collapsed and died 48
   hours after admission.  The heart was not enlarged, but the
   myocardium showed a grossly abnormal appearance with variations in
   thickness and extensive areas of firm pale tissue.  Histology of the
   heart muscle showed very dramatic changes with severe replacement
   fibrosis distributed patchily through the myocardium.  This similar
   mixture of neutral and acid mucopolysaccharides was shown in both the
   pancreas and the salivary glands.  There have now been a number of
   reports of myocardial fibrosis complicating cystic fibrosis.  The
   case reported by Mukherji et al. and this case are the first in which
   mucopolysaccharide deposits have been found in the myocardium.  The
   mixture of neutral and acid mucopolysaccharides in our case does not
   support the hypothesis that cystic fibrosis is simply a genetic acid
   mucopolysaccharidosis.
RF 001   BARNES GL             AUST PAEDIATR J                  6    81 970
   002   HIDE DW               ARCH DIS CHILD                  44   533 969
   003   MUKHERJI RN           ARCH DIS CHILD                  51   563 976
   004   OPPENHEIMER EH        JOHNS HOPKINS MED J            133   252 973
CT   1   TORRIANI R            MONOGR PAEDIATR                 10   155 979
     2   ZIMMERMANN A          HELV PAEDIATR ACTA              37   183 982
     3   VANVLEET JF           AM J PATHOL                    124    95 986

PN 77034
RN 00616 
AN 78079397
AU McCollum-J-P.  Muller-D-P.  Harries-J-T.
TI Test meal for assessing intraluminal phase of absorption in
   childhood.
SO Arch-Dis-Child. 1977 Nov. 52(11). P 887-9.
MJ BILE-ACIDS-AND-SALTS: an.  DIET.  MALABSORPTION-SYNDROMES: di.
   PANCREAS: en.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: en.
   ESTERASES: me.  FEMALE.  HUMAN.  INFANT.  INFANT-NEWBORN.
   LIPASE: me.  MALABSORPTION-SYNDROMES: en.  MALE.  TRYPSIN: me.
AB A test meal for assessing the intraluminal phase of absorption in
   childhood has been validated. 132 test meals were administered to 110
   patients aged 2 weeks to 18 years (mean age 4.3 years). 10 children
   with suspected malabsorption, who were proven to be normal after
   extensive investigation, constituted the control group. The
   activities of pancreatic enzymes, and the total and individual bile
   salt concentrations are presented for the control subjects, and
   pancreatic enzyme levels in this group are compared with those seen
   in children with pancreatic insufficiency (cystic fibrosis). The test
   meal has been designed so that it can be administered to children
   with suspected gluten, cows' milk, or disaccharide intolerance. The
   control data provided a basis for the interpretation of information
   obtained from the application of such a test meal to the clinical
   investigation of children with suspected malabsorption.
RF 001   CESKA M               CLIN CHIM ACTA                  26   437 969
   002   ERLANSON C            SCAND J GASTROENTEROL            5   333 970
   003   ERLANSON C            SCAND J GASTROENTEROL            5   293 970
   004   HADORN B              CLIN GASTROENTEROL               1   125 972
   005   HOFMANN AF            IN: JAMES AT                         362 964
   006   IWATA T               J BIOCHEM (TOKYO)               56   424 964
   007   LUNDH G               GASTROENTEROLOGY                42   275 962
   008   MAKINO I              ANAL LETT                        5   341 972
   009   WIGGINS HS            GUT                              8   415 967
   010   ZOPPI G               PEDIATR RES                      6   880 972
CT   1   HARRIES JT            ARCH DIS CHILD                  54    19 979
     2   WALLER SL             AUST NZ J MED                   10   351 980
     3   FREDRIKZON B          PEDIATR RES                     14  1387 980
     4   AGGETT PJ             ARCH DIS CHILD                  55   331 980
     5   NIESSEN KH            MONATSSCHR KINDERHEILKD        128   746 980
     6   GLASGOW JFT           IR J MED SCI                   149   346 980
     7   GLASGOW JFT           IR J MED SCI                   149   194 980
     8   BANCHINI G            PEDIATR RES                     15  1073 981
     9   MATHIAS PM            J LIPID RES                     22   829 981
    10   MATHIAS PM            J LIPID RES                     22   177 981
    11   MULLER DPR            CLIN GASTROENTEROL              11   119 982
    12   MULLER DPR            ANN CLIN BIOCHEM                19    89 982
    13   MILLA PJ              GUT                             24   818 983
    14   BALI A                BR MED J                       287  1011 983
    15   SAVAGE MO             J PEDIATR GASTROENTEROL NUTR     4   187 985
    16   SARLES J              ARCH FR PEDIATR                 44   311 987

PN 77035
RN 00617 
AN 77200629
AU Edwards-J-H.
TI Heterozygote advantage.
SO Arch-Dis-Child. 1977 May. 52(5). P 343-4.
MJ HEREDITARY-DISEASES.  HETEROZYGOTE.
MN CYSTIC-FIBROSIS: fg.  GENE-FREQUENCY.  HUMAN.  SELECTION-GENETICS.
EX When a genic disorder is only manifest if there are offending
   alleles at both loci, as in fibrocystic disease, there is a loss of
   two abnormal alleles with each affected birth since the homozygotes
   rarely reproduce.  How is this loss compensated?  How could some
   50,000 alleles, which can only survive to convey themselves in
   effective gametes if they have a normal allelic partner, become
   established in the British Isles - and how have some half a million
   or more got into the world currency?  First, migrations and
   settlements involve the proportion of defective alleles at all loci
   being conserved, but their variety being increased.  Secondly, there
   could be a general tendency due to some advantage in health or
   vitality, which could be manifest by disease resistance, cold
   resistance, and by any number of physical or psychological
   mechanisms.  Thirdly, there may be 'compensation' - that is the
   death of an infant may lead to replacement as a result of which the
   replacing sib, if surviving, would have a 2/3 chance of being a
   carrier.  Fourthly, the disease may be maintained by mutation.  Of
   the four possibilities, three are unrealistic, so that substantial
   selective advantage of heterozygotes over the last few hundred years
   must be postulated.
RF 001   SPOCK A               PEDIATR RES                      1   173 967
   002   BOWMAN BH             SCIENCE                        164   325 969
   003   WEISENFELD SL         SCIENCE                        157  1134 967
   004   GIBBON E              DECLINE AND FALL OF THE ROMAN            783
   005   DANKS DM              ANN HUM GENET                   28   323 965
CT   1   SUPER M               CLIN GENET                      16    65 979
     2   BITTLES AH            J SCI INDUSTR RES               39   768 980
     3   HOLLANDER DH          MED HYPOTHESES                   8   191 982
     4   LYEN KR               MED HYPOTHESES                  12    77 983

PN 77036
RN 00618 
AN 77220556
AU Lipson-A.  Meikle-H.
TI Porcine pancreatin as a source of salmonella infection in children
   with cystic fibrosis.
SO Arch-Dis-Child. 1977 Jul. 52(7). P 569-72.
MJ DRUG-CONTAMINATION.  PANCREATIN: ae.  SALMONELLA-INFECTIONS: et.
MN CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: dt.  DRUG-CONTAMINATION: pc.
   FEMALE.  HUMAN.  INFANT.  MALE.  PANCREATIN: st, tu.
AB Contamination of a powdered preparation of pancreatin with Salmonella
   schwarzengrund and S. eimsbuettel resulted in the infection of at
   least 31% of one group of paediatric patients with cystic fibrosis.
   The pancreatin contained very small numbers of Salmonellae, the
   infecting dose in at least one child being less than 44 organisms.
   More stringent bacteriological standards are needed for
   pharmaceuticals and foods used by paediatric patients.
RF 001   ARMSTRONG RW          AM J EPIDEMIOL                  91   300 970
   002   BOHNHOFF M            J INFECT DIS                   111   117 962
   003   BOWMER EJ             AM J MED SCI                   247   467 964
   004   ANON                  BRITISH PHARMACOPOEIA NO 340             973
   005   ANON                  COMMUNICABLE DIS REPORT 1975             975
   006   ANON                  COMMUNICABLE DIS REPORT 1976             976
   007   CHRISTIE AB           INFECT DIS                            20 974
   008   CRAVEN PC             LANCET                           1   788 975
   009   DRACHMAN RH           PEDIATR CLIN NORTH AM           21   711 974
   010   ANON                  CODE OF HYGENIC PRACTICE FOR             976
   011   GLENCROSS EJG         BR MED J                         2   376 972
   012   GORDON JE             MED CLIN NORTH AM               54  1495 970
   013   GUINEE PAM            ZENTRALBL BAKTERIOL            231    97 975
   014   HOOK EW               BULL NY ACAD MED                37   499 961
   015   HORNICK RB            N ENGL J MED                   283   686 970
   016   KALLINGS LO           ACTA PHARMACEUTICA SUEDICA       3   219 966
   017   KRUGMAN S             INFECT DIS CHILDREN AND ADULT        261 973
   018   ANON                  LANCET                           1   830 972
   019   LANG DJ               N ENGL J MED                   276   829 967
   020   MCCULLOUGH NB         J INFECT DIS                    88   276 951
   021   MCCULLOUGH NB         J INFECT DIS                    89   209 951
   022   MCCULLOUGH NB         J INFECT DIS                    89   259 951
   023   PROST E               ANNU REV MICROBIOL              21   495 967
   024   ROWE B                BR MED J                         4    51 975
CT   1   TURNBULL PCB          CLIN GASTROENTEROL               8   663 979
     2   PARK RW               GASTROENTEROLOGY                81  1143 981
     3   CANTEY JR             J INFECT DIS                   143   440 981
     4   CALVERT CA            J AM ANIM HOSP ASSOC            21   499 985

PN 77037
RN 00619 
AN 77201257
AU Elliott-R-B.  Eyre-J.  Robinson-P-G.
TI Salivary amylase in the parents of children with cystic fibrosis.
SO Aust-Paediatr-J. 1977 Mar. 13(1). P 29-32.
MJ AMYLASES: an.  CYSTIC-FIBROSIS: fg.  PARENTS.  SALIVA: en.
MN FEMALE.  HETEROZYGOTE.  HUMAN.  MALE.  SALIVATION.
AB Mixed submaxillary/sublingual saliva from obligate heterozygotes for
   cystic fibrosis shows significantly elevated concentration of
   amylase at high or low salivation rates compared with normals.
   Sixty per cent of known carriers had values outside the range of
   apparently normal controls.
RF 001   BABSON SR             CLIN CHIM ACTA                  44   193 973
   002   BLOMFIELD J           AUST PAEDIATR J                 10    75 974
   003   BLOMFIELD J           SCI PROC AUSTRALIAN PAEDIA               975
   004   BLOMFIELD J           GUT                             14   558 973
   005   BRUNS WT              AM J DIS CHILD                 126   685 973
   006   CHERNICK WS           J PEDIATR                       59   890 961
   007   CHERNICK WS           J PEDIATR                       65   694 964
   008   MANDEL ID             AM J DIS CHILD                 113   431 967
   009   WOTMAN S              J PERIODONTOL                   44   278 973
CT   1   BARDON A              CLIN CHIM ACTA                 101    17 980

PN 77038
RN 00620 
AN 77266353
AU Himmelhoch-A.
TI The effects of chronic illness on children of 0-3 years and their
   families.
SO Australas-Nurses-J. 1977 Jun. 6(11). P 14-6.
MJ ADAPTATION-PSYCHOLOGICAL.  CHRONIC-DISEASE.
   PARENT-CHILD-RELATIONS.
MN AFFECTIVE-SYMPTOMS.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS.  HUMAN.
   INFANT.  INFANT-NEWBORN.  MENTAL-RETARDATION.  NEOPLASMS.
EX I have taken as examples of chronic illness in infancy four
   different types of disability: emotional deprivation, infants with
   sub-normal development, children suffering from mucodiscoidosis, and
   children who have neoplastic disease.
RF 001   KLAUS MH              PEDIATRICS                      46   187 970
   002$  KLAUS MH              IN: GAIRDNER D                       133 976
   003   BUDIN P               NURSLING                                 907
   004   MONCRIEFF J           MENTAL SUBNORMALITY IN LONDON            966
   005   HEWETT S              FAMILY AND HANDICAPPED CHILD             970
   006   KAPLAN DM             MATERNAL REACTION PREMATURE B            965

PN 77039
RN 00621 
AN 78080307
AU Christian-S-T.  Monti-J-A.  Finley-W-H.
TI Membrane fluidity in normal and cystic fibrosis fibroblasts.
SO Biochem-Biophys-Res-Commun. 1977 Dec 7. 79(3). P 966-72.
MJ CELL-MEMBRANE: ul.  CYSTIC-FIBROSIS: pp.
MN CELLS-CULTURED.  FIBROBLASTS: ph.  HUMAN.  MALE.  PHOSPHOLIPIDS.
   SKIN: ph, pp.  SPECTROMETRY-FLUORESCENCE.  TEMPERATURE.
   SUPPORT-U-S-GOVT-NON-P-H-S.
AB We have observed distinct differences in the polarization of
   fluorescence and temperature dependent emission intensity of the
   highly fluoescent phospholipid derivative
   (1-acyl-2-(N-4-nitrobenzo-2-oxa-1,3-diazole)--aminocaproyl
   phosphatidylcholine (NBD-PC), when incorporated in the plasma
   membranes of normal and cystic fibrosis fibroblasts.  Fluorescence
   polarization measurements indicate that the fluorochrome has a much
   higher degree of rotational mobility in cystic fibrosis fibroblasts
   as compared with normal cells.  Temperature dependent transitions in
   the emission intensity of NBD-PC incorporated in normal fibroblasts
   are indicated at 17.7 and 21.2 degrees C while the abnormal cell
   membranes apparently undergo transitions at 8.7 and 13.5 degrees C.
   These differences might be due to changes in plasma membrane
   composition and/or organization, in the case of the cystic fibrosis
   cells.
RF 001   SINGER SJ             SCIENCE                        175   720 972
   002   GITLER C              ANNU REV BIOPHYS BIOENG          1    51 972
   003   SHINITZKY M           FEBS LETTERS                    24   247 973
   004   INBAR M               J MOL BIOL                      81   245 973
   005   RUDY B                BIOCHIM BIOPHYS ACTA           288   231 972
   006   COGAN U               BIOCHEMISTRY                    12   521 973
   007   MONTI JA              PROC AM SOC NEUROCHEM            8    75 977
   008   CHEN RF               SCIENCE                        147   729 965
   009   SKLAR LA              J SUPRAMOL STRUCT                4   449 976
   010   BUTTERFIELD DA        PROC NAT ACAD SCI USA           71   909 974
   011   BUTTERFIELD DA        BIOCHEMISTRY                    13  5078 974
   012   BUTTERFIELD DA        NATURE                         263   159 976
   013   BUTTERFIELD DA        ARCH BIOCHEM BIOPHYS           177   226 976
   014   BUTTERFIELD DA        NATURE                         267   453 977
CT   1   SHINITZKY M           BIOCHIM BIOPHYS ACTA           515   367 978
     2   MONTI JA              ARCH BIOCHEM BIOPHYS           193   496 979
     3   RIORDAN JR            BIOCHIM BIOPHYS ACTA           574    39 979
     4   RIMON G               BIOCHEMISTRY                    19  4451 980
     5   CHASE HP              METABOLISM                      29   365 980
     6   MALER T               BIOCHIM BIOPHYS ACTA           598     1 980
     7   HARRIS A              CLIN CHIM ACTA                 128    41 983

PN 77040
RN 00622 
AN 78080277
AU Hosli-P.  Vogt-E.
TI Cystic fibrosis: leakage of lysosomal enzymes and of alkaline
   phosphatase into the extracellular space.
SO Biochem-Biophys-Res-Commun. 1977 Dec 7. 79(3). P 741-8.
MJ ALKALINE-PHOSPHATASE: me.  CYSTIC-FIBROSIS: en.
   GLYCOSIDE-HYDROLASES: me.  LYSOSOMES: en.
MN CELLS-CULTURED.  FIBROBLASTS: en.  HUMAN.  MUCOLIPIDOSIS: en.
   SKIN: en.
AB Nine lysomal enzymes and alkaline phosphatase have been assayed with
   two different ultramicro techniques in the intra- and extracellular
   space of fibroblast cultures derived from the skin of cystic
   fibrosis patients, cystic fibrosis carriers, and normals controls,
   respectively.  Evidence has been obtained for a multiple leakage of
   lysomal enzymes and of alkaline phosphatase into the medium of
   fibroblast cultures from cystic fibrosis patients and carriers.  The
   situation is comparable to a certain extent, to that observed in
   I-cell-disease (mucolipidosis II).  This multiple leakage results in
   the decrease of intracellular activity of several lysosomal enzymes
   in cultures from cystic fibrosis patients and carriers and due to
   the coordinate regulationof the synthesis of the "leaky enzymes" in
   an overshooting of the intracellular alkaline phosphatase activity
   in cultures from cystic fibrosis patients.  It also explains the
   retarded catabolism of certain molecules, such as the Tamm-Horsfall
   glycoprotein, in cystic fibrosis cells.  It is speculated that the
   basic defect in cystic fibrosis leads to abnormal recognition sites
   on lysosomal enzymes and on alkaline phosphatase, and in consequence
   to the leakage of those enzymes into the extracellular space.  The
   present findings allow one to develop methods for the pre- and
   postnatal diagnosis of cystic fibrosis with cell cultures, and for
   the detection of cystic fibrosis carriers with the peripheral blood.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   002   LIGHTBODY J           LANCET                           1   451 971
   003   HOSLI P               ADV EXP MED BIOL                68     1 976
   004   HOSLI P               TISSUE CULTIVATION ON PLASTIC            972
   005   HOSLI P               IN: MOTULSKY AG                      226 974
   006   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      73   209 976
   007   HOSLI P               ADV EXP MED BIOL               76A   591 977
   008   HOSLI P               CLIN CHEM                       23  1476 977
   009   HICKMAN S             BIOCHEM BIOPHYS RES COMMUN      49   992 972
CT   1   ALHADEFF JA           CLIN GENET                      14   189 978
     2   HOSLI P               ACTA PAEDIATR SCAND             67   617 978
     3   CAREY WF              MED J AUST                       2   604 979
     4   HOSLI P               LANCET                           2   543 979
     5   HOSLI P               MONOGR PAEDIATR                 10    90 979
     6   VLADUTIU GD           LIFE SCI                        24  2369 979
     7   CAREY WF              AUST J EXP BIOL MED SCI         57   225 979
     8   ALHADEFF JA           BIOCHEM BIOPHYS RES COMMUN      86   787 979
     9   SCANLIN TF            CLIN CHIM ACTA                  91   197 979
    10   WILLCOX P             CLIN CHIM ACTA                  91    81 979
    11   OKADA S               CLIN CHIM ACTA                  96   281 979
    12   JAKEL HP              BIOL ZENTRALBL                  98    55 979
    13   BENYOSEPH Y           CLIN CHIM ACTA                  99    31 979
    14   HOSLI P               FEBS LETTERS                   104   271 979
    15   ROSSI E               SCHWEIZ MED WOCHENSCHR         109    33 979
    16   WIJCIK L              BIOCHIM BIOPHYS ACTA           585   374 979
    17   BUCHWALD M            ADV CYCLIC NUCLEO RES           12   243 980
    18   DAVIS PB              PEDIATR RES                     14    83 980
    19   AITKEN DA             J MED GENET                     17   187 980
    20   FASTH A               ACTA PAEDIATR SCAND             69   189 980
    21   ALHADEFF JA           CLIN CHIM ACTA                 105   131 980
    22   MALER T               FEBS LETTERS                   121   153 980
    23   JESSUP W              BIOCHEM J                      190   847 980
    24   VLADUTIU GD           BIOCHEM J                      192   813 980
    25   KRAKAUER KA           PROG DIS SKIN                    1    63 981
    26   HALLINAN F            MED HYPOTHESES                   7   793 981
    27   KATZNELSON D          ISR J MED SCI                   17   687 981
    28   HARRIS A              CLIN GENET                      20   315 981
    29   JAKEL HP              BIOL ZENTRALBL                 100   273 981
    30   SCHONI M              SCHWEIZ MED WOCHENSCHR         111   658 981
    31   HULTBERG B            CLIN CHIM ACTA                 112   167 981
    32   ALHADEFF JA           CLIN CHIM ACTA                 117   227 981
    33   MALER T               J BIOL CHEM                    256  1420 981
    34   FIGARELLA C           EUR J CLIN INVEST               12   145 982
    35   HUGHES WT             PEDIATR RES                     16   874 982
    36   JESSUP W              BIOCHEM BIOPHYS RES COMMUN     105   922 982
    37   ANDERSON PJ           BIOCHEM BIOPHYS RES COMMUN     108   182 982
    38   JESSUP W              CLIN CHIM ACTA                 126   265 982
    39   CEDER O               SCANN ELECTRON MICROSC        1982   723 982
    40   MARGOLIES R           PEDIATR RES                     17   931 983
    41   CEDER O               CLIN GENET                      23   298 983
    42   HEELEY AF             CLIN CHEM                       29  2011 983
    43   CEDER O               ACTA PAEDIATR SCAND             72   291 983
    44   BOURASSA C            CLIN CHIM ACTA                 129   263 983
    45   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
    46   OGLESBEE LH           CLIN CHIM ACTA                 143   135 984
    47   ROOMANS GM            ANN NY ACAD SCI                428   121 984
    48   BOUE A                PRESSE MED                      14   575 985
    49   ALHADEFF JA           PEDIATR RES                     19   171 985
    50   BRAGANZA JM           MED HYPOTHESES                  20   233 986
    51   BOZON D               ARCH BIOCHEM BIOPHYS           249   546 986
    52   HERMELIN B            CELL MOL BIOL                   33    83 987

PN 77041
RN 00623 
AN 78080294
AU Scanlin-T-F.  Matacic-S-S.  Pace-M.  Santer-U-V.  Glick-M-C.
TI Abnormal distribution of alpha-L-fucosidase in cystic fibrosis:
   increased activity in skin fibroblasts.
SO Biochem-Biophys-Res-Commun. 1977 Dec 7. 79(3). P 869-76.
MJ CYSTIC-FIBROSIS: en.  FUCOSIDASE: me.  SKIN: en.
MN ACETYLGLUCOSAMINIDASE: me.  ACID-PHOSPHATASE: me.  ADOLESCENCE.
   ADULT.  CELLS-CULTURED.  CHILD.  CHILD-PRESCHOOL.  COMPARATIVE-STUDY.
   FIBROBLASTS: en.  GLUCURONIDASE: me.  GLYCOSIDE-HYDROLASES: me.
   HUMAN.  INFANT.  REFERENCE-VALUES.  SUPPORT-U-S-GOVT-P-H-S.
AB Alpha-L-Fucosidase activity is elevated in skin fibroblasts from
   cystic fibrosis patients when compared to controls.  The activities
   of nine other acid hydrolases including neuraminidase are similar in
   cystic fibrosis  and control fibroblasts.  The relationship of these
   results to the recent finding of a decreased activity of
   alpha-L-fucosidase in the serum of cystic fibrosis patients is
   discussed.  It is proposed that an abnormal distribution of
   alpha-L-fucosidase is involved in the pathogenesis of this disease.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   003   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   005   LOWRY OH              J BIOL CHEM                    193   265 951
   006   ANTONOWICZ I          PEDIATR RES                      6   803 972
   008   NISHIGAKI M           J BIOCHEM (TOKYO)               75   509 974
   009   ALHADEFF JA           J BIOL CHEM                    250  7106 975
   010   DISCHE Z              PEDIATRICS                      24    74 959
   011   NOVAK RA              TEX REP BIOL MED                34   199 976
   012   PEARSON RD            PEDIATR RES                     11   462 977
   013   ZIELKE K              J EXP MED                      136   197 972
   014   BERMAN ER             CLIN CHIM ACTA                  52   115 974
   015   BERATIS NG            PEDIATR RES                     11   862 977
   016   BUTTERWORTH J         CLIN CHIM ACTA                  40   139 972
   017   DI MATTEO G           BIOCHIM BIOPHYS ACTA           429   527 976
   018   TURNER BM             AM J HUM GENET                  27   651 975
   019   ASHWELL G             ADV ENZYM MOLEC BIOL            41    99 974
   020   NEUFELD EF            ANNU REV BIOCHEM                44   357 975
   021   KAPLAN A              PROC NAT ACAD SCI USA           74  2026 977
CT   1   ALHADEFF JA           CLIN GENET                      14   189 978
     2   ALHADEFF JA           CLIN CHIM ACTA                  89   469 978
     3   SANTER UV             BIOCHIM BIOPHYS ACTA           523   435 978
     4   ALHADEFF JA           BIOCHEM BIOPHYS RES COMMUN      86   787 979
     5   SCANLIN TF            CLIN CHIM ACTA                  91   197 979
     6   WILLCOX P             CLIN CHIM ACTA                  91    81 979
     7   BUTTERWORTH J         CLIN CHIM ACTA                  92   109 979
     8   SCANLIN TF            CLIN CHEST MED                   1   424 980
     9   SANTER UV             BIOCHEM BIOPHYS RES COMMUN      96   219 980
    10   ALHADEFF JA           CLIN CHIM ACTA                 105   131 980
    11   MALER T               FEBS LETTERS                   121   153 980
    12   JAKEL HP              BIOL ZENTRALBL                 100   273 981
    13   BUTTERWORTH J         CLIN CHIM ACTA                 110   319 981
    14   SCANLIN TF            CLIN CHIM ACTA                 114   269 981
    15   ALHADEFF JA           CLIN CHIM ACTA                 117   227 981
    16   MALER T               J BIOL CHEM                    256  1420 981
    17   SCANLIN TF            BIOCHEMISTRY                    21   491 982
    18   FRATES RC             PEDIATR RES                     17    30 983
    19   MARGOLIES R           PEDIATR RES                     17   931 983
    20   ALHADEFF JA           CLIN CHIM ACTA                 134     1 983
    21   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
    22   SCANLIN TF            PEDIATR RES                     19   368 985
    23   PORTER WH             CLIN CHEM                       32   652 986
    24   BOZON D               ARCH BIOCHEM BIOPHYS           249   546 986
    25   HERMELIN B            CELL MOL BIOL                   33    83 987

PN 77042
RN 00624 
AN 78039817
AU Kelly-J-C.  DeBusk-A-G.
TI Membrane function in cystic fibrosis.  I. Putrescine transport in
   normal and cystic fibrosis fibroblasts.
SO Biochem-Genet. 1977 Aug. 15(7-8). P 695-705.
MJ CYSTIC-FIBROSIS: me.  PUTRESCINE: me.
MN BIOLOGICAL-TRANSPORT.  CELL-LINE.  FIBROBLASTS: me.  HUMAN.  SKIN.
   SUPPORT-U-S-GOVT-P-H-S.
AB Putrescine transport was examined in normal and cystic fibrosis
   fibroblasts. No differences were observed in accumulation pattern,
   kinetics of uptake, or efflux between CF and normal cells. In both
   growing and growth-arrested CF and normal fibroblasts, exogenously
   supplied putrescine remained unchanged for at least 60 min. Some
   differences were observed in the response of CF and normal cells to
   environmental (media) changes.
RF 001   NOUSIA-ARVANITAKIS S  PEDIATR RES                      7   336 973
   002   BAKER AP              FED PROC                        33  1300 974
   003   BENKE PJ              LANCET                           1   182 972
   004   BOSE SK               PROC NAT ACAD SCI USA           70  2374 973
   005   BROWN GA              LANCET                           2   639 971
   006   COHEN LF              PEDIATR RES                      9   312 975
   007   FLETCHER DS           CLIN CHIM ACTA                  44     5 973
   008   JOHNSON HG            ESCHERICHIA COLI ARCH BIOCHEM  128   113 968
   009   KANO K                J BIOL CHEM                    251  2795 976
   010   KLETZIEN RF           J BIOL CHEM                    249  3366 974
   011   LOWRY OH              J BIOL CHEM                    193   265 951
   012   LUNDGREN DW           CLIN CHIM ACTA                  62   357 975
   013   MCEVOY FA             PEDIATR RES                      9   721 975
   014   MORTON HJ             IN VITRO                         6    89 970
   015   MUNRO GF              J BIOL CHEM                    247  1272 972
   016   MUNRO GF              J BACTERIOL                    118   952 974
   017   POHJANPELTO P         J CELL BIOL                     68   512 976
   018   RENNERT OM            IN: MANGOS JA                         41 973
   019   ROSENTHAL SM          J PHARMACOL EXP THER           116   131 956
   020   SCHNEIDER EL          EXP CELL RES                    84   311 974
   022   TABOR CW              J BIOL CHEM                    241  3714 966
   023   TABOR H               PHARMACOL REV                   16   245 964
   024   TABOR H               ADV ENZYMOL                     36   203 972
   025   TAUSSIG LM            LANCET                           1  1367 972
   026   WILLIAMS-ASHMAN HG    ANN NY ACAD SCI                171   882 970
CT   1   SULLIVAN JL           BIOCHEM GENET                   15  1125 977
     2   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     3   LIMBOSCH S            CLIN CHIM ACTA                 102    11 980

PN 77043
RN 00625 
AN 78103121
AU Sullivan-J-L.  Kelly-J-C.  Roess-W-B.  DeBusk-A-G.
TI Membrane function in cystic fibrosis.  II.  Methionine transport in
   normal and cystic fibrosis fibroblasts.
SO Biochem-Genet. 1977 Dec. 15(11-12). P 1125-32.
MJ CYSTIC-FIBROSIS: me.  METHIONINE: me.
MN BIOLOGICAL-TRANSPORT-ACTIVE.  CELL-LINE.  CELLS-CULTURED.
   FIBROBLASTS: me.  HUMAN.  KINETICS.  SKIN: cy.
   SUPPORT-U-S-GOVT-P-H-S.
AB Initial rate kinetics of methionine transport, time course of
   accumulation of methionine, and efflux of accumulated methionine were
   studied in three normal and four CF human diploid fibroblast strains.
   The range of apparent Km's was 12.7-32.1 micrometer for the CF
   strains and 18.3-39.2 micrometer for the normal strains. The range of
   apparent Vmax's was 6.69-9.22 nmole mg-1 min-1 for the CF strains and
   5.59-7.87 nmole mg-1 min-1 for the normal strains. The patterns of
   accumulation and efflux are quite similar in all the strains studied
   except for WI-38, which showed somewhat higher efflux and lower
   accumulation than for others. There was no significant difference in
   the kinetic parameters of methionine transport between CF and normal
   skin fibroblasts, and methionine transport will not serve as a marker
   for cystic fibrosis in cultured fibroblasts.
RF 001   BENKE PJ              LANCET                           1   182 972
   002   BERATIS NG            PEDIATR RES                      7   958 973
   003   BOSE SK               PROC NAT ACAD SCI USA           70  2374 973
   004   BOWMAN BH             PROC NAT ACAD SCI USA           70   548 973
   005   CHANGUS JE            ARCH PATHOL LAB MED            100     7 976
   006   DANES BS              LANCET                           1  1061 968
   007   DANES BS              J EXP MED                      129   775 969
   008   FLETCHER DS           CLIN CHIM ACTA                  44     5 973
   009   HODES ME              PEDIATR RES                      8   212 974
   010   KELLY JC              BIOCHEM GENET                   15   695 977
   011   KLAGSBRUN M           PEDIATR RES                      8   205 974
   012   KLETZIEN RF           J BIOL CHEM                    249  3366 974
   013   LOBECK CC             IN: STANBURY JB                     1605 972
   014   LOWRY OH              J BIOL CHEM                    193   265 951
   015   LUNDGREN DW           CLIN CHIM ACTA                  62   357 975
   016   MATALON R             BIOCHEM BIOPHYS RES COMMUN      33   954 968
   017   MCCOMBS ML            TEX REP BIOL MED                31   615 973
   018   PLATTER H             PROC SOC EXP BIOL MED          123   140 966
   019   RENNERT OM            CLIN PEDIATR                    11   351 972
   020   RENNERT OM            PEDIATRICS                      50   485 972
   021   RENNERT OM            IN: MANGOS JA                         41 973
   022   SPOCK A               PEDIATR RES                      1   173 967
   023   WELCH DW              PEDIATR RES                      9   698 975
   024   WILSON RG             CLIN CHIM ACTA                  36   189 972

PN 77044
RN 00626 
AN 78060657
AU Sakula-A.
TI Bronchial asthma due to allergy to pancreatic extract: a hazard in
   the treatment of cystic fibrosis.
SO Br-J-Dis-Chest. 1977 Oct. 71(4). P 295-9.
MJ ASTHMA: ci.  DRUG-HYPERSENSITIVITY: et.  PANCREATIN: ae.
MN ADULT.  CASE-REPORT.  CYSTIC-FIBROSIS: dt.  FEMALE.  HUMAN.
   PANCREATIN: ad, tu.  RESPIRATORY-FUNCTION-TESTS.
AB The mother of two children suffering from cystic fibrosis developed
   marked allergic symptoms affecting the eyes, nose and bronchi and
   severe bronchial asthma ensued. The cause of this allergy proved to
   be the powder released on opening the capsules of pancreatic extract
   which she provided for her children at each mealtime. The risk of
   pancreatic extract to those handling it, and possibly also to
   patients suffering from cystic fibrosis, is emphasized.
RF 001   BERGNER A             PEDIATRICS                      55   814 975
   002   CHIGNELL R            PROC R SOC MED                  65   679 972
   003   COOMBES RRA           IN: GELL PGH                         575 968
   004   DARBY CW              BR MED J                         2   299 970
   005   DAY G                 ARCH DIS CHILD                  48   355 973
   006   DERBES VJ             J ALLERGY                       28   287 957
   007   DOLAN TF JR           AM REV RESPIR DIS              110   812 974
   008   FLINDT MLH            LANCET                           1  1177 969
   009   MCCARTHY DS           IN: LAWSON D PROC 5TH INT CF         194 969
   010   ANON                  MARTINDALE EXTRA PHARMACOPOE         684 972
   011   MITCHELL-HEGGS PF     Q J MED                         45   479 976
   012   NAKAMURA S            JAPAN J ALLERGY                 20   361 971
   013   NAKAMURA S            J ASTHMA RES                    10    37 972
   014   PEPYS J               CLIN EXP IMMUNOL                 1   377 966
   015   PILAT L               REV FR ALLERGIE                  7   153 967
   016   ANON                  BR MED J                         2   161 970
   017   VAN METRE TE JR       J ALLERGY CLIN IMMUNOL          31   141 960
   018   WARREN CPW            CLIN ALLERGY                     5     1 975
   019   WOOD RE               AM REV RESPIR DIS              113   833 976
   020   YOHE RM               ANN ALLERGY                     30   627 972
CT   1   FLINDT MLH            LANCET                           1   430 978
     2   ORMEROD LP            THORAX                          35   768 980
     3   HARTMANN AL           SCHWEIZ MED WOCHENSCHR         114   916 984
     4   LIPKIN GW             LANCET                           1   392 987

PN 77045
RN 00627 
AN 77135753
TI Screening for cystic fibrosis [editorial].
SO Br-Med-J. 1977 Mar 5. 1(6061). P 596-7.
MJ CYSTIC-FIBROSIS: pc.  MASS-SCREENING.
MN HUMAN.  INFANT-NEWBORN.
EX Cystic fibrosis (mucoviscidosis) is the most common potentially
   lethal autosomal recessive disease in Caucasian peoples.  Despite
   much research and several promising leads there is no completely
   reliable test for detecting heterozygotes, nor a test for the
   identification of the affected homozygous fetus in utero.  Attention
   is being focused on the value and the means of screening newborn
   infants.  Pilot studies carried out in the past six years have
   indicated two main possibilities.  Firstly, the examination of
   meconium for excess albumin, refined to include immunoelectrophoretic
   estimation of the albumin alpha-1 antitrypsin ratio, disaccharidases,
   and lysosomal enzymes.  A second approach is based on the work with a
   chloride-sensitive electrode, which has been modified recently to
   give greater precision in measurement of neonatal sweat electrolytes.
   While the tests available are reasonably accurate, collaborative
   trials and respiratory could improve their efficiency still further.
   Nevertheless, any screening test is presumptive only, and there must
   be an adequate back-up service with a specific validated diagnostic
   test.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   002   DI SANTAGNESE PA      N ENGL J MED                   295   597 976
   003   BOWMAN BH             TEX REP BIOL MED                34     1 976
   004   WARD JB JR            TEX REP BIOL MED                34    11 976
   005   PROSSER R             ARCH DIS CHILD                  49   597 974
   006   STEPHAN U             PEDIATRICS                      55    35 975
   007   RYLEY HC              CLIN CHIM ACTA                  64   117 975
   008   KOPITO L              PEDIATRICS                      43   794 969
   009   BRAY PT               PERSPECTIVE OF SODIUM AND CHL            975
   011   LAWSON D              ARCH DIS CHILD                  47     1 972
   012   GIBSON LE             PEDIATRICS                      23   545 959
   013   COCHRANE AL           BR MED BULL                     27     3 968

PN 77046
RN 00628 
AN 77203082
AU Scott-J-K.
TI Cystic fibrosis - Camp Couchiching.  four summers.
SO Can-Nurse. 1977 Jun. 73(6). P 14-9.
MJ CAMPING.  CYSTIC-FIBROSIS: rh.
MN ADOLESCENCE.  CHILD.  CYSTIC-FIBROSIS: dt.  FEMALE.  HUMAN.  MALE.
   ONTARIO.  PATIENTS: ed.  SPORTS.  PATIENT-EDUCATION.
EX The camp on Lake Couchiching for children with CF was started in
   1973.  Initially, certain changes were necessary to make the camp
   suitable for CF campers.  Most of the activities normally available
   to campers at Camp Couchiching are continued as usual for our CF
   campers during the month of August.  Staff members spend a great
   deal of time teaching the campers about the need for pancreatic
   enzymes.  Each cystic child requires two or three physiotherapy
   treatments every day after the inhalation of prescribed
   bronchodilators and antibiotics.
RF 001   CAMPBELL IM           LIPIDS                           9   916 974
   002   CROZIER DN            PEDIATR CLIN NORTH AM           21   935 974
   003   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   004   FRIEDMAN M            LANCET                           1   310 975
   005   ANON                  J PEDIATR                       88   711 976
   006   STERN RC              J PEDIATR                       89   412 976
   007   STERN RC              J PEDIATR                       89   406 976
CT   1   STANGHELLE JK         ACTA PAEDIATR SCAND             72   935 983

PN 77047
RN 00629 
AN 77161496
AU Millis-R-M.  Young-R-C-Jr.  Kulczycki-L-L.
TI Validation of therapeutic bronchoscopic bronchial washing in cystic
   fibrosis.
SO Chest. 1977 Apr. 71(4). P 508-13.
MJ BRONCHOSCOPY.  CYSTIC-FIBROSIS: th.  IRRIGATION.
MN ACETYLCYSTEINE: tu.  ADOLESCENCE.  ADULT.  AGE-FACTORS.
   AIRWAY-RESISTANCE: de.  BRONCHI.  CARBENICILLIN: tu.
   CYSTIC-FIBROSIS: dt.  GENTAMICINS: tu.  HUMAN.
   MAXIMAL-EXPIRATORY-FLOW-VOLUME-CURVES.  MIDDLE-AGE.
   PANCREATIC-EXTRACTS: tu.  SUCTION.  SUPPORT-U-S-GOVT-P-H-S.
AB Validation of rigid-tube bronchoscopy with small-volume (5-ml
   increments not to exceed 300 ml) bronchial washing as a therapeutic
   adjunct was performed on six patients with cystic fibrosis, using
   serial tests of pulmonary function as a yardstick for assessment of
   efficacy. Two patients did not undergo the procedure and served as
   control subjects. All patients were characterized as having varying
   severity of pulmonary involvement. Large central airways were
   severely obstructed, and older patients had more trapped gas in their
   lungs. Hypoxemia and large alveolar-arterial oxygen pressure
   differences [P(A-a)O2] were due to inhomogeneity of alveolar
   ventilation. Results indicated that up to ten days to two weeks,
   bronchoscopic bronchial washing may in some instances improve maximal
   expiratory flow-volume curves and specific airway conductance and
   decrease P(A-a)O2 towards normal. Distribution of alveolar gas P(A-
   a)O2 towards normal. Distribution of alveolar gas became more
   homogeneous. We conclude that bronchoscopic bronchial washing may be
   effective in the management of patients with cystic fibrosis, by
   augmentation of their inadequate cleansing function of the conducting
   airways.
RF 001   WARING WW             PEDIATRICS                      39   166 967
   002   DI SANTAGNESE PA      N ENGL J MED                   277  1399 967
   003   ALTMAN RP             J PEDIATR SURG                   8   809 973
   004   BEIER FR              AM REV RESPIR DIS               94   430 966
   005   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   006   COMROE JH JR          AM J MED                        10   408 951
   007   ROGERS RM             CHEST SUPPL                     62    95 972
   008   RAMIREZ RJ            ANN INTERN MED                  63   819 965
   009   KYLSTRA JA            AM REV RESPIR DIS              103   651 971
   010   THOMPSON HT           THORAX                          21   557 966
   011   KENSLER CJ            AM REV RESPIR DIS SUPPL         93    93 966
   012   LOBER CW              CHEST                           68   382 975
   013   BRAUNSTEIN MS         CHEST                           66    96 974
   014   MACKLEM PT            J APPL PHYSIOL                  22   395 967
   015   LAMARRE A             PEDIATRICS                      50   291 972
   016   CORBET A              AM REV RESPIR DIS              112   513 975
CT   1   EWING CW              CHEST                           73   750 978
     2   KULCZYCKI LL          JAMA                           240    30 978
     3   EMSLANDER HP          INTERNIST                       21    11 980
     4   ROTHMANN BF           ANN OTOL RHINOL LARYNGOL        91   641 982
     5   GEMBITSKAYA TE        SOV MED                              107 984
     6   MOAZAM F              J PEDIATR SURG                  20   398 985
     7   SHERMAN JM            PEDIATR PULMONOL                 2   244 986

PN 77048
RN 00630 
AN 78023435
AU Dahm-L-S.  Ewing-C-W.  Harrison-G-M.  Rucker-R-W.
TI Comparison of three techniques of lung lavage in patients with
   cystic fibrosis.
SO Chest. 1977 Nov. 72(5). P 593-6.
MJ CYSTIC-FIBROSIS: th.  IRRIGATION: mt.
MN ADOLESCENCE.  ADULT.  ANESTHESIA-GENERAL.  ANESTHESIA-LOCAL.
   BLOOD-GAS-ANALYSIS.  BRONCHOSCOPY: ae, mt.  CHILD.  CHILD-PRESCHOOL.
   COMPARATIVE-STUDY.  FEMALE.  HUMAN.  IRRIGATION: ae.  MALE.
   VITAL-CAPACITY.
AB One hundred fifty-three lung lavage procedures were performed on 81
   cystic fibrosis patients during the years 1963 to 1976. Local
   analgesia was used in 24 lavages done via a rigid bronchoscope and in
   a group of 73 lavages directed by a fiberoptic bronchoscope. No
   abnormalities in cardiac rate or rhythm were observed with the
   lavages directed by fiberoptic bronchoscope. Fifty-six lavages were
   performed under general anesthesia with 20 cardiac abnormalities
   being noted among this group. Subjective improvement was noted in 96%
   of the 56 patients who had lavage under general anesthesia. Objective
   improvement was apparent in 45% of the 24 patients who had lavage
   with the rigid bronchoscope and 64% of the 36 patients who had lavage
   by fiberoptic bronchoscopy. It is concluded that patients with cystic
   fibrosis of varying stages of disability can more safety (and with
   good improvement) have bronchial washouts with the fiber-optic
   bronchoscope than with either of the other two techniques.
RF 001   CEZEAUX G JR          JAMA                           199    15 967
   002   HACKETT RR            ANESTHESIOLOGY                  26   248 965
   003   RAMIREZ RJ            ANN INTERN MED                  63   819 965
   004   THOMPSON HT           LANCET                           2     8 964
   005   SACKNER MA            AM REV RESPIR DIS              111    62 975
   006   MURRAY JF             LUNG DISEASE STATE OF THE ART            976
   007   ANON                  RELATIVE VALUE GDE AM SOC ANE            975
CT   1   LUCK JC               CHEST                           74   139 978
     2   LENZINI L             RESPIRATION                     40    81 980
     3   ROTHMANN BF           ANN OTOL RHINOL LARYNGOL        91   641 982
     4   ROSEGGER H            KLIN PAEDIATR                  194   381 982
     5   HARNIK E              ANESTH ANALG CLEVE              62   357 983

PN 77049
RN 00631 
AN 78002389
AU McFarlane-H.  Allan-J-D.  van-der-Zeil-P.
TI Passive cutaneous anaphylaxis (PCA) and specific IgE in cystic
   fibrosis and their heterozygotes.
SO Clin-Allergy. 1977 May. 7(3). P 279-84.
MJ ANTIBODY-SPECIFICITY.  CYSTIC-FIBROSIS: im.  HETEROZYGOTE.  IGE: an.
   PASSIVE-CUTANEOUS-ANAPHYLAXIS.
MN ADOLESCENCE.  ADULT.  ALLERGENS: ad.  ASTHMA: im.  CHILD.
   CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: fg.  DERMATITIS-ATOPIC: im.
   FEMALE.  HAY-FEVER: im.  HUMAN.  HYPERSENSITIVITY-IMMEDIATE: im.
   INTRADERMAL-TESTS.  MALE.  SALIVA: im.  SPUTUM: im.
AB The serum from 75% of the patients with cystic fibrosis (C.F.) who
   had a positive prick test in their skin to at least one or more
   antigens, together with elevated concentrations of total serum IgE,
   also gave strong immediate PCA reactions in the baboon skin to
   Aspergillus fumigatus, bovine serum albumin and egg albumin.  Of the
   C.F. patients, 37% also had elevated serum specific IgE to A.
   fumigatus whereas only 8-10% had either raised specific IgE or PCA
   reaction to Dermatophagoides pteronyssinus.  Abolition of the PCA
   activity by incubating the C.F. sera or sputum at 56 degrees C
   suggested that the reaginic antibody was IgE rather than IgG4.  PCA
   reactions to a number of allergens could be detected in both the
   C.F. sputum and saliva.  Several of the C.F. heterozygotes had a
   strongly positive history of allergy and a significant number of
   these heterozygotes had an elevated serum total IgE as well as
   positive PCA to Timothy grass pollen or to D. pteronyssinus similar
   to the patients with asthma or hay fever.  Three C.F. patients who
   died gave strong prick test reactions to several allergens and their
   sera also had raised serum IgE and positive PCA to at least three
   different allergens, suggesting that immediate hypersensitivity is
   of some significance in patients with C.F.
RF 001   ABBOTT V              CAN MED ASSOC J                 64   419 951
   002   ALLAN JD              CLIN ALLERGY                     5   255 975
   003   BRENCHLEY PEC         PROC EUR CONG ALLER IMMUN 9TH            974
   004   DERBES VJ             J ALLERGY                       28   287 957
   005   HSIA DYY              AM J DIS CHILD                  96   685 958
   006   JOHANSSON SGO         IMMUNOLOGY                      10   265 968
   007   KLETTER B             CLIN ALLERGY                     1   249 971
   008   LAYTON JL             INT ARCH ALLERGY APPL IMMUNOL   23    87 963
   009   LURIE MH              ANN OTOL RHINOL LARYNGOL        68   478 959
   010   MCCARTHY DS           IN: LAWSON D PROC 5TH INT CF         194 969
   011   MCFARLANE H           LANCET                           1  1241 976
   012   ROSE NR               J ALLERGY                       35   520 964
   013   SHWACHMAN H           PEDIATRICS                      30   389 962
   014   SHAKIB F              CLIN ALLERGY                     6   237 976
   015   VAN METRE TE JR       J ALLERGY CLIN IMMUNOL          31   141 960
   016   WARNER JO             LANCET                           1   990 976
   017   WARREN CPW            CLIN ALLERGY                     5     1 975
CT   1   CARSWELL F            MONOGR PAEDIATR                 10   144 979
     2   CARSWELL F            CLIN EXP IMMUNOL                35   141 979
     3   ZAMBIE MF             ANN ALLERGY                     42   290 979
     4   VANASPEREN PP         AUST PAEDIATR J                 16    53 980
     5   HODSON ME             THORAX                          35   801 980
     6   TACIEREUGSTER H       HELV PAEDIATR ACTA              35    31 980
     7   TOBIN MJ              THORAX                          35   807 980
     8   VANASPEREN P          AM J DIS CHILD                 135   815 981
     9   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
    10   FERGUSON A            HUM NUTR CLIN NUTR             40C   255 986

PN 77050
RN 00632 
AN 78062991
AU Warner-J-O.
TI The variability of skin test hypersensitivity reactions in cystic
   fibrosis and asthma.
SO Clin-Allergy. 1977 Jul. 7(4). P 385-9.
MJ ASTHMA: co.  CYSTIC-FIBROSIS: co.  HYPERSENSITIVITY-IMMEDIATE: di.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  FEMALE.  HUMAN.
   HYPERSENSITIVITY-IMMEDIATE: co.  MALE.  SKIN-TESTS.
AB Cystic fibrosis (CF) children had a greater variability of skin prick
   test response compared with asthmatic children, when the tests were
   performed on two occasions. This suggests that there is a different
   cause for the allergy in the two groups, perhaps because the
   asthmatics have a transient period of susceptibility to sensitization
   in infancy and the CF children a persistent vulnerability. Amongst
   the asthmatic children, clinical improvement was associated with loss
   of some skin prick test reactions, and clinical deterioration with an
   increase in the number of positive reactions. Thus continuing
   allergic reactions may maintain a mucosal defect, resulting in a
   persistence of susceptibility to allergen sensitization, and control
   of the reactions may re-establish normal mucosal defence mechanisms.
RF 001   ALLAN JD              CLIN ALLERGY                     5   255 975
   002   LEVINE BB             SCIENCE                        178  1201 972
   003   SOOTHILL JF           CLIN ALLERGY                     3   511 973
   004   TAYLOR B              LANCET                           2   111 973
   005   WARNER JO             ARCH DIS CHILD                  51   507 976
   006   WARNER JO             ARCH DIS CHILD                  51   507 976
   007   WARREN CPW            CLIN ALLERGY                     5     1 975
CT   1   TOBIN MJ              THORAX                          35   807 980
     2   HOLZER FJ             ARCH DIS CHILD                  56   455 981
     3   CLARKE CW             CLIN ALLERGY                    12     1 982

PN 77051
RN 00633 
AN 78002395
AU Guha-A-K.  Kutty-K-M.  Chandra-R-K.  Way-R-C.
TI A study of the salivary glycoprotein in cystic fibrosis patients and
   controls: fucose incorporation and protein pattern.
SO Clin-Biochem. 1977 Aug. 10(4). P 153-5.
MJ CYSTIC-FIBROSIS: me.  FUCOSE: me.  GLYCOPROTEINS: bi.  SALIVA: me.
MN COMPARATIVE-STUDY.  GUANOSINE-DIPHOSPHATE-FUCOSE: me.  HUMAN.
   ISOELECTRIC-FOCUSING.  REFERENCE-VALUES.
AB The incorporation of fucose to glycoprotein acceptors prepared from
   the saliva of Cystic Fibrosis (CF) patients was compared with the
   incorporation into acceptors from controls. The CF acceptor
   glycoprotein incorporated significantly more fucose in the presence
   of either patients' or control plasma. The fucosyl transferase
   activity in the patients' plasma was not significantly different from
   controls. Fucosidase activity was similar also for both groups. The
   protein bands of the acceptor glycoproteins from the patients' saliva
   differed from those of the control in number and electrophoretic
   mobility. On the basis of these studies of fucose incorporation we
   propose that glycoprotein in the salivary secretion of E&Apatients
   are qualitatively different from normal.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   002   LOBECK CC             IN: STANBURY JB                     1605 972
   003   SHETTLES LB           J BIOL CHEM                    192   589 951
   004   WERNER I              ACTA SOC MED UPPSAL             58     1 953
   005   DISCHE Z              ANN NY ACAD SCI                 93   526 962
   006   VAZE D                PROC INT CF CONG 7TH                     976
   007   DI SANTAGNESE PA      PEDIATRICS                      19   252 957
   008   BELLA A JR            ARCH BIOCHEM BIOPHYS           147   753 971
   009   SCHENKEL-BRUNNER H    EUR J BIOCHEM                   30   269 972
   010   RIGHETTI PG           J CHROMATOGR                    98   271 974
   011   GORDON BA             CLIN BIOCHEM                     3   193 970
   012   NORUM KR              FEBS SYMPOSIUM                  19   333 969
   013   BLOMFIELD J           AUST PAEDIATR J                 10    75 974
CT   1   ALHADEFF JA           CLIN GENET                      13   417 978
     2   ALHADEFF JA           CLIN GENET                      14   189 978
     3   BENYOSEPH Y           PEDIATR RES                     15   839 981
     4   BENYOSEPH Y           BIOCHIM BIOPHYS ACTA           718   172 982
     5   DURAND P              RIV ITAL PEDIATR                 9   300 983
     6   WESLEY A              PEDIATR RES                     17    65 983
     7   ALHADEFF JA           CLIN CHIM ACTA                 134     1 983

PN 77052
RN 00634 
AN 77203751
AU Hosli-P.
TI Quantitative assays of enzyme activity in single cells: early
   prenatal diagnosis of genetic disorders.
SO Clin-Chem. 1977 Aug. 23(8). P 1476-84.
MJ ALKALINE-PHOSPHATASE: bi.  METABOLISM-INBORN-ERRORS: di.
   PRENATAL-DIAGNOSIS.
MN AMNIOTIC-FLUID: cy.  CHROMOSOME-ABNORMALITIES: di.
   CYSTIC-FIBROSIS: di.  ENZYME-INDUCTION.  FEMALE.
   HISTOCYTOCHEMISTRY: is.  HUMAN. ISOENZYMES: an.  LYSOSOMES: en.
   PREGNANCY.
AB The combined use of special cell culture techniques and biochemical
   ultramicromethods permits one to handle very small amounts of
   materials, to reduce the costs of chemicals, and more accurately to
   assess gene dosage effects by expressing enzyme activities per cell
   instead of per total cell protein. An alkaline phosphatase induction
   test has been developed which allows one to screen small numbers of
   fibroblasts for lysosomal storage diseases, cystic fibrosis, and
   chromosomal disorders. A successful attempt has been made to automate
   the microtechniques. Combining the alkaline phosphatase induction
   with the ultramicro automatization should eventually permit one to
   screen all pregnancies for major possible fetal genetic defects.
   Automated ultramicro enzyme assays should contribute to the general
   development of clinical chemistry.
RF 001   LEVY HL               ADV HUM GENET                    4     1 973
   002   MILUNSKY A            PRENATAL DIAGNOSIS OF HEREDIT            973
   003   HOSLI P               ANAT ANZ                       120   583 967
   004   HOSLI P               TISSUE CULTIVATION ON PLASTIC            972
   005   HOSLI P               BULL EUR SOC HUM GENET          32       972
   006   HOSLI P               IN: SPERLING O                       811 974
   007   HOSLI P               PRENATAL DIAGNOSIS NEWSLETTER    1    10 972
   008   HOSLI P               IN: MOTULSKY AG                      226 974
   009   HOSLI P               PROC INT CONG ASSOC SCI 3RD          354 974
   010   HOSLI P               IN: VOLK BW                            1 976
   011   LOWRY OH              FLEXIBLE SYSTEM OF ENZYMATIC             972
   012   ROTMAN B              PROC NAT ACAD SCI USA           47  1981 961
   013   WUDL L                SCIENCE                        184   992 974
   014   DE BRUYN CHMM         BIOCHEM BIOPHYS RES COMMUN      68   483 976
   015   NADLER HL             IN: BERGSMA D                         26 970
   016   BROCK DJH             LANCET                           2   923 973
   017   PAUL J                CELL AND TISSUE CULTURE                  970
   018   UITENDAAL MP          ADV EXP MED BIOL               76A   597 977
   019   GABRIEL A             FEBS LETTERS                    39   307 974
   020   SAIFERT A             CLIN CHEM                       20   538 974
   021   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      73   209 976
   023   SCHRODER J            J MED GENET                     12   230 975
CT   1   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      79   741 977
     2   UITENDAAL MP          BIOCHEM GENET                   16  1187 978
     3   HOSLI P               CLIN CHEM                       24  1325 978
     4   HOSLI P               HUM GENET                       41   169 978
     5   HOSLI P               ACTA PAEDIATR SCAND             67   617 978
     6   BAHR GF               ANAL QUANT CYTOL                 1     1 979
     7   CAREY WF              MED J AUST                       2   604 979
     8   JOLLY RD              AM J MED GENET                   4   293 979
     9   HOSLI P               MONOGR PAEDIATR                 10    90 979
    10   HOSLI P               EUR SURG RES                    11   205 979
    11   KAISER E              CLIN BIOCHEM                    12   208 979
    12   OKADA S               ACTA HISTOCHEM CYTOCHEM         12   193 979
    13   SCOTT IV              CLIN BIOCHEM                    12   275 979
    14   HOSLI P               CLIN GENET                      15   487 979
    15   UITENDAAL MP          IN VITRO                        15   103 979
    16   SANDHOFF K            HUM GENET                       50   107 979
    17   CAREY WF              AUST J EXP BIOL MED SCI         57   225 979
    18   GRAVEL RA             PROC NAT ACAD SCI USA           76  6520 979
    19   OKADA S               CLIN CHIM ACTA                  96   281 979
    20   BENZIE RJ             CAN MED ASSOC J                120   685 979
    21   AVRAMEAS S            J IMMUNOL                      122   648 979
    22   MALINBERDEL J         CYTOMETRY                        1   222 980
    23   GALJAARD H            TRENDS BIOCHEM SCI               5   201 980
    24   AITKEN DA             J MED GENET                     17   187 980
    25   BUCHANAN PD           CLIN GENET                      18   177 980
    26   SCHOONDERWALDT HC     CLIN GENET                      18   348 980
    27   VANLAARHOVEN JPRM     J IMMUNOL METH                  39    47 980
    28   GAUSSET P             CLIN EXP IMMUNOL                42   294 980
    29   MARKOVIC O            PERIOD BIOL                     82   491 980
    30   GLICK D               HISTOCHEM J                     13   227 981
    31   GARDNER HA            OTOL CLIN NORTH AM              14    47 981
    32   KATO T                ACTA HISTOCHEM CYTOCHEM         14   343 981
    33   HARRIS A              CLIN GENET                      20   315 981
    34   JAKEL HP              BIOL ZENTRALBL                 100   273 981
    35   DEBERSAQUES J         BR J DERMATOL                  104   147 981
    36   HOSLI P               EUR J PEDIATR                  137   116 981
    37   STEPHENSON SR         AM J OBSTET GYNECOL            141   319 981
    38   FIGARELLA C           EUR J CLIN INVEST               12   145 982
    39   GALJAARD H            METH CELL BIOL                  26   241 982
    40   GRAVEL RA             ANAL BIOCHEM                   119   360 982
    41   CEDER O               SCANN ELECTRON MICROSC        1982   723 982
    42   DEBRUYN CHMM          CLIN BIOCHEM                    16    38 983
    43   BLUTHMANN H           DIFFERENTIATION                 24    65 983
    44   JAKEL HP              BIOMED BIOCHIM ACTA             42  1123 983
    45   GRAVEL RA             HUM GENET                       65   112 983
    46   CEDER O               ACTA PAEDIATR SCAND             72   291 983
    47   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
    48   LEOTARD B             CLIN CHEM                       32  1779 986

PN 77053
RN 00635 
AN 77114515
AU ODonnell-M-D.  FitzGerald-O.  McGeeney-K-F.
TI Differential serum amylase determination by use of an inhibitor, and
   design of a routine procedure.
SO Clin-Chem. 1977 Mar. 23(3). P 560-6.
MJ AMYLASES: bl.  PLANT-PROTEINS: pd.
MN ADOLESCENCE.  ADULT.  AMYLASES: ai.  CYSTIC-FIBROSIS: bl.  FEMALE.
   HUMAN.  ISOENZYMES: bl.  MALE.  MIDDLE-AGE.  MUMPS: bl.
   PANCREAS: en.  PANCREATIC-DISEASES: bl.  SALIVARY-GLANDS: en.  WHEAT.
AB We describe a new method for measuring pancreatic and salivary-type
   amylases in serum that requires no electrophoresis or chromatography.
   An inhibitor protein (from wheat) with a 100-fold greater specificity
   for human salivary than for human pancreatic amylase was used to
   analyze mixtures of the two enzymes. The concentration of pancreatic
   and salivary amyalase was determined in 141 normal sera (72 men and
   69 women). Statistically significant differences were found for serum
   pancreatic amylase between mean and women, higher values being shown
   in women. No sex-related difference was found for the salivary
   component of serum amylase. With this method, the increase in serum
   amylase activity in pancreatitis was shown to be attributable to the
   pancreatic component. In mumps, the increase is attributable to the
   salivary component. In pancreatic insufficiency, serum pancreatic
   amylase activities were significantly lower than in the controls. Our
   method is simple and rapid; our results agree well with those of
   other authors who used chromatographic or electrophoretic methods.
RF 001   BERNFELD P            HELV CHIM ACTA                  31  2165 948
   002   BERNFELD P            HELV CHIM ACTA                  33  1964 950
   003   STIEFEL DJ            BIOCHIM BIOPHYS ACTA           302   345 973
   004   NORBY S               EXP CELL RES                    36   663 964
   005   TAKEUCHI T            CLIN CHIM ACTA                  54   137 974
   006   BERK JE               AM J DIG DIS                    11   695 966
   007   TAKEUCHI T            CLIN CHIM ACTA                  60   207 975
   008   BERK JE               AM J GASTROENTEROL              63   457 975
   009   ODONNELL MD           BIOCHIM BIOPHYS ACTA           422   159 976
   010   HALL FF               AM J DIG DIS                    15  1013 970
   011   STIEFEL DJ            CLIN CHEM                       21   343 975
   012   ODONNELL MD           ENZYME                          18   348 974
   013   ROBYT JF              IN: RADLEY JA                        431 968
   014   LEGAZ ME              CLIN CHEM                       22    57 976
   015   AW SE                 GUT                              8   402 967
   016   OTSUKI M              CLIN CHIM ACTA                  22   439 976
   017   MCGEACHIN RL          ANN NY ACAD SCI                151   208 968
   018   MESSER M              BIOCHEM J                      151    17 975
   019   TAKEUCHI T            BIOCHIM BIOPHYS ACTA           403   122 975
   020   FRIDHANDLER L         CLIN CHEM                       18  1493 972
   021   JANOWITZ HD           AM J MED                        27   924 959
   022   ADLERCREUTZ H         BR MED J                         3   529 972
   023   FITZGERALD O          BR MED J                         1   349 955
   024   KAISER R              AM J OBSTET GYNECOL            122   283 975
   025   SKUDE G               SCAND J GASTROENTEROL           10   577 975
   026   AMMAN RW              ANN INTERN MED                  78   521 973
   027   TAUSSIG LM            PEDIATRICS                      54   229 974
   028   TYE JG                J MED GENET                     13    96 976
CT   1   HEGARTY JE            GUT                             19   350 978
     2   KEOGH JB              GUT                             19  1125 978
     3   BRAGANZA  JM          CANCER                          41  1522 978
     4   BERK JE               AM J GASTROENTEROL              69   417 978
     5   BERK JE               ANN INTERN MED                  88   838 978
     6   KENNY D               CLIN CHIM ACTA                  89   429 978
     7   BERK JE               CLIN BIOCHEM                    12   264 979
     8   GILLARD BK            CLIN CHEM                       25  1919 979
     9   TAKEUCHI T            CLIN CHEM                       25  1406 979
    10   STEPAN J              CLIN CHIM ACTA                  91   263 979
    11   VINICOR F             ANN INTERN MED                  91   200 979
    12   CAILLENS H            NOUV PRESSE MED                  9  3079 980
    13   WALLER SL             AUST NZ J MED                   10   351 980
    14   GILLARD BK            PEDIATR RES                     14  1168 980
    15   MCGEENEY KF           PEDIATR RES                     14   967 980
    16   WOLF RO               PEDIATR RES                     14   968 980
    17   BIRATH K              J CLIN CHEM CLIN BIOCHEM        18   680 980
    18   HOLMBERG H            J CLIN CHEM CLIN BIOCHEM        18   681 980
    19   SOFRANKOVA A          PHYSIOL BOHEMOSLOV              29    89 980
    20   EDERY M               ANN BIOL CLIN                   38   243 980
    21   JACOBSON G            SCAND J CLIN LAB INVEST         40    77 980
    22   FRIDHANDLER L         CLIN CHIM ACTA                 101   135 980
    23   ODONNELL MD           CLIN CHIM ACTA                 104   265 980
    24   LANKISCH PG           DTSCH MED WSCHR                105  1636 980
    25   LANKISCH PG           MONATSSCHR KINDERHEILKD        128   739 980
    26   KLONOFF DC            WEST J MED                     133   392 980
    27   GROARKE JF            IR J MED SCI                   149   102 980
    28   BIRATH K              J CLIN CHEM CLIN BIOCHEM        19   616 981
    29   DERIJKE D             J CLIN CHEM CLIN BIOCHEM        19   815 981
    30   JAFFRAY P             J CLIN CHEM CLIN BIOCHEM        19   711 981
    31   MCGEENEY KF           J CLIN CHEM CLIN BIOCHEM        19   231 981
    32   ODONNELL MD           J CLIN CHEM CLIN BIOCHEM        19   786 981
    33   VADER HL              J CLIN CHEM CLIN BIOCHEM        19   241 981
    34   BOSSUYT PJ            CLIN CHEM                       27   451 981
    35   LANKISCH PG           HEPATOGASTROENTEROLOGY          28   333 981
    36   BENOIT MO             PATHOL BIOL (PARIS)             29   223 981
    37   BERK JE               AM J GASTROENTEROL              75   128 981
    38   TOBIN MJ              IR J MED SCI                   150   325 981
    39   RUDDELL WSJ           BR MED J                       283  1429 981
    40   OCONNOR CM            BIOCHIM BIOPHYS ACTA           635   397 981
    41   TSIANOS EB            LANCET                           1   856 982
    42   HARDY R               CLIN BIOCHEM                    15    95 982
    43   AMMANN RW             SCAND J GASTROENTEROL           17   997 982
    44   LANKISCH PG           GUT                             23   777 982
    45   LANKISCH PG           DIGESTION                       25   211 982
    46   ABRAMSON SB           DIG DIS SCI                     27   889 982
    47   ELLIS C               DIG DIS SCI                     27   897 982
    48   HUANG WY              CLIN CHEM                       28  1525 982
    49   RAMMELOO T            CLIN CHEM                       28   145 982
    50   MIWA I                CHEM PHARMACEUT BULL            30   362 982
    51   BROWN RC              J CLIN PATHOL                   35   547 982
    52   DUCHASSAING D         ANN BIOL CLIN                   40   448 982
    53   MAEDA K               AGRIC BIOL CHEM                 46  2873 982
    54   TSIANOS EB            CLIN CHIM ACTA                 124    13 982
    55   KAMEYA A              CLIN CHIM ACTA                 125    77 982
    56   MOLLERPETERSEN J      ACTA MED SCAND                 211   459 982
    57   BARRETT A             BR MED J                       285   170 982
    58   ROBISON JC            N ENGL J MED                   307   899 982
    59   BRIVET M              GASTROENTEROL CLIN BIOL          7   940 983
    60   KELLEHER J            SCAND J GASTROENTEROL           18   791 983
    61   NASRALLAH SM          GUT                             24   161 983
    62   ANDRIULLI A           DIGESTION                       26    67 983
    63   WARCHALEWSKI JR       NAHRUNG                         27   103 983
    64   DERIJKE D             CLIN CHEM                       29  1100 983
    65   HOEK FJ               CLIN CHEM                       29   995 983
    66   LECLERC P             CLIN CHEM                       29  1020 983
    67   ODONNELL MD           CLIN CHEM                       29   510 983
    68   SKRHA J               CLIN CHEM                       29   407 983
    69   SOBIECH KA            ENZYME                          30    66 983
    70   MURAO S               AGRIC BIOL CHEM                 47   453 983
    71   SATZ N                KLIN WSCHR                      61    91 983
    72   OMICHI K              J BIOCHEM                       94  1797 983
    73   DURR GHK              DTSCH MED WSCHR                108  1876 983
    74   SOYAMA K              CLIN CHIM ACTA                 131   149 983
    75   KIRBY J               IR J MED SCI                   152   394 983
    76   TSIANOS EB            CLIN EXP RHEUMATOL               2   235 984
    77   PELLETIER G           GASTROENTEROL CLIN BIOL          8   792 984
    78   SIMPSON JW            VET RES COMMUN                   8   303 984
    79   WILCOX ER             J FOOD BIOCHEM                   8   189 984
    80   KOOP H                CLIN GASTROENTEROL              13   739 984
    81   PAVESI F              RIC CLIN LAB                    14   443 984
    82   TAIT AD               AUST NZ J MED                   14   600 984
    83   PARVIAINEN MT         J CLIN CHEM CLIN BIOCHEM        22    41 984
    84   BANKS PA              DIG DIS SCI                     29   297 984
    85   GORDON S              CLIN CHEM                       30   339 984
    86   OKABE H               CLIN CHEM                       30  1219 984
    87   ROYSE VL              CLIN CHEM                       30   387 984
    88   TIETZ NW              CLIN CHEM                       30  1227 984
    89   ZAKOWSKI JJ           CLIN CHEM                       30    62 984
    90   MASIAR PJ             NEOPLASMA                       31   351 984
    91   LANG C                THER UMSCH                      41   606 984
    92   MORGENSTERN T         MONATSSCHR KINDERHEILKD        132   661 984
    93   HAFKENSCHEID JCM      CLIN CHIM ACTA                 136   235 984
    94   GILLARD BK            AM J DIS CHILD                 138   577 984
    95   OMICHI K              CLIN CHIM ACTA                 138   197 984
    96   GIVEN F               IR J MED SCI                   153   203 984
    97   MOOSSA AR             N ENGL J MED                   311   639 984
    98   MCMAHON LF            J CLIN GASTROENTEROL             7    17 985
    99   NAGARAJ RH            J BIOSCI                         7   257 985
   100   LAFERLA G             IRCS MED SCI BIOCHEM            13  1034 985
   101   GIBERTINI P           ITAL J GASTROENTEROL            17   211 985
   102   LESI C                CLIN BIOCHEM                    18   317 985
   103   ZAKOWSKI JJ           CRC CRIT REV CLIN LAB SCI       21   283 985
   104   TSIANOS EB            CLIN TRIALS J                   22   239 985
   105   COURTOIS P            J CLIN CHEM CLIN BIOCHEM        23   733 985
   106   STEINBERG WM          DIG DIS SCI                     30  1209 985
   107   HAFKENSCHEID JCM      CLIN CHEM                       31   162 985
   108   MIFFLIN TE            CLIN CHEM                       31  1283 985
   109   BRAULT D              PATHOL BIOL (PARIS)             33   195 985
   110   HAFKENSCHEID JCM      ENZYME                          33   128 985
   111   ARAI M                AGRIC BIOL CHEM                 49   987 985
   112   BRAULT D              SEM HOP PARIS                   61  2847 985
   113   MALFERTHEINER P       KLIN WSCHR                      63    43 985
   114   KAMEYA A              AM J GASTROENTEROL              80    54 985
   115   NIEDERAU C            GASTROENTEROLOGY                88  1973 985
   116   ITO K                 J BIOCHEM                       97  1357 985
   117   STEINBERG WM          ANN INTERN MED                 102   576 985
   118   STRNAD G              J ELECTROAN CHEM INTERF ELECT  194   123 985
   119   MCCORMICK PA          BR MED J                       290  1472 985
   120   SCHNEIDER  MU         LANGENBECKS ARCH CHIR          363   149 985
   121   MAEDA K               BIOCHIM BIOPHYS ACTA           828   213 985
   122   KAMEYA S              J CLIN GASTROENTEROL             8   438 986
   123   MAILLIE AJ            SCAND J GASTROENTEROL           21   941 986
   124   HARMOINEN A           J CLIN CHEM CLIN BIOCHEM        24   903 986
   125   LANKISCH PG           DIG DIS SCI                     31  1299 986
   126   GORUS F               CLIN CHEM                       32   398 986
   127   JIMENEZ A             CLIN CHEM                       32  1577 986
   128   JUNGLEE D             CLIN CHEM                       32   609 986
   129   LACHER DA             CLIN CHEM                       32  1539 986
   130   TIETZ NW              CLIN CHEM                       32   301 986
   131   WOLF RO               CLIN CHEM                       32   296 986
   132   TSIANOS EB            HEPATOGASTROENTEROLOGY          33   247 986
   133   BUCHLER M             KLIN WSCHR                      64  1186 986
   134   BARROS FP             AM J GASTROENTEROL              81   261 986
   135   KAMEYA S              AM J GASTROENTEROL              81   358 986
   136   LANKISCH PG           AM J GASTROENTEROL              81   365 986
   137   NAGARAJ RH            INDIAN J MED RES                84    89 986
   138   OMICHI K              J BIOCHEM                      100  1353 986
   139   ADACHI K              CLIN CHIM ACTA                 154   103 986
   140   MOLLERPETERSEN J      CLIN CHIM ACTA                 157   151 986
   141   HIROISHI S            CLIN CHIM ACTA                 159    89 986

PN 77054
RN 00636 
AN 77089890
AU Applegarth-D-A.  Davidson-A-G.  Haworth-E-M.  Quist-E-E.  Zuk-R.
   Roufogalis-B-D.  Clark-D-G.
TI Cystic fibrosis: the effect of medium from cultured cystic fibrosis
   fibroblasts on ATPase activity.
SO Clin-Chim-Acta. 1977 Jan 17. 74(2). P 183-5.
MJ ADENOSINE-TRIPHOSPHATASE: me.  CYSTIC-FIBROSIS: pa.
MN ADENOSINE-TRIPHOSPHATASE: ai.  CELL-LINE.  CELLS-CULTURED.
   CULTURE-MEDIA: pd.  ERYTHROCYTE-MEMBRANE: en.  FIBROBLASTS: pa.
   HUMAN.
AB Culture medium from fibroblasts of cystic fibrosis patients and
   controls was examined for the ability to inhibit (calcium plus
   magnesium)-activated ATPase and (sodium plus potassium)-activated
   ATPase. The ATPase systems used were both a solubilised preparation
   from dog-fish and a membrane associated preparation from human
   erythrocyes. Contrary to other reports the medium from cystic
   fibrosis fibroblasts did not inhibit ATPase activity.
RF 001   SCHMOYER IR           BIOCHEM BIOPHYS RES COMMUN      58  1066 974
   002   QUIST EE              ARCH BIOCHEM BIOPHYS           168   240 975
   003$  HOKIN LE              J BIOL CHEM                    248  2593 975
   004   SEE YP                ANAL BIOCHEM                    49   430 972
CT   1   JAKEL HP              BIOL ZENTRALBL                  98    55 979

PN 77055
RN 00637 
AN 78022900
AU Bray-P-T.  Clark-G-C.  Moody-G-J.  Thomas-J-D.
TI Sweat testing for cystic fibrosis: errors associated with the
   in-situ sweat test using chloride ion selective electrodes.
SO Clin-Chim-Acta. 1977 Oct 15. 80(2). P 333-8.
MJ CHLORIDES: an.  CYSTIC-FIBROSIS: di.  SWEAT: an.
MN ELECTRODES.  HUMAN.  HYDROGEN-ION-CONCENTRATION.  METHODS.
   SKIN-ABSORPTION.  TEMPERATURE.
AB The in-situ sweat test is prone to errors from various sources. This
   paper examines errors due to evaporation, absorption of water into
   the skin, and pressure of the electrode on the skin. Only evaporation
   caused serious errors. The accuracy and precision when measuring
   small chloride/sweat samples on the skin are not significantly worse
   than when measuring bulk solutions.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   002   ANDERSON CM           CF A MANUAL OF DIAGNOSIS AND             976
   003   ANON                  J PEDIATR                       88   711 976
   004   DI SANTAGNESE PA      GAP CONF REP PROB SWEAT TESTI          6 975
   005   WARWICK WJ            JAMA                           198    59 966
   006   WARWICK WJ            PEDIATRICS                      36   261 965
   007   HANSEN L              AM J CLIN PATHOL                49   834 968
   008   GURSON CT             HELV PAEDIATR ACTA              28   165 973
   009   BRAY PT               PROC EWGCF 5TH ANNU MTG                  974
   010   ANDERSON CM           CF A MANUAL OF DIAGNOSIS AND             976
   011   TARNOKY AL            CLIN CHIM ACTA                  69   505 976
   012   SZABO L               CLIN CHEM                       19   727 973
   013   BRAY PT               CLIN CHIM ACTA                  77    69 977
   014   BRAY PT               PERSPECTIVE OF SODIUM AND CHL            975
   015   BLANK IH              J INVEST DERMATOL               18   433 952
   016   SPOCK A               GAP CONF REP PROB SWEAT TESTI         12 975
CT   1   BARNES GL             AUST PAEDIATR J                 14    78 978
     2   WARWICK WJ            CLIN CHEM                       24  2050 978
     3   BUCK RP               ANAL CHEM                       50  R 17 978
     4   BRAY PT               ARCH DIS CHILD                  53   483 978
     5   ROSENSTEIN BJ         JAMA                           240  1987 978
     6   STAGG BH              ANN CLIN BIOCHEM                16   147 979
     7   SHIRAMIZU B           ANAL CHIM ACTA                 108   161 979
     8   BENSON RG             CLIN CHEM                       28  2447 982
     9   WEBSTER HL            CRC CRIT REV CLIN LAB SCI       18   313 983

PN 77056
RN 00638 
AN 77203773
AU Bray-P-T.  Clark-G-C.  Moody-G-J.  Thomas-J-D.
TI Sweat testing for cystic fibrosis: characteristics of a combination
   chloride ion-selective electrode.
SO Clin-Chim-Acta. 1977 May 16. 77(1). P 69-76.
MJ CYSTIC-FIBROSIS: di.  SWEAT: an.
MN CHEMISTRY-CLINICAL: is.  CHLORIDES: an.  DRUG-STABILITY.  ELECTRODES.
   HUMAN.  METHODS.  TEMPERATURE.
AB Filling solution leakage, reproducibility, stability, interferences
   and temperature effects have been studied in relation to the use of
   the Orion 96-17-01 combination chloride ion-selective electrode in
   sweat testing for cystic fibrosis. While stability and
   reproducibility is good, certain antiseptic systems and especially
   Hibitaine (chlorhexidine gluconate) interfere with the electrode and
   therefore need to be absent during sweat testing. Temperature
   conditions during calibration and sweat testing need to be controlled
   in view of the extent of response variations for even modest
   temperature differences between sensor-skin interface and electrode
   stem.
RF 001   GIBSON LE             PEDIATRICS                      23   545 959
   002   BRAY PT               PERSPECTIVE OF SODIUM AND CHL            975
   003   GIBSON LE             GAP CONF REP PROB SWEAT TESTI            975
   004   ANON                  MODEL 417 SKIN CHLORIDE MEASU            971
CT   1   BRAY PT               CLIN CHIM ACTA                  80   333 977
     2   WARWICK WJ            CLIN CHEM                       24  2050 978
     3   WATTS RWE             EXPERIENTIA                     34   143 978
     4   BRAY PT               ARCH DIS CHILD                  53   483 978
     5   LAWRENCE CA           BR J HOSP MED                   26   625 981
     6   SOLSKY RL             CRC CRIT REV ANALYT CHEM        14     1 982

PN 77057
RN 00639 
AN 77089874
AU Chan-K-Y.  Applegarth-D-A.  Davidson-A-G.
TI Plasma arginine esterase activity in cystic fibrosis of the pancreas.
SO Clin-Chim-Acta. 1977 Jan 3. 74(1). P 71-5.
MJ ARGINASE: df.  CYSTIC-FIBROSIS: en.  PANCREAS: pp.
MN ADOLESCENCE.  ADULT.  ARGINASE: bl.  CHILD.  CHILD-PRESCHOOL.
   CHLOROFORM: pd.  CYSTIC-FIBROSIS: pp.  ELLAGIC-ACID: pd.  HUMAN.
   INFANT.  KINETICS.  METHODS.  MICROCHEMISTRY.  MIDDLE-AGE.
   TRYPSIN-INHIBITOR-KUNITZ-SOYBEAN: pd.
AB Using a micro-method for the determination of plasma arginine
   esterase activity, we have investigated the values for soybean
   trypsin inhibitor (STI)-inhibited arginine esterase activity in
   patients with cystic fibrosis, obligate heterozygotes and age matched
   control individuals. The mean of STI-inhibited activity is lowest for
   cystic fibrosis patients while the mean for normal controls is the
   highest. The mean of STI-inhibited activity for the heterozygotes is
   midway between the values of the patients and the normal individuals.
   The deficiency of arginine esterase activity was statistically
   significant for both cystic fibrosis patients and heterozygotes.
RF 001   RAO GJS               SCIENCE                        177   610 972
   002   RAO GJS               PEDIATR RES                      8   684 974
   003   LIEBERMAN J           AM REV RESPIR DIS              109   399 974
   004   WILSON GB             PEDIATR RES                     10    87 976
   005   HARPEL PC             J EXP MED                      138   508 973
   006   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   007   SIEGELMAN AM          ARCH BIOCHEM BIOPHYS            97   159 962

PN 77058
RN 00640 
AN 77224156
AU Shapira-E.  Ben-Yoseph-Y.  Nadler-H-L.
TI Abnormal breakdown of alpha2-macroglobulin-trypsin complex in cystic
   fibrosis.
SO Clin-Chim-Acta. 1977 Aug 1. 78(3). P 359-63.
MJ ALPHA-MACROGLOBULINS: me.  CYSTIC-FIBROSIS: me.  TRYPSIN: me.
MN COMPARATIVE-STUDY.  HUMAN.  PROTEIN-BINDING.
   TRYPSIN-INHIBITOR-KUNITZ-SOYBEAN: pd.  SUPPORT-U-S-GOVT-P-H-S.
AB The complex of trypsin with purified alpha2-macroglobulin from
   normals and patients with cystic fibrosis was studied. The formed
   complex failed to reveal any proteolytic activity toward a high
   molecular weight substrate whereas the esterolytic activity towards a
   low molecular weight substrate was retained. This esterolytic
   activity was resistant to inhibition by a high molecular weight
   inhibitor. During iincubation at 38 degrees C the complex with normal
   alpha2-macroglobulin was slowly inhibited by the high molecular
   weight inhibitor and regained activity with the high molecular weight
   substrate. This phenomenon was not obtained when the alpha2-
   macroglobulin from cystic fibrosis was examined. These data suggest
   that the gradual conversion of normal alpha2-macroglobulin-trypsin
   complex into an alpha2-macroglobulin fragment-trypsin complex is
   deficient in patients with cystic fibrosis.
RF 001   LAURELL CB            IN: PUTNAM FW                        246 975
   002   HARPEL PC             J EXP MED                      138   508 973
   003   BARRETT AJ            BIOCHEM J                      133   709 973
   004   BAUMSTARK JS          BIOCHIM BIOPHYS ACTA           207   318 970
   005   WILSON GB             PEDIATR RES                     10    87 976
   006   SHAPIRA E             PEDIATR RES                     10   812 976
   007   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      71   864 976
   008   KUNITZ M              J GEN PHYSIOL                   30   291 947
   009   IWAMOTO M             BIOCHIM BIOPHYS ACTA           214   402 970
   010   SCHULTZE HE           MOLECULAR BIOL OF HUMAN PROTE    1       966
CT   1   SHAPIRA E             J BIOL CHEM                    252  7923 977
     2   RAO GJS               ENZYME                          23   314 978
     3   CHOY H                BIOCHEM BIOPHYS RES COMMUN      82  1325 978
     4   VANLEUVEN F           PEDIATR RES                     13  1384 979
     5   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     6   BENYOSEPH Y           CLIN CHIM ACTA                  99    31 979
     7   COMINGS DE            AM J HUM GENET                  32   273 980
     8   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      93    50 980
     9   ROMEO G               J LAB CLIN MED                  95   116 980
    10   BURDON MG             CLIN CHIM ACTA                 100   225 980
    11   SCHIDLOW DV           AM REV RESPIR DIS              121    31 980
    12   COPPENHAVER D         HUM GENET                       57   399 981
    13   RICHMAN JBY           CAN J BIOCHEM                   59   519 981
    14   BLITZER MG            J PEDIATR GASTROENTEROL NUTR     1   289 982
    15   OWENSWILLIAMS L       J PEDIATR GASTROENTEROL NUTR     1   567 982
    16   WILSON GB             MED HYPOTHESES                   8   527 982
    17   BURY AF               IRCS MED SCI BIOCHEM            10   255 982
    18   BLITZER MG            PEDIATR RES                     16   203 982
    19   ROBERTS RC            PEDIATR RES                     16   416 982
    20   CRISTOL P             SEM HOP PARIS                   58   449 982
    21   BRIDGES MA            CLIN CHIM ACTA                 118    33 982
    22   TUMMLER B             CLIN CHIM ACTA                 125   219 982
    23   BRIDGES MA            ANN NY ACAD SCI                421   360 983
    24   SHAPIRA E             ANN NY ACAD SCI                421   352 983
    25   EAGER KB              PEDIATR RES                     18   999 984
    26   MARYNEN P             BIOCHIM BIOPHYS ACTA           799   187 984
    27   GOLDSTEIN W           AM REV RESPIR DIS              134    49 986

PN 77059
RN 00641 
AN 77224220
AU Sunshine-P.  Sinatra-F-R.  Mitchell-C-H.
TI Intractable diarrhoea of infancy.
SO Clin-Gastroenterol. 1977 May. 6(2). P 445-61.
MJ DIARRHEA-INFANTILE.
MN CARBOHYDRATE-METABOLISM-INBORN-ERRORS: co.  COLITIS: co.
   CYSTIC-FIBROSIS: co.  DIARRHEA-INFANTILE: di, et, pp.  GALACTOSE: me.
   GLUCOSE: me.  HUMAN.  IMMUNOLOGIC-DEFICIENCY-SYNDROMES: co.  INFANT.
   INTESTINES: su.  MEGACOLON: co.  NEOPLASMS: co.
   NEOPLASMS-EMBRYONAL-AND-MIXED: co.  POSTOPERATIVE-COMPLICATIONS.
   SUPPORT-U-S-GOVT-P-H-S.
AB The intractable diarrhoea syndrome of infancy continues to be a major
   diagnostic and therapeutic challenge to the paediatrician and
   paediatric gastroenterologist. A carefully organized, staged approach
   to diagnosis will provide the best method of identifying those
   infants in whom a specific aetiology exists and for whom specific
   therapy is often available. Regardless of aetiology, however, the
   early use of appropriate nutritional support will not only reduce
   morbidity and mortality in these infants, but will prevent the
   development of many of the secondary consequences of malnutrition.
   The physician must compulsively pay attention to the details of daily
   management and provide an organized approach to diagnosis and
   treatment in order to improve the outcome of infants with intractable
   diarrhoea.
RF 001   ALVARADO J            AM J CLIN NUTR                  26   595 973
   002   AMENT ME              PEDIATR CLIN NORTH AM           22   807 975
   003   AMENT ME              GASTROENTEROLOGY                62   216 972
   004   AVERY GB              PEDIATRICS                      41   712 968
   005   BARBEZAT GO           PEDIATRICS                      42    77 968
   006   BARNES GL             ARCH DIS CHILD                  48   343 973
   007   BLOOM SR              LANCET                           2    14 973
   008   BOWIE MD              J PEDIATR                       66  1083 965
   009   BURKE V               LANCET                           1  1177 966
   010   CHRISTIE DL           J PEDIATR                       87   657 975
   011   CHRISTIE DL           J PEDIATR                       87   705 975
   012   FEINBERG SB           RADIOLOGY                       80   212 963
   013   FELDMAN EJ            GASTROENTEROLOGY                70   712 976
   014   GHADIMI H             PEDIATR RES                      7   161 973
   015   GRACEY M              ARCH DIS CHILD                  48   331 973
   016   GREENE HL             J PEDIATR                       87   695 975
   017   GRIFFIN JW            J PEDIATR                       59   394 961
   018   HAMILTON JR           AM J MED                        44   453 968
   019   HEIRD WC              J PEDIATR                       86     2 975
   020   HEIRD WC              GASTROENTEROLOGY                66   A55 974
   021   HERSKOVIC T           AM J CLIN NUTR                  22   300 969
   022   HOFMANN AF            GASTROENTEROLOGY                62   918 972
   023   HYMAN CJ              J PEDIATR                       78    17 971
   024   JAMES WPT             LANCET                           1   333 968
   025   JAMES WPT             ARCH DIS CHILD                  46   218 971
   026   KEATING JP            AM J DIS CHILD                 128   369 974
   027   LEE PA                JAMA                           228   585 974
   028   LEENDERS E            SURG CLIN NORTH AM              50   907 970
   029   LIFSHITZ F            J PEDIATR                       77   595 970
   030   LLOYD-STILL JD        AM J DIS CHILD                 125   358 973
   031   MATA LJ               AM J CLIN NUTR                  25  1118 972
   032   MITCHELL C            CLIN RES                        24   169 976
   033   NYLANDER G            ACTA CHIR SCAND                133   131 967
   034   PHILLIPS SF           GASTROENTEROLOGY                63   495 972
   035   PHILLIPS SF           AM J DIG DIS                    18  1017 973
   036   PRESS M               LANCET                           1   597 974
   037   PULLAN JM             PROC R SOC MED                  52    31 959
   038   SAID SI               N ENGL J MED                   293   155 975
   039   SCHNEIDER RE          AM J CLIN NUTR                  25  1092 972
   040   SCHNEIDER RE          AM J CLIN NUTR                  27   777 974
   041   SHWACHMAN H           AM J DIS CHILD                 125   365 973
   042   SINATRA F             J PEDIATR                       88   304 976
   043   STRAUS E              GASTROENTEROLOGY                66   175 974
   044   SUSKIND RM            PEDIATR CLIN NORTH AM           22   873 975
   045   SWENSON O             J PEDIATR SURG                   8   587 973
   046   VEGHELYI PV           AM J DIS CHILD                  79   658 950
   047   VITERI FE             MED CLIN NORTH AM               58  1487 974
   048   VITERI FE             AM J DIG DIS                    18   201 973
   049   WILMORE DW            J PEDIATR                       80    88 972
   050   WINICK M              PEDIATR RES                      3   181 969
   051   WRIGHT HK             IN: RAVITCH M                            971
CT   1   NETZ H                KLIN PAEDIATR                  190   603 978
     2   DESOUSA JS            ARCH DIS CHILD                  55   937 980
     3   ROSSI TM              PEDIATRICS                      66   730 980
     4   FISHER SE             DIG DIS SCI                     26   181 981
     5   ANON                  J AM DIET ASSOC                 78   443 981
     6   THOMAS DW             GASTROENTEROLOGY                80   776 981
     7   STERN M               MONATSSCHR KINDERHEILKD        129    51 981
     8   ELLIS D               AM J DIS CHILD                 136   323 982
     9   LO CW                 PEDIATRICS                      72   786 983
    10   LEBENTHAL E           POSTGRAD MED                    74   153 983
    11   HARMS HK              MONATSSCHR KINDERHEILKD        131   428 983
    12   ROHDE JE              REV INFECT DIS                   6   840 984
    13   MACFARLANE PI         ARCH DIS CHILD                  59   260 984
    14   AURICCHIO S           RIV ITAL PEDIATR                11   383 985
    15   PENNY ME              BR MED J                       292  1223 986

PN 77060
RN 00642 
AN 77244733
AU Watkins-J-B.  Perman-J-A.
TI Bile acid metabolism in infants and children.
SO Clin-Gastroenterol. 1977 Jan. 6(1). P 201-18. (REVIEW).
MJ BILE-ACIDS-AND-SALTS: me.  GASTROINTESTINAL-SYSTEM: me.
   LIVER: me.
MN BILE-ACIDS-AND-SALTS: bi.  CHENODEOXYCHOLIC-ACID: me.
   CHOLESTASIS: me.  CYSTIC-FIBROSIS: me.  DIARRHEA: me.
   ENTEROHEPATIC-CIRCULATION.  FEMALE.  FETUS: me.  GALLBLADDER: me.
   GASTROINTESTINAL-DISEASES: me.  HUMAN.  INFANT.  INFANT-NEWBORN.
   PREGNANCY.  REVIEW.  TAURINE: me.  SUPPORT-U-S-GOVT-P-H-S.
AB It is apparent that bile acid metabolism in the young child must be
   evaluated within the context of a maturing organism. Accordingly
   information has been presented so that the physician and the
   investigator will be able to integrate new data concerning mechanisms
   of bile salt action or pose new questions concerning previously
   existing hypotheses of hepatic and intestinal function in children.
RF 001   ALAGILLE D            J PEDIATR                       86    63 975
   002   BACK P                HOPPE SEYLERS Z PHYSIOL CHEM   354    83 973
   003   BISSELL PM            GASTROENTEROLOGY                69   809 975
   004   BLOOMER JR            ANN INTERN MED                  82   310 975
   005   BONGIOVANNI AM        J CLIN ENDOCRINOL METAB         25   678 965
   006   BOOK LD               PEDIATRICS                      57   201 976
   007   BURKE V               AUST PAEDIATR J                  2   219 966
   008   CAREY MC              AM J MED                        49   590 970
   009   CHALLACOMBE DN        ARCH DIS CHILD                  50   837 975
   010   CHALLACOMBE DN        ARCH DIS CHILD                  49   264 974
   011   CHALLACOMBE DN        ARCH DIS CHILD                  49   270 974
   012   CLAYTON RJ            AM J DIS CHILD                 117   112 969
   013   COELLO-RAMIREZ P      PEDIATRICS                      49   233 972
   014   DANIELSSON H          BIOCHEMISTRY                     7   346 968
   015   DEBELLE RC            GASTROENTEROLOGY                69   815 975
   016   DIETSCHY JM           J LIPID RES                      9   297 968
   017   EYSSEN H              BIOCHIM BIOPHYS ACTA           273   212 972
   018   GARNICA AD            PEDIATR RES                     10   354 976
   019   GRACEY M              LANCET                           2   384 969
   020   GRACEY M              SCAND J GASTROENTEROL            6   273 971
   021   GRACEY M              BIOCHIM BIOPHYS ACTA           225   308 971
   022   GRACEY M              GUT                             12   683 971
   023   GRAND RJ              GASTROENTEROLOGY                70   790 976
   024   HANSON RR             J CLIN INVEST                   56   577 975
   025   HAYES KC              SCIENCE                        188   949 975
   026   HEPNER GW             BIOCHIM BIOPHYS ACTA           291   237 973
   027   HEPNER GW             J CLIN INVEST                   51  1889 972
   028   HEPNER GW             J CLIN INVEST                   52   433 972
   029   HILL MJ               GUT                              9    22 968
   030   HOFMANN AF            J CLIN INVEST                   43   247 964
   031   INGELMAN-SUNDBERG M   BIOCHEMISTRY                    14   429 975
   032   JACKSON BT            J CLIN INVEST                   50  1286 971
   033   JACOBSEN JG           PHYSIOL REV                     48   424 968
   034   JAVITT NB             AM J MED                        51   637 971
   035   JAVITT NB             GASTROENTEROLOGY                70  1172 976
   036   JAVITT NB             PEDIATR RES                      7   119 973
   037   KATZ L                J PEDIATR                       85   608 974
   038   KRISHNA GSG           PEDIATR RES                      9   306 975
   039   LAPEY A               J PEDIATR                       84   328 974
   040   LARUSSO NF            N ENGL J MED                   292  1209 975
   041   LAVY U                PEDIATR RES                      9   306 975
   042   LESTER R              PEDIATR RES                      6   375 972
   043   LEWIS R               ARCH INTERN MED                130   545 972
   044   LINARELLI LG          J PEDIATR                       83   291 973
   045   LINARELLI LG          J PEDIATR                       81   484 972
   046   LITTLE M              GASTROENTEROLOGY                69  1315 975
   047   LOW-BEER TS           BR MED J                         1   338 973
   048   MAKINO I              FEBS LETTERS                    15   161 971
   049   MATA LJ               AM J CLIN NUTR                  25  1118 972
   050   MORRISSEY KP          SURGERY                         74   116 973
   051   NORMAN A              ACTA PAEDIATR SCAND             62   253 973
   052   NORMAN A              ACTA PAEDIATR SCAND             62   161 973
   053   NORMAN A              ACTA PAEDIATR SCAND             61   571 972
   054   OMAILLE ERL           J PHYSIOL (LOND)               180    67 965
   055   PALMER RH             ARCH INTERN MED                130   606 972
   056   POLEY JR              J LAB CLIN MED                  63   838 964
   057   RAIHA NCR             PEDIATRICS                      53   147 974
   058   RICOUR C              BIOL GASTROENTEROL               5   545 972
   059   RICOUR C              REV EUR ETUD CLIN BIOL          17   172 972
   060   ROY CC                J PEDIATR                       86   446 975
   061   SAMUEL P              PEDIATRICS                      54   222 974
   062   SANDBERG DH           PEDIATR RES                      4   262 970
   063   SCHNEIDER RE          AM J CLIN NUTR                  27   777 974
   064   SCHNEIDER RE          AM J CLIN NUTR                  27   777 974
   065   SHARP HL              J PEDIATR                       81   116 972
   066   SHARP HL              J PEDIATR                       71   723 967
   067   SHARP HL              PEDIATR RES                      5   274 971
   068   SINGER E              ARCH DIS CHILD                  49   174 974
   069   SMALL DM              ARCH INTERN MED                130   552 972
   070   SMALLWOOD RA          CLIN SCI MOL MED                45   403 974
   071   SMALLWOOD RA          J CLIN INVEST                   51  1388 972
   072   STIEHL A              N ENGL J MED                   286   858 972
   073   TAMER MA              PEDIATRICS                      53   217 974
   074   VON BERGMANN J        CLIN CHIM ACTA                  64   241 975
   075   WATKINS JB            GASTROENTEROLOGY                70   996 976
   076   WATKINS JB            PEDIATRICS                      53   511 974
   077   WATKINS JB            N ENGL J MED                   288   431 973
   078   WATKINS JB            GASTROENTEROLOGY                69   706 975
   079   WATKINS JB            PEDIATR RES                      7   341 973
   080   WATKINS JB            GASTROENTEROLOGY                68  1087 975
   081   WEBER AM              CLIN CHIM ACTA                  39   524 972
   082   WEBER AM              N ENGL J MED                   289  1001 973
   083   WILLIAMS CN           J PEDIATR                       81   493 972
   084   WILLIAMS RC           GASTROENTEROLOGY                69   483 975
   085   WINGATE DL            J CLIN INVEST                   52  1230 972
   086   ZOPPI G               PEDIATR RES                      6   880 972
CT   1   COWEN AE              AUST NZ J MED                    7   579 977
     2   WATKINS JB            AM J CLIN NUTR                  31  S148 978
     3   HEIKURA S             ACTA PAEDIATR SCAND             69   659 980
     4   MATHIS RK             GASTROENTEROLOGY                79  1311 980
     5   SEWELL RB             AM J PHYSIOL                   239  G354 980
     6   HARDY KJ              J PHYSIOL (LOND)               309     1 980
     7   STRANGE RC            PEDIATR RES                     15  1425 981
     8   BARNES S              J CLIN INVEST                   68   775 981
     9   SUCHY FJ              GASTROENTEROLOGY                80  1037 981
    10   FINNI K               ACTA PAEDIATR SCAND             71   763 982
    11   BALISTRERI WF         J PEDIATR GASTROENTEROL NUTR     2  S207 983
    12   LESTER R              J PEDIATR GASTROENTEROL NUTR     2   355 983
    13   WATKINS JB            J PEDIATR GASTROENTEROL NUTR     2   365 983
    14   FINNI K               ACTA PAEDIATR SCAND             72   215 983
    15   WATKINS JB            GASTROENTEROLOGY                85   793 983
    16   REICHEN J             INT REV EXP PATHOL              26   231 984
    17   TAVOLONI N            J PEDIATR GASTROENTEROL NUTR     4   256 985
    18   BECKETT GJ            CLIN CHEM                       31  1168 985
    19   EGESTAD B             SCAND J CLIN LAB INVEST         45   443 985
    20   WATKINS JB            PEDIATRICS                      75   151 985
    21   WATKINS JB            PEDIATRICS                      75   151 985
    22   PATTON S              J PEDIATR GASTROENTEROL NUTR     5   262 986
    23   GUSTAFSSON J          J LIPID RES                     27   801 986
    24   COLOMBO C             PEDIATR RES                     21   197 987

PN 77061
RN 00643 
AN 77224217
AU Lebenthal-E.  Shwachman-H.
TI The pancreas--development, adaptation and malfunction in infancy and
   childhood.
SO Clin-Gastroenterol. 1977 May. 6(2). P 397-413.
MJ PANCREATIC-DISEASES.  PANCREATITIS: et.
MN AMYLASES: df.  CHILD.  CYSTIC-FIBROSIS: di, th.  ENTEROPEPTIDASE: df.
   HUMAN.  INFANT.  METHODS.  NEUTROPENIA: di.  PANCREAS: ab, em.
   PANCREATIC-CYST: cn.  PANCREATIC-DISEASES: di.  PANCREATIC-NEOPLASMS.
   PEPTIDE-HYDROLASES: df.  SYNDROME.  TRYPSINOGEN: df.
EX Pancreatic development begins during the fourth week of gestation.
   In annular pancreas, the ventral pancreas fails to migrate to the
   right of the duodenum.  Duplication of the pancreatic ducts is a
   rare entity, probably arising from accidental misplacement of
   mucosal cells from the duodenum or stomach during the development of
   the pancreatic pouches.  Congenital pancreatic cysts may be single,
   multiple, unilocular or multilocular and can be associated with
   polycystic disease of the kidney, liver or spleen.  Ectopic pancreas
   occurs before or during the rotation of the ventral pancreas and its
   fusion with the dorsal pancreas.  Few tumours of the pancreas have
   been reported in children less than 15 years of age.  The evaluation
   of patients via different pancreatic function tests is significant
   only when the results are interpreted in the light of clinical
   manifestations.  Tests of exocrine pancreatic function in childhood
   include stool examination, the triolein test, blood examination,
   analysis of duodenal contents, the secretin-pancreozymin test,
   pancreatic scanning with selenomethionine, transduodenal
   pancreatogram, abdominal ultrasound and arteriography, and upper
   gastrointestinal x-ray.  The most prevalent disorder of the pancreas
   in infancy and childhood is exocrine pancreatic insufficiency.  Well
   over 96 per cent of infants and children with pancreatic
   insufficiency have cystic fibrosis.  Shwachman syndrome is the
   second most common cause of pancreatic insufficiency and is
   associated with neutropenia, metaphyseal dystosis, sever stunting of
   growth, eczema, and susceptibility to infections.  Patients with
   cystic fibrosis who have partial pancreatic insufficiency sometimes
   show dissociation of different enzyme activities.  Although
   pancreatitis is comparatively rare in infancy and childhood, we
   suspect that it is often overlooked.
RF 001   ABRUZZO JL            ANN SURG                       147   921 958
   002   ADAMS JT              SURGERY                         63   877 968
   003   AKERS DR              SURGERY                         71   817 972
   004   APPEL MF              ARCH SURG                      108    63 974
   005$  AREY LB               IN: TEXTBOOK LAB MANU EMBRYOL            965
   006   BACHRACH WH           GASTROENTEROLOGY                63   890 972
   007   BALZER E              Z GASTROENTEROL                  5   239 967
   008   BANKS PA              GASTROENTEROLOGY                61   382 971
   009   BARBERO GJ            AM J DIS CHILD                 112   536 966
   010   BARBEZAT GO           PEDIATRICS                      42    77 968
   011   BECKER WF             ANN SURG                       163   892 966
   012   BERK JE               JAMA                           199    98 967
   013   BISHOP RP             AM J GASTROENTEROL              49   112 968
   014   BLAINEY JD            CLIN SCI                        32   377 967
   015   BONIN A               J PEDIATR                       83   594 973
   016   BROOKS FP             N ENGL J MED                   286   300 972
   017   BUNNELL CE            J PEDIATR                       80   465 972
   018   CAREY MC              GUT                              9   700 968
   019   CASTLEMAN B           N ENGL J MED                   286  1353 972
   020   COMFORT MW            GASTROENTEROLOGY                21    54 952
   021   CORNET E              J CHIR (PARIS)                  84   527 962
   022   DI SANTAGNESE PA      PEDIATRICS                      15   683 955
   023   DOLAN RV              ARCH SURG                      109   762 974
   024   DRUMMEY GD            N ENGL J MED                   264    85 961
   025   ERLANGER BF           ARCH BIOCHEM BIOPHYS            95   271 961
   026   FELDMAN M             JAMA                           148   893 952
   027   FRABLE WJ             CANCER                          27   667 971
   028   FREDRICKSON DS        N ENGL J MED                   276    34 967
   029   FRINGLE EM            PROC R SOC MED                  61   776 968
   030   GEOKAS MC             CALIF MED                      117     1 972
   031   GIEDION A             FORTSCHR GEB ROENTG NUKL       108    51 968
   032   GO VLW                J CLIN INVEST                   49  1558 970
   033   GRACES L              PEDIATRICS                      41   789 968
   034   GREENBERGER NJ        MEDICINE (BALTIMORE)            45   161 966
   035   GROSFELD J            ARCH SURG                      101   370 970
   036   GROSS JB              AM J MED                        33   358 962
   037   GRYBOSKI J            MAJ PROB CLIN PEDIATR           13   450 975
   038   GUNDERSEN AE          J PEDIATR SURG                   4   478 969
   039   HADORN B              IN: ANDERSON CM                      289 975
   040   HADORN B              CAN MED ASSOC J                 98   377 968
   041   HADORN B              LANCET                           1   812 969
   042   HOWARD JM             ANN SURG                       165   293 967
   043   JACKSON CE            AM J MED                        43   727 967
   044   KATTWINKEL J          PEDIATRICS                      51    55 973
   045   KILMAN JW             SURGERY                         55   455 964
   046   KLEIN B               CLIN CHEM                       16    32 970
   047   KLEITSCH WP           ARCH SURG                       71   795 955
   048   LAGERLOF HO           ACTA MED SCAND SUPPL           128     1 942
   049   LEBENTHAL E           PEDIATRICS                      56   585 975
   050   LEBENTHAL E           GASTROENTEROLOGY                70   508 976
   051   LIECHTY RD            JAMA                           230  1538 974
   052   LILLIBRIDGE CB        J PEDIATR                       82   279 973
   053   LIFTON LJ             JAMA                           229    47 974
   054   LOWE CU               AM J DIS CHILD                  82   459 951
   055   LUNDH G               GASTROENTEROLOGY                42   275 962
   056   MARCHIS-MOUREN G      ARCH BIOCHEM BIOPHYS            83   309 959
   057   MARTIN DU PAN R       INT Z VITAMINFORSCH              1    67 971
   058   MARTINEZ W            ANN SURG                       147     1 958
   059   MATSUMOTO Y           SURGERY                         76   827 974
   060   MCELROY R             AM J MED                        52   228 972
   061   MOORE JG              AM J DIG DIS                    16    97 971
   062   MOYNAN RW             J PEDIATR                       65   711 964
   063   NAGEL W               PHYSIOL CHEM                   340     1 965
   064   NORTHRUP WF           SURGERY                         71    27 972
   065   PATTEN BM             HUMAN EMBRYOLOGY                         968
   066   REETSMA K             SURGERY                         42    22 957
   067   ROBINSON MJ           PEDIATRICS                      48   232 971
   068   SCHMIDT H             CLIN ORTHOP                     69   135 970
   069   SHELDON W             ARCH DIS CHILD                  39   268 964
   070   SHMERLING DH          HELV PAEDIATR ACTA              24   547 969
   071   SHWACHMAN H           IN: SLEISENGER MH                   1206 973
   072   SHWACHMAN H           BIRTH DEF ORIG ART SER           8    46 972
   073   SHWACHMAN H           ADV PEDIATR                      7   249 955
   074   SHWACHMAN H           PEDIATRICS                      55    86 975
   075   SHWACHMAN H           J PEDIATR                       63   835 963
   076   SHWACHMAN H           J PEDIATR                       65   645 964
   077   SIBERT JR             ARCH DIS CHILD                  50   443 975
   078   SKUDE G               ACTA PAEDIATR SCAND             65   145 976
   079   STOVER SL             J PEDIATR                       73   235 968
   080   TAUSSIG LM            PEDIATRICS                      54   229 974
   081   TOWNES PL             J PEDIATR                       66   275 965
   082   URSING B              BR MED J                         3   524 973
   083   WEITZMAN JJ           SURGERY                         57   309 965
   084   WELCH KJ              IN: BENSON CD                    1   607 962
   085$  WITTE CL              JAMA                           120   132 968
   086   WOODLEY JF            GUT                             13   900 972
   087   WORNING H             SCAND J GASTROENTEROL            1   268 966
   088   WRIGHT E              SURGERY                         69   389 971
   089   ZOPPI G               PEDIATR RES                      6   880 972
CT   1   THONG YH              AUST PAEDIATR J                 14    34 978
     2   BERG NO               ACTA PAEDIATR SCAND             67   403 978
     3   LEBENTHAL E           AM J DIS CHILD                 132   850 978
     4   BRANSKI D             DIG DIS SCI                     24   865 979
     5   CASELITZ J            VIRCHOWS ARCH PATHOL ANAT HIS  385   109 979
     6   FORBES DA             AUST PAEDIATR J                 16   126 980
     7   LEBENTHAL E           J PEDIATR                       97   389 980
     8   SPEER C               MONATSSCHR KINDERHEILKD        128   785 980
     9   LEBENTHAL E           AM J DIS CHILD                 134   834 980
    10   LEBENTHAL E           AM J GASTROENTEROL              75   436 981
    11   COLEMAN BG            RADIOLOGY                      146   145 983
    12   ADDA G                ANAT CLIN                        5   275 984
    13   ISAACS JD             J CLIN GASTROENTEROL             7   533 985
    14   LEBENTHAL E           CLIN PERINATOL                  13    37 986

PN 77063
RN 00644 
AN 77224237
AU Papp-Z.  Ember-I.  Juhasz-E.  Tasnady-Z.  Karsai-T.  Elodi-P.
TI Acid-soluble glycoproteins in amniotic fluid and cystic fibrosis of
   the foetus.
SO Clin-Genet. 1977 Jun. 11(6). P 431-2.
MJ AMNIOTIC-FLUID: an.  CYSTIC-FIBROSIS: di.  GLYCOPROTEINS.
   PRENATAL-DIAGNOSIS.
MN AMNIOCENTESIS.  CYSTIC-FIBROSIS: me.  FEMALE.  GLYCOPROTEINS: an.
   HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.  PREGNANCY.
EX We suggest that the intrauterine detection of cystic fibrosis may be
   based on the investigation of the amniotic fluid.  It is known that
   the protein content of the meconium of homozygotic newborn infants
   is significantly increased, whereas that of heterozygotic infants is
   only moderately increased.  As a result of intrauterine intestinal
   activity, the bowel content may be excreted into the amniotic fluid;
   thus a detectable deviation in the protein content of amniotic fluid
   may be expected.  We decided to determine the total protein content
   and the amount of acid-soluble glycoproteins in 86 amniotic fluid
   samples, both by polography and by measuring the hexose content.  In
   the homozygous case a slight increase was observed in total protein
   content, whereas in the heterozygous cases no changes were observed.
RF 001   CHODOS DD             PROC SOC EXP BIOL MED           99   775 958
   002   DISCHE Z              PEDIATRICS                      24    74 959
   003   GREEN MN              PEDIATRICS                      41   989 968
   004   KNAUFF RE             CLIN CHIM ACTA                  19   245 968
   005   PAPP Z                J PEDIATR                       88   151 976
   006   DI SANTAGNESE PA      PEDIATRICS                      19   252 957
CT   1   ALHADEFF JA           CLIN GENET                      14   189 978
     2   HOSLI P               LANCET                           2   543 979
     3   HOSLI P               FEBS LETTERS                   104   271 979
     4   DANN LG               PRENAT DIAGN                     3   161 983
     5   HUHLE D               Z KLIN MED                      40  1199 985

PN 77064
RN 00645 
AN 77067477
AU Schiotz-P-O.  Magid-E.
TI Serum pancreatic isoamylases in the diagnosis of cystic fibrosis
   heterozygotes: A non-valuable test.
SO Clin-Genet. 1977 Jan. 11(1). P 43-5.
MJ CYSTIC-FIBROSIS: fg.  GLYCOSIDE-HYDROLASES: bl.  ISOAMYLASE: bl.
MN ADULT.  AGED.  CYSTIC-FIBROSIS: di, en.  FEMALE.  HETEROZYGOTE.
   HUMAN.  MALE.  MIDDLE-AGE.  PANCREAS: en.  SALIVA: en.
AB A group of 102 obligate heterozygotes for the cystic fibrosis gene
   were examined for genetic type of pancreatic isoamylases as well as
   enzyme activity of pancreatic iso-amylases, salivary isoamylases and
   total amylase in serum. The analysis was performed using
   electrophoretic separation for detection of the various types of
   isoamylases, and their relative activity was determined by means of
   densitometry. The activities of salivary isoamylases and total
   amylase in serum showed no significant differences between the cystic
   fibrosis heterozygotes and a control group. The frequency of the
   variant gene for pancreatic isoamylase was also the same as in the
   controls. The mean value for pancreatic isoamylase was slightly
   higher in the cystic fibrosis heterozygotes than in the control group
   (0.05 greater than P greater than 0.02).
RF 001   CESKA M               CLIN CHIM ACTA                  26   445 969
   002   DANES BS              LANCET                           1  1061 968
   003   DANES BS              J EXP MED                      129   775 969
   005   GIBSON LE             PEDIATRICS                      23   545 959
   006   KAMARYT J             HUMANGENETIK                     3    41 966
   007   KAMARYT J             HUMANGENETIK                    11   213 971
   008   SKUDE G               SCAND J CLIN LAB INVEST         35    41 975
   009   SKUDE G               ACTA PAEDIATR SCAND             65   145 976
CT   1   HUBBARD VS            J PEDIATR                       92   685 978
     2   GILLARD BK            PEDIATR RES                     14  1168 980
     3   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982

PN 77065
RN 00646 
AN 78063212
AU Bowman-B-H.  Lankford-B-J.  McNeely-M-C.  Carson-S-D.  Barnett-D-R.
   Berg-K.
TI Cystic fibrosis: studies with the oyster ciliary assay.
SO Clin-Genet. 1977 Dec. 12(6). P 333-43.
MJ BIOLOGICAL-ASSAY: mt.  CILIA.  CYSTIC-FIBROSIS: bl.  OYSTERS.
MN CELL-LINE.  CULTURE-MEDIA.  CYSTIC-FIBROSIS: fg.  FIBROBLASTS.
   GENOTYPE.  HUMAN.  TISSUE-CULTURE.  SUPPORT-U-S-GOVT-P-H-S.
AB Bioassays using ciliary systems have detected a factor or factors in
   cystic fibrosis (CF) sera and tissue culture medium derived from CF
   cells. The typical shortcomings of an assay measuring biological
   activity have been studied, and the means to overcome the weaknesses
   of the oyster gill cilia assay have been established. The presence of
   the cystic fibrosis mucociliary inhibitor (CFMI) in experimental
   fractions may be determined by accepting data from only those assays
   in which authentic CF and normal (non-CF) fractions give defined
   reactions, by measuring the reaction of each sample at least three
   times, and by examining each experimental sample at a protein
   concentration greater than the minimum established in this study. The
   relative concentrations of the CFMI present in the first steps of
   purification of serum and medium have been calculated in terms of
   units of inhibition. Generally, the units of inhibition present in
   serum and medium fractions from heterozygotes are close to one-half
   of that in fractions from homozygous sources. Analogous fractions
   concentrated from a normal (non-CF) source never inhibited
   mucociliary activity, even when tested at nearly 100 times the CF
   concentration. Ciliary assays utilizing oyster gills are essential
   for monitoring fractionation procedures aimed at purifying the CFMI,
   and have been shown to be capable and reliable enough to do so.
RF 001   BARNETT DR            TEX REP BIOL MED                31   703 973
   002   BARNETT DR            TEX REP BIOL MED                31   697 973
   003   BAUR PS               TEX REP BIOL MED                34   155 976
   004   BERATIS NG            PEDIATR RES                      7   958 973
   005   BESLEY GTN            J MED GENET                      6   278 969
   006   BOLTON WE             AM J HUM GENET                  27   394 975
   007   BOWMAN BH             PROC NAT ACAD SCI USA           70   548 973
   008   BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      64  1310 975
   009   BOWMAN BH             SCIENCE                        164   325 969
   010   BOWMAN BH             SCIENCE                        167   871 970
   011   CHERRY JD             J PEDIATR                       79   937 971
   012   CONNEALLY PM          TEX REP BIOL MED                31   639 973
   013   CONOVER JH            PEDIATR RES                      7   220 973
   014   DANES BS              J EXP MED                      137  1538 973
   015   GALSTOFF PS           FISHERY BULL                    64     1 964
   016   LOCKHART LH           TEX REP BIOL MED                31   631 973
   017   LOWRY OH              J BIOL CHEM                    193   265 951
   019   SCHMOYER IR           LIFE SCI PART 2                 11  1037 972
   020   SPOCK A               PEDIATR RES                      1   173 967
   021   WILSON GB             PEDIATR RES                     11   143 977
   022   WOOD RE               LANCET                           2  1452 973
CT   1   DANN LG               LANCET                           2   405 978
     2   BOWMAN BH             TEX REP BIOL MED                38    47 979
     3   KURLANDSKY LE         PEDIATR RES                     14  1263 980
     4   MAYO BJ               CLIN GENET                      18   379 980
     5   BOWMAN BH             FED PROC                        39  3195 980
     6   SANDERSON MJ          PEDIATR RES                     15   219 981
     7   CARSON SD             PEDIATR RES                     16    13 982
     8   MCNEELY MC            PEDIATR RES                     16    21 982
     9   DULFANO MJ            THORAX                          37   646 982
    10   SANDERSON MJ          CELL MOTIL                       4   103 984

PN 77066
RN 00647 
AN 77114561
AU Danes-B-S.  Hodson-M-E.  Batten-J.
TI Cystic fibrosis: Evidence for a genetic compound from a family study
   in cell culture.
SO Clin-Genet. 1977 Feb. 11(2). P 83-90.
MJ CYSTIC-FIBROSIS: fg.
MN ADULT.  CASE-REPORT.  CELL-LINE.  CELLS-CULTURED.  FEMALE.
   FIBROBLASTS.  HUMAN.  PEDIGREE.  PHENOTYPE.
AB Although the majority of patients with cystic fibrosis (CF) show a
   typical clinical course, a minority with the same clinical phenotype
   at the time of initial diagnosis have an atypical (mild) course. Skin
   fibroblast cultures were established from 49 members of the family of
   one such atypical CF adult patient, previously identified (Danes et
   al. 1976) as CF Class II (ametachromatic and no metabolic cooperation
   with CF Class I fibroblasts), the offspring of Class I
   (metachromatic, metabolic cooperation with normal fibroblasts)/Class
   II mating. The culture phenotype for Class I was traced on the
   maternal side and for Class II on the paternal side through
   consecutive generations and the culture phenotype of each class
   segregated. This family study added experimental evidence to support
   the hypothesis that the atypical (mild) clinical features and course
   of this adult CF patient were due to two different CF genes combining
   to produce a genetic compound expressing a mild form of CF.
RF 001   BEARN AG              TRANS ASSOC AM PHYSICIANS       82   248 969
   002   DANES BS              BIRTH DEF ORIG ART SER           8   114 972
   003   DANES BS              LANCET                           2   765 973
   004   DANES BS              CLIN GENET                       7   128 975
   005   DANES BS              J EXP MED                      129   775 969
   006   DANES BS              CLIN GENET                       8    85 975
   007   DANES BS              AM J HUM GENET                  23   297 971
   008   DANES BS              CLIN GENET                       9   527 976
   009   HALDANE JBS           ANN EUGEN                        8   263 938
   011   LYKKEGAARD E          DAN MED BULL                    22   177 975
   012   LYKKEGAARD E          DAN MED BULL                    22   169 975
   013   LYKKEGAARD E          DAN MED BULL                    22   175 975
   014   MCKUSICK VA           HERITABLE DISORDERS OF CONNEC            972
   015   MCKUSICK VA           AM J HUM GENET                  25   446 973
   016   MATALON R             LANCET                           2   838 969
   017   SHWACHMAN H           BIRTH DEF ORIG ART SER           8   102 972
   018   WOOD RE               LANCET                           2  1452 973
CT   1   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     2   WILSON GB             PEDIATR RES                     12   801 978
     3   TULLY GW              PEDIATR RES                     13  1078 979
     4   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     5   TARNOKY AL            J ROY SOC MED                   73    73 980
     6   BULLOCK S             CLIN GENET                      21   336 982
     7   WINGE P               DAN MED BULL                    29   358 982
     8   ROSENSTEIN BJ         SOUTH MED J                     79   319 986

PN 77067
RN 00648 
AN 77067550
AU Kapp-J-P.  Arora-B.  Sibinga-M-S.
TI Depression of erythropoiesis, physical growth, and hair growth by
   chloramphenicol in a three-year-old child with cystic fibrosis.
SO Clin-Pediatr (Phila). 1977 Jan. 16(1). P 64-6.
MJ CHLORAMPHENICOL: ae.  CYSTIC-FIBROSIS: dt.  ERYTHROPOIESIS: de.
   GROWTH: de.  HAIR: gd.
MN ANOREXIA: ci.  CHILD-PRESCHOOL.  CHLORAMPHENICOL: tu.
   CYSTIC-FIBROSIS: pp.  DEPRESSION-CHEMICAL.  FEMALE.  HUMAN.
   SUPPORT-U-S-GOVT-P-H-S.
EX In patients with cystic fibrosis (CF) of the pancreas, optic
   neuritis and peripheral neuritis have been reported to follow
   treatment with chloramphenicol.  This toxic sequel appears to be
   related to the dosage and duration of therapy.  In patients with
   other diseases who are treated with chloramphenicol, the risk of
   devastating bone marrow toxicity has been estimated to range from
   1:40,000 to 1:100,000.  We have found only two reports of patients
   with CF who had hematologic complications after treatment with
   chloramphenicol.  We here report a 3-year-old girl who had selective
   depression of the erythroid bone marrow, anorexia, weight loss,
   temporary hair loss and retardation of growth after prolonged
   administration of chloramphenicol.
RF 001   DENNING CR            J PEDIATR                       63   878 963
   002   HUANG NN              ANTIMICROB AGENTS CHEMOTHER      3    79 963
   003   HARLEY RD             TRANS AM ACAD OPHTHALMOL OTOL   74  1011 970
   004   BEST WR               JAMA                           201   181 967
   005   LLOYD AVC             JAMA                           184  1001 963
   006   SHWACHMAN H           PEDIATRICS                      46   335 970
   007   YUNIS AA              SEMIN HEMATOL                   10   225 973
   008   MCCURDY PR            JAMA                           176   588 961
   009   WEISBERGER AS         JAMA                           209    97 969
   010   AMBROSE CT            J EXP MED                      117  1075 963
   011   DANIEL TM             N ENGL J MED                   273   367 965
   012   SAIDI P               J LAB CLIN MED                  57   247 961

PN 77068
RN 00649 
AN 77114688
AU Goldschmidt-Z.  Cohen-H.  Isaacsohn-M.  Schiller-M.
TI Meconium ileus equivalent in an infant, aggravated by soy bean
   formula.
SO Clin-Pediatr (Phila). 1977 Mar. 16(3). P 284-6.
MJ CYSTIC-FIBROSIS: co.  INFANT-NUTRITION.
   INTESTINAL-OBSTRUCTION: co.
MN CASE-REPORT.  HUMAN.  INFANT.  INTESTINE-SMALL.  MALE.  SOY-BEANS.
EX Meconium ileus in the neonate is the presenting symptom in 10 to 20
   per cent of instances of cystic fibrosis of the pancreas.  Similar
   intestinal obstruction occurring later, in the post-neonatal period,
   is a rare occurrence, and was called "Meconium Ileus Equivalent" by
   Jensen.  Of 40 cases affected by this syndrome reported in medical
   literature, only 13 were infants.  We report a 7-week-old patient
   who died 3 days after surgery for small bowel obstruction.  The
   clinical suspicion of cystic fibrosis was confirmed at autopsy.
RF 001   DI SANTAGNESE PA      GASTROENTEROLOGY                40    64 961
   002   KALAYOGLU M           J PEDIATR SURG                   6   290 971
   003   JENSEN KG             ACTA PAEDIATR SCAND             51   344 962
   004   JAFFE BF              ARCH SURG                       92   337 966
   005   DONNISON AB           PEDIATRICS                      37   833 966
   006   SHAW A                J PEDIATR SURG                   4   119 969
   007   THOMAIDIS TS          J PEDIATR                       63   444 963
   008   TUCKER AS             AM J ROENTG RAD THER NUCL MED  112   135 971
   009   HUNTON DB             GASTROENTEROLOGY                50    99 966
   010   BROWN PM              N ENGL J MED                   263   544 960
   011   MULLINS F             JAMA                           192   741 965
   012   CORDONNIER JK         SURGERY                         54   667 963
   013   SIGLER RM             MAYO CLIN PROC                  40   477 965
   014   SNYDER WH JR          PEDIATRICS                      34    72 964
   015   MOSS MH               AM J DIS CHILD                 117   540 969
   016   OPPENHEIMER EH        BULL JOHNS HOPKINS HOSP         98   353 956
   017   OPPENHEIMER EH        ARCH PATHOL                     96   149 973
CT   1   ROSENBERG E           KLIN PAEDIATR                  195   323 983
     2   SAMUEL N              J ULTRASOUND MED                 5   425 986

PN 77069
RN 00650 
AN 77067548
AU Patterson-P-R.
TI Minocycline in the antibiotic regimen of cystic fibrosis patients:
   weight gain and clinical improvement.
SO Clin-Pediatr (Phila). 1977 Jan. 16(1). P 60-3.
MJ BODY-WEIGHT: de.  CYSTIC-FIBROSIS: dt.  MINOCYCLINE: tu.
   TETRACYCLINES: tu.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.
   DRUG-THERAPY-COMBINATION.  FEMALE.  HUMAN.  MALE.  MINOCYCLINE: pd.
   SEX-FACTORS.  SPUTUM: de.  STIMULATION-CHEMICAL.
AB Minocycline hydrochloride was given to 100 patients with cystic
   fibrosis of the pancreas for periods of 3 months over a broad-
   spectrum antibiotic drug rotation which lasted 2 years. Increased
   weight gain and some clinical improvement was seen during treatment
   with minocycline. Those patients with severe disease gained more
   weight than those with mild or moderate disease, and males gained
   more than females. When minocycline hydrochloride was not the drug in
   use, patients lost weight and their health declined.
RF 001   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   002   HUANG NN              AM J DIS CHILD                 120   289 970
   003   STUR O                WIEN MED WOCHENSCHR            119   395 969

PN 77070
RN 00651 
AN 78042532
AU Harrisson-S-P.
TI Dysfunctional aspects of a supportive group.
SO Community-Health (Bristol). 1977 Aug. 9(1). P 17-9.
MJ STRESS-PSYCHOLOGICAL.  VOLUNTARY-HEALTH-AGENCIES.
MN CHILD.  CYSTIC-FIBROSIS: px.  HUMAN.
AB A number of voluntary organizations exist for the support of
   patients and their relatives suffering from specific medical
   conditions.  It is usually assumed that membership will provide
   positive emotional and social support but membership may provide
   dysfunctional responses.  A small-scale study of parents of
   fibrocystic children provides some evidence of dysfunctional aspects
   of membership of one specific organization.  Further research into
   the effects of formal and informal reference group activity and the
   types of support most acceptable to patients and their families is
   suggested.
RF 001   BURTON L              PRACTITIONER                   210   247 973
   002   BURTON L              FAMILY LIFE OF SICK CHILDREN             975
   003   HARRISSON SP          THESIS                                   975
   004   HEWETT S              FAMILY AND HANDICAPPED CHILD             970
   005   MCCOLLUM AT           J PEDIATR                       77   571 970
   006   MERTON RK             SOCIAL THEORY AND SOCIAL STRU        343 968

PN 77071
RN 00652 
AN 78084292
AU Longnecker-D-S.
TI Environmental factors and diseases of the pancreas.
SO Environ-Health-Perspect. 1977 Oct. 20. P 105-12.
MJ ENVIRONMENTAL-POLLUTANTS: ae.  PANCREATIC-DISEASES: ci.
MN AGING.  CYSTIC-FIBROSIS: fg.  DIABETES-MELLITUS: et.  HUMAN.
   PANCREAS: ab.  PANCREATIC-DISEASES: co, pc.
   PANCREATIC-NEOPLASMS: ci.  PANCREATITIS: ci.
AB The five major diseases of the pancreas together make a significant
   contribution to morbidity and mortality among the people of the
   United States. These diseases are diabetes, cystic fibrosis, acute
   and chronic pancreatitis, and carcinoma of the exocrine pancreas.
   Four of these diseases can be modeled in laboratory animals by acute
   or chronic administration of chemical poisons or carcinogens. Human
   pancreatic diseases attributed to the effect of chemical agents
   including alcohol and drugs include many cases of chronic
   pancreatitis and some cases of acute pancreatitis. The cause is not
   known in many cases of human pancreatitis, including interstitial,
   acute, and chronic clinical forms. Epidemiologic studies suggest that
   the increasing incidence of carcinoma of the exocrine pancreas in the
   United States may reflect chemical carcinogenesis. On the basis of
   experimental observations, we know that pancreatic islet cells can be
   damaged directly by toxic chemicals, and that islet cell tumors can
   be chemically induced. Thus, there is adequate background data to
   conclude that several pancreatic diseases of obscure etiology may be
   due in part to hitherto unidentified toxic effects of chemical agents
   encountered in personal or general environments.
RF 001   SARLES H              DIGESTION                        9   389 973
   002   TOKUHATA GK           J CHRON DIS                     28    23 975
   003   TRAPNELL JE           BR MED J                         2   179 975
   004   OSULLIVAN JN          GASTROENTEROLOGY                62   373 972
   005   SARLES H              MED CLIN NORTH AM               58  1333 974
   006   SARLES H              ANN NY ACAD SCI                252   171 975
   007   DREILING DA           ANN NY ACAD SCI                252   187 975
   008   ISHII K               DIGESTION                        9   429 973
   009   DIMAGNO EP            ANN NY ACAD SCI                252   200 975
   010   BOWMAN BH             N ENGL J MED                   294   937 976
   011   CONNEALLY PM          TEX REP BIOL MED                31   639 973
   012   HADORN B              MED CLIN NORTH AM               58  1319 974
   013   KRAIN LS              J CHRON DIS                     23   685 971
   014   BATES RR              J SURG ONCOL                     7   143 975
   015   LI FP                 J NATL CANCER INST              43  1159 969
   016   WYNDER EL             J NATL CANCER INST              50   645 973
   017   FLAKS B               EUR J CANCER                     5   231 969
   018   FLAKS B               CHEM BIOL INTERACT               6    91 973
   019   RODRIGUEZ TG          J ULTRASTRUCT RES               19   116 967
   020   RAO MS                VIRCHOWS ARCH CELL PATHOL       17   149 974
   021   HRUBAN Z              CANCER RES                      25   708 965
   022   VEGHELYI PV           AM J DIS CHILD                  80   390 950
   023   FEDORKO ME            LAB INVEST                      18    27 968
   024   CORNISH AL            N ENGL J MED                   265   673 961
   025   KERN HF               VERH ANAT GES                   64   115 970
   026   STUMPF HH             LAB INVEST                       5   224 956
   027   CHENARD J             AM J PATHOL                     52   825 968
   028   HRUBAN Z              LAB INVEST                      14  1652 965
   029   SARLES H              GUT                             12   377 971
   030   FARBER E              PROC SOC EXP BIOL MED           74   838 950
   031   LOMBARDI B            AM J PATHOL                     79   465 975
   032   WENK ML               J NATL CANCER INST              52   533 974
   033   BOQUIST L             ACTA PATH MICROBIOL SCAND       76    91 969
   034   GOLDBERG RC           PROC SOC EXP BIOL MED           74   869 950
   035   MARTIN BF             J ANAT                         104    93 969
   036   HRUBAN Z              LAB INVEST                      14    70 965
   037   REDDY JK              LAB INVEST                      32    98 975
   038   KONISHI Y             J NATL CANCER INST              52   917 974
   039   BOQUIST L             LAB INVEST                      21    96 969
   040   KAUFMAN N             ARCH PATHOL                     70   331 960
   041   MORGAN WS             J CELL BIOL                     36   261 968
   042   WEISS JM              J EXP MED                      101   213 955
   043   LONGNECKER DS         LAB INVEST                      16   321 967
   044   LONGNECKER DS         ARCH PATHOL                     99     5 975
   045   HRUBAN Z              J ULTRASTRUCT RES                7   273 962
   046   NEVALAINEN TJ         VIRCHOWS ARCH CELL PATHOL       18   119 975
   047   BREUER RI             LAB MED                          8     7 977
   048   JONES MF              N ENGL J MED                   267  1029 962
   049   JOHNSTON DH           JAMA                           170  2054 959
   050   JONES PE              BR MED J                         1   133 975
   051   WILSON AE             LANCET                           1   105 967
   052   NOGUEIRA JR           GASTROENTEROLOGY                62  1040 972
   053   DAVIDOFF F            N ENGL J MED                   289   552 973
   054   LONGNECKER DS         CANCER RES                      35  2249 975
   055   POUR P                CANCER RES                      35  2259 975
   056   MORRIS HP             J NATL CANCER INST              29   977 962
   057   SCHOENTAL R           BR J CANCER                     31   264 975
   058   HAYASHI Y             GANN                            62   329 971
   059   KONISHI Y             GANN                            67   919 976
   060   REDDY JK              CANCER RES                      35  2269 975
   061   RAKIETEN N            PROC SOC EXP BIOL MED          137   280 971
   062   OAKLEY WG             DIABETES AND ITS MANAGEMENT              975
   063   ZONANA J              N ENGL J MED                   295   603 976
   064   DUNN JS               LANCET                           1   484 943
   065   FISCHER LJ            CRC CRIT REV TOXICOL             3   231 975
   066   HRUBAN Z              LAB INVEST                      26   270 972
   067   WOLD JS               TOXICOL APPL PHARMACOL          19   188 971
   068   RAKIETEN N            CANCER CHEMOTHER REPTS          29    91 963
   069   WILANDER E            ACTA PATH MICROBIOL SCAND (A)   83   206 975
   070   BERNE C               LANCET                           1   173 974
   071   ANON                  HEW PUB NO NIH76-1018 TO 76-1            976
   072   DI SANTAGNESE PA      N ENGL J MED                   295   597 976
CT   1   BALLDIN G             J CLIN INVEST                   66   159 980
     2   DANNI O               RES COMMUN SUBST ABUSE           5    67 984
     3   VENA JE               BR J IND MED                    42    85 985
     4   PANG VF               VET PATHOL                      23   310 986
     5   ZELINSKYPAPEZ K       IN VITRO CELL DEVEL BIOL        23   118 987

PN 77072
RN 00653 
AN 77162158
AU Brohet-C-R.  Neal-W-A.  Warwick-W-J.  Tuna-N.
TI Reassessment of the diagnostic value of the vectorcardiogram in
   cystic fibrosis (correlation with clinical score, pulmonary function
   tests and echocardiogram).
SO Eur-J-Cardiol. 1977 May. 5(3). P 221-38.
MJ CYSTIC-FIBROSIS: di.  ECHOCARDIOGRAPHY.  RESPIRATORY-FUNCTION-TESTS.
   VECTORCARDIOGRAPHY.
MN ADOLESCENCE.  ADULT.  CHILD.  FEMALE.  FORCED-EXPIRATORY-VOLUME.
   HUMAN.  MALE.  PEAK-EXPIRATORY-FLOW-RATE.  VITAL-CAPACITY.
AB In 21 children with cystic fibrosis, the vectorcardiogram (VCG) was
   correlated with various indices of the severity of the disease. The
   best correlation was found between (1) the azimuth angle of the
   spatial QRS loop area, representing the rightward and posterior shift
   of the main electrical forces, and pulmonary function tests (PFT):
   FEV1 % predicted (r = -0.671, P less than 0.005) and VC% predicted (r
   = -0.607, P less than 0.005), and (2) the right ventricular anterior
   wall index measured echocardiographically (r = 0.472, P less than
   0.05). More VCG parameters correlated significantly with PFT than
   with the echocardiogram. This shows the major influence of pulmonary
   changes on the VCG of those patients. In several subgroups with
   different clinical scores, the VCG were analyzed and compared to
   normal limits of age- and sex-matched controls. In this small series,
   the VCG was a specific but not very sensitive method for predicting
   the degree of severity of the disease. Echocardiography and
   vectorcardiography can be considered as two complementary techniques
   in the evaluation of cystic fibrosis.
RF 001   CROZIER DN            PEDIATR CLIN NORTH AM           21   935 974
   002   ROYCE SW              PEDIATRICS                       8   255 951
   003   GOLDRING RM           J PEDIATR                       65   501 964
   004   SIASSI B              J PEDIATR                       78   794 971
   005   KEANE JF              PEDIATR RES                      8   355 974
   006   LIEBMAN J             CIRCULATION                     35   552 967
   007   LIEBMAN J             CHEST                           63   218 973
   008   JOHNSON DH            PEDIATR RES                      8   350 974
   009   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   010   SCHMITT OH            ARCH INTERN MED                 96   574 955
   011   BROHET CR             J ELECTROCARDIOL                 8     1 975
   012   BROHET CR             J ELECTROCARDIOL                 8   103 975
   013   DOWNS TD              IEEE TRANS BIOMED ENG           16    87 969
   014   CHOU TC               CLINICAL VECTORCARDIOGRAP            103 974
   015   KILCOYNE MM           CIRCULATION                     42   903 970
   016   MOSS AJ               J PEDIATR                       67   797 965
   017   FEIGENBAUM H          ECHOCARDIOGRAPHY                         972
   018   QUIVERS WW            AM J CARDIOL                    14   616 964
   019   FLAHERTY JT           AM J CARDIOL                    20    29 967
   020   FOWLER RS             PEDIATR RES                      8   349 974
CT   1   FOWLER RS             J ELECTROCARDIOL                14   319 981

PN 77073
RN 00654 
AN 78023997
AU Doering-K-M.  Arglebe-C.  Lubahn-H.  Chilla-R.
TI "Fast isoamylases" in the parotid saliva of children with cystic
   fibrosis and heterozygous carriers.
SO Eur-J-Pediatr. 1977 Oct 12. 126(3). P 185-8.
MJ CYSTIC-FIBROSIS: en.  GLYCOSIDE-HYDROLASES: an.  ISOAMYLASE: an.
   SALIVA: en.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  FEMALE.
   HETEROZYGOTE.  HUMAN.  MALE.  MIDDLE-AGE.  PAROTID-GLAND: se.
AB On electrophoresis, parotid saliva always exhibits a basic pattern of
   6 isoamylases. Additional faster migrating isoamylases occur in
   varying numbers. These "fast isoamylases" are generated, at least in
   part, by deamidation. Compared with juvenile and adult controls, a
   significantly greater number of "fast isoamylases" was found in the
   parotid saliva of children with cystic fibrosis and their healthy
   heterozygous parents. A shift in the equilibrium between amidation
   and deamidation is discussed in terms of its possible connection with
   the metabolic defect responsible for cystic fibrosis.
RF 001   ARGLEBE C             LARYNGOL RHINOL OTOL            54   542 975
   002   ARGLEBE C             CLIN OTOLARYNGOLOGY              1   249 976
   003   GREENBERG DM          METABOLIC PATHWAYS               3       969
   004   IMMICH H              MEDIZINISCHE STATISTIK                   974
   005   KAUFFMAN DL           ARCH BIOCHEM BIOPHYS           137   325 970
   006   KELLER PJ             BIOCHEMISTRY                    10  4867 971
   007   KULCZYCKI LL          AM J DIS CHILD                 127    64 974
   008   LOWRY OH              J BIOL CHEM                    193   265 951
   009   MANN HB               ANN MATH STAT                   18    50 947
   010   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   011   STEPHAN U             INTERNIST (BERL)                17   336 976
   012   STREET HV             CLIN CHIM ACTA                   1   256 956
   013   WRIGHT SW             AM J HUM GENET                  20   157 968
CT   1   SHAPIRO BL            SCIENCE                        203  1251 979
     2   MANDEL ID             CRC CRIT REV CLIN LAB SCI       12   321 980
     3   TARNOKY AL            J ROY SOC MED                   73    73 980
     4   BARDON A              CLIN CHIM ACTA                 101    17 980
     5   HEELEY AF             CLIN CHEM                       29  2011 983

PN 77074
RN 00655 
AN 78064391
AU Breslow-J-L.  Epstein-J.  Vayo-M-M.  Fontaine-J-H.
TI Decreased ouabain binding in cystic fibrosis fibroblasts in
   potassium-free medium.
SO Exp-Cell-Res. 1977 Dec. 110(2). P 399-407.
MJ CYSTIC-FIBROSIS: me.  OUABAIN: me.
MN BIOLOGICAL-TRANSPORT.  CULTURE-MEDIA.  FIBROBLASTS: me.  GLUCOSE: pd.
   HUMAN.  POTASSIUM: pd.  RECEPTORS-DRUG: me.  RUBIDIUM: me.
   SUPPORT-U-S-GOVT-P-H-S.
AB We have previously demonstrated that cystic fibrosis (CF) cells show
   increased survival compared to normal cells when exposed to ouabain
   in medium lacking potassium.  In this report, we show that the CF
   cells bind significantly less ouabain than the normal cells in
   potassium-deficient medium.  Using age-matched normal and CF skin
   fibroblast strains, we show that (1) at ouabain concentrations <
   20x10-9 M binding for both normal and CF cells is linear with time
   for 1 h and reaches equilibrium after 4 h; (2) at ouabain
   concentrations between 2 and 20x10-9 M, the initial rate of binding
   for CF cells is approx. 70% of the normal cells; (3) under
   equilibrium-binding conditions, Scatchard analysis reveals that
   three different CF strains have 12, 16, and 44% fewer
   ouabain-binding sites than their matched normal controls.  In
   addition, studies in potassium-free medium of the inhibition of
   86Rb flux (a K-plus analogue) into the cell by ouabain show no
   differences between CF and normal cells.  We have also previously
   shown that in a low glucose, potassium-deficient medium the CF cells
   survived ouabain exposure no better than normal cells.  In this
   report, equilibrium-binding studies with [3H]ouabain clearly show
   that CF cells bind less ouabain under these conditions than normal
   cells.  These results indicate that ouabain resistance in CF cells
   is not solely a function of differences in ouabain binding.
   Furthermore, the differential ouabain killing may not be due to ion
   transport differences, but rather to as yet unknown mechanisms.  CF
   cells thus appear to be unlike previously characterized
   ouabain-resistant mutants.
RF 001   ANON                  J PEDIATR                       88   711 976
   002   EPSTEIN JL            PROC NAT ACAD SCI USA           74  1676 977
   003   BAKER RM              CELL                             1     9 974
   004   LEVER JE              J CELL PHYSIOL                  88   343 976
   005   ROSENBERG HM          J CELL PHYSIOL                  85   135 975
   006   BAKER RM              IN: COOK JS                           93 976
   007   MAYHEW E              J CELL PHYSIOL                  79   441 972
   008   MANKOVITZ R           CELL                             3   221 974
   009   CORSARO CM            EXP CELL RES                    95    47 975
   010   LOWRY OH              J BIOL CHEM                    193   265 951
   011   FREUND JE             MODERN ELEMENTARY STATISTICS             967
   012   SCATCHARD G           ANN NY ACAD SCI                 51   660 949
   013   QUISSELL DO           NATURE                         247   115 974
   014   AVERDUNK R            EXP CELL RES                    93   331 975
   015   VAUGHAN GL            PROC NAT ACAD SCI USA           69  2627 972
   016   BAKER PF              J PHYSIOL (LOND)               224   441 972
CT   1   EPSTEIN J             SOMATIC CELL GENET               4   451 978
     2   BRESLOW JL            CELL                            13   663 978
     3   BRESLOW JL            SCIENCE                        201   180 978
     4   REZNIK VM             PROC NAT ACAD SCI USA           78  7143 981
     5   BRESLOW JL            N ENGL J MED                   304     1 981
     6   LANGHOFF E            PEDIATR RES                     18   488 984

PN 77075
RN 00656 
AN 77185358
AU Lefebvre-D.  Ratelle-S.  Chartrand-L.  Roy-C-C.
TI Reduced microbial transformation of bile acids in cystic fibrosis.
SO Experientia. 1977 May 15. 33(5). P 616-8.
MJ BILE-ACIDS-AND-SALTS: me.  CYSTIC-FIBROSIS: mi.
MN ADOLESCENCE.  CHENODEOXYCHOLIC-ACID: me.  CHILD.  CHILD-PRESCHOOL.
   CHOLIC-ACIDS: me.  CYSTIC-FIBROSIS: me.  FECES: mi.  GLYCINE: me.
   GLYCOCHOLIC-ACID: me.  HUMAN.  TAURINE: me.  TAUROCHOLIC-ACID: me.
AB The microbial transformation of bile acids by incubates of stool
   homogenates from children with cystic fibrosis is decreased.
RF 002   GORBACH SL            GASTROENTEROLOGY                60  1110 971
   003   NEAL G                AM J CLIN NUTR                  25  1409 972
   004   DRASAR BS             GASTROENTEROLOGY                56    71 969
   005   GRIFFEN WO JR         SOUTH MED J                     64  1056 971
   006   DACK GM               J INFECT DIS                    54   204 934
   007   GOLDSWORTHY NE        BR J EXP PATHOL                 11   192 930
   008   BROWN WR              GASTROENTEROLOGY                62  1143 972
   009   BRYANT MR             AM J CLIN NUTR                  25  1485 972
   010   FLOCH MH              GASTROENTEROLOGY                61   228 971
   011   WILLIAMS RC           GASTROENTEROLOGY                69   483 975
   012   MALLORY A             GASTROENTEROLOGY                64    26 973
   013   WEBER AM              N ENGL J MED                   289  1001 973
   014   WEBER AM              GUT                             17   295 976
   015   SAMUEL P              CIRC RES                        33   393 973
   016   MIDTVEDT T            AM J CLIN NUTR                  27  1341 974
   017   SOONG CS              GASTROENTEROLOGY                63   748 972
   018   BINDER HJ             AM J CLIN NUTR                  28   119 975
   019   PERCY-ROBB IW         BR MED J                         3   813 972
   020   KRAG E                J CLIN INVEST                   53  1686 974
   021   HOFMANN AF            IN: NAIR PP                      2   144 973
CT   1   ROY  CC               AM J CLIN NUTR                  32  2404 979
     2   EKLUND A              SCAND J CLIN LAB INVEST         40   595 980
     3   PARK RW               GASTROENTEROLOGY                81  1143 981
     4   WEBER AM              ACTA PAEDIATR SCAND SUPPL 317 1985     9 985

PN 77076
RN 00657 
AN 77116784
AU Roller-R-J.  Kern-F.
TI Minimal bile acid malabsorption and normal bile acid breath tests in
   cystic fibrosis and acquired pancreatic insufficiency.
SO Gastroenterology. 1977 Apr. 72(4 Pt 1). P 661-5.
MJ BILE-ACIDS-AND-SALTS: me.  BREATH-TESTS.  CYSTIC-FIBROSIS: me.
   MALABSORPTION-SYNDROMES: me.  PANCREATIC-DISEASES: me.
MN ADULT.  AGED.  CARBON-DIOXIDE.  COMPARATIVE-STUDY.
   CYSTIC-FIBROSIS: dt.  DIARRHEA: me.  FECES: an.  FEMALE.
   GLYCOCHOLIC-ACID: me.  HUMAN.  ILEUM: su.  LIPASE: me.  LIPIDS: me.
   MALE.  MIDDLE-AGE.  PANCREATIC-DISEASES: co, dt.  PANCREATIN: me.
   CELIAC-DISEASE: et.  SUPPORT-U-S-GOVT-P-H-S.
AB This study was undertaken because of reports of a marked increase in
   fecal bile acid excretion by children with cystic fibrosis. We
   attempted to confirm this finding by performing [1-14C]cholylglycine
   breath tests and by measuring fecal bile acid and fat excretion in
   patients with cystic fibrosis and acquired pancreatic insufficiency.
   Studies were done when patients were taking pancreatic enzymes
   (Cotazym) and also without medication. 14CO2 excretion in breath was
   normal in patients with acquired pancreatic insufficiency and even
   lower in cystic fibrosis, both with and without Cotazym therapy.
   Fecal bile acid excretion was slightly elevated in both groups
   without Cotazym and became normal with Cotazym in patients with
   acquired pancreatic insufficiency. Steatorrhea was present in both
   patient groups and improved during Cotazym therapy. Bile acid
   malabsorption in cystic fibrosis and acquired pancreatic
   insufficiency is minimal and probably not clinically important.
RF 001   ROLLER RJ             GASTROENTEROLOGY                70   930 976
   002   SMALL DM              ARCH INTERN MED                130   552 972
   003   HOFMANN AF            GASTROENTEROLOGY                52   752 967
   004   KELLY TR              ARCH SURG                      105   352 972
   005   WEBER AM              N ENGL J MED                   289  1001 973
   006   WATKINS JB            GASTROENTEROLOGY                68  1087 975
   007   WOODBURY JF           J CLIN INVEST                   50  2531 971
   008   SHERR HP              N ENGL J MED                   285   656 971
   009   FROMM H               LANCET                           2   621 971
   010   FROMM H               GASTROENTEROLOGY                64  1077 973
   011   ABT AF                BULL JOHNS HOPKINS HOSP        119   316 966
   012   VAN DE KAMER JH       J BIOL CHEM                    177   347 949
   013   ANDERSON CM           LANCET                           1   836 952
   014   WEBER AM              CLIN CHIM ACTA                  39   524 972
   015   ALI SS                CAN J BIOCHEM                   44   957 966
   016   MCGREGOR M            J CLIN INVEST                   40   971 961
   017   LEWIS R               ARCH INTERN MED                130   545 972
   018   ROSS CAC              ARCH DIS CHILD                  30   316 955
   019   KALSER MH             N ENGL J MED                   279   570 968
   020   JORDAN PH             GASTROENTEROLOGY                36   447 959
   021   MIETTINEN TA          J LIPID RES                      6   411 965
   022   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            971
   023   GOODCHILD MC          ARCH DIS CHILD                  50   769 975
CT   1   KERN F                GASTROENTEROLOGY                73   631 977
     2   ROY CC                GASTROENTEROLOGY                73   631 977
     3   WATKINS JB            GASTROENTEROLOGY                73  1023 977
     4   SCHWARZ HP            HELV PAEDIATR ACTA              33   351 978
     5   SMALLEY CA            ARCH DIS CHILD                  53   477 978
     6   BARR RG               PEDIATRICS                      62   393 978
     7   GILAT T               GASTROENTEROLOGY                74   332 978
     8   STARKEY BJ            MONOGR PAEDIATR                 10    12 979
     9   PELED Y               DIGESTION                       19   267 979
    10   LOESCHKE K            INTERNIST                       20   369 979
    11   FARIVAR S             DIG DIS SCI                     24    33 979
    12   HARRIES JT            ARCH DIS CHILD                  54    19 979
    13   BARRY MM              J AM DIET ASSOC                 75   446 979
    14   REGAN PT              GASTROENTEROLOGY                77   285 979
    15   PASANEN AVO           SCAND J GASTROENTEROL           15   503 980
    16   EKLUND A              SCAND J CLIN LAB INVEST         40   595 980
    17   BOYLE BJ              GASTROENTEROLOGY                78   950 980
    18   ISENBERG JN           J PEDIATR GASTROENTEROL NUTR     2   447 983
    19   COLOMBO C             DIG DIS SCI                     28   306 983
    20   ZENTLERMUNRO PL       GUT                             25   500 984
    21   DUTTA SK              GASTROENTEROLOGY                91  1243 986

PN 77077
RN 00658 
AN 77247480
AU Roy-C-C.  Weber-A-M.
TI Minimal bile acid malabsorption [letter].
SO Gastroenterology. 1977 Sep. 73(3). P 631-2.
MJ BILE-ACIDS-AND-SALTS: me.  CYSTIC-FIBROSIS: me.
   MALABSORPTION-SYNDROMES: me.
MN CHILD.  CYSTIC-FIBROSIS: co.  HUMAN.  MALABSORPTION-SYNDROMES: et.
EX Roller and Kern report that bile acid malabsorption in patients with
   cystic fibrosis (CF) and acquired pancreatic insufficiency is
   minimal.  These findings are at variance with other studies and
   deserve comment.  In the absence of fecal bile acid values in
   controls, the authors cannot state that levels in CF are only twice
   normal values, especially since the papers cited on normal bile acid
   excretion refer to measurements obtained by a different technique.
   We also question the validity of the breath test as an index of bile
   acid malabsorption in CF.  Our recent report shows that in 8 older CF
   (mean age 12.1 years) the magnitude of bile acid loss in the stools
   was comparable to that of the younger age group (mean age 3.9 years)
   and that there was no correlation between the age and the degree of
   bile acid loss.  On the other hand, we must take issue with Roller
   and Kern when they suggest that bile acid malabsorption in CF is
   probably not clinically important.  Our findings not only bear
   relevance to the intestinal manifestations of CF and to the increased
   incidence of cholelithiasis but perhaps also to the early deposition
   within the intrahepatic ducts of eosinophilic mucus concretions
   proposed as the cause of biliary cirrhosis in this disease.
RF 001   ROLLER RJ             GASTROENTEROLOGY                72   661 977
   001   ROLLER RJ             GASTROENTEROLOGY                72   661 977
   002   WEBER AM              N ENGL J MED                   289  1001 973
   002   GOODCHILD MC          ARCH DIS CHILD                  50   769 975
   003   WEBER AM              N ENGL J MED                   289  1001 973
   003   WATKINS JB            GASTROENTEROLOGY                67   835 974
   004   GOODCHILD MC          ARCH DIS CHILD                  50   769 975
   004   WEBER AM              GUT                             17   295 976
   005   WOODBURY JF           J CLIN INVEST                   50  2531 971
   005   WEBER AM              GUT                             17   295 976
   006   FROMM H               GASTROENTEROLOGY                64   268 973
   009   ROY CC                GASTROENTEROLOGY                72  1123 977

PN 77078
RN 00659 
AN 77116798
AU Matsehe-J-W.  Go-V-L.  DiMagno-E-P.
TI Meconium ileus equivalent complicating cystic fibrosis in
   postneonatal children and young adults.  Report of 12 cases.
SO Gastroenterology. 1977 Apr. 72(4 Pt 1). P 732-6.
MJ CYSTIC-FIBROSIS: co.  INTESTINAL-OBSTRUCTION: et.  MECONIUM.
MN ADOLESCENCE.  ADULT.  BARIUM-SULFATE: du.  CHILD.  CHILD-PRESCHOOL.
   ENEMA.  FEMALE.  HUMAN.  INFANT.  INTESTINAL-OBSTRUCTION: oc, th.
   MALE.  DIATRIZOATE-MEGLUMINE: du, tu.  MINNESOTA.  PAIN: et.
AB Twelve patients with meconium ileus equivalent complicating cystic
   fibrosis in the postneonatal period were seen at the Mayo Clinic in
   the years 1950 through 1975. In a child or young adult with known or
   suspected cystic fibrosis, the triad of recurrent colicky abdominal
   pain, a mass in the right lower quadrant, and mechanical intestinal
   obstruction provides a clue to diagnosis of meconium ileus
   equivalent. The clinical suspicion of meconium ileus equivalent may
   be confirmed by meglumine diatrizoate (Gastrografin) enema, which in
   most uncomplicated cases also serves as treatment.
RF 001   MULLINS F             JAMA                           192   741 965
   002   RASOR R               ROCKY MT MED J                  38   218 941
   003   JENSEN KG             ACTA PAEDIATR SCAND             51   344 962
   004   FISHER OD             ARCH DIS CHILD                  29   262 954
   005   NIXON HH              GR ORMOND STR J                       43 955
   006   BIRSE EL              BR MED J                         2   286 956
   007   PORCARO F             AM J SURG                      100   113 960
   008   FANCONI A             HELV PAEDIATR ACTA              15   566 960
   009   CORDONNIER JK         SURGERY                         54   667 963
   010   SNYDER WH JR          PEDIATRICS                      34    72 964
   011   SIGLER RM             MAYO CLIN PROC                  40   477 965
   012   GARNHAM JR            GUT                              5   256 964
   013   HUNTON DB             GASTROENTEROLOGY                50    99 966
   014   IBACH EG              MED J AUST                       1   268 968
   015   LYNCH G               J IR MED ASSOC                  61   209 968
   016   SELIGER G             AM J DIG DIS                    17   934 972
   017   BROWN PM              N ENGL J MED                   263   544 960
   018   JAFFE BF              ARCH SURG                       92   337 966
   019   HOLSCLAW DS           AM J DIS CHILD                 109   101 965
   020   SHWACHMAN H           PEDIATRICS                      46   335 970
   021   HOLSCLAW DS           PEDIATRICS                      48    51 971
   022   SHWACHMAN H           N ENGL J MED                   286  1300 972
   023   QUINLAN MF            AUSTRALAS ANN MED               16    84 967
   024   DONNISON AB           PEDIATRICS                      37   833 966
   025   THOMAIDIS TS          J PEDIATR                       63   444 963
   026   COHEN D               AUST NZ J SURG                  34    47 964
   027   BROWN PM              N ENGL J MED                   263   544 960
   028   NEUHAUSER EBD         RADIOLOGY                       46   319 946
   029   HARRIS GBC            POSTGRAD MED                    34   251 963
   030   WEINSTEIN LD          GASTROENTEROLOGY                54  1282 968
   031   BARTRAM CI            BR J RADIOL                     44   195 971
   032   BOWRING AC            J PEDIATR SURG                   5   338 970
   033   LILLIBRIDGE CB        J PEDIATR                       71   887 967
   034   SHWACHMAN H           JAMA                           149  1101 952
   035   LLOYD AVC             JAMA                           184  1001 963

PN 77079
RN 00660 
AN 78004283
AU Watkins-J-B.  Tercyak-A-M.  Szczepanik-P.  Klein-P-D.
TI Bile salt kinetics in cystic fibrosis: influence of pancreatic
   enzyme replacement.
SO Gastroenterology. 1977 Nov. 73(5). P 1023-8.
MJ BILE-ACIDS-AND-SALTS: me.  CYSTIC-FIBROSIS: dt.  PANCREATIN: tu.
MN BILE-ACIDS-AND-SALTS: bi.  CHENODEOXYCHOLIC-ACID: me.
   CHILD-PRESCHOOL.  CHOLIC-ACIDS: me.  CLINICAL-TRIALS.
   CYSTIC-FIBROSIS: me.  DIETARY-FATS: me.  HUMAN.  INFANT.  KINETICS.
   SUPPORT-U-S-GOVT-P-H-S.
AB Bile acid kinetics was investigated by stable isotope dilution
   technique in 6 children (ages 3 1/2 months to 4 1/2 years) with
   previously untreated cystic fibrosis.  All of the patients had
   clinical and laboratory evidence of malabsorption, normal
   intestinal mucosal function, as judged by glucose absorption,
   intestinal histology, disaccharidase levels, and normally
   functioning gallbladders.  The children were maintained on a
   constant diet throughout the study period; fat intake averaged 4.2 g
   per kg per day.  Before administration of pancreatic enzyme
   replacement, fat excretion equalled 50 plus or minus 4% (mean plus
   or minus SE) of intake and was reduced to 20 plus or minus 1.0% of
   intake after therapy.  Total bile acid pool size nearly doubled
   during enzyme replacement from 379 plus or minus 32 micromoles per
   kg to 620 plus or minus 36 micromoles per kg with secondary bile
   acids comprising 57% of the total pool before therapy and 40% after
   therapy.  Total bile acid synthesis changed little with therapy,
   equalling 139 plus or minus 17 micromoles per kg per day (total 602
   plus or minus 109 mg per day) without enzyme replacement and 125
   plus or minus 19 micromoles per kg per day (total 470 plus or minus
   86 milligrams per day) with enzyme replacement.  This was confirmed
   by the fecal excretion of bile acids: 545 plus or minus 166
   milligrams of bile acid per day were excreted without enzymes as
   compared to 513 plus or minus 146 milligrams per day with enzymes.
   After therapy, the fractional turnover rate of the bile acid pool
   was reduced from 0.602 plus or minus 0.05 per day to 0.233 plus or
   minus .03 per day for cholic acidand from 0.696 plus or minus 0.09
   per day to 0.39 plus or minus 0.04 per day for chenodeoxycholic
   acid.  These data indicate that both primary and secondary bile
   acids are conserved within the enterohepatic circulation during
   enzyme therapy, and that the mechanism for the regulation of hepatic
   bile acid synthesis is intact in cystic fibrosis.  However, the
   demonstration that large amounts of bile acid continue to be
   excreted during therapy suggests that interruption of the
   enterohepatic circulation continues and that deficiencies of the
   intraluminal phase may persist during enzyme therapy in this
   disease.
RF 001   WATKINS JB            GASTROENTEROLOGY                67   835 974
   002   LAPEY A               J PEDIATR                       84   328 974
   003   DIMAGNO EP            GASTROENTEROLOGY                70   878 976
   004   WEBER AM              GUT                             17   295 976
   005   WEBER AM              N ENGL J MED                   289  1001 973
   006   GOODCHILD MC          ARCH DIS CHILD                  50   769 975
   007   ROLLER RJ             GASTROENTEROLOGY                72   661 977
   008   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   009   FEIGELSON J           ACTA PAEDIATR SCAND             59   539 970
   010   VAN DE KAMER JH       J BIOL CHEM                    177   347 949
   011   WATKINS JB            N ENGL J MED                   288   431 973
   012   HOFMANN AF            J LIPID RES                      9   707 968
   013   KLEIN PD              CLIN CHEM                       17   735 971
   014   FOLCH J               J BIOL CHEM                    226   497 957
   015   ROOVERS J             CLIN CHIM ACTA                  19   449 968
   016   KLEIN PD              ANAL CHEM                       44   490 972
   017   ADMIRAND WH           J CLIN INVEST                   47  1043 968
   018   LINDSTEDT S           ACTA PHYSIOL SCAND              40     1 957
   019   POMARE EW             CLIN CHIM ACTA                  57   239 974
   020   DOWLING RH            J CLIN INVEST                   50  1917 971
   021   SMALL DM              ARCH INTERN MED                130   552 972
   022   POLEY JR              GASTROENTEROLOGY                71    38 976
   023   MOTSON RW             GASTROENTEROLOGY                71   922 976
   024   GRUNDY SM             GASTROENTEROLOGY                62  1200 972
   025   GO VLW                GASTROENTEROLOGY                58   321 970
   026   MALAGELADA JR         J CLIN INVEST                   58   493 976
   027   LARUSSO NF            GASTROENTEROLOGY                69  1301 975
   028   BRUNNER H             MAYO CLIN PROC                  49   851 974
   029   GO VLW                J CLIN INVEST                   49  1558 970
   030   ROY CC                PEDIATR RES                     11   449 977
   031?  RICOUR C              REV EUR ETUD CLIN BIOL          17   172 972
   032   CAREY MC              AM J MED                        49   590 970
   033   BENDER S              GUT                             16   927 975
   034   HOFFMAN NE            AM J PHYSIOL                   279   298 975
   035   LOW-BEER TS           GASTROENTEROLOGY                64   764 973
   036   MEKHJIAN HS           J CLIN INVEST                   50  1569 971
CT   1   SCHWARZ HP            HELV PAEDIATR ACTA              33   351 978
     2   STARKEY BJ            MONOGR PAEDIATR                 10    12 979
     3   LOESCHKE K            INTERNIST                       20   369 979
     4   HARRIES JT            ARCH DIS CHILD                  54    19 979
     5   REGAN PT              GASTROENTEROLOGY                77   285 979
     6   COX KL                J PEDIATR                       94   488 979
     7   ROY CC                PROC SOC EXP BIOL MED          161   105 979
     8   HEUBI JE              PEDIATR RES                     14   943 980
     9   ELLIOTT WH            LIPIDS                          15   764 980
    10   HUBBARD VS            AM J CLIN NUTR                  33  2281 980
    11   GORIUP U              HELV PAEDIATR ACTA              35   177 980
    12   EKLUND A              SCAND J CLIN LAB INVEST         40   595 980
    13   BOYLE BJ              GASTROENTEROLOGY                78   950 980
    14   BALISTRERI WF         J PEDIATR                       96   582 980
    15   ELIAS E               LANCET                           2  1319 981
    16   WORMSLEY KG           ITAL J GASTROENTEROL            13   144 981
    17   MITCHELL EA           AUST PAEDIATR J                 17   207 981
    18   MITCHELL EA           AUST PAEDIATR J                 17    89 981
    19   PARK RW               GASTROENTEROLOGY                81  1143 981
    20   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
    21   MULLER DPR            CLIN GASTROENTEROL              11   119 982
    22   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
    23   FONDACARO JD          PEDIATR RES                     16   494 982
    24   ROY CC                GASTROENTEROLOGY                83  1156 982
    25   BALISTRERI WF         J PEDIATR GASTROENTEROL NUTR     2   105 983
    26   ISENBERG JN           J PEDIATR GASTROENTEROL NUTR     2   447 983
    27   ROY CC                J PEDIATR GASTROENTEROL NUTR     2   152 983
    28   BASS S                GASTROENTEROLOGY                84  1592 983
    29   COLOMBO C             J PEDIATR GASTROENTEROL NUTR     3   556 984
    30   NORMAN EJ             BIOMED MASS SPECTROMET          11   269 984
    31   ZENTLERMUNRO PL       GUT                             25   500 984
    32   ABRAMS CK             J CLIN INVEST                   73   374 984
    33   KLEIN PD              J PEDIATR GASTROENTEROL NUTR     4     9 985
    34   DARLING PB            PEDIATR RES                     19   578 985
    35   ROBB TA               GUT                             26  1246 985
    36   ZENTLERMUNRO PL       GUT                             26   892 985
    37   SETCHELL KDR          CLIN CHIM ACTA                 151   101 985
    38   KNOPFLE G             KLIN PAEDIATR                  197   481 985
    39   DEROOIJ FWM           ACTA PAEDIATR SCAND SUPPL 317 1985    28 985
    40   WEBER AM              ACTA PAEDIATR SCAND SUPPL 317 1985     9 985
    41   JONAS A               J PEDIATR GASTROENTEROL NUTR     5   143 986
    42   STERN RC              J PEDIATR GASTROENTEROL NUTR     5    35 986
    43   KOHLER JA             J CLIN HOSP PHARM               11    21 986
    44   STEAD RJ              GUT                             27   714 986
    45   WEIZMAN Z             GUT                             27  1043 986
    46   LEROY C               DIG DIS SCI                     31   911 986
    47   DUTTA SK              GASTROENTEROLOGY                91  1243 986

PN 77080
RN 00661 
AN 79129993
AU Kraemer-R.  Hadorn-B.  Rossi-E.
TI Classification at time of diagnosis and subsequent survival in
   children with cystic fibrosis.
SO Helv-Paediatr-Acta. 1977 Jul. 32(2). P 107-14.
MJ CYSTIC-FIBROSIS: mo.
MN CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: di, fg.
   GASTROINTESTINAL-DISEASES: mo.  HUMAN.  INFANT.  INFANT-NEWBORN.
   INTESTINAL-OBSTRUCTION: mo.  LUNG-DISEASES: mo.  MECONIUM.
   SWITZERLAND.
AB The survival rates in 204 patients suffering from cystic fibrosis
   observed between January 1956 and June 1976 were recorded. The
   patients were divided into five groups according to the symptoms
   present at the time of diagnosis and survival rates were recorded
   separately for each group. Survival was less good in the group of
   patients presenting initially with pulmonary symptoms compared to the
   group presenting with gastrointestinal symptoms. In the group
   presenting with meconium ileus survival was poor initially, but later
   in the course of the disease it became similar to that observed in
   the other groups. The differences in survival between the different
   categories occurred during the first two years after diagnosis. The
   study shows that, on clinical grounds, a severe form of the disease
   which is characterized by early manifestation of pulmonary symptoms
   and poor survival can be distinguished from a more protracted form
   with a better survival. Because of the great inter-individual
   variability large numbers of patients will have to be evaluated in
   order to achieve statistically significant results in studies which
   attempt to compare different therapeutic approaches. If such numbers
   cannot be reached, it may be necessary to compare only patients who
   belong to the same symptomatic category.
RF 001   CUTLER SJ             J CHRON DIS                      8   699 958
   002   DOERSHUK CF           J PEDIATR                       65   677 964
   003   GEORGE L              ARCH DIS CHILD                  46   139 971
   004   HADORN B              HANDBUCH DER INNEREN MEDIZIN         889 976
   005   HOGGER GP             HELV PAEDIATR ACTA              30   151 975
   006   HUANG NN              AM J DIS CHILD                 120   289 970
   007   KERREBIJN KF          PROC INT CF CONG 7TH                     976
   008   KRAEMER R             SCHWEIZ MED WOCHENSCHR         107   271 977
   009   LAPEY A               J PEDIATR                       84   328 974
   010   ROBINSON MJ           ARCH DIS CHILD                  50   962 975
   011   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   012   SHWACHMAN H           PEDIATRICS                      46   335 970
   013   WARWICK WJ            J CHRON DIS                     28   609 975
CT   1   SCHWARZ HP            HELV PAEDIATR ACTA              33   351 978
     2   KRAEMER R             ACTA PAEDIATR SCAND             67    33 978
     3   KRAEMER R             MONOGR PAEDIATR                 10    61 979
     4   KRAEMER R             SCHWEIZ MED WOCHENSCHR         109    39 979
     5   CROSSLEY JR           CLIN CHIM ACTA                 113   111 981
     6   TUMMLER B             MONATSSCHR KINDERHEILKD        130   157 982
     7   CHOW CW               EUR J PEDIATR                  139   240 982
     8   ANON                  PEDIATRICS                      72   741 983
     9   WILCKEN B             J PEDIATR                      102   383 983
    10   GROBE H               MONATSSCHR KINDERHEILKD        131   806 983
    11   CASSIO A              ACTA PAEDIATR SCAND             73   554 984
    12   GRUTTNER R            MONATSSCHR KINDERHEILKD        133    54 985
    13   KATZ JN               J PEDIATR                      108   352 986
    14   DANKERTROELSE JE      ACTA PAEDIATR SCAND             76   209 987

PN 77081
RN 00662 
AN 79129994
AU Malmendier-C-L.  Van-Den-Bergen-C-J.  Baran-D.
TI Influence of lyophilized total pancreas on plasma lipids and on fat
   absorption in cystic fibrosis.
SO Helv-Paediatr-Acta. 1977 Jul. 32(2). P 115-28.
MJ CYSTIC-FIBROSIS: th.  LIPIDS: me.  PANCREATIC-EXTRACTS: tu.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  CHOLESTEROL-ESTERS: bl.
   CYSTIC-FIBROSIS: bl, me.  FATTY-ACIDS-NONESTERIFIED: bl.  HUMAN.
   INFANT.  INTESTINAL-ABSORPTION.  LIPIDS: bl.  PHOSPHOLIPIDS: bl.
   TRIGLYCERIDES: bl.
AB 31 children with cystic fibrosis (CF) subdivided into three groups of
   age were studied before and after treatment with lyophilized pancreas
   and compared to 27 controls. CF was characterized by lower
   phospholipid, cholesterol and polyunsaturated fatty acid plasma
   concentrations and reduced coefficient of fat absorption. Treatment
   tended towards normalization of these values. With age
   polyunsaturated fatty acids increased in normals but not in CF. The
   significant correlations existing between fat absorption coefficient
   and polyunsaturated fatty acid percentage in neutral lipids of CF
   children suggests the use of the latter percentage as index of the
   stage of malabsorption.
RF 001   BARAN D               ACTA PAEDIATR BELG              29   117 976
   002   BLOMSTRAND R          ACTA CHEM SCAND                 10  1019 964
   003   BORGSTROM B           ACTA PHYSIOL SCAND              25   101 952
   004   BOY J                 ANN BIOL CLIN                   18   669 960
   005   BRAGDON JH            J BIOL CHEM                    190   513 951
   006   CAREN R               J ATHEROSCLER RES                4   444 964
   007   CAREN R               J CLIN ENDOCRINOL METAB         26   470 966
   008   CARLSON LA            CLIN CHIM ACTA                   4   197 959
   009   CASH R                J PEDIATR                       74   717 969
   010   CHIN HP               CLIN CHIM ACTA                  20   305 968
   011   DEMETRIOU JA          IN: HENRY RJ                         914 974
   012   FOLCH J               J BIOL CHEM                    226   497 957
   013   KATES M               IN: WORK TS                          393 972
   014   KUO PT                J CLIN INVEST                   44  1924 965
   015   LUBIN AH              CF CLUB ABST                    14     4 973
   016   MALMENDIER CL         BIOMEDICINE                     20   398 974
   017   MCCOMBS ML            TEX REP BIOL MED                31   615 973
   018   NIESSEN KH            KLIN PAEDIATR                  185   271 973
   019   NORMAN AP             BR MED J                         2   621 968
   020   NORUM KR              SCAND J CLIN LAB INVEST         20   231 967
   021   REEMTSMA K            PEDIATRICS                      22   525 958
   022   ROSENBERG A           J BIOL CHEM                    232  1031 958
   023   ROSENLUND ML          NATURE                         251   719 974
   024   SHIMOYAMA T           GUT                             14   716 973
   025   SNEDECOR GW           STATISTICAL METHODS APPLIED T            966
   026   STEWART CP            BIOCHEM J                       29  1683 935
   027   WEIJERS HA            ACTA PAEDIATR SCAND             42    24 953
CT   1   ROGIERS V             PEDIATR RES                     14  1088 980
     2   HAMILTON RM           LIPIDS                          16   374 981
     3   ROGIERS V             EUR J PEDIATR                  141    39 983

PN 77082
RN 00663 
AN 77186767
AU Kendig-E-L-Jr.
TI Chronic lung disease in children.
SO Hosp-Pract. 1977 May. 12(5). P 87-93, 95-8.
MJ LUNG-DISEASES.
MN BRONCHIAL-DISEASES: di.  CHILD.  CYSTIC-FIBROSIS: di, th.
   DIAGNOSIS-DIFFERENTIAL.  HISTOPLASMOSIS: di, dt.  HUMAN.
   LUNG-DISEASES-FUNGAL: di, dt.
   MYCOBACTERIUM-INFECTIONS-ATYPICAL: di, dt.  PULMONARY-FIBROSIS: di, dt.
   SARCOIDOSIS: di, dt.  TUBERCULIN-TEST.  TUBERCULOSIS-IN-CHILDHOOD.
   TUBERCULOSIS-PULMONARY: di, dt.
AB Since tuberculosis is still a significant threat, the family
   physician needs to be familiar with methods of its diagnosis and
   treatment. Among other entities discussed are atypical
   mycobacteriosis sarcoidosis, and cystic fibrosis.
RF 001   STEIGMAN AJ           PEDIATRICS                      56   160 975
   002   KENDIG EL JR          N ENGL J MED                   281   250 969
   003   LINCOLN EM            AM REV RESPIR DIS              105   683 972
   004   KENDIG EL JR          N ENGL J MED                   268  1001 963
   005   JAMES DG              ANN NY ACAD SCI                278   321 976
   006   NIITU Y               ANN NY ACAD SCI                278   532 976
   007   KENDIG EL JR          PEDIATRICS                      54   289 974
   008   CHRISTIE A            IN: KENDIG EL JR                 1   608 972
   009   SHWACHMAN H           PEDIATRICS                      46   335 970
   010   DOERSHUK CF           PEDIATRICS                      36   675 965
   011   LIEBOW AA             IN: SIMON M                              968
   012   STOCKS J              PEDIATRICS                      57   352 976
   013   NORTHWAY WH JR        N ENGL J MED                   276   357 967

PN 77083
RN 00664 
AN 78004768
AU Tchen-P.  Bois-E.  Feingold-J.  Feingold-N.  Kaplan-J.
TI Inbreeding in recessive diseases.
SO Hum-Genet. 1977 Sep 22. 38(2). P 163-7.
MJ CONSANGUINITY.  GENES-RECESSIVE.
MN ALBINISM: fg.  COLOR-BLINDNESS: fg.  CYSTIC-FIBROSIS: fg.
   CYSTINOSIS: fg.  FRANCE.  HUMAN.  KIDNEY-DISEASES: fg.
   MUSCULAR-ATROPHY: fg.
AB The consanguinity of parents (born in France) of individuals who have
   a recessive disease has been studied. The frequency of first cousin
   marriages is less than 0.2% in the general French population. Among
   the parents of affected individuals the following frequencies of
   first cousin matings were observed: cystic fibrosis: 1.4% cystinosis:
   7.1% nephronophtisis: 5.6% spinal muscular atrophy: 4.5% albinism:
   5.0% achromatopsia: 12.5% (Albinism and spinal muscular atrophy are
   heterogeneous conditions). The increase in the frequency of first
   cousin marriage relative to that of the general population is much
   greater, as expected, in cystinosis, which is a rare disease, than in
   cystic fibrosis, which is the most frequent recessive disorder in
   France. Inbreeding in cystinosis and cystic fibrosis was also studied
   by computing the distance between parental birth places. This
   distance is smaller in cystinosis than in cystic fibrosis.
RF 001   DE ARAUJO AM          SOCIAL BIOLOGY                  21   249 974
   002   AZEVEDO E             AM J HUM GENET                  21     1 969
   003   BARRAI I              ANN HUM GENET                   25   347 962
   004   BICKEL H              ACTA PAEDIATR SCAND SUPPL       90    22 952
   005   BOIS E                J MED GENET                     13   434 976
   006   BROBERGER O           ACTA PAEDIATR SCAND             49   470 960
   007   CAVALLI-SFORZA LL     GENETICS                        54    37 966
   008   DANKS DM              ANN HUM GENET                   28   323 965
   009   EMERY AEH             PROC INT CONG MUSCLE D 3RD           557 975
   010   FEINGOLD J            ANN GENET (PARIS)               17   257 974
   011   GIRARD A              CHOIX DU CONJOINT                        974
   012   GORDILLO G            BOL MED HOSP INFANTIL MEX       24   533 967
   013   LIRENMAN DS           BIRTH DEF ORIG ART SER          10    32 974
   014   MANGOS JA             PEDIATRICS                      34   337 964
   015   MORTON NE             AM J HUM GENET                  25   347 973
   016   NEEL JV               AM J HUM GENET                   1   156 949
   017   PEARN JH              BRAIN                           96   463 973
   018   SUTTER J              POPULATION                      13   683 958
   019   SUTTER J              POPULATION                      17   683 962
   020   VON SYDOW G           ACTA PAEDIATR SCAND             51   561 962
   021   WITKOP CJ JR          ADV HUM GENET                    2       971
CT   1   BITTLES AH            J SCI INDUSTR RES               39   768 980
     2   ROMEO G               RIV ITAL PEDIATR                 7   201 981
     3   BOIS E                ARCH FR PEDIATR                 42   175 985

PN 77084
RN 00665 
AN 78004791
AU Burdick-A-B.
TI Frequency of the gene for cystic fibrosis with a view of replacement
   and recognition effects and reproduction by homozygotes.
SO Hum-Hered. 1977. 27(5). P 366-71.
MJ CYSTIC-FIBROSIS: fg.  GENE-FREQUENCY.
MN FEMALE.  HOMOZYGOTE.  HUMAN.  MALE.  MUTATION.  REPRODUCTION.
AB The apparent frequency of the recessive autosomal allele for cystic
   fibrosis (cf) is too high to be satisfactorily explained by mutation
   equilibrium. However, higher reproductive fitness by heterozygotes
   (expressed by t greater than 0) or higher gametic viability of the cf
   allele (expressed by a greater than 0.5) can provide reasonable
   explanations of the present frequency. Furthermore, birth replacement
   in families with CF children (RPE) can account for the estimated
   historical values of t. Today, however, t is probably at or
   approaching zero as a result of discontinuation of RPE. In the future
   we can look for an imperceptibly slow decrease in the incidence of
   CF. Reproduction by CF females will not cause an increase in
   incidence; it will only slightly slow the rate of decrease.
RF 001   HALDANE JBS           PROC CAMB PHIL SOC              23   838 927
   002   WARWICK WJ            J CHRON DIS                     28   609 975
   003   GRAND RJ              JAMA                           195   993 966
   004   LI CC                 FIRST COURSE IN POPULATION GE            976
   005   KNUDSON AG JR         AM J HUM GENET                  19   388 967
   006   WRIGHT SW             AM J HUM GENET                  20   157 968
   007   CONNEALLY PM          TEX REP BIOL MED                31   639 973
   008   GLASS B               AM J HUM GENET                   2   269 950
   009   RECORD RG             BR J PREV SOC MED               29   267 975
   010   LARSEN JW             OBSTET GYNECOL                  39   880 972
   011   LUNDGREN DW           CLIN CHIM ACTA                  62   357 975
   012   SAMUELS CE            LANCET                           2   607 975
   013   SHWACHMAN H           LANCET                           2   372 975
   014   WILSON GB             PEDIATR RES                      9   635 975
CT   1   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     2   AFZELIUS BA           AM J HUM GENET                  33   852 981

PN 77085
RN 00666 
AN 77139738
AU Wyatt-P-R.  Cox-D-M.
TI Utilization of electron microscopy in the prenatal diagnosis of
   genetic disease.
SO Hum-Hered. 1977. 27(1). P 22-37.
MJ HEREDITARY-DISEASES: di.  PRENATAL-DIAGNOSIS: mt.
MN LIPOIDOSIS: di.  AMNIOTIC-FLUID: cy.
   ANGIOKERATOMA-CORPORIS-DIFFUSUM: di.  CELL-LINE.
   CYSTIC-FIBROSIS: di.  CYSTINOSIS: di.  EVALUATION-STUDIES.  FEMALE.
   FIBROBLASTS: ul.  GLYCOGENOSIS-2: di.  HUMAN.  INFANT-NEWBORN.
   LESCH-NYHAN-SYNDROME: di.  LEUKODYSTROPHY-METACHROMATIC: di.
   MAPLE-SYRUP-URINE-DISEASE: di.  MICROSCOPY-ELECTRON.
   MUCOLIPIDOSIS: di.  MUSCULAR-DYSTROPHY: di.  PREGNANCY.  SKIN: ul.
AB The use of electron microscopy as a further method of diagnosis of
   disease in cultured skin fibroblasts and cultured amniotic fluid
   fibroblasts is presented. It was demonstrated that Tay-Sachs disease,
   Fabry's disease, and metachromatic leukodystrophy had distinctive
   abnormalities in both cultured skin fibroblasts and cultured amniotic
   fluid fibroblasts. It was shown that control of culturing conditions
   made it possible to distinguish normal cell lines from certain cell
   lines carrying known genetic diseases.
RF 001   AULA P                J PEDIATR                       87   221 975
   002   BARTMAN J             J PEDIATR                       76   430 970
   003   BARTMAN J             OBSTET GYNECOL                  38   838 971
   004   BUTTERWORTH J         AM J OBSTET GYNECOL            119   821 974
   005   COMINGS DE            EXP CELL RES                    61   295 970
   006   CONRAD GW             PEDIATR RES                      6   563 972
   007   EPSTEIN CJ            ADV INTERN MED                  20   325 975
   008   FELIX JS              PEDIATR RES                      8   870 974
   009   FUCHS F               IN: FAIRWEATHER DVI                  262 973
   010   GERBIE AB             AM J OBSTET GYNECOL            114   314 972
   011   GORDON GB             J CELL BIOL SUPPL               25    41 965
   012   HANAI J               AM J DIS CHILD                 122    34 971
   013   HOEHN H               PEDIATR RES                      8   746 974
   014   HOYES AD              J OBSTET GYNAECOL BR COMMONW    75   164 968
   015   HSU LYF               LIFE SCI                        14  2311 974
   016   HUG G                 BIRTH DEF ORIG ART SER           9   160 973
   017   HUISJES HJ            IN: FAIRWEATHER DVI                   95 973
   018   KABACK MM             PEDIATR RES                      5   366 971
   019   KAMENSKY E            AM J PATHOL                     73    59 973
   020   KOHN G                PEDIATR RES                      9   314 975
   021   LIE SO                PEDIATR RES                      7    13 973
   022   LIPETZ J              J ULTRASTRUCT RES               39    43 972
   023   LUCKY AW              EXP CELL RES                    92   383 975
   024   LYON G                J NEUROL SCI                    19   235 973
   025   MACIEIRA-COELHO A     PROC SOC EXP BIOL MED          138   712 971
   026   MCLEAN J              J MED GENET                     11   133 974
   027   MCLEAN J              J MED GENET                     11   257 974
   028   MELLMAN WJ            ADV HUM GENET                    2   259 971
   029   MELLMAN WJ            IN: ROTHBLAT GH                  1   327 972
   030   NADLER HL             N ENGL J MED                   282   596 970
   031   NADLER HL             IN: FAIRWEATHER DVI                  223 973
   032   NIELAND ML            AM J OBSTET GYNECOL            108  1030 970
   033   PRIEST JH             HUMAN CELL CULTURE IN DIAGNOS            972
   034   ROBBINS E             J EXP MED                      131  1211 970
   035   ROOK A                NATURE                         230    53 971
   036   RYAN CA               EXP CELL RES                    71   388 972
   037   RUTSAERT J            LAB INVEST                      29   527 973
   038   STEIN H               ISR J MED SCI                   10   463 974
   039   TENCONI R             AM J DIS CHILD                 124   296 972
   040   TONDEUR M             ACTA PAEDIATR BELG              24   355 970
   041   UHLENDORF BW          IN: HARRIS M                         149 970
   042   WHALSTROM J           HUMANGENETIK                    22   335 974
   043   WOOD S                EXP CELL RES                    96   317 975
CT   1   WYATT PR              PEDIATR RES                     12   310 978
     2   MARTIN JJ             J NEUROL NEUROSURG PSYCHIAT     41   232 978
     3   BURTON BK             SEM PERINATOL                    4   179 980
     4   BURTON BK             CLIN OBSTET GYNAECOL             7    27 980
     5   STEPHENSON SR         AM J OBSTET GYNECOL            141   319 981
     6   WANDALL A             ULTRASTRUCTURAL PATHOL           3    51 982
     7   PATRICK AD            BR MED BULL                     39   378 983
     8   ARNON J               PRENAT DIAGN                     6   351 986
     9   JAFFRAY JY            PATHOL BIOL (PARIS)             34    91 986
    10   HASHOLT L             HUM GENET                       72    72 986

PN 77086
RN 00667 
AN 77139699
AU Lack-E-E.
TI Carotid body hypertrophy in patients with cystic fibrosis and
   cyanotic congenital heart disease.
SO Hum-Pathol. 1977 Jan. 8(1). P 39-51.
MJ CAROTID-BODY: pa.  CYSTIC-FIBROSIS: pa.
   HEART-DEFECTS-CONGENITAL: pa.
MN ADOLESCENCE.  ADULT.  ANOXEMIA: co.  AUTOPSY.  CAROTID-BODY: ah.
   CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: co.  FEMALE.
   HEART-DEFECTS-CONGENITAL: co.  HUMAN.  HYPERTROPHY.  INFANT.
   INFANT-NEWBORN.  MALE.  ORGAN-WEIGHT.
AB The carotid bodies from 71 patients ranging in age from 28 weeks'
   gestation to 30 years were obtained at autopsy. Patients were divided
   into two groups based on the presence or absence of chronic
   hypoxemia. There was a high correlation between the weight of
   individual carotid bodies in each case. Among the 12 patients with
   chronic hypoxemia, eight patients had carotid bodies heavier than
   predicted by statistical analysis. Of these eight patients, six had
   cystic fibrosis and two had cyanotic heart disease. Morphometric and
   cell population analyses of the carotid bodies from these eight
   patients and from those of the control population indicated that
   enlargement of the carotid bodies during normal or abnormal growth
   results from proportionate increases in lobule parenchyma and stroma.
   There was also an increase in the width and length of the lobules
   without an increase in the diameter of the cell cords or a change in
   the size or proportion of the chief cells. Growth and development of
   the carotid bodies were studied in a control group of 59 patients
   without chronic hypoxemia. There were no sex related differences in
   carotid body weights. The combined weight of the carotid bodies
   correlated most strongly with body weight, although there was some
   correlation with age and body length. A regression equation
   reflecting the data relating to body weight (BW) is: Combined weight
   of carotid bodies (in mg.) = 0.29 BW (in kg.) +3.0. Leukemic
   infiltrates were present in two patients with acute lymphocytic
   leukemia, and diffuse lymphocytic infiltration with nodule formation
   was present in one patient with mental retardation. Metaplastic
   cartilage was present in a carotid body of one patient.
RF 001   HEATH D               THORAX                          25   129 970
   002   EDWARDS C             J PATHOL                       104     1 971
   003   ARIAS-STELLA J        AM J PATHOL                     55  150A 969
   004   SALDANA MJ            HUM PATHOL                       4   251 973
   005   HEYMANS C             PHARMACOL REV                    7   119 955
   006   JOELS N               BR MED BULL                     19    21 963
   007   SOLCIA E              HISTOCHEMIE                     20   116 969
   008   GRIMLEY PM            CANCER                          20  1473 967
   009   PRYSE-DAVIES J        CANCER                          17   185 964
   010   WINSON M              ARCH PATHOL                     96    58 973
   011   LUGLIANI R            N ENGL J MED                   285  1105 971
   012   DAVIDSON JT           N ENGL J MED                   290   819 974
   013   COOK CD               J PEDIATR                       59   710 961
   014   LATTES R              CANCER                           3   667 950
   015   OBERMAN HA            CANCER                          21   838 968
   016   LACK EE               ARCH PATHOL                     99   215 975
   017   VALDES-DAPENA MA      N ENGL J MED                   289  1195 973
   018   SALK L                N ENGL J MED                   291   219 974
   019   ARIAS-STELLA J        HUM PATHOL                       7   361 976
   020   NAEYE RL              SCIENCE                        191   567 976
CT   1   LACK EE               AM J PATHOL                     91   497 978
     2   GALLIVAN MVE          AM J SURG PATHOL                 3    85 979
     3   LACK EE               HUM PATHOL                      10   191 979
     4   LACK EE               CANCER                          43   269 979
     5   VERNA A               INT REV CYTOL                   60   271 979
     6   VANZWIETEN MJ         J PATHOL                       128    99 979
     7   DUNCAN AW             RADIOLOGY                      132    99 979
     8   LACK EE               AM J SURG PATHOL                 4   109 980
     9   MCDONALD DM           FED PROC                        39  2627 980
    10   ROBERTSON DI          CANCER                          46  2623 980
    11   GALLIVAN MVE          ARCH PATHOL LAB MED            104    46 980
    12   MERINO MJ             CANCER                          47  1403 981
    13   WETMORE RF            CANCER                          48  2717 981
    14   DELACROIX R           J CHIR (PARIS)                 118    29 981
    15   HABECK JO             ANAT ANZ                       150   374 981
    16   BOCKELMAN HW          CANCER                          50  2513 982
    17   BORGES LF             J NEUROSURG                     59   867 983
    18   GRONBLAD M            MED BIOL                        61   229 983
    19   PERRIN DG             LANCET                           2   535 984
    20   PERRIN DG             PEDIATRICS                      73   646 984
    21   HABECK JO             ANAT ANZ                       157   351 984
    22   DELAMONTE SM          AM J PEDIATR HEMATOL ONCOL       7   109 985
    23   HABECK JO             EXP PATHOL                      27    79 985
    24   LACK EE               AM J PATHOL                    119   301 985
    25   HABECK JO             ANAT ANZ                       162    17 986

PN 77087
RN 00668 
AN 78065932
AU Sorensen-R-U.  Stern-R-C.  Polmar-S-H.
TI Cellular immunity to bacteria: impairment of in vitro lymphocyte
   responses to Pseudomonas aeruginosa in cystic fibrosis patients.
SO Infect-Immun. 1977 Dec. 18(3). P 735-40.
MJ ANTIGENS-BACTERIAL.  CYSTIC-FIBROSIS: im.  LYMPHOCYTE-TRANSFORMATION.
   PSEUDOMONAS-AERUGINOSA: im.
MN ANTIBODIES-BACTERIAL.  CONCANAVALIN-A.  HAEMOPHILUS-INFLUENZAE: im.
   HUMAN.  LECTINS.  STAPHYLOCOCCUS-AUREUS: im.
   STREPTOCOCCUS-PYOGENES: im.  SUPPORT-U-S-GOVT-P-H-S.
AB Lymphocyte responses to the mitogens phytohemagglutinin and
   concanavalin A and to Streptococcus pyogenes, Staphylococcus aureus,
   Haemophilus influenzae, and Pseudomonas aeruginosa were evaluated in
   patients with cystic fibrosis and in normal individuals. Lymphocyte
   proliferation in vitro was stimulated by gentamicin-killed whole
   bacteria, and the proliferative response was measured by
   [3H]thymidine incorporation. The in vitro lymphocyte responses to
   antibiotic-killed bacterial reached maximum thymidine incorporation
   after 5 days in culture and followed a unimodal dose-response curve
   for each of the bacteria studied. A significant specific incapacity
   to respond to P. aeruginosa was detected in cystic fibrosis patients
   with advanced clinical disease.
RF 001   BEKIERKUNST A         INFECT IMMUN                    14    28 976
   002   BURNS MW              LANCET                           1   270 968
   003   DOERSHUK CF           J PEDIATR                       65   677 964
   004   EIJSVOOGEL VP         SEMIN HEMATOL                   11   305 974
   005   FOWLES RE             J EXP MED                      138   952 973
   006   GODAL T               CLIN EXP IMMUNOL                 8   625 971
   007   HANN S                INFECT IMMUN                    14   114 976
   008   HOIBY N               SCAND J RESPIR DIS              56    38 975
   009   HOMMA JY              JAPAN J EXP MED                 41    89 971
   010   KRAHENBUHL JL         INFECT IMMUN                     4   337 971
   011   MACKANESS GB          J EXP MED                      129   973 969
   012   MOONEY JJ             J IMMUNOL                      105  1138 970
   013   ORDAL J               J IMMUNOL                      116  1182 976
   014   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   015   SCHWARTZ RH           AM J DIS CHILD                 111   408 966
   016   SIMON GB              CELL IMMUNOL                     4   163 972
   017   SISKIND GW            FED PROC                        33  1886 974
   018   SOUTH MA              J PEDIATR                       71   645 967
   019   THORSBY E             HISTOCOMPATIBILITY TESTING           655 970
   020   WOOD RE               AM REV RESPIR DIS              111   733 975
   021   YEATES DB             ARCH DIS CHILD                  51    28 976
CT   1   CHO YJ                JAP J EXP MED                   48   491 978
     2   SORENSEN RU           J PEDIATR                       93   201 978
     3   TOURAINE JL           REV FR MAL RESP                  7    41 979
     4   THOMASSEN MJ          PEDIATR RES                     13  1085 979
     5   WILSON GB             J CLIN INVEST                   66  1010 980
     6   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
     7   RUBIN HR              CELL IMMUNOL                    57   307 981
     8   HEYNE K               EUR J PEDIATR                  137   116 981
     9   SEALE TW              ANN CLIN LAB SCI                12   415 982
    10   BODEY GP              REV INFECT DIS                   5   279 983
    11   PETIT JC              BIOMED PHARMACOTHER             37   422 983
    12   RUBIN HR              INFECT IMMUN                    39   630 983
    13   PORWOLL JM            INFECT IMMUN                    40   670 983
    14   PARMELY MJ            J EXP MED                      160  1338 984
    15   LIEBERMAN MM          SURV SYNTH PATHOL RES            4   312 985
    16   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
    17   HEGGIE AD             PROC SOC EXP BIOL MED          181   586 986

PN 77088
RN 00669 
AN 79108764
AU Sahu-S.  Lynn-W-S.
TI Enzymes of phospholipid metabolism in airway secretions of patients
   with asthma, cystic fibrosis, and alveolar proteinosis.
SO Inflammation. 1977 Jun. 2(2). P 93-104.
MJ ASTHMA: en.  CYSTIC-FIBROSIS: en.  PHOSPHOLIPIDS: me.
   PULMONARY-ALVEOLAR-PROTEINOSIS: en.  RESPIRATORY-SYSTEM: en.
MN ADOLESCENCE.  ADULT.  ANIMAL.  CHILD.  CHILD-PRESCHOOL.  HUMAN.
   IN-VITRO.  INFANT.  PHOSPHOLIPASES: me.
   LYSOLECITHIN-ACYLTRANSFERASE: me.  LYSOPHOSPHATIDYLCHOLINES.
   PHOSPHOLIPASES: ip, me.  RABBITS.  RESPIRATORY-SYSTEM: se.
   SUPPORT-U-S-GOVT-NON-P-H-S.  SUPPORT-U-S-GOVT-P-H-S.
AB Phospholipase A2, lysolecithinase, and lysolecithin-lysolecithin
   acyltransferase are present in the airway secretions of patients
   with asthma, cystic fibrosis (CF), and alveolar proteinosis.  Assays
   of these enzymes under the same conditions in extracts of human
   polymorphonuclear leukocytes, alveolar macrophages, and pig tracheal
   mucosa indicated that these extracellular airway enzymes were
   probably not derived from these cell types.  Although the above
   three enzymes were present in secretions of all patients with these
   three diseases, large amounts of palmitoyl lysolecithin, free fatty
   acids, and dipalmitoyl lecithin were found only in patients having
   alveolar proteinosis and asthma.  The amount of free fatty acids in
   these secretions was sufficient to inhibit both the lysolecithinase
   and the lysolecithin-lysolecithin acyltransferase, but not the
   phospholipase A2.  These findings suggest that the large amount of
   dipalmitoyl lecithin, free fatty acids, and lysolecithin found in
   these secretions results from extracellular remodelling by these
   enzymes.  Because the phospholipase A2 was present in large amounts,
   it was possible after delipidation to purify it to homogeneity.  It
   is a stable enzyme with an apparent molecular weight of 75,000 as
   estimated by SDS-mercaptoethanol gel electrophoresis.
RF 001   SAHU S                AM REV RESPIR DIS              114   177 976
   002   SAHU S                AM REV RESPIR DIS              115   233 977
   003   LEWIS RW              LIPIDS                           6   859 971
   004   ROBERTSON AF          BIOCHEMISTRY                     1   804 962
   005   GALLAI-HATCHARD JJ    BIOCHIM BIOPHYS ACTA            98   128 965
   006   GARCIA A              BIOCHEM BIOPHYS RES COMMUN      64   128 975
   007   OLDENBERG V           BIOCHIM BIOPHYS ACTA           441   433 976
   008   KYLSTRA JA            AM REV RESPIR DIS              103   651 971
   009   TURNER S              J EXP MED                      141  1437 975
   010   MYRVIK QN             J IMMUNOL                       86   128 961
   011   MAGEE WL              METHODS ENZYMOL                 14   170 969
   012   NIEUWENHUIZEN W       METHODS ENZYMOL                 32   147 974
   013   BARTLETT GR           J BIOL CHEM                    234   466 959
   014   LONG C                BIOCHEM J                       65   382 957
   015   MOORE JH              BIOCHIM BIOPHYS ACTA            70   348 963
   016   HANAHAN DJ            J BIOL CHEM                    235  1917 960
   017   TAGUCHI R             BIOCHIM BIOPHYS ACTA           409    75 975
   018   BHATTACHARYYA SN      BIOCHIM BIOPHYS ACTA           427    91 976
   019   ERBLAND JF            BIOCHIM BIOPHYS ACTA           106   128 965
   020   ERBLAND JF            BIOCHIM BIOPHYS ACTA           106   139 965
   021   ELSBACH P             BIOCHIM BIOPHYS ACTA           125   510 966
   022   OTTOLENGHI A          LIPIDS                           5   531 970
   023   VAN DEENEN LLM        IN: HOLMAN RT                    8     1 965
   024   AKINO T               BIOCHIM BIOPHYS ACTA           248   274 971
   025   VEREKEN JM            BIOCHIM BIOPHYS ACTA           260    70 972
   026   GATT S                ANNU REV BIOCHEM                42    61 973
   027   DE HAAS GH            BIOCHIM BIOPHYS ACTA           159   103 968
   028   SCOW RO               BIOCHIM BIOPHYS ACTA           431   538 976
CT   1   SMITH FB              NY STATE J MED                  80  1372 980
     2   RAO RH                EXP LUNG RES                     2     9 981
     3   GALABERT C            CLIN RESP PHYSIOL               17   197 981
     4   WIGHTMAN PD           BIOCHEM J                      200   441 981
     5   LANNI C               BIOCHIM BIOPHYS ACTA           658    54 981

PN 77089
RN 00670 
AN 77164475
AU Zegers-J-M.  Stoop-J-W.
TI Deficiency of kappa- or lambda-type immunoglobulins.
SO Int-J-Dermatol. 1977 Apr. 16(3). P 191-3.
MJ DYSGAMMAGLOBULINEMIA: di.  IMMUNOGLOBULINS-KAPPA-CHAIN.
   IMMUNOGLOBULINS-LAMBDA-CHAIN.  IMMUNOGLOBULINS-LIGHT-CHAIN.
   IMMUNOLOGIC-DEFICIENCY-SYNDROMES: di.
MN ADULT.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: co.
   DIABETES-MELLITUS: co.  DYSGAMMAGLOBULINEMIA: co.  FEMALE.  HUMAN.
   IGA.  INTRINSIC-FACTOR: df.  MALABSORPTION-SYNDROMES: co.  MALE.
EX It is widely recognized that immunoglobulins, as the carriers of
   antibody activity, play an important role in the defense of the
   individual against infections.  The known cases of kappa or lambda
   light chain type immunoglobulin deficiencies are heterogenous with
   regard to clinical and immunological findings.  There are also a
   number of similarities which may suggest common underlying factors.
   The accurate investigation of additional patients, if available,
   should provide more insight into the basis of kappa or lambda type
   immunoglobulin deficiencies.
RF 001   BERNIER GM            BLOOD                           40   795 972
   002   YOUNT WJ              J CLIN INVEST                   49  1957 970
   003   SELIGMANN M           REV FR ETUD CLIN BIOL           12   604 967
   004   BARANDUN S            BLOOD                           47    79 976
   005   ZEGERS BJM            N ENGL J MED                   294  1026 976

PN 77090
RN 00671 
AN 77248610
AU Ten-Kate-L-P.
TI Cystic fibrosis in the Netherlands.
SO Int-J-Epidemiol. 1977 Mar. 6(1). P 23-34.
MJ CYSTIC-FIBROSIS: oc.
MN ADOLESCENCE.  AGE-FACTORS.  CAUCASOID-RACE.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: mo.  HUMAN.  INFANT.  INFANT-NEWBORN.
   INTESTINAL-OBSTRUCTION: oc.  NETHERLANDS.  RETROSPECTIVE-STUDIES.
   SAMPLING-STUDIES.  SEASONS.  SEX-FACTORS.
AB In the Netherlands a retrospective study of the prevalence of cystic
   fibrosis (CF) at birth has been performed by means of an inquiry set
   up among 815 medical specialists (paediatricians, lung specialists
   and pathologists) and by analysis of hospital admission data, death
   certificates and data of the national CF foundation. The study was
   confined to the years of birth 1961-1965. On a total of 1,239,566
   live births 342 infants and children were found to have CF (1/3600).
   A list of all studies on the frequency of CF in Caucasian populations
   is presented as an appendix. A seasonal trend in the expression of
   the CF gene at birth (either with or without meconium ileus) was
   noted.
RF 001   KULCZYCKI LL          AM J DIS CHILD                 127    64 974
   002   WRIGHT SW             AM J HUM GENET                  20   157 968
   003   ANON                  HUMANGENETIK                    30   273 975
   004   ANON                  J PEDIATR                       88   711 976
   005   STEPHAN U             PEDIATRICS                      55    35 975
   006   SHWACHMAN H           N ENGL J MED                   255   999 956
   007   GIBSON LE             PEDIATRICS                      23   545 959
   008   EDWARDS JH            ANN HUM GENET                   25    83 961
   009   CUTLER SJ             J CHRON DIS                      8   699 958
   010   WARWICK WJ            J ASTHMA RES                     5   277 968
   011   HOLSCLAW DS           AM J DIS CHILD                 109   101 965
   012   DONNISON AB           PEDIATRICS                      37   833 966
   013   GRACEY M              CF CLUB ABST                             969
   014   GEORGE L              ARCH DIS CHILD                  46   139 971
   015   MCPARTLIN JF          ARCH DIS CHILD                  47   207 972
   016   KESSLER WR            PEDIATRICS                       8   648 951
   017   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   018   STEINBERG AG          AM J HUM GENET                  12   416 960
   019   KRAMM ER              AM J PUBLIC HEALTH              52  2041 962
   020   DANKS DM              ANN HUM GENET                   28   323 965
   021   TEN KATE LP           THESIS                                   975
   022   SHWACHMAN H           PEDIATRICS                      36   689 965
   023   PUGH RJ               ARCH DIS CHILD                  42   544 967
   024   BRUNECKY Z            J MED GENET                      9    33 972
   025   OREILLY D             INT J EPIDEMIOL                  3   247 974
   026   ROBERTS GBS           ANN HUM GENET                   24   127 960
   027   HALL BD               J MED GENET                      5   262 968
   028   CARTER CO             IN: BODIAN M                          49 952
   029   FEINGOLD J            ANN GENET (PARIS)               17   257 974
   030   BERNHEIM M            PEDIATRIE                       16    17 961
   031   GILLY R               ARCH FR PEDIATR                 28    49 971
   032   SELANDER P            ACTA PAEDIATR SCAND             51    65 962
   033   KOLLBERG H            PROC EWGCF 1ST ANNU MTG                  970
   034   NIELSEN EL            ACTA PAEDIATR SCAND             61   377 972
   035   KOCH G                IN: VON WINDORFER A                   30 968
   036   STEPHAN U             PADIATRISCHE PRAXIS             12   487 973
   037   BAUMANN T             HELV PAEDIATR ACTA SUPPL 8      13     1 958
   038   NEVANLINNA HR         HEREDITAS                       71   195 972
   039   ZYCHOWICZ C           PEDIATR POLSKA                  40   289 965
   040   HOUSTEK J             CESK PEDIATR                    17   445 962
   041   SIMANKOVA N           ANN GENET (PARIS)                7    84 964
   042   HOUSTEK J             REV MED LIEGE                   22   421 967
   043   BRUNECKY Z            PAEDIATR GRENZGEB                8    99 969
   044   REIDERMAN MI          GENETIKA (SOV GENETICS)          7   148 971
   045   BOCHKOVA DN           PEDIATRIIA                      12    24 974
   046   GURSON CT             HELV PAEDIATR ACTA              28   165 973
   047   LEVIN S               IN: GOLDSCHMIDT E                    294 963
   048   SUPER M               S AFR MED J                     49   818 975
   049   BECROFT DMO           NZ MED J                        68   113 968
   050   TRIMBLE BK            ANN HUM GENET                   38   199 974
   051   GOODMAN HO            AM J HUM GENET                   4    59 952
   052   MERRITT AD            J LAB CLIN MED                  60   998 962
   053   MERRITT AD            JAMA                           184   152 963
   054   HANNA BL              IN: US PUB HEAL SERV PUB1163           7 963
   055   CONNEALLY PM          TEX REP BIOL MED                31   639 973
   056   STEINBERG AG          IN: GOLDSCHMIDT E                    133 963
   057   LOWE CU               AM J DIS CHILD                  78   349 949
   058   KULCZYCKI LL          AM J DIS CHILD                 100   174 960
   059   HONEYMAN MS           AM J HUM GENET                  17   461 965
   060   ANDERSEN DH           AM J DIS CHILD                  72    62 946
   061   SULTZ HA              AM J PUBLIC HEALTH              56  1461 966
   062   GLUCKSON MM           CF CLUB ABST                             974
   063   CLARKE CA             IN: ROBERTS DF                           969
   064   ANON                  UNO DEMOGRAPHIC YEARBOOK        13       961
   065   CARTER CO             MOD PROBL PEDIATR               10   372 967
   066   ANDERSON CM           MOD PROBL PEDIATR               10   381 967
   067   WRIGHT SW             IN: LAWSON D PROC 5TH INT CF          91 969
   069   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
CT   1   BOIS E                CLIN GENET                      14    73 978
     2   WARWICK WJ            HELV PAEDIATR ACTA              33   117 978
     3   BRACKENRIDGE CJ       ANN HUM GENET                   42   197 978
     4   NEVIN GB              J MED GENET                     16   122 979
     5   DEMENAIS F            REV EPIDEMIOL SANTE PUBLIQUE    27     5 979
     6   BRACKENRIDGE CJ       AM J MED GENET                   5   295 980
     7   BRACKENRIDGE CJ       AM J MED GENET                   5   303 980
     8   ROMEO G               RIV ITAL PEDIATR                 7   201 981
     9   DAVID TJ              J MED GENET                     18   299 981
    10   SINNEMA G             ACTA PAEDIATR SCAND             72   427 983
    11   PASSARGE E            EUR J PEDIATR                  143    54 984
    12   STURGESS JM           AM J MED GENET                  22   383 985
    13   ROMEO G               AM J HUM GENET                  37   338 985
    14   ALLAN JL              ACTA PAEDIATR SCAND             74   286 985
    15   DANKERTROELSE JE      LANCET                           1   802 986
    16   KOLLBERG H            J TROP PEDIATR                  32   293 986
    17   DANKERTROELSE JE      ACTA PAEDIATR SCAND             76   209 987

PN 77091
RN 00672 
AN 77094418
AU Twarog-F-J.  Weinstein-S-F.  Khaw-K-T.  Strieder-D-J.  Colten-H-R.
TI Hypersensitivity to pancreatic extracts in parents of patients with
   cystic fibrosis.
SO J-Allergy-Clin-Immunol. 1977 Jan. 59(13). P 35-40.
MJ CYSTIC-FIBROSIS: im.  HYPERSENSITIVITY-IMMEDIATE: ci.
   PANCREATIC-EXTRACTS: pd.
MN ADULT.  CHILD.  CHILD-PRESCHOOL.  HISTAMINE-LIBERATION.  HUMAN.
   IMMUNIZATION-PASSIVE.  RESPIRATORY-FUNCTION-TESTS.  SKIN-TESTS.
   SUPPORT-U-S-GOVT-P-H-S.
AB Because immediate hypersensitivity reactions can occur in individuals
   exposed to powdered pancreatic extracts, 36 patients with cystic
   fibrosis and 51 patents of such patients wwer studied for evidence of
   sensitization. Sensitivity to the extracts as evidence by history and
   skin testing was infrequent in the children with cystic fibrosis.
   However, skin testing for immediate hypersensitivity with either
   crude pancreatic extracts or inactivated trypsin correlated well in
   their patents with a history of clinical symptoms. IgE mediation of
   these reactions in sensitized individuals was demonstrated by antigen-
   induced histamine release from leukocytes, passive transfer studies,
   and immediate response to inhalation challenge.
RF 001   FRANZ T               J ALLERGY CLIN IMMUNOL          47   170 971
   002   DOLOVICH J            J ALLERGY CLIN IMMUNOL          49    43 972
   003   WATT A                CLIN ALLERGY                     3   133 973
   004   PEPYS J               CLIN ALLERGY                     3   143 973
   005   ZETTERSTROM O         CLIN ALLERGY                     4   273 974
   006   COLTEN HR             N ENGL J MED                   292  1050 975
   007   DOLAN TF JR           AM REV RESPIR DIS              110   812 974
   008   BERGNER A             PEDIATRICS                      55   814 975
   009   HILL D                MED J AUST                       2   553 975
   010   MAY CD                J ALLERGY                       46    12 970
   011   AXEN R                EUR J BIOCHEM                   18   351 971
   012   COOK CD               J PEDIATR                       59   820 961
   013   MURRAY AB             J PEDIATR                       62   186 963
   014   KULCZYCKI LL          JAMA                           175   358 961
   015   RACHELEFSKY GS        AM J DIS CHILD                 128   355 974
   016   SPITZ E               J ALLERGY CLIN IMMUNOL          49   337 972
   017   WARREN CPW            CLIN ALLERGY                     5     1 975
   018   COUNAHAN R            ARCH DIS CHILD                  50   477 975
   019   CHASE MW              PROC SOC EXP BIOL MED           61   257 946
   020   CHASE MW              IN: SHAFFER JH                       507 959
   021   DAVID MF              J ALLERGY CLIN IMMUNOL          55   135 975
   022   LITTMAN A             N ENGL J MED                   281   201 969
   023   FREEDMAN S            J APPL PHYSIOL                  38   974 975
   024   PEPYS J               CLIN ALLERGY SUPPL               3   491 973
   025   PEPYS J               AM REV RESPIR DIS              112   829 975
   026   DOLOVICH J            J ALLERGY CLIN IMMUNOL          52    38 973
   027   ROBERTSON DG          J ALLERGY CLIN IMMUNOL          54   244 974
CT   1   FORSBECK M            LANCET                           2   524 978
     2   KARR RM               J ALLERGY CLIN IMMUNOL          61    54 978
     3   ROMEO G               NATURE                         274   909 978
     4   BAUR X                CLIN ALLERGY                     9    75 979
     5   GANIER M              CLIN ALLERGY                     9   125 979
     6   ROMEO G               PEDIATR RES                     13  1030 979
     7   PARK RW               GASTROENTEROLOGY                81  1143 981
     8   SJOGREN B             SCAND J WORK ENVIRON HEALTH      9   385 983
     9   BAUR X                DTSCH MED WSCHR                109   257 984
    10   PERRY RS              CLIN PHARMACY                    4   161 985
    11   WIESSMANN KJ          EUR J RESPIR DIS                66    13 985

PN 77092
RN 00673 
AN 77228433
AU Blacharsh-C.
TI Dental aspects of patients with cystic fibrosis: a preliminary
   clinical study.
SO J-Am-Dent-Assoc. 1977 Jul. 95(1). P 106-10.
MJ CYSTIC-FIBROSIS: co.  TOOTH-DISEASES: et.
MN COMPARATIVE-STUDY.  DENTAL-PLAQUE: et.  FOOD-HABITS.  GINGIVITIS: et.
   HUMAN.  MOUTH-BREATHING: et.  TOOTH-DISCOLORATION: et.
   TOOTH-MOBILITY: et.
AB The oral conditions of 42 patients being treated for cystic fibrosis
   were evaluated. The patients were grouped by age and, in some
   aspects, were compared with a small control group of their siblings.
   The patient group had a lowered incidence of plaque and less gingival
   disease than did the control group in which every person had some
   amount of plaque or gingival disease. Calculus formation was minimal.
   The reasons for the finding of minimal plaque in the patient group
   could be related to several factors, including the life-long use of
   various antibiotic agents, the chewing of digestive enzyme
   supplements, the effect of medical management on tooth hardness, and
   the effect of stained teeth (possible tetracycline deposition) on the
   plaque microorganisms. It appears that the therapy for cystic
   fibrosis was beneficial to the periodontal health of these patients.
   Much further study is needed to understand the interrelationship
   between an altered oral environment (salivary changes in cystic
   fibrosis), altered microbial flora (by antibiotics, enzymes) and even
   altered tooth surfaces (possible tetracycline deposition). Most
   patients were found to have one or more oral habits. Tooth mobility
   was associated with tension habits. Patients who had clubbed fingers
   (indicating pulmonary compromise) and possibly a severe disease
   process, did not appear to have either stained teeth or the severity
   of the gingivitis associated with this. The relationship of
   tetracycline to tooth staining could not be pinpointed.
RF 002   CHERNICK WS           J PEDIATR                       59   890 961
   003   MANDEL ID             AM J DIS CHILD                 113   431 967
   004   WOTMAN S              J PERIODONTOL                   44   278 973
   005   ZEGARELLI EV          PEDIATRICS                      26  1050 960
   006   APPLEBAUM E           ORAL SURG                       17   366 964
   008   REITMAN AA            JADA                            71  1436 965
   009   GREENE JC             JADA                            68    25 964
   010   ZEGARELLI EV          ORAL SURG                       15   929 962
   011   JENSEN AL             JADA                            59   923 959
   012   ENNEVER J             J PERIODONTOL                   32   331 961
   013   KEYES PH              ARCH ORAL BIOL                   9   377 964
   014   KEYES PH              IADR PROGRAM ABST 67                     965
CT   1   PRIMOSCH RE           ORAL SURG                       50   301 980
     2   SING CF               AM J MED GENET                  13   179 982
     3   MAHANEY MC            ARCH ORAL BIOL                  31   363 986

PN 77093
RN 00674 
AN 77187640
AU Ligas-J-R.  Primiano-F-P-Jr.  Saidel-G-M.  Doershuk-C-F.
TI Comparison of measures of forced expiration.
SO J-Appl-Physiol. 1977 Apr. 42(4). P 607-13.
MJ CYSTIC-FIBROSIS: pp.  LUNG: ph.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.
   FORCED-EXPIRATORY-FLOW-RATES.  HUMAN.  METHODS.  MODELS-BIOLOGICAL.
   SUPPORT-U-S-GOVT-P-H-S.  VITAL-CAPACITY.
AB Theoretical relationships among a number of parameters were derived
   for idealized timed vital capacity (TVC) and maximal expiratory flow-
   volume (MEFV) curves to determine a minimal set of independent
   parameters. Normal pediatric subjects and those with cystic fibrosis
   were studied to verify these relationships experimentally. The
   average flow over the middle half (FEF25-75%) of the forced vital
   capacity (FVC) and flows at various exhaled percentages of the FVC
   (FEF50%, FEF75%), as well as moments of the TVC and MEFV curves were
   computed. From the TVC moments, a mean transit time (MTT) and an
   index of dispersion (ID) were also calculated. The minimum
   information needed to detect pulmonary mechanical changes associated
   with obstructive lung disease requires at least two reproducible
   measures: one related to the mean slope (e.g., FEF25-75%/FVC or MTT)
   and the other to the shape (e.g;, ID) of the effort-independent
   portion of the MEFV curve.
RF 001   ALLEN GW              AM REV RESPIR DIS              104    61 971
   002   BLACK LF              AM REV RESPIR DIS              110   282 974
   003   BOUHUYS A             BREATHING                                974
   004   BOUHUYS A             J CLIN INVEST                   48  1159 969
   005   CLEMENT J             RESPIR PHYSIOL                  15    70 972
   006   CLEMENT J             J APPL PHYSIOL                  31    55 971
   007   DOERSHUK CF           J PEDIATR                       65   677 964
   008   FISH J                AM REV RESPIR DIS              109   700 974
   009   FRY DL                AM J MED                        29   672 960
   010   GREEN M               J APPL PHYSIOL                  37   793 974
   011   GREEN M               J APPL PHYSIOL                  37    67 974
   012   HALD A                STATISTICAL THEORY WITH ENGIN            952
   013   HOEL PG               INTRODUCTION TO MATHEMATICAL             971
   014   HOGG JC               N ENGL J MED                   278  1355 968
   015   HYATT RE              AM REV RESPIR DIS              107   191 973
   016   KNUDSON RJ            AM REV RESPIR DIS              113   587 976
   017   LANDAU LI             AM REV RESPIR DIS              108   593 973
   018   LANDAU LI             AM REV RESPIR DIS              111   725 975
   019   LEUALLEN EC           AM REV TUBERC PULM DIS          72   783 955
   020   MCCALL CB             J APPL PHYSIOL                  10   215 957
   021   MCCARTHY DS           AM REV RESPIR DIS              112   407 975
   022   MEAD J                J APPL PHYSIOL                  22    95 967
   023   NEUBURGER N           J APPL PHYSIOL                  40   329 976
   024   PRIDE NB              J APPL PHYSIOL                  23   646 967
   025   SAIDEL GM             J APPL PHYSIOL                  38   328 975
   026   SOBOL BJ              AM REV RESPIR DIS              107   753 973
   027   TAKISHIMA TG          SCAND J RESPIR DIS              48   384 967
   028   WENG TR               AM REV RESPIR DIS               99   879 969
   029   ZAMEL N               AM REV RESPIR DIS              107   861 973
   030   ZAPLETAL A            PEDIATRICS                      48    64 971
CT   1   TSAI MJ               IEEE TRANS BIOMED ENG           26   293 979
     2   PIMMEL RL             AM REV RESPIR DIS              120  1245 979
     3   PREFAUT C             BULL EUR PHYSIOPATH RESP        16    25 980
     4   MENKES H              ANN BIOMED ENG                   9   501 981
     5   PIMMEL RL             J APPL PHYSIOL                  51  1581 981
     6   PESLIN R              BULL EUR PHYSIOPATH RESP        18   679 982
     7   GILBERT R             ARCH INTERN MED                145  1635 985

PN 77094
RN 00675 
AN 78026551
AU Shapira-E.  Martin-C-L.  Nadler-H-L.
TI Comparison between purified alpha2-macroglobulin preparations from
   normal controls and patients with cystic fibrosis.  Kinetic and
   structural properties of the complex with bovine trypsin.
SO J-Biol-Chem. 1977 Nov 25. 252(22). P 7923-9.
MJ ALPHA-MACROGLOBULINS.  CYSTIC-FIBROSIS: bl.
MN ALPHA-MACROGLOBULINS: im, ip.  CHROMATOGRAPHY-GEL.
   COMPARATIVE-STUDY.  HUMAN.  IMMUNOELECTROPHORESIS.  KINETICS.
   PROTEIN-BINDING.  TRYPSIN.  SUPPORT-U-S-GOVT-P-H-S.
AB Alpha-2-macroglobulin was purified from plasma obtained from three
   healthy controls and three patients with cystic fibrosis.  The
   normal and patient preparations were indistinguishable antigenically
   and in their UV absorption spectra.  Competitive inhibition by these
   preparations of the hydrolysis of benzoyl-L-arginine ethyl ester by
   bovine trypsin was observed.  The Ki value for normal
   alpha-2-macroglobulin was 5.3 x 10-8 M as compared to 1.8 x 10-7 M
   for cystic fibrosis patients preparations.  The km values of the
   alpha-2-macroglobulin-trypsin complex were 6.3 x 10-4 M for the
   normal protein and 1.5 x 10-4 M with the alpha-2-macroglobulin from
   the cystic fibrosis patients.  Gel chromatography of normal
   alpha-2-macroglobulin, preincubated in molar ratios with bovine
   trypsin, revealed the formation of alpha-2-macroglobulin fragments.
   These fragments were not obtained with the preparations from the
   cystic fibrosis patients.  Both the normal and cystic fibrosis
   alpha-2-macroglobulins were shown by gel chromatography in sodium
   dodecyl sulfate to be tetramers, noncovalently bound.  After
   reduction and alkylation the monomers were found to be a single
   polypeptide chain.  The fragments obtained by preincubating normal
   alpha-2-macroglobulin with trypsin had approximately half the
   molecular weight of the intact monomer.  Cystic fibrosis
   alpha-2-macroglobulin preincubated with trypsin in sodium dodecyl
   sulfate a single major component identical to the intact monomers,
   with no formation of alpha-2-macroglobulin fragments.
RF 001   JONES JM              BIOCHEM J                      127   187 972
   002   BARRETT AJ            BIOCHEM J                      133   709 973
   003   ROBERTS RC            IN: FRITZ H                           63 974
   004   DUNN JT               J BIOL CHEM                    242  5549 967
   005   HARPEL PC             J EXP MED                      138   508 973
   006   BAUMSTARK JS          BIOCHIM BIOPHYS ACTA           207   318 970
   007   SAUNDERS R            J CLIN INVEST                   50  2376 971
   008   SUGIHAR H             J BIOCHEM (TOKYO)               70   649 971
   009   BIETH J               FEBS LETTERS                     8   319 970
   010   DOLOVICH J            J LAB CLIN MED                  77   951 971
   011   SCHREIBER AD          J CLIN INVEST                   52  1394 973
   012   OHLSSON K             SCAND J CLIN LAB INVEST         34   349 974
   013   BERTHILLIER G         BIOCHIM BIOPHYS ACTA           170   140 968
   014   MCCONNELL DJ          PROC SOC EXP BIOL MED          147   891 974
   015   SHAPIRA E             PEDIATR RES                     10   812 976
   016   WILSON GB             PEDIATR RES                     10    87 976
   017   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      71   864 976
   018   SHAPIRA E             J LAB CLIN MED                  77   877 971
   019   HUNTER WM             NATURE                         194   495 962
   020   TRAVIS J              J BIOL CHEM                    240  1962 965
   021   DIXON M               BIOCHEM J                       55   170 953
   022   HANES CS              BIOCHEM J                       26  1406 932
   023   DIXON M               ENZYMES                              316 964
   024   ERLANGER BF           ARCH BIOCHEM BIOPHYS            95   271 961
   025   IWAMOTO M             BIOCHIM BIOPHYS ACTA           214   402 970
   026   SCHULTZE HE           MOLECULAR BIOL OF HUMAN PROTE    1       966
   027   SHAPIRA E             CLIN CHIM ACTA                  78   359 977
   028   LENAD J               BIOCHEM BIOPHYS RES COMMUN      45   662 971
   029   RINDERKNECHT H        IMMUNOCHEMISTRY                 12     1 975
   030   ARNON R               IN: SELA M                            88 973
   031   SHAPIRA E             BIOCHEMISTRY                     6  3951 967
   032   CITRI N               ADV ENZYMOL                     37   397 973
   033   BECHET JJ             BIOCHIM BIOPHYS ACTA           178   561 969
   034   BARRETT AJ            IN: FRITZ H                           72 974
   035   GAUTHIER F            C R SOC BIOL (PARIS)           168   437 974
CT   1   ALHADEFF JA           CLIN GENET                      14   189 978
     2   TRAVIS J              BIOCHEMISTRY                    17  5651 978
     3   WILSON GB             J LAB CLIN MED                  92   463 978
     4   BOAT TF               ACS SYMPOSIUM SERIES          1978   108 978
     5   DISANTAGNESE PA       MONOGR PAEDIATR                 10    66 979
     6   VANLEUVEN F           PEDIATR RES                     13  1384 979
     7   BENYOSEPH Y           CLIN CHIM ACTA                  99    31 979
     8   KURECKI T             ANAL BIOCHEM                    99   415 979
     9   BARRETT AJ            BIOCHEM J                      181   401 979
    10   SCANLIN TF            CLIN CHEST MED                   1   424 980
    11   DAVIS PB              PEDIATR RES                     14    83 980
    12   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      93    50 980
    13   ROMEO G               J LAB CLIN MED                  95   116 980
    14   PARSONS M             CLIN CHIM ACTA                 100   215 980
    15   KRESS LF              BIOCHIM BIOPHYS ACTA           613   469 980
    16   NELLES LP             BIOCHIM BIOPHYS ACTA           623    46 980
    17   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
    18   HALLINAN F            MED HYPOTHESES                   7   793 981
    19   BENYOSEPH Y           PEDIATR RES                     15   839 981
    20   RICHMAN JBY           CAN J BIOCHEM                   59   519 981
    21   VANLEUVEN F           J BIOL CHEM                    256  9016 981
    22   LAINE A               BIOCHIM BIOPHYS ACTA           668   429 981
    23   BLITZER MG            J PEDIATR GASTROENTEROL NUTR     1   289 982
    24   OWENSWILLIAMS L       J PEDIATR GASTROENTEROL NUTR     1   567 982
    25   BURY AF               IRCS MED SCI BIOCHEM            10   255 982
    26   BLITZER MG            PEDIATR RES                     16   203 982
    27   ROBERTS RC            PEDIATR RES                     16   416 982
    28   CRISTOL P             SEM HOP PARIS                   58   449 982
    29   BRIDGES MA            CLIN CHIM ACTA                 118    21 982
    30   BRIDGES MA            CLIN CHIM ACTA                 118    33 982
    31   TUMMLER B             CLIN CHIM ACTA                 125   219 982
    32   BACK SA               BIOCHEM MED                     30    34 983
    33   SLOMIANY A            J BIOL CHEM                    258  8535 983
    34   BRIDGES MA            ANN NY ACAD SCI                421   360 983
    35   SHAPIRA E             ANN NY ACAD SCI                421   352 983
    36   EAGER KB              PEDIATR RES                     18   999 984
    37   MARYNEN P             BIOCHIM BIOPHYS ACTA           799   187 984
    38   GOLDSTEIN W           AM REV RESPIR DIS              134    49 986

PN 77095
RN 00676 
AN 77207468
AU Farrell-P-M.  Bieri-J-G.  Fratantoni-J-F.  Wood-R-E.
   di-SantAgnese-P-A.
TI The occurrence and effects of human vitamin E deficiency.  A study
   in patients with cystic fibrosis.
SO J-Clin-Invest. 1977 Jul. 60(1). P 233-41.
MJ CYSTIC-FIBROSIS: co.  VITAMIN-E-DEFICIENCY: co.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: me.
   FEMALE.  HEMOLYSIS.  HUMAN.  INFANT.  INTESTINAL-ABSORPTION.
   MALABSORPTION-SYNDROMES: co.  MALE.  PANCREATIC-DISEASES: co.
   TRIGLYCERIDES: bl.  VITAMIN-E-DEFICIENCY: dt.  VITAMIN-E: me, tu.
AB The role of vitamin E in human nutrition was studied by
   investigation of patients with cystic fibrosis (CF) and associated
   pancreatic insufficiency.  Vitamin E status was assessed by
   measurement of the plasma concentration of the principal circulating
   isomer, alpha-tocopherol.  Results of such determinations in 52 CF
   patients with pancreatogenic steatorrhea revealed that all were
   deficient in the vitamin.  The extent of decreased plasma tocopherol
   varied markedly but correlated with indices of intestinal
   malabsorption, such as the serum carotene concentration and
   percentage of dietary fat absorbed.  Supplementation with 5-10
   times the recommended daily allowance of vitamin E in a
   water-miscible form increased the plasma alpha-tocopherol
   concentrations to normal in all 19 CF patients so evaluated.
   Studies on the effects of vitamin E deficiency focused on possible
   hematologic alterations.  An improved technique was developed to
   measure erythrocyte hemolysis in vitro in the presence of hydrogen
   peroxide.  While erythrocyte suspensions from control subjects
   demonstrated resistance to hemolysis during a 3-h incubation, all
   samples from tocopherol-deficient CF patients showed abnormal
   oxidant susceptibility, evidenced by greater than 5% hemoglobin
   release.  The degree of peroxide-induced hemolysis was related to
   the plasma alpha-tocopherol concentrationin an inverse, sigmoidal
   manner.  The possibility of in vivo hemolysis was assessed by
   measuring the survival of 51Cr-labeled erythrocytes in 19 vitamin-E
   deficient patients.  A moderate but statistically significant
   decrease in the mean 51Cr erythrocyte half-life value was found in
   this group.  Measurement of erythrocyte survival before and after
   supplementation of 6 patients with vitamin E demonstrated that the
   shortened erythrocyte lifespan could be corrected to normal with
   this treatment.  Other hematologic indices in deficient subjects,
   however, were normal and did not change upon supplementation with
   vitamin E.  It is concluded that CF is invariably associated with
   vitamin E deficiency, provided that the patient in question has
   pancreatic achylia and is not taking supplementary doses of
   tocopherol.  Concomitant hematologic effects consistent with mild
   hemolysis, but not anemia, occur and may be reversed with vitamin E
   therapy.  Patients with CF should be given daily doses of a
   water-miscible form of vitamin E to correct the deficiency.
RF 001   BINDER HJ             N ENGL J MED                   273  1289 965
   002   FILER LJ JR           PEDIATRICS                       8   328 951
   003   NITOWSKY HM           VITAM HORM                      20   559 962
   004   GORDON HH             AM J DIS CHILD                  62   328 941
   005   BIERI JG              NUTR REV                        33   161 975
   006   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   007   NITOWSKY HM           BULL JOHNS HOPKINS HOSP         98   361 956
   008   GOLDBLOOM RB          CAN MED ASSOC J                 82  1114 960
   009   MCWHIRTER WR          ACTA PAEDIATR SCAND             64   446 975
   010   HORWITT MK            ANN NY ACAD SCI                203   223 972
   011   BIERI JG              PROC SOC EXP BIOL MED          120   554 965
   012   BIERI JG              IN: MARINETTI GV                 2   459 969
   013   BIERI JG              INT J VITAM RES                 40   344 970
   014   HORWITT MK            AM J CLIN NUTR                   4   408 956
   015   ANON                  BLOOD                           38   378 971
   016   VAN DE KAMER JH       J BIOL CHEM                    177   347 949
   017   KESSLER G             IN: SKEGGS LT                        341 965
   018   DE LA HUERGA J        AM J CLIN PATHOL                23  1163 953
   019   BIERI JG              J NUTR                         100   557 970
   020   HARRIS PL             PROC SOC EXP BIOL MED          107   381 961
   021   BIERI JG              PROC SOC EXP BIOL MED          117   131 964
   022   GORDON HH             AM J DIS CHILD                  90   669 955
   023   MULLER DPR            GUT                             15   966 974
   024   UNDERWOOD BA          PEDIATR RES                      6    26 972
   025   UNDERWOOD BA          ANN NY ACAD SCI                203   237 972
   026   MACMAHON MT           CLIN SCI                        38   197 970
   027   LOSOWSKY MS           ANN NY ACAD SCI                203   212 972
   028   NITOWSKY HM           AM J DIS CHILD                  92   164 956
   029   TSEN CC               CAN J BIOCHEM PHYSIOL           38   957 960
   030   OSKI FA               J PEDIATR                       70   211 967
   031   PANOS TC              AM J CLIN NUTR                  21    15 968
   032   LEONARD PJ            AM J CLIN NUTR                  24   388 971
   033   BIERI JG              AM J CLIN NUTR                  28   717 975
CT   1   ANON                  LANCET                           2  1268 977
     2   ROCKERBIE RA          CLIN CHEM                       25  1411 979
     3   TOMASI LG             NEUROLOGY                       29  1182 979
     4   CHOW CK               AM J CLIN NUTR                  32  1066 979
     5   RACHMILEWITZ EA       AM J CLIN NUTR                  32  1850 979
     6   WOOD RE               SOUTH MED J                     72   189 979
     7   SPIELBERG SP          ANN INTERN MED                  90    53 979
     8   CHIU D                J LAB CLIN MED                  94   542 979
     9   CHASE HP              J PEDIATR                       95   337 979
    10   FARRELL PM            J PEDIATR                       95   869 979
    11   WEISMAN Y             J PEDIATR                       95   416 979
    12   DRAKE JR              AM J CLIN NUTR                  33  2386 980
    13   HORWITT MK            NUTR REV                        38   105 980
    14   SUNG JH               J NEUROPATHOL EXP NEUROL        39   584 980
    15   RACHMILEWITZ EA       BR J HAEMATOL                   46     1 980
    16   SCHULMAN JD           ANN INTERN MED                  93   330 980
    17   HUBBARD VS            CLIN CHIM ACTA                 102   115 980
    18   ROGIERS V             CLIN CHIM ACTA                 105   105 980
    19   SIMON C               EUR J PEDIATR                  133   273 980
    20   CORASH L              N ENGL J MED                   303   416 980
    21   ANDREWS WS            J PEDIATR SURG                  16   284 981
    22   CHO YW                J CLIN PHARMACOL                21   224 981
    23   CAVALIER SJ           NEUROLOGY                       31   714 981
    24   CONGDEN PJ            ARCH DIS CHILD                  56   708 981
    25   ANON                  S AFR MED J                     59   618 981
    26   PARK RW               GASTROENTEROLOGY                81  1143 981
    27   HAGA P                EUR J PEDIATR                  136   143 981
    28   ROSENBLUM JL          N ENGL J MED                   304   503 981
    29   HOOGENRAAD TU         NEUROOPHTHALMOL                  2   267 982
    30   ROGIERS V             PEDIATR RES                     16   761 982
    31   ALBRIGHT RK           KIDNEY INT                      21   161 982
    32   HAGA P                AM J CLIN NUTR                  36  1200 982
    33   HOWARD L              AM J CLIN NUTR                  36  1243 982
    34   VANVLEET JF           AM J VET RES                    43  1049 982
    35   DUTTA SK              ANN INTERN MED                  97   549 982
    36   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
    37   CHIU D                ANN NY ACAD SCI                393   323 982
    38   CORASH LM             ANN NY ACAD SCI                393   348 982
    39   KITABCHI AE           ANN NY ACAD SCI                393   300 982
    40   RACHMILEWITZ EA       ANN NY ACAD SCI                393   336 982
    41   STUART MJ             ANN NY ACAD SCI                393   277 982
    42   KITABCHI AE           BIOCHIM BIOPHYS ACTA           684   200 982
    43   WAGENER JS            AM J PEDIATR HEMATOL ONCOL       5   153 983
    44   NEVILLE HE            NEUROLOGY                       33   483 983
    45   FARRELL PM            J DENT CHILD                    50   385 983
    46   KON K                 ACTA HAEMATOL                   69   111 983
    47   GUGGENHEIM MA         J PEDIATR                      102   577 983
    48   BURTON GW             ARCH BIOCHEM BIOPHYS           221   281 983
    49   BIERI JG              N ENGL J MED                   308  1063 983
    50   DEARBORN DG           PEDIATR RES                     18   890 984
    51   ROGIERS V             PEDIATR RES                     18   704 984
    52   PRENSKY AL            DEVELOP MED CHILD NEUROL        26   669 984
    53   OVESEN L              DRUGS                           27   148 984
    54   BERTONI JM            NEUROLOGY                       34  1046 984
    55   GUTCHER GR            AM J CLIN NUTR                  40  1078 984
    56   BOUGLE D              ARCH FR PEDIATR                 41    63 984
    57   DAVIS PB              J LAB CLIN MED                 104   203 984
    58   ANON                  JAMA                           252  U316 984
    59   SOKOL RJ              N ENGL J MED                   310  1209 984
    60   STEAD RJ              LANCET                           2   862 985
    61   GUTCHER GR            J PEDIATR GASTROENTEROL NUTR     4   604 985
    62   CARPENTER D           SEM NEUROL                       5   283 985
    63   HUBBARD VS            SEM RESPIR MED                   6   308 985
    64   RACHMILEWITZ EA       CLIN HAEMATOL                   14   163 985
    65   FARRELL PM            PEDIATR RES                     19   104 985
    66   COSTAGLIOLA C         METABOLISM                      34   712 985
    67   HADDAD E              AM J CLIN NUTR                  41   599 985
    68   MINO M                AM J CLIN NUTR                  41   631 985
    69   BYE AME               ARCH DIS CHILD                  60   162 985
    70   CLARK JH              CLIN CHIM ACTA                 153   117 985
    71   HARDING AE            N ENGL J MED                   313    32 985
    72   HUGHES RL             ACTA PAEDIATR SCAND SUPPL 317 1985    42 985
    73   KALVARIA I            INT J PANCREATOL                 1   119 986
    74   HANDELMAN GJ          ADV FREE RAD BIOL MED            2     1 986
    75   SOKOL RJ              HEPATOLOGY                       6  1263 986
    76   BOUGLE D              DEVELOP PHARM THER               9   310 986
    77   MISCHLER EH           PEDIATR RES                     20    36 986
    78   STEAD RJ              GUT                             27   714 986
    79   ARANDA JV             PEDIATR CLIN NORTH AM           33   583 986
    80   COSTAGLIOLA C         EXP EYE RES                     43   905 986
    81   ANON                  NUTR REV                        44   373 986
    82   DAVIDAI G             ARCH DIS CHILD                  61   901 986
    83   KAY MMB               PROC NAT ACAD SCI USA           83  2463 986
    84   ASAYAMA K             J LAB CLIN MED                 107   459 986
    85   HAFEZ M               J PEDIATR                      108   558 986
    86   HUANG ML              J CHROMATOGR                   380   331 986
    87   SOKOL RJ              J PEDIATR GASTROENTEROL NUTR     6    10 987
    88   REED JD               AM J HEMATOL                    24   441 987
    89   SITRIN MD             ANN INTERN MED                 107    51 987

PN 77096
RN 00677 
AN 78195444
AU Chakravarty-S-C.  Bhattacharya-S-N.  Sarkar-D-K.
TI Bronchiectasis and mucoviscidosis.
SO J-Indian-Med-Assoc. 1977 Dec 16. 69(12). P 273-5.
MJ BRONCHIECTASIS: co.  CYSTIC-FIBROSIS: co.
MN ADOLESCENCE.  ADULT.  AGED.  BRONCHIECTASIS: me.  CASE-REPORT.
   CHLORIDES: an.  HUMAN.  MALE.  MIDDLE-AGE.  SWEAT: an.
AB Sweat chloride of 25 healthy adults was tested by iontophoresis
   method as a control.  The mean value was 27.4 plus or minus 15.4
   mEq./l.  Thirty-six adult patients of bronchiectasis proved by
   bronchography was investigated for mucoviscidosis.  If a patient had
   sweat chloride above 60 mEq./l., it was considered to be diagnostic
   of mucoviscidosis.  Five (13.9 per cent) of 36 adult bronchiectasis
   patients had mucoviscidosis.  The mean value of sweat chloride in 31
   adult bronchiectasis patients was 32.9 plus or minus 11.7 mEq./l.
   The mean value of sweat chloride in 36 adult bronchiectasis patients
   (including 5 mucoviscidosis patients) was 42.3 plus or minus 26.8
   mEq./l.  Of 36 patients 18 had cylindrical type and 18 had saccular
   type of bronchiectasis.  Three (16.6 per cent) out of 18 cylindrical
   type of bronchiectasis patients and 2 (11.1 per cent) of 18 saccular
   type of bronchiectasis patients had mucoviscidosis.  Five (13.9 per
   cent) patients had emphysema and 6 (16.6 per cent) patients had
   emphysema with cor pulmonale.  One patient of each group had
   mucoviscidosis.  ECG showed P-pulmonale in 3 (8.3 per cent) patients
   one of whom had mucoviscidosis.  Only one mucoviscidosis patient had
   coagulase positive Staph. aureus in sputum.
RF 001   AGREN G               ACTA MED SCAND                  90     1 936
   002   ANDERSEN DH           AM J DIS CHILD                  63   643 942
   003   CHAHRAVARTY SC        J INDIAN MED ASSOC              53   554 969
   004$  CHILDS B              TRANS INT CONF ON CF                 195 960
   005   COHEN JS              ABSTRACT OF WORLD MEDICINE      42   867 968
   006   DI SANTAGNESE PA      IN: CECIL RL                         917 959
   007   DI SANTAGNESE PA      JAMA                           172   135 960
   008   GIBSON LE             PEDIATRICS                      23   545 959
   009   JAGGI OP              INDIAN J CHEST DIS               6   134 964
   010   KARLISH AJ            PROC R SOC MED                  54   980 961
   011   LAGERLOF HO           PANCREATIC FUNCTION AND PANCR            942
   012   LIEBERMAN J           AM J MED SCI                   246   537 963
   013$  PETERSON EM           JAMA                           176     1 959
   014   SARKAR DK             THESIS                                   965
   015   SHWACHMAN H           ANN NY ACAD SCI                 93   600 962
   016   SUN DCH               GASTROENTEROLOGY                38   570 960

PN 77097
RN 00678 
AN 78110292
AU Kim-H-W.  Arrobio-J-O.  Brandt-C-D.  Chanock-R-M.  Parrott-R-H.
TI Safety and antigenicity of inactivated influenza virus vaccines in
   children: trials with monovalent and bivalent A/New Jersey/76
   (HswN1) and A/Victoria/75 virus vaccines in Washington, D.C.
SO J-Infect-Dis. 1977 Dec. 136 Suppl. P S588-91.
MJ INFLUENZA-VACCINE: pd.  ORTHOMYXOVIRUS-TYPE-A-HUMAN: im.
MN ADOLESCENCE.  ANTIBODIES-VIRAL: bi.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: im.  DISTRICT-OF-COLUMBIA.
   DOSE-RESPONSE-RELATIONSHIP-IMMUNOLOGIC.  ENGLAND.
   HEMAGGLUTINATION-INHIBITION-TESTS.  HUMAN.  INFLUENZA-VACCINE: ae.
   NEW-JERSEY.  PATIENT-CARE-TEAM.  SUPPORT-U-S-GOVT-P-H-S.
AB Safety and antigenicity of monovalent and bivalent A/New
   Jersey/NJ)/76 (HssN1) and A/Victoria/75 inactivated influenza virus
   vaccines were studied in 125 children aged three to 18 years. In
   recruitment, families who knew the study team, who were
   professionally involved, and/or who were under close continuing care
   were more likely to volunteer for such studies than those who were
   unfamiliar with the team or institution. Antibody responses and
   systemic reactions occurred more often after administration of
   inactivated whole-virus vaccine than after split-virus vaccine.
   Significant titers (greater than or equal to 1:40) of
   hemagglutination-inhibiting antibody to A/NJ/76 virus occurred in 95%
   of normal children three to 18 years of age who received two doses of
   the same vaccine (whole or split). However, insufficient numbers of
   children achieved a reasonable antibody titer (greater than or equal
   to 1:40) after one dose of vaccine.
CT   1   VASILYEVA  RI         ZH MIKROBIO EPIDEMIO IMMUNOBI 1982    96 982

PN 77098
RN 00679 
AN 78110300
AU Modlin-J-F.  Smith-D-H.  Harding-L.
TI Clinical trials of bivalent A/New Jersey/76-A/Victoria/75 influenza
   vaccines in high-risk children.
SO J-Infect-Dis. 1977 Dec. 136 Suppl. P S626-31.
MJ INFLUENZA-VACCINE: pd.  ORTHOMYXOVIRUS-TYPE-A-HUMAN: im.
MN ADOLESCENCE.  ANTIBODIES-VIRAL: bi.  ASTHMA: im.  CHILD.
   CHRONIC-DISEASE.  CYSTIC-FIBROSIS: im.
   DIABETES-MELLITUS-INSULIN-DEPENDENT: im.  ENDOCRINE-DISEASES: im.
   FEMALE.  HEART-DEFECTS-CONGENITAL: im.  HUMAN.  INFLUENZA-VACCINE: ae.
   LUNG-DISEASES: im.  MALE.  RISK.  SUPPORT-U-S-GOVT-P-H-S.
AB Various doses of two whole-virus and one split-product bivalent
   influenza A/New Jersey/76-A/Victoria/75 vaccines were administered to
   253 children aged six to 18 years. There were no statistically
   significant differences in either reactivity or humoral antibody
   response among the 167 children in seven chronic disease categories
   and 86 healthy children. The whole-virus vaccines were associated
   with unacceptably high rates of reaction when given in sufficiently
   antigenic initial doses but were relatively nonreactive when used for
   booster immunization. Split-product vaccines were no more reactive
   than placebo. All vaccine preparations induced adequate
   seroconversion rates and protective titers of antibody to A/Victoria
   virus after one dose and to A/New Jersey virus after two doses.
RF 001   EICKHOFF TC           JAMA                           176   776 961
   002   WEIL WB               IN: BARNETT HL                       354 972
   003   SCHRIENER GE          IN: STRAUSS MB                       606 971
   004   ANON                  AM ACAD PEDIATRICS                   139 974
   005   LERMAN SJ             J INFECT DIS SUPPL             136   563 977
   006   PABICO RC             ANN INTERN MED                  81   171 974
   007   PHILLIPS CF           PEDIATRICS                      52   416 973
   008   KILBOURNE ED          J INFECT DIS                   129   750 974
   009   NICHOLAS RV           PEDIATRICS                       3   208 949
   010   HIGGONS RA            AM J DIS CHILD                  75   887 948
   011   GRANT HB              J PEDIATR                       29   485 946
   012   REIMER CB             J VIROL                          1  1207 967
   013   MARINE WM             J PEDIATR                       88    26 976
   014   KILBOURNE ED          J INFECT DIS                   127   220 973

PN 77099
RN 00680 
AN 77166681
AU Yaffe-S-J.  Gerbracht-L-M.  Mosovich-L-L.  Mattar-M-E.  Danish-M.
   Jusko-W-J.
TI Pharmacokinetics of methicillin in patients with cystic fibrosis.
SO J-Infect-Dis. 1977 May. 135(5). P 828-31.
MJ CYSTIC-FIBROSIS: me.  METHICILLIN: me.
MN ADOLESCENCE.  ADULT.  BACILLUS-SUBTILIS: de.  CREATININE: ur.
   FEMALE.  HUMAN.  MALE.  METHICILLIN: ur.  SUPPORT-U-S-GOVT-P-H-S.
AB The disposition of methicillin in normal subjects and in subjects
   with cystic fibrosis (CF) was studied after administration of single
   intravenous doses of 15 mg/kg. The area under the serum concentration
   vs. time curve for CF patients was, on the average, only 75% of that
   found for normal subjects. The low concentrations in serum were
   caused by more rapid urinary excretion of the antibiotic, with rates
   of renal clearance averaging 425 ml/min per 1.73 m2 in the patients
   with CF and 362 ml/min per 1.73 m2 in the normal subjects. No
   differences were found in volumes of distribution and metabolic
   clearance rates of methicillin or in rates of creatinine clearance
   between the two groups of subjects. These data support previous
   findings with dicloxacillin which show that patients with CF exhibit
   unusually rapid, active tubular secretion of certain penicillins that
   may necessitate use of larger doses of these drugs in treatment of
   infections.
RF 001   LOWE CU               IN: BARNETT HL                       413 972
   002   JUSKO WJ              PEDIATRICS                      56  1038 975
   003   DITTERT LW            ANTIMICROB AGENTS CHEMOTHER      9    42 969
   004   BENNETT JV            APPL MICROBIOL                  14   170 966
   005   HEINEGARD D           CLIN CHIM ACTA                  43   305 973
   006   METZLER CM            TECHNICAL REPORT UPJOHN COMPA            969
   007   JUSKO WJ              J PHARM SCI                     61  1270 972
   008   LOO JCK               J PHARM SCI                     59    53 970
   009   HIRSCH GH             J PHARMACOL EXP THER           174   152 970
CT   1   SOUICH PD             CLIN PHARMACOKINET               3   257 978
     2   MARKS MI              ANTIMICROB AGENTS CHEMOTHER     13   753 978
     3   BERGAN T              ARZNEIMITTEL FORSCH DRUG RES  29-2  1955 979
     4   FINKELSTEIN E         J PEDIATR                       94   163 979
     5   TOGNONI G             CLIN PHARMACOKINET               5   105 980
     6   BENNETT SW            AM J HOSP PHARM                 37   523 980
     7   BEAUDRY PH            J PEDIATR                       97   144 980
     8   BAGGOT JD             J AM VET MED ASSOC             176  1085 980
     9   MICHALSEN H           ANTIMICROB AGENTS CHEMOTHER     19  1029 981
    10   MARKS MI              J PEDIATR                       98   173 981
    11   STRANDVIK B           LANCET                           1   800 982
    12   LEVY J                J ANTIMICROB CHEMOTHER          10   227 982
    13   BINS JW               BR J CLIN PHARMACOL             14  P611 982
    14   NEU HC                MED CLIN NORTH AM               66    51 982
    15   KEARNS GL             J PEDIATR                      100   312 982
    16   KELLY HB              J PEDIATR                      100   318 982
    17   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
    18   PADOAN R              DRUGS UNDER EXP CLIN RES         9   661 983
    19   HUANG NN              J ANTIMICROB CHEMOTHER          11   205 983
    20   KERCSMAR CM           J ANTIMICROB CHEMOTHER          12   289 983
    21   LEFF RD               PEDIATR CLIN NORTH AM           30    93 983
    22   ARVIDSSON A           ACTA PAEDIATR SCAND             72   293 983
    23   WESLEY AW             NZ MED J                        96   651 983
    24   MACDONALD NE          J PEDIATR                      103   985 983
    25   PADOAN R              J PEDIATR                      103   320 983
    26   ISLES A               AM REV RESPIR DIS              127   417 983
    27   NAHATA MC             DEVELOP PHARM THER               7   221 984
    28   TURNER A              J ANTIMICROB CHEMOTHER          14   521 984
    29   KELLY HW              DRUG INTEL CLIN PHARM           18   772 984
    30   SCHOFIELD DH          DRUG INTEL CLIN PHARM           18   153 984
    31   REED MD               ANTIMICROB AGENTS CHEMOTHER     25   579 984
    32   ZIEMNIAK JA           EUR J CLIN PHARMACOL            26   183 984
    33   LEEDER JS             CLIN PHARMACOL THER             36   355 984
    34   REED MD               J PEDIATR                      104   303 984
    35   SPINO M               J PEDIATR                      105   829 984
    36   ANON                  LANCET                           1  1020 985
    37   KUHN RJ               CLIN PHARMACY                    4   555 985
    38   WOOLF RA              CLIN PHARMACY                    4   664 985
    39   PRANDOTA J            DEVELOP PHARM THER               8   311 985
    40   REED MD               ANTIMICROB AGENTS CHEMOTHER     27   583 985
    41   BLUMER JL             AM J MED                        79    37 985
    42   HORREVORTS AM         CHEST                           88   260 985
    43   JACOBS RF             J PEDIATR                      106  1001 985
    44   WILSON CB             J PEDIATR                      106  1049 985
    45   SPINO M               J PEDIATR                      107    64 985
    46   ASSAEL BM             INT J PEDIATR NEPHROL            7   213 986
    47   MICHALSEN H           METH FIND EXP CLIN PHARMACOL     8   727 986
    48   MICHALSEN H           METH FIND EXP CLIN PHARMACOL     8   685 986
    49   BENDER SW             INFECTION                       14    17 986
    50   WRIGHT DB             DRUG INTEL CLIN PHARM           20   845 986
    51   GOLDFARB J            J CLIN PHARMACOL                26   222 986
    52   RUBIO TT              AM J MED                        81    73 986
    53   REED MD               ANTIMICROB AGENTS CHEMOTHER     31   698 987

PN 77100
RN 00681 
AN 77072953
AU Goldsmith-G-H.  Stern-R-C.  Saito-H.  Ratnoff-O-D.
TI Normal plasma arginine esterase and the Hageman factor (factor XII)
   -prekallikrein-kininogen system in cystic fibrosis.
SO J-Lab-Clin-Med. 1977 Jan. 89(1). P 131-4.
MJ CYSTIC-FIBROSIS: bl.  ESTERASES: bl.  FACTOR-XII.  KALLIKREIN.
   KININOGENS: bl.  PREKALLIKREIN.
MN ADOLESCENCE.  ADULT.  ARGININE.  CHILD.  HUMAN.
   TOSYLARGININE-METHYL-ESTER: me.  SUPPORT-U-S-GOVT-P-H-S.
AB Previous investigators have suggested that the biological activity of
   plasma prekallikrein is defective in cystic fibrosis. In contrast, no
   such difference was demonstrable between normal and cystic fibrosis
   plasma. Esterolytic activity for the synthetic substrate p-toluene
   sulfonyl-arginine methyl ester (TAMe) evolved normally in cystic
   fibrosis plasma treated with chloroform and ellagic acid, a measure
   of generation of plasma kallikrein. Additionally, plasma
   prekallikrein (Fletcher factor) and high molecular weight kininogen
   (Fitzgerald factor), a substrate of plasma kallikrein, were normal.
   Thus, the concept that cystic fibrosis is associated with
   abnormalities in the plasma kallikrein-kinin system could not be
   supported.
RF 001   MANGOS JA             PEDIATR RES                      2   378 968
   002   RAO GJS               J PEDIATR                       80   573 972
   003   SPOCK A               PEDIATR RES                      1   173 967
   004   BOWMAN BH             SCIENCE                        164   325 969
   005   RAO GJS               SCIENCE                        177   610 972
   006   RAO GJS               PEDIATR RES                      8   684 974
   007   LIEBERMAN J           AM REV RESPIR DIS              109   399 974
   008   SIEGELMAN AM          ARCH BIOCHEM BIOPHYS            97   159 962
   010   ZIMMERMAN TS          J CLIN INVEST                   50   244 971
   011   SAITO H               J CLIN INVEST                   55  1082 975
   012   COLMAN RW             J CLIN INVEST                   48    23 969
   013   DONALDSON VH          CIRC RES                        34   652 974
   014   OH-ISHI S             BIOCHEM PHARMACOL               24   591 975
   015   COBURN MD             AM REV RESPIR DIS              110   368 974
   016   TALAMO RC             PEDIATR RES                      6   430 972
   017   RAO GJS               PEDIATR RES                      9   739 975
   018   WILSON GB             PEDIATR RES                     10    87 976

PN 77101
RN 00682 
AN 77120193
AU Berman-J-M.  Colman-B-H.
TI Nasal aspects of cystic fibrosis in children.
SO J-Laryngol-Otol. 1977 Feb. 91(2). P 133-9.
MJ CYSTIC-FIBROSIS: co.  NOSE-DISEASES: et.
MN CASE-REPORT.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: di.  FEMALE.
   HUMAN.  MALE.  NASAL-POLYPS: et, th.  NOSE-DISEASES: th.
AB Despite the extraordinary prevalence of upper respiratory allergy and
   infection in children nasal polyposis is an extremely rare condition.
   Seven cases of cystic fibrosis are presented in order to demonstrate
   the nasal aspects of the disease. All but one had nasal polyposis.
   The literature has been reviewed with particular reference to
   clinical, radiological and histo-pathological features. Conservative
   treatment is stressed.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   002   BLUMSTEIN GI          ARCH OTOLARYNGOL                83   266 966
   003   COHEN SR              ANN OTOL RHINOL LARYNGOL        71  1080 962
   004   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   005   GHARIB R              AM J DIS CHILD                 108   499 964
   006   KULCZYCKI LL          JAMA                           175   358 961
   007   LURIE MH              ANN OTOL RHINOL LARYNGOL        68   478 959
   008   MENDELSOHN RS         ARCH OTOLARYNGOL                79   312 964
   009   NEELY JG              LARYNGOSCOPE                    82   910 972
   010   NEELY JG              TRANS AM ACAD OPHTHALMOL OTOL   76   313 972
   011   SHWACHMAN H           PEDIATRICS                      30   389 962
   012   TOMA GA               J LARYNGOL OTOL                 82   265 968
   013   VAN METRE TE JR       J ALLERGY CLIN IMMUNOL          31   141 960
CT   1   LEE ABD               INT J PEDIATR OTORHINOLARYNGO    4   209 982
     2   MILLS SE              ARCH OTOLARYNGOL               108   530 982
     3   STERN RC              AM J DIS CHILD                 136  1067 982
     4   BENJAMIN B            INT J PEDIATR OTORHINOLARYNGO    5   281 983

PN 77102
RN 00683 
AN 78047117
AU Tos-M.  Mogensen-C.  Thomsen-J.
TI Nasal polyps in cystic fibrosis.
SO J-Laryngol-Otol. 1977 Oct. 91(10). P 827-35.
MJ CYSTIC-FIBROSIS: co.  NASAL-POLYPS: co.
MN CHILD.  CHILD-PRESCHOOL.  EPITHELIUM: pa.  HUMAN.  NASAL-MUCOSA: pa.
   NASAL-POLYPS: pa.
AB In II polyps from patients with cystic fibrosis of the pancreas, the
   density, shape, and architecture of mucous glands were studied by the
   whole-mount method and compared with 102 non-cystic-fibrosis polyps.
   There were no differences in density which was in most polyps less
   than 0.5 gland/mm.2. The shape and architecture as well as other
   histological appearances of the polyp were also alike in both groups
   of polyps which could not be distinguished. The pathogenesis of nasal
   polyps in cystic fibrosis is discussed. Apparently, it is the same as
   that of non-cystic-fibrosis polyps.
RF 001   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   002   MAGID SL              ARCH OTOLARYNGOL                86   106 967
   003   MENDELSOHN RS         ARCH OTOLARYNGOL                79   312 964
   004   MOGENSEN C            INT RHINOLOGY                   15    39 977
   005   NEELY JG              TRANS AM ACAD OPHTHALMOL OTOL   76   313 972
   006   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   007   PENNINGTON CL         ARCH OTOLARYNGOL                63   576 956
   008   SHWACHMAN H           PEDIATRICS                      30   389 962
   009   SORENSEN H            PROC INT SYMP INFECT ALLE            233 977
   010   TAYLOR BW             ARCH DIS CHILD                  49   133 974
   011   TOS M                 ACTA PATH MICROBIOL SCAND     S185       966
   012   TOS M                 ANAT ANZ                       126   146 970
   013   TOS M                 ARCH OTOLARYNGOL               103   407 977
   014   TOS M                 ARCH OTO RHINO LARYNGOL        215   101 977
   015   TOS M                 INT RHINOLOGY                   15    87 977
   016   WOOD RE               AM REV RESPIR DIS              113   833 976
CT   1   NAKASHIMA T           ANN OTOL RHINOL LARYNGOL        88   210 979
     2   TABACHNIK NF          SURG GYNECOL OBSTET            152   837 981
     3   STERN RC              AM J DIS CHILD                 136  1067 982
     4   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
     5   BUNNAG C              ANN ALLERGY                     50   126 983
     6   BENDE M               J LARYNGOL OTOL                 99   167 985
     7   DAVID TJ              J ROY SOC MED                   79    23 986
     8   HIRAIDE F             ACTA OTOLARYNGOL STOCKH SUPPL  430     5 986

PN 77103
RN 00684 
AN 77120676
AU Cohen-L-F.  di-SantAgnese-P-A.  Taylor-A.  Gill-J-R-Jr.
TI The syndrome of inappropriate antidiuretic hormone secretion as a
   cause of hyponatremia in cystic fibrosis.
SO J-Pediatr. 1977 Apr. 90(4). P 574-8.
MJ CYSTIC-FIBROSIS: me.  HYPONATREMIA: et.  VASOPRESSINS: se.
MN ADULT.  CASE-REPORT.  CYSTIC-FIBROSIS: co.  FEMALE.  HUMAN.  MALE.
AB The syndrome of inappropriate secretion of antidiuretic hormone was
   observed in two patients with cystic fibrosis during acute
   exacerbation of chronic pulmonary disease. It was diagnosed by the
   accepted clinical and laboratory criteria and confirmed in one case
   by values for immunoreactive vasopressin that were inappropriately
   high for plasma osmolality. The severe hyponatremia was corrected by
   fluid restriction, alone or combined with intravenous treatment with
   diuretic and hypertonic saline solution. In addition, there was
   simultaneous therapy of the pulmonary disease. SIADH thus must be
   added to salt loss as a cause of hyponatremia in CF, and may be more
   common than realized in patients with CF and severe pulmonary
   disease.
RF 001   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   002   SCHWARTZ WB           AM J MED                        23   529 957
   003   BARTTER FC            AM J MED                        42   790 967
   004   KLENK EL              IN: WINTERS RW                       415 973
   005   ROBERTSON GL          J CLIN INVEST                   52  2340 973
   006   MILLER M              ANN INTERN MED                  77   715 972
   007   MOR J                 AM J DIS CHILD                 129   133 975
   008   BARTTER FC            DISEASE A MONTH                          973
   009   TAUSSIG LM            J PEDIATR                       82   380 973
   010   HABER E               J CLIN ENDOCRINOL METAB         29   134 969
   011   ITO T                 J CLIN ENDOCRINOL METAB         34   106 972
   012   ROLLINS DE            CLIN RES                        24  238A 976
   013   DEWARDNER HE          KIDNEY                                53 967
   014   DERUBERTIS FR         AM J MED                        51    41 971
   015   MILLER M              J CLIN ENDOCRINOL METAB         34   537 972
   016   ROBERTSON GL          ANNU REV MED                    25   315 974
   017   STROBER W             PEDIATRICS                      43   416 969
   018   DI SANTAGNESE PA      ANN NY ACAD SCI                 93   555 962
   019   TAUSSIG LM            J INVEST DERMATOL               60   197 973
   020   ROBSON AM             J PEDIATR                       79    42 971
   021   BOWER BF              N ENGL J MED                   271   934 964
   022   GOLDRING RM           J PEDIATR                       65   501 964
   023   SIASSI B              J PEDIATR                       78   794 971
   024   BENSON H              J CLIN INVEST                   49   791 970
   025   SCHRIER RW            N ENGL J MED                   292    81 975
   026   GOETZ KL              PHYSIOL REV                     55   157 975
   027   HANTMAN D             ANN INTERN MED                  78   870 973
CT   1   SCHIFFER M            J PEDIATR                       91   850 977
     2   POMAREDE R            ARCH FR PEDIATR                 35    75 978
     3   SANTAGNESE PAD        AM J MED                        66   121 979
     4   ZERBE R               ANNU REV MED                    31   315 980
     5   KREMEN AF             MINN MED                        63   385 980
     6   RIVERS RPA            ARCH DIS CHILD                  56   358 981

PN 77104
RN 00685 
AN 77120677
AU Rossman-C.  Dodlovich-J.  Dodlovich-M.  Wilson-W.  Newhouse-M.
TI Cystic fibrosis--related inhibition of mucociliary clearance in vivo
   in man.
SO J-Pediatr. 1977 Apr. 90(4). P 579-84.
MJ CILIA: ph.  CYSTIC-FIBROSIS: pp.  MUCUS: ph.  NASAL-MUCOSA: pp.
MN ADOLESCENCE.  ADULT.  CHILD.  CYSTIC-FIBROSIS: bl.  HUMAN.  IGE.
AB Studies were performed to demonstrate possibly cystic fibrosis-
   related inhibition of mucociliary clearance in man. Topical
   application of normal serum or of CF serum did not inhibit in vivo
   nasal MCC. Induction of local inflammation by topical anti-IgE-
   reduced nasal MCC in CF subjects, but increased MCC in normal
   individuals. Furthermore, nasal MCC was inhibited in normal patients
   by CF serum but not normal serum, applied to the anti-IgE-treated
   nasal mucosa. These observations are consistent with the hypothesis
   that CF serum inhibits MCC in vivo in the inflamed mucosa.
RF 001   SPOCK A               PEDIATR RES                      1   173 967
   002   BOWMAN BH             SCIENCE                        164   325 969
   003   BESLEY GTN            J MED GENET                      6   278 969
   004   CRAWFURD MDA          IN: LAWSON D PROC 5TH INT CF          42 969
   005   WOOD RE               LANCET                           2  1452 973
   006   CHRISTENSEN J         IN: LAWSON D PROC 5TH INT CF          49 969
   007   CHERRY JD             J PEDIATR                       79   937 971
   008   SANCHIS J             N ENGL J MED                   288   651 973
   009   YEATES DB             ARCH DIS CHILD                  51    28 976
   010   THOMSON ML            N ENGL J MED                   289   749 973
   011   WOOD RE               AM REV RESPIR DIS              111   733 975
   012   PROCTOR DF            IN: DAVIES CN                    2    25 967
   013   SANCHIS J             J APPL PHYSIOL                  33   757 972
   014   ISHIZAKA K            J IMMUNOL                      100   554 968
   015   PROCTOR DF            ARCH INTERN MED                131   132 973
   016   ANDERSEN I            ARCH ENVIRON HEALTH             29   290 974
   017   ANDERSEN I            ARCH ENVIRON HEALTH             23   408 971
   018   BANG BG               JOHNS HOPKINS MED J            121    38 967
   019   BOXERBAUM B           AM REV RESPIR DIS              108   777 973
   020   DANES BS              J EXP MED                      136  1313 972
   021   DANES BS              LANCET                           2   765 973
   022   MANGOS JA             PEDIATR RES                      1   436 967
   023   MANGOS JA             SCIENCE                        158   135 967
   024   SPOCK A               POSTGRAD MED J                  50    92 971
   025   BOWMAN BH             SCIENCE                        167   871 970
   026   BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      64  1310 975
   027   DANES BS              J EXP MED                      137  1538 973
   028   WALLWORK JC           CLIN EXP IMMUNOL                18   303 974
   029   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   030   WANNER A              CHEST                           61   287 972
CT   1   GOTZ M                EUR J PEDIATR                  127   133 978
     2   AFZELIUS BA           INT REV EXP PATHOL              19     1 979
     3   PAVIA D               CLIN RESP PHYSIOL               16   335 980
     4   ROSSMAN CM            AM REV RESPIR DIS              121  1011 980
     5   RUTLAND J             THORAX                          36   654 981
     6   BERGAN T              SCAND J INFECT DIS            1981     7 981
     7   NEWHOUSE MT           EUR J RESPIR DIS                64   151 983
     8   ROSSMAN CM            EUR J RESPIR DIS                64    64 983
     9   RUTLAND J             AM REV RESPIR DIS              128  1030 983
    10   ROSSMAN CM            AM REV RESPIR DIS              129   161 984
    11   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
    12   TODISCO T             EUR J RESPIR DIS                66   136 985
    13   KOHLER D              ATEMWEGS LUNGENKRANKH           12   358 986
    14   MATTHYS H             EUR J RESPIR DIS                69   311 986

PN 77105
RN 00686 
AN 77209374
AU Vogelstein-B.  Kowarski-A.  Lietman-P-S.
TI The pharmacokinetics of amikacin in children.
SO J-Pediatr. 1977 Aug. 91(2). P 333-9.
MJ AMIKACIN: bl.  KANAMYCIN: aa.  METABOLIC-CLEARANCE-RATE.
MN ADNEXITIS: bl.  ADOLESCENCE.  AMIKACIN: ad.  ANEMIA-APLASTIC: bl.
   APPENDICITIS: bl.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: bl.
   FEMALE.  HALF-LIFE.  HUMAN.  KIDNEY: me.  LEUKEMIA: bl.  MALE.
   NEOPLASMS: bl.  NEUTROPENIA: bl.  SUPPORT-U-S-GOVT-P-H-S.
AB The pharmacokinetic variables of amikacin were measured in 20
   children  and adolescents, four to 16 years of age.  The mean
   plasma clearance of amikacin was 120 ml/minute/1.73 m2.  The major
   route of elimination was renal (82%).  Simultaneously measured
   inulin clearance showed that a majority (64%) of the drug filtered
   by the kidneys was excreted in the urine.  The mean volume of
   distribution of amikacin was 32% of body weight; half-life during
   the final (pseudoequilibrium) phase averaged 1.6 hours.  No
   significant accumulation of the drug was seen when four doses were
   given intravenously at 420 mg/m2 every 8 hours; the plasma
   concentration just before injection of the fourth dose averaged 2.4
   plus or minus 1.1 microgram/ml.  The mean plasma concentration at 60
   to 75 minutes after injection of the drug was 28.7 microg/ml with
   little interpatient variation (SD 3.5 microg/ml).  When the dose was
   expressed in terms of milligrams per kilogram, it was found that
   children often needed 50 to 100% more of the drug, compared to
   adults, to achieve equivalent plasma concentrations; this larger
   requirement was primarily due to a higher clearance of amikacin in
   proportion to body weight.  Dosages based on surface area, however,
   resulted in uniform requirements and predictable plasma
   concentrations in all patients studied.
RF 001   WOLF SM               N ENGL J MED                   291   733 974
   003   UMEZAWA A             J ANTIBIOT (TOKYO)              24   274 971
   004   SMITH CR              N ENGL J MED                   296   349 977
   005   SHARP PM              ANTIMICROB AGENTS CHEMOTHER      5   435 974
   006   TALLY FP              ANN INTERN MED                  83   484 975
   007   MEYER RD              ANN INTERN MED                  83   790 975
   008   VALDIVIESCO M         AM J MED SCI                   270   453 975
   009   PRICE KE              ANTIMICROB AGENTS CHEMOTHER      5   143 974
   010   RIES K                ANTIMICROB AGENTS CHEMOTHER      3   552 973
   011   HOLMES SW             PROC ICAAC 12TH                        7 972
   012   PRICE KE              J ANTIBIOT (TOKYO)              25   709 972
   013   CLARKE JT             CLIN PHARMACOL THER             15   610 974
   014   CABANA BE             ANTIMICROB AGENTS CHEMOTHER      3   478 973
   015   BODEY GP              ANTIMICROB AGENTS CHEMOTHER      5   508 974
   016   HOWARD JB             ANTIMICROB AGENTS CHEMOTHER      8    86 975
   017   SIBER GR              J INFECT DIS                   132   637 975
   018   NUNNERY AW            J INFECT DIS                   119   402 969
   019   NAGASHIMA R           J PHARM SCI                     57  1888 968
   020   GIBALDI M             J PHARM SCI                     58   193 969
   021   KOWARSKI A            J CLIN ENDOCRINOL METAB         32   356 971
   023   SMITH HW              PRINCIPLES OF RENAL PHYSIOLOG        196 956
   024   COLE BR               N ENGL J MED                   287  1109 972
   025   HAAS MJ               ANTIMICROB AGENTS CHEMOTHER      4   497 973
   026   BOJENSEN E            ACTA MED SCAND SUPPL 266             275 952
   027   DEAN RFA              J PHYSIOL (LOND)               109    81 947
   028   AGUSTA VE             J UROL                         110   113 973
   029   GOMBOS EA             ANTIMICROB AGENTS CHEMOTHER      4   373 964
   030   PRESTON FW            ANTIBIOT ANN                     7   857 960
   031   WYAN JB               ARCH SURG                       98   381 969
   032   GRYSELYNCK AM         J INFECT DIS SUPPL             124    70 971
   033   JUSKO WJ              J PHARM SCI                     61  1270 972
   034   LAUGHMAN PM           J PEDIATR                       88   869 976
   035   SCHMIDT-NIELSEN K     FED PROC                        29  1524 970
   036   SHIRKEY HC            IN: SHIRKEY HC                        22 975
CT   1   MCCRACKEN GH          J PEDIATR                       91   358 977
     2   RODIERE M             NOUV PRESSE MED                  8  3479 979
     3   KOWARSKI CR           DRUG INTEL CLIN PHARM           13   782 979
     4   KOWARSKI CR           DRUG INTEL CLIN PHARM           13   409 979
     5   CLEARY TG             ANTIMICROB AGENTS CHEMOTHER     16   829 979
     6   KRAMER WG             CLIN PHARMACOL THER             26   635 979
     7   KAFETZIS DA           ACTA PAEDIATR SCAND             68   419 979
     8   FINKELSTEIN E         J PEDIATR                       94   163 979
     9   CHRYMKO M             AM J HOSP PHARM                 37   713 980
    10   LANAO JM              KIDNEY INT                      20   115 981
    11   KAUFFMAN RE           PEDIATR CLIN NORTH AM           28    35 981
    12   PIEN FD               AM J HOSP PHARM                 38   981 981
    13   PHILIPS JB            SEM PERINATOL                    6   166 982
    14   LEVY J                J ANTIMICROB CHEMOTHER          10   227 982
    15   LANAO JM              EUR J CLIN PHARMACOL            23   155 982
    16   MEISTAS MT            DIABETES                        31   449 982
    17   KELLY HB              J PEDIATR                      100   318 982
    18   KUMOR KM              DEVELOP PHARM THER               7   368 984
    19   NAHATA MC             DEVELOP PHARM THER               7   221 984
    20   KELLY HW              DRUG INTEL CLIN PHARM           18   772 984
    21   SCHOFIELD DH          DRUG INTEL CLIN PHARM           18   153 984
    22   LEEDER JS             CLIN PHARMACOL THER             36   355 984
    23   COLANGELO PM          AM J HOSP PHARM                 41  2650 984
    24   MISCHLER EH           SEM RESPIR MED                   6   271 985
    25   HORREVORTS AM         CHEST                           88   260 985
    26   HALL JW               INT J PEDIATR OTORHINOLARYNGO   12   187 986
    27   AUTRET E              EUR J CLIN PHARMACOL            31    79 986
    28   KEARNS GL             J PEDIATR                      108   847 986
    29   HORNER GW             DRUG INTEL CLIN PHARM           21   276 987

PN 77106
RN 00687 
AN 77209359
AU Herrod-H-G.  Spock-A.
TI Mother and daughter with cystic fibrosis.
SO J-Pediatr. 1977 Aug. 91(2). P 276-7.
MJ CYSTIC-FIBROSIS: fg.
MN ADULT.  CASE-REPORT.  CHLORIDES: an.  CYSTIC-FIBROSIS: di.  FEMALE.
   FOLLOW-UP-STUDIES.  HUMAN.  INFANT.  INFANT-NEWBORN.  PREGNANCY.
   RESPIRATORY-FUNCTION-TESTS.  SWEAT: an.
EX With improved therapy and recognition of patients with mild disease,
   an increasing number of children with cystic fibrosis are reaching
   the reproductive years.  Although virtually all males with cystic
   fibrosis are sterile, an unknown percentage of females with cystic
   fibrosis will be fertile.  We know of only one case in which a
   mother with cystic fibrosis produced a child with the same disease.
   The purpose of this communication is to report the birth of a child
   with cystic fibrosis whose mother also has the disease.
RF 001   TAUSSIG LM            N ENGL J MED                   287   586 972
   002   HILLMAN B             GAP CONF REP PROB REPRO PHYSI          2 975
   003   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   004   CROZIER DN            PEDIATR CLIN NORTH AM           21   935 974
   005   SIEGEL B              OBSTET GYNECOL                  16   438 960
   006   GRAND RJ              JAMA                           195   993 966
   007   LARSEN JW             OBSTET GYNECOL                  39   880 972
   008   BOYLE IR              J PEDIATR                       88   318 976
CT   1   OPITZ JM              POSTGRAD MED                    66   129 979
     2   SANTAGNESE PAD        AM J MED                        66   121 979
     3   WOOD RE               SOUTH MED J                     72   189 979
     4   HERROD HG             J PEDIATR                       94   676 979
     5   COHEN LF              LANCET                           2   842 980
     6   JACOBS WH             AM J GASTROENTEROL              76   342 981
     7   LIMACHER F            SCHWEIZ MED WOCHENSCHR         112   264 982
     8   JOHNSON SR            OBSTET GYNECOL                  61  S  2 983
     9   PALMER J              ANN INTERN MED                  99   596 983

PN 77107
RN 00688 
AN 77073636
AU Nouisa-Arvanitakis-S.  Stapleton-F-B.  Linshaw-M-A.  Kennedy-J.
TI Therapeutic approach to pancreatic extract-induced hyperuricosuria
   in cystic fibrosis.
SO J-Pediatr. 1977 Feb. 90(2). P 302-5.
MJ CYSTIC-FIBROSIS: th.  PANCREATIC-EXTRACTS: tu.  URIC-ACID: ur.
MN BODY-WEIGHT.  CHILD.  CYSTIC-FIBROSIS: dt.  DIET-THERAPY.
   DIETARY-CARBOHYDRATES.  DIETARY-FATS.  DIETARY-PROTEINS.
   DOSE-RESPONSE-RELATIONSHIP-DRUG.  HUMAN.  KIDNEY-DISEASES: ci.
   NUTRITIONAL-REQUIREMENTS.  TRIGLYCERIDES: tu.
AB The relationship between the dosage of pancreatic extract and the
   excretion of uric acid was investigated in 29 patients with cystic
   fibrosis and exocrine pancreatic insufficiency. Urinary excretion of
   uric acid was normal in patients receiving small doses of pancreatic
   extracts and abnormally high in those receiving large amounts. In the
   latter group, normouricosuria was achieved by reducing the dose of
   pancreatic extract. Normal stool patterns and adequate weight gains
   were preserved by a diet modification that was well accepted by the
   patients. To eliminate the potential renal consequences of
   hyperuricosuria, it seems appropriate to control the need for
   increasing amounts of pancreatic enzymes by limiting the dietary
   intake of fat and maintaining a positive caloric and nitrogen balance
   with high intake of protein and carbohydrates and supplementation
   with medium-chain triglycerides.
RF 001   LITTMAN A             N ENGL J MED                   281   201 969
   002   SHWACHMAN H           IN: SHIRKEY HC                       651 975
   003   HARRIS R              ARCH DIS CHILD                  30   424 955
   004   STAPLETON FB          N ENGL J MED                   295   246 976
   005   EMMERSON B            KIDNEY INT                       8    65 975
   006   TAUSSIG LM            J PEDIATR                       82   380 973
   007   HENRY RJ              CLINICAL CHEMISTRY PRINCIPLES        283 964
   008   SEEGMILLER JE         IN: COHEN AS                         216 967
   009   MICHENER WM           AM J DIS CHILD                 113   195 967
   010   GUTMAN AB             TRANS ASSOC AM PHYSICIANS       74   353 961
   011   HOLMES EW             KIDNEY INT                       2   115 972
   012   ROBSON AM             J PEDIATR                       79    42 971
   013   FAREBROTHER DA        CLIN NEPHROL                     4   243 975
   014   SPENCER HW            KIDNEY INT                       9   489 976
   015   GRACEY M              ARCH DIS CHILD                  45   445 970
CT   1   GAHL WA               N ENGL J MED                   297  1349 977
     2   GAHL WA               N ENGL J MED                   297  1349 977
     3   DAVIDSON GP           J PEDIATR                       93   976 978
     4   SANTAGNESE PAD        AM J MED                        66   121 979
     5   GAHL WA               J PEDIATR                       95   330 979
     6   SACK J                ISR J MED SCI                   16   417 980
     7   NIESSEN KH            MONATSSCHR KINDERHEILKD        128   301 980
     8   JACOBS WH             AM J GASTROENTEROL              76   342 981
     9   PARK RW               GASTROENTEROLOGY                81  1143 981
    10   NASSIF EG             J PEDIATR                       98   320 981
    11   NIESSEN KH            J PEDIATR GASTROENTEROL NUTR     1   349 982
    12   HUBBARD VS            J AM DIET ASSOC                 80   127 982
    13   SORKIN EM             DRUG INTEL CLIN PHARM           17   110 983
    14   NIESSEN KH            EUR J PEDIATR                  141    23 983
    15   LANKISCH PG           CLIN GASTROENTEROL              13   985 984
    16   PERRY RS              CLIN PHARMACY                    4   161 985
    17   ZENTLERMUNRO PL       GUT                             26   892 985
    18   RUSH PJ               SEM ARTHRITIS RHEUM             15   213 986
    19   PHILLIPS BM           J ROY SOC MED                   79    44 986

PN 77108
RN 00689 
AN 78007533
AU Lyrene-R-K.  Polhill-R-B-Jr.  Guthrie-L-A.  Tiller-R-E.
TI Alternative complement pathway activity in cystic fibrosis [letter].
SO J-Pediatr. 1977 Oct. 91(4). P 681-2.
MJ COMPLEMENT: me.  CYSTIC-FIBROSIS: im.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: bl.
   FEMALE.  HUMAN.  MALE.  SUPPORT-U-S-GOVT-P-H-S.
EX The possibility has been raised that complement plays a role in the
   pathogenesis of cystic fibrosis (CF).  This impairment would be
   consistent with the thesis that the alternative pathway had been
   activated in vivo and, therefore, depleted.  The purpose of this work
   is to explore further the function of the alternative pathway in
   cystic fibrosis.  Examination of the data using Student's t test and
   analysis of variance showed no significant difference in the mean
   hemolytic activity of sera of CF patients as compared to the control
   group.  The data presented do not support the work of Polley and
   Bearn who demonstrated an abnormality in CF patients using conversion
   of C3 by inulin as assay.  The reason for this discrepancy is not
   clear.  Our results do not preclude in vivo activation of the
   alternative pathway, since a compensatory increase in synthesis of
   components could offset component consumption.  Since the net result
   is a completely normal level of activity, however, it does not seem
   likely that significant consumption has occurred.
RF 001   ANON                  J PEDIATR                       88   711 976
   002   HOLZHAUER RJ          PEDIATR RES                     10   365 976
   003   HANN S                LANCET                           2   520 974
   004   POLLEY MJ             J MED GENET                     11   249 974
   006   SCHREIBER RD          J EXP MED                      144  1062 976
CT   1   BUESCHER ES           J PEDIATR                       93   530 978
     2   STRAUSS RG            HELV PAEDIATR ACTA              34   429 979
     3   HODSON ME             THORAX                          35   801 980
     4   MOSS RB               AM REV RESPIR DIS              121    23 980
     5   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
     6   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
     7   WISNIESKI JJ          AM REV RESPIR DIS              132   770 985

PN 77109
RN 00690 
AN 78047782
AU Rosenstein-B-J.  Oppenheimer-E-H.
TI Prolonged obstructive jaundice and giant cell hepatitis in an infant
   with cystic fibrosis [letter].
SO J-Pediatr. 1977 Dec. 91(6). P 1022-3.
MJ CYSTIC-FIBROSIS: co.  HEPATITIS: co.  CHOLESTASIS: et.
MN AUTOPSY.  CASE-REPORT.  CYSTIC-FIBROSIS: pa.  HEPATITIS: pa.  HUMAN.
   INFANT.  CHOLESTASIS: pa.  MALE.
EX Histologic evidence of liver involvement, consisting of focal biliary
   cirrhosis and/or intrahepatic mucus, is a frequent autopsy finding in
   infants with cystic fibrosis (CF).  We wish to report an infant with
   CF in which liver biopsy showed features typical of neonatal giant
   cell hepatitis.  In our patient, none of the pathologic features
   usually described in CF were present in either of the biopsies.
   Rather, the changes were those described in neonatal hepatitis and,
   to our knowledge, have not been reported in association with CF.  It
   is likely that the giant cell hepatitis was a coincidental finding,
   unrelated to CF.  It emphasizes, however, that one cannot assume a
   uniform etiology for all instances of obstructive jaundice seen in
   infants with CF.
RF 001   OPPENHEIMER EH        J PEDIATR                       86   683 975
   002   VALMAN HB             ARCH DIS CHILD                  46   805 971
   003   OPPENHEIMER EH        LANCET                           2  1031 973
CT   1   SCHWARZ HP            HELV PAEDIATR ACTA              33   351 978
     2   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
     3   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982

PN 77110
RN 00691 
AN 77167592
AU Lungren-D-W.  Hankins-J-M.  Ulane-M-M.  Willison-J-W.
TI Putrescine uptake in cystic fibrosis fibroblasts [letter].
SO J-Pediatr. 1977 Jun. 90(6). P 1034-5.
MJ CYSTIC-FIBROSIS: me.  FIBROBLASTS: me.  PUTRESCINE: me.
MN CELL-LINE.  CELLS-CULTURED.  CYSTIC-FIBROSIS: pa.  HUMAN.
   KINETICS.
EX Our laboratory has reported abnormal polyamine levels in extracted
   whole blood from individuals with cystic fibrosis (CF).  Since an
   abnormality in putrescine uptake in CF fibroblasts would imply a
   direct relationship to the genetic lesion, we initiated studies to
   confirm and possible extend this observation.  There is no
   significant increase in the Vmax of CF fibroblasts as compared to
   values obtained for control cells.  We conclude that with our growth
   and assay conditions, in which we attempted to duplicate those
   described in the original investigation, there is no consistent or
   significant increase in the Vmax of putrescine uptake in CF
   fibroblasts.
RF 001   DEBUSK AG             PROC INT CF CONG 7TH                  12 976
   002   DEBUSK AG             GAP CONF REP POLYAMINES               13 976
   003   LUNDGREN DW           CLIN CHIM ACTA                  62   357 975
   004   COHEN LF              BLOOD                           48   469 976
   005   FARRELL PM            PROC SOC EXP BIOL MED          149   340 975
CT   1   GAHL WA               IN VITRO                        15   252 979

PN 77111
RN 00692 
AN 77073645
AU Heffer-E-T.
TI Cystic fibrosis in black children.
SO J-Pediatr. 1977 Feb. 90(2). P 324-5.
MJ BLACKS.  CYSTIC-FIBROSIS: oc.
MN HUMAN.  MALE.  NEW-YORK-CITY.
EX We feel that cystic fibrosis in the black population occurs more
   frequently than 1/17,000 as reported by Kulcycki and Schauf.  Our
   experience with black patients does not indicate that their course
   and prognosis is different from that in the white population with
   cystic fibrosis.
RF 001   STERN RC              J PEDIATR                       89   412 976
   002   KULCZYCKI LL          CLIN PEDIATR                     3   692 964
   003   KULCZYCKI LL          AM J DIS CHILD                 127    64 974
CT   1   KULCZYCKI LL          J PEDIATR                       92   855 978
     2   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     3   KARJOO M              J TROP PEDIATR                  30   195 984

PN 77112
RN 00693 
AN 77073637
AU Finberg-L.
TI Pancreatic extracts in the management of cystic fibrosis.
SO J-Pediatr. 1977 Feb. 90(2). P 306.
MJ CYSTIC-FIBROSIS: dt.  PANCREATIC-EXTRACTS: ad.
MN HUMAN.  KIDNEY-DISEASES: ci.  PANCREATIC-EXTRACTS: ae.
   URIC-ACID: ur.
EX The University of Kansas group have established that pancreatic
   extracts, in the doses currently used in the management of patients
   with cystic fibrosis, cause hyperuricosuria which may occasionally be
   symptomatic.  They correctly worry about long-term ill effects of
   such therapy.  In treated CF patients the uricosuria results
   primarily from the increased dietary purine load, though the abnormal
   transport physiology in CF may contribute.  Even though final
   evidence on risk is not at hand, prudence would suggest holding the
   purine load in CF patients to the minimum needed to ensure digestion
   of sufficient foodstuffs without necessarily permitting a "normal"
   diet sans steatorrhea.  Alternatively, purified enzyme preparations
   free of the remaining sweetbread could eliminate the excess nucleic
   acid intake and be administered in a dosage permitting the luxury of
   redundant safety.
RF 001   STAPLETON FB          N ENGL J MED                   295   246 976

PN 77113
RN 00694 
AN 78007587
AU Schiffer-M.  Lynch-R.
TI Inappropriate secretion of ADH as a cause of hyponatremia in cystic
   fibrosis [letter].
SO J-Pediatr. 1977 Nov. 91(5). P 850-1.
MJ CYSTIC-FIBROSIS: co.  HYPONATREMIA: et.  VASOPRESSINS: se.
MN BLOOD-VOLUME.  BODY-WEIGHT.  HUMAN.  HYPONATREMIA: pp.
EX After reading "The syndrome of inappropriate antidiuretic hormone
   [ADH] secretion [SIADH] as a cause of hyponatremia in cystic fibrosis
   [CF]," we are puzzled by certain unusual phenomena in the two cases
   presented.  We agree that it would be important to recognize the
   occurrence of ADH mediated hyponatremia in CF.  We would, though,
   appreciate the authors' comments on the weight losses and the fluid
   and electrolyte balances early in these patients's courses.  Also
   helpful would be information on furosemide dosage and any other
   drugs, such as acetaminophen, which may have been given so we can
   further understand the pathophysiology of these two complex patients.
   - We do not think there was hypovolemia in either case.  Patient 1
   was given only one dose of 600 mg of acetaminophen on the fourth day
   of hospitalization during recovery.  Patient 2 received only one dose
   of acetaminophen (650 mg) at 2 AM on the twenty-first day of
   admission after recovery.  Both patients were receiving antibiotics
   and Patient 2 was receiving digitalis as well.  The reason for
   production of ADH remains obscure as it is in most cases of SIADH,
   although it was mentioned in the discussion that the transient nature
   of SIADH in these patients with cystic fibrosis would argue against
   the production of this hormone in the lung.
RF 001   COHEN LF              J PEDIATR                       90   574 977
   002   NOLPH KD              AM J MED                        49   534 970
   003   STROBER W             PEDIATRICS                      43   416 969
   004   NUSYNOWITZ ML         AM J MED SCI                   252   429 966
CT   1   ZERBE R               ANNU REV MED                    31   315 980

PN 77114
RN 00695 
AN 77167531
AU Lippe-B-M.  Sperling-M-A.  Dooley-R-R.
TI Pancreatic alpha and beta cell functions in cystic fibrosis.
SO J-Pediatr. 1977 May. 90(5). P 751-5.
MJ CYSTIC-FIBROSIS: pp.  ISLANDS-OF-LANGERHANS: pp.
MN ADOLESCENCE.  ADULT.  ARGININE: du.  CHILD.  CYSTIC-FIBROSIS: co.
   FEMALE.  GLUCAGON: se.  GLUCOSE-TOLERANCE-TEST.  HUMAN.  INSULIN: se.
   MALE.  PREDIABETIC-STATE: co.  SUPPORT-U-S-GOVT-P-H-S.
AB Insulin and glucagon secretions were studied during oral glucose
   tolerance testing and arginine infusion in 13 patients with cystic
   fibrosis. Two groups of patients were identified; Group I (N=6) whose
   OGTT was entirely normal and Group II (N=7) who had some abnormality
   in glucose during OGTT. In each group basal glucagon concentrations
   were normal and supressed appropriately (p less than 0.05) after
   glucose; insulin responses were attenuated and the peak responses
   delayed. During arginine stimulation, insulin secretion was impaired
   in each group. However, glucagon secretion was diminished only in
   Group II. Thus, insulinopenia was found in both groups and
   hyperglucagonemia was not found as a contributory factor to the
   hyperglycemia in Group II.
RF 001   HANDWERGER S          N ENGL J MED                   281   451 969
   002   ROSAN RC              AM J DIS CHILD                 104   625 962
   003   WILMSHURST EG         PEDIATRICS                      55    75 975
   004   CHAZAN BI             J PEDIATR                       77    86 970
   005   UNGER RH              N ENGL J MED                   285   443 971
   006   MULLER WA             AM J MED                        54    52 973
   007   GERICH JE             N ENGL J MED                   292   985 975
   008   RASKIN P              J CLIN INVEST                   56  1132 975
   009   SHERWIN RS            N ENGL J MED                   294   455 976
   010   LEVINE R              N ENGL J MED                   294   494 976
   011   STAHL M               J PEDIATR                       84   821 974
   012   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   013   MORGAN CR             DIABETES                        12   115 963
   014   SPERLING MA           CLIN CHEM                       20   566 974
   015   SELTZER HS            IN: FAJANS SS                        101 971
   016   SAVAGE PJ             DIABETES                        24   362 975
   017   RUSHFORTH NB          DIABETES                        24   538 975
   018   DRASH A               PEDIATR RES                      2    94 968
   019   PERLEY MJ             J CLIN INVEST                   46  1954 967
   020   PERLEY MJ             DIABETES                        15   867 966
   021   KALK WJ               DIABETES                        23   257 974
   022   KALK WJ               HORM METAB RES                   6    95 974
   023   VINIK AI              LANCET                           1   485 974
   024   ARONOFF SL            DIABETES                        25   404 976
   025   BARNES AJ             LANCET                           1   219 976
CT   1   ROSS SA               DIABETES                        27   501 978
     2   HASCHKE F             HELV PAEDIATR ACTA              33   385 978
     3   NELSON RL             J CLIN ENDOCRINOL METAB         49   412 979
     4   SANTAGNESE PAD        AM J MED                        66   121 979
     5   WOOD RE               SOUTH MED J                     72   189 979
     6   LIPPE BM              PEDIATRICS                      65  1018 980
     7   ADRIAN TE             GASTROENTEROLOGY                79   460 980
     8   ROSS SA               PEDIATRICS                      67   252 981
     9   BERG U                ACTA PAEDIATR SCAND             71   833 982
    10   BISTRITZER T          ISR J MED SCI                   19   600 983
    11   DANDONA P             J CLIN PATHOL                   36   790 983
    12   IANNUCCI A            HUM PATHOL                      15   278 984
    13   GEFFNER ME            PEDIATR RES                     18  1107 984
    14   GEFFNER ME            AM J DIS CHILD                 138   677 984
    15   MOHAN V               DIABETE METAB                   11   376 985
    16   DESANCTIS V           POSTGRAD MED J                  61   963 985
    17   KNOPFLE G             KLIN PAEDIATR                  197    13 985
    18   DAVIS TME             EUR J CLIN INVEST               17    12 987

PN 77115
RN 00696 
AN 77073569
AU Parry-M-F.  Neu-H-C.  Merlino-M.  Gaerlan-P-F.  Ores-C-N.
   Denning-C-R.
TI Treatment of pulmonary infections in patients with cystic fibrosis:
   a comparative study of ticarcillin and gentamicin.
SO J-Pediatr. 1977 Jan. 90(1). P 144-8.
MJ CYSTIC-FIBROSIS: co.  GENTAMICINS: tu.  PENICILLINS: tu.
   PNEUMONIA: dt.  PSEUDOMONAS-INFECTIONS: dt.  TICARCILLIN: tu.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CLINICAL-TRIALS.
   COMPARATIVE-STUDY.  FEMALE.  GENTAMICINS: ae.  HUMAN.  MALE.
   PNEUMONIA: co.  PSEUDOMONAS-AERUGINOSA: de.
   PSEUDOMONAS-INFECTIONS: co.  TICARCILLIN: ae.
AB The effectiveness of ticarcillin against Pseudomonas aeruginosa in
   acute exacerbations of pulmonary infection in patients with cystic
   fibrosis was evaluated. Seventy-one percent of patients treated with
   ticarcillin alone responded favorably. The response rate was similar
   in patients treated with a combination of ticarcillin plus gentamicin
   or with gentamicin alone. Severity of the underlying disease was the
   most important determinant of response to treatment. Ticarcillin-
   resistant organisms were recovered during treatment in 50% of
   patients who received this drug; recovery of them was not prevented
   by the inclusion of gentamicin in the therapeutic regimen nor did
   they interfere with clinical improvement. The ticarcillin-resistant
   strains persisted at follow-up, two to six months after completion of
   therapy, in only one of ten patients. No serious toxicity to
   ticarcillin was noted during the study period.
RF 001   MEARNS MB             ARCH DIS CHILD                  47   902 972
   002   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   003   MAY JR                ARCH DIS CHILD                  47   908 972
   004   ACRED P               NATURE                         215    25 967
   005   HUANG NN              J PEDIATR                       78   338 971
   006   PHAIR JP              AM J DIS CHILD                 120    22 970
   007   MARKS MI              J PEDIATR                       79   822 971
   008   BOXERBAUM B           J INFECT DIS SUPPL             122    59 970
   009   SWARZ H               ADV MANAG PSEUDOMON PROT INF          27 970
   010   NEU HC                ANTIMICROB AGENTS CHEMOTHER     10   385 970
   011   HUGH R                IN: BLAIR JE                         175 970
   012   EDWARDS PR            IDENTIFICATION OF ENTEROBACTE            972
   013   BAUER AW              AM J CLIN PATHOL                45   493 966
   014   NEU HC                APPL MICROBIOL                  21    66 971
   015   NEU HC                J GEN MICROBIOL                 58   301 969
   016   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   017   JACK GW               J GEN MICROBIOL                 61    43 970
   018   LOWBURY EJL           LANCET                           2   448 969
CT   1   PETERSON CD           DRUG INTEL CLIN PHARM           11   482 977
     2   PICKERING LK          SOUTH MED J                     70  1215 977
     3   FEDER HM              J PEDIATR                       91   354 977
     4   PARRY MF              AM J MED                        64   961 978
     5   APPEL GB              ANN INTERN MED                  89   528 978
     6   CHOW M                CONN MED                        43    25 979
     7   NEU HC                INFECTION                        8  S 62 980
     8   BROGDEN RN            DRUGS                           20   325 980
     9   MARTIN AJ             ARCH DIS CHILD                  55   604 980
    10   BEAUDRY PH            J PEDIATR                       97   144 980
    11   MARKS MI              J PEDIATR                       98   173 981
    12   HYATT AC              J PEDIATR                       99   307 981
    13   MALMBORG AS           SCAND J INFECT DIS            1981    64 981
    14   LEVY J                J ANTIMICROB CHEMOTHER          10   227 982
    15   SCRIBNER RK           ANTIMICROB AGENTS CHEMOTHER     21   939 982
    16   BROWN LA              J ALLERGY CLIN IMMUNOL          69    51 982
    17   REDDING GJ            AM REV RESPIR DIS              126    31 982
    18   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
    19   BODEY GP              REV INFECT DIS                   5   279 983
    20   MCLAUGHLIN FJ         J ANTIMICROB CHEMOTHER          11   195 983
    21   HOOGKAMPKORSTANJE JAA J ANTIMICROB CHEMOTHER          12   175 983
    22   SHLAES DM             PEDIATR CLIN NORTH AM           30   121 983
    23   PENKETH ARL           BR J DIS CHEST                  77   179 983
    24   MCLAUGHLIN FJ         J INFECT DIS                   147   559 983
    25   ARAVIND MK            J LIQUID CHROMATOGR              7  2887 984
    26   KELLY HW              DRUG INTEL CLIN PHARM           18   772 984
    27   NICHOLS L             CHEMIOTERAPIA                    4   102 985
    28   ACAR JF               REV INFECT DIS                   7  S513 985
    29   LAFERRIERE C          CHEMOTHERAPY                    31   255 985
    30   JACOBS RF             J PEDIATR                      106  1001 985
    31   NELSON JD             J PEDIATR                      106  1030 985
    32   WILSON CB             J PEDIATR                      106  1049 985
    33   TABLAN OC             J PEDIATR                      107   382 985
    34   SCHAAD UB             ACTA PAEDIATR SCAND             75   128 986
    35   PITT TL               J ROY SOC MED                   79    13 986
    36   SMITH AL              J PEDIATR                      108   866 986
    37   CHANDRASEKAR PH       J ANTIMICROB CHEMOTHER          19   321 987

PN 77116
RN 00697 
AN 77251783
AU Desai-N.  Nousia-Arvanitakis-S.
TI False negative meconium test results in screening for cystic
   fibrosis.
SO J-Pediatr. 1977 Sep. 91(3). P 447-8.
MJ CYSTIC-FIBROSIS: di.  MASS-SCREENING: st.  MECONIUM.
MN CASE-REPORT.  FALSE-NEGATIVE-REACTIONS.  HUMAN.  INFANT.
   INFANT-NEWBORN.  MALE.  MECONIUM: me.  PANCREAS: en.  PROTEINS: me.
EX The value of the Boehringer-Mannheim (B-M) meconium test for routine
   screening for cystic fibrosis has been questioned recently because
   of the high proportion of false negative results.  This report
   presents our observations on the validity of the B-M meconium test.
   Our findings show that the B-M meconium test may contribute to false
   negative results even when the exocrine pancreatic function of a
   newborn infant with CF is abnormal.  Our observation supports the
   doubts expressed recently in regard to the validity of the B-M
   meconium test in screening neonates for cystic fibrosis.
RF 001   ANON                  J PEDIATR                       88   711 976
   002   IMONDI AR             ANAL BIOCHEM                    54   199 973
   003   PROSSER R             ARCH DIS CHILD                  49   597 974
   004   ROY CC                PEDIATR CLIN GASTROENTEROL               975
CT   1   ARVANITAKIS C         GASTROENTEROLOGY                74   932 978
     2   UXA F                 MINERVA PEDIATR                 31   831 979
     3   BARRY MM              J AM DIET ASSOC                 75   446 979
     4   PARK RW               GASTROENTEROLOGY                81  1143 981
     5   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982

PN 77117
RN 00698 
AN 78068479
AU Schuster-S-R.  Fellows-K-E.
TI Management of major hemoptysis in patients with cystic fibrosis.
SO J-Pediatr-Surg. 1977 Dec. 12(6). P 889-96.
MJ CYSTIC-FIBROSIS: co.  EMBOLIZATION-THERAPEUTIC.  HEMOPTYSIS: th.
MN ADOLESCENCE.  ADULT.  BRONCHIAL-ARTERIES: ra, su.  CHILD.
   CYSTIC-FIBROSIS: ra.  FEMALE.  GELATIN-SPONGE-ABSORBABLE: tu.
   HEMOPTYSIS: di, et.  HEMORRHAGE: di.  HUMAN.  MALE.
AB Although bronchoscopy remains the best definitive method for
   localization of the site of hemorrhage in patients who have massive
   hemopytsis, angiography remains an important adjunct to this
   localization. When combined with embolization of the bleeding
   bronchial artery, it is an effective method of therapy for the
   management of massive hemoptysis in patients with cystic fibrosis.
RF 001   HOLSCLAW DS           J PEDIATR                       76   829 970
   002   FELLOWS KE            RADIOLOGY                      114   551 975
   003   NEWTON TH             RADIOLOGY                       84  1043 965
   004   NORTH LB              AM J ROENTG RAD THER NUCL MED  107   328 969
   005   FEIGELSON HH          RADIOLOGY                       85   663 965
   006   LIEBOW AA             AM J PATHOL                     25   211 949
   007   MARCHAND P            THORAX                           5   207 950
   008   WOOD DA               J THORAC SURG                    7   649 938
   009   BOTENGA ASJ           AM J ROENTG RAD THER NUCL MED  104   829 968
   010   WENTWORTH P           THORAX                          23   582 968
   011   LIEBOW AA             YALE J BIOL MED                 22   637 950
   012   ROOSENBURG JG         DIS CHEST                       26   664 954
   013   REMY J                RADIOLOGY                      122    33 977
CT   1   FILSTON HC            J PEDIATR SURG                  14   276 979
     2   FUCHS WA              RADIOLOGE                       19   505 979
     3   MACERLEAN DP          BR J RADIOL                     52   558 979
     4   FELLOWS KE            J PEDIATR                       95   959 979
     5   FAIRFAX AJ            BR J DIS CHEST                  74   345 980
     6   TOM LWC               ANN OTOL RHINOL LARYNGOL        89   419 980
     7   JANIK JS              PEDIATRICS                      67   671 981
     8   TABACHNIK NF          SURG GYNECOL OBSTET            152   837 981
     9   MARMON L              J PEDIATR SURG                  18   811 983
    10   STEINHERZ PG          MED PEDIATR ONCOL               12    28 984
    11   HOFFER FA             PEDIATR CLIN NORTH AM           32  1461 985
    12   TRENTO A              ANN THORAC SURG                 39   254 985
    13   STANKIEWICZ JA        EAR NOSE THROAT J               64   180 985

PN 77118
RN 00699 
AN 77143411
AU McKenzie-S-A.  Godfrey-S.  Singh-M-P.
TI A new method for investigating regional lung function in children
   with localized lung disease.
SO J-Pediatr-Surg. 1977 Apr. 12(2). P 177-81.
MJ LUNG-DISEASES: di.  RESPIRATORY-FUNCTION-TESTS: mt.
MN ASTHMA: di.  BRONCHIECTASIS: di.  CASE-REPORT.  CHILD.
   CYSTIC-FIBROSIS: di.  CYSTS: di.  FOREIGN-BODIES: di.  HUMAN.
   INFANT.  INFANT-NEWBORN.  MALE.  NITROGEN-RADIOISOTOPES: du.
   PNEUMONIA: di.  PULMONARY-EMPHYSEMA: di.
AB Lung function studies using 13Nitrogen have been used to determine
   regional and total lung function in 16 children suspected of having
   localized lung disease amenable to surgery. This method is simple,
   requires no active co-operation on the part of the child and gives a
   radiation dosage of about one-third of that for a bronchogram. The
   studies provided information about the severity and localization of
   the disease, and in addition, information about the remaining lung
   areas.
RF 001   BALL WC JR            J CLIN INVEST                   41   519 962
   002   RONCHETTI R           ARCH DIS CHILD                  50   595 975
CT   1   HENRIKSEN O           J NUCL MED                      21   333 980

PN 77119
RN 00700 
AN 77143415
AU Schuster-S-R.  Shwachman-H.  Toyama-W-M.  Rubino-A.  Taik-Khaw-K.
TI The management of portal hypertension in cystic fibrosis.
SO J-Pediatr-Surg. 1977 Apr. 12(2). P 201-6.
MJ CYSTIC-FIBROSIS: co.  HYPERTENSION-PORTAL: su.
MN CHILD.  CYSTIC-FIBROSIS: mo.  HUMAN.  POSTOPERATIVE-CARE.
   POSTOPERATIVE-COMPLICATIONS: mo.  PREOPERATIVE-CARE.
AB We have found that with proper selection and preoperative
   preparation, a major portosystemic shunt can be done with
   considerable safety in a majority of cystic fibrosis patients and
   thus provide them with significant palliation and improved quality of
   life.
RF 001   SHWACHMAN H           HOSP PRACT                       9   143 974
   002   CLATWORTHY HW         IN: MUSTARD WT                       777 969
   003   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   004   TYSON KRT             J PEDIATR SURG                   3   271 968
   005   TANK ES               ARCH SURG                       98   451 969
   006   RAFFENSBERGER JG      ARCH SURG                      105   249 972
   007   VOORHEES AB           SURGERY                         58   540 965
   008   DANIELSON GK          JAMA                           195   217 966
   009   DI SANTAGNESE PA      PEDIATRICS                      24   313 959
   010   WILLIS SDV            PROC R SOC MED                  53   320 960
   011   TUCKER AS             AM J ROENTG RAD THER NUCL MED   89  1048 963
   012   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   013   OPPENHEIMER EH        J PEDIATR                       86   683 975
   014   WEBSTER R             ARCH DIS CHILD                  28   343 953
   015   SHWACHMAN H           BIRTH DEF ORIG ART SER           8   102 972
CT   1   STARKEY BJ            MONOGR PAEDIATR                 10    12 979
     2   REDMOND AOB           PRACTITIONER                   224   295 980
     3   PSACHAROPOULOS HT     LANCET                           2    78 981
     4   PARK RW               GASTROENTEROLOGY                81  1143 981
     5   TABACHNIK NF          SURG GYNECOL OBSTET            152   837 981
     6   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
     7   MOWAT AP              CLIN GASTROENTEROL              11   171 982
     8   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
     9   RICHARDSON VF         ACTA PAEDIATR SCAND             73    75 984
    10   HUBBARD VS            SEM RESPIR MED                   6   299 985
    11   VALAYER J             WORLD J SURG                     9   258 985
    12   BERNARD O             CLIN GASTROENTEROL              14    33 985
    13   BERNARD O             ARCH FR PEDIATR                 42   249 985
    14   SCHRODER R            SCHWEIZ MED WOCHENSCHR         115   828 985
    15   PRICE JF              J ROY SOC MED                   79    10 986
    16   TANNER MS             J ROY SOC MED                   79    38 986

PN 77120
RN 00701 
AN 77230292
AU Goldberg-R-T.
TI Rehabilitation research on disability: New horizons.
SO J-Rehabil. 1977 Jul-Aug. 43(3). P 14-8.
MJ CYSTIC-FIBROSIS: rh.  FACIAL-INJURIES: rh.  HANDICAPPED.
   LARYNGEAL-NEOPLASMS: rh.  REHABILITATION.  SPINAL-CORD-INJURIES: rh.
MN ADOLESCENCE.  ADULT.  CHILD.  HUMAN.  RESEARCH.  UNITED-STATES.
AB This paper presents an overview of research on disability, and
   integrates rehabilitation research with the mainstream of scientific
   activity.  Research on disability is an applied science which uses
   the general tools of scientific method in solving specific problems.
   Research on disability embraces a wide variety of physical,
   intellectual, and emotional conditions.  The psychological aspects
   of physical disabilities are especially stressed in the adaptation
   to lost functions.  Examples of research are given from spinal cord
   injury, end-stage renal disease, facial disfigurement, and cancer of
   the larynx.
RF 001   BAER JA               OPTICAL TO TACTILE IMAGE CONV            972
   002   BOBO EC               IN: STAUFFER ES                          969
   003   BORS E                UROLOGICAL SURVEY               57   246 960
   004   COLE T                PARAPLEGIA                      11   111 973
   005   CONANT JB             ARCH OTOLARYNGOL                88    80 968
   006   DALRYMPLE GF          DEVELOPMENT AND DEMONSTRATI              973
   007   GOLDBERG RT           J COUNSELING PSYCH              21   428 974
   008   GOLDBERG RT           SCAND J REHAB MED                6    65 974
   009   GOLDBERG RT           REHAB LIT                       35   354 974
   010   GOLDBERG RT           SCAND J REHAB MED                7     1 975
   011   GUTTMANN L            PROC SYMP ROYAL COLL SURG EDI            963
   012   HAMILTON LS           SPINAL CORD INJURY IN FLORIDA            974
   013   HOLZEL A              PHYSIOTHERAPY                   61   238 975
   014   JACKSON RW            PARAPLEGIA                      10    50 972
   015   KRAUS JF              J CHRON DIS                     28   471 975
   016   MOONEY T              SEXUAL OPTIONS FOR PARAPLEGIC            975
   017   PEARMAN JW            PARAPLEGIA                       9    95 971
   018   POPPER KR             LOGIC OF SCIENTIFIC DISCOVERY            959
   019   ROGERS BO             FACIAL DISFIGUREMENT A REHABI            963
   020   SAVELLE M             SEEDS OF LIBERTY THE GENESIS             948
   021   SCHEIN JD             DEAF POPULATION OF THE US                974
   022   SHARMAN GJ            SPINAL CORD INJURY A REPORT T            970
   023   TRUAX CB              COUNSELING AND PSYCHOTHERAPY             966
   024   TSUKERBERG JS         COMP SERV NEEDS STUDY HEW REP            975
   025   WILCOX NE             STATE WIDE CENSUS SPINAL CORD            972

PN 77121
RN 00702 
AN 78090696
AU Hunt-L-A.  Summers-D-F.
TI Glycosylation of VSV glycoprotein is similar in cystic fibrosis,
   heterozygous carrier, and normal human fibroblasts.
SO J-Supramol-Struct. 1977. 7(2). P 213-21.
MJ CYSTIC-FIBROSIS: me.  GLYCOPROTEINS: me.  HEXOSYLTRANSFERASES: me.
MN CELL-LINE.  FIBROBLASTS: me.  HETEROZYGOTE.  HUMAN.
   MEMBRANE-PROTEINS: me.  SUPPORT-U-S-GOVT-P-H-S.
   SUPPORT-U-S-GOVT-NON-P-H-S.  VESICULAR-STOMATITIS-VIRUS: me.
   VIRAL-PROTEINS: me.
AB The single envelope glycoprotein of vesicular stomatitis virus was
   used as a specific probe of glycosyltransferase activities in
   fibroblasts from two cystic fibrosis patients, an obligate
   heterozygous carrier and a normal individual. Gel filtration of
   pronase-digested glycopeptides from both purified virions and
   infected cell-associated VSV glycoprotein which had been labeled
   with[3H] glucosamine did not reveal any significant differences in
   the glycosylation patterns between the different cell cultures. All 4
   cell lines were apparently able to synthesize the mannose- and
   glucosamine- containing core structure and branch chains terminating
   in sialic acid which are characteristic of asparagine-linked
   carbohydrate side chains in cellular glycoproteins. Analysis of
   tryptic glycopeptides by anion-exchange chromotography indicated that
   the same 2 major sites on the virus polypeptide were recognized and
   glycosylated in all 4 VSV-infected cell cultures. These studies
   suggest that the basic biochemical defect(s) in cystic fibrosis is
   not an absence or deficiency in enzymes responsible for the
   biosynthesis of complex carbohydrate side chains.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   002   WOOD RE               AM REV RESPIR DIS              113   833 976
   003   LOUISOT P             CLIN CHIM ACTA                  48   373 973
   004   SINGER L              CLIN BIOCHEM                     7   146 974
   005   BUTTERWORTH J         CLIN CHIM ACTA                  56   159 974
   006   HOWATSON AF           VIROLOGY                        16   466 962
   007   ZEE YC                J GEN VIROL                      7    95 970
   008   WAGNER RR             J VIROL                         10  1228 972
   009   KLENK HD              J VIROL                          7   416 971
   010   ATKINSON PH           J MOL BIOL                     102   613 976
   011   HUNT LA               J VIROL                         20   637 976
   012   HUNT LA               J VIROL                         20   646 976
   013   ETCHISON JR           VIROLOGY                        60   217 974
   014   ETCHISON JR           PROC NAT ACAD SCI USA           71  4011 974
   015   MOYER SA              J VIROL                         18   167 976
   016   ROBERTSON JR          J VIROL                         19   871 976
   017   ETCHISON JR           VIROLOGY                        78   375 977
   018   MUDD JA               VIROLOGY                        42   328 970
   019   GRUBMAN MJ            J VIROL                         12   265 973
   020   BONNER WM             EUR J BIOCHEM                   46    83 974
   021   DRAEMER PM            J CELL PHYSIOL                  69   199 967
   022   SCHLESINGER S         J VIROL                         17   239 976
   023   GOTTLIEB C            J BIOL CHEM                    251  7761 976
   024   SLY WS                PROC NAT ACAD SCI USA           73  2443 976
CT   1   HUNT LA               PROC NAT ACAD SCI USA           75   754 978
     2   HUNT LA               J VIROL                         35   362 980
     3   MARGOLIES R           PEDIATR RES                     16   181 982
     4   MARGOLIES R           PEDIATR RES                     17   931 983

PN 77122
RN 00703 
AN 78049611
AU Luck-S-R.  Raffensperger-J-G.  Sullivan-H-J.  Gibson-L-E.
TI Management of pneumothorax in children with chronic pulmonary
   disease.
SO J-Thorac-Cardiovasc-Surg. 1977 Dec. 74(6). P 834-9.
MJ CYSTIC-FIBROSIS: co.  PNEUMOTHORAX: th.
MN ADOLESCENCE.  ADULT.  CASE-REPORT.  CHILD.  CHILD-PRESCHOOL.
   CHRONIC-DISEASE.  FEMALE.  HISTIOCYTOSIS-X: co.  HUMAN.  INFANT.
   INTUBATION.  LUNG: su.  MALE.  PNEUMOTHORAX: et, ra.  RECURRENCE.
   SCLEROSING-SOLUTIONS: tu.
AB Cystic fibrosis is the most common form of chronic pulmonary disease
   in the pediatric age group.  As these children survive longer with
   improved therapy, the incidence of pneumothorax has increased.  In
   our patients who were more than 10 years of age, the incidence of
   pneumothorax was 12.5 percent.  We have reviewed the records of 22
   patients who have had 44 episodes of pneumothorax complicating
   cystic fibrosis.  In addition, our experience includes one child
   with histiocytosis in whom pneumothorax was a serious complication.
   One other pneumothorax occurred in a teen-age girl with apical
   bullous disease.  A child who presents with even a minimal
   pneumothorax complicating cystic fibrosis is at considerable risk of
   developing an increasing lung collapse.  Even if the pneumothorax
   resolves, there is a high risk of recurrence.  In children treated
   with only a chest tube there was a 50 percent recurrence.
   Consequently, we recommend a chest tube for any episode of
   pneumothorax in a child with cystic fibrosis, with installation of a
   sclerosing agent when the lung expands.  Three of our patients so
   treated had no recurrence.  Children who have a persistent air leak
   are confined to bed, retain secretions, and pursue a rapid downhill
   course.  A more aggressive approach to these children, consisting of
   thoracotomy, suture of the air leak, pteural symphysis, and
   pulmonary lavage is feasible and the mortality rate is low.  A
   pneumothorax in a child with no evidence of cystic fibrosis is a
   rare event.  A persistent air leak is an indication for thoracotomy,
   suture of the air leak, and lung biopsy.  Histiocytosis X is one
   rare cause for this complication in children.
RF 001   STERN RC              J PEDIATR                       89   406 976
   002   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   003   BODROSSIAN CWM        HUM PATHOL                       1   633 968
   004   DI SANTAGNESE PA      JAMA                           172  2065 960
   005   HOLSCLAW DS           CLIN PEDIATR                     9   346 970
   006   SCHWARTZ EE           AM J ROENTG RAD THER NUCL MED  122   708 974
   007   LIFSCHITZ MI          AM J DIS CHILD                 116   633 968
   008   BOAT TF               JAMA                           209  1498 969
   009   STOWE SM              AM REV RESPIR DIS              111   611 975
   010   MITCHELL-HEGGS PF     THORAX                          25   165 970
   011   KATTWINKEL J          JAMA                           226   557 973
   012   WALLACH HW            CHEST                           68   510 975
   013   CUNNINGHAM GJ         THORAX                           5    43 950
   014   HEPPLESTON AG         THORAX                          11    77 956
   015   ROLAND AS             N ENGL J MED                   270    73 964
   016   GELFAND ET            CAN MED ASSOC J                110   937 974
   017   LAHEY ME              J PEDIATR                       87   179 975
   018   LUCAYA J              AM J DIS CHILD                 121   289 971
CT   1   LARRIEU AJ            ANN THORAC SURG                 28   146 979
     2   SANTAGNESE PAD        AM J MED                        66   121 979
     3   DEVRIES WC            SURG CLIN NORTH AM              60   851 980
     4   OFOEGBU RO            AM J SURG                      140   679 980
     5   TABACHNIK NF          SURG GYNECOL OBSTET            152   837 981
     6   PENKETH ARL           THORAX                          37   850 982
     7   MCLAUGHLIN FJ         J PEDIATR                      100   863 982
     8   SCHUSTER SR           J PEDIATR SURG                  18   492 983
     9   SEGERER H             KLIN PAEDIATR                  196    44 984
    10   JENKINSON SG          CLIN CHEST MED                   6   153 985
    11   LESTER LA             SEM RESPIR MED                   6   285 985
    12   TRIBBLE CG            ANN SURG                       204   677 986

PN 77123
RN 00704 
AN 77210123
AU Hassani-M-A.
TI Cystic fibrosis in Iraqi children.
SO J-Trop-Pediatr. 1977 Jun. 23(3). P 136-7.
MJ CYSTIC-FIBROSIS: oc.
MN CHILD-PRESCHOOL.  FEMALE.  HUMAN.  INFANT.  IRAQ.  MALE.
EX Cystic fibrosis (C.F.) was firmly established as a single disease by
   Anderson in 1938 although previously case reports had appeared in
   the European literature.  Subsequently C.F. has been described in
   many parts of the world.  This is the first report of cystic
   fibrosis in Arab-Iraqi children.  Seventeen cases of cystic fibrosis
   were diagnosed at Medical City Teaching College Hospital, University
   of Baghdad, between 1970 and 1976.  In this study the sex-ratio was
   2:1.  This compared with the roughly equal ratio usually quoted.  A
   possible explanation for this discrepancy is the preference given to
   boys in Iraqi families and medical attention is more likely to be
   sought on their behalf.
RF 001   BENGOA JM             WHO CHRONICLE                   28     1 974
   002   HARFOUCHE JK          GROWTH AND ILLNESS PATTERNS O            966
   003   JELLIFFE DB           ASSESSMENT NUTRITIONAL STATUS            966
   004   JELLIFFE DB           WHO CHRONICLE                   21   127 967
   005   MCLAREN DS            LANCET                           2   146 972
   006   MORLEY D              BR MED J                         4    85 974
   007   PUYET JH              AM J CLIN NUTR                  13   147 963
   008   SHAKIR A              LANCET                           2   143 972
   009   WATERLOW JC           BR MED J                         4    88 974
   010   WRAY JD               J TROP PEDIATR                  15    76 969
   011   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   012   DANKS DM              ANN HUM GENET                   28   323 965
   013   FANCONI G             WIEN MED WOCHENSCHR             86   753 936
   014   GIBSON LE             PEDIATRICS                      23   545 954
   015   JOHN O                TEXTBOOK OF PAEDIATRICS             1989 973
   016   MARIA SALEM H         DRISS LEB MED J                 15     1 962
   017   SALAM MZ              ANN PEDIATR (PARIS)            190   252 958
   018   NELSON WE             TEXTBOOK OF PEDIATRICS               850 964
CT   1   KARJOO M              J TROP PEDIATR                  30   195 984

PN 77124
RN 00705 
AN 78029248
AU Warwick-W-J.  Pogue-R-E.
TI Cystic fibrosis.  An expanding challenge for internal medicine.
SO JAMA. 1977 Nov 14. 238(20). P 2159-62.
MJ CYSTIC-FIBROSIS: oc.
MN ADULT.  AGE-FACTORS.  AGED.  CYSTIC-FIBROSIS: mo.  HUMAN.
   LIFE-EXPECTANCY.  MIDDLE-AGE.  MODELS-THEORETICAL.  PROGNOSIS.
   UNITED-STATES.
AB The number of adults with cystic fibrosis (CF) receiving care from
   the US Cystic Fibrosis Centers has been increasing at an average rate
   of about 200 patients each year. A model based on the continuation of
   this rate of increase predicts that almost 4,000 adults will be
   receiving care at the centers by the end of 1985. Four other models
   developed are based on continuation of a steady state with two
   variations: a 50% reduction in mortality and universal newborn
   screening. These models show the boundaries of an equilibrium
   population to be between 24,000 and 64,000 patients, with 7,000 to
   18,000 adults.
RF 001   POGUE RE              MINN MED                        52  1551 969
   002   WARWICK WJ            J CHRON DIS                     28   609 975
   003   WARWICK WJ            J ASTHMA RES                     5   277 968
   004   SHWACHMAN H           PROC INT CF CONG 7TH                  90 976
CT   1   SCHWARZ HP            HELV PAEDIATR ACTA              33   351 978
     2   HOWIE AD              SCOTT MED J                     24   193 979
     3   STRAUSS GD            AM J DIS CHILD                 133   301 979
     4   ALLAN JL              MED J AUST                       1   600 980
     5   HOLSCLAW DS           CLIN CHEST MED                   1   407 980
     6   SANDERS JS            CHEST                           77   226 980
     7   WILLI UV              AM J ROENTGENOL                134  1005 980
     8   BELL L                J CAN DIET ASSOC                42    62 981
     9   JACOBS WH             AM J GASTROENTEROL              76   342 981
    10   MOSS RB               J PEDIATR                       99   215 981
    11   EVENSEN SA            ACTA MED SCAND                 209   141 981
    12   PETTY TL              SEM RESPIR MED                   3   263 982
    13   JOHNSON SR            OBSTET GYNECOL                  61  S  2 983
    14   MACPHERSON AIS        SCOTT MED J                     29     6 984
    15   COWEN L               PSYCHOSOM MED                   46   363 984
    16   COLE BNL              J PARENT ENTERAL NUTR           11   205 987

PN 77125
RN 00706 
AN 78048779
AU Hirao-Y.  Homma-J-Y.  Zierdt-C-H.
TI Serotyping of Pseudomonas aeruginosa from patients with cystic
   fibrosis of the pancreas.
SO Jpn-J-Exp-Med. 1977 Aug. 47(4). P 249-54.
MJ CYSTIC-FIBROSIS: mi.  PSEUDOMONAS-AERUGINOSA: im.
MN AGGLUTINATION-TESTS: mt.  COMPARATIVE-STUDY.  HUMAN.
   SEROTYPING: mt.
AB Serotyping of 30 mucoid strains isolated from cystic fibrosis
   patients was carried out by slide agglutination tests with both live
   and heat-killed cells and by tube agglutination test with heat-killed
   cells. Comparison of the results obtained by these 2 methods revealed
   that tube agglutination with heat-killed cells was the superior
   method. More than half the strains were found to be Homma's serotype
   15 (group M in the new schema [2]). Slide agglutination with live
   cells did not give clear results: some strains showed occasionally
   positive or negative agglutinations against the same serotype serum.
   Changes in serotypes (groups in the new schema [2]) were found in
   some strains, although the number was very small.
RF 001   HOMMA JY              JAPAN J EXP MED                 44     1 974
   002   HOMMA JY              JAPAN J EXP MED                 46   329 976
   003   YABUUCHI E            JAPAN J EXP MED                 46   393 976
   004   ZIERDT CH             J CLIN MICROBIOL                 1   521 975
   005   HOMMA JY              JAPAN J EXP MED                 40   347 970
   006   SHIONOYA H            JAPAN J EXP MED                 47   185 977
   007   KODAMA H              JAPAN J EXP MED                 46   383 976
   008   KONO M                JAPAN J EXP MED                 47     1 977
   009   HOMMA JY              JAPAN J EXP MED                 42   171 972
   010   KAWAHARAJO K          JAPAN J EXP MED                 43   225 973
CT   1   HOMMA JY              JAP J EXP MED                   49    89 979
     2   JAGGER KN             J CLIN MICROBIOL                17    55 983
     3   OGLE JW               J INFECT DIS                   155   119 987

PN 77126
RN 00707 
AN 77145455
AU Emrich-H-M.  Dahlheim-H.
TI Renin-like (angiotensinogenase) activity in sweat of patients with
   cystic fibrosis and controls.
SO Klin-Wochenschr. 1977 Mar 15. 55(6). P 291-2.
MJ CYSTIC-FIBROSIS: en.  RENIN: an.  SWEAT: en.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  HUMAN.
   SWEAT-GLANDS: en.
AB Using bioassay method (rat blood pressure technique) as well as the
   radioimmunoassay, renin-like activity (RLA) was measured in eccrine
   sweat of patients with cystic fibrosis of the pancreas (CF) and of
   controls. Sweat-formation was induced by pilocarpine-iontophoresis or
   by local injection of carbamylcholine (Doryl). RLA-values between O
   (not measurable) and 460 ng/ml.h were measured. With increasing sweat
   flow-rate a tendency to lower RLA-values was detected. No significant
   difference was observed between CF and controls. From the observation
   that RLA of sweat is up to 30 times higher than that of plasma, it is
   concluded that RLA is probably released not from plasma but from the
   sweat glands themselves, where it is stored or synthesized.
RF 001   OCHWADT B             PROC INT CONG NEPHROL STO 4TH            969
   002   STEVEN K              KIDNEY INT                       6    73 974
   003   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   004   EMRICH HM             PEDIATR RES                      2   464 968
   005   LOBECK CC             IN: STANBURY JB                     1300 966
   006   GIBSON LE             PEDIATRICS                      23   545 959
   007   EMRICH HM             PFLUEGERS ARCH                 290   298 966
   008   DAHLHEIM H            PFLUEGERS ARCH                 312   303 970
   009   SCHUCHARD J           VERH DTSCH GES INN MED BD 80             974
   010   OPARIL S              N ENGL J MED                   291   389 974
CT   1   LIAPPIS N             ARCH DERMATOL RES              261   281 978
     2   KAMOUN P              IRCS MED SCI BIOCHEM            11   605 983
     3   QUINTON PM            ANNU REV MED                    34   429 983

PN 77127
RN 00708 
AN 77231257
AU Heinrich-H-C.  Gabbe-E-E.  Bartels-H.  Oppitz-K-H.  Bender-Gotze-C.
   Pfau-A-A.
TI Bioavailability of food iron-(59Fe), vitamin B12-(60Co) and protein
   bound selenomethionine-(75Se) in pancreatic exocrine insufficiency
   due to cystic fibrosis.
SO Klin-Wochenschr. 1977 Jun 15. 55(12). P 595-601.
MJ CYSTIC-FIBROSIS: me.  IRON: me.  SELENIUM: me.  SELENOMETHIONINE: me.
   VITAMIN-B-12: me.
MN BIOLOGICAL-AVAILABILITY.  CHILD.  CHILD-PRESCHOOL.
   COBALT-RADIOISOTOPES.  DIETARY-PROTEINS: me.  FOOD.  HUMAN.
   INTESTINAL-ABSORPTION.  INTRINSIC-FACTOR: pd.  IRON-RADIOISOTOPES.
   LIVER.  MEAT.  PANCREATIN: pd.  PROTEIN-BINDING.  RADIOISOTOPES.
   VITAMIN-B-12-DEFICIENCY: et.  WHOLE-BODY-COUNTING.
AB The absorption of biosynthetically 59Fe-labeled hemiglobin, pork and
   hog liver, 60 Co-vitamin B12 and 75Se-selenomethionin labeled pork
   was measured in children with cystic fibrosis by whole body counting
   of the absorbed radionuclides within the 4-pi geometry of a large
   volume radioactivity detector with liquid organic scintillator.
RF 001   AWWAD HK              J BIOL CHEM                    242   492 967
   002   BEN PORATH M          J NUCL MED                       9   168 968
   003   DEREN JJ              N ENGL J MED                   288   949 973
   004   EVANS WB              AM J DIG DIS                    11   594 966
   005   HEINRICH HC           PROC UNIV NEW MEXICO CONF ORG        312 960
   006   HEINRICH HC           SEMIN HEMATOL                    1   199 964
   007   HEINRICH HC           IN: HALLBERG L                       213 970
   008   HEINRICH HC           PROC WORKSHOP CONF HOECHS 3RD         34 975
   009   HEINRICH HC           KLIN WOCHENSCHR                 55   587 977
   010   HEINRICH HC           ATOMPRAXIX                      10   477 964
   011   HEINRICH HC           EUR J CLIN INVEST                1   321 971
   012   HEINRICH HC           KLIN WOCHENSCHR                 49   819 971
   013   HEINRICH HC           KLIN WOCHENSCHR                 44   827 966
   015   HENDERSON JT          LANCET                           2   241 972
   016   LE BAUER E            ARCH INTERN MED                122   423 968
   017   MCINTYRE PA           ARCH INTERN MED                 98   541 956
   018   NIEWEG HO             IN: HEINRICH HC                      610 962
   019   TOSKES PP             J CLIN INVEST                   52  1660 973
   020   TOSKES PP             N ENGL J MED                   284   627 971
   021   VEEGER W              N ENGL J MED                   267  1341 962
   022   SEPHTON-SMITH R       BR MED J                         1   608 964
   023   STRAHM HW             ARCH KINDERHEILK               175   270 967
CT   1   HEINRICH HC           KLIN WSCHR                      55   587 977
     2   LLOYDSTILL JD         PEDIATRICS                      65  1010 980
     3   SOLOMONS NW           AM J CLIN NUTR                  34   462 981
     4   YOUNG VR              AM J CLIN NUTR                  35  1076 982
     5   SWANSON CA            AM J CLIN NUTR                  38   169 983
     6   LEVANDER OA           FED PROC                        42  1721 983
     7   CHRISTENSEN MJ        BR J NUTR                       50    43 983
     8   ROTTOLI A             RIV ITAL PEDIATR                10   337 984
     9   LEVANDER OA           BULL NY ACAD MED                60   144 984
    10   WARD KP               EUR J PEDIATR                  142    21 984
    11   SOLOMONS NW           TRACE ELEMENTS MED               2    59 985
    12   WATSON RD             J PARENT ENTERAL NUTR            9    58 985
    13   SOLOMONS NW           J PEDIATR GASTROENTEROL NUTR     5   122 986
    14   DWORKIN B             J PARENT ENTERAL NUTR           11    38 987

PN 77128
RN 00709 
AN 77231256
AU Heinrich-H-C.  Bender-Gotze-C.  Gabbe-E-E.  Bartels-H.  Oppitz-K-H.
TI Absorption of inorganic iron- (59Fe2+) in relation to iron stores in
   pancreatic exocrine insufficiency due to cystic fibrosis.
SO Klin-Wochenschr. 1977 Jun 15. 55(12). P 587-93.
MJ CYSTIC-FIBROSIS: me.  IRON: me.
MN CHILD.  CHILD-PRESCHOOL.  CYTOPLASM: me.  HUMAN.  INFANT.
   INTESTINAL-ABSORPTION.  IRON-RADIOISOTOPES.  IRON: df.
   PANCREATIN: pd.  PANCREATITIS: me.  WHOLE-BODY-COUNTING.
AB The absorption of 59Fe from a diagnostic 0.56 mg 59Fe2+ dose was
   measured by 4pi-geometry whole body counting and related to the
   amount of stainable diffuse cytoplasmatic non heme storage iron in
   the bone marrow macrophages of children with cystic fibrosis. When
   the storage iron was within the normal range (+/2+) children with
   cystic fibrosis absorbed 10-38% (Xa+/-S.D.=21+/-9.3) of the oral
   59Fe2+ dose which is identical with the 59Fe-absorption in normal
   children with normal iron stores (9-45:23+/-8.7%). Depleted iron
   stores caused an increase of 59Fe-absorption to 43-95% (Xa+/-
   S.D.=62+/-19) in children with cystic fibrosis and to 45-100% (Xa+/-
   S.D.=73+/-18) in control children. The interruption or continuation
   of pancreatin maintenance therapy and the simultaneous administration
   of 1-1.5 g pancreatin did not influence 59Fe2+ absorption in cystic
   fibrosis. There is no evidence for a pancreatic factor required for
   or inhibiting inorganic and food iron absorption in human beings.
   Iron absorption is controlled also in cystic fibrosis chiefly by the
   amounts of available storage iron. It is therefore not justified to
   apprehend the development of hemosiderosis in children with cystic
   fibrosis who are not or not sufficiently treated with pancreatin.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   002   BALCERZAK SP          GASTROENTEROLOGY                53   257 967
   003   BIGGS JC              LANCET                           2   814 963
   004   BIGGS JC              AUSTRALAS ANN MED               15    36 966
   005   DAVIS AE              LANCET                           2     6 962
   006   DELLER DJ             AM J DIG DIS                    10   249 965
   007   GILLY R               MOD PROBL PEDIATR               10   263 967
   008   GOTZE CH              MONATSSCHR KINDERHEILKD        118   210 970
   009   GOTZE CH              MONATSSCHR KINDERHEILKD        119    13 971
   010   HAUSMANN K            ACTA HAEMATOL (BASEL)           42   193 969
   011   HEINRICH HC           IN: HALLBERG L                       213 970
   012   HEINRICH HC           ARZNEIMITTEL FORSCH             25   420 975
   013   HEINRICH HC           PROC WORKSHOP CONF HOECHS 3RD         34 975
   014   HEINRICH HC           KLIN WOCHENSCHR                 45   553 967
   015   HEINRICH HC           KLIN WOCHENSCHR                 47   984 969
   016   HEINRICH HC           KLIN WOCHENSCHR                 55   587 977
   017   HEINRICH HC           KLIN WOCHENSCHR                 49   819 971
   018   HEINRICH HC           KLIN WOCHENSCHR                 44   827 966
   019   HEINRICH HC           Z KINDERHEILK                  120   251 975
   020   KAVIN H               GUT                              8   556 967
   021   KINNEY TD             AM J PATHOL                     26   746 950
   022   KINNEY TD             J EXP MED                      102   151 955
   023   LONGNECKER DS         ARCH PATHOL                     80   148 965
   024   MURRAY MJ             GASTROENTEROLOGY                51   694 966
   025   SAUNDERS SJ           LANCET                           1   510 962
   026   TAYLOR J              J PATHOL BACTERIOL              34   793 931
   028   TONZ O                LANCET                           2  1096 965
   029   WEISS S               ARCH KINDERHEILK               174   254 966
CT   1   HEINRICH HC           KLIN WSCHR                      55   595 977
     2   CHASE HP              J PEDIATR                       95   337 979
     3   SOLOMONS NW           AM J CLIN NUTR                  34   462 981
     4   WAGENER JS            AM J PEDIATR HEMATOL ONCOL       5   153 983
     5   ATER JL               PEDIATRICS                      71   810 983
     6   HODGES P              J AM DIET ASSOC                 84   664 984
     7   WONGMONGKOLRIT T      ACTA NEUROPATH (BERL)           65   265 985

PN 77129
RN 00710 
AN 77191056
AU Neutra-M-R.  Grand-R-J.  Trier-J-S.
TI Glycoprotein synthesis, transport, and secretion by epithelial cells
   of human rectal mucosa: normal and cystic fibrosis.
SO Lab-Invest. 1977 May. 36(5). P 535-46.
MJ CYSTIC-FIBROSIS: me.  GLYCOPROTEINS: bi.  INTESTINAL-MUCOSA: me.
   RECTUM: me.
MN ADOLESCENCE.  ADULT.  AMINO-SUGARS: me.  BIOPSY.  CHILD.
   COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: pa.  EPITHELIUM: cy, me.
   FUCOSE: me.  GLUCOSAMINE: me.  GLYCOPROTEINS: me, se.  HUMAN.
   INTESTINAL-MUCOSA: cy.  ORGAN-CULTURE.  RECTUM: cy, pa.
   SULFATES: me.  SUPPORT-U-S-GOVT-P-H-S.  EPITHELIUM: cy.
AB The synthesis, transport, and secretion of glycoprotein by human
   rectal epithelium from normal volunteers, patients with cystic
   fibrosis, and their disease-free siblings were studied by
   autoradiography of rectal biopsies pulse-labeled with 3H-glucosamine
   and maintained in organ culture for various intervals of up to 24
   hours. Human rectal goblet and columnar cells transported 3H-
   glucosamine-labeled secretory products at a substantially slower rate
   than do comparable colonic cells in smaller mammals. Within any one
   biopsy sample, the movement of labeled mucus in goblet cells varied
   widely among cells. Even with individual cells, labeled mucous
   granules often did not move in concert toward the apical cell
   surface. Average transport time in the cells of six cystic fibrosis
   patients and six sibling controls did not differ significantly from
   those of four adult controls. The carbohydrate composition of
   glycoprotein secretions of rectal epithelial cells was investigated
   by comparing autoradiographs of 3H-glucosamine-labeled biopsies with
   those labeled with 3H-fucose, 3H-N-acetylmannosamine, and 35S-
   sulfate. The patterns of incorporation of these four precrusors into
   normal goblet and columnar cells suggested that both cell types may
   alter the quantity and composition of newly synthesized glycoproteins
   as they migrate, mature, and senesce. Incorporation patterns in
   cystic fibrosis biopsies were indistinguishable from those of sibling
   or adult controls. With the techniques used, no abnormalities of
   epithelial glycoprotein production were detected in cystic fibrosis
   rectal mucosa.
RF 001   ADELSTEIN RS          NATURE                         255   106 975
   002   ALPERS DH             J CLIN INVEST                   51  2621 972
   003   BARBERO GJ            IN: MANGOS JA                         83 976
   004   BAUDUIN H             J CELL BIOL                     66   165 975
   005   BENNETT G             J CELL BIOL                     46   409 970
   006   BENNETT G             J CELL BIOL                     60   258 974
   007   BENNETT GC            ANAT REC                       184   357 976
   008   BOAT TF               IN: MANGOS JA                        165 976
   009   BOAT TF               AM REV RESPIR DIS              110   428 974
   010   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   011   BROWNING TH           J CLIN INVEST                   48  1423 969
   012   COFFEY JW             J BIOL CHEM                    239  4011 964
   013   DALTON AJ             ANAT REC                       121   281 955
   014   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   015   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   016   DISCHE Z              PEDIATRICS                      24    74 959
   017   DONNISON AB           PEDIATRICS                      37   833 966
   018   EASTWOOD GL           GASTROENTEROLOGY                64   375 973
   019   EYLAR E               GAP CONF REP CELL BIOCHEM                969
   020   FILIPE MI             GUT                             10   577 969
   021   FLOREY HW             GASTROENTEROLOGY                43   326 962
   022   FORSTNER GG           J BIOL CHEM                    245  3584 970
   023   FORSTNER JF           PEDIATR RES                     10   609 976
   024   FREEMAN JA            ANAT REC                       154   121 966
   025   FREYE HB              J PEDIATR                       64   575 964
   026   GUGLER EC             J PEDIATR                       71   585 967
   027   HOSKINS LC            ANN NY ACAD SCI                106   767 963
   028   ITO S                 FED PROC                        28    12 969
   029   JABBAL I              CAN J BIOCHEM                   54   707 976
   030   JABRO IH              J LANCET                        86   385 966
   031   JOHANSEN PG           LANCET                           1   455 968
   032   JOHANSEN PG           J PATHOL                        99   299 969
   033   KIM YS                J BIOL CHEM                    246  5466 971
   034   LAMB D                BR J DIS CHEST                  66   239 972
   035   LEV R                 AM J PATHOL                     46    23 965
   036   MACDERMOTT RP         J CLIN INVEST                   54   545 974
   037   MICHAELS JE           J MICROSC BIOL CELL             25   243 976
   038   MONACO F              J BIOL CHEM                    248  2072 973
   040   NEUTRA M              J CELL BIOL                     30   119 966
   041   NEUTRA M              J CELL BIOL                     30   137 966
   042   PARKINS RA            LANCET                           2   851 963
   043   RAVETTO C             ARCH ITAL MAL APP DIG           37    49 973
   044   REDMAN CM             J CELL BIOL                     66    42 975
   045   ROELFS RE             AM J DIS CHILD                 113   419 967
   046   SHANTZ A              STAIN TECHNOL                   40   279 965
   047   SHWACHMAN H           N ENGL J MED                   286  1300 972
   048   SKY-PECK HH           ANN NY ACAD SCI                130   951 966
   049   SOERGEL KH            GASTROENTEROLOGY                47   610 964
   050   TRIER JS              IN: CODE CF                      3  1125 968
   051   UGOLEV AM             BIOCHIM BIOPHYS ACTA           300   105 973
   052   WEISER MM             J BIOL CHEM                    248  2536 973
   053   WOOD RE               AM REV RESPIR DIS              113   833 976
CT   1   NEUTRA MR             J CELL BIOL                     74   983 977
     2   ALHADEFF JA           CLIN GENET                      14   189 978
     3   DERMER GB             IN VITRO                        14   804 978
     4   JONES R               BR MED BULL                     34     9 978
     5   NEUTRA MR             GASTROENTEROLOGY                75   701 978
     6   BOAT TF               ACS SYMPOSIUM SERIES          1978   108 978
     7   FILIPE MI             INVEST CELL PATHOL               2   195 979
     8   BERTELOOT A           IN VITRO                        15   294 979
     9   QURESHI R             J CLIN INVEST                   64  1149 979
    10   QUARONI A             BIOCHEM J                      182   213 979
    11   NEUTRA MR             ANAT REC                       193   367 979
    12   DAWSON PA             HISTOCHEM J                     12    23 980
    13   DAVIS PB              PEDIATR RES                     14    83 980
    14   NEUTRA MR             J ULTRASTRUCT RES               70   186 980
    15   SPECIAN RD            J CELL BIOL                     85   626 980
    16   LAMONT JT             BIOCHIM BIOPHYS ACTA           629   553 980
    17   STALEY TE             AM J VET RES                    42   912 981
    18   BENNETT G             J CELL BIOL                     88    16 981
    19   SPECIAN RD            AM J ANAT                      160   461 981
    20   COLES SJ              CELL TISSUE RES                214   107 981
    21   SAKATA T              CELL TISSUE RES                219   371 981
    22   FORSTNER JF           AM J PHYSIOL                   240  G 10 981
    23   FORSTNER J            AM J PHYSIOL                   241  G443 981
    24   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
    25   EHSANULLAH M          J CLIN PATHOL                   35    26 982
    26   MARIN MG              J APPL PHYSIOL                  52   198 982
    27   BOAT TF               CHEST                           81  S 29 982
    28   NEUTRA MR             CHEST                           81  S 14 982
    29   SENIOR PV             J ANAT                         134   459 982
    30   FORSTNER G            ADV EXP MED BIOL               144   199 982
    31   DOUGLAS WHJ           ANAT REC                       202   285 982
    32   NEUTRA MR             AM J PHYSIOL                   242  G380 982
    33   SPECIAN RD            AM J PHYSIOL                   242  G370 982
    34   APPLEGARTH DA         MED HYPOTHESES                  11   277 983
    35   DAWSON PA             HISTOCHEM J                     15     3 983
    36   FRATES RC             PEDIATR RES                     17    30 983
    37   DAVIS PB              J CHRON DIS                     36   269 983
    38   HOWDLE PD             CLIN SCI                        65   105 983
    39   PODOLSKY DK           J CLIN INVEST                   72   142 983
    40   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983
    41   SENIOR PV             BR J CANCER                     49   281 984
    42   TRIER JS              LAB INVEST                      50   673 984
    43   SZABO S               LAB INVEST                      51   121 984
    44   SPECIAN RD            GASTROENTEROLOGY                87  1313 984
    45   NEUTRA MR             CIBA FOUND SYMP                109    20 984
    46   BRADY RC              EXP CELL RES                   150   141 984
    47   PERDUE MH             AM J PHYSIOL                   247  G632 984
    48   ROOMI N               AM J PHYSIOL                   247  G140 984
    49   BASBAUM C             GASTROENTEROL CLIN BIOL          9    45 985
    50   SANDOZ D              BIOL CELL                       54    79 985
    51   BASBAUM CB            CLIN CHEST MED                   7   231 986
    52   SMITH AC              CLIN GASTROENTEROL              15   815 986
    53   PODOLSKY DK           J CLIN INVEST                   77  1263 986
    54   RUBINSTEIN S          PEDIATRICS                      78   473 986
    55   DEITCHER DL           J CELL BIOL                    102   911 986
    56   COAPMAN RA            ARCH PATHOL LAB MED            110   124 986
    57   COLONY PC             GASTROENTEROLOGY                92  1116 987
    58   COOPER HS             ARCH PATHOL LAB MED            111   270 987

PN 77130
RN 00711 
AN 77145963
AU Sanjurjo-P.  Allue-X.  Rodriguez-Soriano-J.
TI Fatty-acid composition of lecithin fraction of mucus in cystic
   fibrosis [letter].
SO Lancet. 1977 Apr 2. 1(8014). P 752.
MJ CYSTIC-FIBROSIS: me.  FATTY-ACIDS-ESSENTIAL: an.  MUCUS: an.
   PHOSPHATIDYLCHOLINES: an.
MN BRONCHI.  CHILD.  FATTY-ACIDS-ESSENTIAL: df.  HUMAN.
EX We have studied seven patients with C.F. and ten normal children and
   have confirmed the low levels of E.F.A. both in plasma and in
   red-cell membrane in the C.F. group.  We would like to report here
   preliminary results on the fatty-acid pattern of the lecithin
   fraction of bronchial mucus in the same group of patients and
   controls.  Content of palmitic acid was lower and that of oleic acid
   was higher in the C.F. patients than in normal children.  This
   abnormality in the fatty-acid composition of the lecithin of the
   mucus could be an important finding in relation to the respiratory
   symptoms in C.F.  Some experimental work supports this hypothesis.
RF 001   KUO PT                J CLIN INVEST                   44  1924 965
   002   ROSENLUND ML          NATURE                         251   719 974
   003   RIVERS JPW            LANCET                           2   642 975
   004   CHASE HP              PEDIATRICS                      57   441 976
   005   ELLIOTT RB            PEDIATRICS                      57   474 976
   006   KYRIAKIDES EC         BIOCHIM BIOPHYS ACTA           431   399 976
   007   HOPKINS DT            PROC SOC EXP BIOL MED          114    82 963
CT   1   ALLUE X               PEDIATRICS                      61   924 978
     2   FRIEDMAN Z            PEDIATRICS                      63   855 979
     3   RIORDAN JR            BIOCHIM BIOPHYS ACTA           574    39 979
     4   MALER T               BIOCHIM BIOPHYS ACTA           598     1 980
     5   GALABERT C            CLIN RESP PHYSIOL               17   197 981
     6   ROGIERS V             PEDIATR RES                     16   761 982
     7   HARPER TB             AM REV RESPIR DIS              126   540 982
     8   ROGIERS V             PEDIATR RES                     18   704 984
     9   CAMPBELL IM           EUR J CLIN MICROBIOL             5   622 986
    10   GILLJAM H             SCAND J CLIN LAB INVEST         46   511 986

PN 77131
RN 00712 
AN 77253838
AU Berger-H-M.  Reynolds-S-J.  Lee-K-H.
TI False-positive meconium screen [letter].
SO Lancet. 1977 Aug 27. 2(8035). P 458.
MJ CYSTIC-FIBROSIS: di.  INFANT-NEWBORN-DISEASES: di.  MECONIUM.
MN FALSE-POSITIVE-REACTIONS.  GLYCERIN: du.  HUMAN.  INFANT-NEWBORN.
   MECONIUM: me.  SUPPOSITORIES.
EX The BM meconium test is a useful screening test for cystic fibrosis.
   However, we have had false-positive results in two babies caused by
   the use of rectal glycerin suppositories.  The babies presented with
   signs suggestive of intestinal obstruction possibly due to meconium
   ileus, and glycerin suppositories were inserted to speed the passage
   of meconium so that the BM test could be done to help confirm the
   diagnosis.  The tests were positive but the babies were subsequently
   shown not to have cystic fibrosis, and we found that the glycerin
   suppositories themselves produce the typical blue colour on the test
   strip.

PN 77132
RN 00713 
AN 78070727
AU Super-M.
TI Heterozygote disadvantage in cystic fibrosis [letter].
SO Lancet. 1977 Dec 17. 2(8051). P 1288.
MJ CYSTIC-FIBROSIS: fg.
MN CAUCASOID-RACE.  HETEROZYGOTE.  HUMAN.  SOUTH-AFRICA.
   TRANSIENTS-AND-MIGRANTS.  TROPICAL-CLIMATE.
EX I have found that cystic fibrosis (C.F.), which is very common in
   South West Africa, occurs almost exclusively in white Afrikaners,
   probably as a result of inbreeding, the drift from the Northern Cape
   Colony, and religious and geographical separation.  However, I have
   not found C.F. in the descendants of the Angola Boers, a small
   proportion (6 - 7%) of the White population who belong to a small
   branch of the Dutch Reformed Church.  The absence of C.F. may stem
   from their limited numbers (7000) but I suggest that it may have at
   least partially a genetic basis.  Homozygotes with C.F. are subject
   to salt-losing crises which can be fatal in hot weather and
   heterozygotes often have an increased concentration of sodium and
   chlorine ions in their sweat.  The influence of environmental
   temperature and drought may explain why C.F. occurs among Blacks in
   temperate zones of the United States but not in Africa, and is less
   frequent in the hot southern regions of Europe than in the colder,
   more northern areas.  Negative selection of this type may have
   operated only in hot, arid environments and the possibility that
   other environments offered advantages to C.F. heterozygotes cannot be
   excluded.
RF 001   SUPER M               S AFR MED J                     49   818 975
   003   GOLDBLATT I           HIST SW AFRICA FROM BEGINNING            971
   004   KESSLER WR            PEDIATRICS                       8   648 951
   005   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            971
   006   VEDDER H              SOUTH WEST AFRICA IN EARLY TI        420 966
   007   TRUMPELMAN GPJ        IN: BOER IN SUID WEST AFRI               948
   009   KULCZYCKI LL          AM J DIS CHILD                 127    64 974
   010   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   011   LEVIN S               IN: GOLDSCHMIDT E                    294 963
CT   1   SUPER M               S AFR MED J                     54    18 978
     2   SUPER M               MONOGR PAEDIATR                 10   106 979

PN 77133
RN 00714 
AN 78070728
AU Whitelaw-A.  Butterfield-A.
TI High breast-milk sodium in cystic fibrosis [letter].
SO Lancet. 1977 Dec 17. 2(8051). P 1288.
MJ CYSTIC-FIBROSIS: me.  MILK-HUMAN: an.  SODIUM: an.
MN FEMALE.  HUMAN.  PREGNANCY.
EX Increased sodium concentration in sweat is a characteristic of cystic
   fibrosis.  However, we have read nothing on the sodium content of
   breast milk in this condition.  A patient with sweat-test-proved
   cystic fibrosis with mild pulmonary disease had her first baby by
   normal delivery at term.  Samples of breast milk were obtained on the
   sixth and seventh days post partum when the mother was not breast
   feeding.  The two sodium concentrations were 132 and 280 mmol/l,
   concentrations much higher than in any other milk sample tested at
   this hospital in a large survey and higher than any we have seen in
   the literature.  Milk of such high sodium content would be unsafe for
   a baby, and we suggest that, if mothers with cystic fibrosis were to
   breast feed, the sodium of the mild should be measured first.  The
   breast, like so many other exocrine glands, seems to be affected by
   the secretory abnormalities of cystic fibrosis.
CT   1   DANN LG               LANCET                           2   405 978
     2   BERLIN CM             OBSTET GYNECOL                  58  S 17 981
     3   WELCH MJ              PEDIATRICS                      67   664 981
     4   WALPOLE IR            J PEDIATR                       98   333 981
     5   MCKIERNAN J           PEDIATR RES                     16    60 982
     6   GRUSKIN AB            PEDIATR CLIN NORTH AM           29   907 982
     7   ALPERT SE             J PEDIATR                      102    77 983
     8   SEALE TW              ANN CLIN LAB SCI                15   152 985
     9   STEAD RJ              ARCH DIS CHILD                  62   433 987

PN 77134
RN 00715 
AN 78091185
AU Hubbard-V-S.  Dunn-G-D.  di-SantAgnese-P-A.
TI Abnormal fatty-acid composition of plasma-lipids in cystic fibrosis.
   A primary or a secondary defect?.
SO Lancet. 1977 Dec 24-31. 2(8052-8053). P 1302-4.
MJ CYSTIC-FIBROSIS: bl.  FATTY-ACIDS: bl.  LIPIDS: bl.
MN ADOLESCENCE.  ADULT.  CYSTIC-FIBROSIS: fg, pp.  FEMALE.
   HETEROZYGOTE.  HUMAN.  MALABSORPTION-SYNDROMES: bl, et.  MALE.
   MIDDLE-AGE.  OLEIC-ACIDS: bl.  PALMITIC-ACIDS: bl.  PANCREAS: pp.
   PHOSPHOLIPIDS: bl.  TRIGLYCERIDES: bl.
AB The percentage fatty-acid composition of the various plasma-lipid
   fractions from cystic-fibrosis patients with and without pancreatic
   insufficiency, obligate heterozygotes, and normal subjects was
   determined. Only the cystic-fibrosis patients with pancreatic
   insufficiency had significantly abnormal fatty-acid composition. This
   general observation did not correlate with vitamin-E deficiency, age,
   sex, or severity of the disease. Thus the altered fatty-acid
   composition of the different plasma-lipid fractions appears to be a
   secondary consequence of the pancreatic insufficiency commonly
   associated with cystic fibrosis and not a direct metabolic defect
   related to the cystic-fibrosis gene itself.
RF 001   BENNETT MJ            AM J CLIN NUTR                  20   415 967
   002   KUO PT                J CLIN INVEST                   44  1924 965
   003   KUO PT                J PEDIATR                       60   394 962
   004   UNDERWOOD BA          ANN NY ACAD SCI                203   237 972
   005   CAREN R               J CLIN ENDOCRINOL METAB         26   470 966
   006   ELLIOTT RB            ARCH DIS CHILD                  50    76 975
   007   RIVERS JPW            LANCET                           2   642 975
   008   ROSENLUND ML          NATURE                         251   719 974
   009   BEVERIDGE J           PEDIATRICS                      58   465 976
   010   ELLIOTT RB            PEDIATRICS                      57   474 976
   011   TAUSSIG LM            PEDIATRICS                      54   229 974
   012   DANON A               BIOCHIM BIOPHYS ACTA           388   318 975
   013   SOBEL AE              J BIOL CHEM                    171   617 947
   014   QUAIFE ML             J BIOL CHEM                    180  1229 949
   015   DODGE JA              BR MED J                         2   192 975
   016   EMERY AEH             LANCET                           2    80 975
   017   MCEVOY FA             LANCET                           2   236 975
   018   THOMPSON G            LANCET                           2   719 975
   019   PRESS M               LANCET                           2   871 975
   020   WATTS R               LANCET                           2   983 975
   021   CAMPBELL IM           PEDIATRICS                      57   480 976
   022   CHASE HP              PEDIATRICS                      57   441 976
   023   COLLINS FD            NUTR METAB                      13   150 971
   024   PRESS M               BR MED J                         2   247 974
   025   WOLFRAM G             NUTR METAB (SUPPL 1)            21   127 977
   026   ALFIN-SLATER RB       PHYSIOL REV                     48   758 968
   027   TAUSSIG LM            J PEDIATR                       82   380 973
CT   1   CHASE HP              LANCET                           2   236 978
     2   GALABERT C            LANCET                           2   903 978
     3   FRIEDMAN Z            SEM PERINATOL                    3   341 979
     4   ANON                  NUTR REV                        37   247 979
     5   LLOYDSTILL JD         PEDIATRICS                      64    50 979
     6   SANTAGNESE PAD        AM J MED                        66   121 979
     7   HUBBARD VS            AM J CLIN NUTR                  33  2281 980
     8   COATES AL             ACTA PAEDIATR SCAND             69   353 980
     9   DAVIS PB              J LAB CLIN MED                  96    75 980
    10   HUBBARD VS            CLIN CHIM ACTA                 102   115 980
    11   ROGIERS V             CLIN CHIM ACTA                 105   105 980
    12   FRIEDMAN Z            AM J DIS CHILD                 134   397 980
    13   PARK RW               GASTROENTEROLOGY                81  1143 981
    14   LLOYDSTILL JD         J PEDIATR                       99   580 981
    15   CHASE HP              J PEDIATR GASTROENTEROL NUTR     1    49 982
    16   ROGIERS V             PEDIATR RES                     16   761 982
    17   GASKIN K              J PEDIATR                      100   857 982
    18   HARPER TB             AM REV RESPIR DIS              126   540 982
    19   FARRELL PM            ANN NY ACAD SCI                393    96 982
    20   KUSOFFSKY E           J PEDIATR GASTROENTEROL NUTR     2   434 983
    21   FARRELL PM            J DENT CHILD                    50   385 983
    22   HANSEN RC             ARCH DERMATOL                  119    51 983
    23   HUBBARD VS            EUR J PEDIATR                  141    68 983
    24   ROGIERS V             EUR J PEDIATR                  141    39 983
    25   ROGIERS V             PEDIATR RES                     18   704 984
    26   DAVIS PB              J LAB CLIN MED                 104   203 984
    27   ROGIERS V             EUR J PEDIATR                  142   305 984
    28   MCKENNA MC            J PEDIATR GASTROENTEROL NUTR     4    45 985
    29   FARRELL PM            PEDIATR RES                     19   104 985
    30   ZENTLERMUNRO PL       GUT                             26   892 985
    31   CHRISTOPHE A          ANN NUTR METAB                  29   239 985
    32   MOILANEN T            AM J CLIN NUTR                  42   708 985
    33   GIBSON RA             J PEDIATR GASTROENTEROL NUTR     5   408 986
    34   LESTER LA             J PARENT ENTERAL NUTR           10   289 986
    35   MISCHLER EH           PEDIATR RES                     20    36 986
    36   CRAIGSCHMIDT MC       AM J CLIN NUTR                  44   816 986
    37   MOORE MC              AM J CLIN NUTR                  44    33 986
    38   PARSONS HG            BIOCHIM BIOPHYS ACTA           860   420 986

PN 77135
RN 00716 
AN 77098975
AU Gyurkovits-K.  Markus-V.  Bittera-I.
TI Cystic-fibrosis heterozygosity in childhood bronchial asthma
   [letter].
SO Lancet. 1977 Jan 22. 1(8004). P 203.
MJ ASTHMA: co.  CYSTIC-FIBROSIS: fg.  HETEROZYGOTE.
MN ASTHMA: et.  BROMIDES: du.  CHILD.  CHLORIDES: an.  HUMAN.
   SODIUM: an.  SWEAT: an.
EX We found that the Szczepanski bromide test, which we simplified with
   the aid of ion-sensitive electrode, is suitable for the detection of
   C.F. heterozygosity in most cases.  We examined the sweat of 74
   randomly selected children with respiratory asthma during the past 2
   years, the sodium and chloride concentrations and bromide index being
   determined.  Sodium and chloride concentrations in the sweat of the
   asthma children were slightly but significantly higher (P < 0.05)
   than those of the controls.  The difference in bromide index was even
   more significant (P < 0.01).  This suggests that C.F. gene carriers
   are unusually prevalent among children with bronchial asthma.  One
   possibility is that enhanced ion loss in various diseases with
   allergic pathological mechanisms is secondary in nature.  However,
   this seems unlikely since in our material high sweat-electrolyte
   concentrations were observed in only a proportion of control children
   whose illness was similar in severity to that of the asthmatic
   children, and normal sweat values were obtained even when the child's
   condition was very serious.
RF 001   WARNER JO             LANCET                           1   990 976
   002   MCFARLANE H           LANCET                           1  1241 976
   003   SZCZEPANSKI Z         Z KINDERHEILK                  113   297 972
   004   GYURKOVITS K          ACTA PAEDIATR ACAD SCI HUNG     15    49 974

PN 77136
RN 00717 
AN 78049968
AU Crossley-J-R.  Berryman-C-C.  Elliott-R-B.
TI Cystic-fibrosis screening in the newborn.
SO Lancet. 1977 Nov 26. 2(8048). P 1093-5.
MJ CYSTIC-FIBROSIS: di.
MN BENZOYLARGININE-NITROANILIDE: du.  COLORIMETRY: mt.
   CYSTIC-FIBROSIS: en.  EVALUATION-STUDIES.  FALSE-POSITIVE-REACTIONS.
   FECES: en.  HUMAN.  HYDROLYSIS.  INFANT-NEWBORN.  TRYPSIN: an.
AB In a new method of testing stool samples from newborn babies for
   cystic fibrosis (C.F.), a colourless substrate, benzoyl-arginine-p-
   nitroanilide (B.A.P.N.A.), releases yellow p-nitroaniline when
   hydrolysed by trypsin. Samples from infants with C.F., who lack
   trypsin, give negligible colour. 2 infants with C.F. were detected
   among 2500 consecutive newborn babies tested. The incidence of false-
   positive results was 1.2% after the first specimen and 0.05% after
   the second specimen. A further refinement has reduced the positive
   rate to 0.1% after the first specimen (2000 samples). Tests on
   samples from 5 other older patients with untreated C.F. have yielded
   no evidence for false-negative results.
RF 001   ROBINSON PG           NZ MED J                        83   268 976
   002   SHWACHMAN H           PEDIATRICS                      46   335 970
   003   ELLIOTT RB            PEDIATRICS                      57   474 976
   004   VERDONK G             PROC INT CONF ON NUTRI 9TH       1   278 972
   005   PROSSER R             ARCH DIS CHILD                  49   597 974
   006   KOLLBERG H            ACTA PAEDIATR SCAND             64   477 975
   007   ROBINSON PG           NZ MED J                        79  1024 974
   008   ROBINSON PG           ARCH DIS CHILD                  51   301 976
   009   ERLANGER BF           ARCH BIOCHEM BIOPHYS            95   271 961
   010   ROBINSON PG           CLIN CHIM ACTA                  62   225 975
   011   RYLEY HC              CLIN CHIM ACTA                  64   117 975
   012   HAVERBACK BJ          GASTROENTEROLOGY                44   588 963
   013   ERLANGER BF           ARCH BIOCHEM BIOPHYS           115   206 966
CT   1   ELLIOTT RB            MED J AUST                       2    95 978
     2   HOLTZMAN NA           PEDIATR CLIN NORTH AM           25   411 978
     3   CROSSLEY JR           LANCET                           1   472 979
     4   STEPHAN U             MONOGR PAEDIATR                 10    41 979
     5   STAGG BH              ANN CLIN BIOCHEM                16   147 979
     6   WARWICK WJ            J CHRON DIS                     33   685 980
     7   TARNOKY AL            J ROY SOC MED                   73    73 980
     8   LAMBOTTE C            J GENET HUM                     29    85 981
     9   CARREL O              HELV PAEDIATR ACTA              36   405 981
    10   FORREST DC            ARCH DIS CHILD                  56   151 981
    11   BORGSTROM A           ACTA PAEDIATR SCAND             70   619 981
    12   SCHONI M              SCHWEIZ MED WOCHENSCHR         111   658 981
    13   CROSSLEY JR           CLIN CHIM ACTA                 113   111 981
    14   DODGE JA              ARCH DIS CHILD                  57   774 982
    15   HEELEY AF             CLIN CHEM                       29  2011 983
    16   LUTHI M               HELV PAEDIATR ACTA              38   149 983
    17   LYON ICT              NZ MED J                        96   673 983
    18   WILCKEN B             J PEDIATR                      102   383 983
    19   WILCKEN B             J PEDIATR                      103   668 983
    20   ROGIERS V             EUR J PEDIATR                  141    39 983
    21   BORGSTROM A           PEDIATR RES                     18   957 984
    22   NAYLOR EW             SEM PERINATOL                    9   232 985

PN 77137
RN 00718 
AN 78049949
AU George-R-H.  Healing-D-E.
TI Thymidine-requiring Haemophilus influenzae and Staphylococcus aureus
   [letter].
SO Lancet. 1977 Nov 19. 2(8047). P 1081.
MJ HAEMOPHILUS-INFLUENZAE: gd.  STAPHYLOCOCCUS-AUREUS: gd.
MN CHILD.  CULTURE-MEDIA.  CYSTIC-FIBROSIS: mi.
   HAEMOPHILUS-INFLUENZAE: ip.  HUMAN.  SPUTUM: mi.
   STAPHYLOCOCCUS-AUREUS: ip.  THYMIDINE: me.
EX In the past year we have isolated thy- Staphylococcus aureus from the
   sputum of four children with cystic fibrosis who were receiving
   co-trimoxazole, and lately we have isolated a thy- strain of
   Haemophilus influenzae from a patient with cystic fibrosis also
   receiving co-trimoxazole.  In view of the exacting growth
   requirements of H. influenzae we feel that thy- strains might easily
   be overlooked or assumed to have died when they fail to grow on
   sensitivity-test media.
RF 001   LACEY RW              BR MED J                         4   165 973
   002   MASKELL R             LANCET                           1   834 976
   003   SEDGWICK B            J BACTERIOL                    123  1208 975
CT   1   SPARHAM PD            J CLIN PATHOL                   31   913 978
     2   DAVIES J              ANNU REV MICROBIOL              32   469 978
     3   DAVIES J              REV INFECT DIS                   1    23 979
     4   WILLIAMS RF           CURR MED RES OPIN                6    43 979
     5   WORMSER GP            ANN INTERN MED                  91   420 979
     6   STURM AW              ANT V LEEUW J MICROBIOL SEROL   47    92 981
     7   NEU HC                REV INFECT DIS                   4  S288 982
     8   LACEY RW              J MED MICROBIOL                 15   403 982
     9   BROGDEN RN            DRUGS                           23   405 982
    10   GRIECO MH             MED CLIN NORTH AM               66    25 982
    11   KING CH               J CLIN MICROBIOL                18    79 983

PN 77138
RN 00719 
AN 77169610
AU Sleisenger-M-H.  Brandborg-L-L.
TI Malabsorption.
SO Major-Probl-Intern-Med. 1977. 13. P v-x, 1-261.
MJ MALABSORPTION-SYNDROMES: di.
MN BIOPSY.  CELIAC-DISEASE: di.  CHILD.  CYSTIC-FIBROSIS: di.
   GASTROENTERITIS: di.  HUMAN.  INTESTINAL-ABSORPTION.
   INTESTINAL-NEOPLASMS: co.  INTESTINE-SMALL: im, mi, pa, pp.
   LIPODYSTROPHY-INTESTINAL: di.  LYMPHOMA: co.
   MALABSORPTION-SYNDROMES: co, pa, pp, th.  CELIAC-DISEASE: di.
EX Laboratory diagnosis of malabsorption syndromes in children is more
   difficult for obvious reasons involving the collection of specimens.
   The early diagnosis of cystic fibrosis is extremely urgent, since
   the disease is treatable.  The standard test is the sweat test.
   Over 99 percent of patients with this disease will have elevation of
   sodium and chloride in the sweat.  Three tests are used to assess
   pancreatic function.  First is the measurement of stool trypsin and
   chymotrypsin.  Second, stimulation with hormones - the standard
   secretin and CCK tests.  A third procedure tests carbohydrate
   tolerance, an increasingly important test since an ever-growing
   number of patients in late childhood and early adulthood with cystic
   fibrosis are being found to have diabetes mellitus.  The commonest
   and most important hereditary disease that affects pancreatic
   function is cystic fibrosis.  The commonest form of pancreatic
   insufficiency in childhood is mucoviscidosis or cystic fibrosis of
   the pancreas.  The incidence of this disease is approximately one
   per 1000 live births.  It occurs in all races, and the defect is
   transmitted as an autosomal recessive.  The classic features are
   frequent bowel movements with the characteristic appearance of
   steatorrheic stools, and a failure to grow and develop normally.
RF 001   SHWACHMAN H           IN: SLEISENGER MH                   1206 973
   001   HAMILTON JR           IN: SLEISENGER MH                    280 973
   002   SHWACHMAN H           MOD PROBL PEDIATR               10   158 967
   002   WORMSLEY KG           IN: HOWAT HT                     1       972
   003   MARKS JF              J PEDIATR                       69   225 966
   004   WINAWER SJ            IN: GLASS GBJ                    1       968
   004   NAVAB F               GUT                             11   373 970
   005   MORIN CL              J CLIN INVEST                   50  1961 971
   005   SCRIBNER BH           JAMA                           212   457 970
   006   KEKOMAKI M            ACTA PAEDIATR SCAND             56   617 967
   006   KRONE CL              MEDICINE (BALTIMORE)            47    89 968
   007   GOODMAN SI            J PEDIATR                       71   246 967
   007   PRIZONT R             GASTROENTEROLOGY                69  1254 975
   008   BANTSOCAS CS          AM J DIS CHILD                 117    93 969
   008   KAHN IJ               N ENGL J MED                   274  1339 966
   009   HOOFT C               ANN PAEDIATR                   205    73 965
   009   PEARSON AJ            AM J DIG DIS                    14   200 969
   010   DRUMMOND KN           AM J MED                        37   928 964
   011   CASH R                J PEDIATR                       74   717 969
   012   HADORN B              CLIN GASTROENTEROL               1   125 972
   013   LAURIALA K            IN: SCHMERLING DH                        968
   014   HALL SD               AM J CLIN NUTR                  22   448 969
   015   SCRIVER CR            PEDIATRICS                      45   361 970
   016   PAUNIER L             PEDIATRICS                      41   385 968
   017   LILLIBRIDGE CB        GASTROENTEROLOGY                52   792 967
   018   MOHAMED SD            Q J MED                         35   433 966
   019   LANZKOWSKY P          AM J MED                        48   580 970
CT   1   RASMUSSEN P           J DENT CHILD                    47    42 980
     2   LO CW                 PEDIATRICS                      72   786 983

PN 77139
RN 00720 
AN 77146553
AU Cohn-D.
TI Multilobular biliary cirrhosis of the liver associated with cystic
   fibrosis (mucoviscidosis).
SO Med-J-Aust. 1977 Jan 22. 1(4). P 101-4.
MJ CYSTIC-FIBROSIS: co.  LIVER-CIRRHOSIS-BILIARY: et.
MN ADULT.  AUTOPSY.  CASE-REPORT.  HUMAN.  MALE.
AB A case (including autopsy findings) is reported of multilobular
   biliary cirrhosis with a strictly nodular liver developing in a 20-
   year-old male with cystic fibrosis (mucoviscidosis). The pathogenesis
   of biliary cirrhosis in cystic fibrosis is briefly discussed.
RF 001   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   002   SORRELL VF            AUST NZ J SURG                  37   217 968
   003   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   004   CRAIG JM              AM J DIS CHILD                  93   357 957
   005   TYSON KRT             J PEDIATR SURG                   3   271 968
   006   GRAND RJ              CLIN PEDIATR                     9   588 970
   007   CAMERON R             BILIARY CIRRHOSIS                        962
   008   SHIER KJ              CAN MED ASSOC J                 89   645 963
   009   MONTGOMERY BK         AM J CLIN PATHOL                26   630 956
   010   WEBSTER R             ARCH DIS CHILD                  28   343 953
   011   KOPEL FB              GASTROENTEROLOGY                62   483 972
   012   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
CT   1   FINBERG L             N ENGL J MED                   300   420 979
     2   CUNNINGHAM DG         J COMPUT ASSIST TOMOGR           4   151 980
     3   BERNARD O             CLIN GASTROENTEROL              14    33 985

PN 77140
RN 00721 
AN 77232262
AU Webster-L.  Lochlin-H.
TI Cystic fibrosis screening by sweat analysis: a critical review of
   techniques.
SO Med-J-Aust. 1977 Jun 18. 1(25). P 923-7.
MJ CYSTIC-FIBROSIS: di.  SWEAT: an.
MN CHILD.  CHILD-PRESCHOOL.  COMPARATIVE-STUDY.  ELECTRIC-CONDUCTIVITY.
   HUMAN.  INFANT.  INFANT-NEWBORN.  OSMOLAR-CONCENTRATION.
   POTASSIUM: an.  SODIUM: an.  SPECIMEN-HANDLING: mt.  TEMPERATURE.
AB Currently employed methods for the assay of electrolytes in sweat,
   relevant to the diagnosis of cystic fibrosis, are critically
   evaluated with particular reference to the measurement of electrical
   conductivity. Attention is drawn to the factors responsible for
   potentially large errors. On the basis of experimentation, supported
   by laboratory practice, recommendations are made for the reduction of
   these errors to clinically acceptable levels. Data concerning sodium
   and potassium content, electrical conductivity and osmolality of
   undiluted sweat collections are compared. The feasibility and
   comparative advantages of measuring sweat osmolality with a vapour
   pressure osmometer are discussed.
RF 001   SHWACHMAN H           PEDIATRICS                      32    85 963
   002   PHILLIPS WR           PEDIATRICS                      32    89 963
   003   WEINER JS             NATURE                         164   351 949
CT   1   SHIRAMIZU B           ANAL CHIM ACTA                 108   161 979
     2   WEBSTER HL            CRC CRIT REV CLIN LAB SCI       18   313 983
     3   KIRK JM               ANN CLIN BIOCHEM                20   369 983
     4   FRANCKX J             HELV PAEDIATR ACTA              39   347 984
     5   SCHONI MH             J PEDIATR                      104   691 984
     6   ITANO M               RESPIRATION                     47   220 985
     7   GEETHA H              BR MED J                       294   156 987

PN 77141
RN 00722 
AN 77146406
AU Shwachman-H.  Kowalski-M.  Khaw-K-T.
TI Cystic fibrosis: a new outlook.  70 patients above 25 years of age.
SO Medicine (Baltimore). 1977 Mar. 56(2). P 129-49.
MJ CYSTIC-FIBROSIS: di.
MN ADULT.  ANTIBIOTICS: tu.  CHILD.  CLUBFOOT: et.
   CYSTIC-FIBROSIS: co, th.  EDUCATIONAL-STATUS.  FAMILY-CHARACTERISTICS.
   FEMALE.  FOLLOW-UP-STUDIES.  HOSPITALIZATION.  HUMAN.  MALE.
   MARRIAGE.  NASAL-POLYPS: et.  OCCUPATIONS.
   OSTEOARTHROPATHY-SECONDARY-HYPERTROPHIC: et.  PATIENT-COMPLIANCE.
   PREGNANCY.  QUALITY-OF-LIFE.  RESPIRATORY-FUNCTION-TESTS.
   SOCIOECONOMIC-FACTORS.  SPUTUM: mi.  SWEAT.
AB We have presented a group of 70 patients over 25 years of age as of
   January 1, 1975, who were diagnosed as having cystic fibrosis (CF) at
   various ages from birth to 28 years. Some patients were diagnosed
   late in life in spite of classical symptoms and a characteristic
   history of the disease. Patients with CF present with a broad
   spectrum of symptoms which vary considerably in severity. This older
   age group represents approximately 10% of our current roster of
   patients with CF. This disease is no longer confined to early life
   and will continue to be seen with increasing frequency in older
   patients. Our experience with this disease indicates that a number of
   affected individuals can attain adulthood and find a useful place in
   society. The quality of life provided to these adults is illustrated
   in their intellectual, socioeconomic achievements and marital life.
   Our aim has been to recognize the disease as early in life as
   possible and to provide a comprehensive medical program which
   includes all aspects of health care.
RF 001   ADDINGTON WW          CHEST                           59   306 971
   002   ANDERSON EG           BR J DIS CHEST                  59   173 965
   003   ANDERSON EL           J S CAROLINA MED ASSOC          68   275 972
   004   ANTONOWICZ I          PEDIATRICS                      42   492 968
   005   ARAKI H               PEDIATR RES                      9   932 975
   007   BATTEN J              RESPIRATION SUPPL               27   163 970
   008   BAUMGARTNER U         SCHWEIZ MED WOCHENSCHR          89   130 959
   009   BIANCO S              GAZZ INT MED CHIR               72  2747 967
   010   BOHLE E               AERZTL PRAXIX                   21   907 969
   011   BOHN H                DTSCH MED WSCHR                 86  1384 961
   012   BOUCHER H             PRESSE MED                      69  2123 961
   013   BOUR H                REV PRAT                        17  3347 967
   014   BRUN J                POUMON COEUR                    22   961 966
   015   BRUSILOW SW           ANNU REV MED                    21    99 970
   016   BURNARD ED            NZ MED J                        52   395 953
   017   CABANEL G             MOD PROBL PEDIATR               10   284 967
   018   CABANEL G             SEM HOP PARIS                   44  1203 968
   019   CALDWELL DM           CALIF MED                       89   280 958
   020   CARBONI M             EPATOLOGIA                      16   465 970
   021   CECE JD               JAMA                           181    31 962
   022   CHEBAT J              J FRANC MED CHIR THORAC         24   771 970
   023   CHEBAT J              IMMEX (PARIS)                        871 963
   024   CHEBAT J              POUMON COEUR                    27     3 971
   025   COATES EO JR          DIS CHEST                       49   195 966
   026   DALFINO G             MED CLIN SPER                   12   403 962
   027   DE HALLER R           REV MED SUISSE ROM              82    42 962
   028   DE KALBERMATTEN JP    POUMON COEUR                    24   459 968
   029   DESMOND FB            NZ MED J                        62   380 963
   030   DI SANTAGNESE PA      N ENGL J MED                   279   103 968
   031   DI SANTAGNESE PA      MOD PROBL PEDIATR               10   135 967
   032   DI SANTAGNESE PA      ANN INTERN MED                  50  1321 959
   033   DOYLE B               PHYS THER REV                   39    24 959
   034   DUBACH UC             SCHWEIZ MED WOCHENSCHR          92   783 962
   035   ANON                  LANCET                           1   963 960
   036   ANON                  JAMA                           150  1407 952
   037   FELLOWS KE            RADIOLOGY                      114   551 975
   038   GALLET M              LYON MED                       225   845 971
   039   GALLET M              MED CHIR DIG                     1   249 972
   040   GEORGE L              BR MED J                         3   718 969
   041   GIBSON LE             PEDIATRICS                      23   545 959
   042   GRAND RJ              JAMA                           195   993 966
   043   GRANDCHAMP A          SCHWEIZ MED WOCHENSCHR          98  1388 968
   044   HOLSCLAW DS           J PEDIATR SURG                   9   867 974
   045   HOLSCLAW DS           PEDIATRICS                      48   442 971
   046   HOLSCLAW DS           MINN MED                        52  1547 969
   047   HOLSCLAW DS           J PEDIATR                       76   829 970
   048   HOLSCLAW DS           PEDIATRICS                      48    51 971
   049   HOLSCLAW DS           J UROL                         106   568 971
   050   JONES JS              BR J DIS CHEST                  64    25 970
   051   KAPLAN E              N ENGL J MED                   279    65 968
   052   KARLISH AJ            LANCET                           2   514 960
   053   KOCH E                DTSCH ARCH KLIN MED            206   470 960
   054$  KOCH E                MED WSCHR                       40  2033 961
   055   KOHL HW               ARIZ MED                         5    47 948
   056   KULCZYCKI LL          JAMA                           175   358 961
   057   KULCZYCKI LL          N ENGL J MED                   257   203 957
   058   KULCZYCKI LL          N ENGL J MED                   259   409 958
   059   LANDING BH            ARCH PATHOL                     88   569 969
   060   LAPEY A               J PEDIATR                       84   328 974
   061   LEPORE MJ             GASTROENTEROLOGY                44   696 963
   062   LIFSCHLITZ NA         KLIN MED                        51   117 973
   063   MARKS BL              LANCET                           1   365 960
   064   MEYERS A              AM J DIS CHILD                 129  1011 975
   065   MURTHY MSN            OHIO STATE MED J                69   768 973
   066   NOWAK S               POL MED J                        7   114 968
   067   ONEAL R               THESIS                                   948
   068   PARKINS RA            LANCET                           2   851 963
   069   PETERSON EM           JAMA                           171    87 959
   070   POLGAR G              AM REV RESPIR DIS               85   319 962
   071   RECANT L              AM J MED                        27   483 959
   072   ROSAN RC              AM J DIS CHILD                 104   625 962
   073   SCHANDEVYL W          ACTA TUBERC PNEUMONOL BELG      62   478 971
   074   SELIGER G             AM J DIG DIS                    17   934 972
   075   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   076   SHWACHMAN H           PEDIATRICS                      36   689 965
   077   SHWACHMAN H           ANN NY ACAD SCI                 93   600 962
   078   SHWACHMAN H           PEDIATRICS                       7   153 951
   079   SHWACHMAN H           AM J DIS CHILD                  92   347 956
   080   SHWACHMAN H           N ENGL J MED                   286  1300 972
   082   SHWACHMAN H           MOD PROBL PEDIATR               10   158 967
   083   SHWACHMAN H           MINN MED                        52  1521 969
   084   SHWACHMAN H           PEDIATRICS                      30   389 962
   085   SHWACHMAN H           IN: SLEISENGER MH                   1206 973
   086   SHWACHMAN H           PEDIATRICS                      55    86 975
   087   SHWACHMAN H           AM J DIS CHILD                  91   223 956
   088   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            971
   089$  SHWACHMAN H           IN: SHIRKEY HC                           964
   090   SHWACHMAN H           CLIN PEDIATR                    14  1115 975
   091   SHWACHMAN H           IN: LEVINE SZ                        249 955
   092   SHWACHMAN H           PEDIATRICS                      46   335 970
   093   SIEGEL B              OBSTET GYNECOL                  16   438 960
   094   SIEGENTHALER P        SCHWEIZ MED WOCHENSCHR          43  1528 963
   095   SIEGENTHALER P        HELV MED ACTA                            965
   096   STEJFA M              BRATISL LEK LISTY               51   523 969
   097   TAUSSIG LM            RADIOLOGY                      106   369 973
   098   TOMASHEFSKI JF        CHEST                           56   270 969
   099   TOMASHEFSKI JF        CHEST                           57    28 970
   100   TOW A                 AM J DIS CHILD                  87   192 954
   101   TREVER RW             ARCH INTERN MED                106   253 960
   102   TYSON KRT             J PEDIATR SURG                   3   271 968
   103   WANG CI               CF CLUB ABST                          51 972
   104   WARING WW             AM REV RESPIR DIS              104   166 971
   105   WARWICK WJ            MOD PROBL PEDIATR               10   353 967
   106   WARWICK WJ            IN: LAWSON D PROC 5TH INT CF         320 969
   107   WARWICK WJ            J ASTHMA RES                     5   277 968
   108   WILMSHURST EG         PEDIATRICS                      55    75 975
CT   1   SCHWACHMAN H          N ENGL J MED                   296  1519 977
     2   SCHWARZ HP            HELV PAEDIATR ACTA              33   351 978
     3   FINK RJ               CHEST                           74   643 978
     4   ANDREWS C             ANN INTERN MED                  88   128 978
     5   GORDEUK V             N ENGL J MED                   299  1137 978
     6   ANON                  BR MED J                         2   626 979
     7   SEALE TW              J CLIN MICROBIOL                 9    72 979
     8   HOWIE AD              SCOTT MED J                     24   193 979
     9   SHWACHMAN H           CLIN CHEM                       25   158 979
    10   GOLDBERG RT           ARCH PHYS MED REHABIL           60   369 979
    11   SANTAGNESE PAD        AM J MED                        66   121 979
    12   HAHN TJ               J PEDIATR                       94    38 979
    13   NEWMAN AJ             J PEDIATR                       94   594 979
    14   PENNINGTON JE         J INFECT DIS                   139   396 979
    15   ALLAN JL              MED J AUST                       1   600 980
    16   HOLSCLAW DS           CLIN CHEST MED                   1   407 980
    17   PARIENTE EA           GASTROENTEROL CLIN BIOL          4   275 980
    18   WARWICK WJ            J CHRON DIS                     33   685 980
    19   HODSON ME             THORAX                          35   801 980
    20   DAVIS PB              AM J MED                        69   643 980
    21   SANDERS JS            CHEST                           77   226 980
    22   WILLI UV              AM J ROENTGENOL                134  1005 980
    23   MALER T               BIOCHIM BIOPHYS ACTA           598     1 980
    24   FICK RB               CLIN CHEST MED                   2    91 981
    25   PASSERO MA            CLIN PEDIATR                    20   264 981
    26   CAVALIER SJ           NEUROLOGY                       31   714 981
    27   BLACKWOOD LL          INFECT IMMUN                    32   443 981
    28   MULLARKEY MF          MED CLIN NORTH AM               65   977 981
    29   WELCH MJ              PEDIATRICS                      67   664 981
    30   JACOBS WH             AM J GASTROENTEROL              76   342 981
    31   LAMBERT JR            GASTROENTEROLOGY                80   169 981
    32   PARK RW               GASTROENTEROLOGY                81  1143 981
    33   VILASECA J            AM J DIS CHILD                 135   667 981
    34   FRIEDMAN PJ           AM J ROENTGENOL                136  1131 981
    35   HODSON ME             EUR J PEDIATR                  137   117 981
    36   EVENSEN SA            ACTA MED SCAND                 209   141 981
    37   MALER T               J BIOL CHEM                    256  1420 981
    38   COLTEN HR             N ENGL J MED                   304   831 981
    39   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
    40   KISTLER I             HELV PAEDIATR ACTA              36   495 982
    41   OHMAN DE              INFECT IMMUN                    37   662 982
    42   SEVENS C              ANN BIOL CLIN                   40   527 982
    43   RIVERA M              AM REV RESPIR DIS              126   833 982
    44   MCGUIRE S             IR J MED SCI                   151   253 982
    45   WIESEMANN HG          ARCH OTO RHINO LARYNGOL        235   329 982
    46   MASARYK TJ            DIG DIS SCI                     28   874 983
    47   PHELAN MS             CLIN RADIOL                     34   573 983
    48   JEFFREY I             J CLIN PATHOL                   36  1292 983
    49   NEVILLE E             THORAX                          38   929 983
    50   DELUMLEY L            ARCH FR PEDIATR                 40   723 983
    51   GUIDOTTI TL           RESPIRATION                     44   351 983
    52   JOHNSON SR            OBSTET GYNECOL                  61  S  2 983
    53   DAVIS PB              AM REV RESPIR DIS              128    34 983
    54   ROSENBERG E           KLIN PAEDIATR                  195   323 983
    55   HANLY JG              BR MED J                       286  1411 983
    56   HODSON ME             BR MED J                       286  1381 983
    57   IANNUCCI A            HUM PATHOL                      15   278 984
    58   RABKIN CS             ANN NEUROL                      15   608 984
    59   MATTHEWS LW           PEDIATR CLIN NORTH AM           31   133 984
    60   COWEN L               PSYCHOSOM MED                   46   363 984
    61   LEWIS MI              S AFR MED J                     65   641 984
    62   HODGES P              J AM DIET ASSOC                 84   664 984
    63   FITZPATRICK SB        CHEST                           86   863 984
    64   GUGGER M              SCHWEIZ MED WOCHENSCHR         114   620 984
    65   RALPH DD              AM REV RESPIR DIS              129   641 984
    66   HANDELSMAN DJ         N ENGL J MED                   310     3 984
    67   HANDELSMAN DJ         N ENGL J MED                   310  1670 984
    68   SPRINCE  NL           N ENGL J MED                   310   375 984
    69   CRAWFORD AM           RHEUMATOL INT                    5   283 985
    70   LESTER LA             SEM RESPIR MED                   6   285 985
    71   AHMAD HR              ATEMWEGS LUNGENKRANKH           11   366 985
    72   SWOBODNIK W           J CLIN ULTRASOUND               13   469 985
    73   SEAMAN WB             HOSP PRACT                      20   123 985
    74   HUNT B                THORAX                          40    23 985
    75   HANLY JG              Q J MED                         56   377 985
    76   GOLDBERG RT           ARCH PHYS MED REHABIL           66   492 985
    77   ROTH RM               SOUTH MED J                     78   573 985
    78   ISPIZUA AU            MED CLIN                        85   628 985
    79   FRIEDMAN HZ           GASTROENTEROLOGY                88   808 985
    80   REITER EO             J PEDIATR                      106    21 985
    81   STOLLINGER O          WIEN MED WOCHENSCHR            135   307 985
    82   OCONNOR KW            ARCH INTERN MED                145   153 985
    83   SCHANKER HMJ          ARCH INTERN MED                145  2201 985
    84   ISPIZUA AU            REV CLIN ESP                   176   417 985
    85   KOHLER JA             J CLIN HOSP PHARM               11    21 986
    86   SOUTTER VL            CLIN GASTROENTEROL              15   137 986
    87   FIEDOREK SC           CLIN PEDIATR                    25   243 986
    88   SUMMERS GD            BR J RHEUMATOL                  25   393 986
    89   OJEDA VJ              DIS COLON RECTUM                29   567 986
    90   BIGGS BG              CANCER                          57  2441 986
    91   RUBINSTEIN S          PEDIATRICS                      78   473 986
    92   BROWN RF              SOUTH MED J                     79  1430 986
    93   PHILLIPS BM           J ROY SOC MED                   79    44 986
    94   ABDULKARIM FW         ARCH PATHOL LAB MED            110   602 986
    95   TRIBBLE CG            ANN SURG                       204   677 986

PN 77142
RN 00723 
AN 77147066
AU Alpers-D-H.  Seetharam-B.
TI Pathophysiology of diseases involving intestinal brush-border
   proteins.
SO N-Engl-J-Med. 1977 May 5. 296(18). P 1047-50. (REVIEW).
MJ INTESTINAL-MUCOSA: me.  MALABSORPTION-SYNDROMES: me.
   MEMBRANE-PROTEINS: me.
MN ADULT.  ANIMAL.  CONTRACTILE-PROTEINS: me.  CYSTIC-FIBROSIS: me.
   DIABETES-MELLITUS: me.  ENTEROPEPTIDASE: df.  EPITHELIUM: en, me.
   GLYCOLYSIS.  GLYCOPROTEINS: me.  HUMAN.  INFANT.  INFANT-NEWBORN.
   INTESTINAL-MUCOSA: en, ul.  MALABSORPTION-SYNDROMES: en.
   MEMBRANE-PROTEINS: bi.  ORGANOIDS: me.  PANCREATITIS: me.  RATS.
   REVIEW.  SUCRASE: df.  SUPPORT-U-S-GOVT-P-H-S.  EPITHELIUM: cy.
AB The intestinal brush border is a complex organelle that contains
   hydrolytic enzymes, receptors, other proteins involved in transport
   and contractile proteins.  In this article, we review the molecular
   organization of brush-border proteins within the whole membrane, and
   discuss their synthesis and turnover.  This knowledge provides a
   framework for understanding the mechanisms by which certain diseases
   are associated with changes in brush-border proteins.
RF 001   MILLER D              BIOCHIM BIOPHYS ACTA            52   293 961
   002   MAESTRACCI D          BIOCHIM BIOPHYS ACTA           433   469 976
   003   LOUVARD D             J MOL BIOL                     106  1023 976
   004   ALPERS DH             GASTROENTEROLOGY                64   471 973
   005   ALPERS DH             BIOCHIM BIOPHYS ACTA           401    28 975
   006   SEETHARAM B           LIFE SCI                        18    89 976
   007   HOSKINS LC            J CLIN INVEST                   57    63 976
   008   GRAY GM               N ENGL J MED                   294   750 976
   009   HADORN B              LANCET                           1   812 969
   010   FREIBURGHAUS AU       N ENGL J MED                   294  1030 976
   011   SEETHARAM B           GASTROENTEROLOGY                70   A78 976
   012   GIANNELLA RA          GASTROENTEROLOGY                67   965 974
   013   ARVANITAKIS C         AM J DIG DIS                    19   417 974
CT   1   STRYKER JA            INT J RADIAT ONCOL BIOL PHYS     4   859 978
     2   BERENSON MM           CLIN GASTROENTEROL               8   141 979
     3   PHILLIPS AD           GUT                             21    44 980
     4   CHENEY CP             INFECT IMMUN                    28  1019 980
     5   KAUFMAN MA            J CLIN INVEST                   65  1174 980
     6   LUK GD                J CLIN INVEST                   66    66 980
     7   KINSELLA TJ           SURG GYNECOL OBSTET            151   273 980
     8   CARONE FA             AM J PHYSIOL                   238  F151 980
     9   PHILLIPS AD           SCAND J GASTROENTEROL           16    65 981
    10   LUK GD                CANCER RES                      41  2334 981
    11   GUTSCHMIDT S          HISTOCHEMISTRY                  71   451 981
    12   YOUNG GP              BIOCHIM BIOPHYS ACTA           640   131 981
    13   HARRIES JT            CLIN GASTROENTEROL              11    17 982
    14   CATALA J              DIGESTION                       24   234 982
    15   BERGOZ R              ANN NUTR METAB                  26   291 982
    16   CARONE FA             J LAB CLIN MED                 100     1 982
    17   WEISS RG              RADIOLOGY                      142   507 982
    18   GUTSCHMIDT S          ARCH DERMATOL RES              273    85 982
    19   WILDGRUBE HJ          Z GASTROENTEROL                 21   628 983
    20   ARIMA T               CELL TISSUE RES                233   549 983
    21   SINCLAIR TS           HISTOPATHOLOGY                   8   739 984
    22   LEVINE JS             J CELL BIOL                     98  1111 984
    23   PRUITT AW             PEDIATRICS                      76   635 985
    24   LINDBERG R            J COMP PATHOL                   95    65 985
    25   STRYKER JA            INT J RADIAT ONCOL BIOL PHYS    12   789 986
    26   LEBENTHAL E           CLIN PERINATOL                  13    37 986
    27   CASPARY WF            CLIN GASTROENTEROL              15   631 986
    28   ORENSTEIN SR          J PEDIATR                      109   277 986
    29   TIRUPPATHI C          ANAL BIOCHEM                   153   330 986
    30   SASAKI T              ANAT REC                       214   353 986

PN 77143
RN 00724 
AN 77192224
TI Case records of the Massachusetts General Hospital.  Weekly
   clinicopathological exercises.  Case 26-1977.
SO N-Engl-J-Med. 1977 Jun 30. 296(26). P 1519-26.
MJ CYSTIC-FIBROSIS: pa.
MN AGE-FACTORS.  CASE-REPORT.  CYSTIC-FIBROSIS: di.
   DIAGNOSIS-DIFFERENTIAL.  EPIDIDYMIS: pa.  HUMAN.  INTESTINES: pa.
   LIVER: pa.  LUNG-ABSCESS: pa.  LUNG: pa.  MALE.  MIDDLE-AGE.
   PANCREAS: pa.  RESPIRATORY-INSUFFICIENCY: di.  SALIVARY-GLANDS: pa.
   SEMINAL-VESICLES: pa.  SWEAT: an.
EX A 46-year-old office worker was admitted to the hospital because
   of dyspnea.  Anatomical diagnoses were cystic fibrosis, involving
   lungs, salivary glands, pancreas, liver, intestine, epididymis, vas
   deferens, and seminal vesicles, and marked bronchiectasis with
   bronchopneumonia, multiple pulmonary abscesses, and bilateral
   empyema.
RF 001   MURTHY MSN            OHIO STATE MED J                69   768 973
   002   MARKS BL              LANCET                           1   365 960
   003   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
   004   SHWACHMAN H           MOD PROBL PEDIATR               10   158 967
   005   ANDERSON CM           ARCH DIS CHILD                  35   581 960
   006   LANDING BH            ARCH PATHOL                     88   569 969
   007   SHWACHMAN H           PEDIATRICS                      55    86 975
   008   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   009   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   010   PARKINS RA            LANCET                           2   851 963
   011   SHWACHMAN H           N ENGL J MED                   286  1300 972
   012   ESTERLY NB            AM J DIS CHILD                 123   200 972
   013   KAPLAN E              N ENGL J MED                   279    65 968
   014   CZEGLEDY-NAGY E       LAB INVEST                      35   588 976
   015   KOPITO LE             PEDIATR RES                     10   742 976
CT   1   GORDEUK V             N ENGL J MED                   299  1137 978
     2   EVENSEN SA            ACTA MED SCAND                 209   141 981
     3   SING CF               AM J MED GENET                  13   179 982
     4   GOLDBERG RT           ARCH PHYS MED REHABIL           66   492 985
     5   OCONNOR KW            ARCH INTERN MED                145   153 985

PN 77144
RN 00725 
AN 78031151
AU Roy-C-C.  Weber-A-M.  Morin-C-L.  Combes-J-C.  Nussle-D.  Megevand-A.
   Lasalle-R.
TI Abnormal biliary lipid composition in cystic fibrosis.  Effect of
   pancreatic enzymes.
SO N-Engl-J-Med. 1977 Dec 15. 297(24). P 1301-5.
MJ BILE: me.  CHOLELITHIASIS: me.  CYSTIC-FIBROSIS: me.  LIPIDS: me.
   PANCREATIC-EXTRACTS: tu.
MN BILE-ACIDS-AND-SALTS: me.  BILE: an.  CHILD.  CHOLESTEROL: me.
   CHOLIC-ACIDS: an.  COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: dt.  FEMALE.
   GLYCINE: an.  HUMAN.  MALE.  PHOSPHOLIPIDS: me.  SEX-FACTORS.
   TAURINE: an.
AB Because of the increased incidence of gallstones in cystic fibrosis
   we compared biliary lipid composition in 26 patients with cystic
   fibrosis, seven children with cholelithiasis but no cystic-fibrosis
   and 13 controls. Eighteen of the cystic fibrosis group had
   cholecystograms, and only one had gallstones. In 14 patients with
   cystic fibrosis who had stopped taking pancreatic enzymes for one
   week molar percentage of lipid composition accounted for by
   cholesterol (mean +/- S.E., 16.3 +/- 2.9) and saturation index (2.0
   +/- 0.3) were comparable to values of the cholelithiasis group and
   higher (P less than 0.01) than those of controls. In 12 patients with
   cystic fibrosis taking pancreatic enzymes, molar percentage of
   cholesterol (8.6 +/- 1.7) and saturation index (1.0 +/- 0.1) did not
   differ from those of controls; in cystic fibrosis there was a
   preponderance of cholic over chenodeoxycholic acid both off (1.7 +/-
   0.2) and on (1.9 +/- 0.3) therapy as compared to the cholelithiasis
   (0.7 +/- 0.1) and control (0.8 +/- 0.0) groups. The glycine/taurine
   ratio of conjugated bile acids were lower in enzyme-treated patients
   with cystic fibrosis (3.7 +/- 0.6) than in patients off treatment
   (6.4 +/- 1.0), but was higher (P less than 0.01) than in controls
   (1.8 +/- 0.2). Bile is lithogenic in untreated cystic fibrosis and
   responds to pancreatic enzymes.
RF 001   CALABRESE C           SURGERY                         70   413 971
   002   VON BERGMANN J        CLIN CHIM ACTA                  64   241 975
   003   ANDRASSY RJ           AM J SURG                      132    19 976
   004   WEBER AM              N ENGL J MED                   289  1001 973
   005   GOODCHILD MC          ARCH DIS CHILD                  50   769 975
   006   WATKINS JB            GASTROENTEROLOGY                67   835 974
   007   ROVSING H             ACTA RADIOL DIAGN STOCKH        14   588 973
   008   FEIGELSON J           ACTA PAEDIATR SCAND             59   539 970
   009   COURCHAINE AJ         CLIN CHEM                        5   609 959
   010   BARTLETT GR           J BIOL CHEM                    234   466 959
   011   WEBER AM              CLIN CHIM ACTA                  39   524 972
   012   HOFMANN AF            J LIPID RES                      3   127 962
   013   RUDMAN D              J CLIN INVEST                   36   530 957
   014   ENEROTH P             IN: NAIR PP                          121 971
   015   EVRARD E              J LIPID RES                      9   226 968
   016   ROOVERS J             CLIN CHIM ACTA                  19   449 968
   017   ADMIRAND WH           J CLIN INVEST                   47  1043 968
   018   THOMAS PJ             GASTROENTEROLOGY                65   698 973
   019   SCHEFFE H             BIOMETRIKA                      40    87 953
   020   WEBER AM              GUT                             17   295 976
   021   HARRIES JT            PROC INT CF CONG 7TH                     976
   022   PALMER RH             AM J DIG DIS                    21   795 976
   023   DOWLING RH            GUT                             13   415 972
   024   HEATON KW             BR MED J                         3   494 969
   025   GARBUTT JT            GASTROENTEROLOGY                56   711 969
   026   GRUNDY SM             GASTROENTEROLOGY                62  1200 972
   027   SHAFFER EA            N ENGL J MED                   287  1317 972
   028$  SHAFFER EA            J CLIN INVEST                   49   828 977
   029   REDINGER RN           GASTROENTEROLOGY                71   470 976
   030   HEPNER GW             GASTROENTEROLOGY                66   556 974
   031   ISENBERG JN           GASTROENTEROLOGY                66   887 974
   032   DANZINGER RG          N ENGL J MED                   286     1 972
   033   ADLER RD              GASTROENTEROLOGY                68   326 975
   034   COYNE MJ              J LAB CLIN MED                  87   281 976
   035   THISTLE JL            N ENGL J MED                   289   655 973
   036   OPPENHEIMER EH        J PEDIATR                       86   683 975
   037   STERN RC              GASTROENTEROLOGY                70   645 976
   038   SHWACHMAN H           PEDIATR CLIN NORTH AM           22   787 975
CT   1   SCHWARZ HP            HELV PAEDIATR ACTA              33   351 978
     2   ROY CC                N ENGL J MED                   298   352 978
     3   BENNION LJ            N ENGL J MED                   299  1221 978
     4   FEIGELSON J           NOUV PRESSE MED                  8  3029 979
     5   PEARLMAN BJ           CLIN GASTROENTEROL               8   123 979
     6   ROY  CC               AM J CLIN NUTR                  32  2404 979
     7   HARRIES JT            ARCH DIS CHILD                  54    19 979
     8   REDINGER RN           POSTGRAD MED                    65    56 979
     9   BOLCK F               NATURWISSENSCHAFTEN             66    35 979
    10   SANTAGNESE PAD        AM J MED                        66   121 979
    11   COX KL                J PEDIATR                       94   488 979
    12   STREMMEL W            MUNCH MED WOCHENSCHR           121  1721 979
    13   ROY CC                PROC SOC EXP BIOL MED          161   105 979
    14   CAPRON JP             GASTROENTEROL CLIN BIOL          4    63 980
    15   SHMERLING DH          NOUV PRESSE MED                  9  1034 980
    16   DURIE PR              GUT                             21   778 980
    17   SHAFFER EA            CAN J SURG                      23   517 980
    18   GORIUP U              HELV PAEDIATR ACTA              35   177 980
    19   BALISTRERI WF         J PEDIATR                       96   582 980
    20   GAREL L               PEDIATR RADIOL                  11    75 981
    21   MITCHELL EA           AUST PAEDIATR J                 17   207 981
    22   MITCHELL EA           AUST PAEDIATR J                 17    89 981
    23   JACOBS WH             AM J GASTROENTEROL              76   342 981
    24   LAMBERT JR            GASTROENTEROLOGY                80   169 981
    25   PARK RW               GASTROENTEROLOGY                81  1143 981
    26   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
    27   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
    28   ABDULKARIM FW         GASTROENTEROLOGY                82   758 982
    29   BALISTRERI WF         J PEDIATR GASTROENTEROL NUTR     2   105 983
    30   ROY CC                J PEDIATR GASTROENTEROL NUTR     2   152 983
    31   GRUNDY SM             SEM LIVER DIS                    3    97 983
    32   BOUCHIER IAD          CLIN GASTROENTEROL              12    25 983
    33   DORVIL NP             AM J CLIN NUTR                  37   221 983
    34   SHAFER AD             AM SURGEON                      49   314 983
    35   TAZAWA Y              ARCH DIS CHILD                  58   819 983
    36   DOHERTY DE            SOUTH MED J                     76  1580 983
    37   BASS S                GASTROENTEROLOGY                84  1592 983
    38   TAZAWA Y              J PEDIATR GASTROENTEROL NUTR     3   378 984
    39   ABRAMS CK             J CLIN INVEST                   73   374 984
    40   DAVIS PB              CHEST                           85   802 984
    41   HUBBARD VS            SEM RESPIR MED                   6   299 985
    42   DARLING PB            PEDIATR RES                     19   578 985
    43   ROBB TA               GUT                             26  1246 985
    44   SETCHELL KDR          CLIN CHIM ACTA                 151   101 985
    45   WEBER AM              ACTA PAEDIATR SCAND SUPPL 317 1985     9 985
    46   STERN RC              J PEDIATR GASTROENTEROL NUTR     5    35 986
    47   LUSSIERCACAN S        CLIN INVEST MED                  9    94 986
    48   WEIZMAN Z             GUT                             27  1043 986
    49   LEROY C               DIG DIS SCI                     31   911 986
    50   BRAGGION C            ARCH DIS CHILD                  62   349 987

PN 77145
RN 00726 
AN 77171258
AU Wilson-C-B.  Fudenberg-H-H.
TI Ciliary dyskinesia factors in cystic fibrosis and asthma.
SO Nature. 1977 Mar 31. 266(5601). P 463-4.
MJ ASTHMA: bl.  BLOOD-PROTEINS: ip.  CILIA: de.  CYSTIC-FIBROSIS: bl.
MN ANTIGENIC-DETERMINANTS.  BIOLOGICAL-ASSAY.  BLOOD-PROTEINS: im, pd.
   COMPARATIVE-STUDY.  COMPLEMENT-3.  EPITHELIUM: de.  HUMAN.
   MOVEMENT: de.  TRACHEA: de.  SUPPORT-U-S-GOVT-NON-P-H-S.
   EPITHELIUM: cy.
EX Using a modified rabbit tracheal bioassay, we have confirmed that
   serum from individuals with bronchial asthma and serum from
   homozygotes and heterozygotes for CF cause ciliary dyskinesia,
   whereas normal healthy control sera do not.  To evaluate the
   specificity of the ciliary dyskinesia activity (CDA) detected, we
   bioassayed serum from eight patients with bronchial asthma.  We
   found that all eight asthmatic sera caused a ciliary dyskinesia
   reaction; however, sera from asthmatics generally caused a
   subsequent ciliostasis (cessation of ciliary beating).  Concurrent
   evaluation of all sera for CDA by bioassay and for cystic fibrosis
   protein (CFP) by electrofocusing showed that all CDA-positive sera
   except seven of the eight asthmatic sera were also positive for CFP
   (our specific marker for the CF gene).  These two finding indicated
   that the activity detected in patients with asthma and other
   respiratory diseases could be a substance different from a
   CF-specific CDF.  To test our hypothesis, we set out to purify the
   CDAs in asthmatic, CF homozygote and OHCF sera.  Representative
   results clearly indicate that the asthmatic CDA is found in DEAE-II
   and Sephadex G-200 Fraction II, whereas the CDA found in CF and OHCF
   sera elutes in DEAE-I and Sephadex G-200 Fractions III and IV (weak
   CDA).  We conclude that the CDAs in asthma and CF are distinct
   substances.  Our findings may facilitate purification of what we
   feel is a CF-specific CDF from CF and OHCF serum.  Purification is a
   prerequisite to elucidating the exact nature of this substance and
   its role in the pathophysiology of CF.
RF 001   SPOCK A               PEDIATR RES                      1   173 967
   002   CONOVER JH            PEDIATR RES                      7   220 973
   003   WILSON GB             CLIN RES                        24   295 976
   004   WILSON GB             PEDIATR RES                     11   143 977
   005   CONOVER JH            LANCET                           1  1194 973
   006   CONOVER JH            LIFE SCI                        14   253 974
   007   CONOVER JH            LANCET                           2  1501 973
   008   CHERRY JD             J PEDIATR                       79   937 971
   009   CHRISTENSEN J         IN: LAWSON D PROC 5TH INT CF          49 969
   010   POSSELT HG            Z KINDERHEILK                  110    93 971
   011   WILSON GB             PEDIATR RES                      9   635 975
   012   WILSON GB             TEX REP BIOL MED                34    51 976
   013   WILSON GB             PEDIATR RES                     10  1001 976
   014   WILSON GB             PEDIATR RES                     11   139 977
   016   WILSON GB             SCAND J IMMUNOL                  5   829 976
   017   DI SANTAGNESE PA      N ENGL J MED                   295   534 976
   020   BOWMAN BH             SCIENCE                        164   325 969
   021   BARNETT DR            PEDIATR RES                      8   687 974
   022   LOCKHART LH           TEX REP BIOL MED                31   631 973
   023$  BERATIS NG            PEDIATR RES                      8   687 974
   024   WILSON GB             PEDIATR RES                     10    87 976
   025   WILSON GB             CLIN RES                        25    34 977
   027   SHAPIRA E             PEDIATR RES                     10   812 976
CT   1   BANSCHBACH MW         BIOCHEM BIOPHYS RES COMMUN      84   922 978
     2   WILSON GB             J LAB CLIN MED                  92   463 978
     3   WILL PC               PEDIATR RES                     13  1129 979
     4   WILSON GB             PEDIATR RES                     13  1079 979
     5   AFZELIUS BA           INT REV EXP PATHOL              19     1 979
     6   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     7   LEWISTON NJ           CHEST                           80   389 981
     8   MCNEELY MC            PEDIATR RES                     16    21 982
     9   DULFANO MJ            THORAX                          37   646 982
    10   DULFANO MJ            CLIN SCI                        63   393 982
    11   GREENSTONE M          EUR J RESPIR DIS                64   480 983
    12   SMALLMAN LA           THORAX                          39   663 984
    13   SCAMBLER  P           HUM GENET                       69   250 985
    14   GREENSTONE M          BR J DIS CHEST                  79     9 985

PN 77146
RN 00727 
AN 77147208
AU Peterson-J-A-Jr.  Harry-R-D.
TI Intussusception in patients with cystic fibrosis.
SO Nebr-Med-J. 1977 Apr. 62(4). P 93-5.
MJ CYSTIC-FIBROSIS: co.  INTUSSUSCEPTION: et.
MN ADOLESCENCE.  CASE-REPORT.  HUMAN.  MALE.
AB A 16-year-old boy with cystic fibrosis had intermittent episodes of
   abdominal pain probably due to recurrent intussusceptions.  This
   type of bowel obstruction is probably more frequent in patients with
   fibrocystic disease.  Thick, vascid, inspissated feces appears to be
   the cause of the intussusceptions.  Prevention of the inspissation
   may reduce the incidence of these obstructions.  The treatment for
   this problem is the same as in other (noncystic) patients.
RF 001   HOLSCLAW DS           PEDIATRICS                      48    51 971
   002   SELIGER G             AM J DIG DIS                    17   934 972
   003   KOPEL FB              GASTROENTEROLOGY                62   483 972
   004   PONKA JL              SURG GYNECOL OBSTET            124    99 967
   005   MCLAUGHLIN CW JR      ARCH SURG                       56    48 948
   006   ELLIS H               IN: MAINGOT R                       1525 969

PN 77147
RN 00728 
AN 77100825
AU Geller-A.  Gilles-F.  Shwachman-H.
TI Degeneration of fasciculus gracilis in cystic fibrosis.
SO Neurology (Minneap). 1977 Feb. 27(2). P 185-7.
MJ CYSTIC-FIBROSIS: pa.  NERVE-DEGENERATION.  SPINAL-CORD: pa.
MN ADOLESCENCE.  AUTOPSY.  CHILD-PRESCHOOL.  CHLORAMPHENICOL: ae.
   CYSTIC-FIBROSIS: co, dt.  HUMAN.  OPTIC-NEURITIS: et.
   SUPPORT-U-S-GOVT-P-H-S.
AB The spinal cords of 19 percent of patients dying with cystic fibrosis
   after 5 years of age showed posterior column degeneration. The risk
   did not appear to increase with advancing age. None of these patients
   had findings of pernicious anemia or spinocerebellar degeneration.
   The lesions had been undetected clinically. It is possible that
   nutritional, toxic, or hereditary factors may play a role in
   producing this lesion.
RF 001   SPENCE AM             NEUROLOGY (MINN)                21   386 971
   002   GILLES FH             J NEUROPATH EXP NEUROL          25   138 966
   003   HARLEY RD             TRANS AM ACAD OPHTHALMOL OTOL   74  1011 970
   004   SUNG JH               J NEUROPATH EXP NEUROL          23   567 964
   005   EINARSON L            EFFECT OF CHRONIC VITAMIN E D            938
   006   PENTSCHEW A           ACTA NEUROPATH (BERL)            1   313 962
   007   SWAIMAN KF            NEUROLOGY (MINN)                23   474 973
   008   SWAIMAN KF            NEUROLOGY (MINN)                25  1084 975
   009   CAMPBELL AW           BRAIN                           20   488 897
CT   1   TOMASI LG             NEUROLOGY                       29  1182 979
     2   FISCHER EG            J PEDIATR                       95   385 979
     3   SHAPIRA Y             ANN NEUROL                      10   266 981
     4   CAVALIER SJ           NEUROLOGY                       31   714 981
     5   NELSON JS             J NEUROPATHOL EXP NEUROL        40   166 981
     6   ROSENBLUM JL          N ENGL J MED                   304   503 981
     7   HOOGENRAAD TU         NEUROOPHTHALMOL                  2   267 982
     8   HARDING AE            ANN NEUROL                      12   419 982
     9   HOWARD L              AM J CLIN NUTR                  36  1243 982
    10   SAITO K               ACTA NEUROPATH (BERL)           58   187 982
    11   GUGGENHEIM MA         J PEDIATR                      100    51 982
    12   GUGGENHEIM MA         ANN NY ACAD SCI                393    84 982
    13   GUGGENHEIM MA         J PEDIATR                      102   577 983
    14   BIERI JG              N ENGL J MED                   308  1063 983
    15   MESSENHEIMER JA       ANN NEUROL                      15   499 984
    16   BERTONI JM            NEUROLOGY                       34  1046 984
    17   CARPENTER D           SEM NEUROL                       5   283 985
    18   WILLISON HJ           J NEUROL NEUROSURG PSYCHIAT     48  1097 985
    19   HARDING AE            N ENGL J MED                   313    32 985
    20   KRENDEL DA            NEUROLOGY                       37   538 987

PN 77148
RN 00729 
AN 78052421
AU Liberi-P-T.
TI Cystic fibrosis.
SO Nurs-Care. 1977 Dec. 10(12). P 22-5, 30.
MJ CYSTIC-FIBROSIS.
MN CASE-REPORT.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: nu.
   HOME-CARE-SERVICES.  HUMAN.  MALE.  PROFESSIONAL-FAMILY-RELATIONS.
EX The nurse is an indispensable member of the team of health
   professionals who provide the comprehensive treatment needed by
   patients with the complex, emotionally, and physically demanding
   disease, cystic fibrosis.  Comprehensive medical management by a
   health care team composed of the physician, nurse, social worker,
   physical therapist, nutritionist, and psychologist is essential for
   patients with CF and other forms of obstructive pulmonary disease.

PN 77149
RN 00730 
AN 78031677
AU Clegg-K-M.
TI Nitrogen balance trials with cystic fibrosis patients.
SO Nutr-Metab. 1977. 21 Suppl 1. P 77-9.
MJ CYSTIC-FIBROSIS: me.  NITROGEN: me.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  DIETARY-PROTEINS: ad.
   FEMALE.  HUMAN.  HYDROLYSIS.  MALE.  PANCREATIC-EXTRACTS: ad.
EX Preliminary nitrogen balance trials have been carried out with six
   patients known to have pancreatic insufficiency to investigate the
   utilisation of protein from a general diet; protein from a general
   diet plus exogenous pancreatic extract; and pre-digested protein,
   comprising 85% of dietary nitrogen intake, in the absence of a
   pancreatic supplement.  In all cases, the addition of pancreatic
   supplement to the general diet improved protein digestibility and
   utilisation.  Substituting 85% of the dietary protein with the
   enzymic casein hydrolysate resulted in further improvement in
   nitrogen balance (but not digestibility) for five of the patients.
   Urinary nitrogen levels of the casein hydrolysate diet tended to be
   lower, which accounts for the finding above.  With the
   acid-hydrolysed protein, urinary nitrogen was higher when compared
   with the excretion from the partial casein hydrolysate and provided
   smaller positive nitrogen balances.  These preliminary findings
   indicate that, for some patients with pancreatic insufficiency,
   partial hydrolysates have greater potential for nitrogen retention
   than the administration of exogenous pancreatic extracts with intact
   protein.  It is suggested that a daily supplement of pre-digested
   protein might be advantageous for CH children to ensure that minimum
   protein requirements are met.
RF 001   CLEGG KM              J FD TECHNOL                     9   425 974

PN 77150
RN 00731 
AN 77233274
AU Buganski-R.
TI Regional pediatric pulmonary centers in Ohio.
SO Ohio-State-Med-J. 1977 Jun. 73(6). P 363-5,369.
MJ CYSTIC-FIBROSIS: th.  HOSPITALS-SPECIAL.
   RESPIRATORY-TRACT-DISEASES: th.
MN CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: di.  FEMALE.  HUMAN.  INFANT.
   INFANT-NEWBORN.  MALE.  OHIO.  REGIONAL-MEDICAL-PROGRAMS.
AB Acute and chronic respiratory disorders play a large role in the
   practitioner's daily care of infants, children, and adolescents.  To
   assist with the more sophisticated problems in these diseases, the
   Ohio Committee on Pulmonary Standards has established pediatric
   pulmonary care centers distributed over the State of Ohio.  Referral
   to these centers may be requested by the practicing physician.  To
   illustrate the validity of this concept, this article reviews the
   care given to patients with cystic fibrosis (CF), the improved
   prognosis for this disease entity, and the advantages of expertise
   and of centralized care.
RF 001$  KENDIG EL JR          IN: DOERSHUK CF                          971
   002   BLACKFAN KD           J PEDIATR                       13   627 938
   003   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   004   MATTHEWS LW           J PEDIATR                       65   558 964
   005   DI SANTAGNESE PA      AM J MED                        15   777 953
   006   DOERSHUK CF           IN: GREEN M                          707 965
   007   GIBSON LE             PEDIATRICS                      23   545 959
   008   STEPHAN U             PEDIATRICS                      55   474 976
   009   ELLIOTT RB            PEDIATRICS                      57   474 976
   010   MATTHEWS LW           PEDIATRICS                      39   176 967
   011   BAU SK                PEDIATRICS                      48   605 971
   012   WARWICK WJ            STATISTICAL ANALYSIS OF NATIO            974

PN 77151
RN 00732 
AN 77172193
AU Jaffe-B-F.  Strome-M.  Khaw-K-T.  Shwachman-H.
TI Nasal polypectomy and sinus surgery for cystic fibrosis--a 10 year
   review.
SO Otolaryngol-Clin-North-Am. 1977 Feb. 10(1). P 81-90.
MJ CYSTIC-FIBROSIS.  NASAL-POLYPS: su.  SINUSITIS: su.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: fg.
   ETHMOID-BONE: su.  HUMAN.  MAXILLARY-SINUS: su.  NASAL-BONE: su.
   NASAL-POLYPS: fg.  NASAL-SEPTUM: su.  NEOPLASM-RECURRENCE-LOCAL.
   OROANTRAL-FISTULA: su.  PREOPERATIVE-CARE.
EX Patients with cystic fibrosis are likely to develop nasal polyps and
   pansinusitis.  This presentation concerns the results of various
   surgical procedures used to treat nasal polyposis in cystic
   fibrosis.  At present recurrent nasal polyposis is still the major
   problem following surgery.  The literature does not deal
   specifically with comparisons of different surgical procedures aimed
   at controlling nasal obstruction or with the surgical management of
   sinus disease in cystic fibrosis patients.  Perhaps this lack
   reflects the unsatisfactory results that would have to be reported,
   since a high recurrence rate is expected.  Also the prolonged
   survival in these children means that more of them are reaching
   adolescence and adulthood with an increasing risk for nasal
   obstruction and nasal polyposis.
RF 001   BAKER DC JR           OTOL CLIN NORTH AM               3   257 970
   002   GHARIB R              AM J DIS CHILD                 108   499 964
   003   NEELY JG              TRANS AM ACAD OPHTHALMOL OTOL   76   313 972
   004   SHWACHMAN H           PEDIATRICS                      30   389 962
   005   SINGH K               J LARYNGOL OTOL                 85   185 971
   006   WALTERS TR            AM J DIS CHILD                 124   641 972
CT   1   SCHRAMM VL            LARYNGOSCOPE                    90  1488 980
     2   JACOBS RL             J ALLERGY CLIN IMMUNOL          67   253 981
     3   BRADLEY PJ            CLIN OTOLARYNGOL                 7    87 982
     4   JOHNSON JT            POSTGRAD MED                    72    87 982
     5   FAIRBANKS DNF         OTOLARYNGOL HEAD NECK SURG      90   527 982
     6   STERN RC              AM J DIS CHILD                 136  1067 982
     7   SHAPIRO ED            J INFECT DIS                   146   589 982
     8   SHWACHMAN H           J PEDIATR SURG                  18   570 983
     9   FAIRBANKS DNF         PEDIATR INFECT DIS               4  S 75 985
    10   DAVIS PB              SEM RESPIR MED                   6   319 985
    11   REILLY JS             LARYNGOSCOPE                    95  1491 985
    12   DAVID TJ              J ROY SOC MED                   79    23 986
    13   MYERS EN              LARYNGOSCOPE                    96   911 986

PN 77152
RN 00733 
AN 77172178
AU Kramer-R-I.
TI Otorhinolaryngologic complications of cystic fibrosis.
SO Otolaryngol-Clin-North-Am. 1977 Feb. 10(1). P 205-8.
MJ CYSTIC-FIBROSIS: co.  OTORHINOLARYNGOLOGIC-DISEASES: et.
MN ADOLESCENCE.  CELL-MEMBRANE-PERMEABILITY.  CHILD.
   CYSTIC-FIBROSIS: et, pp.  HUMAN.  LARYNGEAL-NEOPLASMS: et, su.
   NASAL-POLYPS: et, su.  OTITIS-MEDIA: dt, et.  SALIVARY-GLANDS: se.
AB Inasmuch as cystic fibrosis is a generalized exocrinopathy and
   affects all the mucous glands in the body, the complications of this
   disease involving the ear, nose, and throat are obviously protean.
   This presentation includes a discussion of chronic ear infections
   relative to the diagnosis of cystic fibrosis, a discussion of nasal
   polyps and their treatment, salivary gland involvement in cystic
   fibrosis, and the results of sialography.  The effects of
   respiratory therapy upon the upper respiratory tract and the
   problems of general anesthesia in patients who undergo surgical
   procedures are also discussed.
CT   1   MYER CM               PEDIATRICS                      72   766 983
     2   TODD NW               INT J PEDIATR OTORHINOLARYNGO   10    27 985
     3   DAVID TJ              J ROY SOC MED                   79    23 986

PN 77153
RN 00734 
AN 77256116
AU Holsclaw-D-S.  Tecklin-J-S.
TI A critical evaluation of bronchial hygiene in pediatric pulmonary
   disease.
SO Pediatr-Ann. 1977 Aug. 6(8). P 550-6.
MJ BRONCHI.  CYSTIC-FIBROSIS: th.
MN AEROSOLS.  ANTIBIOTICS: tu.  BRONCHODILATOR-AGENTS: tu.  CHILD.
   CYSTIC-FIBROSIS: dt, pp, su.  DRAINAGE.  EXPECTORANTS: tu.  HUMAN.
   RESPIRATORY-THERAPY.  RESPIRATION.
AB The variables inherent in analyzing the effectiveness of modalities
   used to achieve bronchial hygiene are numerous. Treatments may be
   given in a variety of settings, including intensive-care units,
   pediatric wards, respiratiory therapy departments, physical therapy
   departments, chronic-care hospitals, special education centers, and
   patient homes. Treatments are administered by a variety of medical
   professionals, allied health personnel, and lay volunteers.
   Motivation of the care providers as well as of the patients may vary
   greatly. Also, efforts are needed to study patients at comparable
   stages in their growth and development and in the progression of
   their particular diseases. Rather than perpetuating the unquestioning
   use of these various treatments, a series of carfully constructed and
   controlled studies done in collaborative fashion need to be
   performed. Until that time, the recommendations we have outlined
   dealing with each of the various segments of bronchial hygiene may
   serve as useful guidelines.
RF 001   DENTON R              AM REV RESPIR DIS               86    41 962
   002   LORIN MI              AM J PHYS MED                   50   215 971
   003   WONG JW               AM REV RESPIR DIS              113    97 976
   004   MOTOYAMA EK           IN: MANGOS JA                        335 973
   005   TECKLIN JS            PHYS THER                       55  1081 975
   006   FELDMAN J             AM REV RESPIR DIS              113   272 976
   007   LEVISON H             IN: MANGOS JA                          3 976
   008   WEBB WR               J THORAC CARDIOVASC SURG        44   330 962
   009   REAS HW               J PEDIATR                       62    31 963
   010   REAS HW               SOUTH MED J                     56  1271 963
   011   HUANG NN              CF CLUB ABST                     5    12 964
   012   STAMM SJ              DIS CHEST                       47   414 965
   013   DENTON R              AM REV RESPIR DIS               95   643 967
   014   LIEBERMAN J           JAMA                           205   312 968
   015   ADHIKARI PK           CF CLUB ABST                     9    29 968
   016   LIFSCHITZ MI          CF CLUB ABST                     9    48 968
   017   SOLOMONS CC           PEDIATRICS                      47   384 971
   018   BUSCH-PETERSEN D      Z ERKR ATMUNGSORGANE           143   140 975
   019   DIETZSCH HJ           PEDIATRICS                      55    96 975
   020   GANDEVIA B            ARCH DIS CHILD                  34   511 959
   021   LIFSCHITZ MI          AM REV RESPIR DIS               99   399 969
   022   FEATHERBY EA          CAN MED ASSOC J                102   835 970
   023   ZAPLETAL A            PEDIATRICS                      48    64 971
   024   LANDAU LI             J PEDIATR                       82   863 973
   025   CHANG N               AM REV RESPIR DIS              106   867 972
   026   SHAPIRO GG            PEDIATRICS                      58   740 976
   027   GIBBS GE              ANTIBIOT MED                     2   332 956
   028   GIBBS GE              AM J DIS CHILD                  93    65 957
   029   CAMPBELL RA           CF CLUB ABST                    10    31 969
   030   CAMPBELL RA           CF CLUB ABST                    12    30 971
   031   LIFSCHITZ MI          CLIN PHARMACOL THER             12    91 971
   032   BARAN D               INT J CLIN PHARMACOL            12   336 975
   033   OLSON DL              RESPIR CARE                     21   333 976
   034   TECKLIN JS            PHYS THER                       56   999 976
   035   ANON                  AM REV RESPIR DIS              110   169 974
   036   KEENS TG              PEDIATR RES ABST                11   573 977

PN 77154
RN 00735 
AN 77124776
AU Selekman-J.
TI Cystic fibrosis: what is involved in the home treatment program for
   these children, adolescents and young adults?.
SO Pediatr-Nurs. 1977 Mar-Apr. 3(2). P 32-5.
MJ CYSTIC-FIBROSIS: th.  HEALTH-EDUCATION.  HOME-NURSING.
MN ADOLESCENCE.  ADULT.  BREATHING-EXERCISES.  CHILD.
   CYSTIC-FIBROSIS: dh.  HUMAN.
EX Cystic fibrosis is one of the most frequent of the serious chronic
   diseases of childhood and adolescence and is the most common genetic
   disease among Caucasian children.  Medical research and home
   treatment programs have greatly improved the outlook for these
   children.  The nursing profession has played a significant role in
   this progress at home, the hospital, the school, and the community.
   Our goal is to teach the treatments that may help maintain the
   health of these children for as long as possible and, in the face of
   this, to help them and their families to lead as normal a life as
   possible.

PN 77155
RN 00736 
AN 84192886
AU Matthew-D-J.  Warner-J-O.  Chrispin-A-R.  Norman-A-P.
TI The relationship between chest radiographic scores and respiratory
   function tests in children with cystic fibrosis.
SO Pediatr-Radiol. 1977. 5(4). P 198-200.
MJ CYSTIC-FIBROSIS: ra.  RESPIRATORY-FUNCTION-TESTS.
   THORACIC-RADIOGRAPHY.
MN ADOLESCENCE.  CHILD.  CYSTIC-FIBROSIS: pp.  FORCED-EXPIRATORY-VOLUME.
   FUNCTIONAL-RESIDUAL-CAPACITY.  HUMAN.  VITAL-CAPACITY.
AB Chest radiographic scores and respiratory function on 80 sets of
   results from 50 patients with Cystic Fibrosis were analyzed. Chest
   radiographic scores were assessed independently using the method of
   Chrispin and Norman. Respiratory function tests were found to
   correlate well with the chest radiographic score, the best
   correlation being with the forced expiratory volume in 0.75 sec. to
   forced vital capacity ratio F.E.V. 0.75/ F.V.C. (r = -0.674 n = 80 p
   less than 0.001).
RF 001   BEIER FR              AM REV RESPIR DIS               94   430 966
   002   COGSWELL JJ           BR J DIS CHEST                  69   177 975
   003   COGSWELL JJ           BR J DIS CHEST                  69   177 975
   004   COGSWELL JJ           BR J DIS CHEST                  69   177 975
   005   COOPERMAN EM          CAN MED ASSOC J                105   580 971
   006   CHRISPIN AR           PEDIATR RADIOL                   2   101 974
   007   DOERSHUK CF           J PEDIATR                       65   677 964
   008   DUBOIS AB             J CLIN INVEST                   35   322 956
   009   FEATHERBY EA          AM REV RESPIR DIS              102   737 970
   010   GODFREY S             ARCH DIS CHILD                  46   144 971
   011   KARLSBERG P           ACTA PAEDIATR SCAND             49   345 960
   012   MEARNS MB             ARCH DIS CHILD                  43   528 968
   013   REILLY BJ             RADIOLOGY                       98   281 971
   014   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   015   TAUSSIG LM            J PEDIATR                       82   380 973
   016   WOOD RE               AM REV RESPIR DIS              113   833 976
CT   1   KRAEMER R             HELV PAEDIATR ACTA              34   417 979
     2   BRASFIELD D           PEDIATRICS                      63    24 979
     3   KRAEMER R             SCHWEIZ MED WOCHENSCHR         109    39 979
     4   BRASFIELD D           AM J ROENTGENOL                134  1195 980
     5   VANDERPUT JM          PEDIATR RADIOL                  12    57 982
     6   KRAEMER R             EUR J PEDIATR                  138   172 982
     7   GOODING CA            J PEDIATR                      105   384 984

PN 77156
RN 00737 
AN 78011299
AU Rao-G-J.  Spells-G.  Nadler-H-L.
TI Enhanced UDP-galactose:glycoprotein galactosyl transferase activity
   in cultivated skin fibroblasts from patients with cystic fibrosis
   and its possible relationship to the pathogenesis of the disease.
SO Pediatr-Res. 1977 Sep. 11(9 Pt 1). P 981-5.
MJ CYSTIC-FIBROSIS: en.  GALACTOSYLTRANSFERASES: me.  SKIN: en.
MN CELLS-CULTURED.  CULTURE-MEDIA.  CYSTIC-FIBROSIS: fg.
   ENZYME-ACTIVATION.  FIBROBLASTS.  HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.
   OVALBUMIN.  PEPTIDES: pd.  SUPPORT-U-S-GOVT-P-H-S.
   URIDINE-DIPHOSPHATE-GALACTOSE.
AB Homogenates of cultivated skin fibroblasts derived from patients with
   cystic fibrosis had a higher level of UDP-galactose:ovalbumin
   galactosyl transferase activity compared to fibroblasts derived from
   control subjects. The activity in control subjects was 1.82 +/- 0.43
   nmol galactose transferred/hr/mg protein, whereas the activity in
   fibroblasts of patients was 2.95 +/- 0.77. The difference was
   significant at P less than 0.01. Activity in the fibroblasts of
   obligate heterozygotes was 2.15 +/- 0.60. The difference between the
   activities in fibroblasts of heterozygotes and patients was
   significant at P less than 0.05. The activity in control fibroblasts
   could be enhanced by basic polypeptides like polylysine,
   polyarginine, histone, and protamine but not by neutral or acidic
   polypeptides. Fibroblasts from patients released significantly higher
   amounts of a soluble form of the enzyme activity into the culture
   medium than control fibroblasts.
RF 001   ARMITAGE P            STATISTICAL METHODS IN MEDICA            971
   002   BAKER AP              ARCH BIOCHEM BIOPHYS           165   597 974
   003   BOWMAN BH             PROC NAT ACAD SCI USA           70   548 973
   004   BOWMAN BH             SCIENCE                        167   871 970
   005   BUTTERWORTH J         CLIN CHIM ACTA                  56   159 974
   006   CONOD EJ              PEDIATR RES                      9   724 975
   007   CONOVER JH            PEDIATR RES                      7   220 973
   008   DANES BS              LANCET                           1  1061 968
   009   DEPPERT W             PROC NAT ACAD SCI USA           71  3068 974
   010   FORSTNER JF           PEDIATR RES                     10   609 976
   011   FRASER IH             BIOCHEM J                      156   347 976
   012   FREILICH LS           BIOCHEM J                      146   741 975
   013   GUGLER EC             J PEDIATR                       71   585 967
   014   LANGER GA             SCIENCE                        193  1013 976
   015   LOBECK CC             IN: STANBURY JB                     1605 972
   016   LOUISOT P             CLIN CHIM ACTA                  48   373 973
   017   MANGOS JA             SCIENCE                        158   135 967
   018   MANGOS JA             PEDIATR RES                      1   436 967
   019   MATALON R             FED PROC                        35  1639 976
   020   MICHALISZYN GA        J BIOL CHEM                    251  2531 976
   021   NADLER HL             NATURE                         213  1261 967
   022   RAO GJS               J PEDIATR                       80   573 972
   023   RAO GJS               PEDIATR RES                      8   684 974
   024   RAO GJS               PEDIATR RES                      9   739 975
   025   RAO GJS               SCIENCE                        177   610 972
   026   SCHMOYER IR           BIOCHEM BIOPHYS RES COMMUN      58  1066 974
   027   SCHRAMM M             IN: MANGOS JA                        215 973
   028   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      71   864 976
   029   SHAPIRA E             PEDIATR RES                     10   812 976
   030   SPOCK A               PEDIATR RES                      1   173 967
   031   WILSON GB             PEDIATR RES                     10    87 976
   032   WORK TS               LAB TECH IN BIOCHEM AND MOLEC    1    34 969
CT   1   BERGER EG             EUR J BIOCHEM                   90   213 978
     2   RAO GJS               BIOCHIM BIOPHYS ACTA           541   435 978
     3   AGGETT PJ             MONOGR PAEDIATR                 10     8 979
     4   NAGY EC               PEDIATR RES                     13   729 979
     5   PEARSON RD            PEDIATR RES                     13   834 979
     6   WILSON GB             PEDIATR RES                     13  1079 979
     7   CAMPBELL IM           CAN J BIOCHEM                   57  1099 979
     8   KOTTGEN E             KLIN WSCHR                      57   199 979
     9   JAKEL HP              BIOL ZENTRALBL                  98    55 979
    10   WALSH MMJ             PEDIATR RES                     14   353 980
    11   BENYOSEPH Y           BIOCHIM BIOPHYS ACTA           718   172 982
    12   FRATES RC             PEDIATR RES                     17    30 983
    13   RUDICK VL             J CELL PHYSIOL                 115   143 983
    14   BUTTERWORTH J         BIOCHEM SOC TRANS               13   220 985
    15   BRAGANZA JM           MED HYPOTHESES                  20   233 986
    16   BOZON D               ARCH BIOCHEM BIOPHYS           249   546 986

PN 77157
RN 00738 
AN 77124792
AU Wilson-G-B.  Monsher-M-T.  Fudenberg-H-H.
TI Studies on cystic fibrosis using isoelectric focusing.  III.
   Correlation between cystic fibrosis protein and ciliary dyskinesia
   activity in serum shown by a modified rabbit tracheal bioassay.
SO Pediatr-Res. 1977 Feb. 11(2). P 143-6.
MJ BLOOD-PROTEINS: an.  CYSTIC-FIBROSIS: bl.  ISOELECTRIC-FOCUSING.
MN ANIMAL.  ASTHMA: pp.  BIOLOGICAL-ASSAY.  CILIA: de.
   CYSTIC-FIBROSIS: pp.  HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.  IGG: an.
   IN-VITRO.  METHODS.  MUCOUS-MEMBRANE: se.  RABBITS.  TISSUE-CULTURE.
   TRACHEA: de.
AB We have developed a modified rabbit tracheal bioassay for use in
   investigating a possible correlation between cystic fibrosis protein
   (CFP) and ciliary dyskinesia factor (CDF) in human serum. The
   bioassay requires high standards of tissue selection, and all
   epithelial tissue must be free of underlying connective tissue. When
   serum samples were collected and processed carefully and warmed to 37
   degrees before assay, CDF could be reliably detected in 31 of 31 sera
   from cystic fibrosis (CF) homozygotes or obligate heterozygotes in 35
   min or less without prior fractionation or concentration of sera,
   whereas 13 of 14 normal control sera were nonreactive. CDF-positive
   serum reacts in three consecutive phases: (1) initial increase in
   ciliary beat frequency, (2) ciliary dyskinesia, and (3) tissue
   destruction with extrusion of single ciliated cells, mucus, and
   debris. Our results confirm the association of CDF with cystic
   fibrosis. The bioassay is not specific for CF, however, when whole
   sera are bioassayed, since serum from several patients with bronchial
   asthma also caused ciliary dyskinesia. However, this finding need not
   preclude using rabbit tracheal ciliated epithelial tissue as an assay
   for following the purification of CDF. Isoelectric focusing showed
   that the presence or absence of CFP corresponded with that of
   dyskinesia activity in all sera tested except for the active samples
   from seven asthma patients, which were negative for CFP. The results
   indicate that CFP and CDF may be identical or closely related markers
   for the CF gene, and suggest that the activity detected by the rabbit
   tracheal bioassay in sera from patients with asthma and other
   diseases probably is caused by a substance different from a CF-
   specific CDF.
RF 001   BARNETT DR            TEX REP BIOL MED                31   703 973
   002   BOWMAN BH             IN: MANGOS JA                         29 973
   003   BOWMAN BH             LANCET                           1   404 974
   004   CHERRY JD             J PEDIATR                       79   937 971
   005   CHEUNG ATW            PEDIATR RES                     10   144 976
   006   CHEUNG ATW            PEDIATR RES                     10   144 976
   007   CHRISTENSEN J         IN: LAWSON D PROC 5TH INT CF          49 969
   008   CONOVER JH            PEDIATR RES                      7   220 973
   009   CONOVER JH            LANCET                           1  1194 973
   010   CONOVER JH            LIFE SCI                        14   253 974
   011   LOCKHART LH           TEX REP BIOL MED                31   631 973
   012   MCCOMBS ML            TEX REP BIOL MED                31   615 973
   013   POSSELT HG            Z KINDERHEILK                  110    93 971
   014   SHWACHMAN H           IN: KENDIG EL JR                     541 967
   015   SPOCK A               MOD PROBL PEDIATR               10   200 967
   016   SPOCK A               PEDIATR RES                      1   173 967
   022   WILSON GB             PEDIATR RES                      9   635 975
   023   WILSON GB             CLIN CHIM ACTA                  49    79 973
   024   WILSON GB             CLIN RES                        24   295 976
   025   WILSON GB             CF CLUB ABST                    17    18 976
CT   1   WILSON GB             PEDIATR RES                     11   986 977
     2   WILSON GB             PEDIATR RES                     11   139 977
     3   BOWMAN BH             CLIN GENET                      12   333 977
     4   WILSON GB             NATURE                         266   463 977
     5   CONOVER JH            BIOCHEM BIOPHYS RES COMMUN      83  1595 978
     6   WILSON GB             J LAB CLIN MED                  92   463 978
     7   VERDUGO P             PEDIATR RES                     13   131 979
     8   WILSON GB             J CLIN INVEST                   66  1010 980
     9   WILSON GB             PROC SOC EXP BIOL MED          164   105 980
    10   HALLINAN FM           CLIN CHIM ACTA                 117   103 981
    11   BLITZER MG            PEDIATR RES                     16   203 982
    12   RUTLAND J             AM REV RESPIR DIS              128  1030 983

PN 77158
RN 00739 
AN 77124790
AU Wilson-G-B.  Monsher-M-T.  Fudenberg-H-H.
TI Additional notes on the use of analytic isoelectric focusing for the
   detection of cystic fibrosis protein in serum [letter].
SO Pediatr-Res. 1977 Feb. 11(2). P 139-41.
MJ BLOOD-PROTEINS: an.  CYSTIC-FIBROSIS: bl.  ISOELECTRIC-FOCUSING.
MN BLOOD-SPECIMEN-COLLECTION.  ELECTROPHORESIS-POLYACRYLAMIDE-GEL.
   HETEROZYGOTE.  HUMAN.  METHODS.
EX In a previous communication, written in response to a letter by
   Smith et al., we suggested several possible reasons for the
   inability of Thomas et al. and other investigators to detect cystic
   fibrosis protein (CFP) using electrofocusing techniques.  Thomas and
   coworkers communicated with us for the purpose of determining
   possible reasons for their inability to detect CFP by
   electrofocusing.  Key points made during these conversations are
   reiterated below in a firm attempt to alleviate future problems by
   inexperienced investigators in their attempts to use analytic
   electrofocusing to detect CFP.  In our communications with Thomas
   and coworkers we learned that, despite our suggestions, they had not
   analyzed the samples they screened by either using the equipment of
   Awdeh et al. or employing our standardized procedure.  It is unknown
   whether or not they exercised the requirements for serum sample
   collection, processing, and storage.  We feel the above reasons are
   sufficient to explain the reported failure of Thomas et al. to
   reproduce our results and to detect consistently a CFP in sera from
   individuals with the CF gene.
RF 001   AWDEH ZL              NATURE                         219    66 968
   002   HOWARD A              IN: PEETERS H                   17   449 969
   003   SMITH QT              PEDIATR RES                     10   999 976
   004   THOMAS JM             CF CLUB ABST                    17    19 976
   005   THOMAS JM             PEDIATR RES                     11   138 977
   006   WILLIAMSON AR         IN: WEIR DM                              973
   007   WILSON GB             PEDIATR RES                     10  1001 976
   009   WILSON GB             TEX REP BIOL MED                34    51 976
   010   WILSON GB             PEDIATR RES                     10    87 976
   011   WILSON GB             PEDIATR RES                      9   635 975
   012   WILSON GB             CLIN CHIM ACTA                  49    79 973
   013   WILSON GB             PEDIATR RES                     11   143 977
CT   1   THOMAS JM             PEDIATR RES                     11  1148 977
     2   WILSON GB             PEDIATR RES                     11   986 977
     3   WILSON GB             NATURE                         266   463 977
     4   SCHOLEY J             PEDIATR RES                     12   800 978
     5   WILSON GB             PEDIATR RES                     12   801 978
     6   WILSON GB             J LAB CLIN MED                  92   463 978
     7   WILSON GB             PEDIATR RES                     13  1079 979
     8   BROCK DJH             HUM GENET                       60    30 982
     9   SUPER M               AM J MED GENET                  18   449 984
    10   WILSON GB             CLIN GENET                      26   331 984

PN 77159
RN 00740 
AN 77124789
AU Thomas-J-M.  Merritt-A-D.  Hodes-M-E.
TI Electrophoretic analysis of serum proteins in cystic fibrosis
   [letter].
SO Pediatr-Res. 1977 Feb. 11(2). P 138-9.
MJ BLOOD-PROTEINS: an.  CYSTIC-FIBROSIS: bl.
   ELECTROPHORESIS-POLYACRYLAMIDE-GEL.  ISOELECTRIC-FOCUSING.
MN GAMMA-GLOBULINS: an.  HETEROZYGOTE.  HUMAN.
EX We have attempted to reproduce the isoelectric focusing in thin layer
   polyacrylamide gels (IEFAG) method specified by Wilson et al. in our
   laboratory.  Since the resolution obtained with their procedure
   appeared to be inadequate for identifying single protein bands in the
   relevant region, we have incorporated several methodologic
   improvements into the isoelectric focusing technique.  These
   improvements have significantly enhanced the resolution and have thus
   enabled us to demonstrate a greater degree of heterogeneity of serum
   gamma-globulins than is visible in the paper of Wilson et al.
   Despite the significant increase in the number of bands resolved by
   our method, a difference among CF, heterozygote, and control sera in
   the pH 8.4 - 8.5 region could not be detected.  In addition, the
   two-step IEFAG/disc electrophoresis technique of Altland et al. has
   been tested in our laboratory.  We have also modified this analytic
   procedure, enabling the fractionation of several small proteins from
   a portion of the IgG fraction.  Again, despite an improvement in
   resolution which reveals more heterogeneity, no unique protein has
   been observed consistently in the CF and heterozygote area.
RF 001   ALTLAND K             HUMANGENETIK                    28   207 975
   002   ANON                  J PEDIATR                       88   711 976
   005   WILSON GB             PEDIATR RES                      9   635 975
   006   WILSON GB             CLIN CHIM ACTA                  49    79 973
CT   1   THOMAS JM             PEDIATR RES                     11  1148 977
     2   WILSON GB             PEDIATR RES                     11   986 977
     3   WILSON GB             PEDIATR RES                     11   139 977
     4   WILSON GB             PEDIATR RES                     12   801 978

PN 77160
RN 00741 
AN 77124787
AU Bogart-B-I.
TI The biologic activities of cystic fibrosis serum.  I. The effects of
   cystic fibrosis sera and calcium ionophore A 23187 on rabbit
   tracheal explants.
SO Pediatr-Res. 1977 Feb. 11(2). P 131-4.
MJ A-23187: pd.  ANTIBIOTICS: pd.  CALCIUM: pd.  CYSTIC-FIBROSIS: bl.
   TRACHEA: de.
MN ANIMAL.  CELL-MEMBRANE-PERMEABILITY: de.  CILIA: de.
   CYSTIC-FIBROSIS: pp.  EGTA: pd.  IN-VITRO.  MUCOUS-MEMBRANE: se.
   OSMOLAR-CONCENTRATION.  RABBITS.  TISSUE-CULTURE.  TRACHEA: me.
AB An ionophore A23187-induced increase in membrane permeability to
   calcium ions in culture medium produced a rabbit tracheal mucociliary
   response indistinguishable from that caused by cystic fibrosis (CF)
   sera on three different occasions. Specific chelation of calcium ions
   with EGTA in the basal medium Eagle (BME) media with no additive or
   in native CF sera abolished the mucociliary disturbances in all
   cases. Increased membrane permeability to calcium may be important in
   the production of the mucociliary response by CF serum factor(s) in
   the tracheal assay system.
RF 001   BLOMFIELD J           ARCH DIS CHILD                  48   267 973
   002   CHERNICK WS           J PEDIATR                       59   890 961
   003   COCHRANE DE           PROC NAT ACAD SCI USA           71   408 974
   004   CONOVER JH            PEDIATR RES                      7   220 973
   005   DI SANTAGNESE PA      PEDIATRICS                      12    40 953
   006   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   007   EIMERL S              J BIOL CHEM                    249  3991 974
   008   FOREMAN JC            NATURE                         245   249 973
   009   GUGLER EC             J PEDIATR                       71   585 967
   010   KAGAYAMA M            J CELL BIOL                     62   519 974
   011   LOBECK CC             IN: STANBURY JB                     1605 972
   012   MANGOS JA             SCIENCE                        158   135 967
   013   MANGOS JA             PEDIATR RES                      2   378 968
   014   MANGOS JA             PEDIATR RES                      1   436 967
   015   PRESSMAN BC           FED PROC                        32  1698 973
   016   REED PW               J BIOL CHEM                    247  6970 972
   017   SATIR P               SCIENCE                        190   586 975
   018   SELINGER Z            PROC NAT ACAD SCI USA           71   128 974
   019   SPOCK A               PEDIATR RES                      1   173 967
   020   WILLIAMS JA           BIOCHEM BIOPHYS RES COMMUN      60   542 974
   021   WONG DT               ARCH BIOCHEM BIOPHYS           156   578 973
   022   WOTMAN S              ARCH ORAL BIOL                  16   663 971
CT   1   MARIN MG              J APPL PHYSIOL                  44   900 978
     2   CONOVER JH            BIOCHEM BIOPHYS RES COMMUN      83  1595 978
     3   BANSCHBACH MW         BIOCHEM BIOPHYS RES COMMUN      84   922 978
     4   BOAT TF               ACS SYMPOSIUM SERIES          1978   108 978
     5   FEIGAL RJ             PEDIATR RES                     13   764 979
     6   VERDUGO P             PEDIATR RES                     13   131 979
     7   BOGART BI             BIOCHEM BIOPHYS RES COMMUN      88  1398 979
     8   KENNEDY JR            PEDIATR RES                     14  1173 980
     9   ROSCHER AA            PEDIATR RES                     14   261 980
    10   SATIR P               ENVIRON HEALTH PERSPECT         35    77 980
    11   SANDERSON MJ          PEDIATR RES                     15   219 981
    12   CAMPBELL AK           EXPERIENTIA                     37  1110 981
    13   SORSCHER EJ           LANCET                           1   368 982
    14   MORIARTY CM           J MED                           13   257 982
    15   ANDO T                ACTA HISTOCHEM CYTOCHEM         15   812 982
    16   BOAT TF               PEDIATR RES                     16   792 982
    17   BOGART BI             PEDIATR RES                     16   223 982
    18   MARIN MG              J APPL PHYSIOL                  52   198 982
    19   CEDER O               SCANN ELECTRON MICROSC        1982   723 982
    20   ROOMANS GM            SCANN ELECTRON MICROSC        1982   229 982
    21   CEDER O               ULTRASTRUCTURAL PATHOL           4   305 983
    22   VONEULER AM           ULTRASTRUCTURAL PATHOL           5    37 983
    23   MCPHERSON MA          CLIN CHIM ACTA                 135   181 983
    24   KATZ S                CELL CALC                        5   421 984
    25   BARBIERI EJ           BR J PHARMACOL                  82   199 984
    26   RUSSI EW              CHEST                           86   475 984
    27   VONEULER AM           LIFE SCI                        37  2399 985
    28   VONEULER AM           EXP MOL PATH                    43   142 985
    29   AHMED T               CHEST                           88  S142 985
    30   MORRISSEY SM          DIGESTION                       34    28 986
    31   MARIN MG              PHARMACOL REV                   38   273 986
    32   LOFDAHL CG            ACTA PHARMACOL TOXICOL          58    91 986

PN 77161
RN 00742 
AN 77213827
AU Wood-D-L.  Martinez-R.
TI The chronically reserpinized rat as a possible model for cystic
   fibrosis.  VI.  Synergistic effects of isoproterenol on Ca++ and
   protein in the submaxillary gland.
SO Pediatr-Res. 1977 Jul. 11(7). P 827-32.
MJ CALCIUM: me.  CYSTIC-FIBROSIS: me.  ISOPROTERENOL: pd.  PROTEINS: me.
   RESERPINE: pd.  SUBMANDIBULAR-GLAND: me.
MN ANIMAL.  DISEASE-MODELS-ANIMAL.  DRUG-SYNERGISM.  ISOPROTERENOL: ad.
   MALE.  RATS.  RESERPINE: ad.
AB Elevated calcium and protein concentration are a consistent
   abnormality in submaxillary saliva from patients with cystic fibrosis
   (CF) and from experimental animal models developed by the chronic
   administration of either isoproterenol (IPR) or reserpine. The
   possibility that the effects of the two drugs may be additive was
   investigated by assessing their combined effects on glandular and
   salivary C++ and protein in the rat submaxillary gland. Individually,
   their effects were also assessed in relation to the dose used.
   Results indicate that: (1) treatment for 7 days with 0.05, 0.50, and
   5.0 mg/kg daily dose of reserpine caused, respectively, a 45%, 95%,
   and 120% increase in glandular Ca++ and a 9.3%, 16.5%, and 37.4%
   increase in glandular protein; (2) treatment for 7 days with a 5.0
   mg/kg daily dose of isoproterenol caused a 138% increase in gland
   Ca++ and a 12.38% increase in gland protein. Treatment with a 5.0
   mg/rat daily dose of this drug caused increases of 166% and 10.3% in
   gland Ca++ and protein; (3) in experiments involving a combination of
   the two drugs, isoproterenol was administered in a 5.0 mg/kg daily
   dose from days 1-7 and reserpine in a 0.5 mg/kg daily dose from days
   4-10 of the treatment schedule. This procedure resulted in (a) a 217%
   increase in gland Ca++ and a 25.7% increase in gland protein; (b) a
   marked accumulation of a granular, basophilic material in acinar
   cells and the development of intraductal precipitates; (c) the
   secretion of turbid saliva with high Ca++ and protein concentrations
   after a secretory dose of isoproterenol (this type of stimulation
   also reduced the gland Ca++ (50%) and protein (20%) contents and
   produced vacuolization in the acinar cells); (d) the secretion of
   saliva with elevated Ca++ and protein in response to pilocarpine
   (these elevated concentrations were, however, one-fifth of those
   obtained after isoproterenol stimulation); (e) the secretion of
   smaller volume of saliva after both types of stimulation. These
   findings indicate that both IPR and reserpine have a dose-related and
   significant effect on submaxillary gland Ca++ and protein and that
   their individual effects are synergistic. The implications of this
   synergism for the physiologic state of the submaxillary gland and for
   the secretory abnormality of cystic fibrosis are discussed.
RF 001   ADSHEAD PC            ANN NY ACAD SCI                253   192 975
   002   BLOMFIELD J           ARCH ORAL BIOL                  19  1153 974
   003   BLOMFIELD J           ARCH DIS CHILD                  48   267 973
   004   BOAT TF               PEDIATR RES                      8   531 974
   005   BOWMAN BH             SCIENCE                        164   325 969
   006   CHERNICK WS           ANN NY ACAD SCI                106   698 963
   007   CONOVER JH            CF CLUB ABST                    17     9 976
   008   DI SANTAGNESE PA      N ENGL J MED                   277  1344 967
   009   DREISBACH RH          PROC SOC EXP BIOL MED          126   279 967
   010   EKFORS T              LAB INVEST                      24   197 971
   011   FORSTNER JF           PEDIATR RES                     10   609 976
   012   GUGLER EC             J PEDIATR                       71   585 967
   013   LOWRY OH              J BIOL CHEM                    193   265 951
   014   MANDEL ID             AM J DIS CHILD                 113   431 967
   015   MANGOS JA             IN: LAWSON D PROC 5TH INT CF          25 969
   016   MARTINEZ JR           PEDIATR RES                      9   463 975
   017   MARTINEZ JR           PEDIATR RES                      9   470 975
   018   MARTINEZ JR           J PHARMACOL EXP THER           194   384 975
   019   SCHNEYER CA           AM J PHYSIOL                   203   232 962
   020   SCHNEYER LH           AM J PHYSIOL                   226   821 974
   021   TAYLOR PW JR          FED PROC ABST                   27   709 968
   022   TAYLOR PW JR          J PHARMACOL EXP THER           156   483 967
CT   1   PERLMUTTER J          PEDIATR RES                     12   188 978
     2   MARTINEZ JR           PEDIATR RES                     13  1156 979
     3   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     4   FORSTNER J            AM J PHYSIOL                   241  G443 981
     5   SHIFFMAN ML           PEDIATR RES                     16   104 982
     6   MULLER RM             J ULTRASTRUCT RES               81   377 982
     7   ROOMANS GM            SCANN ELECTRON MICROSC        1982   229 982
     8   MODRZAKOWSKI MC       CAN J MICROBIOL                 29  1339 983
     9   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983
    10   BOYD RL               PEDIATR RES                     18  1028 984
    11   JIRAKULSOMCHOK D      ARCH ORAL BIOL                  29    39 984
    12   MULLER RM             EXP MOL PATH                    40   391 984
    13   MULLER RM             EXP MOL PATH                    41   363 984
    14   KUIJPERS GAJ          ACTA PHYSIOL SCAND             121    85 984
    15   ROOMANS GM            ANN NY ACAD SCI                428   121 984
    16   SCHNEYER CA           J AUTONOM NERV SYST             14   191 985
    17   MULLER RM             EXP MOL PATH                    43    97 985
    18   MULLER RM             ACTA PHYSIOL SCAND             123   383 985
    19   SCHNEYER CA           PROC SOC EXP BIOL MED          179   143 985
    20   MULLER RM             SCANN ELECTRON MICROSC        1985  1583 985
    21   HAZLETT D             PEDIATR RES                     20  1236 986

PN 77162
RN 00743 
AN 77124804
AU Buehler-B.  Wright-R.  Schott-S.  Darby-B.  Rennert-O-M.
TI Ornithine decarboxylase and S-adenosyl methionine decarboxylase in
   skin fibroblasts of normal and cystic fibrosis patients.
SO Pediatr-Res. 1977 Mar. 11(3 Pt 1). P 186-90.
MJ CARBOXY-LYASES: me.  CYSTIC-FIBROSIS: en.
   ORNITHINE-DECARBOXYLASE: me.  S-ADENOSYLMETHIONINE-DECARBOXYLASE: me.
   SKIN: en.
MN ADULT.  CELLS-CULTURED.  CHILD-PRESCHOOL.  FIBROBLASTS: en.  HUMAN.
   INFANT.  MALE.  ORNITHINE-AMINOTRANSFERASE: me.  PUTRESCINE: pd.
AB The key enzymes in the synthesis of the naturally occurring
   polyamines, ornithine decarboxylase (ODC) and S-adenosyl methionine
   (SAM) decarboxylase, were investigated during cell growth and aging
   in fibroblast cultures from normal patients and patients with cystic
   fibrosis. A linear correlation between increased S-adenosyl
   methionine activity and putrescine concentration was apparent in all
   cell lines. A putrescine concentration of 0.8 mM was optimal for
   enhancement of SAM decarboxylase activity. The passage number of the
   cell line correlated inversely with maximal putrescine-stimulated SAM
   decarboxylase activity, earlier passage numbers having the highest
   specific activity (Fig. 1). No significant differences in basal or
   putrescine-stimulated SAM decarboxylase activity were noted between
   normal fibroblast cultures and cells from patients with cystic
   fibrosis (Fig. 2). SAM decarboxylase activity increased as the cell
   lines approached confluence. Activity was lowest during exponential
   growth (Fig. 3). ODC activity was increased during early exponential
   growth and fell as cells reached confluence (Fig. 4). No differences
   in ODC activity and putrescine inhibition between the normal and
   cystic fibrosis cell cultures at equivalent points of exponential
   growth were noted.
RF 001   BACHRACH U            FUNCTION OF NATURALLY OCCURRI            973
   002   CLARK JL              BIOCHEMISTRY                    14  4403 975
   003   HANNONEN P            ACTA CHEM SCAND (A)             29   295 975
   004   HOGAN BLM             BIOCHEM BIOPHYS RES COMMUN      45   301 971
   005   JANNE J               BIOCHEM BIOPHYS RES COMMUN      61   399 974
   006   LOWRY OH              J BIOL CHEM                    193   265 951
   007   RENNERT OM            IN: MANGOS JA                         41 973
   008   RENNERT OM            IN: PREISIG R                        298 976
   009   RENNERT OM            BLOOD                           47   695 976
   010   RICHARDS GM           ANAL BIOCHEM                    57   369 974
   011   RUSSELL DH            POLYAMINES IN NORMAL AND NEOP            973
   012   RUSSELL DH            POLYAMINES IN NORMAL AND NEOP            973
   013   RUSSELL DH            BIOCHIM BIOPHYS ACTA           259   247 972
CT   1   WRIGHT RK             PEDIATR RES                     12   830 978
     2   BRADDON SA            BIOCHEM BIOPHYS RES COMMUN      80    75 978
     3   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     4   BUEHLER BA            ANN CLIN LAB SCI                10   195 980
     5   GAHL WA               PEDIATR RES                     14   118 980
     6   THEOHARIDES TC        LIFE SCI                        27   703 980
     7   BRADDON SA            ADV EXP MED BIOL               143   255 982
     8   KAMOUN PP             CLIN CHIM ACTA                 154   219 986

PN 77163
RN 00744 
AN 78011300
AU Wilson-G-B.  Arnaud-P.  Fudenberg-H-H.
TI Improved method for detection of cystic fibrosis protein in serum
   using the LKB multiphor electrofocusing apparatus.
SO Pediatr-Res. 1977 Sep. 11(9 Pt 1). P 986-9.
MJ BLOOD-PROTEINS: an.  CYSTIC-FIBROSIS: bl.
MN ASTHMA: bl.  CYSTIC-FIBROSIS: fg.  HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.
   ISOELECTRIC-FOCUSING: is.  SUPPORT-U-S-GOVT-P-H-S.
AB We have developed an improved method for the detection of cystic
   fibrosis protein (CFP). The method employs the LKB Multiphor to
   electrofocus whole serum, instead of the apparatus used in previous
   studies. Two basic modifications were necessary: (1) a pH 2.5--10.0
   gradient instead of a pH 5--10 gradient, and (2) constant power for
   focusing the serum proteins instead of constant voltage. The first
   modification ensured adequate dissolution of the CFP-IgG complexes
   (or other precursor complexes which may liberate CFP). The second
   modification ensured a linear gradient (between pH 3.8 and pH 9.2),
   excellent resolution in the pH 8--9 region, and the separation of CFP
   within 2 hr without overheating of the gel. Electrofocusing with the
   LKB Multiphor permits the detection of CFP in as many as 24 serum
   samples per gel. Results obtained from the analysis of 31 cystic
   fibrosis, 28 obligate heterozygote carrier, and 28 normal control
   sera indicate that CFP can be reproducibly and accurately detected in
   sera using the LKB Multiphor.
RF 002   ALTLAND K             HUMANGENETIK                    28   207 975
   003   AWDEH ZL              NATURE                         219    66 968
   004   DI SANTAGNESE PA      N ENGL J MED                   295   534 976
   005   SMITH QT              PEDIATR RES                     10   999 976
   006   THOMAS JM             PEDIATR RES                     11   138 977
   007   WILLIAMSON AR         IN: WEIR DM                              973
   008   WILSON GB             PEDIATR RES                     10  1001 976
   009   WILSON GB             SCAND J IMMUNOL                  5   829 976
   010   WILSON GB             TEX REP BIOL MED                34    51 976
   011   WILSON GB             PEDIATR RES                      9   635 975
   012   WILSON GB             CLIN CHIM ACTA                  49    79 973
   013   WILSON GB             PEDIATR RES                     11   139 977
   014   WILSON GB             PEDIATR RES                     11   143 977
   016   WOOD RE               AM REV RESPIR DIS              113   833 976
CT   1   SCHOLEY J             PEDIATR RES                     12   800 978
     2   WILSON GB             PEDIATR RES                     12   801 978
     3   NAGY EC               PEDIATR RES                     13   729 979
     4   TULLY GW              PEDIATR RES                     13  1078 979
     5   WILSON GB             PEDIATR RES                     13  1079 979
     6   MANSON JC             LANCET                           1   330 980
     7   TARNOKY AL            J ROY SOC MED                   73    73 980
     8   ACKERMAN SJ           J IMMUNOL                      125  2118 980
     9   HALLINAN FM           CLIN CHIM ACTA                 117   103 981
    10   VICKERS MF            ANN CLIN BIOCHEM                19   442 982
    11   BULLOCK S             CLIN GENET                      21   336 982
    12   CAREY WF              MED J AUST                       2   528 983
    13   HEELEY AF             CLIN CHEM                       29  2011 983
    14   WILSON GB             THYMUS                           6   167 984
    15   GRATAROLI R           PEDIATR RES                     18   130 984
    16   ROBINSON PA           ANN CLIN BIOCHEM                21    70 984
    17   WILSON GB             CLIN GENET                      26   331 984
    18   QURESHI AR            J PEDIATR                      106   913 985

PN 77164
RN 00745 
AN 78032149
AU Pivetta-O-H.  Sordelli-D-O.  Labal-M-L.
TI Pulmonary clearance of Staphylococcus aureus in mutant mice with
   some hereditary alterations resembling cystic fibrosis.
SO Pediatr-Res. 1977 Nov. 11(11). P 1133-6.
MJ CYSTIC-FIBROSIS: fg.  DISEASE-MODELS-ANIMAL.  LUNG: im.
   MICE-INBRED-STRAINS: im.  PNEUMONIA-STAPHYLOCOCCAL: im.
   STAPHYLOCOCCUS-AUREUS: py.
MN ANIMAL.  CYSTIC-FIBROSIS: im.  HUMAN.  LUNG: mi.  MALE.  MICE.
   MICE-INBRED-BALB-C.  MICE-INBRED-C57BL.  MICE-INBRED-DBA.  MUTATION.
   PHAGOCYTOSIS.
AB Pulmonary clearance for Staphylococcus aureus has been examined in
   two inbred strains of mice with some hereditary alterations
   resembling cystic fibrosis (CF).  These mice were mice with abnormal
   electrolyte metabolism (DBA/@J-cri), mice with spontaneous
   pneumonitis (C57BL/6J-bg), and mice without any CF-like alterations
   (BALB/c).  The methods used to produce pulmonary infection were
   essentially those of Laurenzi and associates adapted as needed for
   mutant mice.  The animals mentioned above were exposed to a finely
   divided aerosol suspension of a coagulase-positive strain of S.
   aureus in phosphate buffer.  Immediately after the exposure, half of
   the animals were killed, and the remaining half were killed 4 hr
   later.  In each experimental unit the mice killed immediately after
   the exposure were as similar as possible to the mice killed 4 hr
   later with respect to genotype, age, and sex; some were siblings.
   The uncleared bacteria (UBR) in 4 hr were 0.20 for the mice without
   any CF-like alterations (BALB/c) and the C57BL/6J-bg, bg/bg
   genotypes; 0.28 for C57BL/6J-bg, +/? genotypes; 0.50 for the
   DBA/2J-cri, +/? genotypes; and 0.56 for cri/cri mice.  The number of
   viable staphylococci found immediately after the aerosol exposure
   (Co) in the C57BL/6J-bg strain is significantly lower than the Co of
   the BALB/c (P < 0.05) and DBA/2J-cri strain (P < 0.01).  The latter
   two did not differ from each other.  There was no sex difference
   with respect to the UBR and Co data.  The DBA/2J-cri strain of mice,
   where the cri mutation first appeared, has a decreased capacity for
   clearance of S. aureus by the lung.  Together with the other CF-like
   alterations of the cri mutation, namely failure for the reabsorption
   of Na+ by the parotid duct, high level of Na+ in the fur, and CF
   abnormal serum factor activity in the serum of the cri/cri mice, we
   suggest that the cribriform degeneration mouse mutant may provide a
   potential animal model for studying CF.  The finding of a mouse
   mutation with electrolyte alterations and CF-like abnormal serum
   activity, simialr to the activity found in CF children, in an inbred
   strain of mice with a decreased bacterial clearance by the lungs,
   makes these mice very useful for CF studies.
RF 001   ANDERSEN AA           J BACTERIOL                     76   471 958
   002   BARTLETT MS           BIOMETRICS                       3    39 947
   003   DI SANTAGNESE PA      GAP CONF REP LUNG ORGAN DEF              972
   004   DI SANTAGNESE PA      AM J DIS CHILD                  72    17 946
   005   DIXON WJ              ANN MATH STAT                   21   488 950
   006   FEIGIN RD             J PEDIATR                       87   677 975
   007   FINNEY DJ             PROBIT ANALYSIS                          971
   008   GREEN GM              J EXP MED                      119   167 964
   009   GREEN GM              J CLIN INVEST                   43   769 964
   010   GREEN GM              BR J EXP PATHOL                 46   360 965
   011   GREEN MC              SCIENCE                        176   800 972
   012   HARROW EM             AM REV RESPIR DIS              112     7 975
   013   HOFF GE               ACTA PATH MICROBIOL SCAND (B)   83   219 975
   014   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   015   HUANG NN              J PEDIATR                       59   512 961
   016   IACOCCA VF            AM J DIS CHILD                 106   315 963
   017   KAISER D              LIFE SCI                        15   803 974
   018   KASS EH               BACT REV                        30   488 966
   019   LANE PW               GENETICS                        72   451 972
   020   LAURENZI GA           J CLIN INVEST                   43   759 964
   021   LAURENZI GA           AM REV RESPIR DIS SUPPL 3       93   134 966
   022   LAWSON D              GAP CONF REP PSEUDOMON IN CF             974
   023   LURIE MB              AM REV TUBERC                   61   765 950
   024   MIDDLEBROOK G         PROC SOC EXP BIOL MED           80   105 952
   025   MYRVIK QN             GAP CONF REP LUNG ORGAN DEF              972
   027   RUPPERT D             J LAB CLIN MED                  87   544 976
   028   SHWACHMAN H           HOSP PRACT                       9   143 974
CT   1   PIVETTA OH            PEDIATR RES                     13  1160 979
     2   SORDELLI DO           LIFE SCI                        24  2003 979
     3   SORDELLI DO           MED (BUENOS AIRES)              39   457 979
     4   DAVIS PB              PEDIATR RES                     14    83 980
     5   PIVETTA OH            LIFE SCI                        26  1349 980
     6   REHM SR               J CLIN INVEST                   66   194 980
     7   PIVETTA OH            LIFE SCI                        28  2207 981
     8   CERQUETTI MC          IMMUNOL COMMUN                  12   375 983
     9   NOURI LA              PEDIATR RES                     17   657 983
    10   CATANZARO OL          LIFE SCI                        32   825 983
    11   SORDELLI DO           INFECT IMMUN                    39  1275 983

PN 77165
RN 00746 
AN 78032153
AU Thomas-J-M.  Merritt-A-D.  Hodes-M-E.
TI Electrophoretic analysis of serum proteins in cystic fibrosis.
SO Pediatr-Res. 1977 Nov. 11(11). P 1148-54.
MJ BLOOD-PROTEINS: an.  CYSTIC-FIBROSIS: bl.
MN BLOOD-PROTEIN-ELECTROPHORESIS.  BLOOD-PROTEINS: ge.  CHILD.
   COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: fg.  ELECTROPHORESIS-DISC.
   HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.  HYDROGEN-ION-CONCENTRATION.
   IGG: an.  ISOELECTRIC-FOCUSING.
AB This study utilized isoelectric focusing and electrophoresis in an
   attempt to detect a cystic fibrosis (CF) serum factor(s), for which
   there is considerable indirect evidence.  The method of isoelectric
   focusing in polyacrylamide gels (IEFAG) specified by Wilson et al.
   (53), as reproduced in our laboratory, did not enable the detection
   of a CF factor protein reported to focus near pH 8.4-8.5.
   Consequently, we employed our modified IEFAG techniques, which
   enabled us to demonstrate significantly enhanced resolution and
   striking heterogeneity in serum gamm-globulins.  Despite the
   significant increase in the number of bands resolved by our methods,
   neither a difference at pH 8.4-8.5 nor other differences throughout
   the alkaline pH range could be detected consistently in the CF and
   heterozygous sera.  The two-step IEFAG/disc electrophoresis
   technique outline by Altland et al. (2), as reproduced in our
   laboratory, indicated that at least one small, cationic protein
   could be fractioned from all serum samples.  Improvements in the
   method of disc electrophoresis resulted in the observation of
   numerous bands from some samples and of differences among the
   samples, but no protein band unique to the CF genotypes was
   observed.  Our approach, employing different electrophoresis
   techniques and varying the conditions of sample analysis, should
   have increased the likelihood of detecting a protein or proteins
   specific for the CF genotypes.  Despite the many variations in our
   approach, no consistently unique protein was observed in the CF or
   heterozygous sera.  A CF serum factor cannot be readily demonstrated
   by the electrophoretic techniques described.  The value of the
   "biophysical assay" and the "nonbiologic technique" reported in the
   literature is suspect, and the promise and applicability of these
   techniques as diagnostic tests for the CF gene should be carefully
   evaluated.
RF 002   ALTLAND K             HUMANGENETIK                    28   207 975
   003   AWDEH ZL              NATURE                         219    66 968
   004   BARNETT DR            TEX REP BIOL MED                31   697 973
   005   BARNETT DR            TEX REP BIOL MED                31   703 973
   006   BARNETT DR            TEX REP BIOL MED                31   709 973
   007   BERATIS NG            PEDIATR RES                      7   958 973
   008   BOWMAN BH             TEX REP BIOL MED                31   611 973
   009   BOWMAN BH             LANCET                           1   404 974
   010   BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      64  1310 975
   011   BOWMAN BH             N ENGL J MED                   294   937 976
   012   BULL HB               ARCH BIOCHEM BIOPHYS           104   297 964
   013   ANON                  J PEDIATR                       88   711 976
   014   CONNEALLY PM          TEX REP BIOL MED                31   639 973
   015   CONOVER JH            PEDIATR RES                      7   224 973
   016   CROW JF               IN: NEEL JV                           23 965
   017   DANES BS              J EXP MED                      137  1538 973
   018   DANKS DM              ANN HUM GENET                   28   323 965
   019   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   020   GIBSON LE             PEDIATRICS                      23   545 959
   021   HAGLUND H             METHODS BIOCHEM ANAL            19     1 971
   022   HOWARD A              IN: PEETERS H                   17   449 969
   023   JOSEPHSEN RV          ANAL BIOCHEM                    40   476 971
   024   KULCZYCKI LL          CLIN PEDIATR                     3   692 964
   025   LAGOW J               BIOCHEMISTRY                    11  4520 972
   026   LOBECK CC             IN: STANBURY JB                     1605 972
   027   MCCOMBS ML            TEX REP BIOL MED                31   615 973
   028   NAKHLEH ET            ANAL BIOCHEM                    49   218 972
   029   OPPENHEIMER EH        PEDIATRICS                      42   547 968
   030   POLLEY MJ             J MED GENET                     11   249 974
   031   RADOLA BJ             IN: PEETERS H                   18   487 970
   032   RADOLA BJ             BIOCHIM BIOPHYS ACTA           295   412 973
   033   RADOLA BJ             ANN NY ACAD SCI                209   127 973
   034   RADOLA BJ             BIOCHIM BIOPHYS ACTA           386   181 974
   035   SALAMAN MR            BIOCHEM J                      122    93 971
   036   SCHMOYER IR           LIFE SCI PART 2                 11  1037 972
   037   SCHMOYER IR           BIOCHEM BIOPHYS RES COMMUN      46  1923 972
   038   SHWACHMAN H           HOSP PRACT                       9   143 974
   039   SMITH QT              PEDIATR RES                     10   999 976
   040$  SMYTH CJ              J GEN MICROBIOL                  7    41 974
   041   THOMAS JM             CF CLUB ABST                    17    19 976
   042   THOMAS JM             PEDIATR RES                     11   138 977
   044   UI N                  BIOCHIM BIOPHYS ACTA           229   567 971
   045   UI N                  ANN NY ACAD SCI                209   198 973
   046   VALMET E              SCIENCE TOOLS                   15     8 968
   047   VESTERBERG O          BIOCHIM BIOPHYS ACTA           257    11 972
   048   VESTERBERG O          IN: ARBUTHNOTT JP                        975
   049   WANG CI               N ENGL J MED                   279  1216 968
   050   WILLIAMSON AR         IN: WEIR DM                              973
   052   WILSON GB             PEDIATR RES                     10  1001 976
   053   WILSON GB             PEDIATR RES                      9   635 975
   054   WILSON GB             CLIN CHIM ACTA                  49    79 973
   055   WILSON GB             PEDIATR RES                     11   139 977
   056   WRIGHT SW             AM J HUM GENET                  20   157 968
CT   1   SCHOLEY J             PEDIATR RES                     12   800 978
     2   WILSON GB             PEDIATR RES                     12   801 978
     3   SCHAAP T              ISR J MED SCI                   14   201 978
     4   THOMAS JM             ANAL BIOCHEM                    90   596 978
     5   TULLY GW              PEDIATR RES                     13  1078 979
     6   WILSON GB             PEDIATR RES                     13  1079 979
     7   MANSON JC             LANCET                           1   330 980
     8   NEVIN GB              HUM GENET                       56   387 981
     9   THOMAS JM             CLIN CHIM ACTA                 111   199 981
    10   BULLOCK S             CLIN GENET                      21   336 982
    11   BROCK DJH             HUM GENET                       60    30 982
    12   BURY AF               CLIN CHIM ACTA                 118    45 982
    13   GRATAROLI R           PEDIATR RES                     18   130 984
    14   ANON                  LANCET                           2   249 985
    15   KLINGER KW            SEM RESPIR MED                   6   243 985
    16   JAMIESON A            HUM GENET                       70   168 985
    17   GETLIFFE KA           J INHERIT METAB DIS              9   348 986

PN 77166
RN 00747 
AN 78032158
AU Callahan-J-W.  Leung-A.
TI Arginine esterase and lysosomal hydrolases in liver from cystic
   fibrosis subjects.
SO Pediatr-Res. 1977 Nov. 11(11). P 1166-9.
MJ CYSTIC-FIBROSIS: en.  ESTERASES: me.  HYDROLASES: me.  LIVER: en.
MN ADOLESCENCE.  ADULT.  ARGININE: me.  CATHEPSINS: me.  CHILD.
   CHILD-PRESCHOOL.  FEMALE.  HUMAN.  HYDROGEN-ION-CONCENTRATION.
   ISOELECTRIC-FOCUSING.  LYSOSOMES: en.  MALE.
AB The total activity and isoelectric focusing patterns of arginine
   esterase, cathepsin B1, and several lysosomal hydrolases were normal
   in liver from two patients with cystic fibrosis. No abnormalities
   were observed in values for pH optimum, Km, and Vmax for arginine
   esterase and cathepsin B1 in liver from cystic fibrosis patients
   compared to those values for liver from the control subject. Soybean
   trypsin inhibitor at concentrations up to 100 microgram/ml had no
   effect on liver arginine esterase or cathepsin B1.
RF 001   ALHADEFF JA           CLIN GENET                      10    63 976
   002   BARRETT AJ            ANAL BIOCHEM                     7   290 972
   003   BERATIS NG            PEDIATR RES                      7   958 973
   004   CALLAHAN JW           BIOCHIM BIOPHYS ACTA           391   141 975
   005   CALLAHAN JW           PEDIATR RES                      9   908 975
   006   CALLAHAN JW           CLIN RES                        24  679A 976
   007   CHANGUS JE            ARCH PATHOL LAB MED            100     7 976
   008   CONOVER JH            PEDIATR RES                      7   220 973
   009   CONOVER JH            PEDIATR RES                      7   224 973
   010   CONOVER JH            LIFE SCI                        14   253 974
   011   IODICE AA             ARCH BIOCHEM BIOPHYS           117   477 966
   012   LIEBERMAN J           AM REV RESPIR DIS              109   399 974
   013   LOWRY OH              J BIOL CHEM                    193   265 951
   014   RAO GJS               J PEDIATR                       80   573 972
   015   RAO GJS               SCIENCE                        177   610 972
   016   RAO GJS               PEDIATR RES                      8   684 974
   017   RAO GJS               PEDIATR RES                      9   739 975
   018   SCHACHTER H           PHYSIOL REV                     49   509 969
   019   SCHNEIDER PB          J LIPID RES                      8   202 967
   020   SIEGELMAN AM          ARCH BIOCHEM BIOPHYS            97   159 962
   021   THOMAS GH             PEDIATR RES                      7   751 973
   022   VAN HOOF F            EUR J BIOCHEM                    7    34 968
CT   1   PLATT MW              PEDIATR RES                     12   874 978
     2   ALHADEFF JA           CLIN CHIM ACTA                  89   469 978
     3   ALHADEFF JA           CLIN CHIM ACTA                 105   131 980
     4   ALHADEFF JA           CLIN CHIM ACTA                 117   227 981

PN 77167
RN 00748 
AN 77078176
AU Conod-E-J.  Conover-J-H.  Gaerlan-P.
TI Separation of serum ciliary dyskinesia substances from cystic
   fibrosis subjects.
SO Pediatr-Res. 1977 Jan. 11(1 Pt 1). P 45-7.
MJ CYSTIC-FIBROSIS: bl.  IGG: ip.
MN BIOLOGICAL-ASSAY.  CILIA.  CYSTIC-FIBROSIS: et.  HUMAN.  TRACHEA.
   ULTRAFILTRATION.
AB Purified serum immunoglobulin G (IgG), derived from eight cystic
   fibrosis (CF) and five carrier subjects, has been shown to be
   responsible for the mucociliary disturbances noted in the rabbit
   tracheal bioassay. A small molecular substance of less than 10,000
   but greater than 1,000 daltons (by Amicon filtration) was found
   associated with gamma-globulin fractions isolated from sera of these
   same cystic patients and their parents. Once separated by PM-10
   ultrafiltration, this small substance was unable to promote the
   ciliary dyskinesia response in eight of eight CF and five of five CF
   carrier individuals unless pooled purified human IgG was added. In
   addition, the IgG-rich fraction retained by PM-10 ultrafiltration was
   still able to promote the ciliary dyskinesia response in the
   bioassay, an event noted in our earlier work with whole serum. The
   size of the small serum substance and its association with IgG
   closely corresponds to that described for the oyster test system, as
   well as to that produced by cultured cells derived from homozygotes
   and heteroxygotes for this genetic disorder. The persistence of the
   ability to promote mucociliary disturbances by the IgG-rich retentate
   PM-10 fractions may be indicative of the ineffective molecular
   separation by the Amicon ultransfiltration apparatus or may represent
   another CF-related, IgG-associated substance not influenced by
   ultrafiltration. Speculation The genetic disturbance of CF can be
   explained by the presence of a molecule(s) which has an affinity for
   IgG, which in turn gives rise to the various physiologic facets of
   this disorder. This molecule(s) is present in CF only because of a
   deficiency of an enzyme which normally controls its level by
   inactivation.
RF 001   BERATIS NG            PEDIATR RES                      7   958 973
   002   BESLEY GTN            J MED GENET                      6   278 969
   003   BOWMAN BH             PROC NAT ACAD SCI USA           70   548 973
   004   BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      64  1310 975
   005   BOWMAN BH             SCIENCE                        164   325 969
   006   CONOVER JH            PEDIATR RES                      7   224 973
   007   CONOVER JH            PEDIATR RES                      7   220 973
   008   CONOVER JH            LIFE SCI                        14   253 974
   009   CONOVER JH            LANCET                           1  1194 973
   010   CONOVER JH            PEDIATR RES ABST                10   385 976
   011   DANES BS              J EXP MED                      136  1313 972
   012   SPOCK A               PEDIATR RES                      1   173 967
   013   WILLIAMS CA           METHODS IMMUNOL AND IMM          1   307 967
CT   1   CONOVER JH            BIOCHEM BIOPHYS RES COMMUN      83  1595 978
     2   WILSON GB             J LAB CLIN MED                  92   463 978
     3   BOAT TF               ACS SYMPOSIUM SERIES          1978   108 978
     4   WILL PC               PEDIATR RES                     13  1129 979
     5   BOGART BI             BIOCHEM BIOPHYS RES COMMUN      88  1398 979
     6   BARDON A              CLIN CHIM ACTA                 101    17 980
     7   SANDERSON MJ          PEDIATR RES                     15   219 981
     8   FLEMING N             EXPERIENTIA                     37   139 981
     9   CARSON SD             PEDIATR RES                     16    13 982
    10   MCNEELY MC            PEDIATR RES                     16    21 982
    11   BOGART BI             J CHROMATOGR                   381    29 986

PN 77168
RN 00749 
AN 77148152
AU Wilson-G-B.  Fudenberg-H-H.
TI Studies on cystic fibrosis using isoelectric focusing.  IV.
   Distinction between ciliary dyskinesia activity in cystic fibrosis
   and asthmatic sera and association of cystic fibrosis protein with
   the activity in cystic fibrosis serum.
SO Pediatr-Res. 1977 Apr. 11(4). P 317-24.
MJ ASTHMA: bl.  BLOOD-PROTEINS: ip.  CYSTIC-FIBROSIS: bl.
MN ASTHMA: im.  CILIA: pp.  COMPARATIVE-STUDY.  COMPLEMENT-3: ip.
   CYSTIC-FIBROSIS: im.  HUMAN.  IGG: ip.  ISOELECTRIC-FOCUSING.
   MOLECULAR-WEIGHT.  SUPPORT-U-S-GOVT-P-H-S.
AB The cystic fibrosis protein (CFP) and ciliary dyskinesia activities
   (CDA) in sera from CF homozygotes, heterozygote carriers, and
   individuals with bronchial asthma have been partially purified.
   Concurrently, the CDA's in sera from patients with cystic fibrosis
   (CF) or bronchial asthma were shown to be different substances by ion-
   exchange or gel permeation chromatographic procedures. Sephadex G-200
   chromatography indicated that the CF-CDA eluted with a protein
   fraction of molecular weight (MW) 68,000-150,000 and that the asthma
   CDA was found in a protein fraction of MV greater than 150,000. The
   two activities could also be separated by DEAE-cellulose
   chromatography. Prior acidification of whole normal, CF homozygote,
   obligate heterozygote, or asthmatic sera to pH 3.7 using EDTA,
   followed by fractionation of Sephadex G-200 removed all the CDA's
   from fractions of highermolecular  weight and shifted the activities
   to a protein fraction of MW 1,100-13,700. This procedure afforded a
   200-fold purification of the CDA's in sera from patients with asthma
   or CF. EDTA treatment, however, also generated a CDA in previously
   nonreactive normal sera. Subsequent fractionation of the various
   active G-200 fractions on Bio-Gel P10 allowed for the separation of
   three separate activities (Bio-Gel Fractions I, II-IV, and V).
   Fraction I was shown to represent the activity in sera from patients
   with asthma and was determined to be C3a (MW 9,000). Fraction I was
   also found in normal, CF, and carrier sera and therefore is not a
   specific CDA. Fraction II-IV is thought to represent a CF-specific
   CDA (MW 5,000) since it could not be demonstrated in either normal or
   asthmatic sera but was found in sera of obligate heterozygotes.
   Fraction III-IV also did not react with antisera to human C3a.
   Fraction V was generated from all serum types upon acidification of
   the serum with EDTA and is thought to be a nonspecific CDA. Bio-Gel
   P10 filtration of Sephadex G-200 fractions provided 823-fold and 650-
   fold purification of the asthmatic and CF CDA's, respectively.
   Concurrent analysis of column fractions for CDA's by bioassay and for
   CFP by electrofocusing showed CFP only in fractions that contained
   the CF-CDA. Combined analyses employing acid disc gel
   electrophoresis, isoelectric focusing, and EDTA treatment of active
   CF-immunoglobulin (Ig) G and Sephadex G-200 column fractions,
   followed by Bio-Gel P10 chromatography, provided evidence that CFP
   was associated with the CF-CDA. It is unknown as yet whether CFP
   itself is responsible for the CF-CDA activity.
RF 001   BARNETT DR            PEDIATR RES                      8   687 974
   002   BOWMAN BH             IN: MANGOS JA                        277 976
   003   BOWMAN BH             SCIENCE                        164   325 969
   004   CONOVER JH            PEDIATR RES                      7   220 973
   005   CONOVER JH            LANCET                           1  1194 973
   006   CONOVER JH            LIFE SCI                        14   253 974
   007   DI SANTAGNESE PA      N ENGL J MED                   295   534 976
   008   EDER J                J IMMUNOL METH                   2    67 972
   009   GEWURTZ H             IN: INGRAM DG                         56 972
   010   HUGLI TE              J BIOL CHEM                    250  1472 975
   011   JAMES K               CLIN EXP IMMUNOL                19   237 975
   012   LOCKHART LH           TEX REP BIOL MED                31   631 973
   013   LOWRY OH              J BIOL CHEM                    193   265 951
   014   MOSHER DF             J EXP MED                      143   462 976
   015   OUCHTERLONY O         IN: WEIR DM                          191 973
   016   POLLEY MJ             J MED GENET                     11   249 974
   017   REISFELD RA           NATURE                         195   281 962
   018   SHAPIRA E             PEDIATR RES                     10   812 976
   019   SPOCK A               PEDIATR RES                      1   173 967
   021   WILSON GB             PEDIATR RES                     10  1001 976
   022   WILSON GB             PEDIATR RES                     10    87 976
   023   WILSON GB             TEX REP BIOL MED                34    51 976
   024   WILSON GB             ADV POLYMINE RES                 2   281 977
   027   WILSON GB             PEDIATR RES                      9   635 975
   028   WILSON GB             CF CLUB ABST                          59 973
   029   WILSON GB             LIFE SCI                        15   551 974
   030   WILSON GB             CLIN CHIM ACTA                  49    79 973
   031   WILSON GB             CLIN RES                        24   295 976
   034   WILSON GB             CLIN RES                        25    34 977
CT   1   WILSON GB             J LAB CLIN MED                  92   463 978
     2   WILL PC               PEDIATR RES                     13  1129 979
     3   WILSON GB             J CLIN INVEST                   66  1010 980
     4   SORENSEN RU           PEDIATR RES                     15    14 981
     5   BLITZER MG            PEDIATR RES                     16   938 982
     6   BLITZER MG            PEDIATR RES                     18   540 984

PN 77169
RN 00750 
AN 77193146
AU Yokoyama-M.  Chang-J-P.  Hom-D.  Wilson-S-L.
TI An electron microscopic cytochemical study on concanavalin A binding
   sites and their mobility in normal and cystic fibrosis fibroblasts
   in vitro.
SO Pediatr-Res. 1977 Jun. 11(6). P 765-9.
MJ CONCANAVALIN-A: me.  CYSTIC-FIBROSIS: me.
MN BINDING-SITES.  CONCANAVALIN-A: pd.  CYSTIC-FIBROSIS: pa.
   FIBROBLASTS: de, me, ul.  HETEROZYGOTE.  HISTOCYTOCHEMISTRY.
   HOMOZYGOTE.  HUMAN.  IN-VITRO.  TEMPERATURE.  SUPPORT-U-S-GOVT-P-H-S.
AB Concanavalin A (Con A) binding sites were visualized
   ultrastructurally in the cultured fibroblasts from cystic fibrosis
   patients, obligatory heterozygotes, and normal individuals by
   peroxidase labeling technique. Con A binding sites were localized as
   a continuous layer on the external side of the plasma membrane in
   fixed fibroblasts of the three genotypes. In living cells, Con A
   induces both lateral and vertical movements of binding sites as
   expressed by cap formation and internalization of the plasma
   membrane. Fibroblasts of the three genotypes responded similarly to
   Con A treatment and failed to show significant detectable
   differences.
RF 001   ANTOINE JC            J CELL BIOL                     63    12 974
   002   BAIG MM               J PEDIATR                       86    72 975
   003   BARRANCO SC           J CELL PHYSIOL                  88    33 976
   004   BAUR PS               TEX REP BIOL MED                34   113 976
   005   BENKE PJ              LANCET                           1   182 972
   006   BERLIN RD             N ENGL J MED                   292   515 975
   007   BERNARD W             EXP CELL RES                    64   232 971
   008   BESLEY GTN            J MED GENET                      6   278 969
   009   BOLTON WE             AM J HUM GENET                  27   394 975
   010   BORAT N               EXP CELL RES                    76   451 973
   011   BOWMAN BH             PROC NAT ACAD SCI USA           70   548 973
   012   BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      64  1310 975
   013   BOWMAN BH             SCIENCE                        164   325 969
   014   BOWMAN BH             N ENGL J MED                   294   937 976
   015   CHANG JP              J ULTRASTRUCT RES               37   370 971
   016   CHANGUS JE            AM J PATHOL                     80   317 975
   017   COLLARD JG            EXP CELL RES                    86    81 974
   018   EDELSON PJ            J EXP MED                      140  1364 974
   019   FLETCHER DS           CLIN CHIM ACTA                  44     5 973
   020   GOLDSTEIN IJ          BIOCHEMISTRY                     4   876 965
   021   GONATAS NK            EXP CELL RES                    94   426 975
   022   GRAHAM RC             J HISTOCHEM CYTOCHEM            14   291 966
   023   HIRANO H              PROC NAT ACAD SCI USA           69  2945 972
   024   HUET C                INT J CANCER                    13   227 974
   025   MANGOS JA             SCIENCE                        158   135 967
   026   MANGOS JA             PEDIATR RES                      2   378 968
   027   MATALON R             BIOCHEM BIOPHYS RES COMMUN      33   954 968
   028   NICOLSON GL           INT REV CYTOL                   39    89 974
   029   NICOLSON GL           CANCER RES                      35   144 975
   030   QUISSELL DO           NATURE                         247   115 974
   031   ROSENBLITH JZ         PROC NAT ACAD SCI USA           70  1625 973
   032   ROWLATT C             INT J CANCER                    11   314 973
   033   SCHMOYER IR           BIOCHEM BIOPHYS RES COMMUN      58  1066 974
   034   SINGER SJ             SCIENCE                        175   720 972
   035   SPURR AR              J ULTRASTRUCT RES               26    31 969
   036   WOOD JG               J CELL BIOL                     63   541 974
   038   YOKOYAMA M            PROC CONG OF ANATOMY 10TH            501 975
CT   1   MOLLER PC             HISTOCHEMISTRY                  62   289 979
     2   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     3   YOKOYAMA M            ACTA HISTOCHEM CYTOCHEM         13   139 980
     4   YOKOYAMA M            J HISTOCHEM CYTOCHEM            28   543 980
     5   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983

PN 77170
RN 00751 
AN 77148186
AU Rosenthal-A.  Button-L-N.  Khaw-K-T.
TI Blood volume changes in patients with cystic fibrosis.
SO Pediatrics. 1977 Apr. 59(4). P 588-94.
MJ BLOOD-VOLUME.  CYSTIC-FIBROSIS: pp.
MN ADOLESCENCE.  ADULT.  ANOXEMIA: co.  CHILD.  CYSTIC-FIBROSIS: co.
   ERYTHROCYTES.  FEMALE.  HEMATOCRIT.  HUMAN.  MALE.  OXYGEN: bl.
   PULMONARY-HEART-DISEASE: co, pp.  RESPIRATORY-FUNCTION-TESTS.
   SUPPORT-U-S-GOVT-P-H-S.
AB Simultaneous red blood cell (RBC) and plasma volume determinations
   were obtained in 16 patients with cystic fibrosis (CF) and moderately
   severe pulmonary involvement. Hypervolemia with an increase in both
   RBC and plasma volumes was observed. Changes in blood volume were
   marked when values were indexed by weight but less significant when
   indexed by height. Decreasing systemic arterial oxygen saturation was
   associated with a progressive increase in RBC mass, hematocrit value,
   and hemoglobin level and a decrease in mean corpuscular hemoglobin
   concentration. RBC and total blood volumes were highest in patients
   with cor pulmonale and congestive heart failure. However, the
   compensatory polycythemic response in patients with CF was inadequate
   when compared with the response to hypoxemia in patients with
   cyanotic congenital heart disease. The insufficient oxygen-carrying
   capacity may compromise tissue oxygen delivery and necessitate
   treatment.
RF 001   ROSENTHAL A           AM J CARDIOL                    27   162 971
   002   VANIER T              N ENGL J MED                   269   169 963
   003   CAPLAN AH             J PEDIATR                       73   540 968
   004   SCHRIEBER SS          IN: FRIEDBERG CK                      29 962
   005   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   006   BUTTON LN             TRANSFUSION                      5   143 965
   007   KEANE JF              PROG CARDIOVASC DIS             18    57 975
   008   TONZ O                LANCET                           2  1096 965
   009   WENNESLAND R          J CLIN INVEST                   38  1065 959
   010   RUSSELL SJM           ARCH DIS CHILD                  24    88 949
   011   WEIL JV               J CLIN INVEST                   47     7 968
   012   ROSENTHAL A           PEDIATRICS                      47   537 971
   013   ORZALESI MM           AM REV RESPIR DIS              107   928 973
   014$  BORDEN M              CF CLUB ABST                    15       975
CT   1   ROSENTHAL A           PEDIATRICS                      59   919 977
     2   LEMEN RJ              AM REV RESPIR DIS              117   639 978
     3   SANTAGNESE PAD        AM J MED                        66   121 979
     4   LAKE CR               CLIN CHIM ACTA                  92   141 979
     5   FISCHER EG            J PEDIATR                       95   385 979
     6   PEDERSEN PS           ACTA PAEDIATR SCAND             70   507 981
     7   RIFF L                SEM PERINATOL                    6   155 982
     8   MOSS AJ               PEDIATRICS                      70   728 982
     9   BERG U                ACTA PAEDIATR SCAND             71   833 982
    10   WAGENER JS            AM J PEDIATR HEMATOL ONCOL       5   153 983
    11   KELLY HW              DRUG INTEL CLIN PHARM           18   772 984
    12   WAGENER JS            PEDIATRICS                      74   168 984
    13   LESTER LA             SEM RESPIR MED                   6   285 985

PN 77171
RN 00752 
AN 77172346
AU Gibson-B.  Levin-D.  Cubrarino-G.  Weinberg-A.
TI Roentgenographically visible fatty liver in cystic fibrosis.
SO Pediatrics. 1977 May. 59(5). P 778-80.
MJ CYSTIC-FIBROSIS: ra.  FATTY-LIVER: ra.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  FEMALE.  HUMAN.
   MALE.
EX The initial roentgenograms of 178 consecutive newly diagnosed
   patients with cystic fibrosis seen during the past five years were
   reviewed to determine the presence of fatty liver.  Seven cases of
   visibly fatty liver were identified.  The incidence of visibly fatty
   liver on the initial roentgenograms in newly diagnosed cases of
   cystic fibrosis was 4%.  The cause of fatty infiltration of the
   liver in cystic fibrosis is not clear; however, the basis is most
   likely a nutritional deficiency in protein.
RF 001   GRISCOM NT            RADIOLOGY                      117   385 975
   002   SWISCHUK LE           AM J ROENTG RAD THER NUCL MED  122   159 974
   003   SWISCHUK LE           J PEDIATR                       88   452 976
   004   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   005   CRAIG JM              AM J DIS CHILD                  93   357 957
   006   MELHEM RE             PEDIATR RADIOL                   4   153 976
CT   1   YOUSEFZADEH DK        RADIOLOGY                      131   351 979
     2   ARBORGH B             SCAND J GASTROENTEROL           15    73 980
     3   PARK RW               GASTROENTEROLOGY                81  1143 981

PN 77172
RN 00753 
AN 77256215
AU Lau-W-K.  Young-L-S.  Osher-A-B.  Dooley-R-R.
TI Amikacin therapy of exacerbations of Pseudomonas aeruginosa
   infections in patients with cystic fibrosis.
SO Pediatrics. 1977 Sep. 60(3). P 372-7.
MJ AMIKACIN: tu.  CYSTIC-FIBROSIS: co.  KANAMYCIN: aa.
   PSEUDOMONAS-INFECTIONS: dt.  RESPIRATORY-TRACT-INFECTIONS: dt.
MN ACUTE-DISEASE.  ADOLESCENCE.  ADULT.  AMIKACIN: ad.  CHILD.
   CHILD-PRESCHOOL.  FEMALE.  HUMAN.  MALE.  PSEUDOMONAS-AERUGINOSA.
   RESPIRATORY-TRACT-INFECTIONS: et.  SUPPORT-U-S-GOVT-P-H-S.
AB Amikacin, a new semisynthetic aminoglycoside antibiotic with activity
   against Pseudomonas aeruginosa, was used to treat 22 acute
   exacerbations of chronic pulmonary infections in 18 patients with
   cystic fibrosis. Patients ranged from 5 to 32 years of age and had
   mucoid P. aeruginosa isolated from sputum. The amikacin dose was
   usually 7.5 mg/kg every eight hours but was increased to 10 mg/kg
   and/or carbenicillin was added in selected cases depending on
   clinical course. Although P. aeruginosa was not eliminated from our
   patients' sputum except in two cases, there was a good clinical
   response in 19 of 22 courses. Significant improvement in chest x-ray
   films, spirometry, or arterial oxygen tension was documented in 11 of
   17 courses. One instance of serum creatinine level elevation could
   not be attributed to this antibiotic. Two patients showed minimal (15
   dB) unilateral high-frequency hearing loss on serial audiograms.
   Activity against many gentamicin-resistant strains and high blood
   levels are among the attractive properties of amikacin. Amikacin is
   clinically effective in treating Pseudomonas-associated pulmonary
   infections complicating cystic fibrosis.
RF 001   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   002   LAWSON D              IN: WATT PJ                           69 970
   003   DOGGETT RG            IN: LAWSON D PROC 5TH INT CF         175 969
   004   RUCKER RW             PEDIATRICS                      54   358 974
   005   MEARNS MB             ARCH DIS CHILD                  47   902 972
   006   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   007   MAY JR                ARCH DIS CHILD                  47   908 972
   008   HUANG NN              J PEDIATR                       59   512 961
   009   MCCRAE WM             SCOTT MED J                     19   187 974
   010   MEARNS MB             ARCH DIS CHILD                  47     5 972
   011   ROLINSON GN           IN: LAWSON D PROC 5TH INT CF         214 969
   012   HAWLEY HB             CURR THER RES                   16   414 974
   013   HOFF GE               SCAND J INFECT DIS               6   333 974
   014   BOXERBAUM B           J INFECT DIS SUPPL             124   293 971
   015   BOXERBAUM B           J INFECT DIS SUPPL             122    59 970
   016   HUANG NN              J PEDIATR                       78   338 971
   017   PARRY MF              PROC ICAAC 15TH ABST 335                 975
   018   BODEY GP              ANTIMICROB AGENTS CHEMOTHER      4   186 973
   019   YOUNG LS              ANTIMICROB AGENTS CHEMOTHER      4   617 973
   020   YU PKW                ANTIMICROB AGENTS CHEMOTHER      4   133 973
   021   PRICE KE              J ANTIBIOT (TOKYO)              25   709 972
   022   MEYER RD              ANN INTERN MED                  83   790 975
   023   CLARKE JT             CLIN PHARMACOL THER             15   610 974
   024   BODEY GP              ANTIMICROB AGENTS CHEMOTHER      5   508 974
   025   STEVENS P             J LAB CLIN MED                  86   349 975
   026   STEVENS P             ANTIMICROB AGENTS CHEMOTHER      7   374 975
   027   BLACK RE              ANTIMICROB AGENTS CHEMOTHER      9   956 976
CT   1   KRAUSE PJ             CURR THER RES CLIN EXP          25   609 979
     2   BEAUDRY PH            J PEDIATR                       97   144 980
     3   PIEN FD               AM J HOSP PHARM                 38   981 981
     4   MEYER RD              ANN INTERN MED                  95   328 981
     5   MARKS MI              J PEDIATR                       98   173 981
     6   HYATT AC              J PEDIATR                       99   307 981
     7   LEVY J                J ANTIMICROB CHEMOTHER          10   227 982
     8   KELLY HB              J PEDIATR                      100   318 982
     9   FRASER GL             J PEDIATR                      101   792 982
    10   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
    11   GUAY DRP              DRUG INTEL CLIN PHARM           17    83 983
    12   SZAFF M               ACTA PAEDIATR SCAND             72   651 983
    13   KELLY HW              DRUG INTEL CLIN PHARM           18   772 984
    14   FRASER GL             DRUG INTEL CLIN PHARM           19   757 985
    15   HOLM SE               REV INFECT DIS                   8  S305 986
    16   AUTRET E              EUR J CLIN PHARMACOL            31    79 986
    17   PITT TL               J ROY SOC MED                   79    13 986
    18   CHADWICK EG           AM J MED                        80   166 986

PN 77173
RN 00754 
AN 77233615
AU Wong-J-W.  Keens-T-G.  Wannamaker-E-M.  Douglas-P-T.  Crozier-N.
   Levison-H.  Aspin-N.
TI Effects of gravity on tracheal mucus transport rates in normal
   subjects and in patients with cystic fibrosis.
SO Pediatrics. 1977 Aug. 60(2). P 146-52.
MJ CYSTIC-FIBROSIS: th.  GRAVITATION.  MUCUS: ph.  TRACHEA: ph.
MN ADOLESCENCE.  ADULT.  COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: pp.
   FEMALE.  HUMAN.  MALE.  POSTURE.  RADIONUCLIDE-IMAGING: mt.
   RESPIRATORY-TRACT-INFECTIONS: th.
AB A noninvasive, radionuclide imaging technique for measuring the rate
   of mucus clearance in the trachea (RT), was used to study
   gravitational effects on mucus clearance in 13 patients with cystic
   fibrosis (CF), average age 17 years; 7 normal, nonsmoking adults,
   average age 26 years; and a normal subject who was recovering from an
   acute upper respiratory tract infection (URTI). In the upright
   position, nine of the CF patients and the subject with URTI
   demonstrated abnormal tracheal mucus clearance which approached
   normal when they were placed in 25 degrees headdown position. The
   normal subjects and two of the CF patients showed no significant
   difference in the RT measured in the two positions. The results of
   the study indicate that the force of gravity can be a major influence
   on tracheal mucus clearance in CF and URTI subjects. This conclusion
   supports the use of postural drainage as an effective form of therapy
   in patients with cystic fibrosis.
RF 001   ZUELZER WW            PEDIATRICS                       4    53 949
   002   ESTERLY JR            JOHNS HOPKINS MED J            122    94 968
   003   JONES NL              AM REV RESPIR DIS              110   132 974
   004   MELLINS RB            AM REV RESPIR DIS SUPPL        110   137 974
   005   YEATES DB             J APPL PHYSIOL                  39   487 975
   006   WONG JW               THESIS                                   977
   007   YEATES DB             ARCH DIS CHILD                  51    28 976
   008   SNEDECOR GW           STATISTICAL METHODS                      967
   009   BLAKE J               J BIOMECH                        8   179 975
   010   WOOD RE               PEDIATR RES                      8   471 974
   012   IRAVANI J             J PATHOL                       106    81 972
   013   HERS JFP              AM REV RESPIR DIS SUPPL 3       93   162 966
CT   1   BASSETT PG            COMPUT BIOL MED                  9    97 979
     2   OLDENBURG FA          AM REV RESPIR DIS              120   739 979
     3   STURGESS JM           N ENGL J MED                   300    53 979
     4   CLARKE SW             BR J CLIN PHARMACOL              9   537 980
     5   PAVIA D               CLIN RESP PHYSIOL               16   335 980
     6   PAVIA D               EUR J RESPIR DIS                61   157 980
     7   KATZ SM               AM J CLIN PATHOL                73   682 980
     8   DARROW G              AM REV RESPIR DIS              122   155 980
     9   MENKES H              AM REV RESPIR DIS              122   127 980
    10   ROCHESTER DF          AM REV RESPIR DIS              122   133 980
    11   STURGESS JM           N ENGL J MED                   303   318 980
    12   YEATES DB             ANN BIOMED ENG                   9   577 981
    13   BATEMAN JRM           THORAX                          36   683 981
    14   TURNER JAP            PEDIATRICS                      67   805 981
    15   MILNER AD             BR J HOSP MED                   28    89 982
    16   SUTTON PP             EUR J RESPIR DIS                63   188 982
    17   ROSSMAN CM            AM REV RESPIR DIS              126   131 982
    18   ZAPLETAL A            EUR J RESPIR DIS                64   426 983
    19   SUTTON PP             SEM RESPIR MED                   5   353 984
    20   WANNER A              AM REV RESPIR DIS              130   701 984
    21   BROENNLE AM           INT ANESTHESIOL CLIN            23     1 985
    22   WOLLMER P             EUR J RESPIR DIS                66   233 985
    23   KIRILOFF LH           CHEST                           88   436 985
    24   FALING LJ             CLIN CHEST MED                   7   599 986
    25   VANDERSCHANS CP       THORAX                          41   448 986
    26   MATTHYS H             EUR J RESPIR DIS                69   311 986
    27   VERBOON JML           EUR J RESPIR DIS                69   169 986
    28   PIEDRA P              J PEDIATR                      108   817 986
    29   WOODHEAD M            BR MED J                       294   921 987

PN 77174
RN 00755 
AN 77213860
AU Morin-C-L.  van-Caillie-M.  Roy-C-C.  Lasalle-R.
TI Mucosal enterokinase activity in pancreatic insufficiency and celiac
   disease.
SO Pediatrics. 1977 Jul. 60(1). P 114-6.
MJ CELIAC-DISEASE: en.  ENTEROPEPTIDASE: me.  INTESTINAL-MUCOSA: en.
   PANCREATIC-DISEASES: en.  PEPTIDE-PEPTIDOHYDROLASES: me.
MN CHILD.  CHILD-PRESCHOOL.  COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: en.
   HUMAN.  INFANT.  SUCRASE: me.
EX Jejunal biopsy specimens were obtained from children with cystic
   fibrosis (CF), celiac disease (CD), or congenital exocrine
   pancreatic hypoplasia (CEPH) and from control subjects.  Sections
   were examined histologically and homogenates were used for
   measurement of enterokinase and sucrase activities.  This work was
   undertaken because enterokinase is considered a brush border enzyme,
   the release of which into the intestinal lumen is influenced by
   pancreatic enzymes, and also because we have recently shown a small
   bowel mucosal dysfunction in patients with CF.  As expected, sucrase
   activity was reduce (p < .05) in children with CD as compared to the
   other three groups.  On the other hand, enterokinase activity in
   children with pancreatic insufficiency (CF and CEPH) was higher (p <
   .05) than that of control subjects.  The present study has shown
   that in patients with CF and CEPH, mucosal enterokinase activity was
   increased as compared to control subjects.  It seems that the
   pancreatic enzymes play a large role in the turnover of enzymes in
   the brush border membrane and that the observed increase of mucosal
   enterokinase activity is probably explained by a reduced degradation
   in patients with exocrine pancreatic insufficiency.
RF 001   HADORN B              LANCET                           1   812 969
   002   NORDSTROM C           BIOCHIM BIOPHYS ACTA           242   209 971
   003   SCHMITZ J             BIOCHIM BIOPHYS ACTA           343   435 974
   004   NORDSTROM C           BIOCHIM BIOPHYS ACTA           268   711 972
   005   NORDSTROM C           BIOCHIM BIOPHYS ACTA           289   367 972
   006   MORIN CL              J PEDIATR                       88   213 976
   007   NEWCOMER AD           GASTROENTEROLOGY                53   881 967
   008   LOUVARD D             BIOCHIM BIOPHYS ACTA           309   127 973
   009   LEBENTHAL E           GASTROENTEROLOGY                70   508 976
   010   ALPERS DH             BIOCHIM BIOPHYS ACTA           401    28 975
   011   CASPARY WF            GUT                             16    89 975
   012   SEETHARAM B           LIFE SCI                        18    89 976
   013   WOODLEY JF            GUT                             13   900 972
   014   RUTGEERSTS L          ACTA GASTROENTEROL BELG         36   449 973
   015   LEBENTHAL E           PEDIATRICS                      56   585 975
CT   1   MORIN CL              DIGESTION                       18   402 978
     2   SCHMIDT E             CLIN BIOCHEM                    12   247 979
     3   SCHMIDT E             J CLIN CHEM CLIN BIOCHEM        17   693 979
     4   LENTZE MJ             LANCET                           2   504 982
     5   LEBENTHAL E           DIGESTION                       23    39 982
     6   LENTZE MJ             J PEDIATR GASTROENTEROL NUTR     2  S252 983
     7   KAI H                 J PEDIATR GASTROENTEROL NUTR     3   328 984

PN 77175
RN 00756 
AN 77124835
AU Bass-H-N.  Miller-A-A.
TI Cystic fibrosis presenting with anemia and hypoproteinemia in
   identical twins.
SO Pediatrics. 1977 Jan. 59(1). P 126-7.
MJ ANEMIA: fg.  CYSTIC-FIBROSIS: fg.  DISEASES-IN-TWINS.
   HYPOPROTEINEMIA: fg.
MN ANEMIA: co.  CASE-REPORT.  CYSTIC-FIBROSIS: co.  FEMALE.  HUMAN.
   HYPOPROTEINEMIA: co.  INFANT-NUTRITION.  INFANT.  MILK-PROTEINS.
   TWINS-MONOZYGOTIC.
EX Cystic fibrosis of the pancreas is a recessively inherited disorder
   generally considered to result in chronic pulmonary or digestive
   symptoms.  Therefore, it may not be readily appreciated that this
   disease can also present with anemia, edema, and hypoproteinemia,
   especially in infants taking breast milk or soy-based formulas.  The
   following example involving monozygotic twins given cow's milk
   formula since birth will serve to illustrate this association.
RF 001   LEE PA                JAMA                           228   585 974
   002   DOLAN TF JR           CLIN PEDIATR                     9   295 970
   003   FLEISHER DS           J PEDIATR                       64   341 964
   004   LEE PA                YEARBOOK OF PEDIATRICS               210 975
   005   STROBER W             PEDIATRICS                      43   416 969
   006   SHAHIDI NT            J PEDIATR                       59   533 961
CT   1   GUNN T                AM J DIS CHILD                 132   317 978
     2   MARIANELLI L          MINERVA PEDIATR                 31  1787 979
     3   CHU JY                NUTR REV                        37   351 979
     4   BLUMENTHAL I          ARCH DIS CHILD                  55   812 980

PN 77176
RN 00757 
AN 77193185
AU Rosenthal-A.  Khaw-K-T.  Shwachman-H.
TI Hemoglobin-oxygen equilibrium in cystic fibrosis.
SO Pediatrics. 1977 Jun. 59(6). P 919-26.
MJ CYSTIC-FIBROSIS: bl.  HEMOGLOBINS.  OXYGEN: bl.
MN ADOLESCENCE.  ADULT.  CHILD.  CYSTIC-FIBROSIS: pp.
   DIPHOSPHOGLYCERIC-ACIDS: bl.  ERYTHROCYTES: an.  ERYTHROPOIESIS.
   FEMALE.  HEMODYNAMICS.  HUMAN.  MALE.  RESPIRATION.
   SUPPORT-U-S-GOVT-P-H-S.
AB A study of 35 patients with cystic fibrosis demonstrated that
   increasing severity of pulmonary involvement was associated with a
   mild but definite increase in erythrocyte 2,3-diphosphoglycerate (2,3-
   DPG) and a decrease in hemoglobin affinity for oxygen. The
   predominant regulators of 2,3-DPG were blood pH, cardiac output, and
   systemic oxygen transport. No significant relationship was observed
   between erythrocyte 2,3-DPG content and arterial oxygen tension.
   Hypophosphatemia may have prevented a greater increase in erythrocyte
   2,3-DPG content. The inadequate increase in 2,3-DPG and consequent
   insufficient change in hemoglobin-oxygen affinity, coupled with an
   insufficient compensatory erythrocytic response, may adversely affect
   tissue oxygenation in patients with severe cystic fibrosis.
RF 001   EDWARDS MJ            CLIN RES                        16   153 968
   002   ASTE-SALAZAR H        AM J PHYSIOL                   142   733 944
   003   LENFANT C             RESPIR PHYSIOL                   7     7 969
   004   ROSENTHAL A           AM J CARDIOL                    27   162 971
   005   TORRANCE JD           S AFR J MED SCI                 39    33 974
   006   ROSENTHAL A           PEDIATRICS                      47   537 971
   007   ROSENTHAL A           PEDIATRICS                      59   588 977
   008   ORZALESI MM           AM REV RESPIR DIS              107   928 973
   009   FAIRWEATHER LJ        CLIN SCI MOL MED                47   577 974
   010   EDWARDS MJ            CHEST                           61   255 972
   011   SIASSI B              J PEDIATR                       78   794 971
   012   MOSS AJ               J PEDIATR                       67   797 965
   013   LIEBMAN J             IN: MANGOS JA                         41 976
   014   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   015$  ROSE ZB               J BIOL CHEM                    256  3232 970
   016   ROSE AB               ANAL BIOCHEM                    35   117 970
   017   DUVELLEROY MA         J APPL PHYSIOL                  28   227 970
   018   SEVERINGHAUS JW       J APPL PHYSIOL                  21  1108 966
   019   GIBSON DG             BR HEART J                      35   128 973
   020   KEANE JF              PROG CARDIOVASC DIS             18    57 975
   021   OSKI FA               N ENGL J MED                   280  1165 969
   022   LENFANT C             J APPL PHYSIOL                  30   625 971
   023   ROSENTHAL A           PEDIATR RES                      7   301 973
   024   WOODSON RD            J CLIN INVEST                   49  1349 970
   025   CAPLAN AH             J PEDIATR                       73   540 968
   026   LICHTMAN MA           ANN INTERN MED                  74   563 971
   027   TRAVIS SF             N ENGL J MED                   285   763 971
   028   DESFORGES JF          BLOOD                           40   740 972
   029   BELLINGHAM AJ         J CLIN INVEST                   50   700 971
   030   LENFANT C             IN: RORTH M                          736 972
   031   BELLINGHAM AJ         TRANS ASSOC AM PHYSICIANS       83   113 970
   032   LICHTMAN MA           N ENGL J MED                   280   240 969
   033   CHEN GSH              DISSERTATION                             974
   034   WAYBURNE S            IN: MCCANCE RA                           967
   035   KEITT AS              J LAB CLIN MED                  84   275 974
   036   SHAPIRO BL            BIOCHEM BIOPHYS RES COMMUN      39   816 970
   037   METCALF J             IN: RORTH M                          613 972
   038   ROSENTHAL A           PEDIATR CLIN NORTH AM           23   327 976
   039   TUCKER CR             PEDIATR RES                      8   355 974
   040   WHITMAN V             PEDIATRICS                      55    83 975
   041   FILLER RM             N ENGL J MED                   281   589 969
CT   1   MULLER NL             AM REV RESPIR DIS              121   463 980
     2   FRANCIS PWJ           AM J DIS CHILD                 134   734 980
     3   WARWICK WJ            AM J MED TECHNOLOGY             48   539 982
     4   ROSENTHAL A           N ENGL J MED                   306   538 982
     5   WAGENER JS            AM J PEDIATR HEMATOL ONCOL       5   153 983
     6   VICHINSKY EP          J PEDIATR                      105    15 984

PN 77177
RN 00758 
AN 77124877
AU Rosenlund-M-L.  Selekman-J-A.  Kim-H-K.  Kritchevsky-D.
TI Dietary essential fatty acids in cystic fibrosis.
SO Pediatrics. 1977 Mar. 59(3). P 428-32.
MJ CYSTIC-FIBROSIS: dh.  DIETARY-FATS: tu.
   FATTY-ACIDS-ESSENTIAL: tu.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  FATTY-ACIDS: bl.  FEMALE.
   HUMAN.  MALE.  SODIUM: an.  SWEAT: an.  THYROID-HORMONES: bl.
   SUPPORT-U-S-GOVT-P-H-S.
AB Analyses of serum lipids of children with cystic fibrosis (CF) have
   indicated a deficiency in essential fatty acids (EFA). In view of a
   report that intravenous administration of soybean oil emulsions
   normalized sweat sodium values in CF children, we studied the effects
   of orally administered essential fatty acids (as corn oil) for one
   year. Some improvement was noted in all patients, but no one
   consistent factor predominated. However, arachidonic acid, which was
   found only in trace amounts or was absent in sera of all children
   with CF before the clinical trial, was increased significantly in the
   sera after the oral administration of EFA for one year. Other
   findings included a significant decrease in sweat sodium and T3 in
   most patients.
RF 001   ROSENLUND ML          NATURE                         251   719 974
   002   ELLIOTT RB            AUST PAEDIATR J                  8   217 972
   003   ELLIOTT RB            PEDIATRICS                      57   474 976
   004   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   005   GIBSON LE             PEDIATRICS                      23   545 959
   006   HAVERBACK BJ          GASTROENTEROLOGY                44   588 963
   007   RIVERS JPW            LANCET                           2   642 975
   008   ROBINSON PG           PROC INT CF CONG 7TH                  25 976
   009   DODGE JA              PROC INT CF CONG 7TH                  68 976
   010   SAMUELS CE            PROSTAGLANDINS                  10   617 975
   011   DODGE JA              PROC INT CF CONG 7TH                  69 976
CT   1   VAUGHAN WJ            SCIENCE                        199   783 978
     2   HAMDI I               MONOGR PAEDIATR                 10    84 979
     3   CHASE HP              PEDIATRICS                      64   207 979
     4   LLOYDSTILL JD         PEDIATRICS                      64    50 979
     5   WOOD RE               SOUTH MED J                     72   189 979
     6   BARRY MM              J AM DIET ASSOC                 75   446 979
     7   CHASE HP              J PEDIATR                       95   337 979
     8   HAAN GJ               J CHROMATOGR                   162   261 979
     9   RIORDAN JR            BIOCHIM BIOPHYS ACTA           574    39 979
    10   ROGIERS V             PEDIATR RES                     14  1088 980
    11   HUBBARD VS            AM J CLIN NUTR                  33  2281 980
    12   SHEPHERD R            J PEDIATR                       97   351 980
    13   HUBBARD VS            CLIN CHIM ACTA                 102   115 980
    14   MALER T               BIOCHIM BIOPHYS ACTA           598     1 980
    15   LLOYDSTILL JD         AM J CLIN NUTR                  34     1 981
    16   RIVERS JPW            BR MED BULL                     37    59 981
    17   LEVI N                RIV ITAL PEDIATR                 8   695 982
    18   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
    19   HARPER TB             AM REV RESPIR DIS              126   540 982
    20   FARRELL PM            J DENT CHILD                    50   385 983
    21   ROGIERS V             EUR J PEDIATR                  141    39 983
    22   HODGES P              J AM DIET ASSOC                 84   664 984
    23   MCKENNA MC            J PEDIATR GASTROENTEROL NUTR     4    45 985
    24   FARRELL PM            PEDIATR RES                     19   104 985
    25   GIBSON RA             J PEDIATR GASTROENTEROL NUTR     5   408 986
    26   LESTER LA             J PARENT ENTERAL NUTR           10   289 986
    27   MISCHLER EH           PEDIATR RES                     20    36 986
    28   STEAD RJ              PROG LIPID RES                  25   305 986
    29   DUHAMEL JF            ARCH FR PEDIATR                 43   229 986
    30   CARLSTEDTDUKE J       PROC NAT ACAD SCI USA           83  9202 986

PN 77178
RN 00759 
AN 77124890
AU Davis-J-A.
TI Orchitis and cystic fibrosis [letter].
SO Pediatrics. 1977 Mar. 59(3). P 481-2.
MJ CYSTIC-FIBROSIS: co.  EPIDIDYMITIS: co.  ORCHITIS: co.
MN ADOLESCENCE.  CASE-REPORT.  HUMAN.  MALE.
EX I wish to report the case of J. J., a 17-1/2-year-old white boy known
   to have cystic fibrosis since early infancy, who developed an acute
   left orchitis and epididymitis in May 1975.  In my review of the past
   literature and in my current readings, I have been unable to find any
   reported cases of acute orchitis and/or epididymitis in a patient
   with cystic fibrosis.  I offer this case as reported and invite
   comments.
RF 001   TAUSSIG LM            N ENGL J MED                   287   586 972
   002   BUMBALO TS            PEDIATRICS                      43   468 969
   003   KAPLAN E              N ENGL J MED                   279    65 968
   004   DI SANTAGNESE PA      N ENGL J MED                   279   103 968
   005   LANDING BH            ARCH PATHOL                     88   569 969
   006   HOLSCLAW DS           J UROL                         106   568 971

PN 77179
RN 00760 
AN 77193178
AU Gayton-W-F.  Friedman-S-B.  Tavormina-J-F.  Tucker-F.
TI Children with cystic fibrosis: I. Psychological test findings of
   patients, siblings, and parents.
SO Pediatrics. 1977 Jun. 59(6). P 888-94.
MJ CYSTIC-FIBROSIS.  FAMILY.  PERSONALITY.
MN ADAPTATION-PSYCHOLOGICAL.  ADOLESCENCE.  ADULT.
   AFFECTIVE-SYMPTOMS: et.  CHILD.  FEMALE.  HUMAN.
   INTERPERSONAL-RELATIONS.  MALE.  MIDDLE-AGE.  MMPI.  PARENTS.
   PERSONAL-SATISFACTION.  PERSONALITY-TESTS.  STRESS-PSYCHOLOGICAL.
AB Psychological evaluation of 43 families, each with a child with
   cystic fibrosis, is reported. Personality testing of the parents
   showed that 32% of the fathers and 22% of the mothers obtained scores
   in the range suggestive of emotional disturbance. The Family-Concept
   O Sort assessment of family interaction indicated that the primary
   effect of having a child with cystic fibrosis was in terms of
   decreased family satisfaction and family adjustment. The results do
   not support previous estimates of an increased incidence of emotional
   disturbance in children with cystic fibrosis. Evidence for negative
   psychological impact of chronic illness on sibling development was
   also lacking. Future research would benefit from a focus on the
   strengths and resilience of children with cystic fibrosis and their
   families.
RF 001   GAYTON WF             AM J DIS CHILD                 126   856 973
   002   LAWLER RH             CAN MED ASSOC J                 94  1043 966
   003   MCCOLLUM AT           J PEDIATR                       77   571 970
   004   TROPAUER A            AM J DIS CHILD                 119   424 970
   005   TURK J                PEDIATRICS                      34    67 964
   006   MEYEROWITZ JH         SOC SCI MED                      1   249 967
   007   NOVAK AL              FAM PROC                         9   157 970
   008   DAHLSTROM WG          MMPI HANDBOOK                            960
   009   PIERS EV              MANUAL PIERS HARRIS CHILDRENS            969
   010   SINES JO              MANUAL FOR THE MISSOURI CHILD            971
   011   HOLTZMAN WH           INKBLOT PERCEPTION AND PERSON            961
   012   FITTS WH              MANUAL FOR THE TENN SELF-CONC            965
   013   ROTTER JB             PSYCHIATR MONO                  80       966
   014   ANDERSON LM           J CONSULT CLIN PSYCHOL          33   575 969
   015   LIVERANT S            J CONSULT CLIN PSYCHOL          23   256 959
   016   WOLKING WD            J CLIN PSYCHOL                  22    39 966
   017   MCCOLLUM AT           AM J PUBLIC HEALTH              61  1335 971
   018   PIERS EV              J CONSULT CLIN PSYCHOL          38   428 972
   019   TAVORMINA JB          J ABNORM CHILD PSYCHOL           4    99 976
   020   PLESS IB              CHRONIC CHILDHOOD DISORDER               975
   021   HAMBURG DA            PSYCHOTHER PSYCHOSOM            23    13 974
CT   1   BOLL TJ               J PSYCHOSOM RES                 22   209 978
     2   BARRY MM              J AM DIET ASSOC                 75   446 979
     3   CAIRNS NU             J PEDIATR                       95   484 979
     4   HODGMAN CH            J PEDIATR                       95   309 979
     5   VANCE JC              PEDIATRICS                      65   948 980
     6   DROTAR D              PEDIATRICS                      67   338 981
     7   LEWIS BL              J PEDIATR                      101   636 982
     8   BRESLAU N             AM J DIS CHILD                 136   682 982
     9   STEINHAUSEN HC        J AM ACAD CHILD PSYCHIAT        22   559 983
    10   MCKEEVER P            AM J ORTHOPSYCHIATRY            53   209 983
    11   SINNEMA G             ACTA PAEDIATR SCAND             72   427 983
    12   SABBETH B             PEDIATR CLIN NORTH AM           31    47 984
    13   DEWET B               S AFR MED J                     65   526 984
    14   ORR DP                J PEDIATR                      104   152 984
    15   LEWISTON NJ           SEM RESPIR MED                   6   321 985
    16   BRESLAU N             J AM ACAD CHILD PSYCHIAT        24    87 985
    17   JOHNSTON IDA          BR MED J                       290  1636 985
    18   ALLEN L               J AM ACAD CHILD PSYCHIAT        25   708 986
    19   COWEN L               PEDIATRICS                      77   745 986
    20   MEARNS MB             J ROY SOC MED                   79    51 986
    21   NOLAN T               J PEDIATR                      109   201 986
    22   MOLLERING M           KLIN PAEDIATR                  198   369 986
    23   WALKER LS             PEDIATRICS                      79   239 987

PN 77180
RN 00761 
AN 78073115
AU Heycock-J-B.
TI Pulmonary diseases in children.
SO Practitioner. 1977 Nov. 219(1313). P 670-80.
MJ RESPIRATORY-TRACT-DISEASES.
MN ASTHMA: dt.  BRONCHIECTASIS.  BRONCHITIS: di, th.
   BRONCHOPNEUMONIA: co.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS.
   HUMAN.  INFANT.  INFANT-NEWBORN.  PNEUMONIA: th.
   RESPIRATORY-TRACT-DISEASES: co.  RESPIRATORY-TRACT-INFECTIONS: th.
   TUBERCULOSIS-PULMONARY: co, di, dt.
EX Respiratory infections in infants and children cause much ill-health
   and also an appreciable mortality.  They are found at times in most
   school-children and in infants, especially those in large families
   and those living in poor circumstances.  In all respiratory
   infections the whole respiratory tract is involved.  For descriptive
   purposes it is useful to divide these infections into upper
   respiratory-tract infections, in which the infection is
   predominantly at the larynx or above; and lower respiratory-tract
   infections, in which the predominant infection is below the larynx.
   Acute upper respiratory-tract infections are usually viral and the
   poly-virus infection of coryza is the commonest.  Acute lower
   respiratory-tract infections are discussed in two groups: in infants
   under two years of age and in children over two (including cystic
   fibrosis).
RF 001   GARDNER PS            BR MED J                         2   932 967
   002   HEYCOCK JB            BR J CLIN PRACT                 10   457 972

PN 77181
RN 00762 
AN 77148663
AU Swann-I.
TI Anorexia nervosa--a difficult diagnosis in boys.  Illustrated by
   three cases.
SO Practitioner. 1977 Mar. 218(1305). P 424-7.
MJ ANOREXIA-NERVOSA: di.
MN ADOLESCENCE.  ANOREXIA-NERVOSA: et.  CASE-REPORT.
   CEREBRAL-VENTRICLE-NEOPLASMS: di.  CHILD.  CYSTIC-FIBROSIS: di.
   DIAGNOSIS-DIFFERENTIAL.  HUMAN.  MALE.  SEX-FACTORS.
EX The three patients described here have all been seen recently at the
   Royal Hospital for Sick Children in Edinburgh, and each has
   presented a diagnostic problem.  In the three cases presented it has
   been difficult to establish the true diagnosis.  In the first case,
   symptoms compatible with the diagnostic criteria of Beumont and his
   colleagues were directly the result of a slow-growing cerebral
   neoplasm which was elusive to diagnose.  The second patient, a boy
   with cystic fibrosis, showed symptoms strongly suggestive of
   anorexia nervosa and responded to dietary measures without
   pancreatic enzyme replacement.  We have been unable to demonstrate
   any organic disease in the third case and, hence, a presumptive
   diagnosis of anorexia nervosa has been made.  It remains to be said
   that this condition is extremely rare in boys and that anorexia with
   weight loss warrants extremely thorough investigation.
RF 001   BELL ET               ACTA ENDOCRINOL                 51   140 966
   002   BEUMONT PJV           PSYCHOL MED                      2   216 972
   003   ANON                  BR MED J                         4   686 972
   004   COBB S                BORDERLANDS OF PSYCHIATRY                943
   005   GARFINKEL PE          ARCH GEN PSYCHIAT               32   739 975
   006   GULL WW               TRANS R SOC LOND                 7    22 874
   007   KIDD CB               POSTGRAD MED J                  42   443 966
   008   NEMIAH JC             MEDICINE                        29   225 950
   009   RUSSELL GFM           J PSYCHOSOM RES                  9    79 965
   010   SEAVER RL             ADV PSYCHOSOMATIC MED            7   257 972
   011   SELVINI P             IN: MEYER JE                             965
   012   TAIPALE V             PSYCHOSOMATICS                  13   236 972
CT   1   ANON                  S AFR MED J                     52     2 977
     2   ANON                  BR MED J                         1     5 978
     3   HAY GG                LANCET                           2   574 979
     4   ANDERSEN AE           PSYCHOSOMATICS                  24  1066 983

PN 77182
RN 00763 
AN 78053411
AU Warren-Lober-C.
TI Manifestations of cystic fibrosis.
SO Primary-Care. 1977 Dec. 4(4). P 705-20.
MJ CYSTIC-FIBROSIS: di.
MN BILIARY-TRACT-DISEASES: pa.  CYSTIC-FIBROSIS: co, pa.
   DIAGNOSIS-DIFFERENTIAL.  FEMALE.  GASTROINTESTINAL-DISEASES: et.
   GENITAL-DISEASES-FEMALE: pa.  HUMAN.  LIVER-DISEASES: pa.  LUNG: pa.
   MALE.  SWEAT-GLANDS: pa.  SWEATING.  WATER-ELECTROLYTE-IMBALANCE: di.
AB The diagnosis of cystic fibrosis is usually established by the
   presence of chronic obstructive lung disease and/or gastrointestinal
   compromise, together with elevated sweat electrolytes or pathologic
   changes in tissue. Because of its highly variable genetic penetrance,
   the disease is characterized by varying degrees of involvement of
   different exocrine systems.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   002   ANDERSEN DH           PEDIATRICS                       3   406 949
   003   ANDERSON EL           J S CAROLINA MED ASSOC          68   275 972
   004   BARTON AD             J LAB CLIN MED                  88   423 976
   005   BARTRAM CI            BR J RADIOL                     44   195 971
   006   BEDROSSIAN CWM        HUM PATHOL                       7   195 976
   007   BEIER FR              AM REV RESPIR DIS               94   430 966
   008   BIGGS JC              LANCET                           2   814 963
   009   BLACKFAN KD           J PEDIATR                       13   627 938
   010   BLANCK RR             JAMA                           235  1364 976
   011   BOOT T                JAMA                           209  1498 967
   012   COOK CD               PEDIATRICS                      24   181 959
   013   SHWACHMAN H           PEDIATRICS                      30   389 962
   014   ANON                  CF FND 1974 REP SURVI STUD PA            976
   015   DENTON R              PEDIATRICS                      25   611 960
   016   DI SANTAGNESE PA      AM FAM PHYSICIAN                 7   102 973
   017   DI SANTAGNESE PA      PEDIATRICS                      15   683 955
   018   DI SANTAGNESE PA      IN: DOWNEY JA                         25 974
   019   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   020   DI SANTAGNESE PA      GASTROENTEROLOGY                40    64 961
   021   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   022   DOLAN TF JR           CLIN PEDIATR                    14   862 975
   023   ESTERLY JR            THORAX                          23   670 968
   024   ESTERLY JR            BULL JOHNS HOPKINS HOSP        110   247 962
   025   FANCONI G             WIEN MED WOCHENSCHR             86   753 936
   026   FOX WW                PEDIATRICS                      54   293 974
   027   GARROD AE             Q J MED                          6   242 913
   028   GHARIB R              AM J DIS CHILD                 108   499 964
   029   GIBSON LE             PROC FOR QUANTITATIVE ION                975
   030   GRAND RJ              CLIN PEDIATR                     9   588 970
   031   GRAND RJ              JAMA                           195   993 966
   032   HANDWERGER S          N ENGL J MED                   281   451 969
   033   HARPER MH             ARCH DIS CHILD                  13    45 938
   034   HOLSCLAW DS           J PEDIATR SURG                   9   867 974
   035   HOLSCLAW DS           PEDIATRICS                      48    51 971
   036   HUANG NN              CF CLUB ABST                          43 976
   037   HUANG NN              J PEDIATR                       59   512 961
   038   ISENBERG JN           AM J GASTROENTEROL              65   134 976
   039   KOPITO LE             FERTIL STERIL                   24   512 973
   040   KATTWINKEL J          J PEDIATR                       82   234 973
   041   KESSLER WR            PEDIATRICS                       8   648 951
   042   SHWACHMAN H           PEDIATR CLIN NORTH AM           22   787 975
   043   LANDAU LI             AM REV RESPIR DIS              108   593 973
   044   LAPEY A               J PEDIATR                       84   328 974
   045   LOBECK CC             IN: STANBURY JB                     1605 972
   046   LOBER CW              AM J DIS CHILD                 129    10 975
   047   LOBER CW              CHEST                           66     3 974
   048   LIEBERMAN J           ANN INTERN MED                  82   806 975
   049   MAY JR                ARCH DIS CHILD                  47   908 972
   050   MEARNS MB             ARCH DIS CHILD                  47   902 972
   051   NEELY JG              TRANS AM ACAD OPHTHALMOL OTOL   76   313 972
   052   OPPENHEIMER EH        J PEDIATR                       86   683 975
   053   OPPENHEIMER EH        J PEDIATR                       75   806 969
   054   OPPENHEIMER EH        J PEDIATR                       77   991 970
   055   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   056   PONKA JL              SURG GYNECOL OBSTET            124    99 967
   057   REID L                MOD PROBL PEDIATR               10   195 967
   058   ANON                  J PEDIATR                       88   711 976
   059   SHWACHMAN H           PEDIATR CLIN NORTH AM           22   787 975
   060   SHWACHMAN H           CF CLUB ABST                    16    19 975
   061   SHWACHMAN H           PEDIATRICS                      30   389 962
   062   SHWACHMAN H           PEDIATRICS                      55    86 975
   063   STRANG R              BR J SURG                       46   484 958
   064   TAUSSIG LM            N ENGL J MED                   287   586 972
   065   TAUSSIG LM            RADIOLOGY                      106   369 973
   066   TAYLOR BW             ARCH DIS CHILD                  49   133 974
   067   THOMAIDIS TS          J PEDIATR                       63   444 963
   068   TOMASHEFSKI JF        CHEST                           57    28 970
   069   TONZ O                MOD PROBL PEDIATR               10   259 967
   070   WARING WW             ADV PEDIATR                     23   401 976
   071   WARING WW             PEDIATRICS                      39   166 967
   072   WARWICK WJ            MOD PROBL PEDIATR               10   353 967
   073   WARWICK WJ            PEDIATRICS                      34   621 964
   074   WARWICK WJ            J CHRON DIS                     28   609 975
   075   WILMSHURST EG         PEDIATRICS                      55    75 975
   076   WENTWORTH P           THORAX                          23   582 968
   077   WOOD RE               AM REV RESPIR DIS              113   833 976

PN 77183
RN 00764 
AN 78053410
AU Honicky-R-E.
TI Cystic fibrosis.
SO Primary-Care. 1977 Dec. 4(4). P 693-703.
MJ CYSTIC-FIBROSIS: di.
MN ADOLESCENCE.  ADULT.  ANTIBIOTICS: tu.  CHILD.
   CYSTIC-FIBROSIS: co, dt.  FEMALE.  GASTROINTESTINAL-DISEASES: di, dt.
   HUMAN.  MALE.  SWEATING.
AB Cystic fibrosis has been regarded as a disease of infants. Yet, with
   improved management, a high percentage of patients how survive into
   young adulthood. In addition, mild cases may not be detected until
   long after infance. The older patient often has minimal symptoms, and
   the majority are socially active and  productive.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   002   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   003   GIBSON LE             PEDIATRICS                      23   545 959
   004   SHWACHMAN H           ADV PEDIATR                      7   249 955
   005   WARING WW             ADV PEDIATR                     23   401 976
   006   WOOD RE               AM REV RESPIR DIS              113   833 976

PN 77184
RN 00765 
AN 78094465
AU Epstein-J.  Breslow-J-L.  Davidson-R-L.
TI Increased dexamethasone resistance of cystic fibrosis fibroblasts.
SO Proc-Natl-Acad-Sci-USA. 1977 Dec. 74(12). P 5642-6.
MJ CYSTIC-FIBROSIS: me.  DEXAMETHASONE: pd.  OUABAIN: pd.
MN AMINOPTERIN: pd.  BIOLOGICAL-TRANSPORT: de.  CELL-SURVIVAL: de.
   CELLS-CULTURED.  COLCHICINE: pd.  ETHACRYNIC-ACID: pd.  HUMAN.
   STROPHANTHIDIN: pd.  STRUCTURE-ACTIVITY-RELATIONSHIP.
   SUPPORT-U-S-GOVT-P-H-S.
AB We demonstrate previously that fibroblasts from cystic fibrosis (CF)
   patients are significantly more resistant to the toxic effects of
   ouabain than normal human fibroblasts are. Ouabain is generally
   assumed to act primarily at the level of the cell membrane and to
   cause killing of cells by inhibiting ion transport. We have therefore
   examined the ability of normal and CF cells to survive exposure to
   ethacrynic acid, another inhibitor of ion transport, and to survive
   colchicine and aminopterin, resistance to which has been associated
   with membrane alterations in other cells. The effect of
   dexamethasone, which has a sterol nucleus similar to that of ouabain
   but is thought to have a different site of cellular action, was also
   tested. Exposure of the cells to ethacrynic acid, colchicine, or
   aminopterin did not reveal any differences in survival between normal
   and CF fibroblasts. However, CF cells survived exposure to
   dexamethasone significantly better than normal cells did. These
   results suggest that normal and CF cells do not differ in terms of a
   generalized resistance to ion transport inhibitors or to drugs that
   must pass through the membrane to be active. Instead, the results
   raise the possibility that CF cells have an enhanced resistance to
   drugs that have the sterol nucleus found in ouabain and
   dexamethasone.
RF 001   EPSTEIN JL            PROC NAT ACAD SCI USA           74  1676 977
   002   SCHATZMANN JJ         HELV PHYSIOL ACTA               11   346 953
   003   ERLY D                J PHYSIOL (LOND)               214   327 971
   004   CARLSEN SA            BIOCHIM BIOPHYS ACTA           455   900 976
   005   FLINTOFF WF           SOMATIC CELL GENET               2   245 976
   006   WILSON WE             MOL PHARMACOL                    6   449 970
   007   SIBLEY CH             CELL                             2   221 974
   009   YAMAMOTO KR           PROC NAT ACAD SCI USA           71  3901 974
   010   DUGGAN DE             ARCH BIOCHEM BIOPHYS           109   388 965
CT   1   EPSTEIN J             SOMATIC CELL GENET               4   451 978
     2   BRESLOW JL            CELL                            13   663 978
     3   BRESLOW JL            SCIENCE                        201   180 978
     4   HARRIS A              DEVELOP MED CHILD NEUROL        21   675 979
     5   SHWACHMAN H           J PEDIATR                       95   661 979
     6   BRESLOW JL            J CELL PHYSIOL                  99   343 979
     7   KURZ JB               SCIENCE                        206  1317 979
     8   BUCHWALD M            ADV CYCLIC NUCLEO RES           12   243 980
     9   WEICHSELBAUM RR       J CELL PHYSIOL                 103   429 980
    10   BRESLOW JL            SCIENCE                        207  1007 980
    11   DANIEL A              HUM GENET                       57    96 981
    12   BRESLOW JL            N ENGL J MED                   304     1 981
    13   SEALE TW              ANN CLIN LAB SCI                12   415 982
    14   KHALID BAK            CLIN ENDOCRINOL                 18   407 983
    15   LANGHOFF E            PEDIATR RES                     18   488 984
    16   PINSKY L              ADV HUM GENET                   16   299 987

PN 77185
RN 00766 
AN 77172959
AU Epstein-J.  Breslow-J-L.
TI Increased resistance of cystic fibrosis fibroblasts to ouabain
   toxicity.
SO Proc-Natl-Acad-Sci-USA. 1977 Apr. 74(4). P 1676-9.
MJ CYSTIC-FIBROSIS: pp.  OUABAIN: pd.  SKIN: de, pp.
MN ADOLESCENCE.  ADULT.  BIOLOGICAL-TRANSPORT: de.  CELL-SURVIVAL: de.
   DOSE-RESPONSE-RELATIONSHIP-DRUG.  DRUG-RESISTANCE.  FEMALE.
   FIBROBLASTS: de, ph.  HUMAN.  INFANT-NEWBORN.  MALE.  POTASSIUM: pd.
   SKIN: ph.  SUPPORT-U-S-GOVT-P-H-S.
AB Diploid skin fibroblasts derived from several unrelated patients with
   cystic fibrosis (CF) were tested for resistance to the cytotoxic
   effects of ouabain in comparison with cells from normal individuals.
   Cells from CF and normal individuals were plated at low density and
   exposed to ouabain at different concentrations for 24 hr. Dose-
   response curves showed that CF cells survived significantly better
   than did normal cells at all ouabain concentrations from 0.1 nM to 1
   micronM in potassium-deficient medium. In medium containing the usual
   amount of potassium (6.25 mM), survival of the CF cells exposed to
   ouabain was decreased to that of the normal cells. If the glucose
   concentration of the potassium-deficient medium was decreased to 10%
   of the usual amount, the resistance of the CF cells to ouabain
   disappeared and their survival was identical to that of the normal
   cells. These findings may be useful in understanding the biochemical
   basis of CG and its clinical manifestations.
RF 001   ANON                  J PEDIATR                       88   711 976
   002   ANON                  CF FND 1973 REP SURVI STUD PA            975
   003   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   004   MANGOS JA             PEDIATR RES                      1   436 967
   005   TAUSSIG LM            LANCET                           1  1367 972
   006   SCHATZMANN JJ         HELV PHYSIOL ACTA               11   346 953
   007   SHANK BB              J CELL PHYSIOL                  87   377 975
   008   BAKER RM              CELL                             1     9 974
   009   LEVER JE              J CELL PHYSIOL                  88   343 976
   010   CORSARO CM            EXP CELL RES                    95    47 975
   011   MANKOVITZ R           CELL                             3   221 974
   012   QUISSELL DO           NATURE                         247   115 974
   013   BARRANCO SC           J CELL PHYSIOL                  88    33 976
   014   BUCHWALD M            PROC NAT ACAD SCI USA           73  2899 976
CT   1   EPSTEIN J             PROC NAT ACAD SCI USA           74  5642 977
     2   BRESLOW JL            EXP CELL RES                   110   399 977
     3   EPSTEIN J             SOMATIC CELL GENET               4   451 978
     4   BRESLOW JL            CELL                            13   663 978
     5   BRESLOW JL            SCIENCE                        201   180 978
     6   BOAT TF               ACS SYMPOSIUM SERIES          1978   108 978
     7   DISANTAGNESE PA       MONOGR PAEDIATR                 10    66 979
     8   EPSTEIN J             PROC NAT ACAD SCI USA           76  6396 979
     9   BRESLOW JL            J CELL PHYSIOL                  99   343 979
    10   KURZ JB               SCIENCE                        206  1317 979
    11   DAVIS PB              PEDIATR RES                     14    83 980
    12   BRESLOW JL            SCIENCE                        207  1007 980
    13   REZNIK VM             PROC NAT ACAD SCI USA           78  7143 981
    14   BRESLOW JL            N ENGL J MED                   304     1 981
    15   SEALE TW              ANN CLIN LAB SCI                12   415 982

PN 77186
RN 00767 
AN 77257159
AU Raeburn-J-A.
TI Nutrition and immunity in cystic fibrosis.
SO Proc-Nutr-Soc. 1977 May. 36(1). P 77-83. (REVIEW).
MJ CYSTIC-FIBROSIS: im.  INFECTION: co.  NUTRITION-DISORDERS: im.
MN ADULT.  ANTIBODY-FORMATION.  CHILD.  CYSTIC-FIBROSIS: co, et.  HUMAN.
   HYPERSENSITIVITY-IMMEDIATE: co.  IGA-SECRETORY.  IMMUNITY-CELLULAR.
   IMMUNOGLOBULINS: me.  INFANT.  KWASHIORKOR: im.  LYMPHOCYTES: ph.
   MUCOUS-MEMBRANE: pp.  NUTRITION-DISORDERS: co.  NUTRITION.
   PHAGOCYTOSIS.  RESPIRATORY-TRACT-INFECTIONS: co.  REVIEW.
EX Has too much attention been focused on antibiotic therapy in cystic
   fibrosis, thereby overshadowing other measures which have led to the
   improved prognosis?  This may well be true and there is no doubt
   that regular intensive physiotherapy, performed daily by the
   patients' relatives, plays the major part in improving airway
   obstruction.  More skilful nutritional management including adequate
   pancreatic replacement therapy and high-energy, high-protein diets
   will also have had beneficial effects on the respiratory defects.
   The infected CF patient may not require high doses of antibiotics;
   he too might benefit more from simple nutritional alterations.  It
   is not new to suggest that nutritional factors are important
   influences on the resistance to infection of the CF patient.  What
   we can now do is measure the different aspects of the immune
   response in such patients and those with malnutrition, so that the
   simplest and most direct therapy can be chosen.
RF 001   ALLAN JD              CLIN ALLERGY                     5   255 975
   002   BEARN AG              IN: WALKER G                         426 973
   003   BEARN AG              CLIN GASTROENTEROL               2   515 973
   004   BIGGAR WD             PROC NAT ACAD SCI USA           68  1716 971
   006   BRYCESON A            LANCET                           2   685 976
   007   CHANDRA RK            BR MED J                         3   608 974
   009   DOUGLAS SD            CLIN IMMUNOL IMMUNOPATHOL        5     1 976
   010   FAULK WP              IN: BRENT L                      4   355 974
   011   FORBES IJ             AUST NZ J MED                    2   160 971
   012   GEORGE L              ARCH DIS CHILD                  46   139 971
   013   GIBBONS A             BR MED J                         1   120 976
   014   GREEN MN              AM J DIS CHILD                 100   365 960
   015   HARLAND PS            LANCET                           2   719 965
   016   HEYWORTH B            IN: BRENT L                      4   343 974
   017   HILL HR               J PEDIATR                       84    55 974
   019   ANON                  BR MED J                         4    64 973
   020   MCCRAE WM             IN: APLEY J                      4   157 974
   021   MCCRAE WM             SCOTT MED J                     19   187 974
   022   MEARNS MB             ARCH DIS CHILD                  47     5 972
   023   MITCHELL-HEGGS PF     Q J MED                         45   479 976
   024   NEWHOUSE M            IN: MANGOS JA                        319 973
   025   RAEBURN JA            SCOTT MED J                     19    91 974
   026   RAEBURN JA            IRCS J MED SCI                   3   266 975
   027   RAEBURN JA            IN: EMERY AEH                    2       975
   028   RAEBURN JA            J ANTIMICROB CHEMOTHER           2   107 976
   029   RAEBURN JA            IN: DAIKOS GK                    2   730 974
   031   RAEBURN JA            CHEMOTHERAPY                     4    17 976
   032   REDDY V               ARCH DIS CHILD                  51   871 976
   033   REID L                IN: MANGOS JA                        195 973
   034   SCHWARTZ RH           AM J DIS CHILD                 111   408 966
   035   SMYTHE PM             LANCET                           2   939 971
   036   STEPHAN U             IN: MANGOS JA                        281 973
   037   STURGESS JM           IN: LAWSON D PROC 5TH INT CF         368 969
   038   TAYLOR B              LANCET                           2   111 973
   039   VON FURTH R           IN: MACPHEE T                         47 972
   040   WALLWORK JC           CLIN EXP IMMUNOL                18   303 974
   041   WALLWORK JC           CLIN ALLERGY                     6   349 976
   042   WARNER JO             LANCET                           1   990 976
   043   WRIGHT WC JR          CLIN RES                        21   308 973
CT   1   WOOD RE               SOUTH MED J                     72   189 979
     2   ASKANAZI J            CRIT CARE MED                   10   163 982
     3   RISTER M              KLIN PAEDIATR                  195   334 983
     4   IRWIN MM              AM J NURS                       85   274 985

PN 77187
RN 00768 
AN 78094602
AU Sweet-E-M.
TI Causes of 'delayed' respiratory distress in infancy.
SO Proc-R-Soc-Med. 1977 Dec. 70(12). P 863-6.
MJ RESPIRATORY-DISTRESS-SYNDROME: et.  RESPIRATORY-INSUFFICIENCY: et.
MN BONE-DISEASES-DEVELOPMENTAL: co.  CASE-REPORT.  CHYLOTHORAX: co.
   CYSTIC-FIBROSIS: co.  DIAGNOSIS-DIFFERENTIAL.
   HEART-DEFECTS-CONGENITAL: co.  HISTIOCYTOSIS-X: co.  HUMAN.  INFANT.
   LYMPHANGIECTASIS: cn.  PULMONARY-EMPHYSEMA: cn.
   THORACIC-DISEASES: co.
EX There are many causes of respiratory distress staring more than one
   week after birth in infants who have had no, or only transient and
   minor, respiratory problems immediately after birth.  They may be
   divided into two broad groups: those with primary pulmonary
   pathology and those with extrapulmonary pathology with secondary
   effects on lung expansion.  The former category includes
   Wilson-Mikity syndrome, chylothorax and congenital pulmonary
   lymphangiectasia, congenital lobar emphysema, cystic fibrosis,
   hystiocytosis X, and acute infections.  The second group includes
   congenital heart disease, foregut duplication, tracheo-oesophageal
   fistula, diaphragmatic hernia, and asphyxiating thoracic dysplasia.
RF 001   BAKER DH              RADIOL CLIN NORTH AM             1   519 963
   002   BORNHURST RA          RADIOLOGY                       83   476 964
   003   CAFFEY J              PEDIATRIC X-RAY DIAGNOSIS            594 973
   004   CAMPBELL AGM          BR MED J                         1  1322 977
   005   CHATRATH RR           ARCH DIS CHILD                  46   633 971
   006   FLOYD FW              PEDIATRICS                      31    87 963
   007   FROSTIN MH            AM J DIS CHILD                 114   330 967
   008   GROSSMAN H            RADIOLOGY                       85   409 965
   009   HODGMAN JE            PEDIATRICS                      44   179 969
   010   JEUNE M               ARCH FR PEDIATR                 12   886 955
   011   JEUNE M               PEDIATRIE                        9   390 954
   012   KIRKPATRICK JA JR     PROG IN PEDIATR RADIOL           1   294 967
   013   LEAPE LL              PEDIATRICS                      34   246 964
   014   LUCAS RV              PEDIATR CLIN NORTH AM           10   781 963
   015   NEIMANN N             PEDIATRIE                       18   387 963
   016   NORTHWAY WH JR        RADIOLOGY                       91    49 968
   017   RICE RP               RADIOLOGY                       87  1021 966
   018   ROBINSON MJ           ARCH DIS CHILD                  50   962 975
   019   RUDHE U               ANN RADIOL (PARIS)              12   289 967
   020   SAUVEGRAIN J          PROG IN PEDIATR RADIOL           2    39 969
   021   SIEBER WK             PEDIATRICS                      18   935 956
   022   TALNER NS             PEDIATRICS                      56   562 975
   023   TUDOR J               CLIN RADIOL                     27    65 976
   024   WILSON MG             AM J DIS CHILD                  99   489 960
CT   1   STORM W               KLIN PAEDIATR                  197   310 985

PN 77188
RN 00769 
AN 77125703
AU Griffiths-E-K.  Yoonessi-S.  Neter-E.
TI Antibody response to enterobacterial lipoprotein of patients with
   varied infections due to Enterobacteriaceae.
SO Proc-Soc-Exp-Biol-Med. 1977 Feb. 154(2). P 246-9.
MJ ANTIBODIES-BACTERIAL: an.  BACTERIAL-PROTEINS: im.
   ENTEROBACTERIACEAE-INFECTIONS: im.  LIPOPROTEINS: im.
MN ADOLESCENCE.  ADULT.  AGED.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: co.  DYSENTERY-BACILLARY: im.
   ENTEROBACTERIACEAE: im.  HUMAN.  INFANT.  MIDDLE-AGE.  PERITONITIS: im.
   RESPIRATORY-TRACT-INFECTIONS: et, im.  SALMONELLA-INFECTIONS: im.
   SEPTICEMIA: im.  SUPPORT-U-S-GOVT-P-H-S.
EX The present study was initiated to determine the antibody response
   to lipoprotein of patients with various enterobacterial infections.
   This investigation was also considered important because patients
   with these infections respond differently to another antigen common
   to enterobacteriaceae, the common enterobacterial antigen.
   Included were 33 patients with cystic fibrosis, complicated by
   enterobacterial respiratory tract infection.  The lipoprotein (LP)
   antibody levels of healthy subjects and of patients with varied
   enterobacterial infections were determined.  None of the healthy
   children and only one of the healthy adults had antibodies against
   LP.  In contrast, 18% of the children with peritonitis complicating
   appendicitis, 24% of patients with enterobacterial infection of the
   respiratory tract complicating cystic fibrosis, and 42% of adult
   subjects with bacteremia complicating malignancy, had LP antibodies
   in the serum.  The reason for these striking differences in the
   immune response to this common antigen remains to be elucidated.
RF 001   WEIDEL W              ADV ENZYMOL                     26   193 964
   002   BRAUN V               PROC NAT ACAD SCI USA           69   970 972
   003   BRAUN V               IN: PEETERS H                        221 972
   004   BRAUN V               EUR J BIOCHEM                   13   336 970
   005   BRAUN V               BIOCHEMISTRY                     9  5041 970
   006   BRAUN V               EUR J BIOCHEM                   10   426 969
   007   BRAUN V               J INFECT DIS SUPPL             128     9 973
   008   NETER E               INFECTION                        1    12 973
   009   NETER E               ANN NY ACAD SCI                 66   141 956
   010   NETER E               N ENGL J MED                   261  1162 959
   011   RIESEN W              KLIN WOCHENSCHR                 53   353 975
CT   1   MAYER H               CURR TOP MICROBIOL IMMUNOL    1979    99 979
     2   MAYER H               CURR TOP MICROBIOL IMMUNOL    1979    99 979
     3   BLAKE D               EXPERIENTIA                     36   254 980
     4   GRIFFITHS E           INFECT IMMUN                    47   808 985

PN 77189
RN 00770 
AN 77195135
AU Haller-J-O.  Heffer-E-T.  Kassner-E-G.  Pinck-R-L.
TI Unusual radiographic manifestations of cystic fibrosis.
SO Rev-Interam-Radiol. 1977 Jan. 2(1). P 41-2.
MJ CYSTIC-FIBROSIS: ra.
MN ACIDOSIS-DIABETIC: ra.  ADOLESCENCE.  ADULT.  CASE-REPORT.
   DIABETES-MELLITUS: ra.  DIAGNOSIS-DIFFERENTIAL.
   ESCHERICHIA-COLI-INFECTIONS: ra.  FEMALE.  HUMAN.
   PNEUMATOSIS-CYSTOIDES-INTESTINALIS: ra.
AB The authors report 2 radiographic findings that have not previously
   been described in patients with cystic fibrosis: (1) the linear form
   of pneumatosis coli (2) large pancreatic concretions which resembled
   the pancreatic calcificaitons of hereditary pancreatitis. The patient
   with pancreatic calcification also had labile diabetes and episodes
   of ketoacidosis, unusual complications of cystic fibrosis.
RF 001   ELLIOTT GB            AM J ROENTG RAD THER NUCL MED   89   720 963
   002   HUNT CE               PEDIATR RES                      7   292 973
   003   KEYTING WS            RADIOLOGY                       76   733 961
   004   NELSON SW             AM J ROENTG RAD THER NUCL MED  115   225 972
   005   RING EJ               AM J ROENTG RAD THER NUCL MED  117   446 973
   006   ROSAN RC              AM J DIS CHILD                 104   625 962
   007   SMITH BH              AM J CLIN PATHOL                48   455 967
   008   WHITE H               RADIOL CLIN NORTH AM             1   539 963
   009   WOOD RE               AM J DIS CHILD                 129   246 975

PN 77190
RN 00771 
AN 78013568
AU Sorensen-H.  Mygind-N.  Tygstrup-I.  Winge-Flensborg-E.
TI Histology of nasal polyps of different etiology.
SO Rhinology. 1977 Sep. 15(3). P 121-8.
MJ NASAL-MUCOSA: pa.  NASAL-POLYPS: pa.
MN ADOLESCENCE.  ADULT.  AGED.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: co, pa.  EOSINOPHILIA: pa.  FEMALE.  HUMAN.  MALE.
   MIDDLE-AGE.  NASAL-POLYPS: et.
AB The aim of the present study is to elucidate the correlation between
   etiology and histology in nasal polyps with special regard to cystic
   fibrosis (CF). Nasal polyps from 15 children with CF and a control
   group of non-CF polyps from 15 adult patients were examined by light-
   microscopy. The histological evaluation was carried out on a blind
   basis in order to avoid bias. Among the parameters used, the tissue
   eosinophilia proved to be the most valuable factor in the
   differentiation between CF and non-CF polyps, as only few eosinophils
   were found in the CF-polyps. The polyp glands were few and generally
   pathological. Some characteristics abnormalities in the grandular
   morphology are apparently more common in CF polyps. It is concluded,
   that the histological examination of nasal polyps is of importance
   for the correct classification of the patient, but the diagnosis of
   CF cannot be made based on microscopy of polyps. Further studies
   including blinded histological examination of nasal polypous tissue
   might contribute to a more differentiated diagnose of nasal
   polyposis.
RF 001$  CAUNA N               OTOL RHINOL LARYNG ST LOUIS     81    41 972
   002   MAGID SL              ARCH OTOLARYNGOL                86   212 967
   004   MYGIND N              ISIAN PROC TOKYO                     120 977
   005   NEELY JG              TRANS AM ACAD OPHTHALMOL OTOL   76   313 972
   006   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   007   PAULSEN JW            PROC EUR WRK CONF CF WARS 3RD            973
   008   SHWACHMAN H           AM J DIS CHILD                 102   768 961
   009   TAYLOR BW             ARCH DIS CHILD                  49   133 974
   011   WOOD RE               AM REV RESPIR DIS              113   833 976
CT   1   MYGIND N              CLIN OTOLARYNGOL                 3   325 978
     2   MYGIND N              CLIN OTOLARYNGOL                 7   343 982
     3   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
     4   BENDE M               J LARYNGOL OTOL                 99   167 985
     5   HIRAIDE F             ACTA OTOLARYNGOL STOCKH SUPPL  430     5 986

PN 77191
RN 00772 
AN 77259376
AU Edge-W-E.  Nuss-D.  Loening-W-E.
TI Late-onset intestinal obstruction in cystic fibrosis--meconium ileus
   equivalent.
SO S-Afr-Med-J. 1977 Aug 6. 52(7). P 271-4.
MN ADOLESCENCE.  CASE-REPORT.  CECAL-DISEASES: et.  FEMALE.  HUMAN.
   ILEUM.  INFANT.  INTESTINAL-OBSTRUCTION: th.  JEJUNUM.
AB Four patients who suffered from cystic fibrosis and late-onset bowel
   obstruction (meconium ileus equivalent), and who were treated by
   surgery, are discussed. The importance of early correct diagnosis is
   stressed, since surgery may be prevented if bowel washouts and oral
   medications are given before the condition becomes complicated.
RF 001   NOBLETT HR            J PEDIATR SURG                   4   190 969
   002   PERMAN J              AM J DIS CHILD                 129  1210 975
   003   SANTULLI TV           IN: MUSTARD WT                   2   856 969
   004   JENSEN KG             ACTA PAEDIATR SCAND             51   344 962
   005   DONNISON AB           PEDIATRICS                      37   833 966
   006   MACDONALD JA          CAN MED ASSOC J                 83   881 960
   007   OLIM CB               ANN SURG                       140   736 954
   008   LILLIBRIDGE CB        J PEDIATR                       71   887 967
   009   WAGGET J              J PEDIATR                       77   407 970
   010   RICKHAM PP            IN: RICKHAM PP                       366 969
   011   ROWE MI               AM J SURG                      125   185 973

PN 77192
RN 00773 
AN 77259275
AU Super-M.
TI Collecting sweat in patients with cystic fibrosis [letter].
SO S-Afr-Med-J. 1977 Aug 27. 52(10). P 390.
MJ CYSTIC-FIBROSIS: di.  SPECIMEN-HANDLING: mt.  SWEAT.
MN CHILD.  HUMAN.
EX Dr. Soldin describes a method of collecting sweat for the diagnosis
   of cystic fibrosis which involves placing the patient on an electric
   blanket and wrapping him warmly for 2 - 5 hours until profuse
   sweating has occurred for 30 minutes.  One important omission from
   the title and the abstract is any mention of safety.  Children with
   cystic fibrosis may develop heat prostration when exposed to high
   temperatures, which may cause massive sodium and chloride losses via
   the sweat.  This could occur with the method described.  The
   apparatus described by Gibson and Cooke in the classic pilocarpine
   iontophoresis method of collecting sweat is neither overly
   sophisticated nor expensive.  It remains the method of choice,
   although attention to detail is important.
RF 001   SOLDIN P              S AFR MED J                     51   935 977
   002   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   003   SUPER M               S AFR MED J                     49   818 975
   004   GIBSON LE             PEDIATRICS                      23   545 959
   005   ANON                  J PEDIATR                       88   711 976

PN 77193
RN 00774 
AN 77216327
AU Jenkins-T.
TI The role of screening in the prevention of inherited disease in
   South Africa.
SO S-Afr-Med-J. 1977 Jun 4. 51(23). P 832-7.
MJ HEREDITARY-DISEASES: pc.  MASS-SCREENING.
MN ADULT.  LIPOIDOSIS: pc.  AMINO-ACID-METABOLISM-INBORN-ERRORS: oc.
   CYSTIC-FIBROSIS: oc.  FEMALE.  HEMOGLOBINOPATHIES: oc.  HUMAN.
   HYPERLIPIDEMIA: oc.  INFANT.  INFANT-NEWBORN.  JEWS.  MALE.
   PHENYLKETONURIA: oc.  PREGNANCY.  PRENATAL-DIAGNOSIS.
   PSEUDOCHOLINESTERASE: df.  SOUTH-AFRICA.  HYPERLIPIDEMIA: fg.
AB It is now possible to screen for the presence of the carrier state of
   a number of inherited diseases. Such screening can alert one to the
   need for antenatal diagnosis where feasible, it can ensure that early
   treatment is given to affected infants, and it can assist carriers in
   reaching a decision about having children. Facilities for certain
   types of screening already exist in some centres in South Africa, and
   new techniques will be introduced in the future.
RF 001   LEVY HL               ADV HUM GENET                    4     1 973
   002   GOLDSTEIN JL          J CLIN INVEST                   52  1544 973
   003   MOTULSKY AG           IN: MILUNSKY A                       306 975
   004   SUPER M               S AFR MED J                     49   818 975
   005   DEAN G                PORPHYRIAS: A STORY OF IN                963
   006   BENATAR SR            S AFR MED J                     44   999 970
   007   PANNALL PR            S AFR MED J                     50   304 976
   008   JENKINS T             THESIS                                   972
   009   JENKINS T             S AFR J SCI                     71    44 975
   010   MORROW A              SCIENCE                        159   202 962
   011   ZAIL S                S AFR J MED SCI                 27    95 962
   012   PATZ IM               S AFR MED J                     37   377 963
   013   BERNSTEIN RE          S AFR MED J                     37   447 963
   014   ZELLWEGER H           PEDIATRICS                      55    30 975
   015   JENKINS T             S AFR MED J                     51    95 977
   016   LANE AB               S AFR MED J                     50  1553 976
   017   BROCK DJH             LANCET                           2   197 972

PN 77194
RN 00775 
AN 78139020
AU Chappell-J-S.
TI Management of meconium ileus by resection and end-to-end anastomosis.
SO S-Afr-Med-J. 1977 Dec 24. 52(27). P 1093-4.
MJ INFANT-NEWBORN-DISEASES: su.  INTESTINAL-OBSTRUCTION: su.
MN CYSTIC-FIBROSIS: co.  HUMAN.  INFANT-NEWBORN.
   INFANT-NEWBORN-DISEASES: et.  INTESTINAL-OBSTRUCTION: et.  MECONIUM.
AB Six patients with meconium ileus, in whom bowel resection and end-to-
   end anastomosis were performed, are presented. Meconium ileus may be
   simple or complicated. The simple form may be treated by Gastrografin
   enema. Surgery is indicated if conservative treatment fails and for
   patients with a complicated obstruction. Provided the bowel is
   disobstructed and carefully resected, end-to-end anastomosis is
   preferable. Confirmation of the diagnosis by careful histological
   examination of the resected bowel is urged.
RF 001   HIATT RB              SURG GYNECOL OBSTET             87   317 948
   002   MCPARTLIN JF          ARCH DIS CHILD                  47   207 972
   003   NOBLETT HR            J PEDIATR SURG                   4   190 969
   004   GROSS RE              SURGERY OF INFANCY AND CHILDH            953
   005   BISHOP HC             ANN SURG                       145   410 957
   006   SANTULLI TV           ANN SURG                       154   939 961
   007   SWENSON P             PEDIATRIC SURGERY                    319 958
CT   1   ANON                  LANCET                           1  1000 982
     2   MABOGUNJE OA          ARCH SURG                      117    37 982

PN 77195
RN 00776 
AN 78096837
AU Super-M.
TI Cystic fibrosis.
SO SA-Nurs-J. 1977 Nov. 44(11). P 42-3.
MJ CYSTIC-FIBROSIS.
MN CYSTIC-FIBROSIS: di, nu.  HUMAN.  INFANT.  INFANT-NEWBORN.
AB Cystic fibrosis (C.F.) is a serious genetic disorder occurring
   mainly among the Whites and starting in early childhood or even at
   birth.  The name is a shortening of the old term Cystic Fibrosis (or
   Fibrocystic disease) of the pancreas.  This comes from the
   historical appearance at post-mortem first described by Landsteiner
   in 1905.  It was only in 1938 that Dorothee Anderson and Fanconi
   realised that the disease was a separate entity and not simply a
   manifestation of other illnesses.  Another name is Mucoviscidosis
   which gives a clue as to one of the most important features of the
   disease.  Mucus formed is thicker and stickier (more viscid) than
   normal and tends to clog up the bronchi and ducts, particularly the
   pancreatic ducts.  Chronic bronchitis with recurrent severe
   infection and malabsorption are the main symptoms of the disease.
   The other important abnormality is an increased amount of sodium
   chloride (salt) in the sweat.  This fact, used in the diagnosis, was
   first realised during a heat wave in New York in 1953 when it was
   noticed that most of the children with heat prostration suffered
   from C.F.  Little is known of the causes of the abnormalities of
   sweat and mucus.  Some generalised cell abnormality (? enzymatic)
   seems possible.  There is no doubt that the condition is genetically
   transmitted and most evidence favours a recessive mode of
   inheritance.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   002   FANCONI G             SEPARATABDRUCK AUS DER WIENER         27 936
   003   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   004   SUPER M               S AFR MED J                     49   818 975

PN 77196
RN 00777 
AN 77258751
AU Skude-G.
TI On human amylase isoenzymes.
SO Scand-J-Gastroenterol [Suppl]. 1977. 12(44). P 1-37.
MJ AMYLASES.  ISOENZYMES.
MN AMYLASES: an, bl.  CHRONIC-DISEASE.  CYSTIC-FIBROSIS: en.  HUMAN.
   ISOENZYMES: an, bl.  REFERENCE-VALUES.  PANCREATIC-DISEASES: en.
   PANCREATIC-JUICE: en.  PANCREATIC-NEOPLASMS: en.  PANCREATITIS: en.
   SALIVA: en.  SALIVARY-GLAND-DISEASES: en.
EX The purpose of the investigation was to elucidate the variation of
   the isoenzymes of human amylase in health and disease as well as
   physico-chemical differences between individual isoamylases.  In
   cystic fibrosis determination of serum isoamylase is of value,
   although absence of pancreatic serum isoamylase is a normal finding
   during the first year of life.  Demonstrable pancreatic serum
   isoamylase in such early life argues against the diagnosis.  After
   one year of age the test has a positive diagnostic value.
RF 001   SKUDE G               HEREDITAS                       65   277 970
   002   SKUDE G               SCAND J PLAST RECONSTR SURG      7   105 973
   003   SKUDE G               SCAND J CLIN LAB INVEST         35    41 975
   004   SKUDE G               SCAND J GASTROENTEROL           10   577 975
   006   SKUDE G               ACTA PAEDIATR SCAND             65   145 976
   007   SKUDE G               SCAND J GASTROENTEROL           11   525 976
   008   SKUDE G               SCAND J GASTROENTEROL           12    53 977
   010   AFONSO E              CLIN CHIM ACTA                  14   195 966
   011   ALPER CA              VOX SANG                        17   445 969
   012   AMMAN RW              ANN INTERN MED                  78   521 973
   013   AW SE                 NATURE                         209   298 966
   014   AW SE                 BIOCHEM J                       99   16P 966
   015   AW SE                 GUT                              8   402 967
   016   BABSON AL             CLIN CHEM                       14   802 968
   017   BAKER RWR             SCAND J CLIN LAB INVEST          6    94 954
   018   BENJAMIN D            AM J CLIN PATHOL                62   752 974
   019   CARLIER A             CLIN CHIM ACTA                  47   249 973
   020   CESKA M               EXPERIENTIA                     25   555 969
   021   COHNHEIM J            VIRCHOWS ARCH PATHOL PHYSIOL    28   267 972
   022   DAVIES TJ             J CLIN PATHOL                   25   266 972
   023   DREILING DA           ANN INTERN MED                  58   235 963
   024   FRIDHANDLER L         CLIN CHEM                       18  1493 972
   025   GOT R                 CLIN CHIM ACTA                  22   545 968
   026   HAMMERTON JL          IN: BERGSMA D                          6 976
   027   HOBBS JR              IN: DUBACK UC                        308 968
   028   HOEKE JOO             CLIN CHIM ACTA                  16   171 967
   029   KAMARYT J             HUMANGENETIK                     1   579 965
   030   KAMARYT J             HUMANGENETIK                     3    41 966
   031   KAUFFMAN DL           ARCH BIOCHEM BIOPHYS           137   325 970
   032   KELLER PJ             BIOCHEMISTRY                    10  4867 971
   033$  KELLEY ML             JAMA                           164   406 967
   034   KLEIN B               ANAL BIOCHEM                    31   412 969
   035   LAURELL CB            ANAL BIOCHEM                    10   358 965
   036   LEGAZ ME              CLIN CHEM                       22    57 976
   037   LEVITT MD             CLIN RES                        23  394A 975
   038   LEVINE RI             N ENGL J MED                   292   329 975
   039   LUNDH G               GASTROENTEROLOGY                42   275 962
   040   MAGENDIE M            C R ACAD SCI (D)(PARIS)         23   189 846
   042   MARKERT CL            PROC NAT ACAD SCI USA           45   753 959
   043   MAYO JW               ARCH BIOCHEM BIOPHYS           163   498 974
   044   MCGEACHIN RL          J BIOL CHEM                    234   795 959
   045   MEITES S              CRC CRIT REV CLIN LAB SCI        2   103 971
   046   MUUS J                CR TRAV LAB CARLSBERG SER CHI   28   317 953
   047   MUUS J                NATURE                         204   283 964
   048   NORBY S               EXP CELL RES                    36   663 964
   049   OGER A                CLIN CHIM ACTA                  13   670 966
   050   OJALA K               SCAND J CLIN LAB INVEST         35   163 975
   051   PAZUR JH              IN: WHISTLER RL                  1       962
   052   PIMSTONE NR           CLIN CHEM                       10   891 964
   053   RINDERKNECHT H        EXPERIENTIA                     23   805 967
   054   ROBYT JF              ARCH BIOCHEM BIOPHYS           122     8 967
   055   ROSALKI SB            J CLIN PATHOL                   23   373 970
   056   SAX SM                CLIN CHEM                       17   311 971
   057   SCHIWARA HW           Z KLIN CHEM KLIN BIOCHEM        11   319 973
   058   SKUDE G               HUMANGENETIK                    12   255 971
   059   SKUDE G               SCAND J CLIN LAB INVEST         36   399 976
   061   SKUDE G               SCAND J GASTROENTEROL           11    17 976
   062   SKUDE G               AM J OBSTET GYNECOL            126   652 976
   063   SKUDE G               ACTA MED SCAND                 201    53 977
   064   SKUDE G               GUT                             17   127 976
   065   SOMOGYI M             CLIN CHEM                        6    23 960
   066   SPIEKERMAN AM         CLIN CHEM                       20   324 974
   067   STEINORTH AM          POSTGRAD MED                    55   103 974
   068   STIEFEL DJ            BIOCHIM BIOPHYS ACTA           302   345 973
   069   STIEFEL DJ            CLIN CHEM                       21   343 975
   070   SUDO K                CLIN CHIM ACTA                  73     1 976
   071   TAKEUCHI T            CLIN CHIM ACTA                  60   207 975
   072   TAKEUCHI T            CLIN CHIM ACTA                  54   137 974
   073   TAUSSIG LM            PEDIATRICS                      54   229 974
   074   VACIKOVA A            J CHROMATOGR                    69   349 972
   075   WARSHAW AL            N ENGL J MED                   292   325 975
   076   WESTROM L             AM J OBSTET GYNECOL            126   657 976
   077   WILDING P             CLIN CHIM ACTA                   8   918 963
   078   WILDING P             CLIN CHIM ACTA                  12    97 965
   079   WILDING P             ANN INTERN MED                  60  1053 964
   080   WOHLGEMUTH J          BERL KLIN WSCHR                 47    92 910
   081   WOLF RO               AM J CLIN PATHOL                65  1022 976
   082   WOLF RO               NATURE                         213  1128 967
CT   1   SOYZA KD              HUM GENET                       45   189 978
     2   STEPAN J              CLIN CHIM ACTA                  91   263 979
     3   VINICOR F             ANN INTERN MED                  91   200 979
     4   FRIDHANDLER L         CLIN CHIM ACTA                 101   135 980
     5   SKRHA J               DIABETOLOGIA                    20   129 981
     6   COLLINS REC           BR J SURG                       69   373 982
     7   VENTRUCCI M           DIGESTION                       28   114 983
     8   COLLINS REC           SURGERY                         93   845 983
     9   ANDRIULLI A           J CLIN GASTROENTEROL             6   239 984
    10   PUGAEV AV             SOV MED                               53 985
    11   ZAKOWSKI JJ           CRC CRIT REV CLIN LAB SCI       21   283 985
    12   HEINE W               Z KLIN MED                      40   181 985
    13   PACE BW               AM J GASTROENTEROL              80   898 985

PN 77197
RN 00778 
AN 77174552
AU Hoiby-N.  Flensborg-E-W.  Beck-B.  Friis-B.  Jacobsen-S-V.
   Jacobsen-L.
TI Pseudomonas aeruginosa infection in cystic fibrosis.  Diagnostic and
   prognostic significance of Pseudomonas aeruginosa precipitins
   determined by means of crossed immunoelectrophoresis.
SO Scand-J-Respir-Dis. 1977 Apr. 58(2). P 65-79.
MJ CYSTIC-FIBROSIS: co.  PSEUDOMONAS-INFECTIONS: co.
   RESPIRATORY-TRACT-INFECTIONS: co.
MN ANTIBODIES-BACTERIAL: an.  CHRONIC-DISEASE.  CYSTIC-FIBROSIS: mo.
   FEMALE.  FOLLOW-UP-STUDIES.  HUMAN.
   IMMUNOELECTROPHORESIS-TWO-DIMENSIONAL.  MALE.  PRECIPITIN-TESTS.
   PROGNOSIS.  PSEUDOMONAS-AERUGINOSA: im.  PSEUDOMONAS-INFECTIONS: di.
   RESPIRATORY-FUNCTION-TESTS.  RESPIRATORY-TRACT-INFECTIONS: di.
   SPUTUM: mi.
AB A total of 133 patients with cystic fibrosis have been followed for
   up to 5 years with monthly examinations including bacteriological
   examinations of sputum. Sera from the patients were examined by means
   of crossed immunoelectrophoresis for the occurence and number of
   precipitating antibody specificites against Pseudomonas aeruginosa.
   Poor prognosis in cystic fibrosis was associated with chronic
   colonization (9 months - more than 5 years) of the respiratory tract
   with mucoid Pseudomonas aeruginosa, and with an onset of the chronic
   colonization before puberty. Among the patients with chronic
   Pseudomonas aeruginosa colonization, poor prognosis was associated
   with high numbers of precipitins against antigens from these bacteria
   (up to 61). The number of Pseudomonas aeruginosa precipitins
   increased on an average with five per year in chronically colonized
   patients. Rapidly increasing number of precipitins was associated
   with poor prognosis. Patients with any degree of impairment of the
   ventilatory function and any changes on the chest radiographs could
   contract chronic Pseudomonas aeruginosa colonization. Poor
   ventilatory function and severe changes on the chest radiographs was
   associated with high numbers of Pseudomonas aeruginosa precipitins
   and with poor prognosis. Although many O groups of Pseudomonas
   aeruginosa were found in the chronically colonized group of patients,
   53% of the patients harboured strains belonging to O group 3 or 3/9,
   and the highest numbers of precipitins were found in serum from these
   patients.
RF 001   BERGAN T              ACTA PATH MICROBIOL SCAND (B)   83   553 975
   002   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   003   CHRISPIN AR           PEDIATR RADIOL                   2   101 974
   004   DIAZ F                J INFECT DIS                   121   269 970
   005   DIEM K                DOCUMENTA GEIGY SCIENTIFIC TA            962
   006   DI SANTAGNESE PA      N ENGL J MED                   277  1399 967
   007   DOGGETT RG            IN: LAWSON D PROC 5TH INT CF         175 969
   008   DOGGETT RG            INFECT IMMUN                     6   628 972
   009   HABS I                Z HYG                          144   218 957
   010   HOFF GE               SCAND J INFECT DIS               6   333 974
   011   HOFF GE               ACTA PATH MICROBIOL SCAND (B)   83   219 975
   012   HOMMA JY              JAPAN J EXP MED                 44     1 974
   013   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   014   HOIBY N               ACTA PAEDIATR SCAND             63   843 974
   015   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   016   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   017   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   018   HOIBY N               SCAND J RESPIR DIS              56    38 975
   019   HOIBY N               SCAND J IMMUNOL SUPPL 2          4   187 975
   020   HOIBY N               SCAND J IMMUNOL SUPPL 2          4   187 975
   021   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   321 975
   022   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   321 975
   023   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   433 975
   024   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   549 975
   025   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   83   459 975
   026   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   84   372 976
   027   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   84   372 976
   028   HOIBY N               SCAND J RESPIR DIS              57    37 976
   029   HOIBY N               SCAND J RESPIR DIS              57   103 976
   030   HOYBYE G              UGESKR LAEGER                  132  2007 970
   031   LAWSON D              IN: WATT PJ                           69 970
   032   MAY JR                ARCH DIS CHILD                  47   908 972
   033   MEARNS MB             ARCH DIS CHILD                  47   902 972
   034   MIKKELSEN OS          ACTA PATH MICROBIOL SCAND (B)   78   163 970
   035   NETER E               J INFECT DIS SUPPL             130   132 974
   036   POLGAR G              PULMONARY FUNCTION TESTING IN            971
   037   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   83   469 975
   039   THERKELSEN AJ         MEDICINSK STATISTIK AKADEMISK            968
   040   THUESEN-PEDERSEN J    DAN MED BULL                    21    12 974
   041   TURK JL               BOLL IST SIEROTER MILAN SUPPL   53   208 974
   042   WULFF HR              RATIONEL KLINIK                          973
   043   ZAVALA DC             J ALLERGY CLIN IMMUNOL          56   450 975
   044   ZIERDT CH             J CLIN MICROBIOL                 1   521 975
CT   1   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     2   OLLING S              SCAND J INFECT DIS            1977     7 977
     3   SCHIOTZ PO            HUM HERED                       28   293 978
     4   NIELSEN HE            ACTA PAEDIATR SCAND             67   443 978
     5   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   86    37 978
     6   PAPORISZ U            MONOGR PAEDIATR                 10    31 979
     7   SCHIOTZ PO            MONOGR PAEDIATR                 10   131 979
     8   FRIIS B               SCAND J INFECT DIS              11   211 979
     9   MAYBURY BA            ANTIMICROB AGENTS CHEMOTHER     15   494 979
    10   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   87     1 979
    11   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   87   229 979
    12   PAPORISZ U            EUR J PEDIATR                  130   259 979
    13   GOSCINIAK G           ARCH IMMUNOL THER EXP           28   619 980
    14   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   88   125 980
    15   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   88   149 980
    16   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   88   275 980
    17   MOSS RB               AM REV RESPIR DIS              121    23 980
    18   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
    19   PETERSEN NT           ACTA PAEDIATR SCAND             70   623 981
    20   LEWISTON NJ           CHEST                           80   389 981
    21   ESPERSEN F            ACTA PATH MICROBIOL SCAND (B)   89   261 981
    22   MOSS RB               J PEDIATR                       99   215 981
    23   FROLAND SS            SCAND J INFECT DIS            1981    72 981
    24   MALMBORG AS           SCAND J INFECT DIS            1981    64 981
    25   VANGEFFEL R           ANN IMMUNOL (PARIS)           D133   293 982
    26   GOTZ M                CLIN EXP IMMUNOL                50   178 982
    27   PITCHERWILMOTT RW     ARCH DIS CHILD                  57   577 982
    28   SZAFF M               ACTA PAEDIATR SCAND             71   821 982
    29   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
    30   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    63 982
    31   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    32   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
    33   ANON                  LANCET                           2   257 983
    34   JACQUOT J             BULL EUR PHYSIOPATH RESP        19   453 983
    35   DORING G              INFECT IMMUN                    42   197 983
    36   MARHAUG G             ACTA PAEDIATR SCAND             72   861 983
    37   SCHIOTZ PO            ACTA PAEDIATR SCAND             72   283 983
    38   SZAFF M               ACTA PAEDIATR SCAND             72   651 983
    39   DORING G              J INFECT DIS                   147   744 983
    40   BOSSO JA              DRUG INTEL CLIN PHARM           18   825 984
    41   SPEERT DP             PEDIATR RES                     18   431 984
    42   COLLINS MT            J CLIN MICROBIOL                19   757 984
    43   GRANSTROM M           ACTA PAEDIATR SCAND             73   772 984
    44   MCCARTHY VP           ARCH INTERN MED                144   408 984
    45   LITTLEWOOD JM         LANCET                           1   865 985
    46   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
    47   SMITH SR              J CLIN HOSP PHARM               10   243 985
    48   DORING G              INFECT IMMUN                    49   557 985
    49   CONWAY SP             ACTA PAEDIATR SCAND             74   107 985
    50   SCHONHEYDER H         ACTA PATH MICROB IMMU SCA (B)   93   105 985
    51   GOTZ M                MONATSSCHR KINDERHEILKD        133   718 985
    52   WILMOTT RW            AM J DIS CHILD                 139   669 985
    53   PEDERSEN SS           J ANTIMICROB CHEMOTHER          17   505 986
    54   HOIBY N               ANNU REV MICROBIOL              40    29 986
    55   BRETT MM              ARCH DIS CHILD                  61  1114 986
    56   PEDERSEN SS           ACTA PAEDIATR SCAND             75   840 986
    57   KURLAND G             PEDIATRICS                      78  1097 986
    58   LITTLEWOOD JM         J ROY SOC MED                   79    55 986
    59   PHILLIPS BM           J ROY SOC MED                   79    44 986
    60   SUTER S               J INFECT DIS                   153   902 986
    61   BRETT MM              ARCH DIS CHILD                  62   357 987
    62   MOSS RB               CHEST                           91   522 987

PN 77198
RN 00779 
AN 78097268
AU Colman-R-W.  Wong-P-Y.
TI Participation of Hageman factor dependent pathways in human disease
   states.
SO Thromb-Haemostas. 1977 Dec 15. 38(4). P 751-75. (REVIEW).
MJ FACTOR-XII: ph.  HEREDITARY-DISEASES: pp.  METABOLIC-DISEASES: pp.
MN ANGIONEUROTIC-EDEMA: pp.  ARTHRITIS: me.
   BLOOD-COAGULATION-DISORDERS: pp.  BLOOD-TRANSFUSION: ae.
   CORONARY-DISEASE: pp.  CYSTIC-FIBROSIS: me.  DENGUE: bl.
   DISSEMINATED-INTRAVASCULAR-COAGULATION: pp.
   FACTOR-XII-DEFICIENCY: pp.  GRAFT-REJECTION.  HUMAN.
   HYPERLIPIDEMIA: pp.  HYPERSENSITIVITY: me.  KIDNEY: tr.
   KININOGENS: df.  LIVER-CIRRHOSIS: bl.
   MALIGNANT-CARCINOID-SYNDROME: me, pp.  MOLECULAR-WEIGHT.
   NEPHROTIC-SYNDROME: bl.  POLYCYTHEMIA-VERA: pp.
   POSTGASTRECTOMY-SYNDROMES: me.  PREKALLIKREIN.  REVIEW.
   SHOCK-SEPTIC: bl.  TRANSPLANTATION-HOMOLOGOUS.  TYPHOID: bl.
   HYPERLIPIDEMIA: fg.
AB Abnormalities of Hageman factor dependent pathways have been
   described in a wide variety of human disease states. Congenital
   deficiencies of factor XII (Hageman trait) prekallikrein (Fletcher
   trait) and high molecular weight kininogen (Williams, Fitzgerald and
   Flaujeac traits) although resulting in profound in vitro changes, do
   not cause in vivo difficulties. In contrast, deficiency of C1
   esterase inhibitor (hereditary angioedema) results in significant
   morbidity and mortality. Acquired diseases may exhibit decreased
   synthesis of these three proteins in cirrhosis and dengue fever. In
   vivo activation of factor XII initiated pathways occur in septic
   shock, disseminated or localized intravascular coagulation, typhoid
   fever, polycythemia vera, hyperbetalipoproteinemia, coronary artery
   disease, nephrotic syndrome, transfusion reactions, hemodialysis and
   extracorporeal bypass. Activation of both the intrinsic system and
   tissue mediators contribute to the vasomotor phenomena in carcinoid
   syndrome and postgastrectomy dumping. Roles for factor XII,
   prekallikrein and kininogen have been suggested in gouty arthritis,
   allergic disorders and cystic fibrosis but the evidence is not yet
   convincing in these disorders.
RF 001   AUSTEN KF             N ENGL J MED                   272   649 965
   002   BAGDASARIAN A         J BIOL CHEM                    248  3456 973
   003   BAGDASARIAN A         J BIOL CHEM                    248  7742 973
   004   BAGDASARIAN A         J CLIN INVEST                   54  1444 974
   005   BELL G                BR J SURG                       52   300 965
   006   BLUMEL G              BEDEUTUNG DER PLASMAKININ           2751 967
   007   BOKISCH VA            N ENGL J MED                   289   996 973
   008   BOUMA BN              THROMB HAEMOST                  38   136 977
   009   BRISELD K             ACTA ALLERGOL                   31   297 976
   010   BROCKLEHURST WE       J PHYSIOL (LOND)               191   417 967
   011   BROCKWAY WJ           J BIOL CHEM                    246  4641 971
   012   BURROWES CE           PROC SOC EXP BIOL MED          138   959 971
   013   BUSCH GJ              AM J PATHOL                     80     1 975
   014   BUSCH GJ              AM J PATHOL                     79    31 975
   015   CARVALHEIRA AF        HISTOCHEMIE                     14    33 968
   016   CARVALHO AC           N ENGL J MED                   290   434 974
   017   CARVALHO AC           CIRCULATION                     50   570 974
   018   CARVALHO AC           BLOOD                           47   669 976
   019   CARVALHO AC           THROMB RES                       8   843 976
   020   CARVALHO AC           CIRCULATION                     56   114 977
   021   CASTANIA A            BR J PHARMACOL                  50   375 974
   022   COCHRANE CG           J EXP MED                      138  1564 973
   023   COCHRANE CG           J EXP MED                      134   986 971
   024   COHEN SH              J PEDIATR                       68   448 966
   025   COLLIER HOJ           IN: ERDOS EG                         305 966
   026   COLMAN RW             BIOCHEM BIOPHYS RES COMMUN      35   273 969
   027   COLMAN RW             ANN INTERN MED                  85   399 976
   028   COLMAN RW             J CLIN INVEST                   56  1650 975
   029   COLMAN RW             N ENGL J MED                   281   685 969
   030   COLMAN RW             IN: THOMAS CC                         87 972
   031   COLMAN RW             ANN INTERN MED                  71   763 969
   032   COLMAN RW             J CLIN INVEST                   48    23 969
   034   COLMAN RW             IN: PISANO JJ                        487 976
   035   CUEVAS P              GASTROENTEROLOGY                64   285 973
   036   CURRIMBHOY A          AM J CLIN PATHOL                65   970 976
   037   CUSCHIERI A           BR MED J                         3   565 971
   038   DELBIANCO PL          ADV EXP MED BIOL                21   453 972
   039   DOEGLAS HMG           ARCH DERMATOL                  110   382 974
   040   DOEGLAS HMG           ARCH DERMATOL                  111   979 975
   041   DONALDSON VH          J EXP MED                      127   411 968
   042   DONALDSON VH          AM J MED                        35    37 963
   043   DONALDSON VH          J LAB CLIN MED                  89   327 976
   044   DONALDSON VH          J CLIN INVEST                   48   642 969
   045   DONALDSON VH          J CLIN INVEST                   43  2204 964
   046   DONALDSON VH          CLIN RES                        25  520A 977
   047   EDELMAN R             J LAB CLIN MED                  86   410 975
   048   ERDOS EG              IN: MOVAT VASEL HZ                   233 969
   049   ERDOS EG              FED PROC                        27    92 968
   050   FANCIULLACCI M        ADV EXP MED BIOL                70   201 975
   051   FORSSMANN WG          J CELL BIOL                     40   692 969
   052   FRANK MM              N ENGL J MED                   286   808 972
   053   GADEK JE              CLIN RES                        25  357A 977
   054   GALLETTI R            LO SPERIMENTALE                118   253 968
   055   GIGLI I               J IMMUNOL                      104   574 970
   056   GIREY GJD             J LAB CLIN MED                  80   465 972
   057   GJONNAESS H           THROMB HAEMOST                  28   155 972
   058   GJONNAESS H           THROMB HAEMOST                  28   182 972
   059   GLUECK HI             ANN INTERN MED                  64   390 966
   060   GOLDSMITH GH          J LAB CLIN MED                  89   131 977
   061   GREEN J               AM J PHYSIOL                   226   784 974
   062   GRIFFIN JH            PROC NAT ACAD SCI USA           73  2554 976
   063   HABAL FM              BIOCHEM PHARMACOL               23  2291 974
   064   HARPEL PC             J CLIN INVEST                   49   568 970
   065   HASIMOTO K            ADV EXP MED BIOL                70   245 975
   066   HATHAWAY WE           BLOOD                           26   521 965
   067   HATTERSLEY PG         BR J HAEMATOL                   18   411 970
   068   HERMAN CM             J LAB CLIN MED                  84   731 974
   069   HERZHEIMER H          J PHYSIOL (LOND)               158   38P 961
   070   HIRSCH EF             J SURG RES                      17   147 974
   071   HOAK JC               LANCET                           2   884 966
   072   HOLLENBERG NK         TRANSFUSION                      6    59 968
   073   HONIG GR              J PEDIATR                       78   633 971
   074   IZAKA K               TRANSFUSION                     15    46 975
   075   IZAKA K               TRANSFUSION                     14   242 974
   076   JOHNSON LP            SURG FORUM                      12   316 961
   077   JONASSON O            J EXP MED                      123   509 966
   078   KALLEN RJ             PEDIATR RES                      9   705 975
   079   KAPLAN AP             J IMMUNOL                      105   802 970
   080   KAPLAN AP             J EXP MED                      133   696 971
   081   KAPLAN AP             J EXP MED                      136  1378 972
   082   KATORI M              IN: PISANO JJ                        553 976
   083   KELLERMEYER RW        IN: GUTMAN AB                        741 964
   084   KELLERMEYER RW        J LAB CLIN MED                  65   307 965
   085   KELLERMEYER RW        N ENGL J MED                   279   859 968
   086   KELLERMEYER RW        ARTHRITIS RHEUM (SUPPL)         18   765 975
   087   KLEMPERER MR          J CLIN INVEST                   47   604 968
   088   LAAKE K               THROMB RES                       4   285 974
   089   LACOMBE MJ            BLOOD                           46   761 975
   090   LACOMBE MJ            C R ACAD SCI (D)(PARIS)        280  1039 975
   091   LAHIRI B              ARCH BIOCHEM BIOPHYS           175   737 976
   092   LANDERMAN NS          J ALLERGY                       33   316 962
   093   LANDERMAN NS          J ALLERGY                       33   330 962
   094   LANGE LG              AM J MED                        56   565 974
   095   LIEBERMAN J           AM REV RESPIR DIS              109   399 974
   096   LIU CY                J CLIN INVEST                   60     7 977
   097   LOPAS H               AM J PHYSIOL                   225   372 973
   098   LUKIAN H              ALLERGIC AND IMMUNOLOGIC BAND   18    25 972
   099   LUTCHER CL            CLIN RES                        24    47 976
   100   MACDONALD JM          AM J SURG                      117   204 969
   101   MACKAY ME             BR J HAEMATOL                   11   563 965
   102   MANDLE R              PROC NAT ACAD SCI USA           73  4179 976
   104   MASON DT              CIRC RES                        17   106 965
   105   MASON JW              THROMB HAEMOST                  26   325 971
   106   MASON JW              ANN INTERN MED                  73   545 970
   107   MATHESON RT           J CLIN INVEST                   58  1395 976
   108   MCGRATH JM            J EXP MED                      129   833 969
   109   MEIER HK              J CLIN INVEST                   60    18 977
   110   MEIER JL              ANN NY ACAD SCI                283    93 977
   111   MELMON KL             CLIN CHIM ACTA                  12   292 965
   112   MELMON KL             ARTHRITIS RHEUM                 10    13 967
   113   MILLER RL             J INFECT DIS SUPPL             125   144 973
   114   MINNA JD              DISSEMINATED INTRAVASCULAR CO            974
   115   MOVAT HZ              FED PROC                        25   682 966
   116   NIES AS               CIRC RES                        22   155 968
   117   OATES JA              LANCET                           1   514 964
   118   OATES JA              J CLIN INVEST                   45   173 966
   119   ODONNELL TF           SURG GYNECOL OBSTET            143   539 976
   120   PASKHINA TS           VOPR MED KHIM                   20   660 974
   121   PENCE HL              J ALLERGY CLIN IMMUNOL          53   298 974
   122   PETERSON DW           J NUTR                         101   347 971
   123   PHELPS P              J EXP MED                      124   115 966
   124   PHELPS P              J LAB CLIN MED                  68   433 966
   125   PICKERING RJ          LANCET                           1   326 969
   126$  PIERCE JV             FOGARTY INT CENT PROC                121 977
   127   PITT B                TRANS ASSOC AM PHYSICIANS       82    98 969
   129   RAO GJS               J PEDIATR                       80   573 972
   130   RAO GJS               PEDIATR RES                      8   684 974
   131   RAO GJS               PEDIATR RES                      9   739 975
   132   RAO GJS               SCIENCE                        177   610 972
   133   RAPAPORT SA           J CLIN INVEST                   34     9 955
   134   RATNOFF OD            IN: BROWN EB                     5   204 966
   135   RATNOFF OD            N ENGL J MED                   279   760 968
   136   RATNOFF OD            J CLIN INVEST                   34   601 955
   137   RATNOFF OD            J CLIN INVEST                   40   803 961
   138   RATNOFF OD            J EXP MED                      129   315 969
   139$  REVAK SD              FED PROC                        32   845 973
   140   ROBINSON JA           AM J MED                        59    61 975
   141   ROCHA E SILVA M       MEDICAL EXPERIMENTIA (BASEL)     3   371 960
   142   ROCHA E SILVA M       AM J PHYSIOL                   156   261 949
   143   RUDDY S               N ENGL J MED                   287   545 972
   144   SAITO H               BLOOD                           48   941 976
   145   SAITO H               NATURE                         248   597 974
   146   SAITO H               J CLIN INVEST                   55  1082 975
   147   SARDESAI VM           J TRAUMA                        14   945 974
   148   SCHIFFMAN S           BR J HAEMATOL                   27   101 974
   149   SCHIFFMAN S           J CLIN INVEST                   56  1082 975
   150   SEKI T                BIOCHEM PHARMACOL               21  1227 972
   151   SHERRY S              THROMB HAEMOST                  16    18 966
   152   SICUTERI F            ADV EXP MED BIOL                21   445 972
   153   SICUTERI F            ADV EXP MED BIOL                 9   315 970
   154   SNYDER A              INT ARCH ALLERGY                47   400 974
   155   SOLTAY MJ             PROC SOC EXP BIOL MED          138   952 971
   156   SOTER NA              J IMMUNOL                      114   928 975
   157   STEWART D             J CLIN PATHOL                   25   410 972
   158   TALAMO RC             J LAB CLIN MED                  74   816 969
   159   THUNE P               ACTA DERM VENEREOL (STOCKH)     56   217 976
   160   VAN ARMAN CG          IN: PISANO JJ                        471 976
   161   VASSALIO G            Z ZELLFORSCH MIKROSK ANAT       98   333 969
   162   VELTKAMP JM           THROMB HAEMOST                  17   181 965
   163   VENNEROD AM           THROMB RES                       8   519 976
   164   WARDLE EN             J CLIN PATHOL                   25  1045 972
   165   WEBSTER ME            IN: SICUTERI F                           976
   166$  WEBSTER ME            FED PROC                        32   845 973
   167   WERLE E               IN: SCHMID E                         788 963
   168   WIEGERSHAUSEN B       ADV EXP MED BIOL                 8   221 970
   169   WONG PY               ANN INTERN MED                  77   205 972
   170   WONG PY               ANN INTERN MED                  80   577 974
   171   WONG PY               J CLIN INVEST                   55   691 975
   172   WONG PY               IN: PISANO JJ                        415 976
   174   WUEPPER KD            IN: LEPOW IH                          93 972
   175   WUEPPER KD            J EXP MED                      138  1345 973
   176   ZEITLIN IJ            IN: SICUTERI F                       329 970
   177   ZEITLIN IJ            IN: PISANO JJ                        483 976
   178   ZEITLIN IJ            ARCH PHARMACOLOGY              293   159 976
   179   ZEITLIN IJ            LANCET                           1   986 966
CT   1   MORRISON DC           AM J PATHOL                     93   526 978
     2   KOVALAINEN S          LANCET                           1  1035 979
     3   GRIFFIN JH            SEM THROMB HEMOSTAS              5   254 979
     4   WRIGHT IG             GEN PHARMAC                     10   319 979
     5   PRESTON FE            BR J HOSP MED                   21   232 979
     6   DEUTSCH E             MONATSSCHR KINDERHEILKD        127   231 979
     7   ULEVITCH RJ           INFLAMMATION                     4     9 980
     8   KUWAHARA SS           TRANSFUSION                     20   433 980
     9   CARRETERO OA          AM J PHYSIOL                   238  F247 980
    10   ABE K                 CLIN ENDOCRINOL METAB           10   577 981
    11   BORGES DR             BIOCHEM PHARMACOL               30  1065 981
    12   SAITO H               AM J MED                        70   531 981
    13   KATO H                METH ENZYMOL                    80   172 981
    14   KAZAL LA              CLIN BIOCHEM CONTEM THEO TECH    2    73 982
    15   ADDONIZIO VP          BIOMATERIALS                     3     9 982
    16   RAO AK                PATHOBIOL ANNU                  12    35 982
    17   BERGER J              TRANSPLANTAT PROC               14   472 982
    18   HATHAWAY WE           THROMB RES                      25   267 982
    19   COCHRANE CG           ADV IMMUNOL                     33   241 982
    20   THOMPSON AR           THROMB HAEMOST                  48    27 982
    21   FISHER CA             BLOOD                           59   963 982
    22   GRAHAM JB             ADV HUM GENET                   13     1 983
    23   HEDNER U              HAEMOSTASIS                     13   219 983
    24   AASEN AO              ARCH SURG                      118   343 983
    25   LASSON A              SCAND J GASTROENTEROL           19     1 984
    26   LASSON A              THROMB RES                      35    27 984
    27   COLMAN RW             J CLIN INVEST                   73  1249 984
    28   HANCOCK W             SEM NEPHROL                      5    69 985
    29   SCHMAIER AH           SEM HEMATOL                     22   187 985
    30   DOTSENKO VL           VOPR MED KHIM                   31   116 985
    31   FULLER PJ             KIDNEY INT                      29   953 986
    32   WIGGINS RC            CIRC RES                        58   595 986
    33   KIESEWETTER H         KLIN WSCHR                      64   653 986
    34   SCHMAIER AH           BLOOD                           67   119 986
    35   LANG M                SCHWEIZ MED WOCHENSCHR         116  1681 986
    36   SAITO H               SEM THROMB HEMOSTAS             13    36 987
    37   DELACADENA RA         J LAB CLIN MED                 109   601 987

PN 77199
RN 00780 
AN 78034723
AU Safwenberg-J.  Kollberg-H.  Lindblom-J-B.
TI HLA frequencies in patients with cystic fibrosis.
SO Tissue-Antigens. 1977 Oct. 10(4). P 287-90.
MJ CYSTIC-FIBROSIS: im.  HLA-ANTIGENS.
MN ADOLESCENCE.  ADULT.  CELIAC-DISEASE: im.  CHILD.  CHILD-PRESCHOOL.
   FEMALE.  GENE-FREQUENCY.  HUMAN.  HLA-ANTIGENS: an.  INFANT.  MALE.
   CELIAC-DISEASE: im.
AB Thirty-three patients with Cystic Fibrosis were HLA typed.  Relative
   risk values and phenotype frequencies were calculated.  No
   statistically significant differences in the HLA antigen
   distribution were found among the patients with Cystic Fibrosis.
RF 001   ALBERT ED             HISTOCOMPATIBILITY TESTING           221 970
   002   BOYUM A               SCAND J CLIN LAB INVEST SUPPL   97    77 968
   003   FANCONI G             WIEN MED WOCHENSCHR             86   753 936
   004   FRANKLIN JP           AM J DIG DIS                    19   149 974
   005   GIBSON LE             PEDIATRICS                      23   545 959
   006   GOODCHILD MC          J MED GENET                     13   417 976
   007   GOODCHILD MC          ARCH DIS CHILD                  48   684 973
   008   GOTZ M                Z KINDERHEILK                  117   183 974
   009   HIDE DW               ARCH DIS CHILD                  44   533 969
   010   JONGSMA A             HUMANGENETIK                    20   195 973
   011   KAISER GI             HLA AND DISEASE                      252 976
   012   KATZ AJ               PEDIATRICS                      57   715 976
   013   KEUNING JJ            LANCET                           1   506 976
   014   KISSMEYER-NIELSEN F   HISTOCOMPATIBILITY TESTING           381 976
   015   LAMM LU               ANN HUM GENET                   38   383 975
   016   LUDVIGSSON J          DIABETOLOGICA                   13    13 977
   017   NORDIO S              MINERVA MED                           33 967
   018   POLYMENIDIS Z         LANCET                           2  1452 973
   019   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   020   SHWACHMAN H           CF CLUB ABST                     4    23 963
   021   SVEJGAARD A           TISSUE ANTIGENS                  4    95 974
   022   TAYLOR BW             ARCH DIS CHILD                  48   692 973
   023   THORSBY E             VOX SANG                        13   194 967
   024   WOOLF B               ANN HUM GENET                   19   251 955
   025   WRIGHT SW             IN: LAWSON D PROC 5TH INT CF          91 969
CT   1   TACIEREUGSTER H       HELV PAEDIATR ACTA              35    31 980
     2   RUSH PJ               SEM ARTHRITIS RHEUM             15   213 986

PN 77200
RN 00781 
AN 77177039
AU Sheth-K-J.  Heimier-R.
TI Cystic fibrosis in an infant presenting with metabolic alkalosis.
SO Wis-Med-J. 1977 Apr. 76(4). P S47-8.
MJ ALKALOSIS: di.  CYSTIC-FIBROSIS: co.
MN ALKALOSIS: et.  CASE-REPORT.  HUMAN.  INFANT.  MALE.
EX We recently had an opportunity to study a four-month-old boy with
   failure to thrive, hypochloremic metabolic alkalosis, high serum
   aldosterone values, and who was found to have cystic fibrosis.
   Children with cystic fibrosis have moderately elevated plasma renin
   and secondarily elevated serum aldosterone value.  This is due to
   chronic sodium chloride loss through sweat.  Our patient had high
   serum aldosterone values associated with only slightly elevated
   serum cortisol value.  High  serum aldosterone value increased
   further despite correcting conditions which stimulate aldosterone
   secretion.  This suggests that long-standing salt depletion is not
   the only cause for abnormal renin-aldosterone system.
RF 001   WINTERS RW            IN: WINTERS RW                       402 973
   002   WINTERS RW            IN: WINTERS RW                        46 973
   003   NEW MI                J CLIN INVEST                   45   412 966
   004   BARTTER FC            AM J MED                        33   811 962
   005   GOTTLIEB RP           J PEDIATR                       79   930 971
   006   NOUSIA-ARVANITAKIS S  J PEDIATR                       82   535 973
   007   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   008   KESSLER WR            PEDIATRICS                       8   648 951
   009   DI SANTAGNESE PA      JAMA                           172  2014 960
   010   RENDLE-SHORT J        ARCH DIS CHILD                  31    28 956
   011   KASSIER JP            N ENGL J MED                   291   773 974
   012   SIMOPOULOS AP         PEDIATR RES                      5   626 971

